{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/dscott-tantustech/ab_test_guide_in_python/blob/master/Sprint_27_V4__SUBTOPIC_Text_Ingest_pdf_20240523_v2.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 109
        },
        "id": "9ChoCKWHyUaR",
        "outputId": "f44e62ea-6967-46ef-b70b-9f23b6c483cd"
      },
      "outputs": [
        {
          "data": {
            "text/html": [
              "\n",
              "     <input type=\"file\" id=\"files-e3f5c7a9-d13c-4ae1-9a6e-ce83e93568b5\" name=\"files[]\" multiple disabled\n",
              "        style=\"border:none\" />\n",
              "     <output id=\"result-e3f5c7a9-d13c-4ae1-9a6e-ce83e93568b5\">\n",
              "      Upload widget is only available when the cell has been executed in the\n",
              "      current browser session. Please rerun this cell to enable.\n",
              "      </output>\n",
              "      <script>// Copyright 2017 Google LLC\n",
              "//\n",
              "// Licensed under the Apache License, Version 2.0 (the \"License\");\n",
              "// you may not use this file except in compliance with the License.\n",
              "// You may obtain a copy of the License at\n",
              "//\n",
              "//      http://www.apache.org/licenses/LICENSE-2.0\n",
              "//\n",
              "// Unless required by applicable law or agreed to in writing, software\n",
              "// distributed under the License is distributed on an \"AS IS\" BASIS,\n",
              "// WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.\n",
              "// See the License for the specific language governing permissions and\n",
              "// limitations under the License.\n",
              "\n",
              "/**\n",
              " * @fileoverview Helpers for google.colab Python module.\n",
              " */\n",
              "(function(scope) {\n",
              "function span(text, styleAttributes = {}) {\n",
              "  const element = document.createElement('span');\n",
              "  element.textContent = text;\n",
              "  for (const key of Object.keys(styleAttributes)) {\n",
              "    element.style[key] = styleAttributes[key];\n",
              "  }\n",
              "  return element;\n",
              "}\n",
              "\n",
              "// Max number of bytes which will be uploaded at a time.\n",
              "const MAX_PAYLOAD_SIZE = 100 * 1024;\n",
              "\n",
              "function _uploadFiles(inputId, outputId) {\n",
              "  const steps = uploadFilesStep(inputId, outputId);\n",
              "  const outputElement = document.getElementById(outputId);\n",
              "  // Cache steps on the outputElement to make it available for the next call\n",
              "  // to uploadFilesContinue from Python.\n",
              "  outputElement.steps = steps;\n",
              "\n",
              "  return _uploadFilesContinue(outputId);\n",
              "}\n",
              "\n",
              "// This is roughly an async generator (not supported in the browser yet),\n",
              "// where there are multiple asynchronous steps and the Python side is going\n",
              "// to poll for completion of each step.\n",
              "// This uses a Promise to block the python side on completion of each step,\n",
              "// then passes the result of the previous step as the input to the next step.\n",
              "function _uploadFilesContinue(outputId) {\n",
              "  const outputElement = document.getElementById(outputId);\n",
              "  const steps = outputElement.steps;\n",
              "\n",
              "  const next = steps.next(outputElement.lastPromiseValue);\n",
              "  return Promise.resolve(next.value.promise).then((value) => {\n",
              "    // Cache the last promise value to make it available to the next\n",
              "    // step of the generator.\n",
              "    outputElement.lastPromiseValue = value;\n",
              "    return next.value.response;\n",
              "  });\n",
              "}\n",
              "\n",
              "/**\n",
              " * Generator function which is called between each async step of the upload\n",
              " * process.\n",
              " * @param {string} inputId Element ID of the input file picker element.\n",
              " * @param {string} outputId Element ID of the output display.\n",
              " * @return {!Iterable<!Object>} Iterable of next steps.\n",
              " */\n",
              "function* uploadFilesStep(inputId, outputId) {\n",
              "  const inputElement = document.getElementById(inputId);\n",
              "  inputElement.disabled = false;\n",
              "\n",
              "  const outputElement = document.getElementById(outputId);\n",
              "  outputElement.innerHTML = '';\n",
              "\n",
              "  const pickedPromise = new Promise((resolve) => {\n",
              "    inputElement.addEventListener('change', (e) => {\n",
              "      resolve(e.target.files);\n",
              "    });\n",
              "  });\n",
              "\n",
              "  const cancel = document.createElement('button');\n",
              "  inputElement.parentElement.appendChild(cancel);\n",
              "  cancel.textContent = 'Cancel upload';\n",
              "  const cancelPromise = new Promise((resolve) => {\n",
              "    cancel.onclick = () => {\n",
              "      resolve(null);\n",
              "    };\n",
              "  });\n",
              "\n",
              "  // Wait for the user to pick the files.\n",
              "  const files = yield {\n",
              "    promise: Promise.race([pickedPromise, cancelPromise]),\n",
              "    response: {\n",
              "      action: 'starting',\n",
              "    }\n",
              "  };\n",
              "\n",
              "  cancel.remove();\n",
              "\n",
              "  // Disable the input element since further picks are not allowed.\n",
              "  inputElement.disabled = true;\n",
              "\n",
              "  if (!files) {\n",
              "    return {\n",
              "      response: {\n",
              "        action: 'complete',\n",
              "      }\n",
              "    };\n",
              "  }\n",
              "\n",
              "  for (const file of files) {\n",
              "    const li = document.createElement('li');\n",
              "    li.append(span(file.name, {fontWeight: 'bold'}));\n",
              "    li.append(span(\n",
              "        `(${file.type || 'n/a'}) - ${file.size} bytes, ` +\n",
              "        `last modified: ${\n",
              "            file.lastModifiedDate ? file.lastModifiedDate.toLocaleDateString() :\n",
              "                                    'n/a'} - `));\n",
              "    const percent = span('0% done');\n",
              "    li.appendChild(percent);\n",
              "\n",
              "    outputElement.appendChild(li);\n",
              "\n",
              "    const fileDataPromise = new Promise((resolve) => {\n",
              "      const reader = new FileReader();\n",
              "      reader.onload = (e) => {\n",
              "        resolve(e.target.result);\n",
              "      };\n",
              "      reader.readAsArrayBuffer(file);\n",
              "    });\n",
              "    // Wait for the data to be ready.\n",
              "    let fileData = yield {\n",
              "      promise: fileDataPromise,\n",
              "      response: {\n",
              "        action: 'continue',\n",
              "      }\n",
              "    };\n",
              "\n",
              "    // Use a chunked sending to avoid message size limits. See b/62115660.\n",
              "    let position = 0;\n",
              "    do {\n",
              "      const length = Math.min(fileData.byteLength - position, MAX_PAYLOAD_SIZE);\n",
              "      const chunk = new Uint8Array(fileData, position, length);\n",
              "      position += length;\n",
              "\n",
              "      const base64 = btoa(String.fromCharCode.apply(null, chunk));\n",
              "      yield {\n",
              "        response: {\n",
              "          action: 'append',\n",
              "          file: file.name,\n",
              "          data: base64,\n",
              "        },\n",
              "      };\n",
              "\n",
              "      let percentDone = fileData.byteLength === 0 ?\n",
              "          100 :\n",
              "          Math.round((position / fileData.byteLength) * 100);\n",
              "      percent.textContent = `${percentDone}% done`;\n",
              "\n",
              "    } while (position < fileData.byteLength);\n",
              "  }\n",
              "\n",
              "  // All done.\n",
              "  yield {\n",
              "    response: {\n",
              "      action: 'complete',\n",
              "    }\n",
              "  };\n",
              "}\n",
              "\n",
              "scope.google = scope.google || {};\n",
              "scope.google.colab = scope.google.colab || {};\n",
              "scope.google.colab._files = {\n",
              "  _uploadFiles,\n",
              "  _uploadFilesContinue,\n",
              "};\n",
              "})(self);\n",
              "</script> "
            ],
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Saving Reference_Workbook_CY_Provisions_CY2024_DRS_Topics_Subtopics.xlsx to Reference_Workbook_CY_Provisions_CY2024_DRS_Topics_Subtopics.xlsx\n",
            "Saving CMS-2023-0121-0001_content_1920pp.pdf to CMS-2023-0121-0001_content_1920pp.pdf\n"
          ]
        }
      ],
      "source": [
        "# MODULE 0: File Uploads\n",
        "# An interactive menu will pop up to choose the files.\n",
        "# 2 Files to upload:\n",
        "#                   1.'Reference_Workbook_CY_Provisions_CY2024_DRS_Topics_Subtopics.xlsx'\n",
        "#                   2.'CMS-2023-0121-0001_content_1920pp.pdf'\n",
        "\n",
        "from google.colab import files\n",
        "uploaded = files.upload()\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "y1g2vLxFhta9",
        "outputId": "a608a84b-29e9-4b8e-c230-98ef1bf43240"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "<ipython-input-4-741874cf5b43>:10: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  Topic_only_df.drop(columns=['Topic','Subtopic', 'Topic-Subtopic','InsightsAI_Subtopic','InsightsAI_TopicSubtopic'], inplace=True)\n"
          ]
        },
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"Topic_only_df\",\n  \"rows\": 33,\n  \"fields\": [\n    {\n      \"column\": \"Start_Page\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 345,\n        \"min\": 12,\n        \"max\": 1296,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          1220,\n          441,\n          835\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"End Page\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 346,\n        \"min\": 48,\n        \"max\": 1299,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          1295,\n          447,\n          848\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"InsightsAI_Topic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 33,\n        \"samples\": [\n          \"7E_Other Provisions in the Regulation\",\n          \"3F_OUD OTP Coverage\",\n          \"3Q_Changes to the Basic Health Program Regulations\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"L_and_M_Keywords\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 27,\n        \"samples\": [\n          \"Rural Health Clinic Services Act of 1977\\nCAA 2023\\nNurse Practitioner (NP)\\nMarriage and Family Therapist (MFT)\\nMental Health Counselor (MHC)\\n491.2\\n491.8\\nRural Health Clinics (RHC)\\nFederally Qualified Health Center (FQHC)\\nCertification of Coverage (CfC)\\nshortage areas\\nOmnibus Budget Reconciliation Act of 1990 (OBRA)\\nConsensus Model\\nprimary care\",\n          \"Medicare Part B\\nPreventive vaccines\\nPneumococcal\\nInfluenza\\nHepatitis B\\nCOVID-19 vaccines\\nHigh-risk individuals\\nCoinsurance\\nAnnual Part B deductible\\nAverage Wholesale Price (AWP)\\nReasonable cost\\nMedicare Part D\\nZoster vaccine\\nPublic awareness campaign\\nHealth coverage proposal\",\n          \"Clinical diagnostic laboratory tests\\nCDLT\\nLaboratory tests\\nProtecting Medicare and American Farmers from Sequester Cuts Act\\nPMAFSCA\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sort_seq\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39,\n        \"min\": 1,\n        \"max\": 133,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          129,\n          104,\n          120\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"L_and_M_Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Because the underlying criteria for adding services to the Medicare Telehealth Services List are not changing, CMS does not expect this proposal to have an impact on the utilization of Medicare Telehealth services beginning in CY 2024 but will continue to monitor utilization of these services. CMS is proposing that, beginning in CY 2024, claims billed with POS 10 (Telehealth Provided in Patient's Home) would be paid at the nonfacility PFS rate. Claims billed with POS 02 (Telehealth Provided Other than in Patient\\u2019s Home) will continue to be paid at the PFS facility rate. As CMS is currently paying for the majority of services that will be billed with POS 10 at the PFS non-facility rate under the PHE-specific policy of paying the place of service code had the service been furnished in person, these services furnished via telehealth will largely be paid as they are currently. Therefore, the impact of this proposal will roughly neutral even if utilization remains at current levels for these services. CMS anticipates that these provisions will result in continued utilization of Medicare telehealth services during CY 2024 at levels comparable to observed utilization of these services during the PHE for COVID\\u201319.\",\n          \"Background: Appropriate Use Criteria (AUC) are evidence-based guidelines that assist clinicians in selecting the imaging studies most likely to improve health outcomes for patients based on their individual clinical presentation. AUC present information in a manner that links a specific clinical condition or presentation; one or more services; and an assessment of the appropriateness of the service(s). Under Section 1834(q) of the Protecting Access to Medicare Act, CMS was directed to establish a program to promote AUC for advanced diagnostic imaging services. Under the AUC program, clinicians and facilities that furnish the imaging service are responsible for reporting information about the ordering clinician\\u2019s AUC consultation on the imaging service claim. \\nFour major components of the AUC program under section 1834(q) of the Act are:\\n(1) establishment of AUC by November 15, 2015;\\n(2) identification of mechanisms for consultation with AUC by April 1, 2016;\\n(3) AUC consultation by ordering professionals, and reporting on AUC consultation by January 1, 2017; and\\n(4) annual identification of outlier ordering professionals (based on low adherence to AUC) for services furnished after January 1, 2017\\n\\nCMS has taken a diligent, stepwise implementation approach to maximize the opportunity for public comment and engagement with interested parties, and allow for adequate advance notice to physicians and practitioners, beneficiaries and other AUC interested parties of any programmatic changes or updates. Currently, the AUC program is in the educational and operations testing phase that began January 1, 2020. CMS has not met the statutory implementation time frame for the AUC program components. Due to the inability of the Medicare claims processing system to automate claims processing edits that ensure only claims subject to the AUC program requirements as prescribed in section 1834(q) of the Act will be processed as such, returned or denied accordingly, CMS believes the inherent risks in terms of data integrity and accuracy, beneficiary access, and potential beneficiary financial liability for advanced diagnostic imaging services render the AUC program impracticable. Working within the parameters prescribed under section 1834(q) of the Act, CMS has not identified any practical way to move the AUC program forward beyond the educational and operations testing period. Further, without a way forward to fully implement the AUC program, CMS believes there is no utility in continuing the educational and operations testing period. CMS will continue efforts to identify a workable implementation approach and will propose to adopt any such approach through subsequent rulemaking.\\n\\nProvision: CMS proposes to  pause implementation of the AUC program for reevaluation. CMS proposes to remove the text of \\u00a7 414.94 and save for future use. This section contains the entirety of the regulations adopted in the course of implementing elements of section 1834(q) of the Act. CMS believes the removal of these regulations is consistent with their proposal to pause efforts to implement the AUC program for reevaluation, and would avoid the potential confusion that could result if the text was retained or amended at \\u00a7 414.94. CMS expects this to be a hard pause to facilitate thorough program reevaluation and, as such, we are not proposing a time frame within which implementation efforts may recommence.\",\n          \"Background:\\nSection 2005 of the SUPPORT Act created a new Medicare Part B benefit for OUD treatment services furnished by OTPs. In CY2023 PFS final rule, CMS modified the pricing of the drug component of the methadone weekly bundle and the add-on code for take home supplied of methadone by using the payment amount for methadone for CY2021 to better reflect the change in methadone costs for OTPs over time. In addition, CMS finalized modification to the payment rate for individual therapy in the non-drug component of the bundled payment for an episode of care to base the payment rate on the rate for longer therapy sessions that better account for the greater severity of needs for patients with an OUD and receiving treatment in OTP setting. Lastly, services furnished via OTP mobile units will be treated as services furnished in the physical location of the OTP. CMS believes this would allow OTPs to better serve Medicare beneficiaries in underserved areas and will continue to monitor use of OUD treatment services furnished by OTPs to ensure adequate access to care for beneficiaries. \\n\\nProvisions:\\nCMS is proposing several modifications to policies governing Medicare coverage and payment for OUD treatment services furnished by OTPs. \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Pages\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 55,\n        \"min\": 1,\n        \"max\": 238,\n        \"num_unique_values\": 24,\n        \"samples\": [\n          42,\n          24,\n          36\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "Topic_only_df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-347b5fd9-6358-4f6c-a44c-306e614697a6\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Start_Page</th>\n",
              "      <th>End Page</th>\n",
              "      <th>InsightsAI_Topic</th>\n",
              "      <th>L_and_M_Keywords</th>\n",
              "      <th>Sort_seq</th>\n",
              "      <th>L_and_M_Summary</th>\n",
              "      <th>Pages</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>12</td>\n",
              "      <td>48</td>\n",
              "      <td>2B_Determination of Practice Expense RVUs</td>\n",
              "      <td>1848(c)(1)(B)\\nIndirect Cost PE RVU\\nIndirect ...</td>\n",
              "      <td>1</td>\n",
              "      <td>Background: Practice Expense (PE) is the porti...</td>\n",
              "      <td>36</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>49</td>\n",
              "      <td>67</td>\n",
              "      <td>2C_Potentially Misvalued Services</td>\n",
              "      <td>Potentially misvalued codes\\npotentially misva...</td>\n",
              "      <td>5</td>\n",
              "      <td>Background: Section 1848(c)(2)(B) of the Act d...</td>\n",
              "      <td>18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>68</td>\n",
              "      <td>129</td>\n",
              "      <td>2D_Telehealth Services</td>\n",
              "      <td>Category 1\\nCategory 2\\nCategory 3\\ntemporary\\...</td>\n",
              "      <td>6</td>\n",
              "      <td>Background: In the 2003 PFS final rule, a regu...</td>\n",
              "      <td>61</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>130</td>\n",
              "      <td>239</td>\n",
              "      <td>2E_Valuation of Specific Codes</td>\n",
              "      <td></td>\n",
              "      <td>20</td>\n",
              "      <td>NaN</td>\n",
              "      <td>109</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>240</td>\n",
              "      <td>256</td>\n",
              "      <td>2F_E&amp;M Visits</td>\n",
              "      <td>Evaluation and Management (E/M) Visits\\nE/M vi...</td>\n",
              "      <td>49</td>\n",
              "      <td>Background: Over the past several years, CMS h...</td>\n",
              "      <td>16</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>51</th>\n",
              "      <td>257</td>\n",
              "      <td>260</td>\n",
              "      <td>2G_Geographic Practice Cost Indices</td>\n",
              "      <td>Geographic practice cost indices\\nGPCIs\\nWork ...</td>\n",
              "      <td>52</td>\n",
              "      <td>NaN</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>54</th>\n",
              "      <td>261</td>\n",
              "      <td>264</td>\n",
              "      <td>2H_Payment for Skin Substitutes</td>\n",
              "      <td>Skin substitutes\\nSynthetic skin</td>\n",
              "      <td>55</td>\n",
              "      <td>Background: In the CY 2023 PFS proposed rule, ...</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>57</th>\n",
              "      <td>265</td>\n",
              "      <td>276</td>\n",
              "      <td>2I_Supervision of OP Therapy Svcs, KX Modifier...</td>\n",
              "      <td></td>\n",
              "      <td>58</td>\n",
              "      <td>N/A section immediately starts with 2I1a</td>\n",
              "      <td>11</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>63</th>\n",
              "      <td>277</td>\n",
              "      <td>307</td>\n",
              "      <td>2J_Advancing Access to Behavioral Health Services</td>\n",
              "      <td></td>\n",
              "      <td>64</td>\n",
              "      <td>N/A section immediately starts with 2J1</td>\n",
              "      <td>30</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>72</th>\n",
              "      <td>308</td>\n",
              "      <td>350</td>\n",
              "      <td>2K_Medicare Parts A and B Payment for Dental S...</td>\n",
              "      <td></td>\n",
              "      <td>73</td>\n",
              "      <td>NaN</td>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>79</th>\n",
              "      <td>351</td>\n",
              "      <td>385</td>\n",
              "      <td>3A_Drugs and Biological Products Paid Under Pa...</td>\n",
              "      <td></td>\n",
              "      <td>80</td>\n",
              "      <td>N/A section immediately starts with 3A1</td>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>86</th>\n",
              "      <td>386</td>\n",
              "      <td>420</td>\n",
              "      <td>3B_RHCs and FQHCs</td>\n",
              "      <td>Rural Health Clinics (RHCs)\\nFederally Qualifi...</td>\n",
              "      <td>87</td>\n",
              "      <td>Background: This section is an overview of the...</td>\n",
              "      <td>34</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>421</td>\n",
              "      <td>428</td>\n",
              "      <td>3C_RHCs and FQHCs Conditions for Certification...</td>\n",
              "      <td>Rural Health Clinic Services Act of 1977\\nCAA ...</td>\n",
              "      <td>99</td>\n",
              "      <td>Background: The Rural Health Clinic Services A...</td>\n",
              "      <td>7</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>429</td>\n",
              "      <td>437</td>\n",
              "      <td>3D_Clinical Lab Fee Schedule</td>\n",
              "      <td>Clinical diagnostic laboratory tests\\nCDLT\\nLa...</td>\n",
              "      <td>100</td>\n",
              "      <td>Background: \\nSection 1834A of the Act, as est...</td>\n",
              "      <td>8</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>102</th>\n",
              "      <td>438</td>\n",
              "      <td>440</td>\n",
              "      <td>3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...</td>\n",
              "      <td>Pulmonary rehabilitation\\nCardiac rehabilitati...</td>\n",
              "      <td>103</td>\n",
              "      <td>Background: Conditions of coverage for pulmona...</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>103</th>\n",
              "      <td>441</td>\n",
              "      <td>447</td>\n",
              "      <td>3F_OUD OTP Coverage</td>\n",
              "      <td>Section 2005\\nSUPPORT Act\\nOUD (opioid use dis...</td>\n",
              "      <td>104</td>\n",
              "      <td>Background:\\nSection 2005 of the SUPPORT Act c...</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>106</th>\n",
              "      <td>448</td>\n",
              "      <td>686</td>\n",
              "      <td>3G_MSSP</td>\n",
              "      <td>MSSP\\nShared savings \\nACO(s)\\naccountable car...</td>\n",
              "      <td>107</td>\n",
              "      <td>Background: The Medicare Shared Savings Progra...</td>\n",
              "      <td>238</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>107</th>\n",
              "      <td>687</td>\n",
              "      <td>700</td>\n",
              "      <td>3H_Part B Payment Preventive Vaccine</td>\n",
              "      <td>Medicare Part B\\nPreventive vaccines\\nPneumoco...</td>\n",
              "      <td>108</td>\n",
              "      <td>Background:   Currently, Medicare Part B cover...</td>\n",
              "      <td>13</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>111</th>\n",
              "      <td>701</td>\n",
              "      <td>725</td>\n",
              "      <td>3I_MDPP</td>\n",
              "      <td>Medicare Diabetes Prevention Program\\nMDPP\\nMD...</td>\n",
              "      <td>112</td>\n",
              "      <td>Background: The Centers for Medicare &amp; Medicai...</td>\n",
              "      <td>24</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>112</th>\n",
              "      <td>726</td>\n",
              "      <td>744</td>\n",
              "      <td>3J_Appropriate Use Criteria for Advanced Diagn...</td>\n",
              "      <td>Appropriate use criteria\\nAUC\\nClinical decisi...</td>\n",
              "      <td>113</td>\n",
              "      <td>Background: Appropriate Use Criteria (AUC) are...</td>\n",
              "      <td>18</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>113</th>\n",
              "      <td>745</td>\n",
              "      <td>785</td>\n",
              "      <td>3K_Medicaid Provider Enrollment</td>\n",
              "      <td>Provider, Enrollment, Chain and Ownership Syst...</td>\n",
              "      <td>114</td>\n",
              "      <td>\\nBackground: Section 1866(j)(1)(A) requires a...</td>\n",
              "      <td>40</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>114</th>\n",
              "      <td>786</td>\n",
              "      <td>798</td>\n",
              "      <td>3L_Expand Diabetes Screening and Diabetes Defi...</td>\n",
              "      <td>HbA1c\\nA1c\\nDefinition of diabetes \\nHemoglobi...</td>\n",
              "      <td>115</td>\n",
              "      <td>Background: The USPSTF recommended the HbA1C t...</td>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>115</th>\n",
              "      <td>799</td>\n",
              "      <td>813</td>\n",
              "      <td>3M_EPCS Part D</td>\n",
              "      <td>SUPPORT Act\\nCMS EPCS Program\\nPrescription Dr...</td>\n",
              "      <td>116</td>\n",
              "      <td>Background\\nThe current Prescription Drug Even...</td>\n",
              "      <td>14</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>116</th>\n",
              "      <td>814</td>\n",
              "      <td>823</td>\n",
              "      <td>3N_Ambulance Fee and GADCS</td>\n",
              "      <td>ambulance services\\nambulance fee schedule (AF...</td>\n",
              "      <td>117</td>\n",
              "      <td>Background: When other methods of transportati...</td>\n",
              "      <td>9</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>117</th>\n",
              "      <td>824</td>\n",
              "      <td>827</td>\n",
              "      <td>3O_Hospice: Changes to Conditions of Participa...</td>\n",
              "      <td>TEFRA\\n1861(dd)\\nconditions of participation (...</td>\n",
              "      <td>118</td>\n",
              "      <td>Background: CMS has the authority to establish...</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>118</th>\n",
              "      <td>828</td>\n",
              "      <td>834</td>\n",
              "      <td>3P_Solicitation: Histopathology, Cytology, and...</td>\n",
              "      <td>CLIA of 1988\\nHistopathology\\nIHC staining\\nH&amp;...</td>\n",
              "      <td>119</td>\n",
              "      <td>Background \\nCMS has not updated the CLIA of 1...</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>119</th>\n",
              "      <td>835</td>\n",
              "      <td>848</td>\n",
              "      <td>3Q_Changes to the Basic Health Program Regulat...</td>\n",
              "      <td>Immigration status\\npremium tac credit\\nCost-s...</td>\n",
              "      <td>120</td>\n",
              "      <td>Background: In section 1331 of the Patient Pro...</td>\n",
              "      <td>13</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>120</th>\n",
              "      <td>849</td>\n",
              "      <td>855</td>\n",
              "      <td>3R_Updates to the Definitions of CEHRT</td>\n",
              "      <td>Health IT certification\\nIT\\nMedicaid\\nOffice ...</td>\n",
              "      <td>121</td>\n",
              "      <td>Background: The American Recovery and Reinvest...</td>\n",
              "      <td>6</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>121</th>\n",
              "      <td>856</td>\n",
              "      <td>868</td>\n",
              "      <td>3S_SDOH Risk Assessment in the AWV</td>\n",
              "      <td>Annual Wellness Visit\\nAWV\\nSocial Determinant...</td>\n",
              "      <td>122</td>\n",
              "      <td>Background: The AWV includes the establishment...</td>\n",
              "      <td>12</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>122</th>\n",
              "      <td>869</td>\n",
              "      <td>1085</td>\n",
              "      <td>4_QPP</td>\n",
              "      <td>NaN</td>\n",
              "      <td>123</td>\n",
              "      <td>\\nBackground: CMS is proposing changes to the ...</td>\n",
              "      <td>216</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>127</th>\n",
              "      <td>1219</td>\n",
              "      <td>1219</td>\n",
              "      <td>7D_Changes Related to Telehealth Services</td>\n",
              "      <td>POS 10\\nnon-facility rate</td>\n",
              "      <td>128</td>\n",
              "      <td>Because the underlying criteria for adding ser...</td>\n",
              "      <td>1</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>128</th>\n",
              "      <td>1220</td>\n",
              "      <td>1295</td>\n",
              "      <td>7E_Other Provisions in the Regulation</td>\n",
              "      <td></td>\n",
              "      <td>129</td>\n",
              "      <td>NaN</td>\n",
              "      <td>75</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>132</th>\n",
              "      <td>1296</td>\n",
              "      <td>1299</td>\n",
              "      <td>7F_Alternatives Considered</td>\n",
              "      <td>no alternatives were considered</td>\n",
              "      <td>133</td>\n",
              "      <td>2. Alternatives to Provider Enrollment Provisi...</td>\n",
              "      <td>3</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-347b5fd9-6358-4f6c-a44c-306e614697a6')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-347b5fd9-6358-4f6c-a44c-306e614697a6 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-347b5fd9-6358-4f6c-a44c-306e614697a6');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-46f5ec61-3ae4-4371-8ed2-5eb1e250131d\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-46f5ec61-3ae4-4371-8ed2-5eb1e250131d')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-46f5ec61-3ae4-4371-8ed2-5eb1e250131d button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_247962e9-03f5-4ff6-b9ac-a843bfe2d6d4\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('Topic_only_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_247962e9-03f5-4ff6-b9ac-a843bfe2d6d4 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('Topic_only_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "     Start_Page  End Page                                   InsightsAI_Topic  \\\n",
              "0            12        48          2B_Determination of Practice Expense RVUs   \n",
              "4            49        67                  2C_Potentially Misvalued Services   \n",
              "5            68       129                             2D_Telehealth Services   \n",
              "19          130       239                     2E_Valuation of Specific Codes   \n",
              "48          240       256                                      2F_E&M Visits   \n",
              "51          257       260                2G_Geographic Practice Cost Indices   \n",
              "54          261       264                    2H_Payment for Skin Substitutes   \n",
              "57          265       276  2I_Supervision of OP Therapy Svcs, KX Modifier...   \n",
              "63          277       307  2J_Advancing Access to Behavioral Health Services   \n",
              "72          308       350  2K_Medicare Parts A and B Payment for Dental S...   \n",
              "79          351       385  3A_Drugs and Biological Products Paid Under Pa...   \n",
              "86          386       420                                  3B_RHCs and FQHCs   \n",
              "98          421       428  3C_RHCs and FQHCs Conditions for Certification...   \n",
              "99          429       437                       3D_Clinical Lab Fee Schedule   \n",
              "102         438       440  3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...   \n",
              "103         441       447                                3F_OUD OTP Coverage   \n",
              "106         448       686                                            3G_MSSP   \n",
              "107         687       700               3H_Part B Payment Preventive Vaccine   \n",
              "111         701       725                                            3I_MDPP   \n",
              "112         726       744  3J_Appropriate Use Criteria for Advanced Diagn...   \n",
              "113         745       785                    3K_Medicaid Provider Enrollment   \n",
              "114         786       798  3L_Expand Diabetes Screening and Diabetes Defi...   \n",
              "115         799       813                                     3M_EPCS Part D   \n",
              "116         814       823                         3N_Ambulance Fee and GADCS   \n",
              "117         824       827  3O_Hospice: Changes to Conditions of Participa...   \n",
              "118         828       834  3P_Solicitation: Histopathology, Cytology, and...   \n",
              "119         835       848  3Q_Changes to the Basic Health Program Regulat...   \n",
              "120         849       855             3R_Updates to the Definitions of CEHRT   \n",
              "121         856       868                 3S_SDOH Risk Assessment in the AWV   \n",
              "122         869      1085                                              4_QPP   \n",
              "127        1219      1219          7D_Changes Related to Telehealth Services   \n",
              "128        1220      1295              7E_Other Provisions in the Regulation   \n",
              "132        1296      1299                         7F_Alternatives Considered   \n",
              "\n",
              "                                      L_and_M_Keywords  Sort_seq  \\\n",
              "0    1848(c)(1)(B)\\nIndirect Cost PE RVU\\nIndirect ...         1   \n",
              "4    Potentially misvalued codes\\npotentially misva...         5   \n",
              "5    Category 1\\nCategory 2\\nCategory 3\\ntemporary\\...         6   \n",
              "19                                                            20   \n",
              "48   Evaluation and Management (E/M) Visits\\nE/M vi...        49   \n",
              "51   Geographic practice cost indices\\nGPCIs\\nWork ...        52   \n",
              "54                    Skin substitutes\\nSynthetic skin        55   \n",
              "57                                                            58   \n",
              "63                                                            64   \n",
              "72                                                            73   \n",
              "79                                                            80   \n",
              "86   Rural Health Clinics (RHCs)\\nFederally Qualifi...        87   \n",
              "98   Rural Health Clinic Services Act of 1977\\nCAA ...        99   \n",
              "99   Clinical diagnostic laboratory tests\\nCDLT\\nLa...       100   \n",
              "102  Pulmonary rehabilitation\\nCardiac rehabilitati...       103   \n",
              "103  Section 2005\\nSUPPORT Act\\nOUD (opioid use dis...       104   \n",
              "106  MSSP\\nShared savings \\nACO(s)\\naccountable car...       107   \n",
              "107  Medicare Part B\\nPreventive vaccines\\nPneumoco...       108   \n",
              "111  Medicare Diabetes Prevention Program\\nMDPP\\nMD...       112   \n",
              "112  Appropriate use criteria\\nAUC\\nClinical decisi...       113   \n",
              "113  Provider, Enrollment, Chain and Ownership Syst...       114   \n",
              "114  HbA1c\\nA1c\\nDefinition of diabetes \\nHemoglobi...       115   \n",
              "115  SUPPORT Act\\nCMS EPCS Program\\nPrescription Dr...       116   \n",
              "116  ambulance services\\nambulance fee schedule (AF...       117   \n",
              "117  TEFRA\\n1861(dd)\\nconditions of participation (...       118   \n",
              "118  CLIA of 1988\\nHistopathology\\nIHC staining\\nH&...       119   \n",
              "119  Immigration status\\npremium tac credit\\nCost-s...       120   \n",
              "120  Health IT certification\\nIT\\nMedicaid\\nOffice ...       121   \n",
              "121  Annual Wellness Visit\\nAWV\\nSocial Determinant...       122   \n",
              "122                                                NaN       123   \n",
              "127                          POS 10\\nnon-facility rate       128   \n",
              "128                                                          129   \n",
              "132                    no alternatives were considered       133   \n",
              "\n",
              "                                       L_and_M_Summary  Pages  \n",
              "0    Background: Practice Expense (PE) is the porti...     36  \n",
              "4    Background: Section 1848(c)(2)(B) of the Act d...     18  \n",
              "5    Background: In the 2003 PFS final rule, a regu...     61  \n",
              "19                                                 NaN    109  \n",
              "48   Background: Over the past several years, CMS h...     16  \n",
              "51                                                 NaN      3  \n",
              "54   Background: In the CY 2023 PFS proposed rule, ...      3  \n",
              "57            N/A section immediately starts with 2I1a     11  \n",
              "63             N/A section immediately starts with 2J1     30  \n",
              "72                                                 NaN     42  \n",
              "79             N/A section immediately starts with 3A1     34  \n",
              "86   Background: This section is an overview of the...     34  \n",
              "98   Background: The Rural Health Clinic Services A...      7  \n",
              "99   Background: \\nSection 1834A of the Act, as est...      8  \n",
              "102  Background: Conditions of coverage for pulmona...      2  \n",
              "103  Background:\\nSection 2005 of the SUPPORT Act c...      6  \n",
              "106  Background: The Medicare Shared Savings Progra...    238  \n",
              "107  Background:   Currently, Medicare Part B cover...     13  \n",
              "111  Background: The Centers for Medicare & Medicai...     24  \n",
              "112  Background: Appropriate Use Criteria (AUC) are...     18  \n",
              "113  \\nBackground: Section 1866(j)(1)(A) requires a...     40  \n",
              "114  Background: The USPSTF recommended the HbA1C t...     12  \n",
              "115  Background\\nThe current Prescription Drug Even...     14  \n",
              "116  Background: When other methods of transportati...      9  \n",
              "117  Background: CMS has the authority to establish...      3  \n",
              "118  Background \\nCMS has not updated the CLIA of 1...      6  \n",
              "119  Background: In section 1331 of the Patient Pro...     13  \n",
              "120  Background: The American Recovery and Reinvest...      6  \n",
              "121  Background: The AWV includes the establishment...     12  \n",
              "122  \\nBackground: CMS is proposing changes to the ...    216  \n",
              "127  Because the underlying criteria for adding ser...      1  \n",
              "128                                                NaN     75  \n",
              "132  2. Alternatives to Provider Enrollment Provisi...      3  "
            ]
          },
          "execution_count": 4,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "#MODULE 1: Create data frame from the attached Topic/Subtopic file\n",
        "import pandas as pd\n",
        "Topic_SubTopic_df = pd.read_excel('Reference_Workbook_CY_Provisions_CY2024_DRS_Topics_Subtopics.xlsx')\n",
        "#sort so that Topics come directly before each of their respective subtopics\n",
        "#Topic_SubTopic_df = Topic_SubTopic_df.sort_values(by=['Start_Page', 'InsightsAI_Topic'], ascending=[True, True])\n",
        "Topic_SubTopic_df = Topic_SubTopic_df.sort_values(by=['Sort_seq'], ascending=True)\n",
        "\n",
        "#Topic Only Data Frame\n",
        "Topic_only_df = Topic_SubTopic_df[Topic_SubTopic_df['InsightsAI_Topic'].notnull()]\n",
        "Topic_only_df.drop(columns=['Topic','Subtopic', 'Topic-Subtopic','InsightsAI_Subtopic','InsightsAI_TopicSubtopic'], inplace=True)\n",
        "\n",
        "# *SUB-* topic Only data frame\n",
        "Subtopic_only_df = Topic_SubTopic_df[Topic_SubTopic_df['InsightsAI_Subtopic'].notnull()]\n",
        "Subtopic_only_df = Subtopic_only_df[Subtopic_only_df['InsightsAI_Topic'].isnull()]\n",
        "Subtopic_only_df = Subtopic_only_df[Subtopic_only_df['InsightsAI_Subtopic']!=\" \"]\n",
        "\n",
        "Subtopic_only_df.drop(columns=['Topic','Subtopic', 'Topic-Subtopic','InsightsAI_TopicSubtopic'], inplace=True)\n",
        "\n",
        "Topic_only_df\n",
        "#Subtopic_only_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "YDl_nWXcgou2",
        "outputId": "a1a55c72-9f30-4a3f-84af-e799e83f6912"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Collecting PyPDF2\n",
            "  Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
            "\u001b[?25l     \u001b[90m\u001b[0m \u001b[32m0.0/232.6 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[91m\u001b[0m\u001b[90m\u001b[0m\u001b[90m\u001b[0m \u001b[32m204.8/232.6 kB\u001b[0m \u001b[31m5.9 MB/s\u001b[0m eta \u001b[36m0:00:01\u001b[0m\r\u001b[2K     \u001b[90m\u001b[0m \u001b[32m232.6/232.6 kB\u001b[0m \u001b[31m4.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: PyPDF2\n",
            "Successfully installed PyPDF2-3.0.1\n",
            "<class 'list'>\n"
          ]
        }
      ],
      "source": [
        "# MODULE 2: Convert Proposed Rules PDF to Text\n",
        "!pip install PyPDF2\n",
        "import PyPDF2\n",
        "\n",
        "def convert_pdf_to_txt(file):\n",
        "    pdf_file = open(file, 'rb')\n",
        "    read_pdf = PyPDF2.PdfReader(pdf_file)\n",
        "    number_of_pages = len(read_pdf.pages)\n",
        "\n",
        "    segments = []\n",
        "    for page_number in range(number_of_pages):\n",
        "        page = read_pdf.pages[page_number]\n",
        "        page_content = page.extract_text()\n",
        "        segments.append(page_content)\n",
        "\n",
        "    return segments\n",
        "\n",
        "segments = convert_pdf_to_txt('CMS-2023-0121-0001_content_1920pp.pdf')\n",
        "print(type(segments))  # Output: <class 'list'>\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "NpJONehbllG1",
        "outputId": "db535c1e-f1d2-4bef-882d-8e5243a5d3ed"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.10/dist-packages (4.41.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from transformers) (3.14.0)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.23.0)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (1.25.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from transformers) (24.0)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (6.0.1)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (2023.12.25)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from transformers) (2.31.0)\n",
            "Requirement already satisfied: tokenizers<0.20,>=0.19 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.19.1)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.4.3)\n",
            "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.10/dist-packages (from transformers) (4.66.4)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.23.0->transformers) (2023.6.0)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.23.0->transformers) (4.11.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2024.2.2)\n",
            "Requirement already satisfied: nltk in /usr/local/lib/python3.10/dist-packages (3.8.1)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from nltk) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from nltk) (1.4.2)\n",
            "Requirement already satisfied: regex>=2021.8.3 in /usr/local/lib/python3.10/dist-packages (from nltk) (2023.12.25)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from nltk) (4.66.4)\n",
            "Collecting openai\n",
            "  Downloading openai-1.30.1-py3-none-any.whl (320 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m320.6/320.6 kB\u001b[0m \u001b[31m6.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai) (3.7.1)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai) (1.7.0)\n",
            "Collecting httpx<1,>=0.23.0 (from openai)\n",
            "  Downloading httpx-0.27.0-py3-none-any.whl (75 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m75.6/75.6 kB\u001b[0m \u001b[31m8.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from openai) (2.7.1)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai) (1.3.1)\n",
            "Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.4)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.7 in /usr/local/lib/python3.10/dist-packages (from openai) (4.11.0)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (3.7)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (1.2.1)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (2024.2.2)\n",
            "Collecting httpcore==1.* (from httpx<1,>=0.23.0->openai)\n",
            "  Downloading httpcore-1.0.5-py3-none-any.whl (77 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m77.9/77.9 kB\u001b[0m \u001b[31m8.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting h11<0.15,>=0.13 (from httpcore==1.*->httpx<1,>=0.23.0->openai)\n",
            "  Downloading h11-0.14.0-py3-none-any.whl (58 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m6.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (0.6.0)\n",
            "Requirement already satisfied: pydantic-core==2.18.2 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (2.18.2)\n",
            "Installing collected packages: h11, httpcore, httpx, openai\n",
            "Successfully installed h11-0.14.0 httpcore-1.0.5 httpx-0.27.0 openai-1.30.1\n",
            "Requirement already satisfied: ipywidgets in /usr/local/lib/python3.10/dist-packages (7.7.1)\n",
            "Requirement already satisfied: ipykernel>=4.5.1 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (5.5.6)\n",
            "Requirement already satisfied: ipython-genutils~=0.2.0 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (0.2.0)\n",
            "Requirement already satisfied: traitlets>=4.3.1 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (5.7.1)\n",
            "Requirement already satisfied: widgetsnbextension~=3.6.0 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (3.6.6)\n",
            "Requirement already satisfied: ipython>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (7.34.0)\n",
            "Requirement already satisfied: jupyterlab-widgets>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from ipywidgets) (3.0.10)\n",
            "Requirement already satisfied: jupyter-client in /usr/local/lib/python3.10/dist-packages (from ipykernel>=4.5.1->ipywidgets) (6.1.12)\n",
            "Requirement already satisfied: tornado>=4.2 in /usr/local/lib/python3.10/dist-packages (from ipykernel>=4.5.1->ipywidgets) (6.3.3)\n",
            "Requirement already satisfied: setuptools>=18.5 in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (67.7.2)\n",
            "Collecting jedi>=0.16 (from ipython>=4.0.0->ipywidgets)\n",
            "  Downloading jedi-0.19.1-py2.py3-none-any.whl (1.6 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m1.6/1.6 MB\u001b[0m \u001b[31m11.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: decorator in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (4.4.2)\n",
            "Requirement already satisfied: pickleshare in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (0.7.5)\n",
            "Requirement already satisfied: prompt-toolkit!=3.0.0,!=3.0.1,<3.1.0,>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (3.0.43)\n",
            "Requirement already satisfied: pygments in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (2.16.1)\n",
            "Requirement already satisfied: backcall in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (0.2.0)\n",
            "Requirement already satisfied: matplotlib-inline in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (0.1.7)\n",
            "Requirement already satisfied: pexpect>4.3 in /usr/local/lib/python3.10/dist-packages (from ipython>=4.0.0->ipywidgets) (4.9.0)\n",
            "Requirement already satisfied: notebook>=4.4.1 in /usr/local/lib/python3.10/dist-packages (from widgetsnbextension~=3.6.0->ipywidgets) (6.5.5)\n",
            "Requirement already satisfied: parso<0.9.0,>=0.8.3 in /usr/local/lib/python3.10/dist-packages (from jedi>=0.16->ipython>=4.0.0->ipywidgets) (0.8.4)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (3.1.4)\n",
            "Requirement already satisfied: pyzmq<25,>=17 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (24.0.1)\n",
            "Requirement already satisfied: argon2-cffi in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (23.1.0)\n",
            "Requirement already satisfied: jupyter-core>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (5.7.2)\n",
            "Requirement already satisfied: nbformat in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (5.10.4)\n",
            "Requirement already satisfied: nbconvert>=5 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (6.5.4)\n",
            "Requirement already satisfied: nest-asyncio>=1.5 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.6.0)\n",
            "Requirement already satisfied: Send2Trash>=1.8.0 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.8.3)\n",
            "Requirement already satisfied: terminado>=0.8.3 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.18.1)\n",
            "Requirement already satisfied: prometheus-client in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.20.0)\n",
            "Requirement already satisfied: nbclassic>=0.4.7 in /usr/local/lib/python3.10/dist-packages (from notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.0.0)\n",
            "Requirement already satisfied: python-dateutil>=2.1 in /usr/local/lib/python3.10/dist-packages (from jupyter-client->ipykernel>=4.5.1->ipywidgets) (2.8.2)\n",
            "Requirement already satisfied: ptyprocess>=0.5 in /usr/local/lib/python3.10/dist-packages (from pexpect>4.3->ipython>=4.0.0->ipywidgets) (0.7.0)\n",
            "Requirement already satisfied: wcwidth in /usr/local/lib/python3.10/dist-packages (from prompt-toolkit!=3.0.0,!=3.0.1,<3.1.0,>=2.0.0->ipython>=4.0.0->ipywidgets) (0.2.13)\n",
            "Requirement already satisfied: platformdirs>=2.5 in /usr/local/lib/python3.10/dist-packages (from jupyter-core>=4.6.1->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (4.2.2)\n",
            "Requirement already satisfied: jupyter-server>=1.8 in /usr/local/lib/python3.10/dist-packages (from nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.24.0)\n",
            "Requirement already satisfied: notebook-shim>=0.2.3 in /usr/local/lib/python3.10/dist-packages (from nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.2.4)\n",
            "Requirement already satisfied: lxml in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (4.9.4)\n",
            "Requirement already satisfied: beautifulsoup4 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (4.12.3)\n",
            "Requirement already satisfied: bleach in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (6.1.0)\n",
            "Requirement already satisfied: defusedxml in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.7.1)\n",
            "Requirement already satisfied: entrypoints>=0.2.2 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.4)\n",
            "Requirement already satisfied: jupyterlab-pygments in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (2.1.5)\n",
            "Requirement already satisfied: mistune<2,>=0.8.1 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.8.4)\n",
            "Requirement already satisfied: nbclient>=0.5.0 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.10.0)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (24.0)\n",
            "Requirement already satisfied: pandocfilters>=1.4.1 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.5.1)\n",
            "Requirement already satisfied: tinycss2 in /usr/local/lib/python3.10/dist-packages (from nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.3.0)\n",
            "Requirement already satisfied: fastjsonschema>=2.15 in /usr/local/lib/python3.10/dist-packages (from nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (2.19.1)\n",
            "Requirement already satisfied: jsonschema>=2.6 in /usr/local/lib/python3.10/dist-packages (from nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (4.19.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.1->jupyter-client->ipykernel>=4.5.1->ipywidgets) (1.16.0)\n",
            "Requirement already satisfied: argon2-cffi-bindings in /usr/local/lib/python3.10/dist-packages (from argon2-cffi->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (21.2.0)\n",
            "Requirement already satisfied: attrs>=22.2.0 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=2.6->nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (23.2.0)\n",
            "Requirement already satisfied: jsonschema-specifications>=2023.03.6 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=2.6->nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (2023.12.1)\n",
            "Requirement already satisfied: referencing>=0.28.4 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=2.6->nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.35.1)\n",
            "Requirement already satisfied: rpds-py>=0.7.1 in /usr/local/lib/python3.10/dist-packages (from jsonschema>=2.6->nbformat->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.18.1)\n",
            "Requirement already satisfied: anyio<4,>=3.1.0 in /usr/local/lib/python3.10/dist-packages (from jupyter-server>=1.8->nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (3.7.1)\n",
            "Requirement already satisfied: websocket-client in /usr/local/lib/python3.10/dist-packages (from jupyter-server>=1.8->nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.8.0)\n",
            "Requirement already satisfied: cffi>=1.0.1 in /usr/local/lib/python3.10/dist-packages (from argon2-cffi-bindings->argon2-cffi->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.16.0)\n",
            "Requirement already satisfied: soupsieve>1.2 in /usr/local/lib/python3.10/dist-packages (from beautifulsoup4->nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (2.5)\n",
            "Requirement already satisfied: webencodings in /usr/local/lib/python3.10/dist-packages (from bleach->nbconvert>=5->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (0.5.1)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.10/dist-packages (from anyio<4,>=3.1.0->jupyter-server>=1.8->nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (3.7)\n",
            "Requirement already satisfied: sniffio>=1.1 in /usr/local/lib/python3.10/dist-packages (from anyio<4,>=3.1.0->jupyter-server>=1.8->nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.3.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<4,>=3.1.0->jupyter-server>=1.8->nbclassic>=0.4.7->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (1.2.1)\n",
            "Requirement already satisfied: pycparser in /usr/local/lib/python3.10/dist-packages (from cffi>=1.0.1->argon2-cffi-bindings->argon2-cffi->notebook>=4.4.1->widgetsnbextension~=3.6.0->ipywidgets) (2.22)\n",
            "Installing collected packages: jedi\n",
            "Successfully installed jedi-0.19.1\n"
          ]
        }
      ],
      "source": [
        "#MODULE 3\n",
        "#installations for the model below\n",
        "!pip install transformers\n",
        "!pip install nltk\n",
        "!pip install openai\n",
        "!pip install ipywidgets\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "H714b28yvW_G",
        "outputId": "533c426e-bab5-4976-9fe8-e0216a6cf415"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Unzipping tokenizers/punkt.zip.\n"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "['from p. 6: [Amy Gruber, (410) 786-1542, or AmbulanceDataCollection@cms.hhs.gov, for issues \\nrelated to the Ambulance Fee Schedule (AFS) and the Medicare Ground Ambulance Data \\nCollection System.]', 'from p. 6: [Mary Rossi-Coajou (410) 786-6051, for issues related to hospice Conditions of \\nParticipation.]', 'from p. 6: [Cameron Ingram (410) 409-8023 for issues related to Histopathology, Cytology, and \\nClinical Cytogenetics Regulations under CLIA of 1988.]', 'from p. 6: [Meg Barry (410)786-1536, for issues related to the Basic Health Program (BHP) \\nprovisions.]', 'from p. 6: [Renee ONeill, (410) 786-8821, or Sophia Sugumar, (410) 786-1648, for inquiries related \\nto Merit-based Incentive Payment System (MIPS).]']\n"
          ]
        }
      ],
      "source": [
        "#MODULE 4: Separate Document into Sentences with Page Information and then add the Topic\n",
        "import nltk\n",
        "nltk.download('punkt')\n",
        "from nltk.tokenize import sent_tokenize\n",
        "\n",
        "sentences_with_pages = []\n",
        "page_number = 1\n",
        "\n",
        "for page_content in segments:\n",
        "    page_sentences = sent_tokenize(page_content)\n",
        "    for sentence in page_sentences:\n",
        "        sentences_with_pages.append(f\"from p. {page_number}: [{sentence}]\")\n",
        "    page_number += 1\n",
        "\n",
        "print(sentences_with_pages[50:55])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "Y7T2YMicfbYS",
        "outputId": "8afd3b8e-8bb3-40f3-aea5-65de1142b635"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"merged_df_Topic_text_combined\",\n  \"rows\": 33,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Topic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 33,\n        \"samples\": [\n          \"7E_Other Provisions in the Regulation\",\n          \"3F_OUD OTP Coverage\",\n          \"3Q_Changes to the Basic Health Program Regulations\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sort_seq\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39.02762230818453,\n        \"min\": 1.0,\n        \"max\": 133.0,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          129.0,\n          104.0,\n          120.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 33,\n        \"samples\": [\n          \"Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [E.  Other Provisions of the Regulation \\n1.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Impact of Proposals for Medicare Parts A and B Payment for Dental Services Inextricably \\nLinked to Specific Covered Medical Services \\nIn section II.K.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [of this proposed rule, we are: (1) proposing to allow payment for dental \\nexaminations, diagnostic, and treatment services prior to and during certain treatments for cancer \\n(chemotherapy and CAR-T cell therapy); (2) proposing to allow payment for dental \\nexaminations, diagnostic, and treatment services prior to and during antiresorptive and/or \\nantiangiogenic drug therapy associated with the treatment for cancer; and (3) requesting \\ncomments on other types of cardiovascular interventions (analogous to cardiac valve \\nreplacements and valvuloplasty procedures) where dental services may be inextricably linked to, \\nand substantially related and integral to the clinical success of, other cardiovascular covered \\nmedical services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [If we were to finalize the proposal that Medicare Part A and Part B payment can be made \\nfor oral or dental examination, and necessary treatment, performed prior to and during certain \\ncancer treatments or drug therapies associated with managing cancer related care, we do not \\nanticipate any significant increase in utilization or payment impact for additional dental services \\ngiven the historically low utilization of these therapies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Although, we acknowledge that the \\nobserved utilization of these services might have been low because of the size of the population \\nof patients whose treatment would include such dental services and also because the dental \\nservices have been viewed as subject to the payment preclusion under section 1862(a)(12).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Based on an analysis of 2018-2022 incurred claims experience, we estimate that there are \\npotentially 155,000 additional beneficiaries who might receive dental services for which \\nMedicare payment could be made, relative to the current number of beneficiaries that received \\ndental services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [These are beneficiaries who would receive any of the treatments identified in our \\nproposals for CY 2024 (that is, chemotherapy/CAR T/bone-modifying agent therapies used in \\nthe treatment of cancer) who would likely require dental services, and could utilize dental]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [services for which services Medicare could pay in CY 2024, if these proposals are finalized.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [The \\nestimated average cost for these additional dental services is about $525 per person.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [This \\nassumption is based on an analysis of 2019 incurred claims, but we believe results using more \\nrecent data would not be likely to change, due to the limited claims involving these services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Based on this same analysis, the effective rate of coverage was less than 0.2 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We do \\nacknowledge that the actual take-up rate of services could be higher due to the proposed \\nadditional examples of medical services to which dental services are inextricably linked, which \\nmay raise awareness that payment is available.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Therefore, we prepared impact estimates under \\nthe utilization assumptions of 0.2 percent and between 1-3 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We then applied these \\nutilization ratios to estimate projected payments for dental exams and treatments in connection \\nwith cancer therapies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We found that the estimated yearly impact beginning in CY 2024 to be \\nroughly $162,000 per year with a 0.2 percent utilization assumption, and roughly $800,000 to 2 \\nmillion per year for the utilization assumptions of 1-3 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Therefore, we do not anticipate a \\nsignificant payment impact for these provisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We note, however, that if we were to finalize, as \\ndiscussed in section II.K.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [of this proposed rule, payment in other clinical scenarios for dental \\nservices inextricably linked to, and substantially related and integral to the clinical success of, \\ncertain covered medical services, we may adjust this estimate for the final rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We continue to believe that because we are updating existing Medicare payment policies \\nby proposing additional examples of clinical scenarios where dental services are inextricably \\nlinked to covered medical services, as stated in the CY 2023 PFS final rule, it is not appropriate \\nto incorporate these budget neutrality adjustments into the conversion factor.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Additionally, while \\nthe impact of access to these services to some individuals enrolled in Medicare could be very \\nsignificant, we do not anticipate a significant impact in the context of overall spending and \\nutilization under the PFS nor do we anticipate significant utilization and spending impact of \\nthese policies finalized in section II.K.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We acknowledge that the actual take-up rate of services could be higher than the \\nutilization assumptions included within our current estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We continue to be open to \\nupdating and conducting further impact analysis once we have additional data and input from \\ninterested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [Impact of Proposal to Implement Separate Payment for the Office/Outpatient (O/O) E/M Visit \\nInherent Complexity Add-on Code (HCPCS G2211)\\nIn recent years, the AMA\\u2019s CPT Editorial Committee has restructured the E/M visit code \\nsets largely to acknowledge changes in medical practice.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [The AMA RUC has reviewed and \\nprovided us recommendations for the revised E/M visit code sets in the context of the generally \\nrecognized need to better recognize resources involved in furnishing different types of services \\nwithin the broader PFS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [While we adopted the RUC-recommended values for the O/O E/M visit \\ncode family in the CY 2021 final rule, recognizing that those values generally reflect the \\nresources involved in furnishing those services, we did not believe those valuations appropriately \\nreflected the resource costs involved in furnishing primary and other similarly longitudinal \\nmedical care for a serious or complex condition in office settings.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [To address this concern, \\neffective beginning in CY 2021, we finalized an add-on code to separately pay for visit \\ncomplexity inherent to O/O E/M visits for primary care and other medical care services that are \\npart of ongoing care related to a patient's single, serious, or complex condition in the office \\nsetting (the O/O E/M visit inherent complexity add-on).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [After we finalized the CY 2021 \\npayment changes for O/O E/M visits, in the CAA of 2021, Congress imposed a statutory \\nmoratorium on Medicare payment for the O/O E/M visit inherent complexity add-on code until \\nJanuary 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We propose to implement payment for the O/O E/M visit inherent complexity add-on, \\nHCPCS code G2211, with significant refinements to target improved payment for primary and \\nother similar longitudinal care for serious or complex conditions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [Specifically, we are proposing \\nthat the O/O E/M visit complexity add-on code cannot be billed with visits reported using]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Modifier 25 which is used to indicate that the service is billed on the same day as a minor \\nprocedure or another E/M visit.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [(Previously, in the CY 2021 final rule, we stated we would not \\nexpect such billing; but as there was no explicit prohibition, these visits were included in the \\nbudget neutrality adjustment (85 FR 84572)).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [We also propose to set PFS rates with a refined, \\nmore specific utilization assumption that better recognizes likely uptake of the code, differential \\nuse among specialties, and new and established patient visits, among other changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [These \\nrefined assumptions were developed, taking into consideration perspectives and information \\nprovided by interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [The resulting estimate reflects that the O/O E/M visit inherent \\ncomplexity add-on code would likely be reported with approximately 38 percent of all O/O E/M \\nvisits for CY 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [As discussed previously and shown below, we estimate the specific portion \\nof the total budget neutrality adjustment attributable to the proposal to make payment for the \\nO/O E/M inherent complexity add-on code to be approximately 2.00 percent compared to an \\nattributable budget neutrality adjustment of 3.20 percent as calculated in CY 2021 rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Advancing Access to Behavioral Health \\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Impact of Proposed Payment for Marriage and Family Therapist (MFT) Services and Mental \\nHealth Counselor (MHC) Services \\nAs discussed in section II.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [of this proposed rule, section 4121 of CAA, 2023 added \\nsection 1861(s)(2)(II) to establish a new Medicare benefit category for MFT services and MHC \\nservices furnished and billed by MFTs and MHCs, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [MFT and MHC services are \\ndefined in section 1861(lll)(2) and 1861(lll)(4), respectively, as services for the diagnosis and \\ntreatment of mental illnesses (other than services furnished to an inpatient of a hospital).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [An \\nMFT or MHC is defined as an individual who possesses a master\\u2019s or doctor\\u2019s degree, is \\nlicensed or certified by the State in which they furnish services, who has performed at least 2 \\nyears of clinical supervised experience, and meets other requirements as the Secretary \\ndetermines appropriate.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Section 1833(a)(1)(FF) of the statute requires that MFT and MHC \\nservices be paid at 75 percent of the amount determined for payment of a clinical psychologist.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [MFT and MHC services are excluded from consolidated billing requirements under the skilled \\nnursing facility prospective payment system.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Services furnished by an MFT and MHC are \\ncovered when furnished in a rural health clinic and federally qualified health center.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In addition, \\nthe hospice interdisciplinary team is required to include at least one social worker, MFT or \\nMHC.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Expenditures associated with payment for services furnished by MFTs and MHCs in CY \\n2024 will be incorporated into budget neutrality for PFS ratesetting in future years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Drugs and Biological Products Paid Under Medicare Part B \\nSection 90004 of the Infrastructure Investment and Jobs Act (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [L. 117-9, November \\n15, 2021) amended section 1847A of the Act to require manufacturers to provide a refund to \\nCMS for certain discarded amounts from a refundable single-dose container or single-use \\npackage drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [The refund amount is either as noted in section 1847A(b)(1)(B) of the Act in the \\ncase of a single source drug or biological or as noted in section 1847A(b)(1)(C) of the Act in the \\ncase of a biosimilar biological product, multiplied by the amount of discarded drug that exceeds \\nan applicable percentage, which is required to be at least 10 percent, of total charges (subject to \\ncertain exclusions) for the drug in a given calendar quarter.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In the CY 2023 final rule, we \\nfinalized several policies to implement the provision, including: reporting requirements for the \\nJW and JZ modifiers; the date upon which we will begin to edit claims for appropriate use of the \\nJW and JZ modifiers, October 1, 2023; the definition of \\u201crefundable single-dose container or \\nsingle-use package drug\\u201d; the manner in which refund amounts will be calculated; the annual \\nbasis we will send reports to manufacturers; the dispute resolution process; and enforcement \\nprovisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In section III.A of this proposed rule, we are proposing the date of the initial report to \\nmanufacturers, the date for subsequent reports, method of calculation when there are multiple \\nmanufacturers for a refundable drug, increased applicable percentages for drugs with unique \\ncircumstances, and a future application process by which manufacturers may apply for an \\nincreased applicable percentage for a drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [For this proposed rule, we reanalyzed JW modifier data from 2021 as if the data \\nrepresented dates of service on or after the effective date of section 90004 of the Infrastructure \\nAct (that is, January 1, 2023).368 That is, to assess if there was a change in the status of the billing \\nand payment codes that were identified in the proposed rule as met the definition of refundable \\nsingle-dose container or single-use package drug and have 10 percent or more discarded units, \\nexcept for five drugs with higher applicable percentages finalized in the CY 2023 final rule or as \\nproposed under this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Overall in the 2021 calendar year, Medicare paid nearly $1.56 billion for discarded \\namounts of drugs from a single-dose container or single-use package paid under Part B.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [In that \\nyear, there were 51 billing and payment codes with 10 percent or more discarded units based on \\nJW modifier data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Of these, 11 did not meet the definition of refundable single-dose container or \\nsingle-use package drug in section 1847A(h)(8) of the Act because they are multiple source drug \\ncodes; 5 were excluded from the definition of refundable single-dose container or single-use \\npackage drug (as specified in section 1847A(h)(8)(B) of the Act) because they are identified as \\nradiopharmaceuticals or imaging agents in FDA-approved labeling; and 3 are products referred \\nto as skin substitutes, which were removed because we anticipate making changes to coding and \\npayment policies regarding those products in future rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [After these exclusions, there \\nwere 31 billing and payment codes that met the definition of refundable single-dose container or \\nsingle-use package drug and have discarded units above the relevant finalized applicable \\npercentage.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Of these, three have discarded units that would fall below increased applicable \\npercentages proposed in this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [We estimated refund amounts as described in section 1847A(h)(3) of the Act were \\ncalculated based on this data by subtracting the percent units discarded by 10 percent (the \\napplicable percentage), except for drugs with higher applicable percentages finalized in the CY \\n368 https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-\\npart-b-discarded-drug-units.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [2023 final rule or as proposed under this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [Then, we multiplied the appropriate \\npercentage by the CY 2021 total allowed amount to estimate the annual refund for a given billing \\nand payment code.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [The quarterly refund was estimated by dividing the annual estimate by 4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [Based on this data, there would be approximately $83.1 million in refunds due from \\nmanufacturers for the calendar year of 2021 ($20.8 million each calendar quarter).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [See Table \\n108.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1227: [TABLE 108:  Estimated Refund Amounts Based on CY 2021 JW Modifier Data369\\nHCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nQ9965 $2,276,001.01 67.41% Y; Radiopharm \\nor imaging agent10%\\nJ7342 $4,559.95 53.26% N 10% 43.26% $1,972.63 $493.16 \\nJ9281 $26,703,749.86 37.60% N 35% 2.60% $694,297.50 $173,574.37 \\nJ9262 $220,987.21 30.98% N 26% (proposed) 4.98% $11,005.16 $2,751.29\\nJ9043 $146,745,385.39 29.11% N 10% 19.11% $28,043,043.15 $7,010,760.79 \\nJ9041 $380,429,509.43 27.00% Y; multiple \\nsource10%\\nJ9351 $475,677.64 26.37% Y; multiple \\nsource10%\\nQ9961 $19,366.66 26.28% Y; Radiopharm \\nor imaging agent10%\\nJ0894 $17,872,985.28 24.16% Y; multiple \\nsource10%\\nJ9044 $4,616,507.83 21.91% N; see new single \\nsource codes \\nJ9046, J9048, \\nJ904910% 11.91% $549,826.08 $137,456.52 \\nJ9025 $37,997,710.06 21.83% Y; multiple \\nsource10%\\nJ9017 $1,733,222.58 21.25% Y; multiple \\nsource10%\\nJ1448 $1,739,523.98 20.85% N 10% 10.85% $188,738.35 $47,184.59 \\nJ0775 $68,490,974.85 20.83% N 45% proposed \\nJ9065 $451,404.96 20.26% Y; multiple \\nsource10%\\nJ9223 $90,785,710.74 20.25% N 10% 10.25% $9,305,535.35 $2,326,383.84 \\nJ0565 $3,928,811.98 19.53% N 10% 9.53% $374,415.78 $93,603.95 \\nJ9178 $9,922.54 18.95% Y; multiple \\nsource10%\\n369 https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-b-discarded-drug-units.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1228: [HCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nJ9229 $17,911,595.08 18.21% N 10% 8.21% $1,470,541.96 $367,635.49 \\nJ0223 $10,731,531.69 17.00% N 26% (proposed)\\nQ9966 $2,230,516.82 16.89% Y; Radiopharm \\nor imaging agent10%\\nJ1640 $8,405,837.59 15.52% Y; filtered 10%\\nJ9153 $5,526,153.53 15.00% N 10% 5.00% $276,307.68 $69,076.92 \\nJ2425 $124,548.01 14.07% N 10% 4.07% $5,069.10 $1,267.28 \\nJ9027 $62,602.70 13.98% Y; multiple \\nsource10%\\nJ9264 $347,464,875.59 13.86% N 10% 3.86% $13,412,144.20 $3,353,036.05 \\nJ2796 $257,348,654.37 13.60% N 10% 3.60% $9,264,551.56 $2,316,137.89 \\nQ9956 $737,908.86 13.03% Y; Radiopharm \\nor imaging agent10%\\nJ0515 $16,911.88 12.88% Y; multiple \\nsource10%\\nJ2562 $18,752,340.26 12.81% N 10% 2.81% $526,940.76 $131,735.19 \\nJ9179 $43,581,966.38 12.71% N 10% 2.71% $1,181,071.29 $295,267.82 \\nJ9307 $22,805,063.36 12.65% N 10% 2.65% $604,334.18 $151,083.54 \\nJ9037 $33,082,159.80 12.10% N 10% 2.10% $694,725.36 $173,681.34 \\nJ3396 $2,537,428.32 11.93% N 10% 1.93% $48,972.37 $12,243.09 \\nJ9042 $169,482,924.33 11.89% N 10% 1.89% $3,203,227.27 $800,806.82 \\nJ9319 $6,572,808.69 11.78% Y; multiple \\nsource10%\\nQ9950 $516,142.11 11.77% Y; Radiopharm \\nor imaging agent10%\\nJ0485 $76,861,131.89 11.61% N 10% 1.61% $1,237,464.22 $309,366.06 \\nJ9205 $59,413,621.44 11.55% N 10% 1.55% $920,911.13 $230,227.78 \\nJ9228 $417,946,062.94 11.40% N 10% 1.40% $5,851,244.88 $1,462,811.22 \\nJ3241 $306,975,463.35 11.32% N 10% 1.32% $4,052,076.12 $1,013,019.03 \\nJ2997 $66,254,826.34 11.31% N 10% 1.31% $867,938.23 $216,984.56]] Topic: 7E_Other Provisions in the Regulation: [from p. 1229: [HCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nJ3300 $8,964,090.01 10.97% N 90% proposed\\nJ0122 $144,528.76 10.84% N 10% 0.84% $1,214.04 $303.51 \\nJ3101 $12,921,647.56 10.67% N 10% 0.67% $86,575.04 $21,643.76 \\nJ9315 $23,154,637.13 10.33% Y; multiple \\nsource10%\\nJ9269 $7,755,186.19 10.15% N 26% proposed \\nJ9352 $9,225,195.63 10.10% N 10% 0.10% $9,225.20 $2,306.30 \\nQ4121 $6,484,123.19 17.85% Y; skin substitute\\n(proposed)10% 7.85%\\nQ4106 $1,511,046.28 16.64% Y; skin substitute\\n(proposed)10% 6.64%\\nQ4101 $2,176,035.02 14.58% Y; skin substitute\\n(proposed)10% 4.58%\\nTOTAL $82,883,368.59 $20,720,842.15]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [There are several limitations to this analysis that could substantially affect the total \\nquarterly refund.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Since new drugs are continually being approved, this estimate does not \\nconsider newer drugs that will meet the definition of refundable single-dose container or single-\\nuse package drug on or after the effective date of January 1, 2023.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Since section \\n1847A(h)(8)(B)(iii) of the Act excludes drugs approved by FDA on or after November 15, 2021 \\nand for which payment has been made under Part B for fewer than 18 months from this \\ndefinition, we expect an impact on refund amounts after the 18-month exclusion has ended if the \\ndrug otherwise meets the definition.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [We also note that this estimate is based on CY 2021 data \\nfor discarded drug amounts, which, for reasons discussed in the CY 2023 final rule (87 FR \\n69716), we believe to be an underestimate due to the frequent omission of the JW modifier.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Once \\nwe begin to edit claims for both the JW and JZ modifiers, reported discarded drug amounts will \\nlikely increase.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Other substantial changes to this estimate may occur if a billing and payment \\ncode no longer meets this definition.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [For example, if a generic version of one of these drugs is \\nmarketed, the billing and payment code will become a multiple source drug code and will no \\nlonger meet the definition of refundable single-dose container or single-use package drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Subsequently, the manufacturers will not be responsible for refunds under this provision.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [There \\nmay be changes in the percent discarded units for a given refundable single-dose container or \\nsingle-use package drug if the manufacturer introduces additional vial sizes or modifies the vial \\nsize to reduce the amount discarded.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Lastly, since data from the CMS website only includes \\nbilling and payment codes on the ASP drug pricing file370 and implementation of section 90004 \\nof the Infrastructure Act is not restricted to billing and payment codes included on the file, there \\nmay be other applicable data that was not assessed as part of this estimate.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [a. Impacts Related to the Issuance of the Initial Report\\nIn section III.A.3.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [of this proposed rule, we propose to issue the initial refund report to \\nmanufacturers, to include all calendar quarters for 2023, no later than December 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [370 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Accordingly, as discussed in section III.A.3.c., we propose to require that the refund amounts \\nspecified in the initial refund report be paid no later than February 28, 2025, except in \\ncircumstances where a report is under dispute.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Delaying the receipt of the rebate, that is in 2025 instead of 2024, only represents a cost \\nto the extent the SMI trust fund receives less interest revenue.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Only a portion of SMI trust fund \\nrevenue ends up invested in the bond portfolio.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Based on current SMI trust fund operation \\npatterns a delay in rebate collection as described in the rule would represent a cost less than $2 \\nmillion dollars in any given year and therefore would be negligible to SMI trust fund operations.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [b. Impacts Related to the Application for Consideration \\nAs described in section VII.B.1.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [of this proposed rule, the information collection \\nrequirements, we estimate the annual burden per applicant to be 5 hours.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [If we anticipate no \\nmore than 25 applications per year, the total annual drafting and submitting burden would be 125 \\nhours (25 applications per year x 5 hours per applicant).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [We estimate an annual cost of this \\nburden to be $4,937.50 ($39.50/hour x 125 hours).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs)\\nIn section III.B.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [of this proposed rule, we are proposing to include Remote Patient \\nMonitoring (RPM) and Remote Therapeutic Monitoring (RTM) services, and the proposed  \\nCommunity Health Integration (CHI) and Principal Illness Navigation (PIN) services if finalized, \\nin the general care management HCPCS code G0511 when these services are provided by RHCs \\nand FQHCs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Due to the growing number of services in the code, we are also proposing to revise \\nthe calculation for G0511 to include the weighted average of these services based on utilization \\nunder the PFS as this may provide a more complete and accurate payment amount.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [In terms of estimated impacts to the Medicare program, expanding use of General Care \\nManagement HCPCS code G0511 to include RPM, RTM, CHI, and PIN may result in an \\nincrease in spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Prior updates to G0511 have resulted in negligible increases.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [6.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [RHC and FQHC CfC changes: Permitting MFTs and MHCs to furnish services]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Section 4121 of the CAA, 2023 amends section 1861(aa)(1)(B) of the Act by adding \\nMFTs and MHCs as eligible practitioners of RHCs and FQHCs beginning January 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We \\nare proposing regulation text changes to permit MFT and MHCs to provide services furnished at \\nRHCs and FQHCs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [These changes would include MFTs and MHCs as members of the staff who \\nmay be the owner or an employee of the clinic or center, or furnish services under contract to the \\nclinic or center.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Along with other permitted physicians and nonphysician practitioners, MFT and \\nMHCs may be available to furnish patient care services at all times the clinic or center operates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [At \\u00a7 491.9(b)(3) RHCs and FQHCs must have patient care policies that include: (1) a \\ndescription of the services the clinic or center furnishes directly or through agreement or \\narrangement; (2) guidelines for medical management of health problems; and (3) rules for \\nstorage, handling, and administration of drugs and biologicals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Additionally, \\u00a7 491.9(b)(4) states \\nthat the RHC and FQHC patient policies must regularly be reviewed at least once every 2 years \\nby a group of professional personnel that includes one or more physicians, one or more physician \\nassistants (PAs) or nurse practitioners (NPs), and at least one person who is not a member of the \\nclinic or center staff.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [If an RHC or FQHC provides services furnished by an MHC or MFT they \\nmust update their patient care policies with a description of the services they will provide.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [The most recently published collection of information for RHCs and FQHCs (OMB \\ncontrol number 0938-0334), estimates that an annual review of the patient care policies may take \\napproximately 2 hours.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Therefore, we assume, it would take each medical professional (at least \\none physician and at least one PA or NP) 1 hour to review all policies and procedures, annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Based on the prior analysis, we estimate it will take 15 minutes to add the description of MFT \\nand MHC services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We also assume that only half of the RHCs and half of the FQHCs would \\nhave this burden applied to them, for a total burden estimate of $361,891.05.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We note that there \\nwould be variations in how many clinics or centers employ or contract with an MFT and MHC \\nbased on their ability to expand their services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We also recognize that some RHCs and FQHCs \\nmay already provide these services as some States provide reimbursement under the Medicaid]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [program; however, we do not know the exact number of clinics or centers that already have these \\npractitioners on staff and would not incur the burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [While this proposed rule does have a 1-time burden, there is evidence to suggest there are \\nlong-term financial savings in integrating mental health in medical care.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [Effectively integrating \\nmental and medical care can save upwards of $52 billion annually due to the existing Medicare \\nmental health coverage gap.371 Though this total encompasses all facility types, expanding access \\nto MFT and MHC services in RHCs and FQHCs will have individual and societal cost savings.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [Older adults with mental health conditions have poorer health outcomes, higher hospitalization \\nrates, and emergency room visits.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [372 While there is an increasing need for mental health \\nservices, one barrier to effective treatment is access to mental health services.373  Ensuring access \\nto mental health care in rural communities is challenging as there are fewer mental health \\nproviders per capita in nonmetropolitan counties.374 This coincides with HRSA\\u2019s second quarter \\nof the fiscal year 2023 designated health professional shortage area (HPSA) quarterly summary, \\nwhich breaks down the number of HPSAs by primary medical care, dental, and mental health \\nHPSAs based on four categories (rural, non-rural, partial rural, and unknown); and as population \\nHPSAs, geographic HPSAs, or Facility HPSAs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [The report does not provide accumulative \\nHPSAs by the four categories.375 Approximately 65 percent of federally designated health \\nprofessional shortage areas are located in rural areas, and about 30 percent are located in non-\\nrural areas.376 The shortage of professionals in rural areas is severe, and the shortage of qualified \\nprofessionals in combination with geographic limitations only exacerbates the mental health \\n371 https://onlinelibrary.wiley.com/doi/full/10.1002/jcad.12409?casa_token=z412GCn3OuYAAAAA%3AHO3p-\\ncHeiVrLww0dZjTkIcuCbwMxvYtRUo4aj8AwB-tq2w_ZJV11gGpWW-oxilDK3awU0xIc2XKMnKhtAQ#jcad12409-\\nbib-0003.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [372 https://onlinelibrary.wiley.com/doi/full/10.1002/jcad.12409?casa_token=z412GCn3OuYAAAAA%3AHO3p-\\ncHeiVrLww0dZjTkIcuCbwMxvYtRUo4aj8AwB-tq2w_ZJV11gGpWW-oxilDK3awU0xIc2XKMnKhtAQ#jcad12409-\\nbib-0005.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [373 https://psycnet.apa.org/fulltext/2020-75725-002.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [374 https://psycnet.apa.org/record/2018-25164-007.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [375 https://data.hrsa.gov/topics/health-workforce/shortage-areas.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [376 https://data.hrsa.gov/Default/GenerateHPSAQuarterlyReport.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [crisis in older adults.377 While there are disparities in the availability of the behavioral workforce \\nbetween rural and nonrural areas, counselors are integral to providing care in rural areas.378  \\n7.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Clinical Laboratory Fee Schedule\\nIn section III.D of this proposed rule, we discuss statutory revisions to the data reporting \\nperiod and phase-in of payment reductions under the CLFS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In accordance with section 4114 of \\nthe CAA, 2023, we are proposing certain conforming changes to the data reporting and payment \\nrequirements in our regulations at 42 CFR part 414, subpart G.  Specifically, for CDLTs that are \\nnot ADLTs, we are proposing to update certain definitions and revise \\u00a7 414.504(a)(1) to indicate \\nthat initially, data reporting begins January 1, 2017, and is required every 3 years beginning \\nJanuary 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [The CAA, 2023 delays the next data reporting period under the CLFS for CDLTs \\nthat are not ADLTs by 1 year, that is, it requires the next data reporting period for these tests to \\ntake place during the period of January 1, 2024 through March 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Subsequently, the next \\nprivate payor rate-based CLFS update for these tests will be effective January 1, 2025, instead of \\nJanuary 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In addition, we are proposing to make conforming changes to our requirements \\nfor the phase-in of payment reductions to reflect the CAA, 2023 amendments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Specifically, we \\nare proposing to revise \\u00a7 414.507(d) to indicate that for CY 2023, payment may not be reduced \\nby more than 0.0 percent as compared to the amount established for CY 2022, and for CYs 2024 \\nthrough 2026, payment may not be reduced by more than 15 percent as compared to the amount \\nestablished for the preceding year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [We recognize that private payor rates for CDLTs paid on the CLFS and the volumes paid \\nat each rate for each test, which are used to determine the weighted medians of private payor \\nrates for the CLFS payment rates, have changed since the first data collection period (January 1, \\n2016 through June 30, 2016) and data reporting period (January 1, 2017 through March 31, \\n2017).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In addition, as discussed in section III.D.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [of this proposed rule, in the CY 2019 PFS final \\n377 https://psycnet.apa.org/fulltext/2020-75725-002.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [378 chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://depts.washington.edu/fammed/rhrc/wp-\\ncontent/uploads/sites/4/2016/09/RHRC_DB160_Larson.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [rule (83 FR 59671 through 59676), we amended the definition of applicable laboratory to include \\nhospital outreach laboratories that bill Medicare Part B using the CMS-1450 14x Type of Bill.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [As such, the CAA, 2023 amendments to the data reporting period will delay using updated \\nprivate payor rate data to set revised CLFS payment rates for CDLTs that are not ADLTs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Due to unforeseen changes in private payor rates due to shifts in market-based pricing for \\nlaboratory tests and the unpredictable nature of test volumes and their impact on calculating \\nupdated CLFS payment rates based on the weighted median of private payor rates, it is uncertain \\nwhether the delay in data reporting will result in a measurable budgetary impact.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [In other words, \\nto assess the impact of delayed reporting and subsequent implementation of updated CLFS rates, \\nwe will need to calculate weighted medians of private payor rates based on new data and \\ncompare the revised rates to the current rates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [As such, we believe that we will only know the \\nimpact of the delay in data reporting after collecting actual updated applicable information from \\napplicable laboratories, and calculating the updated CLFS rates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Regarding the conforming changes to our requirements for the phase-in of payment \\nreductions that we are proposing in this rule, we note that for CYs 2024 through 2026, payment \\nmay not be reduced by more than 15 percent as compared to the amount established for the \\npreceding year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Based on data reported in the 2017 data collection period, we estimate 14.8 \\npercent (191) of tests on the CLFS may be subject to the full 15 percent phase-in reduction in CY \\n2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [8.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Pulmonary Rehabilitation (PR), Cardiac Rehabilitation (CR) and Intensive Cardiac \\nRehabilitation (ICR) Expansion of Supervising Practitioners\\nAs discussed in section III.E.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [of this proposed rule, we are proposing revisions to \\n\\u00a7\\u00a7 410.47 (PR) and 410.49 (CR/ICR) to codify the statutory changes made in section 51008 of \\nthe Bipartisan Budget Act of 2018 (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [L. 115-123, enacted February 9, 2018) (BBA of 2018) \\nwhich permit other specific types of practitioners to supervise these services effective January 1, \\n2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [The amendments add to the types of practitioners who may supervise PR, CR and ICR]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [programs to also include a physician assistant (PA), nurse practitioner (NP) or clinical nurse \\nspecialist (CNS).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Accordingly, we are proposing additions and revisions to the PR and CR/ICR \\nregulations to reflect these statutory amendments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [To assess the potential impact from expanding the types of practitioners that may \\nsupervise PR/CR/ICR we searched the literature for articles that evaluated the utilization rates of \\nPR, CR and ICR to determine the historical utilization trends of these services as well as known \\nbarriers to utilization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Based on historical utilization trends as well as barriers to utilization \\ndiscussed in the literature, we do not expect the proposed changes to make a significant impact \\non the Medicare program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Nishi et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [(2016) investigated the number of Medicare beneficiaries with COPD who \\nreceived PR from January 1, 2003, to December 31, 2012.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Their results included both individuals \\nwho had experienced hospitalizations for COPD and those who were outpatients only.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [The \\nnumber of unique patients with COPD who initially participated in PR during the study period \\nwas 2.6 percent in 2003 (before conditions of coverage at \\u00a7 410.47 were established) and 2.88 \\npercent in 2012 (after conditions of coverage at \\u00a7 410.47 were established).379  In 2019, Spitzer, \\net al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [published an article based on Medicare claims data from 2012, finding that 2.7 percent of \\neligible Medicare beneficiaries received PR within 12 months of hospitalization with COPD.380  \\nUsing claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, \\nLindenauer et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [(2020) reported that only 3 percent initiated PR within 1 year of their hospital \\ndischarge.381 Taken together, this data informs us that utilization of PR in the Medicare \\npopulation is very low.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [379 Nishi SP, Zhang W, Kuo YF, Sharma G. Pulmonary Rehabilitation Utilization in Older Adults With Chronic \\nObstructive Pulmonary Disease, 2003 to 2012.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2016;36(5):375-382. \\ndoi:10.1097/HCR.0000000000000194.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [380 Spitzer KA, Stefan MS, Priya A, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Participation in pulmonary rehabilitation after hospitalization for chronic \\nobstructive pulmonary disease among Medicare beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Ann Am Thorac Soc.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2019;16:99-106.DOI: \\n10.1513/AnnalsATS.201805-332OC.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [PMID: 30417670; PMCID: PMC6344454.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [381 Lindenauer PK, Stefan MS, Pekow PS, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Association Between Initiation of Pulmonary Rehabilitation After \\nHospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [JAMA.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2020;323(18):1813\\u20131823.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [doi:10.1001/jama.2020.4437.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Million Hearts\\u00ae 2027, a national initiative co-led by the Centers for Disease Control and \\nPrevention (CDC) and CMS to prevent 1 million preventable cardiovascular disease (CVD) \\nevents in the next 5 years382, includes a goal of increasing use of CR and states that CR \\nparticipation rates remain low, ranging from 19 percent to 34 percent.383  Fleg and colleagues \\n(2020) report that less than 25 percent \\u201cof eligible patients participate in CR\\u201d with a smaller \\nproportion completing 36 sessions as recommended.384  In their 2022 article, Varghese and \\ncolleagues state that less than 30 percent of eligible patients participate in CR in the United \\nStates.385 Husaini and colleagues (2022) analyzed a sample of Medicare fee-for-service claims \\nbetween 2012 and 2016 and reported that within 1 year of a qualifying event, 16 percent of \\npatients completed one or more CR session and 0.1 percent of patients completed one or more \\nICR sessions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [They observed an increase of combined CR and ICR utilization from 14 percent \\n(patients with qualifying events in 2012) to 18 percent (patients with qualifying events in \\n2015).386 Taken together, this data informs us that utilization of CR and ICR is low, although not \\nas low as PR.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Underutilization of PR, CR and ICR has been attributed to numerous factors as described \\nby Fleg et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [\\u201cincluding a lack of referral or strong recommendation from a physician and \\ninadequate follow-up or facilitation of enrollment after referral.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Financial issues such as limited \\nor absent health insurance coverage and the inability to afford copayments, even when insured, \\nalso limit CR/PR participation as do conflicting work and home responsibilities and distance and\\n382 https://millionhearts.hhs.gov/about-million-hearts/index.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [383 https://millionhearts.hhs.gov/about-million-hearts/optimizing-care/cardiac-rehabilitation.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [384 Fleg JL, Keteyian SJ, Peterson PN, Benzo R, Finkelstein J, Forman DE, Gaalema DE, Cooper LS, Punturieri A, \\nJoseph L, Shero S, Zieman S. Increasing Use of Cardiac and Pulmonary Rehabilitation in Traditional and \\nCommunity Settings: OPPORTUNITIES TO REDUCE HEALTH CARE DISPARITIES.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [J Cardiopulm Rehabil.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2020 Nov;40 (6):350-355. doi: 10.1097/HCR.0000000000000527.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [PMID: 33074849; PMCID: PMC7644593.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [385 Varghese MS, Beatty AL, Song Y, et al., Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Circ Cardiovasc \\nQual Outcomes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2022;15:e009618.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [DOI: 10.1161/CIRCOUTCOMES.122.009618.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [386 Husaini M, Deych E, Racette SB, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Intensive Cardiac Rehabilitation Is Markedly Underutilized by Medicare \\nBeneficiaries: RESULTS FROM A 2012-2016 NATIONAL SAMPLE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2022 May \\n1;42(3):156-162. doi: 10.1097/HCR.0000000000000632.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Epub 2021 Sep 9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [PMID: 34508035.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [transportation difficulties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Social and cultural factors, including the lack of gender and racial \\ndiversity among CR/PR staff, language and cultural barriers, and lack of program availability \\nand access are additional challenges\\u2026 Many eligible patients are also commonly perceived as \\ntoo frail...\\u201d387 Husaini et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [(2022) reinforce the impact of similar factors in CR underuse.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [They \\ncite \\u201clower reimbursements relative to cost and variability in access\\u201d, physician \\u201cskepticism over \\nbenefit and a primary emphasis on cardiac medications and procedures\\u201d, and patient \\u201creluctance \\nor inability to commit 3-6 hr/wk for 8-12 wk to CR, logistical (transportation, work, etc) or \\nfinancial impediments, a preference for exercise/rehabilitation at home, fear of failure, and \\nphysical limitations.\\u201d388  \\nWhile the expansion of supervision requirements to include nonphysician practitioners \\ncould offer greater flexibility for PR and CR programs to operate, the barriers to utilization as \\ndescribed by Fleg and colleagues (2020) and Husiani and colleagues (2022) are widespread and \\ncomplex and low participation in PR, CR and ICR has remained steady for many years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [We do \\nnot believe the expansion of supervising practitioners is likely to address these barriers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Therefore, we do not anticipate any significant increase in utilization of PR, CR and ICR \\nservices and subsequent impact to the Medicare program or interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Modifications Related to Medicare Coverage for Opioid Use Disorder (OUD) Treatment \\nServices Furnished by Opioid Treatment Programs (OTPs)\\nAs discussed in section III.F.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [of this proposed rule, we are proposing allowing periodic \\nassessments to be furnished via audio-only communication when two-way audio-video \\ncommunications technology is not available to the beneficiary through the end of CY 2024, to \\n387 Fleg JL, Keteyian SJ, Peterson PN, Benzo R, Finkelstein J, Forman DE, Gaalema DE, Cooper LS, Punturieri A, \\nJoseph L, Shero S, Zieman S. Increasing Use of Cardiac and Pulmonary Rehabilitation in Traditional and \\nCommunity Settings: OPPORTUNITIES TO REDUCE HEALTH CARE DISPARITIES.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [J Cardiopulm Rehabil.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [2020 Nov;40 (6):350-355. doi: 10.1097/HCR.0000000000000527.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [PMID: 33074849; PMCID: PMC7644593.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [388 Husaini M, Deych E, Racette SB, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Intensive Cardiac Rehabilitation Is Markedly Underutilized by Medicare \\nBeneficiaries: RESULTS FROM A 2012-2016 NATIONAL SAMPLE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [2022 May \\n1;42(3):156-162. doi: 10.1097/HCR.0000000000000632.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Epub 2021 Sep 9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [PMID: 34508035.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [the extent that it is authorized by SAMHSA and DEA at the time the service is furnished and all \\nother applicable requirements are met.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [We believe the Part B cost impact of this flexibility for the use of telecommunications \\nwill be minimal because we do not expect that these flexibilities will increase the frequency with \\nwhich medically necessary assessments are furnished.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [10.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [Medicare Shared Savings Program \\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [General Impacts\\nAs of January 1, 2023, 10.9 million Medicare beneficiaries receive care from a health \\ncare provider in one of the 456 ACOs participating in the Shared Savings Program, the largest \\nvalue-based care program in the country.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The Shared Savings Program proposed policies \\nadvance Medicare\\u2019s overall value-based care strategy of growth, alignment, and equity, with \\nmany proposals overlapping these categories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The proposed policies in this proposed rule are \\nincremental refinements to the broader changes finalized in the CY 2023 PFS final rule (87 FR \\n69777 through 69968).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [Those changes were designed to reverse recent trends where program \\nparticipation had plateaued, higher spending populations were increasingly underrepresented in \\nthe program since the change to regionally-adjusted benchmarks, and access to ACOs appeared \\ninequitable as evidenced by data indicating underserved populations are less likely to be assigned \\nto a Shared Savings Program ACO, and to encourage growth of ACOs in underserved \\ncommunities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The changes to the Shared Savings Program regulations finalized with the CY 2023 PFS \\nfinal rule were designed to increase program participation for new ACOs through the AIP option \\nintended to promote health equity, and provide ACOs greater choice in the pace of progression to \\nperformance-based risk; sustain program participation by reducing the effect of ACO \\nperformance on benchmark updates and benchmark rebasing; mitigate the bias in regional \\nexpenditure calculations that benefits ACOs electing prospective assignment; strengthen \\nincentives for ACOs serving high risk and high dual populations; improve the risk adjustment]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [methodology to better account for medically complex, high cost beneficiaries while continuing \\nto guard against coding initiatives; increase opportunities for low revenue ACOs in the BASIC \\ntrack to share in savings by allowing ACOs that do not meet the minimum savings rate (MSR) \\nrequirement to share in savings at a lower rate; encourage ACOs to transition more quickly to \\nall-payer quality measure reporting; update the ACO beneficiary assignment methodology; and \\nreduce administrative burden on ACOs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The proposed changes to Shared Savings Program \\npolicies in this proposed rule include modifications designed to further these goals in concert \\nwith implementation of certain changes finalized in the CY 2023 PFS final rule, which are \\napplicable for agreement periods beginning on January 1, 2024, and in subsequent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [On average, updated benchmarks would marginally increase as a result of the proposal to \\nmodify the calculation of the regional component of the blended update factor used to update the \\nhistorical benchmark between benchmark year (BY) 3 and the performance year (PY) by \\ncapping an ACO\\u2019s regional service area risk score growth through use of an adjustment factor to \\nprovide more equitable treatment for ACOs and for symmetry with the cap on ACO risk score \\ngrowth (section III.G.4.b of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [This change is expected to increase the regional \\nupdate factor amount in certain cases where an ACO may operate in a regional service area with \\nrapid change in the average prospective HCC risk score for the FFS assignable beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The current methodology for calculating the regional update factor risk adjusts \\ncounty-level FFS expenditures in an ACO\\u2019s regional service area by Medicare enrollment type \\nby dividing average county-level FFS expenditures for assignable beneficiaries in the county by \\nthe average prospective HCC risk score for both the performance year and BY3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The expenditure \\ngrowth between BY3 and the performance year calculated  using risk-adjusted regional \\nexpenditures could therefore be reduced by large increases in average prospective HCC risk \\nscores in the ACO\\u2019s regional service area that would only be partly offset by the increase in \\nprospective HCC risk score growth for the ACO\\u2019s assigned beneficiary population due to the cap \\non ACO assigned beneficiary prospective HCC risk score growth when updating the benchmark]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [between BY3 and the performance year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [The proposed adjustment, applicable for agreement \\nperiods beginning on January 1, 2024, and in subsequent years, would effectively strengthen the \\nregional portion of the three-way blended update factor and help to limit losses ACOs may face \\nwhen operating in regional service areas with high risk score growth and a beneficiary \\npopulation that becomes more medically complex between BY3 and the performance year, \\nincreasing incentives for ACOs to form or continue participation in such areas.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [By utilizing a \\nmarket share adjusted cap to account for ACO market share in the ACO\\u2019s regional service area, \\nthe proposed adjustment would still retain a disincentive against coding intensity for ACOs that \\nmay have a high market share in their region and consequently have greater influence on \\nregional service area risk score changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [For example, this feature of the proposal would help \\ndissuade such ACOs from attempting to artificially increase their benchmark by selectively \\nserving lower risk beneficiaries and increasing the intensity of diagnoses submitted for those \\nbeneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [Analyses described in the section III.G.4.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [(2) of this proposed rule, surrounding tables \\n33 and 34, provide the basis for estimating the impact for the proposal to cap regional service \\narea risk score growth.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [Analysis of average prospective HCC risk score changes at the Hospital \\nReferral Region (HRR) level over an extended 2007 to 2021 historical period consistently \\nindicated that risk score changes would be highly unlikely to exceed the proposed cap in the first \\ntwo years of an ACO\\u2019s agreement period but would increase somewhat as the 5-year agreement \\nperiod progresses.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [The analysis also notably showed that average prospective HCC risk score \\nvariation increased markedly in 2020 and 2021 with the COVID-19 PHE.389 The 11 percent of \\nACOs simulated to be impacted by the proposed adjustment in PY 2021 (a mix of ACOs with 2-\\nyear and 3-year gaps between their respective BY3 and the simulated PY 2021) is therefore \\n389 Public use data on Medicare Geographic Variation \\u2013 by Hospital Referral Region, used for this analysis, is \\navailable at https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-geographic-\\ncomparisons/medicare-geographic-variation-by-hospital-referral-region.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [anticipated to overstate variation expected in agreement periods that start on January 1, 2024 or \\nlater.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [Based on the simulation in the context of the longer-run HRR data, we project that \\nstarting in 2024 the proposed adjustment would impact less than 1 percent of ACOs in PY1 of an \\nagreement period, between 5 to 7 percent of ACOs by PY3, and up to 10 to 15 percent of ACOs \\nby PY5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The adjustment for ACOs that are simulated to be impacted is relatively small, \\nincreasing updated benchmarks by about 0.2 percent up to 0.4 percent on average by PY5, but \\nwith the potential for up to a net adjustment of about 1.5 percent in extreme scenarios.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The \\nestimated cost from additional shared savings payments resulting from these adjustments totals \\n$370 million over 10 years as shown in Table 109.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [TABLE 109:  Projected Impact of Proposed Adjustment Factor to Apply Risk Score Cap to \\nRegional Portion of Blended Update Factor Calculation ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 10 10 20 40 70 50 20 40 40 70 370\\nEstimate Range:            \\nLow Estimate 0 0 10 20 40 40 20 20 30 40 220\\nHigh Estimate 10 20 30 60 90 80 40 50 60 100 540\\nA material, albeit uncertain impact, is also estimated for the proposals to (a) use a rolling \\n3-year historical period instead of contemporary performance to calculate the 40th percentile of \\nthe MIPS Quality performance category scores starting in PY 2024 and (b) the proposal to use \\nthe higher of the ACO\\u2019s health equity adjusted quality performance score or the 40th percentile \\nMIPS Quality performance category score across all MIPS Quality performance scores if \\nmeasure suppression is required.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [It is likely that MIPS Quality performance will improve at least \\nmarginally over time and therefore the historical performance could produce a target that \\neffectively is lower than the contemporary 40th percentile stipulated at baseline.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The effective \\nreduction in the threshold when using the historical MIPS scores, combined with the \\u2018higher of\\u2019 \\nproposal when suppression is necessary, are assumed to effectively reduce the quality target by 0]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [to 5 percentage points (mode 1.5 percentage points), which would produce an estimated $110 \\nmillion in additional shared savings payments over 10 years, as shown in the Table 110.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [TABLE 110:  Projected Combined Impact of Quality Proposals to (a) Use Rolling 3-Year \\nHistorical Period to Calculate the 40th Percentile of the MIPS Quality Performance \\nCategory Scores and (b) Use the \\u2018Higher Of Value\\u2019 When Measures are Suppressed ($ \\nMillions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 0 10 10 10 10 10 10 10 20 20 110\\nEstimate Range:            \\nLow Estimate 0 0 0 0 0 0 0 0 0 0 0\\nHigh Estimate 0 30 30 30 40 40 30 40 40 40 320\\nThe impact is also estimated to be material for the proposal to mitigate the impact of the \\nnegative regional adjustment on the benchmark.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [In the CY 2023 PFS final rule, CMS finalized \\nchanges applicable for agreement periods beginning on January 1, 2024, and in subsequent years, \\nthat would reduce the cap on negative regional adjustments from 5 percent to 1.5 percent and \\nprovide an offset factor to gradually decrease the negative regional adjustment amount as an \\nACO\\u2019s proportion of dually eligible Medicare and Medicaid beneficiaries increases or its \\nweighted average prospective HCC risk score increases, or both.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [Removing the regional \\nadjustment entirely, when the ACO\\u2019s regional adjustment amount (expressed as a single per \\ncapita value) is negative, would incrementally increase benchmarks for higher spending ACOs \\n(increasing shared savings payments) but would also improve the incentive for higher spending \\nACOs to join the Shared Savings Program and drive down unnecessary spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [For a high cost \\nestimate we conservatively assume no new participation is generated in response to this change \\nand estimate the higher benchmarks would generate about $1.8 billion in additional shared \\nsavings payments partly offset by about $1.6 billion in reduced spending in response to improved \\nincentives.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [For a mean estimate we additionally assume 10 percent growth in participation from]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [new high spending ACOs leading to about $490 million net savings over 10 years.390 For a low \\ncost estimate we instead assume 20 percent growth in participation from high spending ACOs \\nleading to about $1.2 billion in net savings over 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Table 111 shows these estimates over \\nthe 2024-2033 window.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [TABLE 111:  Projected Impact of Proposal to Mitigate the Impact of Negative Regional \\nAdjustment on Benchmarks ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 0 30 10 -20 -70 -110 -100 -70 -90 -70 -490\\nEstimate Range:  \\nLow Estimate -10 -10 -40 -80 -130 -200 -200 -180 -200 -170 -1,220\\nHigh Estimate 10 60 50 30 0 -20 0 30 20 30 210\\nThe proposal to specify the use of the CMS-HCC risk adjustment model(s) applicable to \\nthe calendar year corresponding to the performance year to calculate a Medicare FFS \\nbeneficiary\\u2019s prospective HCC risk score for the performance year, and for each benchmark year \\nof the ACO\\u2019s agreement period for agreement periods beginning January 1, 2024, and in \\nsubsequent years, is anticipated to remove a potential bias that may otherwise reduce \\nbenchmarks particularly for ACOs with beneficiaries exhibiting higher average renormalized risk \\nscores at baseline.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [An increase in average shared savings payments to ACOs that would have \\nparticipated regardless of this proposed modification is expected to ultimately be more than \\noffset by additional savings from increased participation from ACOs serving high risk \\nbeneficiaries that would have otherwise dropped out or avoided entering the Shared Savings \\nProgram under the current approach to calculating prospective HCC risk scores.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Net savings are \\nexpected to be greater at the end of the 10 year scoring window because residual savings from \\n390 Elimination of overall negative regional adjustments, under the proposed approach, would likely generate \\nparticipation growth from ACOs that will face significant negative adjustments despite the changes from the CY \\n2023 PFS final rule to reduce the impact of the negative regional adjustment, but also from other prospective high \\nspending ACOs that may have difficulty estimating the relief they will ultimately receive from the offsets applicable \\nto agreement periods beginning on January 1, 2024, and in subsequent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Eliminating overall negative regional \\nadjustment entirely would materially improve the business case for participation from ACOs in the former category \\nand may at least optically improve the business case for ACOs in the latter category without actually incurring cost \\nto the program by increasing their benchmarks.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [added participation would grow, whereas benchmarks would not be as impacted in the later part \\nof the scoring window because there is lower likelihood that later agreement periods would have \\nbeen impacted by changes in the CMS HCC risk adjustment methodology.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [Table 112 shows \\nthese estimates over the 2024-2033 window.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [TABLE 112:  Projected Impact of Proposal to Use Uniform Approach to Calculate Risk \\nScores in the Shared Savings Program Benchmark Calculations ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 10 20 60 100 140 -70 -130 -180 -160 -110 -320\\nEstimate Range:  \\nLow Estimate 10 -10 10 30 50 -120 -200 -270 -280 -260 -1,040\\nHigh Estimate 20 80 130 190 240 70 10 -50 -40 -20 630\\nAn overall net impact is difficult to quantify for the proposed changes in section III.G.3.a \\nof this proposed rule, to incorporate use of a new third step in the step-wise beneficiary \\nassignment methodology and the proposed changes to identification of the assignable beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [These proposed changes are not currently estimated to have a net impact on program \\nspending in either direction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [Impacts on benchmark calculations for individual ACOs would \\nlikely be mixed and of relatively limited magnitude.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The proposed changes could allow some \\nACOs to increase efficiency by utilizing more non-physician clinicians in delivering primary \\ncare without jeopardizing assignment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [On the other hand, they could marginally increase shared \\nsavings payments for efficiencies that currently would accrue entirely to the program as spillover \\neffects on beneficiaries unable to be assigned.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The overall impact is currently anticipated to be \\nroughly neutral.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [We will continue to analyze data on the potential impact of these proposed \\nchanges on existing ACOs, and will monitor effects if the proposals are finalized and \\nimplemented in future agreement periods.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The remaining proposed changes to the Shared Savings Program regulations are not \\nestimated to have an impact on program spending at the aggregate level.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [These proposed changes \\ninclude modifying the definition of primary care services for purposes of determining beneficiary \\nassignment, recalculating the prior savings adjustment for changes in the amount of savings]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [earned by an ACO in a benchmark year due to compliance action taken to address avoidance of \\nat-risk beneficiaries or changes in the amount of savings or losses for a benchmark year as a \\nresult of the issuance of a revised initial determination of financial performance, expanding \\nquality reporting options to include Medicare CQMs, requiring reporting of MIPS PI \\nperformance category for all eligible clinicians participating in ACOs, and using beneficiary \\ncounts instead of person years in health equity adjustment calculations, as well as proposals to \\nfurther refine AIP policies, revise program eligibility requirements, and make technical changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [Compliance with Requirements of Section 1899(i)(3) of the Act\\nCertain policies, including both existing policies and the proposed new policies described \\nin this proposed rule, rely upon the authority granted in section 1899(i)(3) of the Act to use other \\npayment models that the Secretary determines will improve the quality and efficiency of items \\nand services furnished under the Medicare program, and that do not result in program \\nexpenditures greater than those that would result under the statutory payment model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [The \\nfollowing proposals require the use of our authority under section 1899(i) of the Act: the \\nproposed modifications to the calculation of regional component of the three-way blended update \\nfactor to cap regional service area risk score growth for symmetry with the ACO risk score \\ngrowth cap, as described in section III.G.4.b of this proposed rule and the refinements to AIP \\npolicies as described in section III.G.5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [Further, certain existing policies \\nadopted under the authority of section 1899(i)(3) of the Act that depend on use of the assigned \\npopulation and assignable beneficiary populations, would be affected by the proposed addition of \\na new third step of the beneficiary assignment methodology and the proposed revisions to the \\ndefinition of assignable beneficiary, described in section III.G.3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [of this proposed rule, including \\nthe following: the amount of advance investment payments; factors used in determining shared \\nlosses for ACOs under two-sided models (including calculation of the variable MSR/MLR based \\non the ACO\\u2019s number of assigned beneficiaries, and the applicability of the extreme and \\nuncontrollable circumstances policy for mitigating shared losses for two-sided model ACOs);]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [and calculation of the ACPT, regional and national components of the three-way blended \\nbenchmark update factor.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [When considered together these changes to the Shared Savings \\nProgram\\u2019s payment methodology are expected to improve the quality and efficiency of items and \\nservices furnished under the Medicare program by improving the ability for ACOs to sustain \\neffective participation in regions with changing populations and increasing the overall proportion \\nof Medicare beneficiaries assigned to ACOs, and are not expected to result in a situation in \\nwhich the payment methodology under the Shared Savings Program, including all policies \\nadopted under the authority of section 1899(i) of the Act, results in more spending under the \\nprogram than would have resulted under the statutory payment methodology in section 1899(d) \\nof the Act.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [In the CY 2023 PFS final rule we estimated that the projected impact of the payment \\nmethodology that incorporates all finalized changes from that final rule would result in $4.9 \\nbillion in greater program savings compared to a hypothetical baseline payment methodology \\nthat excludes the policies that require section 1899(i)(3) of the Act authority (see 87 FR 70195 \\nand 70196).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [The marginal impact of the proposed changes discussed in this proposed rule is \\nestimated to be $330 million lower net spending over the ten year window for all new proposals \\ncombined, including the proposal to cap an ACO\\u2019s regional service area risk score growth and \\nthe proposals to add a new third step to the beneficiary assignment methodology and to revise the \\napproach to identify the assignable beneficiary population.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [Therefore, we believe the \\nrequirements of section 1899(i)(3)(B) of the Act would not be violated by these relatively minor \\nchanges to program spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [We will continue to reexamine this projection in the future to ensure that the requirement \\nunder section 1899(i)(3)(B) of the Act that an alternative payment model not result in additional \\nprogram expenditures continues to be satisfied.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [In the event that we later determine that the \\npayment model that includes policies established under section 1899(i)(3) of the Act no longer \\nmeets this requirement, we would undertake additional notice and comment rulemaking to make]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [adjustments to the payment model to assure continued compliance with the statutory \\nrequirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Medicare Part B Payment for At-Home Preventive Vaccine Administration Services\\nIn section III.H.3.c of this proposed rule, we propose to maintain the additional payment \\nwhen a COVID\\u201319 vaccine is administered in a beneficiary\\u2019s home under certain circumstances, \\nand to extend this payment to the administration of a pneumococcal, hepatitis B or influenza \\nvaccines.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [We estimated the impact of the proposal to maintain the additional payment for in-home \\nCOVID-19 vaccine administrations and to expand the policy to the administration of all Part B \\npreventive vaccines.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [For this estimate, we analyzed CY 2021-2022 utilization of HCPCS code \\nM0201 for the providers and suppliers that billed it, along with their utilization of the relevant \\npreventive vaccine administration codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [During this period, the in-home additional payment was \\nbilled about 200,000 times by roughly 1,500 different providers and suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [For those \\nproviders or suppliers who administered COVID-19 vaccine in the home in 2021-2022, HCPCS \\ncode M0201 was billed about 2 percent of the time they administered any COVID-19 \\nvaccination.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Total Medicare payments for this service in 2021 and 2022 were $4 million and $3 \\nmillion, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [While we expect that in-home administrations of COVID vaccines will continue into CY \\n2024, we note that the overall utilization of the COVID-19 vaccine was significantly lower in \\n2022 than in 2021, and future utilization is unknown.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Further, if we apply the prevalence of the \\nutilization of HCPCS code M0201 for in-home administration of the COVID-19 vaccine to the \\nutilization of the other three Part B preventive vaccinations, it would result in higher spending of \\nroughly $1-2 million.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Therefore, the overall estimated impact of this proposal is increased \\nspending of less than $5 million in 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [We note that our analysis assumed that there would be \\nno additional providers or suppliers who would decide to begin providing these vaccines at home \\nfor CY2024, given that COVID-19 PHE ended on May 11, 2023]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [Effects of Proposals Relating to the Medicare Diabetes Prevention Program Expanded \\nModel\\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [Effects on Beneficiaries\\nWe propose to modify certain Medicare Diabetes Prevention Program (MDPP) expanded \\nmodel policies to: (1) Extend the flexibilities allowed during the PHE for the COVID-191135 \\nwaiver event by 4 years (or until December 31, 2027), (2) update the MDPP payment structure to \\npay for beneficiary attendance on a fee-for-service basis while retaining the diabetes risk \\nreduction performance payments, (3) remove the requirement for MDPP interim preliminary \\nrecognition and replace it with CDC preliminary recognition, and (4) remove most references to, \\nand requirements of, the Ongoing Maintenance Sessions given that eligibility for these services \\nwill end on December 31, 2023.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [We anticipate that these proposed changes will have a positive \\nimpact on beneficiaries\\u2019 access to MDPP services by increasing the number of MDPP eligible \\norganizations that enroll in Medicare as MDPP suppliers and, more importantly, increasing \\nbeneficiary access to the Set of MDPP services by allowing them continued access to MDPP \\nthrough a live in-person or virtual classroom (or a combination of both modalities).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [The \\nproposed changes would also remove barriers specific to attending these classes solely in-person, \\nwhich may include a lack of MDPP suppliers in certain communities and challenges related to \\nbeneficiary logistics concerning course attendance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [These proposed modifications address MDPP supplier and beneficiary needs based upon \\navailable monitoring and evaluation data received to date, feedback from Medicare Advantage \\nplans and existing MDPP suppliers, and feedback from beneficiary focus groups.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [The proposed \\nchanges are also in response to comments from interested parties made through public comments \\nin response to prior rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [During the initial rulemaking for the MDPP expanded model, we sought to ensure that \\nMDPP would be delivered in-person, in a classroom-based setting, and within an established \\nperiod of service to maintain consistency with the original DPP model test.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [At the time, priority]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [was placed on establishing a structured expanded model that, when delivered within the confines \\nof the rule, would create the least risk of fraud, waste, and abuse, increase the likelihood of \\nsuccess, and maintain the integrity of the data collected for evaluation purposes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [However, circumstances such as the PHE for COVID-19 led us to make changes to the \\nMDPP expanded model through implementation of an Emergency Policy for MDPP that allows \\nfor temporary flexibilities while prioritizing availability and continuity of services for MDPP \\nsuppliers and MDPP beneficiaries impacted by such section 1135 waiver events.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [For example, in \\nthe CY 2021 PFS, we finalized the regulations in the March 31st COVID-19 IFC to amend the \\nMDPP expanded model to revise certain MDPP policies during the COVID-19 PHE as well as \\nany future 1135 waiver events where such 1135 waiver event may cause a disruption to in-\\nperson MDPP service delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [These flexibilities allowed beneficiaries to either continue to \\nhave access to MDPP through participation in virtual sessions, pause an in-person MDPP class \\nand resume with the most recent attendance session of record, or restart MDPP from the \\nbeginning in accordance with the March 31st COVID-19 IFC (85 FR 19230).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [When establishing these flexibilities, we could not predict that the COVID-19 PHE \\nwould continue for over 3 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [Although beneficiary participation decreased significantly \\nduring the initial year of the COVID-19 PHE, MDPP participation has slowly increased since \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [As this additional modality of delivery has helped improve supplier access to beneficiaries, \\nremoving the PHE flexibilities and suppliers\\u2019 ability to deliver MDPP virtually after 3 years \\nwould not only be disruptive to suppliers, it may in-fact be detrimental to the operations of the \\nMDPP expanded model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [During the COVID-19 PHE, we permitted virtual delivery of the Set of MDPP services \\nby MDPP suppliers who were recognized by the CDC with Diabetes Prevention Recognition \\nProgram (DPRP) in-person delivery mode, but did not permit suppliers who were only \\nrecognized by the CDC with either online or distance learning delivery modes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [Although we \\nfinalized in the CY 2021 PFS that suppliers had to be prepared to return to in-person delivery]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [when the PHE ended, the PHE lasted for over 39 months.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Therefore, returning to a solely in-\\nperson, pre-PHE delivery model may not be as simple for some suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Post-PHE, many beneficiaries and suppliers have reported the desire to continue utilizing \\nvirtual delivery of MDPP for a wide range of reasons.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Maintaining suppliers\\u2019 ability to offer both \\nsynchronous virtual (distance learning) and in-person MDPP may increase beneficiary uptake of \\nthese services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [It is important to note that permitting virtual delivery of MDPP throughout the \\nPHE has not resulted in a spike in MDPP utilization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [A reason for a lack of beneficiary \\nparticipation may be tied to the fact that suppliers still had to maintain the ability to deliver in-\\nperson services (rent or own physical space), while some suppliers were unfortunately unable to \\npivot to virtual delivery during the COVID-19 PHE for a variety of reasons.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Current data depict that the most impactful MDPP results correspond to attending MDPP \\nsessions virtually or through utilizing a hybrid approach (attending classes both virtually and in-\\nperson).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Interim MDPP evaluation data illustrated that average participant weight loss is 5.1 \\npercent since the expanded model launched on April 1, 2018, surpassing the expanded model\\u2019s \\nweight loss goal of 5 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [In addition, the interim evaluation data show that, 53 percent of \\nMDPP participants attained the 5 percent weight-loss goal, and 24.6 percent attained the 9 \\npercent weight-loss goal.391 Aligning with the Diabetes Prevention Program (DPP) model test392 \\nand studies on the National DPP,393,394 MDPP participants who attended more sessions lost more \\nweight.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [For example, among beneficiaries who attended at least 9 sessions, 64 percent met the 5 \\npercent weight loss goal and 30 percent met the 9 percent weight loss goal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [For MDPP \\nparticipants impacted by the COVID-19 PHE, evaluation data confirm significantly increased \\n391 MDPP 2nd Annual Evaluation Report.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [392 RTI International.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Evaluation of the Health Care Innovation Awards: Community Resource Planning, \\nPrevention, and Monitoring:   THIRD ANNUAL REPORT.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [March 2017.  https://downloads.cms.gov/files/cmmi/hcia-\\ncrppm-thirdannrptaddendum.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [393 Knowler WC, Barrett-Connor E, Fowler SE, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Reduction in the incidence of type 2 diabetes with lifestyle \\nintervention or metformin.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [N Engl J Med.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [2002;346(6):393-403. doi:10.1056/NEJMoa012512.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [394 Diabetes Prevention Program Research Group.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Long-term effects of lifestyle intervention or metformin on \\ndiabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program \\nOutcomes Study.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Lancet Diabetes Endocrinol.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [2015;3(11):866-875. doi:10.1016/S2213-8587(15)00291-0.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [weight loss accompanied with a higher number of sessions attended by participants completing \\nthe expanded model in 2021, with these participants attending primarily virtual sessions or a \\nmixture of virtual and in-person sessions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [To date, there have been no preliminary indications that the synchronous virtual delivery \\nof MDPP has limited supplier instruction or beneficiary success, as defined by achievement of \\nthe 5 percent weight loss goal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [However, it is too early to determine the impact of synchronous \\nvirtual delivery of MDPP on other outcomes such as cost-savings or incidence of diabetes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [MDPP has been fundamentally limited by low beneficiary participation and corresponding small \\nsample sizes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [We believe that an increase in supplier uptake, which may be accomplished \\nthrough our proposal to maintain more options of MDPP delivery modalities, will result in an \\nincrease in beneficiary enrollment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [This will be critical to conducting robust programmatic \\nevaluations, including a potential future certification of the synchronous virtual delivery of \\nMDPP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [To assist with our ability to improve monitoring and evaluation of the synchronous \\nvirtual delivery of MDPP, we have proposed a new HCPCS G-code specific to distance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Additionally, extending the flexibilities allowed during the PHE for COVID-19 by 4 years would \\nimprove MDPP eligible organizations\\u2019 MDPP service delivery opportunities due to the use of \\nmultiple modalities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Effects on the Market\\nWhile we acknowledge that additional changes will likely be necessary to improve \\nbeneficiary access to MDPP, we anticipate that the enhancements proposed in this rule are likely \\nto result in an increase of MDPP suppliers and increased beneficiary access to the Set of MDPP \\nservices.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [We anticipate that this will assist in contributing to a reduction of the incidence of \\ndiabetes among eligible Medicare beneficiaries, and in particular, those residing in underserved \\ncommunities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Currently, there are approximately 786 in-person organizations nationally that are \\neligible to become MDPP suppliers based on their preliminary or full CDC Diabetes Prevention]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Recognition Program (DPRP) status.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [However, only 25 percent of eligible in-person \\norganizations are participating in MDPP, and only one-third of MDPP suppliers have submitted \\nMDPP-related claims.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Through updating the payment structure to one that is similar to those of \\nexisting CMS Medicare Preventive Services such as the Intensive Behavioral Counseling for \\nObesity, the MDPP claims submission process may be more intuitive for existing Medicare \\nsuppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [In addition, we anticipate that simplifying the MDPP payment structure will address \\nsome of the complexities related to the process for submitting claims, while encouraging more \\nsuppliers to submit claims for MDPP due to a reduced set of codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Since MDPP was established through the CY 2017 PFS, we have consistently heard from \\ninterested parties that we should include virtual delivery of MDPP as part of the expanded model \\ntest, which would increase beneficiary access to the Set of MDPP services while providing \\nflexibility of where both a beneficiary may take the course and from where a supplier may \\ndeliver the course.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Although we did not allow for a fully virtual delivery of MDPP until the \\nCOVID-19 PHE, we did allow a limited number of virtual make-up sessions, which could be \\ndelivered either synchronously or asynchronously.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [The rationale for allowing a limited number \\nof virtual make-up sessions was due to the fact that the data used to certify MDPP were based \\nupon in-person delivery, thereby fully virtual delivery was arguably outside the scope of \\ncertification.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [The COVID-19 PHE led CMS to establish MDPP flexibilities that allowed fully virtual \\ndelivery of the Set of MDPP services by suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [We established several emergency \\nflexibilities within the IFC-1 that removed the limit on the number of virtual makeup sessions, \\nand in the CY 2021 PFS, we finalized the MDPP flexibilities from the IFC-1 while establishing \\nthe MDPP Emergency Policy that allowed for virtual delivery of MDPP, including virtual weight \\ncollection.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [However, the CY 2021 PFS stated that MDPP suppliers must retain the capacity to \\ndeliver the Set of MDPP services in-person, precluding organizations with CDC DPRP \\nrecognition solely in the distance learning or online modalities from participating in MDPP]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [during the COVID-19 PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Interested parties commented that some beneficiaries may have \\nlimited access or ability to use the technology required for participation in virtual MDPP sessions \\nIn the CY 2022 PFS, although outside the scope of rule, interested parties recommended \\nthat we continue the virtual option following the end of the COVID-19 PHE to assist in \\nincreasing access to MDPP, especially for those with transportation needs as well as for \\nbeneficiaries in rural and low-income communities, who may suffer from a lack of in-person \\nsuppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [As a result of these recommendations, in this rule, we are proposing to extend the \\nPHE flexibilities, specific to allowing synchronous virtual delivery of MDPP, also known as \\ndistance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Currently, there are numerous large geographic gaps of MDPP supplier locations, and \\nsynchronous virtual delivery may be part of the solution to increasing the accessibility of MDPP \\nto more beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [It is unclear how the market will respond to the proposed extension of the \\nPHE flexibilities allowed during the COVID-19 PHE, especially since we are still requiring \\nsuppliers to have and maintain an in-person DPRP recognition, but we believe organizations will \\nbe ready to engage in the delivery of the Set of MDPP services either in-person, through distance \\nlearning, or through a combination of in-person and distance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [We also believe that \\nhaving more flexibility in how the Set of MDPP services are delivered will make MDPP more \\naccessible to beneficiaries, particularly those who live in rural areas or in communities with gaps \\nin MDPP supplier locations.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [c.  Payment for MDPP Services\\nRegulations at \\u00a7 414.84 specify MDPP suppliers may be eligible to receive payments for \\nfurnishing MDPP services and meeting performance targets related to beneficiary weight loss \\nand/or attendance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [However, we have consistently heard from suppliers and interested parties \\nthat the MDPP performance-based payment structure has been confusing to some suppliers, \\nincluding those new to Medicare as well as existing suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Approximately 37 percent of]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [MDPP suppliers have submitted FFS claims for MDPP.395 Confusion with claims submission has \\nbeen due, in part, to the MDPP payment structure, which pays for performance-based milestones \\nversus paying for traditional fee-for-service.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [The performance-based payment structure requires \\n15 HCPCS G-codes if including ongoing maintenance sessions, and 11 G-codes for the 12-\\nmonth MDPP service period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [Therefore, we are proposing to shift this payment structure to pay \\nfor attendance on a fee-for-service basis while retaining the diabetes risk reduction performance \\nmilestones, for example 5 percent and 9 percent weight loss as well as the maintenance of the 5 \\npercent weight loss in months 7-12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [This proposed streamlined payment structure will allow \\nsuppliers to receive a more consistent set of payments for their delivery of the Set of MDPP \\nservices and reduce the number of G-codes for easier billing.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [We anticipate that this updated payment structure will reduce the upfront beneficiary \\nretention costs while motivating eligible suppliers to enroll in Medicare to become MDPP \\nsuppliers and provide the Set of MDPP services to eligible Medicare beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [In the current \\nMDPP payment structure, suppliers submit claims after the 1st, 4th, and 9th sessions attended \\nduring the core sessions interval, and following attendance of the two (2) sessions during each of \\nthe core maintenance intervals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [Although the proposed per session payment of $25 is less than \\nthe current per session payment of $38, suppliers will receive up to 22 payments for attendance \\nin the proposed payment structure compared to seven attendance-based payments, for \\nparticipants who began participation in 2022 or later, or eleven attendance-based payments for \\nparticipants whose first core session was in 2021 or earlier.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [The total attendance-based payments \\nwill increase by $54 to $550 in the proposed payment structure, compared to $496 in the current \\none.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [This proposed payment schedule would not only eliminate gaps in payment by providing \\nsmaller but more frequent per-session payments, it would also reduce or eliminate some of the \\ncoding challenges related to the number of existing HCPCS codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [We have proposed to \\n395 Unpublished data from Acumen LLC, Quarter 4 2022 Quarterly Monitoring Report to CMS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [decrease the one-time performance payments for beneficiary achievement of the 5 percent and 9 \\npercent weight loss goals as well as propose a new HCPCS G-code for the maintenance of the 5 \\npercent weight loss during months 7-12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [The proposed total maximum payment of $768 consists \\nof the attendance-based payments and the weight loss performance payments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Although the \\nproposed maximum payment of $768 over a one-year service period is the same as the current \\nmaximum payment, we believe this simplified payment structure will lead to fewer claims \\nrejections while encouraging more suppliers to submit MDPP claims for the beneficiaries they \\nserve, as well as motivate more eligible organizations enroll in Medicare to participate in MDPP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [d.  Effects on the Medicare Program \\n(a)  Estimated 10-Year Impact of MDPP \\nThere are two proposed changes to the Medicare Diabetes Prevention Program (MDPP) \\nwhich are relevant to this impact analysis.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Both changes will be implemented in 2024 if \\nfinalized: Simplifying the MDPP payment schedule; and allowing specified Public Health \\nEmergency (PHE) flexibilities to continue for 4 years after the PHE ends\\u2014namely, allowing for \\nsynchronous virtual delivery of the Set of MDPP services .]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Table 113 shows the estimated impact (in millions) of these two proposed changes on \\nMedicare spending:\\nTABLE 113: Estimated Impact (in millions) of the Two Proposed Changes on Medicare \\nSpending\\nYear 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact on \\nMedicare \\nSpending$0.3 $0.3 $0.1 $0.0 \\u2212$0.2 \\u2212$0.8 \\u2212$0.7 \\u2212$0.6 \\u2212$0.5 \\u2212$0.3 \\u2212$2.4\\n(b) Assumptions/Notes\\n\\u25cf  Simplifying the payment schedule will lead to fewer claim denials and more \\nparticipation from MDPP suppliers .]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [For example, only 55-62% of FFS participants listed in the \\nsupplier crosswalks have an associated MDPP claim over the past 2 years, meaning that \\norganizations have submitted data to the CDC as part of their Diabetes Prevention Recognition]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Program (DPRP) requirements, and also have FFS claims submitted for the same participants for \\nthe same sessions recorded in the DPRP data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [The proposed payment schedule will reduce the \\nnumber of HCPCS codes to from 15 to 6 and eliminate some of the coding issues.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [It will also \\neliminate the gaps in payment by providing smaller but more frequent per-session payments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  The average payment per MDPP participant will increase by $150.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [The new payment \\nschedule will likely lead to more successful claim payment submissions and will motivate MDPP \\nproviders to retain participating beneficiaries for longer periods of time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  In 2022, 551 FFS claims were paid for the initial MDPP session, compared with 514 in \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [According to counts of new FFS participants, there have been about 700 new entrants per \\nyear in recent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [With the implementation of a simpler payment schedule and the extension \\nof PHE flexibilities, we assume that new participation will be more in line with claim payments \\nfor HCPCS code G9873 and will increase to 1,000 in 2024 and 1,250 during the following years \\nuntil the extended flexibilities end.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [We estimate that there will be 500 new (in-person only) \\nparticipants each year starting in 2029.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  Since the start of the PHE, synchronous virtual delivery of MDPP services has been \\nmore prevalent than in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [However, given the coding/reporting issues during the \\nPHE, it is difficult to determine how many beneficiaries are still receiving MDPP services in-\\nperson.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Without the proposed changes, we assume that new participation will be capped at 400 \\nbeneficiaries per year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  For preventing diabetes progression, synchronous virtual delivery of the Set of MDPP \\nservices  has the same level of effectiveness as in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Following 3 years of \\ndelivering MDPP almost solely virtually, suppliers and beneficiaries have become adept at \\nutilizing virtual delivery, as many providers in numerous healthcare settings have shifted to \\nutilizing technology.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Furthermore, preliminary MDPP data collected during the PHE indicates \\nthat beneficiaries have achieved similar weight loss and attendance goals as participants in both]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [the in-person DPP test and MDPP participants who enrolled in MDPP prior to the pandemic.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [This assumption is revisited in the Sensitivity Analysis section.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [(c) Sensitivity Analysis \\nOn March 14, 2016, the Office of the Actuary (OACT) published a certification \\nmemorandum setting out the conditions for expansion of the Medicare Diabetes Prevention \\nProgram (MDPP), which can be found at https://www.cms.gov/Research-Statistics-Data-and-\\nSystems/Research/ActuarialStudies/Downloads/Diabetes-Prevention-Certification-2016-03-\\n14.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Assumptions about the 10-year cost impacts of virtual delivery of MDPP services takes \\ninto account the assumptions of the original certification, and adjusts for diabetes costs in 2023 \\ndollars, and trends those costs over the next 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Since both the effectiveness and the future participation level of synchronous virtual \\ndelivery of MDPP services are largely unknown, Table 114 shows 10-year cost impacts (in \\nmillions) of varying levels of effectiveness of the virtual delivery of the Set of MDPP services \\nrelative to the in-person delivery of the Set of MDPP services, paired with varying levels of \\nvirtual MDPP participation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [TABLE 114: 10-year Cost Impacts (in millions) of Virtual Delivery of MDPP \\nServices\\nVirtual Beneficiaries Per Year/Effectiveness 25% 50% 75%\\n1,000 $0.7 \\u2212$0.8 \\u2212$2.3\\n2,000 $1.3 \\u2212$1.6 \\u2212$4.6\\n3,000 $2.0 \\u2212$2.4 \\u2212$6.9\\nAs indicated in Table 114, virtual delivery of MDPP services is estimated to produce \\nsavings when it is at least 50 percent as effective as in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [13.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Appropriate Use Criteria for Advanced Diagnostic Imaging\\nSection 1834(q)(2) of the Act, as added by section 218(b) of the Protecting Access to \\nMedicare Act (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [L. 113-93, April 1, 2014) (PAMA), directs CMS to establish a program to \\npromote the use of appropriate use criteria (AUC) for applicable imaging services furnished in an \\napplicable setting.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As discussed in detail in section III.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [of this proposed rule, since 2015, we have taken a \\nthoughtful, stepwise approach that maximized engagement and involvement of interested parties \\nto implement the statutory provisions set forth in section 1834(q), as added by section 218(b) of \\nthe PAMA, using notice and comment rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As codified at \\u00a7 414.94, we established the \\nfirst two components of the AUC statutory requirements - establishment of AUC and \\nmechanisms for consultation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [We began to build the parameters for the fourth component, outlier \\nidentification and prior authorization, leading to prior authorization, by establishing the priority \\nclinical areas (PCAs).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [We began implementing the third component, the AUC consultation and \\nreporting requirement, using the ongoing educational and operations testing period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [However, as \\ndiscussed previously in this proposed rule, at this time, we have exhausted all reasonable options \\nfor fully operationalizing the AUC program consistent with the statutory provisions as prescribed \\nin section 1834(q)(B) of the Act directing CMS to require real-time claims-based reporting to \\ncollect information on AUC consultation and imaging patterns for advanced diagnostic imaging \\nservices to ultimately inform outlier identification and prior authorization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As a result, we have \\nproposed to pause implementation of the AUC program for reevaluation and to rescind the \\ncurrent AUC program regulations at \\u00a7 414.94.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [In the CY 2019 PFS final rule (83 FR 59452), we performed an RIA for this program and \\nupdated that RIA in the CY 2022 PFS final rule (86 FR 64996).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [The estimated impacts in the CY \\n2022 PFS final rule are as follows:\\n\\u25cf  Cost to ordering clinicians of required AUC consultation: $51,039,109 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to Medicare beneficiaries for additional office visit time: $54,789,518 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to ordering clinicians of transmitting consultation information: $94,495,192 \\nannually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to furnishing clinicians to update processes to report AUC information: \\n$1,851,356,888 (one time).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Potential savings to Medicare program from decrease in imaging utilization:]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [$700,000,000 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Table 115 also includes the AUC program-related activities and their corresponding \\nimpact estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [By pausing efforts to implement the AUC program for reevaluation and \\nrescinding the AUC program regulation at \\u00a7 414.94, the Medicare program may not realize the \\nestimated savings, and clinicians and beneficiaries will not experience the estimated costs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [TABLE 115:  AUC Program Related Activities with Impact Estimates From CY2022 PFS\\nAUC Program Related Activity CY 2022 PFS Rule Impact Estimate\\nImpact of required AUC consultations by ordering \\nprofessional$51,039,109\\nImpact to Medicare beneficiaries $54,789,518\\nImpact on transmitting orders for advanced diagnostic \\nimaging services$94,495,192\\nAUC automated solution $1,851,356,888\\nMedicare program impacts associated with advanced \\ndiagnostic imaging services$700,000,000\\n14.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Medicare and Medicaid Provider and Supplier Enrollment Changes \\nIn this section, we discuss the impact of our proposed Medicare provider enrollment \\nrevocation provisions and our Medicaid termination database proposal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [For all provider \\nenrollment proposals not referenced in this section, we have determined that they would not have \\nan economic impact.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [a.  Medicare Revocation Reasons\\nAs discussed in section III.J of this proposed rule, we are proposing several new or \\nexpanded revocation reasons in \\u00a7 424.535(a).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [First, we propose to expand \\u00a7 424.535(a)(1) to include instances where the provider or \\nsupplier is non-compliant with the enrollment requirements in Title 42.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Paragraph (a)(1) would \\nno longer be restricted to non-compliance with the provisions of 42 CFR part 424, subpart P.\\nSecond, new \\u00a7 424.535(a)(15) would give CMS the authority to revoke enrollment if the \\nprovider or supplier, an owning or managing employee or organization thereof, or an officer or \\ndirector thereof has had a civil judgment under the False Claims Act (31 U.S.C.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [\\u00a7\\u00a7 3729 \\u2013 3733) \\nimposed against them within the previous 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Third, \\u00a7 424.535(a)(16) would permit CMS to revoke enrollment if a provider or \\nsupplier, or any owner, managing employee or organization, officer, or director thereof, has been \\nconvicted of a misdemeanor under Federal or State law within the previous 10 years that CMS \\ndeems detrimental to the best interests of the Medicare program and its beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Fourth, we propose in new \\u00a7 424.535(a)(243) that CMS may revoke an IDTF\\u2019s, \\nDMEPOS supplier\\u2019s, OTP\\u2019s, or HIT supplier\\u2019s, or MDPP\\u2019s enrollment based on a violation of \\nany standard or condition in, respectively, \\u00a7\\u00a7 410.33(g), 424.57(c), 424.67(b) or (e), or 424.68(c) \\nor (e), or 424.205(b) or (d)..     \\nBased on CMS statistics concerning the average annual amount of Medicare payments a \\nprovider or supplier receives, we project a figure of $50,000.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [We note that we have recently \\nused this figure when estimating the potential savings associated with several new revocation \\nreasons.396  For purposes of consistency and accuracy, we propose to use this $50,000 amount in \\nthis proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Table 116 outlines the estimated annual number of revocations that would ensue with the \\nfour aforementioned revocation proposals:\\nTABLE 116:  Estimated Annual Number of Revocations\\nProposed Revocation \\nReasonNumber of Revocations\\n\\u00a7 424.535(a)(1) 5\\n\\u00a7 424.535(a)(15) 5\\n\\u00a7 424.535(a)(16) 5\\n\\u00a7 424.535(a)(23) 5\\nTotal 20\\nThese revocations would represent a savings to the Federal Government because Trust \\nFund dollars would no longer be paid to the revoked providers and suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Accordingly, we \\nproject an annual savings to the Federal Government of $1,000,000 ($50,000 x 20 revocations).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [396 For example, see the final rule published in the Federal Register on November 18, 2022 (87 FR 69404), titled \\nMedicare and Medicaid Programs; CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes \\nto Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Implementing \\nRequirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs To Provide Refunds \\nWith Respect to Discarded Amounts; and COVID-19 Interim Final Rules\\u201d.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [b.  Medicaid Termination Database\\nAs discussed in section III.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [of this proposed rule, we are proposing certain provisions in \\n42 CFR part 455 concerning the length of time a provider remains in the Medicaid termination \\ndatabase and how this interacts with the termination periods that States impose upon terminated \\nproviders.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We do not believe these proposals involve any additional impact or burden on \\nproviders or States.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [In fact, it could result in a reduction of burden because a provider\\u2019s potential \\nlength of time in the termination database would be capped at 10 years, although we have no data \\navailable with which to assist us in calculating the possible burden reduction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [As a result, since \\nwe are uncertain of how much of the burden will be reduced, we are seeking public comments \\nfrom the public to aid in understanding how to measure said burden reduction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [15.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [Expand Diabetes Screening and Diabetes Definitions\\nAs discussed in section III.L.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [in this proposed rule, we propose to: (1) expand coverage of \\ndiabetes screening tests to include the Hemoglobin A1C test (HbA1c) test, ( 2) expand and \\nsimplify the frequency limitations for diabetes screening, and (3) simplify the regulatory \\ndefinition of \\u201cdiabetes\\u201d for diabetes screening, Medical Nutrition Therapy (MNT) and Diabetes \\nOutpatient Self-Management Training Services (DSMT).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We anticipate that expanding coverage of diabetes screening to include the HbA1c test \\nand expanding and simplifying the frequency limitations for diabetes screening to result in some \\nadditional service utilization, but we also anticipate the additional utilization may be balanced, in \\npart, by potential long term benefits and savings resulting from increased prevention and early \\ndetection (allowing for less invasive and more effective treatment).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [As described earlier in our \\nproposal, Medicare currently covers the Fasting Plasma Glucose (FPG) test and the Glucose \\nTolerance Test (GTT) for diabetes screening.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [The HbA1c test does not require fasting and is \\nmore convenient than the currently covered FPG and GTT.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We also propose to expand and \\nsimplify the frequency limitations for diabetes screening by aligning to the statutory limitation of]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [\\u201cnot more often than twice within the 12-month period following the date of the most recent \\ndiabetes screening test of that individual.\\u201d  \\nWe estimate our proposal to expand diabetes screening to result in approximately $68.5 \\nmillion in additional annual expenditures for the Medicare Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Our estimate is based on the \\nfollowing assumptions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Based on calendar year 2022 actual experience, approximately 27.3 \\npercent of beneficiaries had a blood panel test that did not include the HbA1c test.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Medicare \\ncurrently pays approximately $9.50 per HbA1c test for diabetes management.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [The Medicare \\nstatutory and regulatory eligibility factors for an individual at risk for diabetes (section \\n1861(yy)(2) of the Act, 42 CFR 410.18(e)) cover much of the current Medicare beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We assume that approximately 7.6 million potential additional HbA1c tests for \\ndiabetes screening to be billed under our proposal in calendar year 2024 and that the HbA1c test \\nwould be billed with a blood panel 95 percent of the time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Our estimate does not reflect \\nsecondary effects of the proposed policies, such as increased utilization of preventive screening \\nservices, additional follow-up services, and potential offsetting savings (including prevention and \\nmore effective treatment through early detection) that may result from these coverage \\nexpansions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Secondary effects are difficult to predict, may materialize many years after the \\nintervention and may, in part, offset one another.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We do not anticipate that our proposal to simplify and expand the regulatory definition of \\n\\u201cdiabetes\\u201d for diabetes screening, MNT and DSMT to result in a significant economic impact on \\nthe Medicare program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [As described earlier, we propose to remove the regulatorily codified \\nclinical test requirements from the definition of \\u201cdiabetes\\u201d for diabetes screening, MNT and \\nDSMT and propose a shortened version of the existing definition that would simply define \\ndiabetes as diabetes mellitus, a condition of abnormal glucose metabolism.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We believe that our \\nproposal will empower health care professionals to apply clinically accurate and appropriate \\ncriteria and that we can ensure certain safeguards through medical coding and claims processing \\ninstructions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We do not anticipate our proposal to simplify and expand the regulatory definition]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of \\u201cdiabetes\\u201d for diabetes screening, MNT and DSMT to result in a significant economic impact \\non the Medicare Program because the regulatory simplification would not otherwise change \\nrequirements or conditions of coverage and payment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [16.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Requirement for Electronic Prescribing for Controlled Substances for a Covered Part D \\nDrug under a Prescription Drug Plan or an MA-PD Plan (section 2003 of the SUPPORT Act) \\nIn section III.M.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of this proposed rule, we are proposing several updates to the CMS \\nEPCS Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We are proposing to remove the same entity exception at \\u00a7 423.160(a)(5)(i) \\nfrom the CMS EPCS Program and to add \\u201csubject to the exemption in paragraph (a)(3)(iii) of \\nthis section\\u201d to \\u00a7 423.160(a)(5).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Under this proposal, prescriptions that are prescribed and \\ndispensed within the same legal entity are included in CMS EPCS Program compliance \\ncalculations as part of the 70 percent compliance threshold at \\u00a7 423.160(a)(5).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [This proposal \\nprovides flexibility to prescribers and dispensing pharmacies that are the same entity to choose \\neither of the electronic standards available at \\u00a7 423.160(a)(3)(iii) to conduct e-prescribing \\nappropriate for their internal systems without us having to exclude these prescriptions completely \\nfrom the CMS EPCS Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [This proposal would affect prescriptions where the prescriber and \\nthe dispensing pharmacy are part of the same legal entity.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Due to the limitations in identifying \\nthese prescriptions in the Prescription Drug Event (PDE) data, the ability to quantify the impact \\nof this proposal is unknown.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Please see section III.M.3.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of this proposed rule for our \\ndiscussion.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We are proposing to specify how we count prescriptions for the compliance calculation \\nby proposing to use the unique identifier given to a prescription by the pharmacy in the \\nmeasurement year and included in the Part D claims data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We will count renewals as an \\nadditional prescription in the CMS EPCS Program compliance threshold calculation, and we will \\nnot count refills as an additional prescription in the CMS EPCS Program compliance threshold \\ncalculation unless the refill is the first occurrence of the unique prescription in the measurement \\nyear.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [If each refill included on the original prescription were counted as a separate prescription,]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [we believe there would be an incremental impact on small prescribers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Preliminary analysis of \\n2021 Part D data shows that approximately 23,000 prescribers would no longer qualify for the \\nsmall prescriber exception and that approximately 6,900 additional prescribers would be \\nnoncompliant.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing updates to the CMS EPCS Program recognized emergency exception \\nand waiver exception presently found at \\u00a7 423.160(a)(5)(iii) and (iv) and proposed to be codified \\nat \\u00a7 423.160(a)(5)(ii) and \\u00a7 423.160(a)(5)(iii) respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing to have discretion \\nto determine which emergencies trigger the recognized emergency exception starting in the 2024 \\nmeasurement year and proposing that prescribers to whom the exception applies would be \\nexcepted from the CMS EPCS Program requirements for the entire measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are \\nproposing to modify how we have previously defined \\u201cextraordinary circumstance\\u201d for purposes \\nof the waiver exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We propose that an \\u201cextraordinary circumstance\\u201d means a situation \\noutside of the control of a prescriber that prevents the prescriber from electronically prescribing a \\nSchedule II-V controlled substance that is a Part D drug and does not exclude \\u201ccases of an \\nemergency or disaster.\\u201d In cases of extraordinary circumstances, we are proposing the timeframe \\nthat would be covered by a waiver authorized under the CMS EPCS Program to be the entire \\nmeasurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing that a prescriber has a period of 60 days from the date of \\nthe notice of non-compliance to request a waiver.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Approved waivers would apply to \\nprescriptions written by a prescriber for the entire measurement year, and the waiver would \\nexpire on December 31 of the applicable measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Although we are modifying the \\nsituations in which a prescriber can apply for an extraordinary circumstances waiver and limiting \\nthe recognized emergencies exception that applies to the CMS EPCS Program, we do not \\nanticipate these proposals to affect many clinicians compared to the current policies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [First, we \\nbelieve that the proposal for CMS to identify which emergencies trigger the recognized \\nemergency exception would still capture the vast majority of emergencies or disasters that affect \\na prescriber's ability to achieve EPCS compliance and would remove any need for additional]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [prescribers to apply for a waiver.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Second, some prescribers who experience an emergency may \\nstill meet the 70 percent compliance threshold by the end of the emergency period and would not \\nneed to apply for a waiver exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Finally, we are unable to quantify the additional number of \\npotential disasters or emergencies prescribers might experience due to variability in the number \\nof disasters and emergencies in a given measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Therefore, we are not increasing our \\nassumption that 100 waiver requests would be submitted to the CMS EPCS program, as we \\ndiscussed in the CY 2022 PFS final rule (86 FR 65562).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We are proposing to continue sending non-compliance notices to prescribers identified as \\nnon-compliant with the CMS EPCS Program for any individual measurement year, and we do \\nnot believe that causes additional costs or will require additional time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Please see section III.M.6.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [of this proposed rule for our discussion.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We do not anticipate the provisions to have any \\nincremental impact on the cost or time associated with prescriber compliance with the electronic \\nprescribing for controlled substances requirement or the cost to interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [17.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Proposed Changes to the Regulations Associated with the Ambulance Fee Schedule and the \\nMedicare Ground Ambulance Data Collection System (GADCS) \\nAs discussed in section III.N.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [of this proposed rule, section 4103 of the CAA amended \\nsection 1834(l)(12)(A) and (l)(13) of the Act to extend the payment add-ons set forth in those \\nsubsections through December 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [The ambulance extender provisions are enacted through \\nlegislation that is self-implementing.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [A plain reading of the statute requires only a ministerial \\napplication of the mandated rate increase and does not require any substantive exercise of \\ndiscretion on the part of the Secretary.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [As a result, there are no policy proposals associated with \\nthese legislative provisions legislative provisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [The Congressional Budget Office (CBO)\\u2019s \\nestimated cost of these provisions was $55 million in 2023, $91 million in 2024, and $29 million \\nin 2025 (https://www.cbo.gov/system/files/2023-01/PL117-328_1-12-23.pdf, p. 17).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We are \\nproposing only to revise the dates in \\u00a7 414.610(c)(1)(ii) and (c)(5)(ii) to conform the regulations \\nto these self-implementing statutory requirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [In addition, as discussed in section III.N.3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [of this proposed rule, we are proposing the \\nfollowing changes to the Medicare Ground Ambulance Data Collection Instrument: Adding the \\nability to address partial year responses from ground ambulance organizations, introducing a \\nminor edit to improve the reporting consistency of hospital-based ambulance organizations, and \\nfour technical corrections to typos.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [The changes and clarifications aim to reduce burden on \\nrespondents, improve data quality, or both.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [While we believe that these changes and clarifications will be well received by the \\nground ambulance interested parties, we do not believe that these changes would have any \\nsubstantive impact on the cost or time associated with completing the Medicare Ground \\nAmbulance Data Collection Instrument.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [We note that the overall length of the Medicare Ground \\nAmbulance Data Collection Instrument will be the same as previously finalized (84 FR 62888) \\nwith these changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Additionally, some of the instructions which we propose to add are intended \\nto improve clarity and may therefore reduce the time the ground ambulance organizations spend \\naddressing the questions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [18.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Hospice CoP Changes\\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Permitting MFT and MCH to serve as members of the interdisciplinary group (IDG)\\nUnder the Medicare Program in accordance with Subtitle C, Section 4121 of the CAA \\n2023, we are proposing conforming regulations text changes to permit MFT or MHC to serve as \\nmembers of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [These proposed changes will require hospices to include at least one SW, \\nMFT or MHC to serve as a member of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Hospices will have the flexibility to determine \\nwhich discipline(s) are appropriate to serve on the IDG based on the needs of the patients.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Modification of the hospice personnel requirements with the addition of MFT and MHC\\nUnder the Medicare Program in accordance with Subtitle C, Section 4121 of the CAA \\n2023, we are proposing conforming regulations text changes to permit MFT or MHC to serve as \\nmembers of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [With the proposed addition of MFT and MHC into the hospice CoPs, it is \\nimportant to include these new disciplines into the personnel qualifications at \\u00a7 418.114.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [However, in section III.C.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [of this rule, we are proposing to add both MHC and MFT to the \\nprovider requirements under 42 CFR subpart B Medical and Other Health Services at \\u00a7\\u00a7 410.53 \\nand 410.54.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Therefore, to avoid duplication and confusion between the CoP and the provider \\nrequirements under the Medical and Other Health Services provision, we are proposing to add \\nboth MHC and MFT to the requirements at \\u00a7 418.114(c)(3) and (4) and referencing the new \\nrequirement at \\u00a7\\u00a7 410.53 and 410.54 respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We do not expect any increase in burden for \\nthis modification.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [In addition, we do not expect the changes for this provision to cause any \\nappreciable amount of expense or anticipated saving and we do not believe this standard would \\nimpose any additional regulatory burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [19.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [RFI:  Histopathology, Cytology, and Clinical Cytogenetics Regulations under the Clinical \\nLaboratory Improvement Amendments (CLIA) of 1988\\nWe are publishing this RFI in this proposed rule to seek comments from interested \\nparties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [There is no impact for this RFI.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [20.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Basic Health Program Provisions\\nIn this proposed rule, we are proposing to update the requirements for a BHP Blueprint \\nrevision.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We also propose to allow a State with a BHP to suspend its BHP, if necessary, and \\nprovide requirements related to a BHP suspension.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We also propose updates to the annual report \\ncontent and timing, if a BHP is suspended.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [This proposal includes requirements for accessible \\nnotices.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Finally, we propose changes related to an individual\\u2019s appeals rights.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We do not \\nanticipate that these provisions would impose any additional regulatory burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [21.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [A Social Determinants of Health Risk Assessment in the Annual Wellness Visit\\nWe propose in section III.S.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [to exercise our authority in section 1861(hhh)(2)(I) of the \\nAct to add elements to the Annual Wellness Visit (AWV) by adding a new Social Determinants \\nof Health (SDOH) Risk Assessment as an optional, additional element with an additional \\npayment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We propose that the SDOH Risk Assessment be separately payable with no beneficiary \\ncost sharing when furnished as part of the same visit with the same date of service as the AWV.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Our proposal builds upon our separate proposal described earlier to establish a stand-alone G \\ncode (GXXX5) for SDOH Risk Assessment furnished in conjunction with an Evaluation and \\nManagement (E/M) visit.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [See section II.E.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [of this proposed rule for additional information on \\ncoding, pricing, and additional conditions of payment for the proposed new SDOH Risk \\nAssessment service.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We anticipate our proposal to add a SDOH Risk Assessment as an optional, \\nadditional element with additional payment within the AWV to result in some additional service \\nutilization, but we also anticipate the additional utilization may be balanced, in part or in whole, \\nby potential long term benefits and savings resulting from a more effective AWV and increased \\nprevention and early detection (allowing for less invasive and more effective treatment).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We do \\nnot anticipate that the addition of an optional SDOH Risk Assessment to the AWV would result \\nin a significant impact to the Medicare Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [22.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Updates to the Quality Payment Program \\nIn this section, we estimate the overall and incremental impacts of the Quality Payment \\nProgram policies proposed in this rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We estimate participation, final scores, and payment \\nadjustment for clinicians participating through traditional MIPS, MVPs, and the Advanced \\nAPMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We also present the incremental impacts to the number of expected Qualified \\nParticipants (QPs) and associated APM Incentive Payments that result from our policies relative \\nto a baseline model that reflects the status quo in the absence of any modifications to the \\npreviously finalized policies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Overall MIPS Modeling Approach and Data Assessment \\n(1) MIPS Modeling Approach\\nFor this proposed rule we create two MIPS RIA models: a baseline and proposed policy \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Our baseline model includes previously finalized policies that would be in effect for the \\nCY 2024 performance period/2026 MIPS payment year if none of our proposed policies are \\nfinalized.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Examples of previously finalized policies are an updated methodology for calculating \\nthe complex patient bonus, and an increase in the data completeness threshold for quality]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [measures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The proposed policies model builds off the baseline model and incorporates the MIPS \\npolicy proposals for the CY 2024 performance period/2026 MIPS payment year included in this \\nproposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The aim of the baseline and proposed policy models is to estimate the incremental \\nimpacts of the policies in this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [We used a similar approach in the CY 2023 PFS \\nfinal rule (87 FR 70199 through 70200).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [As discussed in the CY 2023 PFS final rule, our modeling approach utilizes the same \\nscoring engine that is used to determine MIPS payment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [This modeling approach \\nenables our model to align as much as possible with actual MIPS scoring and minimizes \\ndifferences between our projections and policy implementation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [There are still some limitations \\nto our model due to data limitations and assumptions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [These limitations are discussed later in this \\nRIA.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The aim of the baseline model is to reflect participation, final scores, and payment \\nadjustments for the upcoming performance period and associated MIPS payment year based on \\npreviously finalized policies for the performance period and MIPS and MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [(2)  Data Used to Estimate Future MIPS Performance\\nIn the 2023 PFS final rule (87 FR 70200), we discussed our decision to use the \\nsubmissions data for the CY 2021 performance period to estimate eligibility, final scoring, and \\npayment adjustments supplemented by CY 2019 performance period data to estimate \\nparticipation and payment adjustments for the sake of estimating the size of the budget neutral \\npool.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [To mitigate the potential effect of the PHE on our engagement estimates for the CY 2024 \\nperformance period/2026 MIPS payment year, for MIPS eligible clinicians who submitted data \\nfor the CY 2019 performance period and did not submit data for the CY 2021 performance \\nperiod, we assigned their participation status and final score data from the CY 2023 PFS \\nproposed rule baseline model (87 FR 46408).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [This is because the CY 2023 PFS proposed rule \\nbaseline model (87 FR 46408) is based on submissions data for the CY 2019 performance period \\n(hereafter called \\u201c2019 data supplement\\u201d).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [We indicated that we believed this approach would reflect data that is generally more]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [current while mitigating the impacts of changes in reporting behavior during the PHE on our \\nparticipation estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Although we believe that this is the best data source to accurately model \\nthe impact of our proposed policies, the use of data from the CY 2021 performance period \\nsupplemented by data from the CY 2019 performance period, has the same limitations as \\ndiscussed in the 2023 PFS final rule (87 FR 70200).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [We took a similar approach this year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [The submissions for the CY 2022 performance period were not available in time to assess \\nwhether the data for that performance period can be used to predict future performance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [For the \\nfinal rule, we will evaluate whether it is appropriate to use the CY 2022 performance period data \\nand whether adjustments to this RIA model based on factors such as clinician behavior or \\nperformance category data availability would need to be made if CY 2022 performance category \\nsubmissions data were used instead.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Estimated APM Incentive Payments to QPs in Advanced APMs and Other Payer Advanced \\nAPMs\\nFor payment years from 2019 through 2025, through the Medicare Option, eligible \\nclinicians who have a sufficient percentage of their Medicare Part B payments for covered \\nprofessional services or Medicare patients through Advanced APMs will be QPs for the \\napplicable QP Performance Period for a year and the corresponding payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [In payment \\nyears 2019 through 2024 these QPs will receive a lump-sum APM Incentive Payment equal to 5 \\npercent of their estimated aggregate paid amounts for covered professional services furnished \\nduring the calendar year immediately preceding the payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [In payment year 2025, QPs \\nwill receive a lump-sum APM Incentive Payment equal to 3.5 percent payment of their estimated \\naggregate paid amounts for covered professional services furnished during CY 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Beginning \\nin payment year 2021, in addition to the Medicare Option, eligible clinicians may become QPs \\nthrough the All-Payer Combination Option.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [The All-Payer Combination Option allows eligible \\nclinicians to become QPs by meeting the QP payment amount or patient count threshold through \\na pair of calculations that assess a combination of both Medicare Part B covered professional]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [services furnished or patients through Advanced APMs and services furnished or patients \\nthrough Other Payer Advanced APMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Eligible clinicians who become QPs for a year are not \\nsubject to MIPS reporting requirements and payment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Eligible clinicians who do not \\nbecome QPs but meet a lower threshold to become Partial QPs for the year may elect to report to \\nMIPS and, if they elect to report, will then be scored under MIPS and receive a MIPS payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Partial QPs are not eligible to receive the APM Incentive Payment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [If an eligible clinician does not attain either QP or Partial QP status, and is not excluded \\nfrom MIPS on another basis, the eligible clinician will be subject to the MIPS reporting \\nrequirements and will receive the corresponding MIPS payment adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Beginning in payment year 2026, the update to the PFS CF for services that are furnished \\nby clinicians who achieve QP status for a year is 0.75 percent, while the update to the PFS CF \\nfor services that are furnished by clinicians who do not achieve QP status for a year is 0.25 \\npercent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Thus, eligible clinicians who are QPs for the year will receive differentially higher PFS \\npayment rates than those who are not QPs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [We incorporated this change into our baseline eligibility determination.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [In addition, the \\nthresholds to achieve QP status beginning in the 2024 QP Performance Period will increase to 75 \\npercent for the payment amount method, and 50 percent for the patient count method.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Overall, \\nwe estimate that for the 2024 QP Performance Period between 187,000 and 241,000 eligible \\nclinicians will become QPs, and therefore be excluded from MIPS reporting requirements and \\npayment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [In section VII.E.23.b of this proposed rule, we projected the number of eligible clinicians \\nthat will be QPs, and thus excluded from MIPS, using several sources of information.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [First, the \\nprojections are anchored in the most recently available public information on Advanced APMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [The projections reflect Advanced APMs that will be operating during the 2024 QP Performance \\nPeriod, as well as some Advanced APMs anticipated to be operational during the 2024 QP \\nPerformance Period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [The projections also reflect an estimated number of eligible clinicians that]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [will attain QP status through the All-Payer Combination Option.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [The following APMs are \\nexpected to be Advanced APMs for the 2024 QP Performance Period:  \\n\\u25cf  Bundled Payments for Care Improvement Advanced Model; \\n\\u25cf  Comprehensive Care for Joint Replacement Payment Model (CEHRT Track); \\n\\u25cf  ACO REACH Model (formerly Global and Professional Direct Contracting) Model;\\n\\u25cf  Kidney Care Choices Model (Comprehensive Kidney Care Contracting Options, \\nProfessional Option and Global Option);\\n\\u25cf  Maryland Total Cost of Care Model (Care Redesign Program; Maryland Primary Care \\nProgram);\\n\\u25cf  Medicare Shared Savings Program (Level E of the BASIC Track and the ENHANCED \\nTrack);\\n\\u25cf  Primary Care First (PCF) Model; and,\\n\\u25cf  Vermont All-Payer ACO Model (Vermont Medicare ACO Initiative).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [\\u25cf  Making Care Primary (MCP) tracks 2 and 3 \\nWe used the Participation Lists and Affiliated Practitioner Lists, as applicable, (see 42 \\nCFR 414.1425(a) for information on the APM Participant Lists and QP determinations) for the \\n2022 QP performance period third snapshot QP determination date to estimate the number of \\nQPs, total Part B paid amounts for covered professional services, and the aggregate total of APM \\nIncentive Payments for the 2024 QP Performance Period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [We examined the extent to which \\nAdvanced APM participants will meet the QP Thresholds of having at least 75 percent of their \\nPart B covered professional services or at least 50 percent of their Medicare beneficiaries \\nfurnished Part B covered professional services through the APM Entity.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [c. Estimated Number of MIPS Eligible Clinicians for the CY 2024 Performance Period/2026 \\nMIPS Payment Year\\n(1) Clinicians Included in the RIA Baseline and Final Policies Models Prior to Applying the \\nLow-Volume Threshold Exclusion]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [For this proposed rule, we applied the same assumptions as in the CY 2023 PFS final rule \\n(87 FR 70201 through 70202), unless otherwise noted.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In the CY 2023 PFS final rule (87 FR \\n70202), we explained that we modified some of our assumptions to estimate engagement in \\nMIPS to mitigate the effects of potential non-engagement due to the extreme and uncontrollable \\ncircumstances policies related to the PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In the CY 2023 PFS final rule (87 FR 70201), we explained our use of the final \\nreconciled eligibility determination file.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [This file reconciles eligibility from two determination \\nperiods and aligns with the CY 2021 performance period submissions data on which we based \\nthis model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In this proposed rule, we again used the final reconciled 2021 eligibility \\ndetermination file which aligns with CY 2021 performance period submissions data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [We did not \\npropose any modifications to MIPS eligibility requirements, therefore the same eligibility \\nassumptions apply to both the baseline and proposed policies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [Our analysis found that \\nthere were 1.7 million clinicians who had PFS claims from October 1, 2020 to September 30, \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [This initial population of clinicians was used to determine eligibility using the processes \\ndescribed in the following sections.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [(2)  Estimated Number of MIPS Eligible Clinicians after Applying Assumptions for the Low-\\nVolume Threshold Exclusion and Considering the Extreme and Uncontrollable Circumstances \\nPolicies Related to COVID-19 PHE\\nThe low-volume threshold policy may be applied at the individual (TIN/NPI) or group \\n(TIN) levels based on how data are submitted to MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [Generally, if a clinician or group does \\nnot exceed the low-volume threshold criteria then that clinician or group is excluded from \\nparticipation in MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [The low volume threshold uses three criteria: allowed charges, number of \\nMedicare patients who receive covered professional services, and number of services provided.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [A clinician or group that exceeds at least one, but not all three low-volume threshold criteria may \\nbecome MIPS eligible by electing to opt-in and subsequently submitting data to MIPS, thereby \\nbeing measured on performance and receiving a MIPS payment adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We describe below the estimated MIPS eligibility status and the associated PFS allowed \\ncharges of clinicians in the initial population of 1.7 million clinicians for the proposed policies \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We applied the same assumptions as in the CY 2023 PFS final rule (87 FR 70201 through \\n70202) to apply the low-volume threshold and to determine whether clinicians participate in \\nMIPS as a group, virtual group, APM entity, or as individuals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [In the CY 2023 PFS final rule (87 \\nFR 70202), we explained our use of the CY 2019 performance period data to update eligibility \\nassumptions to account for the effects of the extreme and uncontrollable circumstances (EUC) \\npolicy that was applied due to the PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We noted that the use of CY 2021 performance period \\ndata alone might overstate the number of clinicians with \\u201crequired eligibility\\u201d who do not \\nparticipate in MIPS due to the PHE under the EUC policy and therefore may not have submitted \\ndata.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [If we assumed in this RIA model, which estimates of CY 2024 performance period/CY \\n2026 payment year, participation and non-participation to be similar to the CY 2019 performance \\nperiod, we would likely overstate the number of clinicians receiving a negative payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [Since these clinicians actually would have received a neutral score under the CY \\n2021 performance period EUC reweighting policy but would receive a negative payment \\nadjustment in our simulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [As we noted in section VII.E.22 of this RIA, in order to mitigate the potential effect of \\nthe PHE on our engagement estimates for the CY 2024 performance period, for MIPS eligible \\nclinicians who submitted data for the CY 2019 performance period and did not submit data for \\nthe CY 2021 performance period, we followed the same process described in the CY 2023 PFS \\nfinal rule (87 FR 70202) and assigned their participation status and final score data from the CY \\n2023 PFS proposed rule baseline model (87 FR 46408).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [This is because the CY 2023 PFS \\nproposed rule baseline model (87 FR 46408) is based on the 2019 data supplement.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We believed \\nthese clinicians may participate and perform more similarly to the CY 2019 performance period \\nthan the CY 2021 performance period during the CY 2024 performance period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [We do not have ability to assess the performance of clinicians reflected in our 2019 data \\nsupplement in our model, so we used the same score for this final rule\\u2019s baseline and proposed \\npolicies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [Because we used the same score for the baseline and proposed policies model, \\nwe were not able to assess the incremental impact of policies for this group.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [However, we \\nbelieve making this adjustment is valuable because it helps mitigate the potential effect of \\noverestimating the number of clinicians eligible for, and participating in MIPS, versus non-\\nparticipants, which in turn would affect our estimation of the MIPS redistribution payment and \\nthe size of the budget neutral pool.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [For our RIA model, we established the \\u201crequired eligibility\\u201d category, which means the \\nclinician exceeds the low-volume threshold in all 3 criteria and is subject to a payment \\nadjustment is separated into three buckets this year: (1) \\u201cClinicians who Report\\u201d; (2) \\u201cDid not \\nreport in 2021, but did report in 2019\\u201d; and (3) \\u201cDid not report in either 2021 or 2019.\\u201d  We have \\ndone this so that we can isolate both the effects of our proposed policies, which are modeled \\nusing 2021 data, the effect of the 2019 data supplement, and model the population of clinicians \\nwho did not engage in either year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [The year refers to which population of data we used (that is, \\nthe 2021 population of clinicians or the 2019 supplement).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [a) MIPS Eligibility Estimates\\nTable 117 summarizes our eligibility estimates for the proposed policies model after \\napplying our assumptions discussed previously.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [We estimate approximately 122,183 MIPS eligible clinicians have the required eligibility \\ncriteria and submitted data for at least one performance category in MIPS for the CY 2019 and \\n2021 performance periods, 9,906 MIPS eligible clinicians who did not engage in MIPS based on \\n2021 performance period MIPS data but did engage based on 2019 performance period MIPS \\ndata, and 14,289 MIPS eligible clinicians counted in our model as \\u201cdid not submit in data to \\nMIPS for the CY 2019 or CY 2021 performance period.\\u201d These are clinicians who did not]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [submit data to MIPS for the CY 2019 or CY 2021 performance periods, or did not submit data to \\nMIPS for the CY 2021 performance period and do not have CY 2019 performance period data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We estimate approximately 664,562 MIPS eligible clinicians as having \\u201cgroup \\neligibility\\u201d in Table 117.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [\\u201cGroup eligibility\\u201d means that these clinicians belong to a group that \\nexceeds the low-volume threshold.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [If they were not associated with the group submission, these \\nclinicians will not be eligible for MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [Finally, we estimate about 9,107 clinicians will be eligible for MIPS and participate \\nthrough \\u201copt-in eligibility\\u201d through the \\u201copt-in\\u201d policy.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We updated our opt-in policy to reflect \\nthat a clinician can elect to opt-in into MIPS and will be scored, even if they do not submit data \\nto MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We estimate a total MIPS eligible clinician population of approximately 1,741,607 with \\n$9 billion PFS allowed charges estimated to be included in the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [TABLE 117:  Description of MIPS Eligibility Status for CY 2023 Performance Period/2025 \\nMIPS Payment Year Using the CY 2023 PFS Final Rule Assumptions**\\nCY 2024 PFS Proposed Rule \\nestimates \\nEligibility StatusPredicted Participation \\nStatus in MIPS Among \\nClinicians *Number of \\nCliniciansPFS allowed \\ncharges ($ in \\nmil)***\\nRequired eligibility\\n(always subject to a MIPS payment adjustment because \\nindividual clinicians exceed the low-volume threshold in all 3 \\ncriteria)Reported to MIPS *122,183 $34,134\\nDid not Report in 2021 \\nbut Reported in 20199,906 $2,963\\nDid not Report in 2021 \\nand did not Report 2019 \\n(or did not have data in \\n2019)*14,289$4,261\\nGroup eligibility\\n(only subject to payment adjustment because clinicians' groups \\nexceed low-volume threshold in all 3 criteria)Had a group submission664,562 $17,533\\nOpt-In eligibility assumptions \\n (only subject to a positive, neutral, or negative adjustment \\nbecause the individual or group exceeds the low-volume \\nthreshold in at least 1 criterion but not all 3, and they elect to \\nopt-in to MIPS)Opted-in To MIPS 9,107 $473\\nTotal Number of MIPS Eligible Clinicians and the associated PFS allowed charges 820,047 $59,363]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [CY 2024 PFS Proposed Rule \\nestimates \\nEligibility StatusPredicted Participation \\nStatus in MIPS Among \\nClinicians *Number of \\nCliniciansPFS allowed \\ncharges ($ in \\nmil)***\\nPotentially MIPS Eligible \\n(not subject to payment adjustment for non-participation; could \\nbe eligible for one of two reasons: (1) meet group eligibility; or \\n(2) opt-in eligibility criteria)Opt-in Eligible; Do not \\nopt-in185,342 $6,211\\nGroup Eligible; Did not \\nReport294,729 $6,701\\nBelow the low-volume threshold \\n(never subject to payment adjustment; both individual and group \\nis below all 3 low-volume threshold criteria) Not applicable 123,231 $834\\nExcluded for other reasons \\n(Non-eligible clinician type, newly enrolled) Not applicable 75,836 $4,442\\nQualified Participant (QP)***Not applicable 242,422 $13,502\\nTotal Number of Clinicians Not MIPS Eligible 921,560 $31,690\\nTotal Number of Clinicians (MIPS and Not MIPS Eligible) 1,741,607 $91,053\\n* Participation excludes facility-based clinicians who do not have scores in the 2021 MIPS submission data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [** Allowed charges estimated in 2021 dollars.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [Low-volume threshold is calculated using allowed charges.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [MIPS payment adjustments \\nare applied to the paid amount.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [*** Our QP estimate differs from that reported in section VII.E.23.b) of this proposed rule because we 2021 data and a different \\nsimulation methodology \\nFurthermore, we estimate there will be approximately 185,342 clinicians who are not \\nMIPS eligible, but could be if the clinician or their group elects to opt-in.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We describe this group \\nas \\u201cPotentially MIPS eligible\\u201d in Table 117.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [These potentially MIPS clinicians would all be \\nincluded as MIPS eligible in the unlikely scenario in which all group practices elect to submit \\ndata as a group, or clinicians in a group that does not submit are eligible to opt-into MIPS \\nindividually and choose to do so.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We do not expect that every potentially MIPS eligible clinician \\nwill elect to submit data to MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We estimate another 294,729 clinicians would be eligible for \\nparticipation as a group but do not report data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [These assumptions are important because they \\nquantify the maximum number of MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [When this unlikely scenario is \\nmodeled, we estimate the MIPS eligible clinician population could be as high as 1,300,118 \\nclinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [Finally, we estimate approximately 123,231 clinicians will not be MIPS eligible]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [because they and their group are below the low-volume threshold on all three criteria and another \\napproximately 318,258 will not be MIPS eligible for other reasons, including 242,422 clinicians \\nwith QP status.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [Eligibility among many clinicians is contingent on submission to MIPS as a group or \\nelection to opt-in, therefore we will not know the number of MIPS eligible clinicians who submit \\nuntil the submission period for the CY 2023 performance period is closed.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [For the remaining \\nanalysis, we use the estimated population of 820,047 MIPS eligible clinicians described above.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [c. Estimated Impacts on Payments to MIPS Eligible Clinicians for the CY 2023 Performance \\nPeriod/2025 MIPS Payment Year\\n(1) Summary of Approach for MIPS Value Pathways (MVPs) and Traditional MIPS \\nIn this proposed rule, we present several proposals which impact the measures and \\nactivities, the performance category scores, final score calculation, and the MIPS payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [We discuss these changes in more detail in section VII.E.23.d.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [(3) of this RIA as we \\ndescribe our methodology to estimate MIPS payments for the CY 2024 performance period/2026 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [We then present the impact of the overall proposed policies in the CY 2024 \\nperformance period/2026 MIPS payment year and then compare select metrics to the baseline \\nmodel, which only incorporates previously finalized policies for the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [By comparing the baseline model to the proposed policies \\nmodel, we are able to estimate the incremental impact of the proposed policies for the CY 2024 \\nperformance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [The payment impact for a MIPS eligible clinician is based on the clinician\\u2019s final score, \\nwhich is calculated based on the clinician\\u2019s performance on measures and activities under the \\nfour MIPS performance categories: quality, cost, improvement activities, and Promoting \\nInteroperability.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [MIPS eligible clinicians can participate as an individual, group, virtual group, \\nAPM Entity, clinicians participating in MIPS through the APM Performance Pathway (APP) or \\nthrough an MVP in the four MIPS performance categories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [MIPS APM participants can]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [participate in the APP as an individual, group, virtual group, APM Entity and are only scored on \\nthree MIPS performance categories:  quality, improvement activities, and Promoting \\nInteroperability.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [The average percentage change in total revenues that clinicians earn is less than the \\nimpact displayed here because MIPS eligible clinicians generally furnish services to both \\nMedicare and non-Medicare patients; MIPS does not impact payment from non-Medicare \\npatients.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [In addition, MIPS eligible clinicians may receive Medicare revenues for services under \\nother Medicare payment systems, such as the Medicare Federally Qualified Health Center \\nProspective Payment System, that will not be affected by MIPS payment adjustment factors.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [(2) Methodology to Assess Impact for MIPS Value Pathways \\nIn the CY 2022 PFS final rule (86 FR 65394 through 65397), we finalized policies at \\u00a7 \\n414.1365 for implementing MVPs beginning in the CY 2023 performance period/2025 MIPS \\npayment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [In this RIA, we take a similar approach to modeling MVP participation and \\nscoring as described in the CY 2022 PFS final rule (87 FR 70204), incorporating changes to our \\nproposed policies model as described below.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [(a) MVP Participant Assumptions\\nAt \\u00a7 414.1365(b), we require MVP Participants (which can be a group, individual, \\nsubgroup, or APM entity) to register prior to submitting an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [As we do not yet have \\ninformation on who will register, we assume for purposes of this model, that MVP Participants \\nare MIPS eligible individual clinicians or groups that currently submit at least four quality \\nmeasures that are in an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [For these MVP Participants, we calculate both an MVP and a \\ntraditional MIPS score and take the highest score consistent with the existing scoring hierarchy \\nwhich was finalized in the CY 2023 PFS final rule (86 FR 65537).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [For the baseline model, we \\nused the quality measures finalized for MVPs in the CY 2023 PFS final rule Appendix 3: MVP \\nInventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [In section IV.A.4.b and Appendix 3 of this proposed rule, we propose modifications to \\nthe 12 existing MVPs finalized in the CY 2022 PFS final rule (86 FR 65998 through 66031) and \\nCY 2023 PFS final rule (87 FR 70037) and the consolidation of the previously finalized \\nPromoting Wellness and Optimizing Chronic Disease Management MVPs into a single \\nconsolidated primary care MVP titled Value in Primary Care.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [In section IV.A.4.a of this proposed rule, we are proposing the inclusion of 5 new MVPs\\n\\u25cf Focusing on Women\\u2019s Health;\\n\\u25cf  Prevention and Treatment of Infectious Disease Including Hepatitis C and HIV; \\n\\u25cf  Quality Care in Mental Health and Substance Use Disorder; \\n\\u25cf  Quality Care for Ear, Nose, and Throat (ENT); and \\n\\u25cf  Rehabilitative Support for Musculoskeletal Care\\nFor the proposed policies model, we incorporate the quality measure revisions for the \\nexisting MVPs and use the quality measures to model scores for the new MVPs in Appendix 3 of \\nthis proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [Our MVP Participant assumptions have limitations: we are not incorporating subgroups \\ndue to a lack of data, not all of the assumed participants may elect to register for an MVP, and \\nwe may have additional clinicians or groups register for an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [However, we believe this is a \\nreasonable approach to simulate the impact of MVPs and we sought comment on this \\nassumption, but did not receive any feedback.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [(b) MVP Scoring Methods and Assumptions\\nWe simulate an MVP score using the same data sources as we did for traditional MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We scored according to \\u00a7 414.1365(d) and \\u00a7 414.1365(e) using the MVP reporting requirements \\nlisted in \\u00a7 414.1365(c) with one exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We did not restrict the improvement activities to the \\nactivities listed in the MVP inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We believed this would lower our estimated MVP score \\nas clinicians and groups were not required to select from a limited inventory in the CY 2021 \\nperformance period (upon which our model is based).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [Therefore, we scored any improvement]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [activities the MVP Participants submitted in 2021 as if those improvement activities are in the \\nMVP inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(3) Methodology to Assess Impact for Traditional MIPS\\nTo estimate the impact of the proposed policies on MIPS eligible clinicians, we generally \\nused the CY 2021 performance period\\u2019s submissions data, including data submitted or calculated \\nfor the quality, cost, improvement activities, and Promoting Interoperability performance \\ncategories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [As discussed in section VII.E.23.a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(2) of this proposed rule, we supplemented with \\n2019 data supplement.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [We supplemented this information with the most recent data available for CAHPS for \\nMIPS and CAHPS for ACOs, administrative claims data for the new quality performance \\ncategory measures, and other data sets.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [We calculated a hypothetical final score for the CY 2024 \\nperformance period/2026 MIPS payment year for the baseline and proposed policies scoring \\nmodels for each MIPS eligible clinician using score estimates for quality, cost, Promoting \\nInteroperability, and improvement activities performance categories, where each are described in \\ndetail in the following sections.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(a) Methodology to Estimate the Quality Performance Category Score\\nWe estimated the quality performance category score using a methodology like the one \\ndescribed in the CY 2023 PFS final rule (87 FR 70205) for the baseline and proposed policies \\nRIA models for the CY 2024 performance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [To create the baseline policies RIA model, which does not reflect the policies proposed in \\nthis rule, we made the following modifications to the CY 2023 PFS final rule final policies \\nmodel to reflect the previously finalized quality performance category policies for the CY 2024 \\nperformance period/2026 MIPS payment year:\\n\\u25cf  As discussed in the CY 2023 PFS final rule (87 FR 70049), we increased the data \\ncompleteness criteria threshold to at least 75 percent for CY 2024 and CY 2025 performance \\nperiods/2026 and 2027 MIPS payment years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [For the proposed policies model, we did not implement any changes to the quality \\nperformance category relative to the baseline model because we use 2021 data and cannot \\nsimulate the addition of new measures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(b) Methodology to Estimate the Cost Performance Category Score\\nWe estimated the cost performance category score using a methodology similar to the \\nmethodology described in the CY 2023 PFS final rule (87 FR 70205) for the baseline and the \\nproposed policies RIA models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [For this proposed rule, the baseline policies RIA model included \\nthe same method used for the final policies RIA model in the CY 2023 PFS final rule (87 FR \\n70205).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [Due to technical limitations, we did not model cost improvement scoring in the baseline \\npolicies RIA model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [The proposed policies RIA model incorporated and implemented the following changes: \\nIn section IV.A.4.f.(2).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(a) of this proposed rule, we proposed 5 new episode-based cost \\nmeasures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [\\u25cf  In section IV.A.4.g.(1).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(c) of this proposed rule, we proposed to: \\n++ Determine cost improvement scoring at the category level; \\n++  Modify how to calculate cost improvement scoring and remove statistical \\nsignificance requirement; and \\n++  Set the maximum improvement scoring to 1 percentage point, beginning in CY 2023 \\nperformance period/2025 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(c) Methodology to Estimate the Facility-Based Measurement Scoring\\nA limitation of using data from the CY 2021 performance period is that we are not able to \\nestimate facility-based scores because there are no Hospital Value-Based Purchasing total \\nperformance scores calculated for the performance period due the COVID-19 PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [However, \\nfor clinicians who did not participate in MIPS during the CY 2021 performance period, we did \\nuse the 2019 data supplement to identify final scores based on the CY 2019 performance period \\nsubmission and these scores include facility-based scores.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(d) Methodology to Estimate the Promoting Interoperability Performance Category Score\\nWe estimated the baseline Promoting Interoperability performance category score by \\nusing the same methodology that we used in the CY 2023 PFS final rule (87 FR 70206) final \\npolicies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [We incorporated the final policies model from that rule into our baseline model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [In \\nsection IV.A.4.F.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(4)(f) of this proposed rule, we proposed to continue reweighting clinical social \\nworkers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [This is incorporated into our proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [We did not incorporate changes \\nto the performance period or measure level changes because we are not able to model this using \\ndata for the CY 2021 performance period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(e) Methodology to Estimate the Improvement Activities Performance Category Score\\nFor the baseline and proposed policies model we used the same method to estimate the \\nimprovement activities performance category score as described in the CY 2023 PFS final rule \\n(87 FR 70206).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(f) Methodology to Estimate the Complex Patient Bonus Points\\nFor the baseline and proposed policies RIA model, we used the previously established \\nmethod to calculate the complex patient bonus as described in the CY 2022 PFS final rule (86 \\nFR 64996).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(g) Methodology to Estimate the Final Score\\nWe did not propose any changes for how we calculated the MIPS final score.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [Our \\nbaseline and proposed policies RIA models assigned a final score for each TIN/NPI by \\nmultiplying each estimated performance category score by the corresponding performance \\ncategory weight, adding the products together, multiplying the sum by 100 points, adding the \\ncomplex patient bonus, and capping at 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For the baseline policies RIA model, we applied the performance category weights and \\nredistribution weights finalized in the CY 2022 PFS final rule (86 FR 65519 through 65524).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For both models, after adding any applicable bonus for complex patients, we reset any \\nfinal scores that exceeded 100 points to equal 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For MIPS eligible clinicians who were]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [assigned a weight of zero percent for any performance category, we redistributed the weights \\naccording to \\u00a7 414.1380(c).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(h) Methodology to Estimate the MIPS Payment Adjustment\\nFor the baseline and proposed policies RIA models, we applied the hierarchy as finalized \\nin the CY 2022 PFS final rule (86 FR 65536 through 65537) to determine which final score \\nshould be used for the payment adjustment for each MIPS eligible clinician when more than one \\nfinal score is available.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [We then calculated the parameters of an exchange function in accordance \\nwith the statutory requirements related to the linear sliding scale, budget neutrality, and \\nminimum and maximum adjustment percentages.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For the baseline model, we applied the performance threshold of 75 points finalized in \\nthe CY 2023 PFS final rule (87 FR 70097).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In section IV.A.4.h.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(2) of this proposed rule, we are \\nproposing a performance threshold of 82 points for the CY 2024 performance period/2026 MIPS \\npayment year, which we incorporated into our proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For both the baseline \\nand proposed policies models, we used these resulting parameters to estimate the positive or \\nnegative MIPS payment adjustment based on the estimated final score and the allowed charges \\nfor covered professional services furnished by the MIPS eligible clinician.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(4) Impact of Payments \\nWe noticed minimal changes to the mean and median final score between our baseline \\nand proposed policies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In our baseline model, the mean and median final scores are 73.26 \\nand 79.99 points, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In the proposed policies model, the mean final score is 73.52 and \\nthe median final score is 80.53.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [Many clinicians have scores clustered near the proposed \\nperformance threshold of 82 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For instance, 51% of clinicians have a final score between \\n80 and 100 points and 63.28% of clinicians have final score between 75 and 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [Because \\nso many clinicians have final scores near our proposed performance threshold, a small change in \\nactual final scores relative to our model would significantly impact the number of clinicians with \\na positive, neutral, or negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Our proposed policies are expected to increase the number of clinicians receiving a \\nnegative adjustment from 36.75 percent of eligible clinicians to 54.31 percent of eligible \\nclinicians, but decrease the average negative adjustment from -2.89 percent to -2.40 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [This \\nis because the increased performance threshold will cause many clinicians who previously scored \\nslightly above the performance threshold to now score slightly below the performance threshold, \\nshifting their expected payment from a small positive adjustment to a small negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Among MIPS eligible clinicians who reported data, 35.38 percent receive a negative \\nadjustment in our baseline model compared to 52.24 percent in the proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Because many clinicians\\u2019 scores are close to the performance threshold, the payment adjustments \\nfor these clinicians are fairly small and many negative adjustments are much lower in magnitude \\nthan the statutory maximum negative adjustment of 9 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our proposed policies model, \\nwe project the maximum negative payment adjustment of negative 9 percent for clinicians with a \\nscore of 20 points or below compared to a score of 18 in our baseline model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our baseline model, 2.13 percent of MIPS eligible clinicians and 1.41 percent of \\nclinicians who report clinicians receive the max negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our proposed rule \\nmodel, 1.99 percent of MIPS eligible clinicians and 1.19 percent of clinicians who report data \\nreceive the max negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [This is because, while the range of scores subject to the \\nmaximum negative adjustment increases slightly (from 18 to 20 points), slightly fewer clinicians \\nin our proposed policies model have a final score below 20 points compared to the baseline \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [The increase in the number of clinicians receiving a negative score will contribute to an \\nincrease in the size of the budgetary dollars available, as a result of the budget neutral nature of \\nthe program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In the baseline model, we anticipate redistributing $7.4 million and, in the proposed \\npolicies model we anticipate, redistributing $8.9 million as a result of budget neutrality.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Because of this increase in the size of the budget neutral pool, the size of our positive \\npayment adjustments increases.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our baseline model, the average positive payment adjustment]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [is 1.99 percent among MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [In the CY 2024 performance period/2026 MIPS \\npayment year proposed policies model, the average positive payment adjustment is 3.35 percent \\namong MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [The maximum positive payment adjustment increased from 4.60 \\npercent in the baseline model to 8.82 percent in the proposed rule model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [We want to highlight that we are primarily using submissions data for the CY 2021 \\nperformance period to simulate a final score for the CY 2024 performance period/2026 MIPS \\npayment year, and it is likely that there will be changes that we cannot account for at this time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [It \\nshould also be noted that the estimated number of clinicians who do not submit data to MIPS \\nmay be an overestimate of non-engagement in MIPS for the CY 2023 performance period/2025 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [This is because the PHE may have resulted in fewer clinicians submitting \\ndata to MIPS or more clinicians electing to apply for the extreme and uncontrollable \\ncircumstances policies due to the PHE for the CY 2019 and CY 2021 performance periods.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [Therefore, engagement levels in MIPS for the CY 2024 performance period/2026 MIPS payment \\nyear may differ from these reported estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [We also note this participation data is generally \\nbased off participation for the CY 2021 performance period/2023 MIPS payment year, which is \\nassociated with a performance threshold of 60 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [TABLE 118: Estimated Proportion of Eligible Clinicians with a Positive or Neutral and a \\nNegative Payment Adjustment CY 2024 Performance Period/2026 MIPS Payment year by \\nPractice Size\\nPractice Size*Percent Eligible Clinicians with \\nPositive or Neutral Payment \\nAdjustmentPercent Eligible Clinicians with Negative \\nPayment Adjustment\\nBaseline\\n1) Solo 46.94% 53.05%\\n2) 2-15 53.76% 46.23%\\n3) 16-99 54.55% 45.44%\\n4) 100+ 68.68% 31.31%\\nOverall 63.24% 36.75%\\nProposed Policies Model\\n1) Solo 35.39% 64.60%\\n2) 2-15 39.81% 60.18%\\n3) 16-99 37.44% 62.55%\\n4) 100+ 50.15% 49.84%\\nOverall 45.68% 54.31%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1288: [TABLE 119: Average and Maximum Positive Adjustments for Eligible Clinicians in the CY \\n2024 Performance Period /2026 MIPS Payment Year By Practice Size \\nPractice \\nSize Number of \\nMIPS \\nEligible \\nClinicians Average \\nPositive \\nAdjustmentMaximum Positive Payment \\nAdjustment\\nBaseline\\nSolo (1) 7,059 2.49% 4.60%\\nSmall \\n(2-15)50,559 2.40% 4.60%\\nMedium \\n(16-99)104,742 2.01% 4.60%\\nLarge \\n(>99)353,970 1.92% 4.60%\\nOverall 516,330 1.99% 4.60%\\nCY 2024 PFS Proposed Rule\\nSolo (1) 5,322 4.62% 8.82%\\nSmall \\n(2-15)37,503 4.10% 8.82%\\nMedium \\n(16-99)72,935 3.38% 8.82%\\nLarge \\n(>99)258,849 3.21% 8.82%\\nOverall 374,609 3.35% 8.82%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1289: [TABLE 120: Average and Maximum Negative Adjustments for Eligible Clinicians in the \\nCY 2024 Performance Period /2026 MIPS Payment Year By Practice Size\\nPractice Size  Number of MIPS \\nEligible Clinicians Average \\nNegative \\nAdjustmentMaximum Negative \\nPayment \\nAdjustment\\nBaseline\\nSolo (1) 7,977 -4.32% -9.00%\\nSmall (2-15) 43,476 -4.17% -9.00%\\nMedium (16-99) 87,250 -2.95% -9.00%\\nLarge (>99) 161,379 -2.44% -9.00%\\nOverall 300,082 -2.89%\\nCY 2024 PFS Proposed Rule\\nSolo (1) 9,714 -3.93% -9.00%\\nSmall (2-15) 56,683 -3.59% -9.00%\\nMedium (16-99) 121,819 -2.54% -9.00%\\nLarge (>99) 257,222 -2.01% -9.00%\\nOverall 445,438 -2.40% -9.00%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [FIGURE 4: Distribution of Final Scores in the Baseline and Proposed Policies Model\\ne. Additional Impacts from Outside Payment Adjustments\\n(1) Burden Overall\\nIn addition to policies affecting the payment adjustments, we are proposing several \\npolicies that have an impact on burden in the CY 2024 performance period/2026 MIPS payment \\nyear.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [In section V.B.11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [of this proposed rule, we outline estimates of the costs of data collection \\nthat includes both the effect of proposed policy updates and adjustments due to the use of \\nupdated data sources.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [For each proposed provision included in this proposed rule which impacts \\nour estimate of collection burden, the incremental burden for each is summarized in Table 121.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [We also provide proposed additional burden discussions that we are not able to quantify.020,00040,00060,00080,000100,000120,000140,000160,000\\n0-4.99 5-9.9910-14.99 15-19.99 20-24.99 25-29.99 30-34.99 35-39.99 40-44.99 45-49.99 50-54.99 55-59.99 60-64.99 65-69.99 70-74.99 75-79.99 80-84.99 85-89.99 90-94.9995-100\\nBaseline NPRMDistribution of Final Scores in Baseline and Number of MIPS Eligible Clinicians\\nFinal Score Range]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [TABLE 121:  Incremental Burden from Associated Proposed Policies\\nBurden Description and associated finalized provisions Burden Hours Burden Dollars\\nTotal burden associated with the provision to continue the \\npolicies and ICRs set forth in the CY 2023 PFS final rule into \\nthe CY 2024 performance period/2026 MIPS payment year (as \\ndiscussed in section V.B11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [630,570 $71,317,983\\nBurden change for MVP registration ICR due to the provision of \\nadditional MVPs (as discussed in section V.B.11e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(7)(a) of this \\nproposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*+321 +$33,192\\nBurden change for Quality Data Submission by Clinicians: \\nMedicare Part B Claims-Based Collection Type ICR for \\ncapturing reduced number of quality submissions due to the \\nprovision of additional MVPs (as discussed in section \\nV.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(4) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-4,743 -$530,492\\nBurden change for Quality Data Submission by Clinicians: \\nCQM/QCDR Collection Type ICR for capturing reduced \\nnumber of quality submissions due to the provision of additional \\nMVPs (as discussed in section V.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(5) of this proposed \\nrule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-3,697 -$423,093\\nBurden change for Quality Data Submission by Clinicians: \\neCQM Collection Type ICR for capturing reduced number of \\nquality submissions due to the provision of additional MVPs (as \\ndiscussed in section V.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(6) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-4,344 -$503,665\\nBurden change for MVP Quality Submission ICR submissions \\ndue to the provision of additional MVPs (as discussed in section \\nV.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(7)(a)(iii) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*+8,461 +$964,505\\nTotal change in burden due to policy for CY 2024 -4,002 -$459,553\\nTotal burden set forth in the CY 2024 PFS proposed rule 626,568 $70,858,430\\n* The total change in burden due to this provision includes an increase in burden due to an anticipated increase in the number of \\nrespondents that will participate in MVP reporting based on the proposed addition of new MVPs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [Therefore, there will be a \\ndecrease in burden in the \\u201cQuality Data Submission: MIPS CQM and QCDR collection type,\\u201d \\u201cQuality Data Submission: eCQM \\ncollection type,\\u201d and \\u201cQuality Data Submission: Claims collection type\\u201d ICRS due to respondents who previously submitted \\nMIPS through those collection types submitting data with reduced Quality submission requirements as a MVP participant.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [Total \\nchange in burden also includes the increase in submission burden due to the increase in the number of respondents for \\u201cMVP \\nregistration.\\u201d See section V.B.11 of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(2) Additional Impacts to Clinicians\\n(a) Impact on Third Party Intermediaries\\nIn section IV.A.4.k of this rule, we are proposing to: (1) add requirements for third party \\nintermediaries to obtain documentation; (2) add requirements for third party intermediaries to \\nsubmit data in the form and manner specified by CMS; (3) specify the use of a simplified self-\\nnomination process for existing QCDRs and qualified registries; (4) add requirements for \\nQCDRs and qualified registries to provide measure numbers and identifiers for performance \\ncategories; (5) Add a requirement for QCDRs and qualified registries to attest that information \\non the qualified posting is correct; (6) Modify requirements for QCDRs and qualified registries \\nto support MVP reporting; (7) Specify requirements for a transition plan for QCDRs and]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [qualified registries; (8) Specify requirements for data validation execution reports; (9) Add \\nadditional criteria for rejecting QCDR measures; (10) Add a requirement for QCDR measure \\nspecifications to be displayed throughout the performance period and data submission period; \\n(10) eliminate the Health IT vendor category; (11) Add failure to maintain updated contact \\ninformation as criteria for remedial action; (12) Revise corrective action plan requirements; (13) \\nSpecify the process for publicly posting remedial action; and (14) Specify the criteria for audits.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [Due to the technical nature of these proposed changes, we are unable to quantify the burden for \\nthird party intermediaries during the CY 2024 performance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We \\nrefer readers to section V.B.11.c of this rule for additional information on proposed changes to \\nthe third party intermediary requirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [(b) Compare Tools: Public Reporting \\nIn section IV.A.4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [of this rule, we are proposing to update our policy for identifying \\nclinicians furnishing telehealth services, such that we remain current with CMS coding changes, \\nwithout proposing and finalizing such coding changes via rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [Specifically, instead of \\nonly using place of service (POS) codes 02, 10, or modifier 95 to identify telehealth services \\nfurnished for the telehealth indicator, we would use the most recent codes at the time the data are \\nrefreshed.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing that at the time of such a data refresh we would publish the details \\nof which codes are used for the telehealth indicator through education and outreach, such as via a \\nfact sheet, listserv, or information posted on the Care Compare: Doctors and Clinicians Initiative \\npage, available at https://www.cms.gov/medicare/quality-initiatives-patient-assessment-\\ninstruments/care-compare-dac-initiative.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing to revise the policy to publicly report \\na subset of the Medicare public use file (PUF) on the Provider Data Catalog (PDC) to instead \\nprovide a single downloadable dataset reflecting including the procedure utilization data that \\nwould appear on clinician profile pages.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing to modify the existing policy such \\nthat, in addition to the two previously finalized sources (Restructured BETOS categorization \\nsystem and code sources used in MIPS), we may use alternate sources to create clinically]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [meaningful and appropriate procedural categories, particularly when no relevant grouping exists.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [If we develop new procedure categories for publicly reporting utilization data on clinician profile \\npages, we are proposing to engage subject matter experts and interested parties through periodic \\nrequests for feedback using methods outside of rulemaking, such as but not limited to listserv \\nemails, listening sessions, and focus groups, to solicit feedback on bespoke procedure categories \\nplanned for future releases of utilization data, as appropriate and technically feasible.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We are also \\nproposing to publicly report aggregated counts of procedures performed by providers based on \\nMedicare Advantage (MA) encounter data (also known as MA risk adjustment data) in addition \\nto Medicare fee-for-service (FFS) utilization data counts; as part of this proposal, we are \\nproposing to amend 42 CFR \\u00a7 422.310(f) (the regulation that addresses permissible uses and \\nreleases of MA risk adjustment data) to permit use of MA encounter data in developing the data \\nposted on the Care Compare website and release of the MA encounter data as part of the data set \\nthat will be downloadable from the Care Compare website more quickly than the regulation \\nwould currently permit releases of MA encounter data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [While the Compare tool provisions do \\nnot increase the burden of collections, we note that the PRA package may require relevant \\nmodification to reflect the Compare tool\\u2019s new uses and public display.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We refer readers to \\nsection IV.A.I of this rule for additional information on the proposed changes to public reporting \\non Compare tools.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [(c) Data Completeness Criteria for the Quality Measures, Excluding the Medicare CQMs\\nIn section IV.A.5.a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [(1) of this proposed rule, we are proposing to maintain the data \\ncompleteness criteria threshold at 75 percent for the CY 2025 and 2026 performance \\nperiods/2027 and 2028 MIPS payment years, and increase the data completeness criteria \\nthreshold by 5 percent from 75 percent to 80 percent for the CY 2027 performance period/2029 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We believe that the proposed policy to maintain the threshold for data \\ncompleteness at 75 percent for the CY 2025 and 2026 performance periods/2027 and 2028 MIPS \\npayment years is consistent with the existing data completeness criteria and therefore, would not]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [result in additional burden to the applicable interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We assume that the proposed \\nincrease in data completeness criteria threshold from 75 to 80 percent for the CY 2027 \\nperformance period/2029 MIPS payment year would not result in substantive burden to the \\napplicable interested parties We believe that the increase in data completeness criteria threshold \\nwould reduce burden for clinicians using EHRs and eCQMs as the collection of eCQM data \\nwithin the EHR can allow eligible clinicians to report on 100 percent of the eligible population \\nwith data in the EHR for a measure.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [Additionally, we recognize that individual MIPS eligible \\nclinicians, groups, virtual groups, subgroups, and APM Entities that continue to utilize other \\nmeans of data collection for MIPS CQMs, including the collection of MIPS CQM data reported \\nby registries and/or QCDRs, would need have the logic code of their EHRs to be updated to \\naccount for the increased data completeness criteria threshold.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We believe that increasing the \\ndata completeness criteria threshold would not pose a substantial burden to MIPS eligible \\nclinicians, groups, virtual groups, subgroups, and APM Entities, unless they are manually \\nextracting and reporting quality data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We refer readers to section IV.A.4.f.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(1)(d) of this rule for \\nadditional information on proposed changes to the data completeness threshold criteria.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(d) Modifications to the Improvement Activities Inventory\\nAs discussed in section IV.A.4.f.(3).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(b)(ii) of this proposed rule, we are proposing \\nchanges to the improvement activities Inventory for the CY 2024 performance period/2026 \\nMIPS payment year and future years as follows:  adding five new improvement activities; \\nmodifying one existing improvement activity; and removing three previously adopted \\nimprovement activities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We refer readers to Appendix 2: Improvement Activities of this \\nproposed rule for further details.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We do not believe these proposed changes to the improvement \\nactivities inventory would significantly impact time or financial burden on interested parties \\nbecause MIPS eligible clinicians are still required to submit the same number of activities and \\nthe per response time for each activity is uniform.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We do not expect these proposed changes to \\nthe improvement activities inventory to affect our currently approved information collection]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [burden estimates in terms of neither the number of estimated respondents nor the burden per \\nresponse.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We anticipate most clinicians performing improvement activities, to comply with \\nexisting MIPS policies, would continue to perform the same activities under the policies in this \\nproposed rule because previously finalized improvement activities continue to apply for the \\ncurrent and future years unless otherwise modified per rulemaking (82 FR 54175).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Most of the \\nimprovement activities in the Inventory remain unchanged for the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We refer readers to section IV.A.4.f.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [(3)(b) of this rule for \\nadditional information on proposed changes to the improvement activities Inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [(3)  Update to CEHRT Definition for the Medicare Promoting Interoperability Program and the \\nQuality Payment Program\\nIn section III.R of this proposed rule, we propose to update the definitions of CEHRT for \\nthe Medicare Promoting Interoperability Program for eligible hospitals and CAHs and for the \\nMIPS Promoting Interoperability performance category.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Under this proposal, we would revise \\nthe definitions of CEHRT for the Medicare Promoting Interoperability Program at \\u00a7\\u2009495.4, and \\nfor the Quality Payment Program at \\u00a7\\u2009414.1305.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Specifically, we propose to add a reference to \\nthe \\u201cBase EHR Definition\\u201d where the regulatory text refers to the \\u201c2015 Edition Base EHR \\ndefinition,\\u201d remove \\u201c2015 Edition\\u201d where we reference \\u201c2015 Edition health IT certification \\ncriteria,\\u201d and add a cross-reference to health IT certification criteria at \\u00a7 170.315.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We also \\npropose to specify that technology meeting the CEHRT definitions must meet ONC\\u2019s \\ncertification criteria at \\u00a7 170.315, \\u201cas adopted and updated by ONC.\\u201d  We believe that these \\nrevisions to the CEHRT definitions, if finalized, would ensure that updates to the definition at \\u00a7 \\n170.102 and updates to applicable health IT certification criteria in \\u00a7 170.315 would be \\nincorporated into CEHRT definitions, without requiring additional regulatory action by CMS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Finally, we note that while this proposal is consistent with the approach in ONC\\u2019s HTI-1 \\nproposed rule (88 FR 23746 through 23917), we do not believe that ONC must finalize their \\nproposed revisions for us to be able to finalize the changes proposed in this section for our]]\",\n          \"Topic: 3F_OUD OTP Coverage: [from p. 441: [We are proposing to amend language at \\u00a7\\u00a7 410.47(d) and 410.49(e) by specifying that \\nthese sections include supervising practitioner standards, rather than just supervising physician \\nstandards.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [We are also removing the third standard in each section (\\u00a7\\u00a7 410.47(d)(3) and \\n410.49(e)(3)) because specifying that a physician or NPP is licensed to practice medicine in the \\nstate where a PR/CR/ICR program is offered, or any corresponding reference to a NPP being \\nlicensed or authorized to practice, is redundant to the definition for each practitioner type in the \\nAct.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Since the physicians and NPPs that may supervise PR/CR/ICR are defined at \\u00a7\\u00a7 410.47(a) \\nand 410.49(a) by cross-reference to the Act, we believe repeating part of that definition in these \\nsections is unnecessary.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [4.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Summary\\nWe are proposing additions and revisions that are necessary to implement the \\namendments to section 1861(eee) and (fff) of the Act set forth in section 51008 of the BBA of \\n2018, which expand the types of practitioners that may supervise PR, CR and ICR.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [This \\nincludes changes to the regulatory language in the definitions, settings and supervising \\npractitioner standards sections under \\u00a7\\u00a7 410.47 and 410.49.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [We believe these proposed \\namendments to \\u00a7\\u00a7 410.47 and 410.49 would serve to implement the provisions in the BBA of \\n2018 regarding the types of practitioners that may supervise PR, CR and ICR beginning January \\n1, 2024.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [All other provisions of these regulations would remain unchanged.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [F.  Modifications Related to Medicare Coverage for Opioid Use Disorder (OUD) Treatment \\nServices Furnished by Opioid Treatment Programs (OTPs) \\n1.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Background\\nSection 2005 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery \\nand Treatment (SUPPORT) for Patients and Communities Act (SUPPORT Act) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [L. 115-\\n271, October 24, 2018) established a new Medicare Part B benefit for OUD treatment services \\nfurnished by OTPs during an episode of care beginning on or after January 1, 2020.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [In the CY \\n2020 PFS final rule (84 FR 62630 through 62677 and 84 FR 62919 through 62926), we]] Topic: 3F_OUD OTP Coverage: [from p. 442: [implemented Medicare coverage and provider enrollment requirements and established a \\nmethodology for determining the bundled payments for episodes of care for the treatment of \\nOUD furnished by OTPs.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [We also established in the CY 2020 PFS final rule new codes and \\nfinalized bundled payments for weekly episodes of care that include methadone, oral \\nbuprenorphine, implantable buprenorphine, injectable buprenorphine or naltrexone, and non-\\ndrug episodes of care, as well as add-on codes for intake and periodic assessments, take-home \\ndosages for methadone and oral buprenorphine, and additional counseling.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [In the CY 2021 PFS \\nfinal rule (85 FR 84683 through 84692), we adopted new add-on codes for take home supplies of \\nnasal naloxone and injectable naloxone.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [In the CY 2022 PFS final rule (86 FR 65340 and \\n65341), we established a new add-on code and payment for a higher dose of nasal naloxone.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [We \\nalso revised paragraphs (iii) and (iv) in the definition of \\u201cOpioid disorder treatment service\\u201d at \\n\\u00a7 410.67(b) to allow OTPs to furnish individual and group therapy and substance use counseling \\nusing audio-only telephone calls rather than two-way interactive audio/video communication \\ntechnology after the conclusion of the public health emergency (PHE) for COVID-19 in cases \\nwhere audio/video communication technology is not available to the beneficiary, provided all \\nother applicable requirements are met (86 FR 65342).]] Topic: 3F_OUD OTP Coverage: [from p. 442: [More recently, CMS made further modifications and expansions to covered services for \\nthe treatment of OUD by OTPs in the CY 2023 PFS final rule (87 FR 69768 through 69777).]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Specifically, we revised our methodology for pricing the drug component of the methadone \\nweekly bundle and the add-on code for take-home supplies of methadone by using the payment \\namount for methadone for CY 2021 updated by the PPI for Pharmaceuticals for Human Use \\n(Prescription) to better reflect the changes in methadone costs for OTPs over time.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Additionally, \\nwe finalized a modification to the payment rate for individual therapy in the non-drug component \\nof the bundled payment for an episode of care to base the payment rate on the rate for longer \\ntherapy sessions that better account for the greater severity of needs for patients with an OUD \\nand receiving treatment in the OTP setting.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Moreover, for the purposes of the geographic]] Topic: 3F_OUD OTP Coverage: [from p. 443: [adjustment, we clarified that services furnished via OTP mobile units will be treated as if the \\nservices were furnished in the physical location of the OTP for purposes of determining \\npayments to OTPs under the Medicare OTP bundled payment codes and/or add-on codes to the \\nextent that the services are medically reasonable and necessary and are furnished in accordance \\nwith Substance Abuse and Mental Health Services Administration (SAMHSA) and Drug \\nEnforcement Administration (DEA) guidance.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [We believe that this policy enables OTPs to \\nbetter serve Medicare beneficiaries living in underserved areas by providing access to many of \\nthe same OUD treatment services offered at the brick and mortar location of the OTP.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [We are \\ncontinuing to monitor utilization of OUD treatment services furnished by OTPs to ensure that \\nMedicare beneficiaries have appropriate access to care.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [For CY 2024, we are proposing several \\nmodifications to the policies governing Medicare coverage and payment for OUD treatment \\nservices furnished by OTPs.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [2.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [Additional Flexibilities for Periodic Assessments furnished via Audio-only \\nTelecommunications\\nWe have finalized several flexibilities for OTPs regarding the use of telecommunications, \\nboth during the PHE for COVID-19 and outside of the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [In the CY 2020 PFS final rule, we \\nfinalized a policy allowing OTPs to furnish substance use counseling and individual and group \\ntherapy via two-way interactive audio-video communication technology.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [In the IFC entitled \\n\\u201cMedicare and Medicaid Programs:  Policy and Regulatory Revisions in Response to the \\nCOVID-19 Public Health Emergency,\\u201d which appeared in the April 6, 2020 Federal Register \\n(85 FR 19258), we revised paragraphs (iii) and (iv) in the definition of opioid use disorder \\ntreatment service at \\u00a7 410.67(b) on an interim final basis to allow the therapy and counseling \\nportions of the weekly bundles, as well as the add-on code for additional counseling or therapy, \\nto be furnished using audio-only telephone calls rather than via two-way interactive audio-video \\ncommunication technology during the PHE for the COVID-19 if beneficiaries do not have access \\nto two-way audio-video communications technology, provided all other applicable requirements]] Topic: 3F_OUD OTP Coverage: [from p. 444: [are met.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [In the CY 2022 PFS final rule (86 FR 65341 through 65343), we finalized that after the \\nconclusion of the PHE for COVID-19, OTPs are permitted to furnish substance use counseling \\nand individual and group therapy via audio-only telephone calls when audio and video \\ncommunication technology is not available to the beneficiary.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [As we explained in the CY 2022 \\nPFS final rule (86 FR 65342), we interpret the requirement that audio/video technology is \\u201cnot \\navailable to the beneficiary\\u201d to include circumstances in which the beneficiary is not capable of \\nor has not consented to the use of devices that permit a two-way, audio/video interaction because \\nin each of these instances audio/video communication technology is not able to be used in \\nfurnishing services to the beneficiary.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [More recently in the CY 2023 PFS final rule (87 FR \\n69775 through 69777), we further extended telecommunication flexibilities for the initiation of \\ntreatment with buprenorphine outside of the COVID-19 PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [Specifically, we allowed the OTP \\nintake add-on code to be furnished via two-way, audio-video communications technology when \\nbilled for the initiation of treatment with buprenorphine, to the extent that the use of audio-video \\ntelecommunications technology to initiate treatment with buprenorphine is authorized by DEA \\nand SAMHSA at the time the service is furnished.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [We also permitted the use of audio-only \\ncommunication technology to initiate treatment with buprenorphine in cases where audio-video \\ntechnology is not available to the beneficiary, provided all other applicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [In the IFC entitled \\u201cMedicare and Medicaid Programs, Basic Health Program, and \\nExchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public \\nHealth Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility \\nQuality Reporting Program,\\u201d which appeared in the May 8, 2020 Federal Register (85 FR \\n27558), we revised paragraph (vii) in the definition of \\u201cOpioid use disorder treatment service\\u201d at \\n\\u00a7 410.67(b) on an interim final basis to allow periodic assessments to be furnished during the \\nPHE for COVID-19 via two-way interactive audio-video telecommunication technology and, in \\ncases where beneficiaries do not have access to two-way audio-video communication \\ntechnology, to permit the periodic assessments to be furnished using audio-only telephone calls]] Topic: 3F_OUD OTP Coverage: [from p. 445: [rather than via two-way interactive audio-video communication technology, provided all other \\napplicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [In the CY 2021 PFS final rule (85 FR 84690), we finalized our \\nproposal to revise paragraph (vii) in the definition of \\u201cOpioid use disorder treatment service\\u201d at \\n\\u00a7 410.67(b) to provide that periodic assessments (HCPCS code G2077) must be furnished during \\na face-to-face encounter, which includes services furnished via two-way interactive audio-video \\ncommunication technology, as clinically appropriate, provided all other applicable requirements \\nare met, on a permanent basis.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Furthermore, in the CY 2023 PFS proposed rule (87 FR 46093), we sought comment on \\nwhether we should allow periodic assessments to continue to be furnished using audio-only \\ncommunication technology following the end of the PHE for COVID-19 for patients who are \\nreceiving treatment via buprenorphine, and if this flexibility should also continue to apply to \\npatients receiving methadone or naltrexone.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [In response, several commenters advocated for CMS \\nto continue to allow periodic assessments to be furnished audio-only when video is not available \\nafter the end of the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Commenters highlighted that making audio-only flexibilities permanent \\nwould further promote equity for individuals who are economically disadvantaged, live in rural \\nareas, are racial and ethnic minorities, lack access to reliable broadband or internet access, or do \\nnot possess devices with video capability.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Additionally, a commenter cited a 2020 HHS Issue \\nBrief indicating higher utilization of audio-only visits for older adults.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Specifically, evidence \\nsuggests that the proportion of telephonic audio-only visits increases with the age of the patient, \\nwith \\u201c17 percent of visits delivered via audio-only interaction for patients 41-60 years of age, 30 \\npercent for patients 61-80 years of age, and 47 percent of visits for patients over 81.\\u201d 142 One \\ncommenter stated that periodic assessments are no less complex than intake/initial assessments, \\nand thus are equally appropriate for audio-video and audio-only care.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Lastly, several commenters \\nexpressed support for the use of telecommunications in circumstances when the provider and \\n142 HHS ASPE Issue Brief: Medicare beneficiary use of telehealth visits: Early Data from the Start of the COVID-19 \\nPandemic (July 27, 2020).]] Topic: 3F_OUD OTP Coverage: [from p. 445: [https://aspe.hhs.gov/reports/medicare-beneficiary-use-telehealth-visits-early-data-start-\\ncovid-19-pandemic.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [patient have together determined that the patient would individually benefit from telehealth \\nservices and a high quality of care is maintained.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [They encouraged CMS to expand flexibilities \\nto furnish substance use disorder (SUD) services via telecommunications to allow providers and \\npatients to decide collaboratively the best modality for individualized care.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [After considering \\nthese comments, CMS determined that it would be appropriate to allow periodic assessments to \\nbe furnished audio-only when video is not available through the end of CY 2023, to the extent \\nthat it is authorized by SAMHSA and DEA at the time the service is furnished and, in a manner \\nconsistent with all applicable requirements.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [We stated our belief that this modification would \\nallow continued beneficiary access to these services for the duration of CY 2023 in the event the \\nPHE terminated before the end of 2023 and that it would also grant additional time for CMS to \\nfurther consider telecommunication flexibilities associated with periodic assessments.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Accordingly, we revised the requirements related to the periodic assessment services in \\nparagraph (vii) in the definition of \\u201cOpioid use disorder treatment services\\u201d at \\u00a7 410.67(b) of the \\nregulations to reflect these changes.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Section 4113 of Division FF, Title IV, Subtitle A of the Consolidated Appropriations Act \\nof 2023 (CAA, 2023) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [L. 117-328, December 29, 2022) extended the telehealth flexibilities \\nenacted in the Consolidated Appropriations Act of 2022 (CAA, 2022) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [L. 117-103, March \\n15, 2022).]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Specifically, it amended sections 1834(m), 1834(o), and 1834(y) of the Act to delay \\nthe requirement for an in-person visit prior to furnishing certain mental health services via \\ntelecommunications technology by physicians and other practitioners, Rural Health Clinics \\n(RHCs), and Federally Qualified Health Centers (FQHCs) until dates of service on or after \\nJanuary 1, 2025 if the COVID-19 PHE ends prior to that date.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Additionally, it extended the \\nflexibilities available during the PHE that allow for certain Medicare telehealth services defined \\nin section 1834(m)(4)(F)(i) of the Act to be furnished via an audio-only telecommunications \\nsystem through December 31, 2024 if the PHE for COVID-19 ends prior to that date.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [The PHE \\nfor COVID-19, which was declared under section 319 of the Public Health Service Act, expired]] Topic: 3F_OUD OTP Coverage: [from p. 447: [at the end of the day on May 11, 2023, so the aforementioned flexibilities will be extended \\nthrough the end of CY 2024 or CY 2025, as applicable.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [To better align coverage for periodic assessments furnished by OTPs with the telehealth \\nflexibilities described in section 4113 of the CAA, 2023, we are proposing to extend the audio-\\nonly flexibilities for periodic assessments furnished by OTPs through the end of CY 2024.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [Under \\nthis proposal, we would allow periodic assessments to be furnished audio-only when video is not \\navailable to the extent that use of audio-only communications technology is permitted under the \\napplicable SAMHSA and DEA requirements at the time the service is furnished and all other \\napplicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [We believe extending this flexibility would promote continued \\nbeneficiary access to these services following the end of the PHE and for the duration of CY \\n2024.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [During the COVID-19 pandemic, substance use disorder treatment facilities increased \\ntelemedicine offerings by 143 percent, and as of 2021, almost 60 percent of SUD treatment \\nfacilities offer telehealth.143 Notably, telephone-based (that is, audio-only) therapy and recovery \\nsupport services provided by SUD programs have been found to be one of the most common \\nmodes of telehealth for treatment of opioid use disorder.144 Therefore, extending these audio-\\nonly flexibilities for an additional year may minimize disruptions associated with the conclusion \\nof the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [Additionally, evidence has shown that Medicare beneficiaries who are older than 65 \\nyears-old, racial/ethnic minorities, dual-enrollees, or living in rural areas, or who experience low \\nbroadband access, low-income, and/or not speaking English as their primary language, are more \\nlikely to be offered and use audio-only telemedicine services than audio-video services.145 Other \\nevidence also suggests that while Tribal populations, including American Indian and Alaska \\nNatives, have the highest rates of OUD prevalence among Medicare beneficiaries, one-third of \\nthese populations do not have adequate access to high-speed broadband and continue to rely on \\n143 https://pubmed.ncbi.nlm.nih.gov/34407631/.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [144 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250742/.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [145 https://pubmed.ncbi.nlm.nih.gov/33471458/; https://www.kff.org/medicare/issue-brief/medicare-and-telehealth-\\ncoverage-and-use-during-the-covid-19-pandemic-and-options-for-the-future/; https://journals.lww.com/lww-\\nmedicalcare/Fulltext/2021/11000/Disparities_in_Audio_only_Telemedicine_Use_Among.10.aspx.]]\",\n          \"Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [b.  Histopathology and Cytology Testing at Remote Locations\\nWe are seeking public comments on the following:\\n\\u25cf  How should \\u201cremote testing location\\u201d be defined?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should the CLIA regulations be revised to allow pathologists to examine \\nhistopathology and cytology slides/images at a remote testing location?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What conditions (including, location(s)) should apply for a pathologist to examine \\nhistopathology or cytology slides/images remotely without obtaining a separate CLIA \\ncertification?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  Under what conditions should a primary location cease permitting testing at the remote \\nlocation?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should the remote location be included on the final patient report?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should CMS, SAs, or Accreditation Organizations perform onsite surveys at \\nremote locations?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [c.  Clinical cytogenetics\\nWe are seeking public comments on the following: \\n\\u25cf  Under what circumstances should CLIA allow remote locations or testing facilities to \\nexamine clinical cytogenetics images without obtaining a separate CLIA certification?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  Under what circumstances would the examination of clinical cytogenetics images be \\nunacceptable for the remote location scenario?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What clinical cytogenetics testing processes should the primary laboratory have in \\nplace to ensure the remote site complies with the CLIA requirements?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What \\u201cconditions\\u201d or \\u201ccriteria\\u201d  would be necessary for the remote location to ensure \\nquality testing for the examination of clinical cytogenetics images?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [Q.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [Changes to the Basic Health Program Regulations \\nSection 1331 of the Patient Protection and Affordable Care Act (Pub.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [L. 111-148, enacted \\nMarch 23, 2010), as amended by the Health Care and Education Reconciliation Act of 2010]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [(Pub.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [L. 111-152, enacted March 30, 2010) (collectively referred to as the Affordable Care Act \\nor ACA), provides States with the option to operate a Basic Health Program (BHP).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [In the States \\nthat elect to operate a BHP, the State\\u2019s BHP makes affordable health benefits coverage available \\nfor lawfully present individuals under age 65 with household incomes between 133 and 200 \\npercent of the Federal poverty level (or in the case of a lawfully present non-citizen, ineligible \\nfor Medicaid or the Children\\u2019s Health Insurance Program (CHIP) due to immigration status, \\nwhose household income is between zero and 200 percent of the FPL) who are not eligible for \\nMedicaid, CHIP, or other minimum essential coverage.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [As of the date of this proposed rule, only \\nNew York and Minnesota have implemented a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Federal funding for BHP is based on 95 percent of the value of the premium tax credits \\n(PTC) and cost sharing reduction (CSR) subsidies that BHP enrollees would have received had \\nthey instead enrolled in Qualified Health Plans (QHPs) through the Exchange in accordance with \\nsection 1331(d)(3)(A)(i) of the ACA.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [These funds are paid to trusts established by the States and \\ndedicated to the BHP, and the States then administer the payments to BHP standard health plans \\nwithin the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Under section 1331(d)(2) of the ACA, Federal funding for the BHP can only be \\nused to reduce the premiums and cost-sharing of, or to provide additional benefits for, eligible \\nindividuals enrolled in standard health plans within the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [1.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Allowing States to Suspend a BHP \\nCurrent regulations require States to operate a BHP under a certified Blueprint approved \\nby CMS, and to operate the BHP as long as their approved certified Blueprint is in place.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Under \\n42 CFR 600.140, a State may terminate its BHP, which requires that the BHP trust fund balance \\nmust be refunded to the Federal government.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [A State has inquired about whether it could \\n\\u201csuspend\\u201d its program for a portion of time, so that it could shift BHP enrollees to other coverage \\nwith comparable benefits and cost sharing, while maintaining its BHP trust fund, which it could \\nuse if the State were to resume the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We see the value in allowing a State currently operating a BHP to experiment with other \\nways of providing coverage that may increase the number of people covered while not increasing \\nFederal costs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose to give a State the option of temporarily \\u201csuspending\\u201d its BHP \\nprogram, while retaining accrued funds in the BHP trust fund for a limited period of time.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Should \\nthe State decide to resume operating its BHP, the suspension would allow the State to leverage \\naccrued funds and avoid the processes of terminating the program and refunding trust funds, and \\nthen later having to submit a new BHP application for approval.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [For that reason, under the \\nauthority of section 1331(c)(4) of the ACA, which requires coordination with other State health \\nprograms, we are proposing to amend \\u00a7 600.140 to add an option at paragraph (b) for a State to \\nsuspend its BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose at \\u00a7 600.140(b)(1) that States wishing to suspend their BHP must submit an \\napplication to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Under proposed \\u00a7 600.140(b)(1), States could also seek approval to extend a \\nBHP suspension previously approved by HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [In \\u00a7 600.140(b)(1)(vi), we propose that the \\napplication must be submitted at least 9 months in advance of the proposed effective date of the \\nsuspension or extension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [In \\u00a7 600.140(c), we propose that the State cannot implement the \\nsuspension or extension without prior approval by the Secretary.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [However, for States seeking to \\nsuspend a BHP in the first plan year that begins following publication of a final rule adopting \\nthis proposal, States must submit an application within 30 days of the publication of such a final \\nrule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [HHS will approve or deny such application as expeditiously as possible.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose in \\u00a7 \\n600.140(b)(2) that a suspension application would need to be approved prior to the effective date \\nof suspension, except in the case of a State seeking to suspend a BHP in the first plan year that \\nbegins following publication of a final rule adopting this proposal.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [The proposed substantive requirements for the suspension application are described in \\n\\u00a7 600.140(b)(1)(i) through (v).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [During the period of suspension, BHP enrollees should receive \\ncomparable coverage that is as comprehensive and affordable as, or more comprehensive and \\naffordable than, BHP coverage during the period of suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Therefore, in \\u00a7 600.140(b)(1)(i)]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [through (iii), we propose to require that the suspension and extension application demonstrates \\nthat the benefits that will be provided to individuals that meet the BHP eligibility criteria are at \\nleast equivalent to the benefits offered in the State\\u2019s BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We propose that the cost sharing and \\npremiums that will be charged to such individuals under the new coverage option do not exceed \\nthe amounts charged under the BHP to reduce the risk that these individuals are harmed by the \\ntransition to other coverage.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We propose at \\u00a7 600.140(b)(1)(i) to require that benefits provided under the new \\ncoverage option must be at least equal to the BHP benefits in the certified Blueprint in effect on \\nthe effective day of suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [This is the same standard that is used in the Medicaid regulations \\nat \\u00a7 440.330 to determine if a State\\u2019s alternative benefit package is equivalent to the benchmark \\nbenefit package.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [Additionally, it is similar to the standard that is used by CHIP at \\u00a7 457.420 to \\ndetermine if a State\\u2019s CHIP benefit package is equivalent to the benchmark benefit package, \\nalthough the CHIP standard allows for some variation if the State is adding additional benefits as \\nrequired by Title XXI.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We note that it would be acceptable to provide additional benefits under \\nthe new coverage option, such that individuals receive more or greater benefits under the new \\ncoverage option.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We considered whether there should be a look back period, such that benefits \\nunder the new coverage option would be compared to the BHP benefits provided under the \\ncertified Blueprint in effect for a period of time prior to the effective date of the suspension and \\nseek comments on this alternative approach.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [In order to determine that the cost sharing required of individuals under the new coverage \\noption does not exceed the BHP cost sharing levels, we propose at \\u00a7 600.140(b)(1)(ii) to require \\nthat the actuarial value of the new coverage option must meet or exceed the actuarial value of the \\nBHP standard health plans in effect immediately prior to the suspension period.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [This may result \\nin cost sharing for individual benefits differing between the BHP and the new coverage program, \\nprovided the actuarial value of the new coverage options meets or exceeds the actuarial value of \\nthe BHP standard health plans.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [If there are multiple health plans being offered under the new]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [coverage option and/or multiple standard health plans in effect in the State, we propose that the \\nmedian actuarial value of the health plans offered under the new coverage option must meet or \\nexceed the median actuarial value of the BHP standard health plans.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We considered whether to \\nrequire that cost sharing under the new coverage option instead meet the cost sharing \\nrequirements under current regulations at \\u00a7 600.520(c) and seek comment on whether this \\nalternative approach should be adopted in the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Similarly, we propose at \\u00a7 600.140(b)(1)(iii) to require that the premiums charged to \\nindividuals under the new coverage option must be comparable to BHP standard health plan \\npremiums in effect immediately prior to the suspension period, beyond reasonable increases due \\nto inflation as measured by the Consumer Price Index (CPI).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We considered alternative methods \\nfor measuring equivalency in premiums.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [First, we considered whether to require that premiums \\nunder the new coverage option instead meet the premium requirements under \\u00a7 600.505(a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Second, we considered whether premiums charged to individuals under the new coverage option \\nshould instead not exceed the premiums in effect on December 31, 2020, as these premiums \\nlevels do not account for any additional premium tax credit subsidies offered under the American \\nRescue Plan Act or the Inflation Reduction Act.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Third, we considered whether premium and cost \\nsharing levels, considered together, under the new coverage option would be considered \\nsufficient, if those levels meet the requirements under a section 1115 demonstration or section \\n1332 waiver.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also seek comment on whether these alternative approaches should be adopted \\nin the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also considered alternatives to the timing of the comparison of benefits and cost \\nsharing in BHP to the new coverage option.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Specifically, we considered whether benefits and \\ncost sharing under the new coverage option should be compared to the benefits and cost sharing \\nunder the BHP on the date the suspension application is submitted to HHS, or some other date.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also seek comment on the potential adoption of these alternatives in the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Finally, we believe that the suspension period should not result in individuals losing \\ncoverage, solely due to a change in eligibility criteria for the program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Therefore, we are \\nproposing in \\u00a7 600.140(b)(1)(iv) that a state must demonstrate in its application that the \\neligibility criteria for coverage during the suspension is not more restrictive than the criteria \\ndescribed in \\u00a7 600.305.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We believe that the suspension period should be long enough to allow the State to \\nevaluate the alternative coverage provided to BHP eligible individuals, but should not be \\nindefinite.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Therefore, we are proposing in \\u00a7 600.140(b)(1)(v) that a State could request a \\nsuspension of up to 5 years in an initial suspension application, after which a State could request \\nan extension of up to 5 additional years.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Additional extension periods would not be allowed.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [When the suspension period, including any extension period, ends, we propose that the State \\nwould need to transition the BHP eligible population back to the BHP, or terminate the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We \\npropose at \\u00a7 600.140(b)(7) that at least 9 months before the end of the suspension period, a State \\nmust submit a transition plan to HHS that explains how the State will reinstate its BHP, or \\nterminate the program under \\u00a7 600.140(a) of the current regulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [The state must also notify \\nthe public of this change.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Under proposed \\u00a7 600.140(b)(7), a State also could elect to end a BHP \\nsuspension before the end of the initial or extended suspension period by following the same \\nprocess.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We chose 5 years for the initial approval period because this aligns with the duration of \\ninitial waivers and demonstration projects approved under section 1332 of the ACA and section \\n1115 of the Act.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We believe these are the most likely authorities under which States could seek \\nto provide alternative coverage to BHP enrollees.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Similarly, we chose 5 years for the extension \\nperiod because it aligns with the duration of typical extensions or amendment periods under \\nsection 1332 waiver and section 1115 demonstration projects.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We considered a shorter extension]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [period of 2 or 3 years, and allowing multiple extension periods given both section 1332 waiver \\nand 1115 demonstrations can be extended.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We seek comment on these alternatives.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Under proposed \\u00a7 600.140(b)(1)(vii), States requesting an extension of a previously-\\napproved BHP suspension also would need to provide an evaluation of the alternative coverage \\nin its application.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [In the case of alternative coverage provided through a section 1115 \\ndemonstration project or section 1332 waiver, the evaluation and application required for such \\ndemonstration projects and waivers would satisfy this requirement.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [If individuals and/or standard health plans will experience a change in the terms of the \\ncoverage, including receiving additional benefits or being charged different cost sharing \\namounts, in \\u00a7 600.140(b)(3), we propose to require that the state provide notice to them at least \\n90 days prior to the effective date of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [The notices would need to include \\ninformation regarding the State\\u2019s assessment of their eligibility for all other insurance \\naffordability programs in the State, and meet the accessibility and readability standards at 45 \\nCFR 155.230(b).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [In order to calculate a State\\u2019s BHP payments, the State provides CMS an estimate of the \\nnumber of BHP enrollees it projects will enroll in the upcoming BHP program quarter each \\nquarter of program operations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We use those estimates to calculate the prospective payment, \\nwhich is deposited in the State\\u2019s BHP trust fund.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Once the State provides us with actual \\nenrollment data for those periods, the actual enrollment data is used to calculate the final BHP \\npayment amount and make any necessary reconciliation adjustments to the prior quarters\\u2019 \\nprospective payment amounts due to differences between projected and actual enrollment.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We believe that having an accurate accounting of the balance of the State\\u2019s trust fund is \\ncritical for any State suspending its BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Therefore, we propose to require in \\u00a7 600.140(b)(4) \\nthat States that suspend their BHP must submit the data necessary to complete the BHP payment \\nreconciliation process within 12 months of the effective date of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We believe that]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [12 months is a reasonable amount of time for a State to submit the actual enrollment data for the \\nperiods it was operating a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [One reason it is important for a State to complete the BHP payment reconciliation \\nprocess is to establish a baseline balance for calculating interest.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Currently, States\\u2019 BHP trust \\nfunds can accrue interest, and this interest is retained in the BHP trust fund.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [However, we believe \\nthat interest accrued on the BHP trust fund during any suspension must be remitted to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Since the State is not operating a BHP during the suspension period, suspension should not \\ngenerate additional funds for the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We propose in \\u00a7600.140(b)(6) that while the State is not \\nproviding BHP coverage, any accrued interest on the trust fund must be remitted to HHS on an \\nannual basis in the form and manner set out by HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [States currently submit the balance of their trust fund and any interest accrued through \\nthe BHP annual report described in \\u00a7600.170.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We proposed revisions to \\u00a7\\u00a7 600.140(b) and \\n600.170(a) to require States that suspend their BHP continue to submit an annual report in order \\nto document the interest earned and to provide assurance that the coverage provided to BHP-\\neligible individuals meets the standards discussed above.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We propose in \\u00a7 600.140(b)(5) to \\nrequire States that suspend their BHP continue to submit an annual report during the suspension \\nperiod.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We proposed amendments to \\u00a7 600.170(a), which describes the requirements for the \\nannual reports, to describe the standards that will apply to States that have suspended their BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Specifically, we propose to redesignate the introductory language in paragraph (a) as paragraph \\n(a)(1), to redesignate paragraphs (a)(1) through (a)(4) as paragraphs (a)(1)(i) through (a)(1)(iv), \\nand to add a new paragraph \\u00a7 600.170(a)(2) to require that States that have suspended their BHP \\nunder \\u00a7 600.140(b) must submit an annual report that includes (1) the balance of the BHP trust \\nfund and any interest accrued on that balance; (2) an assurance that the coverage provided to \\nindividuals who would be eligible for a BHP under \\u00a7 600.305 continues to meet the standards \\ndescribed in \\u00a7 600.140(b)(1)(i) through (iii); and (3) any additional information specified by the \\nSecretary at least 120 days prior to the date that the annual report is due.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [ If a State does not meet the proposed requirements (that is, completing the financial \\nreconciliation process, remitting interest on the trust fund, and submitting the required \\ninformation in its annual report), we propose in \\u00a7 600.140(d) that the Secretary can withdraw \\napproval of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Specifically, we propose that the Secretary can withdraw approval of \\nthe suspension if the State ends implementation of the alternative coverage program for any \\nreason, or if the State fails to continue to meet the coverage and cost sharing requirements of the \\nalternative coverage program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [If the State seeks an amendment to the alternative coverage \\nprogram, the State must inform CMS of this proposed change so that CMS may evaluate if the \\ncoverage is sufficient.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [In addition, we propose at paragraph (d) that we could also withdraw \\napproval if we have significant evidence of harm, financial malfeasance, fraud, waste, or abuse \\nconsistent with \\u00a7 600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [In \\u00a7 600.140(d)(1) through (4), we propose a process for withdrawing \\napproval, which mirrors the process for withdrawing certification of a BHP Blueprint in \\u00a7 \\n600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Specifically, we propose that the Secretary will withdraw approval only after providing \\nthe State with notice of the findings upon which the Secretary is basing the withdrawal, a \\nreasonable period for the State to address the finding, and an opportunity for a hearing before \\nissuing a final finding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [We propose that the Secretary shall make every reasonable effort to \\nresolve proposed findings without withdrawing approval of the suspension plan and in the event \\nof a decision to withdraw approval, will accept a request from the State for reconsideration.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [The \\neffective date of an HHS determination withdrawing approval of the suspension plan would not \\nbe earlier than 120 days following issuance of a final finding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Within 30 days following a final \\nfinding under paragraph (d)(1) of this paragraph, the State shall submit a transition plan to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [During the transition period from the BHP to other coverage the state may not use funds \\nfrom the BHP trust fund toward the unwinding of the BHP program and transition to the new \\ncoverage program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Under section 1331(d)(2) of the ACA and current regulations at \\u00a7 600.705(c), \\nFederal funding for BHP can only be used to reduce the premiums and cost-sharing, or to \\nprovide additional benefits, for BHP-eligible individuals enrolled in standard health plans within]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Therefore, Federal funding is not available for administrative expenses associated with \\ntransitioning BHP enrollees to a new coverage program or for costs associated with providing \\nnew coverage after the transition has occurred.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [States cannot use Federal BHP funding to cover \\npremiums and cost sharing (or additional benefits) for individuals that would otherwise be \\neligible for BHP funding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We solicit comment on these proposals.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We seek comment on the proposed process for suspending a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Specifically, we seek \\ncomment on how far in advance of suspension a state must submit a suspension application to \\nCMS and how far in advance of suspension CMS must approve or deny the suspension request.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We also seek comment on duration of time a state may suspend their BHP, without terminating \\nthe program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [2.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Submission and Review of BHP Blueprints\\nAs noted above, under current \\u00a7 600.110, States must submit to the Secretary and receive \\ncertification of a BHP Blueprint describing their operational design choices prior to \\nimplementation.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Under the current \\u00a7 600.125(a) a State that seeks to make significant changes to \\nits BHP must submit a revised Blueprint to the Secretary for review and certification; however, \\nthe current regulation does not specify any timeframes for the submission and review of revised \\nBlueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [The current \\u00a7 600.125(a) also describes a limited number of changes under which \\nsubmission of a revised Blueprint is required.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Most notably, the current regulation does not \\nrequire the submission of a revised Blueprint in response to changes in Federal law or \\nregulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Additionally, under current \\u00a7 600.125(a) and (b), any changes made in a revised \\nBlueprint can be implemented prospective from the date of certification; no changes can be \\nimplemented until HHS certifies the revised Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We believe that additional parameters are necessary in order to ensure effective and \\nefficient operation of the BHPs and HHS review of a revised Blueprint, consistent with section \\n1331(a)(1) of the ACA.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Therefore, we propose changes to \\u00a7 600.125 to establish timeframes and \\nprocedures for the submission and review of BHP Blueprints, similar to the Medicaid and CHIP]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [State plan amendment (SPA) submission and review processes.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We note that these proposed \\ntimeframes only apply to the submission and review of revised Blueprints; we are not proposing \\nchanges to the timeframes for the submission and review of an initial Blueprint, set forth in \\ncurrent regulations at \\u00a7 600.120, in the event additional States seek to establish BHPs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Additionally, we believe States need flexibility to receive approval of a retroactive \\neffective date for changes to their BHP Blueprint, similar to flexibilities allowed under \\nregulations at \\u00a7\\u00a7 430.20(b) and 457.60 for the submission of Medicaid and CHIP SPAs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We \\nnote, however, that in the event that a State implements a change to its BHP Blueprint that is \\nultimately disapproved by HHS, the State could be required to implement a corrective action \\nplan under \\u00a7\\u2009600.715.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Specifically, under existing regulations at \\u00a7 600.125(a), States must submit a revised \\nBlueprint whenever they seek to make significant change(s) that alter program operations the \\nBHP benefit package, enrollment, disenrollment and verification policies described in its \\ncertified BHP Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Under the proposed revisions to \\u00a7 600.125(a), we would broaden the \\ncircumstances requiring submission of a revised Blueprint to include States\\u2019 significant changes \\nthat alter any core program operations under \\u00a7 600.145(f).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [States also would be required to \\nsubmit a revised Blueprint to HHS whenever necessary to reflect changes in Federal law, \\nregulations, policy interpretations, or court decisions that affect provisions in their certified \\nBlueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [States would continue to be required to submit a revised Blueprint to make changes to \\nthe BHP benefit package or to enrollment, disenrollment, and verification policies described in \\nthe certified Blueprint, as currently required under \\u00a7 600.125(a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [At \\u00a7 600.125, we also propose to redesignate paragraph (b) as paragraph (d) and to add \\nnew paragraph (b) to provide that the effective date of a revised Blueprint may be as early as, but \\nnot earlier than, the first day of the quarter in which an approvable revision is submitted to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [This policy mirrors the standards for submission of a Medicaid SPA at \\u00a7 430.20(b).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [The current \\nregulations do not specify as to when revision is considered received.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We believe that it is]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [reasonable to consider a revised Blueprint to be received when HHS receives an electronic copy \\nof a cover letter signed by the Governor or Governor\\u2019s designee and a copy of the currently \\napproved Blueprint with proposed changes indicated in track changes.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [In the event a State is \\nunable to submit a revised Blueprint electronically, due to a disaster or other event outside of the \\nState\\u2019s control, CMS may consider other modes of submission on a case-by-case basis.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\ncurrent regulations at \\u00a7 600.125(b), redesignated at \\u00a7 600.125(d) in this proposed rule, the State \\nis responsible for continuing to operate under the terms of the existing certified Blueprint until \\nthe State adopts a revised Blueprint, the State terminates or suspends the BHP, or the Secretary \\nwithdraws certification for the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [We are also proposing to redesignate paragraph (c) as paragraph (g) and to add a new \\nparagraph (c) to create clear timelines for HHS\\u2019s review, approval, and disapproval of revised \\nBlueprints similar to the timelines currently applicable to CHIP SPAs under \\u00a7 457.150.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\nproposed \\u00a7 600.125(c)(1), a revised Blueprint will be deemed approved unless HHS, within 90 \\ndays after receipt of the revised Blueprint, sends the State written notice of disapproval or written \\nnotice of additional information HHS needs in order to make a final determination.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [If HHS \\nrequests additional information, the 90-day review period will be stopped and will resume the \\nday after HHS receives all of the requested additional information from the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\nproposed paragraph (c)(2), if 90 days from the date a Blueprint revision is received does not fall \\non a business day, the 90-day review period will end on the next business day.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under proposed \\nparagraph (c)(3), HHS may send written requests for additional information as many times as \\nneeded to obtain all information necessary to certify the revised Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [This mirrors the \\nprocess used by CHIP, of having one 90-day review period that can start and stop multiple times \\nwith a request for additional information and response.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [It differs from Medicaid, which has a 90-\\nday review period that can be stopped once by a request for additional information, followed by \\na second 90-day review period when the state responds.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [At paragraph (c), we propose that HHS \\nmay disapprove a Blueprint amendment if the Secretary determines that the Blueprint revision is]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [not consistent with section 1331 of the ACA or the regulations set forth in this part at any time \\nduring the review process, including when the 90-day review clock is stopped due to a request \\nfor additional information.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Once a Blueprint is approved, current paragraph (b) specifies that the State is responsible \\nfor continuing to operate under the terms of the existing certified Blueprint until and unless a \\nrevised Blueprint that seeks to make significant change(s) is certified, except during a public \\nhealth emergency, as described in paragraph (c).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [We propose to revise paragraph (b), \\nredesignated as paragraph (d) in this proposed rulemaking, to provide that the State must \\ncontinue to operate under the terms of an existing certified Blueprint until the State adopts a \\nrevised Blueprint, terminates the BHP following the procedures described in \\u00a7 600.140(a), \\nsuspends the BHP following the procedures described in \\u00a7 600.140(b), or the Secretary \\nwithdraws certification of the BHP under \\u00a7 600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Finally, we propose to apply some of the existing parameters for initial Blueprint \\nsubmissions to Blueprint revisions.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [In paragraph (e), we propose that a State may withdraw the \\nproposed revised Blueprint during HHS review if the State has not yet implemented the proposed \\nchanges and provides written notice to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [This proposal mirrors current \\u00a7 600.130 for initial \\nBHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [In paragraph (f), we propose that HHS will accept a State\\u2019s request for \\nreconsideration of a decision not to certify a revised Blueprint and provide an impartial review \\nagainst standards for certification if requested.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [This proposal mirrors current \\u00a7 600.135(c) for \\ninitial BHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Under current \\u00a7 600.135, HHS must act on all initial BHP Blueprint certification and \\nrevision requests in a timely matter.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Because we are proposing to specify timeframes for the \\nsubmission and review of revised BHP Blueprints under \\u00a7600.125, we propose to revise \\n\\u00a7 600.135 to apply only to the submission of initial BHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Specifically, we propose to \\nrevise the title to clearly state that this section is applicable to only initial Blueprints and to \\nremove the reference to BHP Blueprint revisions in paragraph (a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [3.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [BHP Notices\\nUnder current \\u00a7 600.330, States must provide written notice to beneficiaries conveying \\nfinal determination of eligibility or ineligibility.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [The regulation does not require States to provide \\nthose notices in a manner that is accessible to individuals with disabilities or limited English \\nproficiency (LEP).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Although HHS Office for Civil Rights regulations at 45 CFR 92.101, which \\napply to programs such as Medicaid, CHIP and BHP, require States to take reasonable steps to \\nprovide meaningful access for individuals with LEP and to ensure effective communication with \\nindividuals with disabilities, we believe it is important for these obligations to also be described \\nclearly in the BHP regulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Therefore, we are proposing to add paragraph (f) to \\u00a7 600.330 to \\nrequire that BHP eligibility notices be written in plain language and be provided in a manner \\nwhich ensures that eligible individuals with LEP are provided with meaningful language access \\nand individuals with disabilities are provided with effective communication.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [4.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [BHP Appeals\\nUnder current \\u00a7 600.335(b), individuals must be given the opportunity to appeal BHP \\neligibility determinations through the appeals rules of the State\\u2019s Medicaid program or the \\nExchange, as indicated in the State\\u2019s Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Current BHP and Exchange regulations do not \\nprovide for appeals of health services matters.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [We believe all BHP enrollees should be afforded \\nthe opportunity to appeal not only eligibility determinations but also decisions about health \\nservices matters.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [The Exchange rules do not include an opportunity to appeal a health services \\nmatter, as such appeals are typically handled by State Departments of Insurance, as opposed to \\nby the Exchange itself.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Therefore, we propose in paragraph (b) to remove the option for States to \\nconduct their BHP appeals process according to Exchange rules.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [In paragraph (b)(2), we propose \\nto require States to provide individuals an opportunity to appeal a delay, denial, reduction, \\nsuspension, or termination of health services, in whole or in part, including a determination about \\nthe type or level of service, after individuals exhaust appeals or grievances through the BHP \\nstandard health plans.]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "merged_df_Topic_text_combined"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-0b523f3f-1262-494a-b516-bd5a6be90c9f\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Topic</th>\n",
              "      <th>Sort_seq</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B_Determination of Practice Expense RVUs</td>\n",
              "      <td>1.0</td>\n",
              "      <td>Topic: 2B_Determination of Practice Expense RV...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2C_Potentially Misvalued Services</td>\n",
              "      <td>5.0</td>\n",
              "      <td>Topic: 2C_Potentially Misvalued Services: [fro...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2D_Telehealth Services</td>\n",
              "      <td>6.0</td>\n",
              "      <td>Topic: 2D_Telehealth Services: [from p. 68: [D...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2E_Valuation of Specific Codes</td>\n",
              "      <td>20.0</td>\n",
              "      <td>Topic: 2E_Valuation of Specific Codes: [from p...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2F_E&amp;M Visits</td>\n",
              "      <td>49.0</td>\n",
              "      <td>Topic: 2F_E&amp;M Visits: [from p. 240: [F.  Evalu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>2G_Geographic Practice Cost Indices</td>\n",
              "      <td>52.0</td>\n",
              "      <td>Topic: 2G_Geographic Practice Cost Indices: [f...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>2H_Payment for Skin Substitutes</td>\n",
              "      <td>55.0</td>\n",
              "      <td>Topic: 2H_Payment for Skin Substitutes: [from ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>2I_Supervision of OP Therapy Svcs, KX Modifier...</td>\n",
              "      <td>58.0</td>\n",
              "      <td>Topic: 2I_Supervision of OP Therapy Svcs, KX M...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>2J_Advancing Access to Behavioral Health Services</td>\n",
              "      <td>64.0</td>\n",
              "      <td>Topic: 2J_Advancing Access to Behavioral Healt...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>2K_Medicare Parts A and B Payment for Dental S...</td>\n",
              "      <td>73.0</td>\n",
              "      <td>Topic: 2K_Medicare Parts A and B Payment for D...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>3A_Drugs and Biological Products Paid Under Pa...</td>\n",
              "      <td>80.0</td>\n",
              "      <td>Topic: 3A_Drugs and Biological Products Paid U...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>3B_RHCs and FQHCs</td>\n",
              "      <td>87.0</td>\n",
              "      <td>Topic: 3B_RHCs and FQHCs: [from p. 386: [admin...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>3C_RHCs and FQHCs Conditions for Certification...</td>\n",
              "      <td>99.0</td>\n",
              "      <td>Topic: 3C_RHCs and FQHCs Conditions for Certif...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>3D_Clinical Lab Fee Schedule</td>\n",
              "      <td>100.0</td>\n",
              "      <td>Topic: 3D_Clinical Lab Fee Schedule: [from p. ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...</td>\n",
              "      <td>103.0</td>\n",
              "      <td>Topic: 3E_Pulm/Cardiac/Intensive Cardiac Rehab...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>3F_OUD OTP Coverage</td>\n",
              "      <td>104.0</td>\n",
              "      <td>Topic: 3F_OUD OTP Coverage: [from p. 441: [We ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>3G_MSSP</td>\n",
              "      <td>107.0</td>\n",
              "      <td>Topic: 3G_MSSP: [from p. 448: [audio-only visi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>3H_Part B Payment Preventive Vaccine</td>\n",
              "      <td>108.0</td>\n",
              "      <td>Topic: 3H_Part B Payment Preventive Vaccine: [...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>3I_MDPP</td>\n",
              "      <td>112.0</td>\n",
              "      <td>Topic: 3I_MDPP: [from p. 701: [information on ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>3J_Appropriate Use Criteria for Advanced Diagn...</td>\n",
              "      <td>113.0</td>\n",
              "      <td>Topic: 3J_Appropriate Use Criteria for Advance...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>3K_Medicaid Provider Enrollment</td>\n",
              "      <td>114.0</td>\n",
              "      <td>Topic: 3K_Medicaid Provider Enrollment: [from ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>3L_Expand Diabetes Screening and Diabetes Defi...</td>\n",
              "      <td>115.0</td>\n",
              "      <td>Topic: 3L_Expand Diabetes Screening and Diabet...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>3M_EPCS Part D</td>\n",
              "      <td>116.0</td>\n",
              "      <td>Topic: 3M_EPCS Part D: [from p. 799: [Medicare...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>3N_Ambulance Fee and GADCS</td>\n",
              "      <td>117.0</td>\n",
              "      <td>Topic: 3N_Ambulance Fee and GADCS: [from p. 81...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>3O_Hospice: Changes to Conditions of Participa...</td>\n",
              "      <td>118.0</td>\n",
              "      <td>Topic: 3O_Hospice: Changes to Conditions of Pa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>3P_Solicitation: Histopathology, Cytology, and...</td>\n",
              "      <td>119.0</td>\n",
              "      <td>Topic: 3P_Solicitation: Histopathology, Cytolo...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>3Q_Changes to the Basic Health Program Regulat...</td>\n",
              "      <td>120.0</td>\n",
              "      <td>Topic: 3Q_Changes to the Basic Health Program ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>3R_Updates to the Definitions of CEHRT</td>\n",
              "      <td>121.0</td>\n",
              "      <td>Topic: 3R_Updates to the Definitions of CEHRT:...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>3S_SDOH Risk Assessment in the AWV</td>\n",
              "      <td>122.0</td>\n",
              "      <td>Topic: 3S_SDOH Risk Assessment in the AWV: [fr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>4_QPP</td>\n",
              "      <td>123.0</td>\n",
              "      <td>Topic: 4_QPP: [from p. 1175: [ICR Title Change...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>7D_Changes Related to Telehealth Services</td>\n",
              "      <td>128.0</td>\n",
              "      <td>Topic: 7D_Changes Related to Telehealth Servic...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>7E_Other Provisions in the Regulation</td>\n",
              "      <td>129.0</td>\n",
              "      <td>Topic: 7E_Other Provisions in the Regulation: ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>7F_Alternatives Considered</td>\n",
              "      <td>133.0</td>\n",
              "      <td>Topic: 7F_Alternatives Considered: [from p. 12...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-0b523f3f-1262-494a-b516-bd5a6be90c9f')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-0b523f3f-1262-494a-b516-bd5a6be90c9f button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-0b523f3f-1262-494a-b516-bd5a6be90c9f');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-9e8f394e-a5f2-4a2d-ae24-7265da8f1fa3\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-9e8f394e-a5f2-4a2d-ae24-7265da8f1fa3')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-9e8f394e-a5f2-4a2d-ae24-7265da8f1fa3 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_9486f878-c51b-483f-9679-178e2c0ad726\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('merged_df_Topic_text_combined')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_9486f878-c51b-483f-9679-178e2c0ad726 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('merged_df_Topic_text_combined');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                     InsightsAI_Topic  Sort_seq  \\\n",
              "0           2B_Determination of Practice Expense RVUs       1.0   \n",
              "1                   2C_Potentially Misvalued Services       5.0   \n",
              "2                              2D_Telehealth Services       6.0   \n",
              "3                      2E_Valuation of Specific Codes      20.0   \n",
              "4                                       2F_E&M Visits      49.0   \n",
              "5                 2G_Geographic Practice Cost Indices      52.0   \n",
              "6                     2H_Payment for Skin Substitutes      55.0   \n",
              "7   2I_Supervision of OP Therapy Svcs, KX Modifier...      58.0   \n",
              "8   2J_Advancing Access to Behavioral Health Services      64.0   \n",
              "9   2K_Medicare Parts A and B Payment for Dental S...      73.0   \n",
              "10  3A_Drugs and Biological Products Paid Under Pa...      80.0   \n",
              "11                                  3B_RHCs and FQHCs      87.0   \n",
              "12  3C_RHCs and FQHCs Conditions for Certification...      99.0   \n",
              "13                       3D_Clinical Lab Fee Schedule     100.0   \n",
              "14  3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...     103.0   \n",
              "15                                3F_OUD OTP Coverage     104.0   \n",
              "16                                            3G_MSSP     107.0   \n",
              "17               3H_Part B Payment Preventive Vaccine     108.0   \n",
              "18                                            3I_MDPP     112.0   \n",
              "19  3J_Appropriate Use Criteria for Advanced Diagn...     113.0   \n",
              "20                    3K_Medicaid Provider Enrollment     114.0   \n",
              "21  3L_Expand Diabetes Screening and Diabetes Defi...     115.0   \n",
              "22                                     3M_EPCS Part D     116.0   \n",
              "23                         3N_Ambulance Fee and GADCS     117.0   \n",
              "24  3O_Hospice: Changes to Conditions of Participa...     118.0   \n",
              "25  3P_Solicitation: Histopathology, Cytology, and...     119.0   \n",
              "26  3Q_Changes to the Basic Health Program Regulat...     120.0   \n",
              "27             3R_Updates to the Definitions of CEHRT     121.0   \n",
              "28                 3S_SDOH Risk Assessment in the AWV     122.0   \n",
              "29                                              4_QPP     123.0   \n",
              "30          7D_Changes Related to Telehealth Services     128.0   \n",
              "31              7E_Other Provisions in the Regulation     129.0   \n",
              "32                         7F_Alternatives Considered     133.0   \n",
              "\n",
              "                                                 text  \n",
              "0   Topic: 2B_Determination of Practice Expense RV...  \n",
              "1   Topic: 2C_Potentially Misvalued Services: [fro...  \n",
              "2   Topic: 2D_Telehealth Services: [from p. 68: [D...  \n",
              "3   Topic: 2E_Valuation of Specific Codes: [from p...  \n",
              "4   Topic: 2F_E&M Visits: [from p. 240: [F.  Evalu...  \n",
              "5   Topic: 2G_Geographic Practice Cost Indices: [f...  \n",
              "6   Topic: 2H_Payment for Skin Substitutes: [from ...  \n",
              "7   Topic: 2I_Supervision of OP Therapy Svcs, KX M...  \n",
              "8   Topic: 2J_Advancing Access to Behavioral Healt...  \n",
              "9   Topic: 2K_Medicare Parts A and B Payment for D...  \n",
              "10  Topic: 3A_Drugs and Biological Products Paid U...  \n",
              "11  Topic: 3B_RHCs and FQHCs: [from p. 386: [admin...  \n",
              "12  Topic: 3C_RHCs and FQHCs Conditions for Certif...  \n",
              "13  Topic: 3D_Clinical Lab Fee Schedule: [from p. ...  \n",
              "14  Topic: 3E_Pulm/Cardiac/Intensive Cardiac Rehab...  \n",
              "15  Topic: 3F_OUD OTP Coverage: [from p. 441: [We ...  \n",
              "16  Topic: 3G_MSSP: [from p. 448: [audio-only visi...  \n",
              "17  Topic: 3H_Part B Payment Preventive Vaccine: [...  \n",
              "18  Topic: 3I_MDPP: [from p. 701: [information on ...  \n",
              "19  Topic: 3J_Appropriate Use Criteria for Advance...  \n",
              "20  Topic: 3K_Medicaid Provider Enrollment: [from ...  \n",
              "21  Topic: 3L_Expand Diabetes Screening and Diabet...  \n",
              "22  Topic: 3M_EPCS Part D: [from p. 799: [Medicare...  \n",
              "23  Topic: 3N_Ambulance Fee and GADCS: [from p. 81...  \n",
              "24  Topic: 3O_Hospice: Changes to Conditions of Pa...  \n",
              "25  Topic: 3P_Solicitation: Histopathology, Cytolo...  \n",
              "26  Topic: 3Q_Changes to the Basic Health Program ...  \n",
              "27  Topic: 3R_Updates to the Definitions of CEHRT:...  \n",
              "28  Topic: 3S_SDOH Risk Assessment in the AWV: [fr...  \n",
              "29  Topic: 4_QPP: [from p. 1175: [ICR Title Change...  \n",
              "30  Topic: 7D_Changes Related to Telehealth Servic...  \n",
              "31  Topic: 7E_Other Provisions in the Regulation: ...  \n",
              "32  Topic: 7F_Alternatives Considered: [from p. 12...  "
            ]
          },
          "execution_count": 8,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "#Module 5b: Add Topics to segments\n",
        "import pandas as pd\n",
        "from nltk.tokenize import sent_tokenize\n",
        "#!pip install transformers --upgrade\n",
        "\n",
        "def num_tokens_from_string(string: str, encoding_name: str='gpt-4') -> int:\n",
        "    # Simulating encoding length function, adjust as needed\n",
        "    return len(string)\n",
        "\n",
        "def merge_with_topic(segments, Topic_only_df):\n",
        "  \"\"\"\n",
        "  Merges segments with topics based on page numbers and adds a 'Topic' column.\n",
        "\n",
        "  Args:\n",
        "      segments (list): List of page content strings.\n",
        "      Topic_only_df (pd.DataFrame): Dataframe with topics, start pages, and end pages.\n",
        "\n",
        "  Returns:\n",
        "      pd.DataFrame: Dataframe with segments, page numbers, and a 'Topic' column.\n",
        "  \"\"\"\n",
        "\n",
        "  # Initialize variables\n",
        "  page_number = 1\n",
        "  all_sentences = []\n",
        "\n",
        "  for page_content in segments:\n",
        "    # Tokenize sentences\n",
        "    page_sentences = sent_tokenize(page_content)\n",
        "    for sentence in page_sentences:\n",
        "      # Create a dictionary for each sentence with page and topic (initially None)\n",
        "      all_sentences.append({\n",
        "          'text': f\"from p. {page_number}: [{sentence}]\",\n",
        "          'page': page_number\n",
        "      })\n",
        "    page_number += 1\n",
        "\n",
        "\n",
        "\n",
        "  # Convert list of dictionaries to a dataframe\n",
        "  df_sentences = pd.DataFrame(all_sentences)\n",
        "\n",
        "  # Merge Dataframes\n",
        "  merged_df = df_sentences.merge(Topic_only_df, how='left', left_on='page', right_on='Start_Page')\n",
        "\n",
        "  # Forward fill 'Topic' and handle sentences exceeding last topic's end page\n",
        "  merged_df['InsightsAI_Topic'] = merged_df['InsightsAI_Topic'].fillna(method='ffill')\n",
        "  merged_df['Sort_seq'] = merged_df['Sort_seq'].fillna(method='ffill')\n",
        "  merged_df.loc[merged_df['page'] > Topic_only_df['End Page'].max(), 'InsightsAI_Topic'] = 'NA'\n",
        "\n",
        "  return merged_df\n",
        "\n",
        "merged_df = merge_with_topic(segments, Topic_only_df)\n",
        "\n",
        "merged_df = merged_df[merged_df['InsightsAI_Topic'].notnull()]\n",
        "#Remove stubborn last row:\n",
        "merged_df = merged_df[merged_df['InsightsAI_Topic']!=\"NA\"]\n",
        "\n",
        "\n",
        "\n",
        "### THIS OPTIONAL BLOCK OF CODE CAN ADD THE TOPIC TO THE ACTUAL TEXT BEING CONSIDERED.\n",
        "merged_df['text'] = 'Topic: ' + merged_df['InsightsAI_Topic'].astype(str) + ': [' + merged_df['text'] + ']'\n",
        "merged_df = merged_df.loc[:, ['text', 'page','InsightsAI_Topic','Sort_seq']]\n",
        "\n",
        "###\n",
        "#merged_df[\"Topic_and_Text\"]=merged_df['InsightsAI_Topic']+merged_df['text']\n",
        "#Remove the single (And long) Non-Contiguous section of text pages\n",
        "merged_df = merged_df[~merged_df['page'].isin([i for i in range(869, 1175)])]\n",
        "\n",
        "#len(merged_df.text)\n",
        "merged_df.head()\n",
        "\n",
        "# Aggregate text for each Topic into a single entry\n",
        "#merged_df_Topic_text_combined = merged_df.groupby('InsightsAI_Topic')['text'].agg(lambda x: ' '.join(x)).reset_index()\n",
        "\n",
        "merged_df_Topic_text_combined = merged_df.groupby(['InsightsAI_Topic', 'Sort_seq'])['text'].agg(lambda x: ' '.join(x)).reset_index()\n",
        "merged_df_Topic_text_combined"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 933,
          "referenced_widgets": [
            "608be4b8f7fc425faa20c56f43a807e8",
            "b612e793a28e41b09c1147ff52abd98d",
            "e5c0b0427732417cacbcfd314b86b726",
            "e15182da196b4a3ba9700be629b5324c",
            "00835d565ba04fda95d1dea9643fe26f",
            "44be0214b2214a368fa29738f4ee29c1",
            "1506b629451440dc96342b20f2a1f791",
            "847d0c4c150e46b09185a28a1a544fb9",
            "1321ede0616f4288b369b2aa42928f15",
            "d6125b1938ce4ec587a78a8949d2ca6d",
            "634165b43f3e4eeaab8172e47c56df06",
            "425db4e707f3444884986688383e2de5",
            "1451ae94d89f4b0fbcccc03605b684a9",
            "999cb180dd7e4e96924f5ee8511c56ba",
            "f598b9e1d39048e6867047c41026fee2",
            "bf78d4323a4d4b9cb1a44b59996ab542",
            "e95b2ac8238b4a1787c4ab0c1f343eed",
            "912f30acc17e42439365560bb042b341",
            "ab4093c42ef749d0a42e6c14a5ef69c7",
            "36cab25a61eb4ed9a03e3e134ba827d0",
            "5cd92255d25049758053ac0243f147e3",
            "efffabced29441cea3cf9cc1eaa8f6f9",
            "fee2f61428284a18a1c93f9e7137e898",
            "fcd6cf741bf446da872abe50d78e8976",
            "8694343126d441cda72cc50b868edf59",
            "0bfbc9ec33764a5282505b682e663ccb",
            "8d9066a597c64276a2060644f5f50880",
            "3195fbb2b11d495da35c07c063ca37c2",
            "72fd7769030b43f09094f5fd85a7725e",
            "f14ea7e54d5a47ee833d651019395d3d",
            "717e4b7fa01844c8b7a754ebbfe7295d",
            "393e229e1e3d47a6ae8885b7f035d697",
            "7eeff785256f4ba1a3eeaee104b681ba",
            "304c94c436014f64870dbe2c1699a6b1",
            "d81442e3ba804b22a240ea7a6d470cea",
            "0b1fc0c655734f889de3e4e894194a72",
            "995ac051cef14ba99e69e5e398ca3d1d",
            "44a44fdca8d4468e9d59c7717d522be6",
            "7d91c1caf307493da3684eb1ea025cf1",
            "9ac9cf0c11484128a05220e830852879",
            "0d2b9bf8b5704515b3477717956cc753",
            "3464245b802b4ed9a545f93076b90d24",
            "e56fada64e654c07b8311e773f8fe9cb",
            "f9303b7b134a4995b174c60fafadb9a4",
            "895d58c14786498db587df3a16078556",
            "6d298a3b32fb427db3bfe45aa905e4da",
            "2280f7628adb4a9b9cd2ae550c1d556d",
            "74f32e11b4ad47d59cc5f7a457a96e3c",
            "174f5a3e07294927a7c57e49979bffbc",
            "bfab5b22b27143ee915e2928258dedd9",
            "06433f4c888243a9ad597e6c2348ee7c",
            "981ba01bf9ba4a16a7d3941d35dc355d",
            "3a36911cccd444f3aff7beb51f825819",
            "9af4123ce8524e34aa9bad508e308942",
            "11b1f4d1a27d439995c23b3267ff18cc"
          ]
        },
        "collapsed": true,
        "id": "KKSc5ggxdu-E",
        "outputId": "9d2753d4-40eb-4282-8b4f-487331e0911c"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_token.py:89: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "608be4b8f7fc425faa20c56f43a807e8",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/460 [00:00<?, ?B/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "425db4e707f3444884986688383e2de5",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "vocab.json:   0%|          | 0.00/2.01M [00:00<?, ?B/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "fee2f61428284a18a1c93f9e7137e898",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "merges.txt:   0%|          | 0.00/917k [00:00<?, ?B/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "304c94c436014f64870dbe2c1699a6b1",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "tokenizer.json:   0%|          | 0.00/4.23M [00:00<?, ?B/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "895d58c14786498db587df3a16078556",
              "version_major": 2,
              "version_minor": 0
            },
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/98.0 [00:00<?, ?B/s]"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        },
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Special tokens have been added in the vocabulary, make sure the associated word embeddings are fine-tuned or trained.\n",
            "Token indices sequence length is longer than the specified maximum sequence length for this model (28149 > 8192). Running this sequence through the model will result in indexing errors\n"
          ]
        },
        {
          "data": {
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAA88AAAJOCAYAAACJEDUKAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzdd1QU1//w8feK0hcQBQFFsIAiKjZsWLBiwxK7RMUaI0YxtphEBRtqNJYkGqMR7BijYItGVFBjRSNWQmyIiRhLAMUuzPOHD/NzXao1yffzOmfOcWbu3LazK3funXs1iqIoCCGEEEIIIYQQIkeF3nUGhBBCCCGEEEKIfzppPAshhBBCCCGEEHmQxrMQQgghhBBCCJEHaTwLIYQQQgghhBB5kMazEEIIIYQQQgiRB2k8CyGEEEIIIYQQeZDGsxBCCCGEEEIIkQdpPAshhBBCCCGEEHmQxrMQQgghhBBCCJEHaTwLIYQQQgiVRqNh2LBh7zob/2lBQUFoNBpu3br1rrPySvz9/XF2dn7pa83NzV9vhv4HJCYmotFoCAsLe21xHj16FENDQ65cufLa4vynePEevX37NmZmZvz0008vFZ80noUQQggh/uU0Gk2+tpiYmHed1ZcSERFB69atKV68OIaGhjg4ONCtWzf27NnzrrMGwLVr1wgKCiIuLu5dZ0WHt7c3lStXftfZeCX3798nKCjotdy7tWvXRqPRsGjRomzPh4WFodFoOHbsWL7i8/b2ztf3Ligo6JXz/iZ99tln9OzZEycnJ/VYZmYmK1asoE6dOlhbW6PVanF1daVPnz4cPnz4taZ/7tw5goKCSExMfK3xZqdYsWIMHDiQCRMmvNT1hV9zfoQQQgghxFu2cuVKnf0VK1YQFRWld9zNze1tZuuVKYpC//79CQsLo3r16nz88cfY2dmRnJxMREQEzZo148CBA9SvX/+d5vPatWsEBwfj7OxMtWrV3mle3qYlS5aQmZn5RtO4f/8+wcHBwLPG6ss6f/48sbGxODs7s3r1aj788MNXzttnn33GwIED1f3Y2FgWLFjAp59+qvNdq1q16iunlcXJyYkHDx5QpEiR1xJfXFwcu3bt4uDBgzrHhw8fzjfffEOHDh3w8/OjcOHCJCQksH37dsqWLUvdunVfS/rwrPEcHByMt7f3S49kKIghQ4awYMEC9uzZQ9OmTQt0rTSehRBCCCH+5d5//32d/cOHDxMVFaV3/N9mzpw5hIWFERgYyJdffolGo1HPffbZZ6xcuZLCheXP2XfldTXg3oZVq1Zha2vLnDlz6NKlC4mJia/cUGvRooXOvrGxMQsWLKBFixav1NDPjUajwdjY+LXFFxoaSunSpXUaw3/99RcLFy5k0KBBfPfddzrh582bx82bN19L2g8fPsTQ0PC1xFUQbm5uVK5cmbCwsAI3nmXYthBCCCHE/4B79+4xatQoHB0dMTIyokKFCsyePRtFUfK8durUqRQqVIivvvpKPbZ9+3YaNmyImZkZWq2Wtm3bcvbsWZ3rst5r/fPPP+nYsSPm5ubY2NgwevRoMjIyck3zwYMHhISEULFiRWbPnq3TcM7Su3dvateure5funSJrl27Ym1tjampKXXr1mXbtm0612QNzX1xiGhMTIze0PasYc/nzp2jSZMmmJqaUrJkSWbNmqVznaenJwD9+vVTh+rm553UW7du0a1bNywsLChWrBgjRozg4cOH6vnGjRvj4eGR7bUVKlTAx8cnzzRelPVOe2RkJJUrV8bIyAh3d3d27NihE+7u3bsEBgbi7OyMkZERtra2tGjRgl9//VUNk907z7dv36Z3795YWFhgZWVF3759OXnyZI51ktu9kZiYiI2NDQDBwcF6w6CvX79Ov379KFWqFEZGRtjb29OhQ4dsh/+uWbOGLl260K5dOywtLVmzZk2B6+5lLVy4EHd3d4yMjHBwcCAgIIDU1FSdMFn32vHjx6lfvz4mJiaUKVOGb7/9VidcTu88//bbb3Tr1g0bGxtMTEyoUKECn332WZ55i4yMpGnTpjrfr8uXL6MoCl5eXnrhNRoNtra2Osfy873L+n6Fh4fz+eefU7JkSUxNTVmwYAFdu3YFoEmTJtm+YpKf35qsslSuXBljY2MqV65MREREjuVu0aIFW7Zsydfv3/Ok8SyEEEII8R+nKArt27dn7ty5tGrVii+//JIKFSowZswYPv7441yv/fzzz5k4cSKLFy/mo48+Ap4NE2/bti3m5ubMnDmTCRMmcO7cORo0aKDXcMnIyMDHx4dixYoxe/ZsGjduzJw5c/R6tF70yy+/8Pfff9OrVy8MDAzyLONff/1F/fr1+fnnnxk6dCjTpk3j4cOHtG/fPtc/ovOSkpJCq1at8PDwYM6cOVSsWJFx48axfft24Fkv1uTJkwEYPHgwK1euZOXKlTRq1CjPuLt168bDhw8JCQmhTZs2LFiwgMGDB6vne/fuzalTpzhz5ozOdbGxsfz+++8vPbLgl19+YejQofTo0YNZs2bx8OFDOnfuzO3bt9UwQ4YMYdGiRXTu3JmFCxcyevRoTExMiI+PzzHezMxMfH19Wbt2LX379mXatGkkJyfTt2/fbMPndW/Y2Nio7yd36tRJrdv33nsPgM6dOxMREUG/fv1YuHAhw4cP5+7duyQlJemkc+TIES5cuEDPnj0xNDTkvffeY/Xq1S9VdwUVFBREQEAADg4OzJkzh86dO7N48WJatmzJkydPdMKmpKTQpk0batasyaxZsyhVqhQffvghy5YtyzWNU6dOUadOHfbs2cOgQYOYP38+HTt2ZMuWLble9+eff5KUlESNGjV0jme9+7x+/Xru37+faxwF/d5NmTKFbdu2MXr0aKZPn07Lli0ZPnw4AJ9++qn6GWcNe8/vb83OnTvp3LkzGo2GkJAQOnbsSL9+/XJ8f71mzZqkpqZm2wjPlSKEEEIIIf5TAgIClOf/zIuMjFQAZerUqTrhunTpomg0GuXChQvqMUAJCAhQFEVRRo0apRQqVEgJCwtTz9+9e1exsrJSBg0apBPX9evXFUtLS53jffv2VQBl8uTJOmGrV6+u1KxZM9cyzJ8/XwGUiIiIfJU5MDBQAZT9+/fr5LVMmTKKs7OzkpGRoSiKooSGhiqAcvnyZZ3ro6OjFUCJjo5WjzVu3FgBlBUrVqjHHj16pNjZ2SmdO3dWj8XGxiqAEhoamq+8Tpo0SQGU9u3b6xwfOnSoAignT55UFEVRUlNTFWNjY2XcuHE64YYPH66YmZkp6enpuabTuHFjxd3dXecYoBgaGup85idPnlQA5auvvlKPWVpaqvdBTvr27as4OTmp+xs2bFAAZd68eeqxjIwMpWnTpnr1k9974+bNmwqgTJo0SSdcSkqKAihffPFFrnlUFEUZNmyY4ujoqGRmZiqKoig7d+5UAOXEiRM64bLujdjY2DzjzM769et17qEbN24ohoaGSsuWLdX7T1EU5euvv1YAZdmyZeqxrHttzpw56rFHjx4p1apVU2xtbZXHjx8riqIoly9f1qvLRo0aKVqtVrly5YpOfrLKm5Ndu3YpgLJlyxa9c3369FEApWjRokqnTp2U2bNnK/Hx8Xrh8vu9y/p+lS1bVrl//36u9fZ8PPn9ralWrZpib2+vpKamqseyPufn79EsBw8eVABl3bp1OVdQNqTnWQghhBDiP+6nn37CwMBA7eHJMmrUKBRFUXtRsyiKwrBhw5g/fz6rVq3S6TmMiooiNTWVnj17cuvWLXUzMDCgTp06REdH66U/ZMgQnf2GDRty6dKlXPN8584dALRabb7LWLt2bRo0aKAeMzc3Z/DgwSQmJnLu3Ll8xfMic3NznR5eQ0NDateunWf+8yMgIEBnP6tnP2sZHUtLSzp06MDatWvV4aUZGRmsW7eOjh07YmZm9lLpNm/enHLlyqn7VatWxcLCQqdMVlZWHDlyhGvXruU73h07dlCkSBEGDRqkHitUqJBeOZ/3MvcGgImJCYaGhsTExJCSkpJjuKdPn7Ju3Tq6d++uDk1u2rQptra2b7z3edeuXTx+/JjAwEAKFfq/ZtegQYOwsLDQG9pcuHBhPvjgA3Xf0NCQDz74gBs3bnD8+PFs07h58yb79u2jf//+lC5dWudcdq86PC9rpEHRokX1zoWGhvL1119TpkwZIiIiGD16NG5ubjRr1ow///xTDVfQ713fvn0xMTHJNV9Z8vtbk5ycTFxcHH379sXS0lK9vkWLFlSqVCnbuLPKXNDl4qTxLIQQQgjxH3flyhUcHBz0GqJZQyNfXN91xYoVfPPNN3z11Vf07NlT59z58+eBZw0QGxsbnW3nzp3cuHFDJ7yxsbH63mqWokWL5trgAbCwsACevXub3zJWqFBB73hOZcyvUqVK6TVC8pP//HBxcdHZL1euHIUKFdIZjtqnTx+SkpLYv38/8KxB9tdff9G7d++XTvfFRhbol2nWrFmcOXMGR0dHateuTVBQUJ6N2itXrmBvb4+pqanO8fLly2cb/mXvDQAjIyNmzpzJ9u3bKVGiBI0aNWLWrFlcv35dJ9zOnTu5efMmtWvX5sKFC1y4cIHLly/TpEkT1q5d+0ZnC8+65168Lw0NDSlbtqzePeng4KD3QMTV1RUgx2Wcsj6TV1mSTMnmvd+shx7Hjx/n1q1bbNq0idatW7Nnzx569Oihhivo965MmTL5zld+f2uy0njx+wT6dZ8lq8x5PWB4kUxPKIQQQgghdHh5eREXF8fXX39Nt27dsLa2Vs9lNTZWrlyJnZ2d3rUvzn6dn/eVs1OxYkUATp8+TceOHV8qjuzk9MdyThOY5ZT/7Bocryq7vPn4+FCiRAlWrVpFo0aNWLVqFXZ2djRv3vyl08lPmbp160bDhg2JiIhg586dfPHFF8ycOZONGzfSunXrl047P/nIr8DAQHx9fYmMjOTnn39mwoQJhISEsGfPHqpXrw6g9i5369Yt2zj27t1LkyZNXikf/1bFihUDyPNhRbFixWjfvj3t27fH29ubvXv3cuXKFZ11ofMrv73OUPDfmoLIKnPx4sULdJ30PAshhBBC/Mc5OTlx7do1vV7c3377TT3/vPLly7Nz506uXbtGq1atdK7LGu5ra2tL8+bN9bbXtURPgwYNKFq0KGvXrs1zZu6sMiQkJOgdf7GMWcM1X5zt+GV7pqHgvVdZsnrWsly4cIHMzEydGawNDAzo1asXP/74IykpKURGRtKzZ89Xbnjmh729PUOHDiUyMpLLly9TrFgxpk2blmN4JycnkpOT9SaZunDhwkvnIa+6LVeuHKNGjWLnzp2cOXOGx48fM2fOHODZDPObNm2ie/furF+/Xm+zt7d/o0O3s+65F+/Lx48fc/nyZb3v3bVr17h3757Osd9//x0gx2W1ypYtC6A3qVx+ZD2gunz5cr6vqVWrFvBsqDTk/3uXm5w+4/z+1mSl8eL3CfTrPktWmZ9fjzs/pPEshBBCCPEf16ZNGzIyMvj66691js+dOxeNRpNtT2LVqlX56aefiI+Px9fXlwcPHgDPekItLCyYPn263mzBwGtbA9bU1JRx48YRHx/PuHHjsu3pXbVqFUePHgWelfHo0aMcOnRIPX/v3j2+++47nJ2d1Xcfs/4g37dvnxouIyMjz9m/c5M11PbFBnlevvnmG539rKXAXvw8evfuTUpKCh988AHp6elvfP3ujIwM0tLSdI7Z2tri4ODAo0ePcrzOx8eHJ0+esGTJEvVYZmamXjkLImsI+It1e//+fZ1lveDZZ6vVatU8RkREcO/ePQICAujSpYve1q5dOzZs2JBrmV5F8+bNMTQ0ZMGCBTr37/fff09aWhpt27bVCf/06VMWL16s7j9+/JjFixdjY2NDzZo1s03DxsaGRo0asWzZMr1ZxvMaHVGyZEkcHR31ZqS+fv16tnMEPH78mN27d1OoUCF1KH5+v3e5yen7k9/fGnt7e6pVq8by5ct17tuoqKgc5zo4fvw4lpaWuLu755m/58mwbSGEEEKI/zhfX1+aNGnCZ599RmJiIh4eHuzcuZNNmzYRGBioM3nU8+rWrcumTZto06YNXbp0ITIyEgsLCxYtWkTv3r2pUaMGPXr0wMbGhqSkJLZt24aXl5deI/1ljRkzhrNnzzJnzhyio6Pp0qULdnZ2XL9+ncjISI4ePcrBgwcB+OSTT1i7di2tW7dm+PDhWFtbs3z5ci5fvsyGDRvUCZvc3d2pW7cu48eP5++//8ba2prw8HCePn360vksV64cVlZWfPvtt2i1WszMzKhTp06e73devnyZ9u3b06pVKw4dOsSqVavo1auX3trO1atXp3Llyqxfvx43Nze9pYVet7t371KqVCm6dOmCh4cH5ubm7Nq1i9jYWLVXNzsdO3akdu3ajBo1igsXLlCxYkU2b97M33//DbxcD72JiQmVKlVi3bp1uLq6Ym1tTeXKlXn69CnNmjWjW7duVKpUicKFCxMREcFff/2lvpO7evVqihUrRv369bONu3379ixZsoRt27apy1+9TjY2NowfP57g4GBatWpF+/btSUhIYOHChXh6euo9BHFwcGDmzJkkJibi6urKunXriIuL47vvvqNIkSI5prNgwQIaNGhAjRo1GDx4MGXKlCExMZFt27YRFxeXax47dOhAREQEiqKon88ff/xB7dq1adq0Kc2aNcPOzo4bN26wdu1aTp48SWBgoDrcOb/fu9xUq1YNAwMDZs6cSVpaGkZGRuqkbvn9rQkJCaFt27Y0aNCA/v378/fff/PVV1/h7u5Oenq6XppRUVH4+voW/J4s0NzcQgghhBDiH+/FpaoU5dmyLyNHjlQcHByUIkWKKC4uLsoXX3yht5wNzy1VlWXTpk1K4cKFle7du+ssPePj46NYWloqxsbGSrly5RR/f3/l2LFj6nV9+/ZVzMzM9PKXtVRTfv34449Ky5YtFWtra6Vw4cKKvb290r17dyUmJkYn3MWLF5UuXbooVlZWirGxsVK7dm1l69atevFdvHhRad68uWJkZKSUKFFC+fTTT5WoqKhsl6p6camnrHK9uPzNpk2blEqVKimFCxfOc9mqrPKfO3dO6dKli6LVapWiRYsqw4YNUx48eJDtNbNmzVIAZfr06TlX1AtyWqoquyWonJyclL59+yqK8myJpDFjxigeHh6KVqtVzMzMFA8PD2XhwoU612RXDzdv3lR69eqlaLVaxdLSUvH391cOHDigAEp4eLjOtfm9Nw4ePKjUrFlTMTQ0VJetunXrlhIQEKBUrFhRMTMzUywtLZU6deooP/zwg6IoivLXX38phQsXVnr37p1j/dy/f18xNTVVOnXqpCjK61+qKsvXX3+tVKxYUSlSpIhSokQJ5cMPP1RSUlJ0wmR9VseOHVPq1aunGBsbK05OTsrXX3+tEy67paoURVHOnDmjdOrUSb33K1SooEyYMCHPPP/66696S03duXNHmT9/vuLj46OUKlVKKVKkiKLVapV69eopS5Ys0fvNyM/3LmupqvXr12ebjyVLlihly5ZVDAwM9OowP781ivJsqTQ3NzfFyMhIqVSpkrJx48Zs79H4+HgFUHbt2pVn/bxIoyhvYLYDIYQQQgghxGszf/58Ro4cSWJiYrazZf+TRUZG0qlTJ3755Re8vLzedXb+kby9vbl169ZLvbv8qpo1a4aDgwMrV65862m/C4GBgezbt4/jx48XuOdZGs9CCCGEEEL8gymKgoeHB8WKFct2He1/kgcPHujMqJyRkUHLli05duwY169fL9Bsy/9L3mXj+ciRIzRs2JDz58+/1Aza/ya3b9/GycmJH374gTZt2hT4ennnWQghhBBCiH+ge/fusXnzZqKjozl9+jSbNm1611nK00cffcSDBw+oV68ejx49YuPGjRw8eJDp06f/qxrOjx8/Vt/VzomlpeW/qkw5qVOnDo8fP37X2XgrihUrlu070PkljWchhBBCCCH+gW7evEmvXr2wsrLi008/pX379u86S3lq2rQpc+bMYevWrTx8+JDy5cvz1VdfMWzYsHedtQI5ePBgnus/h4aG4u/v/3YyJP4RZNi2EEIIIYQQQjwnJSWF48eP5xrG3d0de3v7t5Qj8U8gjWchhBBCCCGEECIPeS+8JYQQQgghhBBC/I+Td56FEEIIIf7FMjMzuXbtGlqttsDLrgghxP86RVG4e/cuDg4OFCqUe9+yNJ6FEEIIIf7Frl27hqOj47vOhhBC/KtdvXqVUqVK5RpGGs9CCCGEEP9iWq0WePaHn4WFxTvOjRBC/LvcuXMHR0dH9bc0N9J4FkIIIYT4F8saqm1hYSGNZyGEeEn5ee1FJgwTQgghhBBCCCHyII1nIYQQQgghhBAiD9J4FkIIIYQQQggh8iCNZyGEEEIIIYQQIg/SeBZCCCGEEEIIIfIgjWchhBBCCCGEECIP0ngWQgghhBBCCCHyII1nIYQQQgghhBAiD9J4FkIIIYQQQggh8iCNZyGEEEIIIYQQIg/SeBZCCCGEEEIIIfIgjWchhBBCCCGEECIP0ngWQgghhBBCCCHyII1nIYQQQgghhBAiD9J4FkIIIYQQQggh8iCNZyGEEEIIIYQQIg/SeBZCCCGEEEIIIfIgjWchhBBCCCGEECIP0ngWQgghhBBCCCHyII1nIYQQQgghhBAiD4XfdQaEEEL8syQmJlKmTBlOnDhBtWrV3mhaYWFhBAYGkpqa+kbTyY/IyEhGjx7N5cuX+eijj5g3b967zlKu/kl1J/4ZKk/6mUJGpu86G29c4oy27zoLQoj/UdLzLIT4TwsJCcHT0xOtVoutrS0dO3YkISFBJ4yzszMajQaNRoOBgQEODg4MGDCAlJSUfKURExOjXl+oUCEsLS2pXr06Y8eOJTk5uUD5TUxMRKPREBcXV6DrXidHR0eSk5OpXLnya43X2dlZr0HavXt3fv/999eazsv64IMP6NKlC1evXmXKlCnZhnn+XjEzM6NGjRqsX7/+jeftXdXd8+V9fpsxY8YbTfefwNvbWy2vsbExrq6uhISEoCgKjx8/pnjx4jnWw5QpUyhRogRPnjwhKCgo24dQ/4TvuhBCiIKRxrMQ4j9t7969BAQEcPjwYaKionjy5AktW7bk3r17OuEmT55McnIySUlJrF69mn379jF8+PACpZWQkMC1a9eIjY1l3Lhx7Nq1i8qVK3P69OnXWaR8e/LkyUtdZ2BggJ2dHYULv/nBSSYmJtja2r7xdPKSnp7OjRs38PHxwcHBAa1Wm2PYrHvlxIkTeHp60r17dw4ePJht2MePH7+pLL+1ussq7/PbRx999MbT/ScYNGgQycnJJCQkMH78eCZOnMi3336LoaEh77//PqGhoXrXKIpCWFgYffr0oUiRIu8g10IIId4UaTwLIf7TduzYgb+/P+7u7nh4eBAWFkZSUhLHjx/XCafVarGzs6NkyZI0adKEvn378uuvvxYoLVtbW+zs7HB1daVHjx4cOHAAGxsbPvzwQ51wS5cuxc3NDWNjYypWrMjChQvVc2XKlAGgevXqaDQavL2983VdVi/WunXraNy4McbGxqxevRp/f386duzI9OnTKVGiBFZWVkyePJmnT58yZswYrK2tKVWqlE4j4MUesaye9d27d1OrVi1MTU2pX7++Tg/+xYsX6dChAyVKlMDc3BxPT0927dqlnvf29ubKlSuMHDlS7c2DZ0OPraysdOpn0aJFlCtXDkNDQypUqMDKlSt1zms0GpYuXUqnTp0wNTXFxcWFzZs35/rZpKSk0KdPH4oWLYqpqSmtW7fm/PnzavmyGstNmzZFo9EQExOTY1xZ94qrqyvffPMNJiYmbNmyBXjWUztlyhT69OmDhYUFgwcPBmDcuHG4urpiampK2bJlmTBhgt7DjS1btuDp6YmxsTHFixenU6dOBa67nOIAePToEaNHj6ZkyZKYmZlRp06dXMv5Ynmf38zMzIBnDWsHBwdu376thm/bti1NmjQhMzMTePZ5LVq0iNatW2NiYkLZsmX58ccfddK4evUq3bp1w8rKCmtrazp06EBiYqJ6Pus+nj17Nvb29hQrVoyAgACdOly4cCEuLi4YGxtTokQJunTpop7LzMwkJCSEMmXKYGJigoeHh14esmNqaoqdnR1OTk7069ePqlWrEhUVBcCAAQP4/fff+eWXX3Su2bt3L5cuXWLAgAF5xv+8K1eu4OvrS9GiRTEzM8Pd3Z2ffvqpQHEIIYR4s6TxLIT4n5KWlgaAtbV1jmH+/PNPtmzZQp06dV4pLRMTE4YMGcKBAwe4ceMGAKtXr2bixIlMmzaN+Ph4pk+fzoQJE1i+fDkAR48eBWDXrl0kJyezcePGfF2X5ZNPPmHEiBHEx8fj4+MDwJ49e7h27Rr79u3jyy+/ZNKkSbRr146iRYty5MgRhgwZwgcffMAff/yRa3k+++wz5syZw7FjxyhcuDD9+/dXz6Wnp9OmTRt2797NiRMnaNWqFb6+viQlJQGwceNGSpUqpdOLmZ2IiAhGjBjBqFGjOHPmDB988AH9+vUjOjpaJ1xwcDDdunXj1KlTtGnTBj8/P/7+++8c8+7v78+xY8fYvHkzhw4dQlEU2rRpw5MnT3QeBGzYsIHk5GTq16+fa11kKVy4MEWKFNHpYZ49ezYeHh6cOHGCCRMmAM8aoGFhYZw7d4758+ezZMkS5s6dq16zbds2OnXqRJs2bThx4gS7d++mdu3aBaq73OIAGDZsGIcOHSI8PJxTp07RtWtXWrVqpT5EeBmfffYZzs7ODBw4EIBvvvmGgwcPsnz5cgoV+r8/MSZMmEDnzp05efIkfn5+9OjRg/j4eODZCAkfHx+0Wi379+/nwIEDmJub06pVK516jY6O5uLFi0RHR7N8+XLCwsIICwsD4NixYwwfPpzJkyeTkJDAjh07aNSokXptSEgIK1as4Ntvv+Xs2bOMHDmS999/n7179+arnIqisH//fn777TcMDQ0BqFKlCp6enixbtkwnbGhoKPXr16dixYoFqsuAgAAePXrEvn37OH36NDNnzsTc3LxAcQghhHizNIqiKO86E0II8TZkZmbSvn17UlNTdXqLnJ2dSU5OpkiRImRkZPDw4UPq1KnDjh079Hr2shMTE0OTJk1ISUnRC79jxw5at27NkSNHqF27NuXLl2fKlCn07NlTDTN16lR++uknDh48mONkXfm9bt68eYwYMUIN4+/vT0xMDJcuXVIbMxUrVsTW1pZ9+/YBkJGRgaWlJUuXLqVHjx56ecgq365du2jWrBkAP/30E23btuXBgwcYGxtnWy+VK1dmyJAhDBs2TK3nwMBAAgMD1TAvTnrl5eWFu7s73333nRqmW7du3Lt3j23btgHPejI///xz9b3ke/fuYW5uzvbt22nVqpVePs6fP4+rqysHDhxQG8W3b9/G0dGR5cuX07VrV1JTUylatCjR0dE6vf0ver4Mjx8/Zs6cOXz66ads3bqVtm3b4uzsTPXq1YmIiMgxDnjWwA4PD+fYsWMA1K9fn7Jly7Jq1ao8082p7nKLIykpibJly5KUlISDg4N6vHnz5tSuXZvp06fnmG7Wd+N527dvp2HDhgBcunSJatWqMXToUBYsWMDSpUvp1auXGlaj0TBkyBAWLVqkHqtbty41atRg4cKFrFq1iqlTpxIfH6/2qj9+/BgrKysiIyNp2bKleh9fvHgRAwMD4Nl9UahQIcLDw9m4cSP9+vXjjz/+0Bty/+jRI6ytrdm1axf16tVTjw8cOJD79++zZs2abMvu7e3NwYMHMTQ05PHjxzx58gRjY2N2796t3keLFy9m9OjRJCcnY25uzt27d7Gzs2PBggVqz3NQUBCRkZF67za/+D2rWrUqnTt3ZtKkSdnm58UyPXr0SN2/c+cOjo6OOAb+IBOGCSFEAd25cwdLS0vS0tKwsLDINaz0PAsh/mcEBARw5swZwsPD9c6NGTOGuLg4Tp06xe7du4Fnw08zMjJeKc2s55MajYZ79+5x8eJFBgwYgLm5ubpNnTqVixcv5hhHQa6rVauW3vXu7u46vYAlSpSgSpUq6r6BgQHFihVTe8dzUrVqVfXf9vb2AOo16enpjB49Gjc3N6ysrDA3Nyc+Pl7tec6v+Ph4vLy8dI55eXmpvZTZ5cXMzAwLC4sc8x8fH0/hwoV1RhIUK1aMChUq6MWbH+PGjcPc3BxTU1NmzpzJjBkzaNv2//6Yz+4zWLduHV5eXtjZ2WFubs7nn3+uUzdxcXHqg4mXlVscp0+fJiMjA1dXV517aO/evbnee/B/343nt+fLWLZsWWbPns3MmTNp3769TsM5y/ON1qz9rLo/efIkFy5cQKvVqvmytrbm4cOHOnlzd3dXG87w7B7M+sxbtGiBk5MTZcuWpXfv3qxevZr79+8DcOHCBe7fv0+LFi10yr5ixYo8y+7n50dcXBwHDhygdevWfPbZZzqjEnr27ElGRgY//PAD8OxzLlSoEN27d8813uwMHz6cqVOn4uXlxaRJkzh16lSOYUNCQrC0tFQ3R0fHAqcnhBCi4GSpKiHE/4Rhw4axdetW9u3bR6lSpfTOFy9enPLlywPg4uLCvHnzqFevHtHR0TRv3vyl081qIDg7O5Oeng7AkiVL9IaEP98oeFFBrst6F/V5L/YaajSabI9lvaOak+evyeohzLpm9OjRREVFMXv2bMqXL4+JiQldunR5YxNmvUz+X5cxY8bg7++Pubk5JUqUUOsiy4ufwaFDh/Dz8yM4OBgfHx8sLS0JDw9nzpw5ahgTE5NXzlducaSnp2NgYMDx48f17pm8hgY//93Iyb59+zAwMCAxMZGnT58WaLK59PR0atasyerVq/XO2djYqP/O7TPXarX8+uuvxMTEsHPnTiZOnEhQUBCxsbHq92fbtm2ULFlSJw4jI6Nc82ZpaamW/YcffqB8+fLUrVtX/U2wsLCgS5cuhIaG0r9/f0JDQ+nWrZtOnVpYWKivizwva8SApaUl8Kwn3MfHh23btrFz505CQkKYM2dOtpOzjR8/no8//ljdz+p5FkII8WZJz7MQ4j9NURSGDRtGREQEe/bsUSfkyktWA+PBgwcvnfaDBw/47rvvaNSoETY2NpQoUQIHBwcuXbpE+fLldbasfGW9T/l8j3d+rnvXDhw4gL+/P506daJKlSrY2dnpTPgEz8qWV0++m5sbBw4c0Iu7UqVKL503Nzc3nj59ypEjR9Rjt2/fJiEh4aXizWpM2tnZ6TWcs3Pw4EGcnJz47LPPqFWrFi4uLly5ckUnTNWqVdURD9nJT93lFkf16tXJyMjgxo0beveQnZ1dnmXIzbp169i4cSMxMTEkJSVlu8zX4cOH9fbd3NwAqFGjBufPn8fW1lYvb1kNy/woXLgwzZs3Z9asWZw6dYrExET27NlDpUqVMDIyIikpSS/+gjQ4zc3NGTFiBKNHj+b5N94GDBjAL7/8wtatWzl48KDeRGEVKlTgjz/+4K+//tI5/uuvv2JsbEzp0qXVY46OjgwZMoSNGzcyatQolixZkm1ejIyMsLCw0NmEEEK8edLzLIT4TwsICGDNmjVs2rQJrVbL9evXgWe9Pc/31N29e5fr16+jKApXr15l7Nix2NjY5HviKHg2hPnhw4fcvXuX48ePM2vWLG7duqVO+gXPJroaPnw4lpaWtGrVikePHnHs2DFSUlL4+OOPsbW1xcTEhB07dlCqVCmMjY2xtLTM87p3zcXFhY0bN+Lr64tGo2HChAl6PcHOzs7s27ePHj16YGRkRPHixfXiGTNmDN26daN69eo0b96cLVu2sHHjRp2Zu18mbx06dGDQoEEsXrwYrVbLJ598QsmSJenQocNLx1uQ9JOSkggPD8fT05Nt27bpvRM9adIkmjVrRrly5ejRowdPnz7lp59+Yty4cUD+6i63OFxdXfHz86NPnz7MmTOH6tWrc/PmTXbv3k3VqlV1hp2/KOu78TxTU1MsLCz4448/+PDDD5k5cyYNGjQgNDSUdu3a0bp1a+rWrauGX79+PbVq1aJBgwasXr2ao0eP8v333wPPhkZ/8cUXdOjQgcmTJ1OqVCmuXLnCxo0bGTt2bLYjRV60detWLl26RKNGjShatCg//fQTmZmZVKhQAa1Wy+jRoxk5ciSZmZk0aNCAtLQ0Dhw4gIWFBX379s0z/iwffPABU6ZMYcOGDeps3o0aNaJ8+fL06dOHihUr6v1m+Pj4UKFCBXr27MnUqVOxs7Pj119/5fPPP2fEiBHqg7rAwEBat26Nq6srKSkpREdHqw8YhBBC/DNIz7MQ4j9t0aJFpKWl4e3tjb29vbqtW7dOJ9zEiROxt7fHwcGBdu3aYWZmxs6dOylWrFi+06pQoQIODg7UrFmTGTNm0Lx5c86cOaPTuzlw4ECWLl1KaGgoVapUoXHjxoSFhak9yIULF2bBggUsXrwYBwcHtXGX13Xv2pdffknRokWpX78+vr6++Pj4UKNGDZ0wkydPJjExkXLlyukMx31ex44dmT9/PrNnz8bd3Z3FixcTGhqa6yRe+REaGkrNmjVp164d9erVQ1EUfvrpp7eyDm/79u0ZOXIkw4YNo1q1ahw8eFCdhTuLt7c369evZ/PmzVSrVo2mTZuqM69D/uourzhCQ0Pp06cPo0aNokKFCnTs2JHY2Fidns/sZH03nt/Gjh2Loij4+/tTu3ZtdVI4Hx8fPvzwQ95//311uDQ8e2gUHh5O1apVWbFiBWvXrlW/F6ampuzbt4/SpUvz3nvv4ebmxoABA3j48GG+e1StrKzYuHEjTZs2xc3NjW+//Za1a9fi7u4OwJQpU5gwYQIhISG4ubnRqlUrtm3bVuDvj7W1NX369CEoKEhnKa7+/fuTkpKiMwN9lsKFC7Nz505Kly5Nz549qVy5MpMmTWLEiBE6vfQZGRkEBASo+XN1ddVZjk4IIcS7J7NtCyGEEOKN0Wg0RERE0LFjx3edlf+sgswUK4QQQpfMti2EEEIIIYQQQrxG0ngWQog8tG7dWmeJm+e3nNbHFUIIIYQQ/y0yYZgQQuRh6dKlOc66bW1t/ZZzI940f39/UlNTiYyMzFf4xMREypQpw4kTJ6hWrRoxMTE0adKElJQUrKys3mhes3h7e1OtWjXmzZv3VtJzdnYmMDCQwMDAPMO+ytthb7tcBfEuPue8VJ70M4WMTN9qmokzcp5sTggh/muk51kIIfJQsmRJvSVusrZ/c+M5JCQET09PtFottra2dOzYkYSEBL1wJ06coGvXrpQoUQJjY2NcXFwYNGgQv//+e55pJCYmotFo1K1YsWK0bNmSEydO5Dufzs7Ob6TxlJW3uLg4nePz588nLCzstadXEP7+/mg0GoYMGaJ3LiAgAI1Gg7+/v3ps48aN2S4R9V+XkZHBjBkzqFixIiYmJlhbW1OnTh2WLl36xtOuX78+ycnJBVpOSwghxL+bNJ6FEOJ/1N69ewkICODw4cNERUXx5MkTWrZsyb1799QwW7dupW7dujx69IjVq1cTHx/PqlWrsLS01JsxOje7du0iOTmZn3/+mfT0dFq3bk1qauobKNWrs7S0/Ef0JDo6OhIeHq4z6uHhw4esWbNGb4Zsa2trtFrt287iOxccHMzcuXOZMmUK586dIzo6msGDB7/SvaUoCk+fPs0znKGhYb7X+hZCCPHfII1nIYT4H7Vjxw78/f1xd3fHw8ODsLAwkpKSOH78OAD379+nX79+tGnThs2bN9O8eXPKlClDnTp1mD17NosXL853WsWKFcPOzo5atWoxe/Zs/vrrL44cOQLAhg0bcHd3x8jICGdnZ+bMmaNe5+3tzZUrVxg5cqTae53ll19+oWHDhpiYmODo6Mjw4cN1Gv7Ozs5Mnz6d/v37o9VqKV26NN999516PmuZourVq6PRaNTlsPz9/XVmht6xYwcNGjTAysqKYsWK0a5dOy5evJivct+7dw8LCwt+/PFHneORkZGYmZlx9+7dHK+tUaMGjo6OOuuEb9y4kdKlS1O9enWdsN7e3jpDqBcuXIiLiwvGxsaUKFFCXZP4u+++w8HBQW8N7g4dOqjLLF28eJEOHTpQokQJzM3N8fT0zHWd7ex68FNTU9FoNMTExKjHzpw5o84fUKJECXr37s2tW7d06qpPnz6Ym5tjb2+vcx/kZPPmzQwdOpSuXbtSpkwZPDw8GDBgAKNHj1bDZGZmEhISQpkyZTAxMcHDw0Pn84iJiUGj0bB9+3Zq1qyJkZERy5YtQ6PR8Ntvv+mkN3fuXMqVK6dz3fMN9QMHDuDt7Y2pqSlFixbFx8eHlJSUfOUjJSUFPz8/bGxsMDExwcXFhdDQ0DzrQAghxNsjjWchhBAApKWlAf/3HvfPP//MrVu3GDt2bLbhX7Z31sTEBIDHjx9z/PhxunXrRo8ePTh9+jRBQUFMmDBBHTa9ceNGSpUqxeTJk0lOTiY5ORl41sBr1aoVnTt35tSpU6xbt45ffvlFXW84y5w5c6hVqxYnTpxg6NChfPjhh+rQ9Kw1kLN6xZ9vpD7v3r17fPzxxxw7dozdu3dTqFAhOnXqpNcAzY6ZmRk9evTQawSFhobSpUuXPHuL+/fvr3PtsmXL6NevX67XHDt2jOHDhzN58mQSEhLYsWMHjRo1AqBr167cvn2b6OhoNfzff//Njh078PPzAyA9PZ02bdqwe/duTpw4QatWrfD19SUpKSnP8uYkNTWVpk2bUr16dY4dO8aOHTv466+/6NatmxpmzJgx7N27l02bNrFz505iYmL49ddfc43Xzs6OPXv2cPPmzRzDhISEsGLFCr799lvOnj3LyJEjef/999m7d69OuE8++YQZM2YQHx9Ply5dqFWrFqtXr9YJs3r1anr16pVtOnFxcTRr1oxKlSpx6NAhfvnlF3x9fcnIyMhXPiZMmMC5c+fYvn078fHxLFq0iOLFi+dafiGEEG+XTBgmhBCCzMxMAgMD8fLyonLlygCcP38egIoVK762dFJTU5kyZQrm5ubUrl2bjz/+mGbNmqlDwF1dXTl37hxffPEF/v7+WFtbY2BggFarxc7OTo0nJCQEPz8/tbfVxcWFBQsW0LhxYxYtWoSxsTEAbdq0YejQoQCMGzeOuXPnEh0dTYUKFbCxsQH+r1c8J507d9bZX7ZsGTY2Npw7d06tq9wMHDhQfT/W3t6eGzdu8NNPP+Xam5vl/fffZ/z48Vy5cgV41rMZHh6u06P7oqSkJMzMzGjXrh1arRYnJye1p7po0aK0bt2aNWvW0KxZMwB+/PFHihcvTpMmTQDw8PDAw8NDjW/KlClERESwefNmvYcT+fX1119TvXp1ndnply1bhqOjI7///jsODg58//33rFq1Ss3X8uXLKVWqVK7xfvnll3Tp0gU7Ozvc3d2pX78+HTp0oHXr1gA8evSI6dOns2vXLurVqwdA2bJl+eWXX1i8eDGNGzdW45o8eTItWrRQ9/38/Pj666/Vd8l///13jh8/zqpVq7LNy6xZs6hVqxYLFy5Uj7m7u+c7H0lJSVSvXp1atWoBz0ZO5OTRo0c8evRI3b9z506u9SSEEOL1kJ5nIYQQBAQEcObMGcLDw9VjrzJL8ovq16+Pubk5RYsW5eTJk6xbt44SJUoQHx+Pl5eXTlgvLy/Onz+v9thl5+TJk4SFheksG+bj40NmZiaXL19Ww1WtWlX9t0ajwc7Ojhs3bhQo7+fPn6dnz56ULVsWCwsLtVGT357Y2rVr4+7uzvLlywFYtWoVTk5Oam9wbmxsbGjbti1hYWGEhobStm3bPHsjW7RogZOTE2XLlqV3796sXr2a+/fvq+f9/PzYsGGD2vhavXo1PXr0oFChZ38SpKenM3r0aNzc3LCyssLc3Jz4+PhX6nk+efIk0dHROp9X1kOZixcvcvHiRR4/fkydOnXUa6ytralQoUKu8VaqVIkzZ85w+PBh+vfvz40bN/D19WXgwIEAXLhwgfv379OiRQudtFesWKE39D6r0ZqlR48eJCYmcvjwYbWeatSokePDpKye5+zkJx8ffvgh4eHhVKtWjbFjx3Lw4MEcyx0SEoKlpaW6OTo65lpPQgghXg/peRZCiP9xw4YNY+vWrezbt0+np8/V1RWA3377Te0te1nr1q2jUqVKFCtW7LVMxpWens4HH3zA8OHD9c49P5lWkSJFdM5pNJp8Dbd+nq+vL05OTixZskR9X7hy5co8fvw433EMHDiQb775hk8++YTQ0FD69euX74mm+vfvr/b4fvPNN3mG12q1/Prrr8TExLBz504mTpxIUFAQsbGxWFlZ4evri6IobNu2DU9PT/bv38/cuXPV60ePHk1UVBSzZ8+mfPnymJiY0KVLlxzLm9Xofv5hy5MnT3TCpKen4+vry8yZM/Wut7e358KFC3lXRA4KFSqEp6cnnp6eBAYGsmrVKnr37s1nn31Geno6ANu2baNkyZI61xkZGensm5mZ6ezb2dnRtGlT1qxZQ926dVmzZg0ffvhhjvnIeh0hO/nJR+vWrbly5Qo//fQTUVFRNGvWjICAAGbPnq0X3/jx4/n444/V/Tt37kgDWggh3gLpeRZCiP9RiqIwbNgwIiIi2LNnjzqBVpaWLVtSvHhxZs2ale31BZnR2NHRkXLlyuk1nN3c3Dhw4IDOsQMHDuDq6oqBgQHwbFbjF3uha9Sowblz57JdPszQ0DBfecoKl1sP9+3bt0lISODzzz+nWbNmuLm5qRNAFcT777/PlStXWLBgAefOnaNv3775vrZVq1Y8fvyYJ0+e4OPjk69rChcuTPPmzZk1axanTp0iMTGRPXv2AGBsbMx7773H6tWrWbt2LRUqVKBGjRrqtQcOHMDf359OnTpRpUoV7OzsSExMzDGtrOHvWe+jA3rLf9WoUYOzZ8/i7Oys93mZmZlRrlw5ihQpok4iB88m0MrPcmgvqlSpEvDsXfVKlSphZGREUlKSXrr5aWz6+fmxbt06Dh06xKVLl+jRo0eOYatWrcru3btzzFN+8mFjY0Pfvn1ZtWoV8+bN05ng7nlGRkZYWFjobEIIId486XkWQoj/UQEBAaxZs4ZNmzah1Wq5fv068GypJhMTE8zMzFi6dCldu3alffv2DB8+nPLly3Pr1i1++OEHkpKSdIZ5v4xRo0bh6enJlClT6N69O4cOHeLrr7/WeW/U2dmZffv20aNHD4yMjChevDjjxo2jbt26DBs2jIEDB2JmZsa5c+eIiori66+/zlfatra2mJiYsGPHDkqVKoWxsbHemr1FixalWLFifPfdd9jb25OUlMQnn3xS4HIWLVqU9957jzFjxtCyZcs83+V9noGBAfHx8eq/87J161YuXbpEo0aNKFq0KD/99BOZmZk6Q6D9/Pxo164dZ8+e5f3339e53sXFhY0bN+Lr64tGo2HChAm59tabmJhQt25dZsyYQZkyZbhx4waff/65TpiAgACWLFlCz549GTt2LNbW1ly4cIHw8HCWLl2Kubk5AwYMYMyYMRQrVgxbW1s+++wztVc7J126dMHLy4v69etjZ2fH5cuXGT9+PK6urlSsWJHChQszevRoRo4cSWZmJg0aNCAtLY0DBw5gYWGR50OM9957jw8//JAPP/yQJk2a4ODgkGPY8ePHU6VKFYYOHcqQIUMwNDQkOjqarl27Urx48TzzMXHiRGrWrIm7uzuPHj1i69atuLm55Zo/IYQQb5f0PAshxP+oRYsWkZaWhre3N/b29uq2bt06NUyHDh04ePAgRYoUoVevXlSsWJGePXuSlpbG1KlTXzkPNWrU4IcffiA8PJzKlSszceJEJk+ejL+/vxpm8uTJJCYmUq5cObWXs2rVquzdu5fff/+dhg0bUr16dSZOnJhr4+ZFhQsXZsGCBSxevBgHBwc6dOigF6ZQoUKEh4dz/PhxKleuzMiRI/niiy9eqqwDBgzg8ePH6pJQBVGQ3kUrKys2btxI06ZNcXNz49tvv2Xt2rXq5FUATZs2xdramoSEBL3Zo7/88kuKFi1K/fr18fX1xcfHR6dnOjvLli3j6dOn1KxZk8DAQL17w8HBgQMHDpCRkUHLli2pUqUKgYGBWFlZqQ3kL774goYNG+Lr60vz5s1p0KABNWvWzDVdHx8ftmzZgq+vL66urvTt25eKFSuyc+dOChd+1j8wZcoUJkyYQEhICG5ubrRq1Ypt27bpjbTIjlarxdfXl5MnT6qzkefE1dWVnTt3cvLkSWrXrk29evXYtGlTvvNhaGjI+PHjqVq1Ko0aNcLAwOCVH04JIYR4vTTK65wRRgghhBDZWrlyJSNHjuTatWv5HlouRH7cuXMHS0tL0tLSZAi3EEIUUEF+Q2XYthBCCPEG3b9/n+TkZGbMmMEHH3wgDWchhBDiX0qGbQshhHhpQ4YM0Vl65/ltyJAh7zp7/wizZs2iYsWK2NnZMX78+HedHSGEEEK8JBm2LYQQ4qXduHGDO3fuZHvOwsICW1vbt5yj/13+/v6kpqYSGRmZr/AxMTE0adKElJSU17J8WE7CwsIIDAzMc3Z2jUZDREQEHTt2fGN5eZ0KWt9vUtaQQ8fAHyhkZPqus/Ofkzij7bvOghDiDSrIsG3peRZCCPHSbG1ts10uqnz58v+phnNISAienp5otVpsbW3p2LEjCQkJOmGcnZ3RaDRoNBpMTExwdnamW7du6hJReQkKClKvz2n7LwgKCqJatWqvJa7Lly/Tq1cvHBwcMDY2plSpUnTo0IHffvvttcSfm/nz5xMWFvbG0xFCCPHPIY1nIYQQIg979+4lICCAw4cPExUVxZMnT2jZsiX37t3TCTd58mSSk5NJSEhgxYoVWFlZ0bx5c6ZNm5ZnGqNHjyY5OVndSpUqpcaXtYn/8+TJE1q0aEFaWhobN24kISGBdevWUaVKlQKtQf6ix48f5yucpaXlG+2xF0II8c8jjWchhBAiDzt27MDf3x93d3c8PDwICwsjKSmJ48eP64TTarXY2dlRunRpGjVqxHfffceECROYOHGiXk/1i8zNzbGzs1M3AwMDNT47OzuePHlCt27dsLKywtramg4dOpCYmJhjfJmZmYSEhFCmTBlMTEzw8PDgxx9/1At3/PhxatWqhampKfXr19fL56ZNm6hRowbGxsaULVuW4OBgnj59qp7/8ssvqVKlCmZmZjg6OjJ06FDS09OzzVNYWBjBwcGcPHlS7U1/vvf21q1bdOrUCVNTU1xcXNi8eXOO5Tt79iwXL15k4cKF1K1bFycnJ7y8vJg6dSp169ZVw129ejXXevP396djx45MmzYNBwcHKlSowKeffkqdOnX00vTw8GDy5Mk61z1f37NmzaJ8+fIYGRlRunRpnYcmeeUjJiaG2rVrY2ZmhpWVFV5eXly5ciXH8gshhHj7pPEshBBCFFBaWhoA1tbWeYYdMWIEiqKwadOml07vyZMn+Pj4oNVq2b9/PwcOHMDc3JxWrVrl2FMaEhLCihUr+Pbbbzl79iwjR47k/fffZ+/evTrhPvvsM+bMmcOxY8coXLiwzjrU+/fvp0+fPowYMYJz586xePFiwsLCdBqFhQoVYsGCBZw9e5bly5ezZ88exo4dm22eunfvzqhRo3B3d1d707t3766eDw4Oplu3bpw6dYo2bdrg5+fH33//nW1cNjY2FCpUiB9//JGMjIxXqrfdu3eTkJBAVFQUW7duxc/Pj6NHj3Lx4kU1zNmzZzl16pTeuthZxo8fz4wZM5gwYQLnzp1jzZo1lChRIl/5ePr0KR07dqRx48acOnWKQ4cOMXjw4P/MUH0hhPivkKWqhBBCiALIzMwkMDAQLy8vKleunGd4a2trbG1tc+0lzsu6devIzMxk6dKlaoMqNDQUKysrYmJiaNmypU74R48eMX36dHbt2kW9evUAKFu2LL/88guLFy+mcePGathp06ap+5988glt27bl4cOHGBsbExwczCeffELfvn3VOKZMmcLYsWOZNGkSAIGBgWpczs7OTJ06lSFDhrBw4UK9cpiYmGBubk7hwoWxs7PTO+/v70/Pnj0BmD59OgsWLODo0aO0atVKL2zJkiVZsGABY8eOJTg4mFq1atGkSRP8/PwoW7ZsgerNzMyMpUuX6iwj5uHhwZo1a5gwYQIAq1evpk6dOpQvX14vL3fv3mX+/Pl8/fXXal2VK1eOBg0a5CsftWrVIi0tjXbt2lGuXDkA3Nzc9NLJ8ujRIx49eqTu5zRpnxBCiNdLep6FEEKIAggICODMmTOEh4fn+xpFUV6pF/HkyZNcuHABrVarLgVmbW3Nw4cPdXpHs1y4cIH79+/TokULneXDVqxYoRe+atWq6r/t7e2BZ7OoZ6U7efJknTgGDRpEcnIy9+/fB2DXrl00a9aMkiVLotVq6d27N7dv31bPF8TzeTEzM8PCwkLNS3YCAgK4fv06q1evpl69eqxfvx53d3eioqIKVG9VqlTRW3/bz8+PNWvWAM8+v7Vr1+Ln55dtPuLj43n06BHNmjXL9nxe+bC2tsbf3x8fHx98fX2ZP39+ru+4h4SEYGlpqW6Ojo45hhVCCPH6SM+zEEIIkU/Dhg1j69at7Nu3j1KlSuXrmtu3b3Pz5k3KlCnz0ummp6dTs2ZNVq9erXfOxsYm2/AA27Zto2TJkjrnjIyMdPaLFCmi/jurgZ+ZmanGExwczHvvvaeXhrGxMYmJibRr144PP/yQadOmYW1tzS+//MKAAQN4/PgxpqYFWzbp+bxk5ScrLznRarX4+vri6+vL1KlT8fHxYerUqbRo0SLf9WZmZqZ3vmfPnowbN45ff/2VBw8ecPXqVZ0h5s8zMTHJNY/5yUdoaCjDhw9nx44drFu3js8//5yoqCid97ezjB8/no8//ljdv3PnjjSghRDiLZDGsxBCCJEHRVH46KOPiIiIICYmpkAN4fnz51OoUKFXWr+4Ro0arFu3Dltb2zzXoASoVKkSRkZGJCUl6QzRfpl0ExISsh2qDM8mG8vMzGTOnDkUKvRsMNsPP/yQa5yGhoY5vqP8qjQaDRUrVuTgwYNAwevteaVKlaJx48asXr2aBw8e0KJFixyXX3NxccHExITdu3czcOBAvfP5zUf16tWpXr0648ePp169eqxZsybbxrORkZHeQxAhhBBvngzbFkIIIfIQEBDAqlWrWLNmDVqtluvXr3P9+nUePHigE+7u3btcv36dq1evsm/fPgYPHszUqVOZNm1ajg3Q/PDz86N48eJ06NCB/fv3c/nyZWJiYhg+fDh//PGHXnitVsvo0aMZOXIky5cv5+LFi/z666989dVXLF++PN/pTpw4kRUrVhAcHMzZs2eJj48nPDyczz//HIDy5cvz5MkTvvrqKy5dusTKlSv59ttvc43T2dmZy5cvExcXx61bt3Te3S2IuLg4OnTowI8//si5c+e4cOEC33//PcuWLaNDhw5AwevtRX5+foSHh7N+/foch2zDs174cePGMXbsWHVo/OHDh/n+++/zlY/Lly8zfvx4Dh06xJUrV9i5cyfnz5/P9b1nIYQQb580noUQQog8LFq0iLS0NLy9vbG3t1e3devW6YSbOHEi9vb2lC9fnt69e5OWlsbu3bsZN27cK6VvamrKvn37KF26NO+99x5ubm4MGDCAhw8f5tiTOWXKFCZMmEBISAhubm60atWKbdu2FajX3MfHh61bt7Jz5048PT2pW7cuc+fOxcnJCXg2qdaXX37JzJkzqVy5MqtXryYkJCTXODt37kyrVq1o0qQJNjY2rF27Nv8V8ZxSpUrh7OxMcHAwderUoUaNGsyfP5/g4GA+++wz4OXq7XldunRR39/Oa+TAhAkTGDVqFBMnTsTNzY3u3bur72vnlQ9TU1N+++03OnfujKurK4MHDyYgIIAPPvjgpepGCCHEm6FRFEV515kQQgghhBAv586dO1haWpKWllbg4elCCPG/riC/odLzLIQQQgghhBBC5EEaz0IIIcRbMmTIEJ1ln57fhgwZ8q6zJ4QQQohcyGzbQggh/ifFxMTQpEkTUlJSsLKyeqNpBQUFERkZyc6dOxk9enS2Yd7WcNvvvvuOKVOm8Oeff/Lll18SGBj4VtItqLCwMAIDA0lNTVWPvZj31NRUIiMjiYuLe2f5zEl2+X/TKk/6mUJGBVseTIiCSpzR9l1nQYh3RnqehRBCvHYhISF4enqi1WqxtbWlY8eOJCQk6IRxdnZGo9HobTNmzMg17uPHj6PRaDh8+HC255s1a5btusRvi0ajITIyUufY6NGj2b17N7a2tpQvXz7bLadlkF6nO3fuMGzYMMaNG8eff/7J4MGDsw23d+9emjZtirW1Naampri4uNC3b18eP378xvOYpXv37vz+++/qfnZ5z6rXV3Hnzh0+++wzKlasiLGxMXZ2djRv3pyNGzci08IIIYR4nvQ8CyGEeO327t1LQEAAnp6ePH36lE8//ZSWLVty7tw5zMzM1HCTJ09m0KBBOtdqtdpc465ZsyYeHh4sW7ZMbw3cxMREoqOj2bJly+srzGuQNTT7XUtKSuLJkye0bdsWe3v7bMOcO3eOVq1a8dFHH7FgwQJMTEw4f/48GzZseGPrM2fHxMQEExMTdT+nvL9KvaamptKgQQPS0tKYOnUqnp6eFC5cmL179zJ27FiaNm36xkclCCGE+PeQnmchhBCv3Y4dO/D398fd3R0PDw/CwsJISkri+PHjOuG0Wi12dnY62/ON65wMGDCAdevWcf/+fZ3jYWFh2Nvb06pVK1auXEmtWrXUNHr16qUuHZSdoKAgqlWrpnNs3rx5ODs7q/uxsbG0aNGC4sWLY2lpSePGjfn111/V81lhO3XqhEajUfdfjDszM5PJkydTqlQpjIyMqFatGjt27FDPJyYmotFo2LhxI02aNMHU1BQPDw8OHTqUa70kJSXRoUMHzM3NsbCwoFu3bvz1119q3VSpUgWAsmXLotFoSExM1Itj586d2NnZMWvWLCpXrky5cuVo1aoVS5YsURuzYWFhWFlZERkZiYuLC8bGxvj4+HD16lWduDZt2kSNGjUwNjambNmyBAcH8/TpU/V8amoqH3zwASVKlMDY2JjKlSuzdetWnTRyy3t2n9myZctwd3fHyMgIe3t7hg0blmN9ffrppyQmJnLkyBH69u1LpUqVcHV1ZdCgQcTFxakN85SUFPr06UPRokUxNTWldevWnD9/XieusLAwSpcujampKZ06deL27dt66eVWH4qiEBQUROnSpTEyMsLBwYHhw4fnmHchhBBvnzSehRBCvHFpaWkAWFtbv5b4/Pz8ePToET/++KN6TFEUli9fjr+/PwYGBjx58oQpU6Zw8uRJIiMjSUxMxN/f/5XSvXv3Ln379uWXX37h8OHDuLi40KZNG+7evQs8a1wDhIaGkpycrO6/aP78+cyZM4fZs2dz6tQpfHx8aN++vV6D7LPPPmP06NHExcXh6upKz549dRqfz8vMzKRDhw78/fff7N27l6ioKC5dukT37t2BZ8Ogd+3aBcDRo0dJTk7G0dFRLx47OzuSk5PZt29frnVx//59pk2bxooVKzhw4ACpqan06NFDPb9//3769OnDiBEjOHfuHIsXLyYsLIxp06ap+W3dujUHDhxg1apVnDt3jhkzZmBgYKCXVn7zvmjRIgICAhg8eDCnT59m8+bNlC9fPsf6Cg8Px8/PDwcHB73z5ubmFC78bICev78/x44dY/PmzRw6dAhFUWjTpg1PnjwB4MiRIwwYMIBhw4YRFxdHkyZNmDp1qk58edXHhg0bmDt3LosXL+b8+fNERkaqDwyEEEL8M8iwbSGEEG9UZmYmgYGBeHl5UblyZZ1z48aN4/PPP9c5tn37dho2bJhrnNbW1nTq1Illy5bRp08fAKKjo0lMTKRfv34A9O/fXw1ftmxZFixYgKenJ+np6S891Ldp06Y6+9999x1WVlbs3buXdu3aYWNjA4CVlRV2dnY5xjN79mzGjRunNjZnzpxJdHQ08+bN45tvvlHDjR49mrZtn03OExwcjLu7OxcuXKBixYp6ce7evZvTp09z+fJltWG5YsUK3N3diY2NxdPTk2LFigFgY2OTY/66du3Kzz//TOPGjbGzs6Nu3bo0a9aMPn366Exq9uTJE77++mvq1KkDwPLly3Fzc+Po0aPUrl2b4OBgPvnkE/r27Qs8+wymTJnC2LFjmTRpErt27eLo0aPEx8fj6uqqhsmOiYlJvvI+depURo0axYgRI9Rjnp6e2Ya9desWKSkp2dbl886fP8/mzZs5cOAA9evXB2D16tU4OjoSGRlJ165dmT9/Pq1atWLs2LEAuLq6cvDgQZ3RBHnVR1JSkvq+dZEiRShdujS1a9fONk+PHj3i0aNH6v6dO3dyLYMQQojXQ3qehRBCvFEBAQGcOXOG8PBwvXNjxowhLi5OZ6tVq1a+4u3fvz/79u3j4sWLwLPhuo0bN1Z7Go8fP46vry+lS5dGq9XSuHFj4NnQ5pf1119/MWjQIFxcXLC0tMTCwoL09PQCxXnnzh2uXbuGl5eXznEvLy/i4+N1jlWtWlX9d9Z7vjkNPY+Pj8fR0VGnR7ZSpUpYWVnpxZsbAwMDQkND+eOPP5g1axYlS5Zk+vTpuLu7k5ycrIYrXLiwTsO0YsWKOmmdPHmSyZMn6yzHNWjQIJKTk7l//z5xcXGUKlVKbTi/qhs3bnDt2jWaNWuWr/D5nQwsPj6ewoULqw8JAIoVK0aFChXUssbHx+ucB6hXr57Ofl710bVrVx48eEDZsmUZNGgQEREROY4yCAkJwdLSUt2y64UXQgjx+knjWQghxBszbNgwtm7dSnR0NKVKldI7X7x4cb1Zp5+fJCo3zZo1o3Tp0oSFhXHnzh02btzIgAEDALh37x4+Pj5YWFiwevVqYmNjiYiIAMhxxuhChQrpNaiyhuVm6du3L3FxccyfP5+DBw8SFxdHsWLF3tgs1EWKFFH/rdFogGc9+W9DyZIl6d27N19//TVnz57l4cOHfPvtt/m+Pj09neDgYJ0HI6dPn+b8+fMYGxvn+3POr4LGZ2Njg5WVFb/99ttrzUdO8qoPR0dHEhISWLhwISYmJgwdOpRGjRrp3YMA48ePJy0tTd1efNdcCCHEmyGNZyGEEK+doigMGzaMiIgI9uzZQ5kyZV57GoUKFaJfv34sX76cNWvWYGhoSJcuXQD47bffuH37NjNmzKBhw4ZUrFgx18nC4Flj6vr16zoN6BfXDz5w4ADDhw+nTZs26qRUt27d0glTpEiRXGeltrCwwMHBgQMHDujFXalSpfwUPVtubm5cvXpVpyF17tw5UlNTXylegKJFi2Jvb8+9e/fUY0+fPuXYsWPqfkJCAqmpqbi5uQFQo0YNEhISsl2Wq1ChQlStWpU//vhDZzmqV6HVanF2ds730lWFChWiR48erF69mmvXrumdT09P5+nTp7i5ufH06VOOHDminrt9+zYJCQlqvbq5uemcB/SWUsurPuDZAwBfX18WLFhATEwMhw4d4vTp03p5MzIywsLCQmcTQgjx5sk7z0IIIV67gIAA1qxZw6ZNm9BqtVy/fh0AS0tLnR7Cu3fvqueymJqa5rsx0K9fPyZPnsynn35Kz5491bhLly6NoaEhX331FUOGDOHMmTNMmTIl17i8vb25efMms2bNokuXLuzYsYPt27fr5MXFxUWdxfvOnTuMGTNGr8czqwHn5eWFkZERRYsW1UtrzJgxTJo0iXLlylGtWjVCQ0OJi4tj9erV+Sp3dpo3b06VKlXw8/Nj3rx5PH36lKFDh9K4ceN8D4UHWLx4MXFxcXTq1Ily5crx8OFDVqxYwdmzZ/nqq6/UcEWKFFGXsypcuDDDhg2jbt266nu6EydOpF27dpQuXZouXbpQqFAhTp48yZkzZ5g6dSqNGzemUaNGdO7cmS+//JLy5cvz22+/odFoaNWq1UvVQVBQEEOGDMHW1pbWrVtz9+5dDhw4wEcffZRt+GnTphETE0OdOnWYNm0atWrVokiRIuzfv5+QkBBiY2NxcXGhQ4cODBo0iMWLF6PVavnkk08oWbIkHTp0AGD48OF4eXkxe/ZsOnTowM8//6zzvnN+6iMsLIyMjAzq1KmDqakpq1atwsTEBCcnp5eqCyGEEK+f9DwLIYR47RYtWkRaWhre3t7Y29ur27p163TCTZw4Uee8vb29OulSfpQuXZrmzZuTkpKiM0GYjY0NYWFhrF+/nkqVKjFjxgxmz56da1xubm4sXLiQb775Bg8PD44ePcro0aN1wnz//fekpKRQo0YNevfuzfDhw7G1tdUJM2fOHKKionB0dKR69erZpjV8+HA+/vhjRo0aRZUqVdixYwebN2/GxcUl32V/kUajYdOmTRQtWpRGjRrRvHlzypYtq1fnealduzbp6ekMGTIEd3d3GjduzOHDh4mMjFTfG4dnDznGjRtHr1698PLywtzcXCctHx8ftm7dys6dO/H09KRu3brMnTtXpzG4YcMGPD096dmzJ5UqVWLs2LGvtJZ03759mTdvHgsXLsTd3Z127drpzWD+PGtraw4fPsz777/P1KlTqV69Og0bNmTt2rV88cUXWFpaAs9mT69Zsybt2rWjXr16KIrCTz/9pA6rr1u3LkuWLGH+/Pl4eHiwc+dOvYnw8qoPKysrlixZgpeXF1WrVmXXrl1s2bJFnShNCCHEu6dR8jtjhhBCCCEEz9Y0DgwMJDU19V1nRfBsEjpLS0vS0tJkCLcQQhRQQX5DpedZCCGEEEIIIYTIgzSehRBC/OMMGTJEZ0mf57chQ4a86+wJIYQQ4n+QDNsWQgjxj3Pjxg3u3LmT7TkLCwu994yFeNucnZ0JDAwkMDDwtYZ9GVlDDh0Df6CQkekbSSNxRts3Eq8QQrxrMmxbCCHEv5qtrW22S/qUL19eGs7vQEhICJ6enmi1WmxtbenYsSMJCQk6YZydndFoNDpbdmt7Zye7azUaDTNmzFDDZGZmMm7cOBwcHDAxMaFq1aps2rRJL66wsDA0Go26ZNbz1q9fj0ajwdnZOdt8/PXXXxQpUoTw8PBszw8YMIAaNWoAEBsby+DBg/NVvhfDajQaIiMj83WtEEKIfw5pPAshhBAiV3v37iUgIIDDhw8TFRXFkydPaNmypc66zwCTJ08mOTlZ3U6cOJHvNF68Njk5WWeJqVWrVjF37ly+/PJL4uPj+fLLLzEzM8s2LjMzM27cuMGhQ4d0jn///feULl06xzyUKFGCtm3bsmzZMr1z9+7d44cffmDAgAHAsxndTU3z18tbkLBCCCH+uaTxLIQQQohc7dixA39/f9zd3fHw8CAsLIykpCSOHz+uE06r1WJnZ6duNjY2+U7jxWvt7Ox0GseFChXCxsaGHj164OzsTPPmzWnevHm2cRUuXJhevXrpNIL/+OMPYmJi6NWrV675GDBgALt37yYpKUnn+Pr163n69Cl+fn7As97yefPmAaAoCkFBQZQuXRojIyMcHBwYPny4eu3zYbN6vTt16qTTC37y5EmaNGmCVqvFwsKCmjVrcuzYsTzrTQghxNsjjWchhBBCFEhaWhrwbJ3kt6VZs2akpaUxYcKEfIXv378/P/zwA/fv3weeDedu1aoVJUqUyPW6Nm3aUKJECcLCwnSOh4aG8t5772FlZaV3zYYNG5g7dy6LFy/m/PnzREZGUqVKlWzjj42NVeNLTk5W9/38/ChVqhSxsbEcP36cTz75RF1HWgghxD+DNJ6FEEIIkW+ZmZkEBgbi5eVF5cqVdc6NGzdOZ2b0BQsW5DveF681Nzdn//79ANy/f58WLVrQq1cvoqKiGD16NM/Pd2phYcGPP/6oE1/16tUpW7YsP/74I4qiEBYWRv/+/fPMh4GBAX379iUsLExN4+LFi+zfvz/H65OSkrCzs6N58+aULl2a2rVrM2jQoGzDZvXGW1lZ6fTOJyUl0bx5cypWrIiLiwtdu3bFw8Mj2zgePXrEnTt3dDYhhBBvnjSehRBCCJFvAQEBnDlzJttJtcaMGUNcXJy69enTJ9/xvnhtXFwctWrVAp71GqempvLNN9+wfft2oqKi6NevH0+fPiUxMZH09HS8vLz04uzfvz+hoaHs3buXe/fu0aZNm3zlpX///ly+fJno6GjgWS+xs7MzTZs2zTZ8165defDgAWXLlmXQoEFERETw9OnTfJcd4OOPP2bgwIE0b96cGTNmcPHixRzDhoSEYGlpqW6Ojo4FSksIIcTLkcazEEIIIfJl2LBhbN26lejo6Gxn0i5evLjOzOjZDXHOyYvXli9fHhMTEwBOnTqFu7s7RYoUoWjRokRFRXHo0CE6derEggULaNWqFfb29npx+vn5cfjwYYKCgujduzeFCxfOV15cXFxo2LAhoaGhZGZmsmLFCvr164dGo8k2vKOjIwkJCSxcuBATExOGDh1Ko0aNePLkSb7LHxQUxNmzZ2nbti179uyhUqVKREREZBt2/PjxpKWlqdvVq1fznY4QQoiXJ41nIYQQQuRKURSGDRtGREQEe/bsoUyZMm81/ZIlSxIXF8fdu3eBZ0uZ7dq1i9OnTzN37lymTp2a7XXW1ta0b9+evXv35mvI9vMGDBjAhg0b2LBhA3/++Sf+/v65hjcxMcHX15cFCxYQExPDoUOHOH36dLZhixQpQkZGht5xV1dXRo4cyc6dO3nvvfcIDQ3N9nojIyMsLCx0NiGEEG+eNJ6FEEIIkauAgABWrVrFmjVr0Gq1XL9+nevXr/PgwYPXlsbdu3fVeLO2rHd5BwwYQEZGBu3bt+fgwYMkJCTw888/k56ejqmpKd9//32O8YaFhXHr1i0qVqxYoPx07dqVIkWK8MEHH9CyZctch0aHhYXx/fffc+bMGS5dusSqVaswMTHByckp2/DOzs7s3r2b69evk5KSwoMHDxg2bBgxMTFcuXKFAwcOEBsbm+1a1UIIId4daTwLIYQQIleLFi0iLS0Nb29v7O3t1W3dunWvLY2JEyfqxG1vb8/YsWMBcHBw4OjRoxQvXpz33nuP6tWrs2LFClasWMG2bdv47rvv+PLLL7ON18TEhGLFihU4P6ampvTo0YOUlJQ8e62trKxYsmQJXl5eVK1alV27drFly5Yc050zZw5RUVE4OjpSvXp1DAwMuH37Nn369MHV1ZVu3brRunVrgoODC5xvIYQQb45GeX66SiGEEEII8a9y584dLC0tSUtLkyHcQghRQAX5DZWeZyGEEEIIIYQQIg/SeBZCCCHEG7N69Wq99ZuzNnd393edPSGEECLf8rdmgxBCCPEfFRYWRmBgIKmpqTmG8ff3JzU1lcjIyLeWrzclMTGRMmXKcOLECapVq/bG02vfvj116tTJ9lyRIkXeePqvi7e3N9WqVWPevHnAs0m/AgMDCQwMfKf5el7lST9TyMhU73jijLbvIDdCCPHfIz3PQgjxLxESEoKnpydarRZbW1s6duxIQkKCXrgTJ07QvXt37O3tMTIywsnJiXbt2rFlyxYKMs3Fhg0baNq0KUWLFsXExIQKFSrQv39/Tpw48TqL9a8wf/58wsLCXvp6f39/NBoNGo0GQ0NDypcvz+TJk3n69Onry2QO6Xbs2FHnmKOjI8nJyVSuXPmNpn39+nU++ugjPDw8cHd3p0mTJowcOZIrV66o6zjnNBt1foSFheVrHen8hiuo2NhYBg8e/NrjFUII8c8ljWchhPiX2Lt3LwEBARw+fJioqCiePHlCy5YtuXfvnhpm06ZN1K1bl/T0dJYvX058fDw7duygU6dOfP7556SlpeUrrXHjxtG9e3eqVavG5s2bSUhIYM2aNZQtW5bx48e/qSLm2+PHj99qepaWlq/cAGvVqhXJycmcP3+eUaNGERQUxBdffJFt2DdZPgMDA+zs7Chc+M0NPktMTKRmzZrs2bOHL774gtOnT7Njxw6aNGlCQEDAG0v3bbKxscHUVL+XVwghxH+YIoQQ4l/pxo0bCqDs3btXURRFSU9PV4oVK6Z06tQpx2syMzPzjPfQoUMKoMyfPz9fcURGRirVq1dXjIyMlDJlyihBQUHKkydP1PNXrlxR2rdvr5iZmSlarVbp2rWrcv36dZ04pkyZotjY2Cjm5ubKgAEDlHHjxikeHh7q+b59+yodOnRQpk6dqtjb2yvOzs6KoijKihUrlJo1ayrm5uZKiRIllJ49eyp//fWXel10dLQCKFu3blWqVKmiGBkZKXXq1FFOnz6thgkNDVUsLS2VHTt2KBUrVlTMzMwUHx8f5dq1a3rpZ8nIyFBmzpyplCtXTjE0NFQcHR2VqVOn5linL16vKIrSokULpW7duq9UPkVRlDNnziht27ZVtFqtYm5urjRo0EC5cOGCMmnSJAXQ2aKjo5XLly8rgHLixIk848iyZMkSpWLFioqRkZFSoUIF5ZtvvsmxrIqiKK1bt1ZKliyppKen651LSUlR/53XvREXF6d4e3sr5ubmilarVWrUqKHExsaqn+vz26RJk7LNS9bnm2XSpEmKh4eHsmLFCsXJyUmxsLBQunfvrty5c0cNk56ervTu3VsxMzNT7OzslNmzZyuNGzdWRowYoYZxcnJS5s6dq1OuwYMHK7a2toqRkZHi7u6ubNmyRT2/f/9+pUGDBoqxsbFSqlQp5aOPPtKpn2+++UYpX768YmRkpNja2iqdO3fOtY6fl5aWpgCKY+APitO4rXqbEEKInGX9hqalpeUZVnqehRDiXyqrF9na2hqAnTt3cvv2bXVt3OxoNJo84127di3m5uYMHTo0zzj2799Pnz59GDFiBOfOnWPx4sWEhYUxbdo0ADIzM+nQoQN///03e/fuJSoqikuXLtG9e3c1jtWrVzNt2jRmzpzJ8ePHKV26NIsWLdJLd/fu3SQkJBAVFcXWrVsBePLkCVOmTOHkyZNERkaSmJiIv7+/3rVjxoxhzpw5xMbGYmNjg6+vL0+ePFHP379/n9mzZ7Ny5Ur27dtHUlISo0ePzrGOxo8fz4wZM5gwYQLnzp1jzZo1lChRIveKfYGJiYlOD/PLlO/PP/+kUaNGGBkZsWfPHo4fP07//v15+vQpo0ePplu3bmqPd3JyMvXr19fLR25xwLPPZ+LEiUybNo34+HimT5/OhAkTWL58ebbl+vvvv9mxYwcBAQGYmZnpnc/qwc/PveHn50epUqWIjY3l+PHjfPLJJxQpUoT69eszb948LCws1LLl9nm96OLFi0RGRrJ161a2bt3K3r17mTFjhnp+zJgx7N27l02bNrFz505iYmL49ddfc4wvMzOT1q1bc+DAAVatWsW5c+eYMWMGBgYGanqtWrWic+fOnDp1inXr1vHLL78wbNgwAI4dO8bw4cOZPHkyCQkJ7Nixg0aNGuW7PEIIId6St9CYF0II8ZplZGQobdu2Vby8vNRjM2bMUADl77//Vo8dPXpUMTMzU7fne8Jy0qpVK6Vq1ao6x+bMmaMTT2pqqqIoitKsWTNl+vTpOmFXrlyp2NvbK4qiKDt37lQMDAyUpKQk9fzZs2cVQDl69KiiKIpSp04dJSAgQCcOLy8vvZ7nEiVKKI8ePco177GxsQqg3L17V1GU/+t5Dg8PV8Pcvn1bMTExUdatW6coyrOeSUCnp/Wbb75RSpQooZN+Vs/xnTt3FCMjI2XJkiW55uV5z1+fmZmpREVFKUZGRsro0aNfqXzjx49XypQpozx+/DjPdLO82POcVxzlypVT1qxZo3NsypQpSr169bINf+TIEQVQNm7cmGtZ8nNvaLVaJSwsLNvrX+xRzkl2Pc+mpqY6Pc1jxoxR6tSpoyiKoty9e1cxNDRUfvjhB/V81j2TU8/zzz//rBQqVEhJSEjINg8DBgxQBg8erHNs//79SqFChZQHDx4oGzZsUCwsLHTylJuHDx8qaWlp6nb16lXpeRZCiJckPc9CCPEfFxAQwJkzZwgPD881XNWqVYmLiyMuLo579+699ARV/fv3Jy4ujsWLF3Pv3j114rGTJ08yefJkneWHBg0aRHJyMvfv3yc+Ph5HR0ccHR3VuCpVqoSVlRXx8fEAJCQkULt2bZ30XtwHqFKlCoaGhjrHjh8/jq+vL6VLl0ar1dK4cWMAkpKSdMLVq1dP/be1tTUVKlRQ0wcwNTWlXLly6r69vT03btzIti7i4+N59OgRzZo1y7nCsrF161bMzc0xNjamdevWdO/enaCgoFcqX1xcHA0bNnylWatzi+PevXtcvHiRAQMG6HzGU6dO5eLFi9nGp+RzUrr83Bsff/wxAwcOpHnz5syYMSPHNAvK2dkZrVar7j//eV+8eJHHjx/rzBCedc/kJC4ujlKlSuHq6prt+ZMnTxIWFqZThz4+PmRmZnL58mVatGiBk5MTZcuWpXfv3qxevZr79+/nmF5ISAiWlpbq9nwdCiGEeHOk8SyEEP8yw4YNY+vWrURHR1OqVCn1uIuLC4DODNxGRkbqzMb55eLiwqVLl3SGNVtZWVG+fHlKliypEzY9PZ3g4GC1gR4XF8fp06c5f/48xsbGL1vEbL04BPjevXv4+PhgYWHB6tWriY2NJSIiAij4hFsvNhw1Gk2OjUATE5MCxZ2lSZMmxMXFcf78eR48eMDy5ct1yvQy5XvZvDwvtzjS09MBWLJkic5nfObMGQ4fPpztNS4uLmg0Gn777bdXzltQUBBnz56lbdu27Nmzh0qVKql18Cqy+7wzMzNfOr68Pof09HQ++OADnTo8efIk58+fp1y5cmi1Wn799VfWrl2Lvb09EydOxMPDI8fl08aPH09aWpq6Xb169aXzLoQQIv+k8SyEEP8SiqIwbNgwIiIi2LNnD2XKlNE537JlS6ytrZk5c+YrpdOzZ0/S09NZuHBhnmFr1KhBQkKC2kB/fitUqBBubm5cvXpV54/7c+fOkZqaSqVKlQCoUKECsbGxOvG+uJ+d3377jdu3bzNjxgwaNmxIxYoVc+wtfr6hl5KSwu+//46bm1ueaWTHxcUFExMTdu/eXaDrzMzMKF++PKVLl87XTNf5KV/VqlXZv3+/zoOO5xkaGpKRkZFrOrnFUaJECRwcHLh06ZLe5/vi/ZfF2toaHx8fvvnmG52Z4LNkNQjzc28AuLq6MnLkSHbu3Ml7771HaGhovsv2MsqVK0eRIkU4cuSIeizrnslJ1apV+eOPP3IMU6NGDc6dO5ft9yRrtEHhwoVp3rw5s2bN4tSpUyQmJrJnz55s4zMyMsLCwkJnE0II8eZJ41kIIf4lAgICWLVqFWvWrEGr1XL9+nWuX7/OgwcPADA3N2fp0qVs27aNtm3b8vPPP3Pp0iVOnTrFrFmzANQJjHJTr149Ro0axahRo/j444/55ZdfuHLlCocPH+b7779Ho9FQqNCz/z4mTpzIihUrCA4O5uzZs8THxxMeHs7nn38OQPPmzalSpQp+fn78+uuvHD16lD59+tC4cWNq1aoFwEcffcT333/P8uXLOX/+PFOnTuXUqVN5Tm5WunRpDA0N+eqrr7h06RKbN29mypQp2YadPHkyu3fv5syZM/j7+1O8eHG99Y/zy9jYmHHjxjF27FhWrFjBxYsX1bp5nfJTvmHDhnHnzh169OjBsWPHOH/+PCtXrlRHHzg7O3Pq1CkSEhK4detWtg3kvOIIDg4mJCSEBQsW8Pvvv3P69GlCQ0P58ssvc8z7N998Q0ZGBrVr12bDhg2cP3+e+Ph4FixYoA6hz+veePDgAcOGDSMmJoYrV65w4MABYmNj1Ycezs7OpKens3v3bm7dupXrMOeCMDc3Z8CAAYwZM4Y9e/ao90zWPZ+dxo0b06hRIzp37kxUVBSXL19m+/bt7NixA3i29NvBgwcZNmyYOvpg06ZN6oRhW7duZcGCBcTFxXHlyhVWrFhBZmZmrkPFhRBCvH3SeBZCiH+JRYsWkZaWhre3N/b29uq2bt06NUynTp04ePAgpqam9OnThwoVKtC0aVP27NlDeHg47dq1y1das2fPZs2aNZw4cYJ27drh4uJC165dyczM5NChQ2pPl4+PD1u3bmXnzp14enpSt25d5s6di5OTE/BsOOymTZsoWrQojRo1onnz5pQtW1Ynz35+fowfP57Ro0dTo0YNLl++jL+/f57Dvm1sbAgLC2P9+vVUqlSJGTNmMHv27GzDzpgxgxEjRlCzZk2uX7/Oli1b9N4vLogJEyYwatQoJk6ciJubG927d8+x1/tl5ad8xYoVY8+ePaSnp9O4cWNq1qzJkiVL1GHJgwYNokKFCtSqVQsbGxsOHDigl05ecQwcOJClS5cSGhpKlSpVaNy4MWFhYTn2PAOULVuWX3/9lSZNmjBq1CgqV65MixYt2L17tzqTel73hoGBAbdv36ZPnz64urrSrVs3WrduTXBwMAD169dnyJAhdO/eHRsbG/UB0evwxRdf0LBhQ3x9fWnevDkNGjSgZs2auV6zYcMGPD096dmzJ5UqVWLs2LFqz3jVqlXZu3cvv//+Ow0bNqR69epMnDgRBwcH4NlrERs3bqRp06a4ubnx7bffsnbtWtzd3V9bmYQQQrw6jZLfmT2EEEKIt6RFixbY2dmxcuXKV4onJiaGJk2akJKSoi6RJMR/zZ07d7C0tCQtLU2GcAshRAEV5Dc075euhBBCiDfo/v37fPvtt/j4+GBgYMDatWvZtWsXUVFR7zprQgghhBAqGbYthBD/Y4YMGaKzZM7z25AhQ956fjQaDT/99BONGjWiZs2abNmyhQ0bNtC8efO3nhchhBBCiJzIsG0hhPgfc+PGDe7cuZPtOQsLC2xtbd9yjgRAZGQko0eP5vLly3z00UfMmzfvraav0WiIiIjIcSI1Z2dnAgMDCQwMfKv5elFYWBiBgYE5LuP0sv4p5XsZWUMOHQN/oJCRqc65xBlt31GuhBDi36Egw7al51kIIf7H2NraZrtkTvny5XUaziEhIXh6eqLVarG1taVjx446a0jDswZHdo28oKAgqlWrlq/8BAUFodFo0Gg0FC5cGGdnZ0aOHKmuMfxvFhMTg0ajyVdD74MPPqBLly5cvXo1x1nDX9bNmzf58MMPKV26NEZGRtjZ2eHj45PtBGI5iY2NZfDgwa+Uj8uXL9OrVy8cHBwwNjamVKlSdOjQ4bWsCZ1fYWFh2b7//mL5NBoNkZGRBY7f29v7X9kAF0IIkTd551kIIUS29u7dS0BAAJ6enjx9+pRPP/2Uli1bcu7cOczMzF5rWu7u7uzatYunT59y4MAB+vfvz/3791m8ePFrTeefKj09nRs3buDj46POwPwyHj9+nO0s4p07d+bx48csX76csmXL8tdff7F7925u376d77htbGxeOl8AT548oUWLFlSoUIGNGzdib2/PH3/8wfbt2197L/LLeNXyCSGE+O+TnmchhBDZ2rFjB/7+/ri7u+Ph4UFYWBhJSUkcP378tadVuHBh7OzsKFWqFN27d8fPz4/NmzcDsHLlSmrVqoVWq8XOzo5evXqpy0IpikL58uX1lnCKi4tDo9Fw4cIF4Fkv4uLFi2nXrh2mpqa4ublx6NAhLly4gLe3N2ZmZtSvX5+LFy/qxLNp0yZq1KiBsbExZcuWJTg4mKdPn6rnNRoNS5cupVOnTpiamuLi4qLmOzExkSZNmgBQtGhRNBoN/v7+emWPiYlBq9UC0LRpUzQaDTExMcCz5Y/c3d0xMjLC2dmZOXPm6Fzr7OzMlClT6NOnDxYWFtn2DKemprJ//35mzpxJkyZNcHJyonbt2owfP5727dvn+JlMmjQJe3t7Tp06pab1/CiD3MqenbNnz3Lx4kUWLlxI3bp1cXJywsvLi6lTp1K3bl21Ll7sqc/6LBMTE3Xii4yMxMXFBWNjY3x8fLh69ap67uTJkzRp0gStVouFhQU1a9bk2LFjxMTE0K9fP9LS0tTRDkFBQXrlc3Z2Bp4t/abRaNR9f39/vWHtgYGBeHt7q+f37t3L/Pnz1fiz8n3mzBlat26Nubk5JUqUoHfv3ty6dUuN58cff6RKlSqYmJhQrFgxmjdvzr1793KsTyGEEG+fNJ6FEELkS1paGgDW1tZvPC0TExMeP34MPOuxnDJlCidPniQyMpLExES1EarRaOjfvz+hoaE614eGhtKoUSPKly+vHstqZMbFxVGxYkV69erFBx98wPjx4zl27BiKojBs2DA1/P79++nTpw8jRozg3LlzLF68mLCwMKZNm6aTVnBwMN26dePUqVO0adMGPz8//v77bxwdHdmwYQMACQkJJCcnM3/+fL2y1q9fXx0Ov2HDBpKTk6lfvz7Hjx+nW7du9OjRg9OnTxMUFMSECRMICwvTuX727Nl4eHhw4sQJJkyYoBd/1mRwkZGRPHr0KM+6VxSFjz76iBUrVrB//36qVq2aY9icyp4dGxsbChUqxI8//qiuf/yy7t+/z7Rp01ixYgUHDhwgNTWVHj16qOf9/PwoVaoUsbGxHD9+nE8++YQiRYpQv3595s2bh4WFBcnJySQnJzN69Gi9+GNjY4Fn91FycrK6n5f58+dTr149Bg0apMbv6OhIamoqTZs2pXr16hw7dowdO3bw119/0a1bNwCSk5Pp2bMn/fv3Jz4+npiYGN577z1kWhohhPiHUYQQQog8ZGRkKG3btlW8vLx0jjs5OSmGhoaKmZmZzlakSBHFw8MjX3FPmjRJJ+yxY8eU4sWLK126dMk2fGxsrAIod+/eVRRFUf7880/FwMBAOXLkiKIoivL48WOlePHiSlhYmHoNoHz++efq/qFDhxRA+f7779Vja9euVYyNjdX9Zs2aKdOnT9dJe+XKlYq9vX2O8aanpyuAsn37dkVRFCU6OloBlJSUlFzrICUlRQGU6Oho9VivXr2UFi1a6IQbM2aMUqlSJXXfyclJ6dixY65xK4qi/Pjjj0rRokUVY2NjpX79+sr48eOVkydP6oQBlPXr1yu9evVS3NzclD/++EPnvJOTkzJ37tx8lz07X3/9tWJqaqpotVqlSZMmyuTJk5WLFy+q57OrrxMnTiiAcvnyZUVRFCU0NFQBlMOHD6th4uPjFUC9B7Rarc7n/7zQ0FDF0tJS73h25YuIiNAJ07dvX6VDhw46x0aMGKE0btxY3W/cuLEyYsQInTBTpkxRWrZsqXPs6tWrCqAkJCQox48fVwAlMTEx2zy/6OHDh0paWpq6ZcXlGPiD4jRuq84mhBAid2lpaQqgpKWl5RlWep6FEELkKSAggDNnzhAeHq53bsyYMcTFxelsBV3y6vTp05ibm2NiYkLt2rWpV68eX3/9NQDHjx/H19eX0qVLo9Vqady4MQBJSUkAODg40LZtW5YtWwbAli1bePToEV27dtVJ4/ke1BIlSgBQpUoVnWMPHz5UZyI/efIkkydP1lnKK6tH8f79+9nGa2ZmhoWFhTqs/FXEx8fj5eWlc8zLy4vz58/r9NzWqlUrz7g6d+7MtWvX2Lx5M61atSImJoYaNWro9WKPHDmSI0eOsG/fPkqWLJlnvAUte0BAANevX2f16tXUq1eP9evX4+7uXuA1vQsXLoynp6e6X7FiRaysrIiPjwfg448/ZuDAgTRv3pwZM2boDcd/206ePEl0dLTOvVSxYkUALl68iIeHB82aNaNKlSp07dqVJUuWkJKSkmN8ISEhWFpaqpujo+PbKooQQvxPk8azEEKIXA0bNoytW7cSHR1NqVKl9M4XL15cb9bugg7trlChAnFxccTHx/PgwQM2b95MiRIluHfvHj4+PlhYWLB69WpiY2OJiIgAUId1AwwcOJDw8HAePHhAaGgo3bt3x9RUd8meIkWKqP/WaDQ5HsvMzASeTeIVHBys81Dg9OnTnD9/HmNj42zjzYonK463Ib+TtxkbG9OiRQsmTJjAwYMH8ff3Z9KkSTphWrRowZ9//snPP/+crzhfpuxarRZfX1+mTZvGyZMnadiwIVOnTgWgUKFnf5Yozw1XfvLkSb7y8rygoCDOnj1L27Zt2bNnD5UqVVLvm1dRqFAhvaHU+clfeno6vr6+eg+Zzp8/T6NGjTAwMCAqKort27dTqVIlvvrqKypUqMDly5ezjW/8+PGkpaWp2/PvewshhHhzZLZtIYQQ2VL+/7uvERERxMTEUKZMmTeWlqGhoc77yVl+++03bt++zYwZM9TetWPHjumFa9OmDWZmZixatIgdO3awb9++V85TjRo1SEhIyDZf+ZU18/XLvOPr5uamt5TUgQMHcHV1xcDA4KXzlKVSpUp6SzG1b98eX19fevXqhYGBgc57xG+CRqOhYsWKHDx4EPi/Ga+Tk5MpWrQo8GzCsBc9ffqUY8eOUbt2beDZO+Wpqam4ubmpYVxdXXF1dWXkyJH07NmT0NBQOnXqhKGhYb4+jyJFiuiFs7Gx4cyZMzrH4uLidB4iZBd/jRo12LBhA87OzhQunP2fXhqNBi8vL7y8vJg4cSJOTk5ERETw8ccf64U1MjLCyMgozzIIIYR4vaTnWQghRLYCAgJYtWoVa9asQavVcv36da5fv86DBw/eWh5Kly6NoaEhX331FZcuXWLz5s3ZroFsYGCAv78/48ePx8XFhXr16r1y2hMnTmTFihUEBwdz9uxZ4uPjCQ8P5/PPP893HE5OTmg0GrZu3crNmzcLtHb1qFGj2L17N1OmTOH3339n+fLlfP3119lOcJWb27dv07RpU1atWsWpU6e4fPky69evZ9asWXTo0EEvfKdOnVi5ciX9+vXjxx9/LFBauYmLi6NDhw78+OOPnDt3jgsXLvD999+zbNkyNR/ly5fH0dGRoKAgzp8/z7Zt2/RmGIdnDduPPvqII0eOcPz4cfz9/albty61a9fmwYMHDBs2jJiYGK5cucKBAweIjY1VG9bOzs6kp6eze/dubt26pTME/3nOzs7s3r2b69evq0OomzZtyrFjx1ixYgXnz59n0qRJeo1pZ2dnjhw5QmJiIrdu3SIzM5OAgAD+/vtvevbsSWxsLBcvXuTnn3+mX79+ZGRkcOTIEaZPn86xY8dISkpi48aN3Lx5U+dhgBBCiHdPGs9CCCGytWjRItLS0vD29sbe3l7d1q1b99byYGNjQ1hYGOvXr6dSpUrMmDFDb1mqLAMGDODx48f069fvtaTt4+PD1q1b2blzJ56entStW5e5c+fi5OSU7zhKlixJcHAwn3zyCSVKlNCZzTsvNWrU4IcffiA8PJzKlSszceJEJk+enO1yV7kxNzenTp06zJ07l0aNGlG5cmUmTJjAoEGD1PfKX9SlSxeWL19O79692bhxY4HSy0mpUqVwdnYmODiYOnXqUKNGDebPn09wcDCfffYZ8KxRvHbtWn777TeqVq3KzJkz1SHdzzM1NWXcuHH06tULLy8vzM3N1fvSwMCA27dv06dPH1xdXenWrRutW7cmODgYeDa7+ZAhQ+jevTs2NjbMmjUr2/zOmTOHqKgoHB0dqV69OvDsnpgwYQJjx47F09OTu3fv0qdPH53rRo8ejYGBAZUqVcLGxoakpCQcHBw4cOAAGRkZtGzZkipVqhAYGIiVlRWFChXCwsKCffv20aZNG1xdXfn888+ZM2cOrVu3fi11L4QQ4vXQKC++vCOEEEL8C+3fv59mzZpx9epVdUIwIf4X3LlzB0tLS9LS0rCwsHjX2RFCiH+VgvyGyjvPQggh/tUePXrEzZs3CQoKomvXrtJwFkIIIcQbIcO2hRBCvFHPL8/z4rZ///5Xjn/t2rU4OTmRmpqa4xBcIYQQQohXJcO2/+MSExMpU6YMJ06coFq1aq8t7Jv222+/4e/vT1xcHBUrVsx2ttV3zd/fn9TUVL3ZaoXIzYv3jbe3N9WqVWPevHkA3L9/n969exMVFcXdu3dJSUmhWrVqBAYGEhgY+M7y/SouXLiQ47mSJUtiYmLyFnPz3/HivfO/LCgoiMjIyHz/X/G2/r+LiYmhSZMmpKSkYGVllWM4Z2fnV/qOZw05dAz8gUJGpnlfUECJM9q+9jiFEOKfoiDDtv9zPc8hISF4enqi1WqxtbWlY8eOJCQk6IRxdnbO9x8bJ0+epH379tja2mJsbIyzszPdu3fnxo0bbyD3r5+joyPJyclUrlz5tYZ90yZNmoSZmRkJCQns3r07x3BXr16lf//+ODg4YGhoiJOTEyNGjOD27ds64by9vdFoNGg0GoyNjalUqRILFy7MNs6wsDA1bE5bYmLi6yzuP0ZGRgYzZsygYsWKmJiYYG1tTZ06dVi6dOm7zprqxe+voiiMHj0aCwsLYmJiuHbtGkWLFmXBggU61x05coQiRYqwc+fOHOPO+nwPHz6sc/zRo0cUK1YMjUZDTEzM6ywOGzdu1Jk9evny5ezfv5+DBw+SnJyMpaUlsbGxDB48+LWmmxNnZ2e1HkxMTHB2dqZbt27s2bNHL2xERAR169bF0tISrVaLu7u7zh//Wd8lX19fvXWgT5w4gYuLizqb8PPf0ew2b2/vbPN7//59xo8fT7ly5TA2NsbGxobGjRuzadOmN1E9/yrP/5YZGBhQtGhR6tSpw+TJk0lLS9MJe/PmTT788ENKly6NkZERdnZ2+Pj46CyVlXVvhIeH66Xl7u6ORqMhLCyMmJiYPH9DX/we/a/87oaFheXaiBZCCPHP9p9rPO/du5eAgAAOHz5MVFQUT548oWXLlty7d6/Acd28eZNmzZphbW3Nzz//THx8PKGhoTg4OLxUfK/bkydP8gxjYGCAnZ1djutKvmzYN+3ixYs0aNAAJycnihUrlm2YS5cuUatWLc6fP8/atWu5cOEC3377Lbt376ZevXr8/fffOuEHDRpEcnIy586do1u3bgQEBLB27Vq9eLt3705ycrK61atXT702a8tab/Z1y8jIIDMz843EnR/BwcHMnTuXKVOmcO7cOaKjoxk8eDCpqanvLE+5ycjIYMCAAaxYsYLo6Gi8vb1xcHDgq6++Yvz48Zw/fx6ABw8e0LdvXwYOHEjLli1zjdPR0ZHQ0FCdYxEREZibm7+RMlhbW6PVatX9ixcv4ubmRuXKlbGzs0Oj0WBjY4Op6cv3Jj1+/LhA4SdPnkxycjIJCQmsWLECKysrmjdvzrRp09Qwu3fvpnv37nTu3JmjR49y/Phxpk2bpve7ZGZmxo0bNzh06JDO8e+//57SpUur+xs3blS/X0ePHgVg165d6rGcZnweMmQIGzdu5KuvvuK3335jx44ddOnSRe8B2v8qCwsLkpOT+eOPPzh48CCDBw9mxYoVVKtWjWvXrqnhOnfuzIkTJ1i+fDm///47mzdvxtvbW68es/t+HD58mOvXr2NmZgY8m836+d/Lbt260apVK51j9evX14njXf7uCiGEEPn1n2s879ixA39/f9zd3fHw8CAsLIykpCSOHz9e4LgOHDhAWloaS5cupXr16pQpU4YmTZowd+5cypQpA2T/FDkyMhKNRqPuBwUFUa1aNRYvXoyjoyOmpqZ069ZN78n/0qVLcXNzw9jYmIoVK+r0jCYmJqLRaFi3bh2NGzfG2NiYRYsWYWJiwvbt23XiiYiIQKvVcv/+ffW6rKFsKSkp+Pn5YWNjg4mJCS4uLuofQi+GhWcPI2rXro2RkRH29vZ88sknPH36VD3v7e3N8OHDGTt2LNbW1tjZ2REUFJRrvWZmZjJ58mRKlSqFkZER1apVY8eOHep5jUbD8ePHmTx5MhqNJsf4AgICMDQ0ZOfOnTRu3JjSpUvTunVrdu3axZ9//qkufZLF1NQUOzs7ypYtS1BQEC4uLmzevFkvXhMTE+zs7NTN0NBQvTZrMzAwUMPPnj0be3t7ihUrRkBAgE7j4dGjR4wePZqSJUtiZmZGnTp1dHpcsu6fzZs3U6lSJYyMjEhKSiI2NpYWLVpQvHhxLC0tady4Mb/++qtOPjUaDYsWLaJ169aYmJhQtmxZnTVZmzZtqrcszs2bNzE0NMyxN3/z5s0MHTqUrl27UqZMGTw8PBgwYIC6rux3332Hg4ODXgO/Q4cO9O/fX93fsmULnp6eGBsbU7x4cTp16qSeW7hwIS4uLhgbG1OiRAm6dOmSbV7y8ujRI7p27cquXbvYv38/NWvWVM+9//77+Pj44O/vT2ZmJuPHj+fJkyd88cUXecbbt29fwsPDddYyXrZsGX379tULe/r0aZo2bYqJiQnFihVj8ODBOuv4ZmRk8PHHH2NlZUWxYsUYO3YsL74p4+3trfbWent7M2fOHPbt26fT2/pib3tqaioDBw7ExsYGCwsLmjZtysmTJ9XzWb85S5cupUyZMhgbG+dZ7udptVrs7OwoXbo0jRo14rvvvmPChAlMnDhRHcmzZcsWvLy8GDNmDBUqVMDV1ZWOHTvyzTff6MRVuHBhevXqxbJly9Rjf/zxBzExMfTq1Us9lvX7YWdnh42NDQDFihVTj1lbW2eb182bN/Ppp5/Spk0bnJ2dqVmzJh999JF6P3766afUqVNH7zoPDw8mT56s7i9btgx3d3f1ty7ru6MoCkFBQWqPrIODA8OHDy9QfY4bNw5XV1dMTU0pW7YsEyZM0PmdyPq8Vq5cibOzM5aWlvTo0YO7d++qYe7du0efPn0wNzfH3t4+27WPs6PRaLCzs8Pe3h43NzcGDBjAwYMHSU9PZ+zYscCz+2n//v3MnDmTJk2a4OTkRO3atRk/fjzt27fXic/Pz4+9e/dy9epVnbrz8/NTH7waGhrq/F6amJiovdnP/64+L6/fXWNjYz744IMc7/ns5PZ/apZLly7RpEkTTE1N8fDw0HvI88svv9CwYUNMTExwdHRk+PDhOg/PV65cSa1atdTvTK9evXIcmRYTE0O/fv1IS0tTe9Of///t/v379O/fH61WS+nSpfnuu+9yLZ8QQoi37z/XeH5RVgM1pz+8cmNnZ8fTp0+JiIjQ+4O3oC5cuMAPP/zAli1b2LFjBydOnGDo0KHq+dWrVzNx4kSmTZtGfHw806dPZ8KECSxfvlwnnk8++YQRI0YQHx9P165dadeuHWvWrNEJs3r1ajp27JhtT9WECRM4d+4c27dvJz4+nkWLFlG8ePFs8/znn3/Spk0bPD09OXnyJIsWLeL777/XW3Nz+fLlmJmZceTIEWbNmsXkyZOJiorKsS7mz5/PnDlzmD17NqdOncLHx4f27durvYTJycm4u7szatQokpOT1Ybb8/7++29+/vlnhg4dqve+pJ2dHX5+fqxbty7Xz83ExKTAPXIvio6O5uLFi0RHR7N8+XLCwsIICwtTzw8bNoxDhw4RHh7OqVOn6Nq1K61atVLLCs/+YJo5cyZLly7l7Nmz2NracvfuXfr27csvv/zC4cOHcXFxoU2bNjp/TMOzz7Nz586cPHkSPz8/evToQXx8PAADBw5kzZo1PHr0SA2/atUqSpYsSdOmTbMtj52dHXv27OHmzZvZnu/atSu3b98mOjpaPfb333+zY8f/Y+/M42ra/v//Os3DOUUpFSmapQHFTZcMEZHM3XQbrsySsegaytxFyHVlrlDGZMiYVKikUtEgROIqQyjH1LR+f/Q7+9vRqc5JuPd+1vPx2I9He6/pvddae3fWfr/X+30BLi4uAICzZ89i9OjRsLe3R2ZmJuLi4tCrVy8AQHp6Ory9vbFy5UoUFBTgwoUL6Nevnwg9XgeXy8Xw4cORl5eHpKQkGBgYNMizY8cO3L9/Hy4uLti2bRtCQ0OF0h737NkT2traiIqKAgAUFxfj6tWrcHV15cv3/v172NnZoW3btkhLS8OxY8dw+fJlvg8WQUFBCAsLw759+3D9+nW8fv0a0dHRjbZ94sQJTJkyBVZWVk1qW8ePH48XL17g/PnzyMjIQI8ePTBo0CA+a4sHDx4gKioKJ06caBWfAXPmzAEhhDGHVlNTQ25uLnJycpotO2nSJBw9ehQfPnwAUPfRaOjQoa3iFVtNTQ3nzp1r8GzwcHFxwc2bN1FYWMhcy83Nxe3bt5nFe0hICGbNmoWpU6fizp07OH36NHR1dQEAUVFR2Lx5M3bu3In79+/j5MmTMDExEUlGDoeDsLAw5OXlITg4GLt378bmzZv58hQWFuLkyZOIiYlBTEwMEhMTERgYyKT7+PggMTERp06dwqVLl5CQkNDgg5qwqKqqwsXFBadPn0ZNTQ3jvO3kyZN87wtBtG/fHnZ2dsz/pg8fPuDIkSN8H8++BcLM+foI+z91yZIlWLhwIbKysqCvrw9nZ2fmA3FhYSGGDh2KsWPH4vbt2zhy5AiuX7/O94xXVVVh1apVyM7OxsmTJ1FUVNRoHO4+ffpgy5YtjDXAl//fgoKCYGFhwfw+mDFjRoNtZxQKhUL5wZAW8PjxY3L16lVy4cIFkpGRQT59+tSSar45NTU1ZPjw4cTa2prvupaWFtm8ebNQdfz+++9EQkKCKCkpkaFDh5L169eT0tJSJj00NJQoKirylYmOjib1u9bf35+Ii4uTp0+fMtfOnz9PxMTESElJCSGEEB0dHRIZGclXz6pVq4iVlRUhhJBHjx4RAGTLli0N2mKz2eT9+/eEEELKy8uJjIwMOX/+PF+5zMxMQgghDg4O5LfffhN4r1/m/f3334mBgQGpra1l8vz111+EzWaTmpoaQgghNjY25Oeff+arx9LSkixatEhgG4QQoqGhQdasWdOgzMyZM5lzMzMz4u/v32gdN27cIABIdHS0wPRNmzYRAOT58+eMnHPmzCGEEFJdXU0OHDhAAJBt27Y12gaP+mXr4+7uTrS0tEh1dTVzbfz48cTJyYkQUveciIuLk7///puv3KBBg4ifnx8hpG7+ACBZWVlNylBTU0M4HA45c+YMcw0AmT59Ol++3r17kxkzZhBCCPn48SNp27YtOXLkCJNuampKAgICGm0nNzeXGBkZETExMWJiYkKmTZtGzp07x5fH0dGRTJo0iTnfuXMn0dDQYOaElZUVcXFxEVh/VFQUUVBQIBUVFU3eb1NoaWkRKSkpoqysTF68eNFk3h07dhAATJ80B29ObdmyhQwYMIAQQsiKFSvI6NGjyZs3bwgAEh8fTwghZNeuXaRt27aEy+Uy5c+ePUvExMSYd4S6ujpZv349k15VVUU6duxIHB0dmWtfzq85c+YQGxubBvfMe2ddu3aNKCgoNHjv6ujokJ07dxJC6t45kpKSzfaPIJp6P7Zv357pSy6XS+zt7QkAoqWlRZycnMjevXv55Kr/fjQ3Nyfh4eGktraW6OjokFOnTpHNmzcTLS2tBu18+S5qisTERNKxY0ciKSlJLCwsyNy5c8n169f58piZmZGVK1cy535+fqR3797MuYaGBlmyZInA+oOCgoi+vj6prKxsVhZh2bBhA+nZsydz7u/vT+Tk5PieCx8fH0bGd+/eESkpKXL06FEmvaysjMjKygp8N/EQ9P+JR0hICN878vjx46Rt27ZERkaG9OnTh/j5+ZHs7Gy+Mry5cfLkSaKjo0Nqa2tJeHg46d69OyGEEEVFRRIaGtqgLXd3d745Lwz1nwth57yZmRlfmjD/U/fs2cOk5+bmEgAkPz+fEEKIp6cnmTp1Kl8d165dI2JiYuTjx48C5U5LSyMAyLt37wghhMTHxxMA5M2bN4SQxsdES0uL/Prrr8x5bW0tUVVVJSEhIQLb+fTpEykvL2eOJ0+eEABEc+5RorUoptUPCoVC+S9TXl5OAJDy8vJm8wqteS4qKsKiRYugpaWFzp07w8bGBsOGDYOFhQUUFRUxePBgHDt27Ifu1/ySWbNmIScnR6BzE2FZs2YNSktLsWPHDhgbG2PHjh0wNDTEnTt3RKqnU6dO6NChA3NuZWWF2tpaFBQU4P379ygsLISnpydfCJfVq1fzaUsAwMLCgu/c3t4ekpKSjPlxVFQUFBQUYGtrK1COGTNm4PDhwzA3N4evry+Sk5MblTk/Px9WVlZ8JujW1tbgcrl4+vQpc83U1JSvnLq6eqNmaxUVFXj27Bmsra35rltbWzMaU1EgIlgEbN++HWw2G7KyspgyZQrmzZuHGTNmiNxmfYyNjflMuOvf+507d1BTUwN9fX2+cU1MTOQbVykpqQZ9+Pz5c0yZMgV6enpQVFSEgoICuFwuiouL+fJZWVk1OOf1o4yMDFxdXRlz2Vu3biEnJ6dRrQgAdO3aFTk5Obhx4wYmTZqEFy9ewMHBAZMnT2byuLi4ICoqitFQRURE4JdffoGYWN3rJCsrC4MGDRJY/+DBg6GlpYUuXbrA1dUVERERjDZSFHh+DNauXdtonpqaGoSFhUFOTg43btzg227QHL/++itSUlLw8OFDhIWFCdSq5efnw8zMjNnnCdTNY95zXV5ejpKSEj6TYQkJiQbPsKhkZ2eDy+VCWVmZb149evSIb15paWkx5s+tBSGEeR/Iy8vj7NmzePDgAZYuXQo2m40FCxagV69eAsd00qRJCA0NRWJiIt6/fw97e/tWkalfv354+PAh4uLiMG7cOOTm5qJv3758TthcXFwYCx1CCA4dOsRYSrx48QLPnj1rdM6OHz8eHz9+RJcuXTBlyhRER0eLNJcA4MiRI7C2toaamhrYbDaWLl3a4FnW1tbm2/te/11SWFiIyspKvrmkpKQk0OJCWHjvTt54jh07Fs+ePcPp06cxdOhQJCQkoEePHnyWNDyGDx8OLpeLq1evYt++fd9c6yzsnOchyv/U+u9edXV1AGD6PTs7G2FhYXx12NnZoba2Fo8ePQIAZGRkwMHBAZ06dQKHw4GNjQ0ANBhfYagvC8/cvrH/pevWrYOioiJz0P3gFAqF8n0QavHs7e0NMzMzPHr0CKtXr0ZeXh7Ky8tRWVmJ0tJSnDt3Dj///DOWL18OU1NTpKWlfWu5m8XLywsxMTGIj49Hx44dv6ouZWVljB8/Hhs3bkR+fj40NDSwceNGAICYmFiDBZwwjrzqw9sjuXv3bmRlZTEHbxFTn/o/1IG6hde4ceOYH4aRkZFwcnJq1OnXsGHD8PjxY8ybN4/5wSjILFoUJCUl+c5ZLNY3/4iiq6sLFovV6II7Pz8fbdu25Vs8uLi4ICsrC48ePcL79++xadMmZsHXUpq6dy6XC3FxcWRkZPCNa35+PoKDg5kysrKyfB8ogLp9t1lZWQgODkZycjKysrKgrKwsspn55MmTERsbi6dPnyI0NBQDBw6ElpZWk2XExMRgaWmJuXPn4sSJEwgLC8PevXuZH4sODg4ghODs2bN48uQJrl27xixEePfTGBwOB7du3cKhQ4egrq6O5cuXw8zMTGSHZIMGDcKpU6ewY8cOzJkzR2CejRs34uHDh0hPT8fTp0+bXGh/ibKyMkaMGAFPT098+vQJw4YNE0m+bwmXy4W6ujrfnMrKykJBQQF8fHyYfF++K76WsrIyvHz5kvH3wENHRweTJ0/Gnj17cOvWLeTl5eHIkSMNyru4uODGjRsICAiAq6trqzomlJSURN++fbFo0SJcunQJK1euxKpVq5jnxdnZGQUFBbh16xaSk5Px5MkTODk5AWh6vgJ1DrIKCgqwfft2yMrKYubMmejXr5/Q7/mUlBS4uLjA3t4eMTExyMzMxJIlSxo8y9/7PZqfnw8FBQU+h4wyMjIYPHgwli1bhuTkZHh4eMDf379BWQkJCbi6usLf3x+pqal8z/+3QNg5Xz8/INz/1Pr9znsP13+HT5s2ja+O7Oxs3L9/Hzo6OszWDQUFBURERCAtLY3ZltGSLUGizAE/Pz+Ul5czR/096BQKhUL5dgi1cpCXl8fDhw9x9OhRuLq6wsDAABwOBxISElBVVcXAgQPh7++P/Px8bNy48Ye+xAkh8PLyQnR0NK5cudLgh97XIiUlxfzTBAAVFRW8e/eOz4GIoP2FxcXFfJ5Nb9y4ATExMRgYGKB9+/bQ0NDAw4cPG4RzEUZ+FxcXXLhwAbm5ubhy5UqzP2RUVFTg7u6OgwcPYsuWLY06JTEyMkJKSgrfx4GkpCRwOJwWf5BQUFCAhoYGX/gTXr1du3YVuh5lZWUMHjwY27dv53PsBAClpaWIiIiAk5MT36JUUVERurq66NChw1cvmoWhe/fuqKmpwYsXLxqMq5qaWpNlk5KS4O3tDXt7e8aJ0atXrxrk+/KH4I0bN5jQPwBgYmICCwsL7N69G5GRkS3SEPHGhTfHZWRkMGbMGERERODQoUMwMDBAjx49mPympqZNhheTkJCAra0t1q9fj9u3b6OoqEhgGKTmGDJkCM6cOYPdu3c3cOCUm5sLf39/hISEwMjICCEhIVi9ejVu374tdP2TJk1CQkIC3Nzc+KwLeBgZGSE7O5vv2U9KSmKea0VFRairqyM1NZVJr66ubpHzwvr06NEDpaWlkJCQaDCvGvNf0BoEBwdDTEwMo0aNajSPtrY25OTkBEYjUFJSwsiRI5GYmPjNNZVdu3ZFdXU1Pn36BADo2LEjbGxsEBERgYiICAwePBiqqqoA6j7oaGtrNzlnZWVl4eDggK1btyIhIQEpKSlCWx8lJydDS0sLS5YsgYWFBfT09PD48WOR7kdHRweSkpJ8c+nNmze4d++eSPXwePHiBSIjIzFq1Kgm34Vdu3ZtNLLEpEmTkJiYCEdHR7Rt27ZFcgiLqHP+a/+n1m83Ly+vQR26urqQkpLC3bt3UVZWhsDAQPTt2xeGhobNhrGUkpJCTU2NyH3wJdLS0lBQUOA7KBQKhfLtEerT/7p164SucOjQoS0WpjWYNWsWIiMjcerUKXA4HJSWlgKoWzg1p2H4kpiYGBw+fBi//PIL9PX1QQjBmTNncO7cOcZDde/evSEnJ4fff/8d3t7eSE1NFWjmJiMjA3d3d2zcuBEVFRXw9vbGhAkTmEXUihUr4O3tDUVFRQwdOhSfP39Geno63rx5g/nz5zcpZ79+/RgnWZ07dxboWZbH8uXL0bNnTxgbG+Pz58+IiYnhW2zVZ+bMmdiyZQtmz54NLy8vFBQUwN/fH/Pnz/+qxaePjw/8/f2ho6MDc3NzhIaGIisrCxERESLVs23bNvTp0wd2dnZYvXo1OnfujNzcXPj4+KBDhw58YXV+BPr6+nBxcYGbmxuCgoLQvXt3vHz5EnFxcTA1NcXw4cMbLaunp8d4ca2oqICPj4/A+Xvs2DFYWFjg559/RkREBG7evIm9e/fy5Zk8eTK8vLwgLy/P5/VaEOPGjYO1tTX69OkDNTU1PHr0CH5+ftDX14ehoSGTz8XFBSNGjEBubi5+/fVXvjr8/f0xaNAg6Ojo4JdffkF1dTXOnTuHRYsWISYmBg8fPkS/fv3Qtm1bnDt3DrW1tS02P7W1tUVMTAwcHBxQW1uLbdu2obq6Gu7u7hgzZgzGjBkDoM4kdezYsfDw8MDNmzeF0noOHToUL1++bPRHqYuLC/z9/eHu7o6AgAC8fPkSs2fPhqurK+MIa86cOQgMDISenh4MDQ2xadOmrw77ZWtrCysrK4waNQrr16+Hvr4+nj17xjhq+1qzcAB49+4dSktLUVVVhUePHuHgwYPYs2cP1q1bxzjSCggIwIcPH2Bvbw8tLS28ffsWW7duRVVVFQYPHiyw3rCwMGzfvr3R8HMtoX///nB2doaFhQWUlZWRl5eH33//HQMGDOAbO954VVZWNnDWFRAQgOnTp0NVVRXDhg3Du3fvkJSUhNmzZyMsLAw1NTXMu/7gwYOQlZVt1oKDh56eHoqLi3H48GFYWlri7NmzTTqNEwSbzYanpyd8fHygrKwMVVVVLFmyRKj3MCEEpaWlIITg7du3SElJwdq1a6GoqMg4JCsrK8P48eMxadIkmJqagsPhID09HevXr4ejo6PAeo2MjPDq1auvCqEmLC2Z81/zP5XHokWL8NNPP8HLywuTJ0+GvLw88vLyEBsbi23btqFTp06QkpLCn3/+ienTpyMnJ4dvu4AgtLW1weVyERcXBzMzM8jJyX2XPqRQKBRK6/Cf87YdEhKC8vJy9O/fH+rq6swhyIywObp27Qo5OTksWLAA5ubm+Omnn3D06FHs2bOH8byrpKSEgwcP4ty5czAxMcGhQ4cEhlbS1dXFmDFjYG9vjyFDhsDU1JQvbAbP7DE0NBQmJiawsbFBWFiYUF/JWSwWnJ2dGY/LTSElJQU/Pz+YmpqiX79+EBcXb3RPeIcOHXDu3DncvHkTZmZmmD59Ojw9PbF06dJmZWoKb29vzJ8/HwsWLICJiQkuXLiA06dPQ09PT6R69PT0kJ6eji5dumDChAnQ0dHB1KlTMWDAAKSkpLTIw3prExoaCjc3NyxYsAAGBgYYNWoU0tLS+OLbCmLv3r148+YNevToAVdXV3h7ezOasvqsWLEChw8fhqmpKfbv349Dhw410OA7OztDQkICzs7OzYYssrOzw5kzZ+Dg4AB9fX24u7vD0NAQly5d4ltwDhw4EEpKSigoKOALNwTULWaOHTuG06dPw9zcHAMHDmTi9rZp0wYnTpzAwIEDYWRkhB07duDQoUMwNjYGULe4+tKEvTkGDhyIs2fPIiwsDLNmzcKaNWvw999/Y9u2bXz5/vrrL5SUlAhtvs1isdCuXbsGIXV4yMnJ4eLFi3j9+jUsLS0xbtw4DBo0iK/dBQsWwNXVFe7u7rCysgKHw2n2A4Ywcp07dw79+vXDb7/9Bn19ffzyyy94/Phxs96rhe3f5cuXQ11dHbq6unB1dUV5eTni4uKwaNEiJo+NjQ0ePnwINzc3GBoaYtiwYSgtLcWlS5ca/RjCC+nVmvA8Pw8ZMgRGRkaYPXs27OzscPToUb58vNjPHz58aKA9d3d3x5YtW7B9+3YYGxtjxIgRjEf8Nm3aYPfu3bC2toapqSkuX76MM2fOMPcREBAAbW3tRuUbOXIk5s2bBy8vL5ibmyM5ORnLli0T+T43bNiAvn37wsHBAba2tvj555/5wrM1RkVFBdTV1dGhQwdYWVlh586dcHd3R2ZmJrPHl81mo3fv3ti8eTP69euHbt26YdmyZZgyZUqD56g+ysrKIn+UbgktmfNf8z+Vh6mpKRITE3Hv3j307dsX3bt3x/Lly6GhoQGgzoorLCwMx44dQ9euXREYGMhs6WqMPn36YPr06XBycoKKigrWr18vfEdQKBQK5YfDIqJ4XEKdKaqwP25bGkbjv0ZAQABOnjzZKuFiKBQeLBYL0dHRTZrRAnXO/nR0dJCWlsZnXv1PxN/fH4mJiXyxsCmtB+3f1sfd3R0sFkugxRGF8r2oqKiAoqIiysvLqQk3hUKhiIgo71CRPbYMHToU27dvR9euXRlPvzdu3EBubi5mzJjxXb5CUyiU5qmqqkJZWRmWLl2Kn3766R+/cAaA8+fPN6nponwdtH9bF0IIEhIScP369R8tCoVCoVAolO+AyIvnly9fwtvbu8G+Hn9/fzx58oQJi/NvICIiAtOmTROYpqWlhdzc3O8sEYXSeiQlJWHAgAHQ19fH8ePHf7Q4QsEz76Z8G2j/ti4sFktk518UCoVCoVD+vYhstq2oqIj09PQG+1Pv378PCwsLlJeXt6qA35J3797h+fPnAtMkJSWFdghDoVC+Pf3794e5uTm2bNnyo0Vh8PDwwNu3b3Hy5MkfLQrlK/he4yjsVouvJSEhAQMGDMCbN2/Qpk2bb9qWMAizdamoqAidO3dGZmYmzM3Nv5tsX8M/6Z3EMznUnHsUYtL/HgdkRYGNO86kUCiU74UoZtsiOwyTlZVtEGYIqNNyNeeM6J8Gh8MRGIJCV1eXLpwplP/PunXrYGlpCQ6HA1VVVYwaNQoFBQV8ebS1tUX+Ablu3TqIi4tjw4YNrSjt9yU4OPi77nVNSUmBuLh4k57a/+kUFRWBxWK1ig8IDw8PsFgs5lBWVsbQoUNFCkn2PSkpKfnHxAxv7JkNCAj45otXDw+PVvuAkJ2djZEjR0JVVRUyMjLQ1taGk5NTsyGjWoMTJ040612bQqFQKP8tRF48z507FzNmzIC3tzcOHjyIgwcPYvbs2Zg1axbmzZv3LWSkUCg/kMTERMyaNQs3btxAbGwsqqqqMGTIkEbjvwrLvn374Ovr+6/a6vElioqK31Wzt3fvXsyePRtXr17lixv/v8zQoUNRUlKCkpISxMXFQUJCAiNGjPjRYglETU0N0tLSLS5fWVnZitL8+3n58iUGDRoEJSUlXLx4Efn5+QgNDYWGhsZXvZ+E7WclJSVwOJwWt0OhUCiUfx8iL54XL16M8PBwZGRkwNvbG97e3rh16xZCQ0OxePHibyEjhUL5gVy4cAEeHh4wNjaGmZkZwsLCUFxcjIyMjBbXmZiYiI8fP2LlypWoqKhAcnIyX/r79+/h5uYGNpsNdXV1BAUF8aX//vvvAuOZm5mZYeXKlQCAtLQ0DB48GO3atYOioiJsbGwaRABgsVjYs2cPRo8eDTk5Oejp6eH06dN8eXJzczFixAgoKCiAw+Ggb9++KCwsBNBQg9a/f394e3vD19cXSkpKUFNTaxC67u7du/j5558hIyODrl274vLly2CxWM2aDHO5XBw5cgQzZszA8OHDBWq8z5w5A0tLS8jIyKBdu3Z8YbE+f/6MRYsWQVNTE9LS0tDV1eWLCZ6Tk4Nhw4aBzWajffv2cHV1xatXr5j048ePw8TEhAk3ZWtryyxQEhIS0KtXL8jLy6NNmzawtrZudC8wL1QQL3JD//79AQC1tbVYuXIlOnbsCGlpaZibm+PChQtN9gkASEtLQ01NDWpqajA3N8fixYvx5MkTvHz5ksnz5MkTTJgwAW3atIGSkhIcHR1RVFTUoK6NGzdCXV0dysrKmDVrFqqqqpg0Xtx1DocDNTU1TJw4kdFu1tbWomPHjggJCeGrLzMzE2JiYkxffDnOd+7cwcCBA5k+nTp1KrhcLpPOm19r1qyBhoYGEwKsKVm+BXv27IGRkRFkZGRgaGjIF2YRqIuHrK+vDzk5OXTp0gXLli3j67v6BAQEIDw8HKdOnWIsBup7f3/48CEGDBgAOTk5mJmZISUlpVG5kpKSUF5ejj179qB79+7o3LkzBgwYgM2bN/OFpGpubvfv3x9eXl6YO3cu2rVrBzs7O0ycOBFOTk587VVVVaFdu3bYv38/U27u3LlM+rd8xigUCoXyz6BFcZ4nTJiApKQkvH79Gq9fv0ZSUhImTJjQ2rJRKJR/IDy/Bl8TR3vv3r1wdnaGpKQknJ2d+X5gAoCPjw8SExNx6tQpXLp0CQkJCXwLXxcXF9y8eZNZxAJ1i9zbt28zcaffvXsHd3d3XL9+HTdu3ICenh7s7e3x7t07vrZWrFiBCRMm4Pbt27C3t4eLiwtev34NAPj777/Rr18/SEtL48qVK8jIyMCkSZNQXV3d6L2Fh4dDXl4eqampWL9+PVauXInY2FgAQE1NDUaNGgU5OTmkpqZi165dWLJkiVB9dvToURgaGsLAwAC//vor9u3bh/ouK86ePYvRo0fD3t4emZmZiIuLQ69evZh0Nzc3HDp0CFu3bkV+fj527twJNpsNAHj79i0GDhyI7t27Iz09HRcuXMDz58+Z93pJSQmcnZ0xadIk5OfnIyEhAWPGjAEhBNXV1Rg1ahRsbGxw+/ZtpKSkYOrUqY2GNOQ5Lbt8+TJKSkpw4sQJAHUm8EFBQdi4cSNu374NOzs7jBw5kom3LAxcLhcHDx6Erq4uE4e5qqoKdnZ24HA4uHbtGpKSksBmszF06FA+DWN8fDwKCwsRHx+P8PBwhIWF8X2gqKqqwqpVq5CdnY2TJ0+iqKgIHh4eAAAxMTE4OzsjMjKST56IiAhYW1sL3Ab0/v172NnZoW3btkhLS8OxY8dw+fJleHl58eWLi4tDQUEBYmNjERMT06wsrU1ERASWL1+ONWvWID8/H2vXrsWyZcsQHh7O5OFwOAgLC0NeXh6Cg4Oxe/dubN68WWB9CxcuxIQJE/gsBvr06cOkL1myBAsXLkRWVhb09fXh7Ozc6POmpqaG6upqREdHozH3Lc3NbR7h4eGQkpJCUlISduzYARcXF5w5c4bvY8bFixfx4cOHRmO1f6tnjEKhUCj/IEgLePPmDdm9ezfx8/MjZWVlhBBCMjIyyNOnT1tSHYVC+ZdQU1NDhg8fTqytrfmua2lpkc2bNwtVR3l5OZGVlSVZWVmEEEIyMzMJm80m7969I4QQ8u7dOyIlJUWOHj3KlCkrKyOysrJkzpw5zDUzMzOycuVK5tzPz4/07t27Sdk5HA45c+YMcw0AWbp0KXPO5XIJAHL+/Hmmzs6dO5PKykqBdbq7uxNHR0fm3MbGhvz88898eSwtLcmiRYsIIYScP3+eSEhIkJKSEiY9NjaWACDR0dGNyk4IIX369CFbtmwhhBBSVVVF2rVrR+Lj45l0Kysr4uLiIrBsQUEBAUBiY2MFpq9atYoMGTKE79qTJ08IAFJQUEAyMjIIAFJUVNSgbFlZGQFAEhISmpSfx6NHjwgAkpmZyXddQ0ODrFmzhu+apaUlmTlzZqN1ubu7E3FxcSIvL0/k5eUJAKKurk4yMjKYPAcOHCAGBgaktraWufb582ciKytLLl68yNSjpaVFqqurmTzjx48nTk5OjbadlpZGADDzNjMzk7BYLPL48WNCSN1869ChAwkJCWHK1B/nXbt2kbZt2xIul8uknz17loiJiZHS0lJGrvbt25PPnz83KocgWeLj4wkA8ubNm0bLaGlpESkpKabveIekpCQxMzNj8uno6JDIyEi+sqtWrSJWVlaN1r1hwwbSs2dP5tzf35+vzi+fG0L+b17s2bOHuZabm0sAkPz8/Ebb+v3334mEhARRUlIiQ4cOJevXr2f6jydrU3ObkLrntnv37nx5eM/Y/v37mWvOzs58c8LGxoZ5J33LZ0wQnz59IuXl5czBq0tz7lGitSjmX3NQKBTKP4Hy8nICgJSXlzebV2TN8+3bt6Gvr48//vgDGzZswNu3bwHUOc7w8/P7imU8hUL5pzNr1izk5OTg8OHDLa7j0KFD0NHRgZmZGQDA3NwcWlpaOHLkCACgsLAQlZWVfGbZSkpKjMkqDxcXF0bTRwjBoUOH4OLiwqQ/f/4cU6ZMgZ6eHhQVFaGgoAAul4vi4mK+ekxNTZm/5eXloaCgwJjAZmVloW/fvpCUlBT6/urXBwDq6upMfQUFBdDU1ISamhqTXl873BgFBQW4efMmnJ2dAQASEhJwcnLi09hnZWVh0KBBAstnZWVBXFwcNjY2AtOzs7MRHx8PNpvNHIaGhgDqxsPMzAyDBg2CiYkJxo8fj927d+PNmzcA6sbGw8MDdnZ2cHBwQHBwMEpKSpq9p/pUVFTg2bNnsLa25rtubW2N/Pz8JssOGDAAWVlZyMrKws2bN2FnZ4dhw4YxptLZ2dl48OABOBwOc29KSkr49OkTn+WCsbExxMXFmfP64wYAGRkZcHBwQKdOncDhcJi+5M0nc3NzGBkZMXMyMTERL168wPjx4wXKnZ+fDzMzM8jLy/Pdb21tLZ9DPhMTE0hJSfGVbU4WYfHx8WH6jndMnz6dSX///j0KCwvh6enJNzdWr17N13dHjhyBtbU11NTUwGazsXTpUpFl4VH/+VFXVweAJk3S16xZg9LSUuzYsQPGxsbYsWMHDA0NcefOHQDNz20ePXv25KtXQkICEyZMQEREBNMXp06d4nvH1OdbPmOCWLduHRQVFZlDU1Oz0bwUCoVCaT1EXjzPnz8fHh4euH//Pp93bXt7e1y9erVVhaNQKP8cvLy8EBMTg/j4eHTs2LHF9ezduxe5ubmQkJBgjry8PJEdhzk7O6OgoAC3bt1CcnIynjx5wrdH0d3dHVlZWQgODkZycjKysrKgrKzcwBnQlwtjFouF2tpaAHXRBUSlqfpayt69e1FdXQ0NDQ2mz0JCQhAVFcWY0Tcla3P3weVy4eDg0GAhdf/+ffTr1w/i4uKIjY3F+fPn0bVrV/z5558wMDDAo0ePAAChoaFISUlBnz59cOTIEejr6+PGjRtfdc/CIi8vz0RJsLS0xJ49e/D+/Xvs3r2bubeePXs2uLd79+4xJv5A0+PGM7FWUFBAREQE0tLSEB0dDYDfuVT9DzqRkZEYOnQoYz7+NfdXH2FlEYZ27do1iDRRfzsGz2R59+7dfH2Xk5PDjG9KSgpcXFxgb2+PmJgYZGZmYsmSJS12blZ/HHim/809P8rKyhg/fjw2btyI/Px8aGhoYOPGjcw9NDW3eXzZz0DdeMbFxeHFixc4efIkZGVlMXToUIEyfOtn7Ev8/PxQXl7OHE+ePGmyfQqFQqG0DhKiFkhLS8POnTsbXO/QoQNKS0tbRSgKhfLPgRCC2bNnIzo6GgkJCXyOeETlzp07SE9PR0JCAt+P9NevX6N///64e/cudHR0ICkpidTUVHTq1AkA8ObNG9y7d49Pq9OxY0fY2NggIiICHz9+xODBg6GqqsqkJyUlYfv27bC3twdQ5zSqvnMeYTA1NUV4eDiqqqpE0j43hoGBAZ48eYLnz5+jffv2AOreqU1RXV2N/fv3IygoCEOGDOFLGzVqFA4dOoTp06fD1NQUcXFx+O233xrUYWJigtraWiQmJsLW1rZBeo8ePRAVFQVtbW1ISAj+t8BisWBtbQ1ra2ssX74cWlpaiI6Oxvz58wHUOQDr3r07/Pz8YGVlhcjISPz0008N6uFpUWtqaphrCgoK0NDQQFJSEt8YJyUlCaWZ/1JOMTExfPz4kbm3I0eOQFVVtdnYjY1x9+5dlJWVITAwkNHwpaenN8g3ceJELF26FBkZGTh+/Dh27NjRaJ1GRkYICwvD+/fvmYVbUlISxMTEGlhZtESW1qB9+/bQ0NDAw4cPG9W4JicnQ0tLi2/vfmPO4nhISUnxjX9rIiUlBR0dHcbRljBzuzH69OkDTU1NHDlyBOfPn8f48eMbfQ98j2esPtLS0l/luZ1CoVAoLUNkzbO0tDQqKioaXL937x5UVFRaRSgKhfLPYdasWTh48CAiIyPB4XBQWlqK0tJSZnEiCnv37kWvXr3Qr18/dOvWjTn69esHS0tL7N27F2w2G56envDx8cGVK1eQk5MDDw8PiIk1fF25uLjg8OHDOHbsWIMf93p6ejhw4ADy8/ORmpoKFxcXkTXJXl5eqKiowC+//IL09HTcv38fBw4caBDnWlgGDx4MHR0duLu74/bt20hKSsLSpUsBoFEHWzExMXjz5g08PT35+qxbt24YO3YsY7rt7++PQ4cOwd/fH/n5+bhz5w7++OMPAHUxfd3d3TFp0iScPHkSjx49QkJCAo4ePQqgboxfv34NZ2dnpKWlobCwEBcvXsRvv/2GmpoapKamYu3atUhPT0dxcTFOnDiBly9fwsjICI8ePYKfnx9SUlLw+PFjXLp0Cffv34eRkZHA+1FVVYWsrCzjMImnOffx8cEff/yBI0eOoKCgAIsXL0ZWVhbmzJnTZJ9+/vyZmZP5+fmYPXs2o+UD6uZIu3bt4OjoiGvXrjH37u3tjadPnwo1bp06dYKUlBT+/PNPPHz4EKdPnxYY31dbWxt9+vSBp6cnampqMHLkyEbrdHFxgYyMDNzd3ZGTk4P4+HjMnj0brq6uzIeVr5GltVixYgXWrVuHrVu34t69e7hz5w5CQ0OxadMmAHXPWXFxMQ4fPozCwkJs3bqV0YQ3hra2Nm7fvo2CggK8evWqUc/czRETE4Nff/0VMTExuHfvHgoKCrBx40acO3cOjo6OAJqf280xceJE7NixA7GxsY1+QODd07d6xigUCoXyz0HkxfPIkSOxcuVK5p8di8VCcXExFi1ahLFjx7a6gBQK5ccSEhKC8vJy9O/fH+rq6szB26MM1JlVNqfVqaysxMGDBxt9T4wdOxb79+9HVVUVNmzYgL59+8LBwQG2trb4+eefG+xJBIBx48ahrKwMHz584AsZBdQt1N+8eYMePXrA1dUV3t7efJppYVBWVsaVK1fA5XJhY2ODnj17Yvfu3S3WQouLi+PkyZPgcrmwtLTE5MmTGY1d/W0wX96Hra0tFBUVG6SNHTsW6enpuH37Nvr3749jx47h9OnTMDc3x8CBAxnP1kDdOI4bNw4zZ86EoaEhpkyZwmjneFrfmpoaDBkyBCYmJpg7dy7atGkDMTExKCgo4OrVq7C3t4e+vj6WLl2KoKAgDBs2DHJycrh79y7Gjh0LfX19TJ06FbNmzcK0adME3o+EhAS2bt2KnTt3QkNDg1nkeHt7Y/78+ViwYAFMTExw4cIFnD59Gnp6ek326YULF5g52bt3b8ZzNS8ElpycHK5evYpOnTphzJgxMDIygqenJz59+iS0JlpFRQVhYWE4duwYunbtisDAQMYs+EtcXFyQnZ2N0aNHN/mxRk5ODhcvXsTr169haWmJcePGYdCgQdi2bVurydIaTJ48GXv27EFoaChMTExgY2ODsLAwxgJl5MiRmDdvHry8vGBubo7k5GQsW7asyTqnTJkCAwMDWFhYQEVFBUlJSS2SrWvXrpCTk8OCBQtgbm6On376CUePHsWePXvg6uoKoPm53RwuLi7Iy8tDhw4dGuzJ/5Jv9YxRKBQK5Z8DixDR4iCUl5dj3LhxSE9Px7t376ChoYHS0lJYWVnh3LlzAvcNUSiU/y41NTVQUFBAeHg4xo0b96PF+deRlJSEn3/+GQ8ePICOjs6PFodCofwLqaiogKKiIsrLy1u8PYFCoVD+VxHlHSrynmdFRUXExsYiKSkJ2dnZ4HK56NGjh8A9PhQK5b/N06dPsX//ftTU1ODnn3/+0eL8K4iOjgabzYaenh4ePHiAOXPmwNrami6cKRQKhUKhUP7hiLx45sFzagGACVdFoVD+tzA3N4eysjIOHDgANTU1RERENGquq6Wlhdzc3O8s4T+Pd+/eYdGiRSguLka7du1ga2uLoKCgHy0WhUKhUCgUCqUZRDbb/uOPP6Ctrc2EhJkwYQKioqKgpqaGc+fOMbFbKRTK/x7v3r3D8+fPG1zfunUrLl++jLy8PACAh4cH3r59i5MnT35nCSmtSf/+/WFubo4tW7b8aFH+kyQlJWH69Om4e/cuhg8f/j/5vAQEBODkyZPIysr60aIIhMViITo6uoHPhe8Nz+RQc+5RiEnL/VBZ/i0UBQ7/0SJQKJR/CKKYbYvsMGzHjh1MeIzY2FgmLuGwYcPg4+PTMokpFIpA1q1bB0tLS3A4HKiqqmLUqFENPD1ra2vzLV4IIVi4cCEUFBSQkJDQbBva2tpgsVg4fPhwgzRjY2OwWCyEhYUJJS+Hw2kQN5YXO5YXoggAgoODha7ze8NisZhDUVER1tbWuHLlSqvU21qLn3Xr1kFcXBwbNmxolfq+FWFhYXz9yWaz0bNnT5w4cULocmJiYujYsSN+++03vHjx4jtJ/u0oKioCi8USajE4f/58mJub49GjR63+vAQEBDB9LCEhgXbt2qFfv37YsmULPn/+3KptAXUfzL7VAjM6Oho//fQTFBUVweFwYGxsjLlz536Ttr6kpKSEOvWiUCiU/yFEXjyXlpYyi+eYmBhMmDABQ4YMga+vb7PxSikUimgkJiZi1qxZuHHjBmJjY1FVVYUhQ4YwHly/pKamBp6enti/fz/i4+MZj8PNoampidDQUL5rN27cQGlp6TdxAqioqIg2bdq0er08Kisrv6p8aGgoSkpKkJSUhHbt2mHEiBF4+PDhD5FFEPv27YOvry/27dvX6nW3NgoKCigpKUFJSQkyMzNhZ2eHCRMmNBvui1fu6dOn2L17N86fP894UP5fobCwEAMHDkTHjh1b/Lw0Nf+MjY1RUlKC4uJixMfHY/z48Vi3bh369OmDd+/etVDq70tcXBycnJwwduxY3Lx5ExkZGVizZk2Lw1/xELa8mpoajbdMoVAo/0OIvHhu27Ytnjx5AqAuRAjPURghRKiYiRQKRXguXLgADw8PGBsbw8zMDGFhYSguLkZGRkaDvJ8/f8b48eNx+fJlXLt2TWBop8ZwcXFBYmIi82wDdQs0FxeXBiGo3r59i8mTJ0NFRQUKCgoYOHAgsrOz+fIEBgaiffv24HA4TFig+nyphaqtrcX69euhq6sLaWlpdOrUCWvWrGHSFy1aBH19fcjJyaFLly5YtmwZ34/bgIAAmJubY8+ePejcuTMT9kkYWQXRpk0bqKmpoVu3bggJCcHHjx8RGxuLsrIyODs7o0OHDpCTk4OJiQkOHTrEV7Z///7w8vLC3Llz0a5dO9jZ2UFbWxsAMHr0aLBYLOY8OzsbAwYMAIfDgYKCAnr27In09PQmZUtMTMTHjx+xcuVKVFRUIDk5udn7Ebb/Dhw4AG1tbSgqKuKXX37hW0C9f/8ebm5uYLPZUFdXF3qfNovFgpqaGtTU1KCnp4fVq1dDTEwMt2/fFqqchoYGhg0bBm9vb1y+fBkfP37EhQsX8PPPP6NNmzZQVlbGiBEjUFhYyJQdOHAgvLy8+Op7+fIlpKSkEBcXB6DO4mL16tXMPWlpaeH06dN4+fIlHB0dwWazYWpq2mA8rl+/jr59+0JWVhaamprw9vbm+5ilra2NtWvXYtKkSeBwOOjUqRN27drFpPNCPHXv3h0sFkvgBy6edrqsrAyTJk3is/5ITExEr169IC0tDXV1dSxevBjV1dVMWUHzrzEkJCSYPjYxMcHs2bORmJiInJwcJkY4UPduWbhwITp06AB5eXn07t2bz6olLCwMbdq0wcWLF2FkZAQ2m42hQ4eipKQEQN38Cg8Px6lTpxhtN698c3OzOc6cOQNra2v4+PjAwMAA+vr6GDVqFP766y++fKdOnUKPHj0gIyODLl26YMWKFXz9xmKxEBISgpEjR0JeXh6rVq1Cx44dERISwldPZmYmxMTE8PjxY6ZcfYuSp0+fwtnZGUpKSpCXl4eFhQVSU1OFkoMQgoCAAHTq1AnS0tLQ0NCAt7e30H1BoVAolG+PyIvnMWPGYOLEiRg8eDDKysoYc6XMzEzo6uq2uoAUCuX/KC8vBwAoKSnxXedyuRg+fDjy8vKQlJQEAwMDkept37497OzsEB4eDgD48OEDjhw5gkmTJjXIO378eLx48QLnz59HRkYGevTogUGDBuH169cAgKNHjyIgIABr165Feno61NXVsX379ibb9/PzQ2BgIJYtW4a8vDxERkaiffv2TDqHw0FYWBjy8vIQHByM3bt3Y/PmzXx1PHjwAFFRUThx4gRjEtucrMLAi9VbWVmJT58+oWfPnjh79ixycnIwdepUuLq68sVTBoDw8HBISUkhKSkJO3bsYKxyeBpt3rmLiws6duyItLQ0ZGRkYPHixc3GkN67dy+cnZ0hKSkJZ2dn7N27t9l7EKb/CgsLcfLkScTExCAmJgaJiYkIDAxk0n18fJCYmIhTp07h0qVLSEhIwK1bt5rvwHrU1NQwc6xHjx4ilZWVlUVtbS2qq6vx/v17zJ8/H+np6YiLi4OYmBhGjx6N2tpaAHWxiSMjI/nMjw8ePIgOHTpg4MCBzLXNmzfD2toamZmZGD58OFxdXeHm5oZff/0Vt27dgo6ODtzc3MBzDVJYWIihQ4di7NixuH37No4cOYLr1683WKgHBQXBwsICmZmZmDlzJmbMmMFo2nlz5fLlyygpKRFowq6pqYmSkhIoKChgy5YtKCkpgZOTE/7++2/Y29vD0tIS2dnZCAkJwd69e7F69Wq+8l/OP1EwNDTEsGHD+OTy8vJCSkoKDh8+jNu3b2P8+PEYOnQo7t+/z+T58OEDNm7ciAMHDuDq1asoLi7GwoULAQALFy7EhAkTmAV1SUkJ+vTpA0C4udkUampqyM3NRU5OTqN5rl27Bjc3N8yZMwd5eXnYuXMnwsLC+D7QAXWL/NGjR+POnTuYPHkynJ2dERkZyZcnIiIC1tbW0NLSatAOLx7833//jdOnTyM7Oxu+vr7MvGxOjqioKGzevBk7d+7E/fv3cfLkSZiYmAjdFxQKhUL59ojsbXvz5s3Q1tbGkydPsH79erDZbAB1+35mzpzZ6gJSKJQ6amtrMXfuXFhbW6Nbt258aatWrQKHw0F+fj5UVFRaVP+kSZOwYMECLFmyBMePH4eOjg7Mzc358ly/fh03b97EixcvGFPFjRs34uTJkzh+/DimTp2KLVu2wNPTE56engCA1atX4/Llyw20zzzevXuH4OBgbNu2De7u7gAAHR0dvtBXS5cuZf7W1tbGwoULcfjwYfj6+jLXKysrsX//fub+hZG1OT58+IClS5dCXFwcNjY26NChA7MgAIDZs2fj4sWLOHr0KHr16sVc19PTw/r16xvUx9No8yguLoaPjw8MDQ2Zck1RUVGB48ePIyUlBQDw66+/om/fvggODmbexYIQpv9qa2sRFhYGDocDAHB1dUVcXBzWrFkDLpeLvXv34uDBgxg0aBCAugVax44dm5QXqPvgw5Pt48ePkJSUxK5du0QKzXX//n3s2LEDFhYW4HA4GDt2LF/6vn37oKKigry8PHTr1g1jxoyBl5cXTp06hQkTJgCo0456eHiAxWIx5ezt7Rnv8MuXL0dISAgsLS0xfvx4AHVaUSsrKzx//hxqampYt24dXFxcmP20enp62Lp1K2xsbBASEsJYPNjb2zP/DxctWoTNmzcjPj4eBgYGzPxUVlbmmwv1ERcXh5qaGrPvnpdv+/bt0NTUxLZt28BisWBoaIhnz55h0aJFWL58OcTExBi5BM0/YTE0NMSlS5cA1M3R0NBQFBcXQ0NDA0DdYvjChQsIDQ3F2rVrAdSZOe/YsYMZVy8vL6xcuRIAwGazISsri8+fPze4Z2HmZlPMnj0b165dg4mJCbS0tPDTTz9hyJAhcHFxYZ77FStWYPHixcz7pUuXLli1ahV8fX3h7+/P1DVx4kT89ttvzLmLiwuCgoJQXFyMTp06oba2FocPH+aTuT6RkZF4+fIl0tLSmA+c9ZUKzclRXFwMNTU12NraQlJSEp06deJ7r9Tn8+fPfB+HKioqhOovCoVCoXwdImueJSUlsXDhQgQHB6N79+7M9Xnz5mHy5MnM+fDhwxmTLQqF8vXMmjULOTk5Ah178fZB837ItoThw4eDy+Xi6tWr2Ldvn0CtMy+2u7KyMthsNnM8evSIMZvNz89H7969+cpZWVk12m5+fj4+f/7MLMoEceTIEVhbW0NNTQ1sNhtLly5FcXExXx4tLS2+DwfCyNoYzs7OYLPZ4HA4iIqKwt69e2FqaoqamhqsWrUKJiYmUFJSApvNxsWLFxvIIqzJ/Pz58zF58mTY2toiMDCwWbkOHToEHR0dJqqBubk5tLS0cOTIkSbLCdN/2trazMIZANTV1RkHXYWFhaisrOQbVyUlJaEsHDgcDrKyspCVlYXMzEysXbsW06dPx5kzZ5osx1t0y8nJwcDAAO3bt0dERASAusW0s7MzunTpAgUFBcYMnndPMjIycHV1ZfaE37p1Czk5OfDw8OBrw9TUlPmbZ+lQX9PHu8brh+zsbISFhfHNJzs7O9TW1uLRo0cC6+WZn7eGs7P8/HxYWVnxfQCwtrYGl8vF06dPmWuibNkQBCGEaePOnTuoqamBvr4+330nJibyzVc5OTm+DyL1509TCDM3m0JeXh5nz57FgwcPsHTpUrDZbCxYsAC9evXChw8fANSN28qVK/nknzJlCkpKSpg8AGBhYcFXt7m5OYyMjBjtc2JiIl68eMF8XPmSrKwsdO/evYFlEI/m5Bg/fjw+fvyILl26YMqUKYiOjuYzLa/PunXroKioyBw8XzQUCoVC+ba0OM5zc1y9ehUfP378VtVTKP9TeHl5ISYmBlevXhWo7Rs0aBBmz54NR0dH1NbWIjg4WOQ2JCQk4OrqCn9/f6SmpiI6OrpBHi6XC3V1dYFevFvq0IhnFt0YKSkpcHFxwYoVK2BnZwdFRUUcPny4wZ7bLx2bfY2smzdvhq2tLRQVFfkW5Bs2bEBwcDC2bNkCExMTyMvLY+7cuQ2cMgnrZC0gIAATJ07E2bNncf78efj7++Pw4cMYPXq0wPx79+5Fbm4u3z702tpa7Nu3j9H0f4mw/feluTiLxWLMTb8GMTExPu2bqakpLl26hD/++AMODg6NluNwOLh16xbExMSgrq7ON08cHBygpaWF3bt3Q0NDA7W1tejWrRvfOEyePBnm5uZ4+vQpQkNDMXDgwAamtvXvmbdYFHSN1w9cLhfTpk0TuA+1U6dOAuvl1dMafSksX+vkLz8/n9mbzeVyIS4ujoyMDIiLi/Plq2/tIOiem4uEKezcFAYdHR3o6Ohg8uTJWLJkCfT19XHkyBH89ttv4HK5WLFiBcaMGdOgHM9aABDcby4uLoiMjMTixYsRGRmJoUOHQllZWaAMzb3LmpNDU1MTBQUFuHz5MmJjYzFz5kxs2LABiYmJDfrXz88P8+fPZ84rKiroAppCoVC+A99s8UyhUL4eQghmz56N6OhoJCQkMD9oBTFkyBCcOXMGI0eOBCEEW7duFbm9SZMmYePGjXByckLbtm0bpPfo0QOlpaWQkJBgtH1fYmRkhNTUVLi5uTHXbty40Wibenp6kJWVRVxcHJ/1Co/k5GRoaWlhyZIlzDWes56mEEbWxlBTUxPowyEpKQmOjo749ddfAdQtqu7du4euXbs2W6ekpKRAp4r6+vrQ19fHvHnz4OzsjNDQUIGL5zt37iA9PR0JCQl8mq3Xr1+jf//+uHv3LmP+XZ+W9l99dHR0ICkpidTUVGaR+ObNG9y7dw82NjYi1QXUmSU393H1y0U3j7KyMhQUFGD37t3o27cvgDoT/S8xMTGBhYUFdu/ejcjISGzbtk1kOb+kR48eyMvL+yr/HryQbS1xsGlkZISoqCg+zXBSUhI4HI5QJvTCcPfuXVy4cAF+fn4A6hyb1dTU4MWLF0x/twQpKakG99wac1MQ2trakJOTYxy59ejRAwUFBS0at4kTJ2Lp0qXIyMjA8ePHm9xDbmpqij179uD169cCtc/CyCErKwsHBwc4ODhg1qxZMDQ0xJ07dxr4CJCWlqZevikUCuUHQBfPFMo/mFmzZiEyMhKnTp0Ch8NBaWkpgLpQT4K0HLa2toiJiYGDgwNqa2tFXjAYGRnh1atXkJOTE5hua2sLKysrjBo1CuvXr4e+vj6ePXuGs2fPYvTo0bCwsMCcOXPg4eEBCwsLWFtbIyIiArm5uejSpYvAOmVkZLBo0SL4+vpCSkoK1tbWePnyJXJzc+Hp6Qk9PT0UFxfj8OHDsLS0xNmzZwVqxVsiq6jo6enh+PHjSE5ORtu2bbFp0yY8f/5cqMWztrY24uLiYG1tDWlpacjIyMDHxwfjxo1D586d8fTpU6SlpTXYz8tj79696NWrF/r169cgzdLSEnv37hUY97ml/VcfNpsNT09P+Pj4QFlZGaqqqliyZAmzx7YpCCHMvOV5Lb948SKWL18ukgw82rZtC2VlZezatQvq6uooLi7G4sWLBeadPHkyvLy8IC8v36g2XxQWLVqEn376CV5eXpg8eTLk5eWRl5eH2NhYoZ81VVVVyMrK4sKFC+jYsSNkZGSgqKgoVNmZM2diy5YtmD17Nry8vFBQUAB/f3/Mnz9fqLH4kurqapSWlqK2thZlZWVISEjA6tWrYW5uDh8fHwB1H3dcXFzg5uaGoKAgdO/eHS9fvkRcXBxMTU0xfPhwodrS1tbGxYsXUVBQAGVlZSgqKrbK3AwICMCHDx9gb28PLS0tvH37Flu3bkVVVRUGDx4MoG4/+4gRI9CpUyeMGzcOYmJiyM7ORk5OTgNna4Lk7tOnDzw9PVFTU4ORI0c2mtfZ2Rlr167FqFGjsG7dOqirqyMzMxMaGhqwsrJqVo6wsDDU1NSgd+/ekJOTw8GDByErKyvQORmFQqFQfgyi/7elUCjfjZCQEJSXl6N///5QV1dnjqb2uA4cOBBnz55FWFgYZs2a1azp5JcoKys3an7IYrFw7tw59OvXD7/99hv09fXxyy+/4PHjx8z+UCcnJyxbtgy+vr7o2bMnHj9+jBkzZjTZ5rJly7BgwQIsX74cRkZGcHJyYvZLjhw5EvPmzYOXlxfMzc2RnJyMZcuWNXsfwsgqKkuXLkWPHj1gZ2eH/v37Q01NjS/kVlMEBQUhNjYWmpqa6N69O8TFxVFWVgY3Nzfo6+tjwoQJGDZsGFasWNGgbGVlJQ4ePNjownrs2LHYv3+/wBA/Le2/L9mwYQP69u0LBwcH2Nra4ueffxZqb21FRQUzb42MjBAUFISVK1fyaRtFQUxMDIcPH0ZGRga6deuGefPmCfxoANQtZiQkJODs7MxnnttSTE1NkZiYiHv37qFv377o3r07li9fzjjSEgYJCQls3boVO3fuhIaGBhwdHYUu26FDB5w7dw43b96EmZkZpk+fDk9Pz0YdWDVHbm4u1NXV0alTJ/Tv3x9Hjx6Fn58frl27xmeSHRoaCjc3NyxYsAAGBgYYNWoU0tLS+EzVm2PKlCkwMDCAhYUFVFRUkJSU1Cpz08bGBg8fPoSbmxvjKby0tBSXLl1i9uTb2dkhJiYGly5dgqWlJX766Sds3rxZ6EWpi4sLsrOzMXr06CZNs6WkpHDp0iWoqqrC3t4eJiYmCAwMZMzdm5OjTZs22L17N6ytrWFqaorLly/jzJkzjZqJUygUCuX7wyKi/rIWEg6Hg+zs7Ea1TRQKhUKhfEuKioqgo6ODtLQ0kUNjUSj/JioqKqCoqIjy8nIoKCj8aHEoFArlX4Uo71Bqtk2hUCiU/xRVVVUoKyvD0qVL8dNPP9GFM4VCoVAolFZBZLPtq1evCgydUF1djatXrzLnv//+e6PhGigUyvchIiKCLyxK/cPY2PhHi0ehfBOSkpKgrq6OtLS0Jh08USgUCoVCoYiCyGbb4uLiKCkpgaqqKt/1srIyqKqqtsiDKIVC+Ta8e/cOz58/F5gmKSlJHdH8AAICAnDy5ElkZWV9VT0eHh54+/YtTp48KVT+hIQEDBgwAG/evGlxWDFBsFgsREdHC733uzm0tbUxd+5czJ07t1Xq+xpaa6z+aQjTx609rqLyT5oH/wZ4Joeac49CTFqww8d/K0WBwjmlo1AolJYiitm2yJrn+iEy6lNWVvbVsSUpFErrwuFwoKurK/DQ0tJCSEgITE1NoaCgAAUFBVhZWeH8+fMC61q3bh3ExcUbdc7UGGFhYWCxWGCxWBAXF0fbtm3Ru3dvrFy5EuXl5a1xm/8pioqKmP5isViQkpKCrq4uVq9ezef8LTg4GGFhYT9O0P9PSUkJhg0b9t3aCwgIYPqGF4Zs3rx54HK5302GlpKQkAAWi4W3b9+2uI4v54eysjKGDBmCzMxMoetIS0vD1KlTWywDAPTv31/gwjYsLKxVP860Nrwx4B3t27fH2LFj8fDhw1apt7mx/bJ9WVlZGBsbY9euXV/VPoVCoVC+D0LveR4zZgyAuq/RHh4efPEFa2pqcPv2bfTp06f1JaRQKN+Mjh07IjAwEHp6eiCEIDw8HI6OjsjMzGxg1r1v3z74+vpi3759TBgbYVFQUEBBQQEIIXj79i2Sk5Oxbt06hIaGIikpqVFvxZWVlUxc3P81Ll++DGNjY3z+/BnXr1/H5MmToa6uDk9PTwAQOrzRt0ZNTe27t2lsbIzLly+juroaSUlJmDRpEj58+ICdO3c2yPtfnUO8+fH06VN4e3tj2LBhuHv3rlALVxUVlW8v4A+muXEvKCgAh8PB/fv3MXXqVDg4OOD27duMZ2xREOTlvjkKCgqgoKCAjx8/4syZM5gxYwZ0dHQwaNAgkeuiUCgUyvdDaM2zoqIiFBUVQQgBh8NhzhUVFaGmpoapU6fi4MGD31JWCoXSyjg4OMDe3h56enrQ19fHmjVrwGazcePGDb58iYmJ+PjxI1auXImKigokJyeL1A6LxYKamhoTrsjT0xPJycngcrnw9fVl8vXv3x9eXl6YO3cu2rVrBzs7O0bTVt909u3bt2CxWEhISGCunT59Gnp6epCRkcGAAQMQHh7Opwl6/PgxHBwc0LZtW8jLy8PY2Bjnzp1rVOYDBw7AwsICHA4HampqmDhxIhM+C/g/DVJcXBwsLCwgJyeHPn36oKCggK+ewMBAtG/fHhwOB56envj06ZNQfaasrAw1NTVoaWnBxcUF1tbWuHXrFpPu4eHBZ1L7+fNneHt7Q1VVFTIyMvj555+RlpbWZBtRUVEwNjaGtLQ0tLW1ERQUxJdeUlKC4cOHQ1ZWFp07d0ZkZCS0tbWxZcsWJg+LxeIzHX/69CmcnZ2hpKQEeXl5WFhYIDU1FQBQWFgIR0dHtG/fHmw2G5aWlrh8+bJQ/VEfCQkJqKmpoWPHjnBycoKLiwtOnz4NoE4zbW5ujj179qBz585MiKri4mI4OjqCzWZDQUEBEyZMaLClobmxEqRtHTVqFDw8PJjzz58/Y9GiRdDU1IS0tDR0dXWxd+9eFBUVYcCAAQDqYlXzPkQDwPHjx2FiYgJZWVkoKyvD1tYW79+/b7IPePPDwsICGzduxPPnz5GamipUH385hvfv30e/fv0gIyODrl27IjY2tsm2RYE3Tzdu3Ah1dXUoKytj1qxZfAvOFy9ewMHBgZlnERERDep5+/YtJk+eDBUVFSgoKGDgwIHIzs5m0hsb98ZQVVWFuro6+vXrh+XLlyMvLw8PHjxAWloaBg8ejHbt2kFRURE2NjZ8zx1QN+dDQkIwcuRIyMvLY8qUKY2ObVPtq6mpoXPnzvD29kbnzp0btEOhUCiUfx5Ca55DQ0MZk8E///yTLwYkhUL591NTU4Njx47h/fv3sLKy4kvbu3cvnJ2dISkpCWdnZ+zdu/erLU1UVVXh4uKCffv2oaamhtH4hIeHY8aMGUhKShK6rkePHmHcuHGYM2cOJk+ejMzMTCxcuJAvz6xZs1BZWYmrV69CXl4eeXl5Tb7HqqqqsGrVKhgYGODFixeYP38+PDw8Giy4lyxZgqCgIKioqGD69OmYNGkSI/vRo0cREBCAv/76Cz///DMOHDiArVu3ihzCLz09HRkZGXBzc2s0j6+vL6KiohAeHg4tLS2sX78ednZ2ePDggUDnjRkZGZgwYQICAgLg5OSE5ORkzJw5E8rKyswPfzc3N7x69QoJCQmQlJTE/Pnz+T4gfAmXy4WNjQ06dOiA06dPQ01NDbdu3UJtbS2Tbm9vjzVr1kBaWhr79++Hg4MDCgoKRIoZ/CWysrKorKxkzh88eICoqCicOHEC4uLiqK2tZRbOiYmJqK6uxqxZs+Dk5MR8gGmtsXJzc0NKSgq2bt0KMzMzPHr0CK9evYKmpiaioqIwduxYRusoKyuLkpISODs7Y/369Rg9ejTevXuHa9euiRSfnRd7uLKyUuQ+rq2txZgxY9C+fXukpqaivLy81fcZx8fHQ11dHfHx8Xjw4AGcnJxgbm6OKVOmAKhbYD979gzx8fGQlJSEt7d3g3k2fvx4yMrK4vz581BUVMTOnTsxaNAg3Lt3j5nfX467sNTvv3fv3sHd3R1//vknCCEICgqCvb097t+/Dw6Hw5QJCAhAYGAgtmzZAnFxcYwcObLB2AoDIQQXL15EcXExevfuLbTMFAqFQvkxiBSqihCCiIgI/P7779DT0/tWMlEolO/InTt3YGVlhU+fPoHNZiM6Ohpdu3Zl0isqKnD8+HGkpKQAAH799Vf07dsXwcHBX/0RzdDQEO/evWMcDgKAnp4e1q9fz+QpKipqtp6dO3fCwMCA2Y9tYGCAnJwcrFmzhslTXFyMsWPHwsTEBACaXRRNmjSJ+btLly7YunUrLC0tweVy+e57zZo1sLGxAQAsXrwYw4cPx6dPnyAjI4MtW7bA09OTMbVevXo1Ll++LJT2uU+fPhATE0NlZSWqqqowderURhfP79+/R0hICMLCwpj9x7t370ZsbCz27t0r0Mx+06ZNGDRoEJYtWwYA0NfXR15eHjZs2AAPDw/cvXsXly9fRlpaGiwsLAAAe/bsafLdHxkZiZcvXyItLY1Z0Ojq6jLpZmZmMDMzY85XrVqF6OhonD59Gl5eXs32iSAyMjIQGRmJgQMHMtcqKyuxf/9+xjw5NjYWd+7cwaNHj6CpqQkA2L9/P4yNjZGWlgZLS8uvGise9+7dw9GjRxEbGwtbW1sA/POM1yeqqqqMeXVhYSGqq6sxZswYxoEfb44Kw9u3b7Fq1Sqw2Wz06tUL7du3F6mPL1++jLt37+LixYvM9om1a9e26j72tm3bYtu2bRAXF4ehoSGGDx+OuLg4TJkyBffu3cP58+dx8+ZNWFpaAqj7WGdkZMSUv379Om7evIkXL14wW8Y2btyIkydP4vjx48z+7S/HXRhKSkqwceNGdOjQAQYGBg36fteuXWjTpg0SExMxYsQI5vrEiRPx22+/MeePHj0CwD+2TdGxY0cAdZYKtbW1WLlyJfr16ye03J8/f8bnz5+Z84qKCqHLUigUCqXliOQwTExMDHp6eigrK/tW8lAolO+MgYEBsrKykJqaihkzZsDd3R15eXlM+qFDh6Cjo8P8IDc3N4eWlhaOHDny1W3ztGv1nRD27NlT5HoKCgqYH948evXqxXfu7e2N1atXw9raGv7+/rh9+3aTdWZkZMDBwQGdOnUCh8NhFsjFxcV8+UxNTZm/1dXVAYDRmuXn5zfQJn2p1W+MI0eOICsrC9nZ2Th69ChOnTqFxYsXC8xbWFiIqqoqWFtbM9ckJSXRq1cv5OfnCyyTn5/Plx8ArK2tcf/+fdTU1KCgoAASEhJ8MZJ1dXXRtm3bRmXOyspC9+7dGw1TyOVysXDhQhgZGaFNmzZgs9nIz89v0KfNcefOHbDZbMjKyqJXr16wsrLCtm3bmHQtLS2+BVR+fj40NTWZhTMAdO3aFW3atGH652vGikdWVhbExcWZuSIMZmZmGDRoEExMTDB+/Hjs3r0bb968abZcnz59wGaz0bZtW2RnZ+PIkSNo3769yH3M65v6fgdEve/mMDY25tMEq6ur8z0jEhISfM+9oaEh3wI0OzsbXC4XysrKfOH2Hj16hMLCQibfl+PeFB07doS8vDw0NDTw/v17REVFQUpKCs+fP8eUKVOgp6cHRUVFKCgogMvlNug/3gellnLt2jVkZWUhKysLe/bswdq1axESEiJ0+XXr1vFtn6s/tykUCoXy7RBJ8wzU7Qnz8fFBSEgIunXr9i1kolAo3xGeN2egbuGalpaG4OBgxvnS3r17kZubCwmJ/3td1NbWYt++fYyWrqXk5+dDQUEBysrKzLUvvfaLidV946tvxtoSBz2TJ0+GnZ0dzp49i0uXLmHdunUICgrC7NmzG+R9//497OzsYGdnh4iICKioqKC4uBh2dnZ85sFA3SKVB+8jAM9M+WvQ1NRkxsXIyAiFhYVYtmwZAgICmt3P+aNozlR14cKFiI2NxcaNG6GrqwtZWVmMGzeuQZ82h4GBAU6fPg0JCQloaGg0cAz1rSI/iImJNTCnrj8XhTXVrY+4uDhiY2ORnJyMS5cu4c8//8SSJUuQmpqKzp07N1ruyJEj6Nq1K5SVlfkWmq3Vx82hoKAg0Fv+27dvGzizq/+MAHXPiSjPCJfLhbq6Op+PAx71712Ucb927RoUFBSgqqrKZ47t7u6OsrIyBAcHQ0tLC9LS0rCysmrQf187xzp37szIbmxsjNTUVKxZswYzZswQqryfnx/mz5/PnFdUVNAFNIVCoXwHRA5V5ebmhps3b8LMzAyysrJQUlLiOygUyr+b2tpaxhzwzp07SE9PR0JCAqMlycrKQkJCAlJSUnD37t0Wt/PixQtERkZi1KhRzAJZEDxNUklJCXPty7i7BgYGSE9P57smyFmWpqYmpk+fjhMnTmDBggXYvXu3wDbv3r2LsrIyBAYGom/fvjA0NGxyr29jGBkZMc6yeHzpjE1YxMXFUV1dLXARpKOjAykpKb594lVVVUhLS+Mzwf9Sti/3lSclJUFfXx/i4uIwMDBAdXU1XwikBw8eNKkVNTU1RVZWFl6/fi0wPSkpCR4eHhg9ejRMTEygpqYmlFn+l/A++GhrawvlSdvIyAhPnjzBkydPmGt5eXl4+/Yt0z/CjJWKigrfPKypqUFOTg5zbmJigtraWiQmJjYqN69cfVgsFqytrbFixQpkZmZCSkoK0dHRTd6TpqYmdHR0GpgIi9rHvL6pf1/CzFEDAwOBDq5u3boFfX39ZsvzMDQ0RHV1NTIyMphrBQUFfCGfevTogdLSUkhISDQIudeuXTuh26pP586doaOjw7dwBur6z9vbG/b29owzvVevXjVbX2NjKyzi4uL4+PGj0PmlpaWZEIO8g0KhUCjfHpE1z/U9dFIolH83fn5+GDZsGDp16oR3794hMjISCQkJuHjxIoA6rXOvXr0E7sWztLTE3r17hYr7TAhBaWkpE6oqJSUFa9euhaKiIgIDA5ssKysri59++gmBgYHo3LkzXrx4gaVLl/LlmTZtGjZt2oRFixbB09MTWVlZTAxknjZ47ty5GDZsGPT19fHmzRvEx8fz7ausT6dOnSAlJYU///wT06dPR05ODlatWtXsfX7JnDlz4OHhAQsLC1hbWyMiIgK5ublCOaEqKytDaWkpqqurcefOHQQHB2PAgAECfyTLy8tjxowZ8PHxgZKSEjp16oT169fjw4cPjVoHLFiwAJaWlli1ahWcnJyQkpKCbdu2Yfv27QDqFjW2traYOnUqQkJCICkpiQULFkBWVpbPzL4+zs7OWLt2LUaNGoV169ZBXV0dmZmZ0NDQgJWVFfT09HDixAk4ODiAxWJh2bJlraKlbw5bW1uYmJjAxcUFW7ZsQXV1NWbOnAkbGxvG/FaYsRo4cCDmz5+Ps2fPQkdHB5s2beJb5Glra8Pd3R2TJk1iHIY9fvwYL168wIQJE6ClpQUWi4WYmBjY29tDVlYWubm5iIuLw5AhQ6CqqorU1FS8fPmy0bnZHKL2sa2tLfT19eHu7o4NGzagoqICS5YsabadGTNmYNu2bfD29sbkyZMhLS2Ns2fP4tChQzhz5ozQ8hoYGGDo0KGYNm0aQkJCICEhgblz5/Jp8W1tbWFlZYVRo0Zh/fr10NfXx7Nnz3D27FmMHj36q02o66Onp8d42q+oqICPj49QFgWCxrYpnxAvXrzAp0+f8PnzZ9y8eRMHDhzAuHHjWu0+KBQKhfJtEFnz7O7u3uRBoVD+Pbx48QJubm4wMDDAoEGDkJaWhosXL2Lw4MGorKzEwYMHMXbsWIFlx44di/379wtlQl1RUQF1dXV06NABVlZW2LlzJ9zd3ZGZmcnsE26Kffv2obq6Gj179sTcuXOxevVqvvTOnTvj+PHjOHHiBExNTRESEsIsAHgOhmpqajBr1iwYGRlh6NCh0NfXZxaKX6KiooKwsDAcO3YMXbt2RWBgIDZu3NisnF/i5OSEZcuWwdfXFz179sTjx4+FNsu0tbWFuro6tLW1MXXqVNjb2ze5zzwwMBBjx46Fq6srevTogQcPHuDixYuN7lHu0aMHjh49isOHD6Nbt25Yvnw5Vq5cyRdiZ//+/Wjfvj369euH0aNHY8qUKeBwOI2ajUtJSeHSpUtQVVWFvb09TExMEBgYyOx33bRpE9q2bYs+ffrAwcEBdnZ2fHuqvxUsFgunTp1C27Zt0a9fP9ja2qJLly58/SnMWE2aNAnu7u5wc3ODjY0NunTpwoQo4hESEoJx48Zh5syZMDQ0xJQpU5iwUx06dMCKFSuwePFitG/fHl5eXlBQUMDVq1dhb28PfX19LF26FEFBQS122CVqH4uJiSE6OhofP35Er169MHnyZD5He43RpUsXXL16FXfv3oWtrS169+6No0eP4tixYxg6dKhIMoeGhkJDQwM2NjYYM2YMpk6dyjgQBOrG79y5c+jXrx9+++036Ovr45dffsHjx4/Rvn17kdpqjr179+LNmzfo0aMHXF1dmfBvzSFobJvCwMAA6urq0NXVxaJFizBt2jT8+eefrXUbFAqFQvlGsIgo8TD+PzU1NTh58iTjaMXY2BgjR44UKTQEhUKhfEvWrFmDHTt28JnqUr6Op0+fQlNTE5cvX8agQYN+tDgUCuX/U1FRAUVFRZSXl1MTbgqFQhERUd6hIpttP3jwAPb29vj7779hYGAAoM7ro6amJmPKRqFQKN+b7du3w9LSEsrKykhKSsKGDRtaHP6IUseVK1fA5XJhYmKCkpIS+Pr6QltbW6SQOhQKhUKhUCj/FUQ22/b29oaOjg6ePHmCW7du4datWyguLkbnzp3h7e39LWSkUCj/YIyNjfnCx9Q/IiIivpsc9+/fh6OjI7p27YpVq1ZhwYIFCAgI+G7t/xepqqrC77//DmNjY4wePRoqKipISEho4D2ZQqFQKBQK5X8Bkc225eXlcePGDZiYmPBdz87OhrW1NbhcbqsKSKFQ/tk8fvy40X3P7du3b+DNlkKhUL4V/fv3h7m5+f+cc1OeyaHm3KMQk5b70eK0GkWBw3+0CBQK5X8AUcy2RdY8S0tL4927dw2uc7lcoUKGUCiU/xZaWloNwsfwDrpwplD+j5CQEJiamjKhhaysrHD+/Hm+PNra2mCxWGCxWBAXF4eGhgY8PT2bDBFWn4SEBKY8i8WCiooK7O3tcefOHb58Hh4eGDVqVKPl63sRJ4Rg165d6N27N9hsNtq0aQMLCwts2bIFHz58ELkffiRhYWF8/cM79uzZw+T5+PEj/P39oa+vD2lpabRr1w7jx49Hbm4uX10BAQEwNzdv0EZRURFYLFaDkHpRUVHo378/FBUVwWazYWpqipUrVzYa2o1CoVAo/zxEXjyPGDECU6dORWpqKgghIITgxo0bmD59OkaOHPktZKRQKBQK5V9Px44dERgYiIyMDKSnp2PgwIFwdHRssChbuXIlSkpKUFxcjIiICFy9elXkbVEFBQUoKSnBxYsX8fnzZwwfPlxgjHBhcHV1xdy5c+Ho6Ij4+HhkZWVh2bJlOHXqFC5dutSiOn8kCgoKKCkp4TtcXFwAAJ8/f4atrS327duH1atX4969ezh37hyqq6vRu3fvFsdpX7JkCZycnGBpaYnz588jJycHQUFByM7OxoEDB1rz9igUCoXyDRF58bx161bo6OjAysoKMjIykJGRgbW1NXR1dREcHPwtZKRQKBQK5V+Pg4MD7O3toaenB319faxZswZsNrvBgozD4UBNTQ0dOnTAgAED4O7ujlu3bonUlqqqKtTU1NCjRw/MnTsXT548wd27d0WW+ejRo4iIiMChQ4fw+++/w9LSEtra2nB0dMSVK1eYUF0JCQno1asX5OXl0aZNG1hbW+Px48eN1rto0SLo6+tDTk4OXbp0wbJly/i2f/C0ugcOHIC2tjYUFRXxyy+/8Fm+vX//Hm5ubmCz2VBXV0dQUJBQ98RisaCmpsZ38GI5b9myBSkpKYiJiWFic/fq1QtRUVEwMjKCp6cnRA1ScvPmTaxduxZBQUHYsGED+vTpA21tbQwePBhRUVFMmM/s7GwMGDAAHA4HCgoK6NmzJ9LT00Vqi0KhUCjfFpG9bbdp0wanTp3CgwcPmFBVRkZG0NXVbXXhKBQKhUL5L1JTU4Njx47h/fv3sLKyajTf33//jTNnzqB3794taqe8vByHDx8GgBZtrYqIiICBgQEcHR0bpLFYLCgqKqK6uhqjRo3ClClTcOjQIVRWVuLmzZtgsViN1svhcBAWFgYNDQ3cuXOHiSHu6+vL5CksLMTJkycRExODN2/eYMKECQgMDGTiUPv4+CAxMRGnTp2Cqqoqfv/9d9y6dUugKbWwREZGYvDgwTAzM+O7LiYmhnnz5sHFxQXZ2dkitREREQE2m42ZM2cKTG/Tpg0AwMXFBd27d0dISAjExcWRlZVFnfNRKBTKPwyRF888eHsaq6ur8enTp9aUiUKhUCiU/yR37tyBlZUVPn36BDabjejoaHTt2pUvz6JFi7B06VLU1NTg06dP6N27NzZt2iRSOx07dgRQp50FgJEjR8LQ0JAvT0xMDNhsNt+1mpoavvP79+8zYSkbo6KiAuXl5RgxYgQTrtLIyKjJMkuXLmX+1tbWxsKFC3H48GG+xXNtbS3CwsIY3wmurq6Ii4vDmjVrwOVysXfvXhw8eJCJOR4eHs7cd1OUl5fz3TebzUZpaSkA4N69e4w2/Ut493Tv3j1m8Xznzp0GffilZvr+/fvo0qVLswvh4uJi+Pj4MOOkp6fXaN7Pnz/j8+fPzHlFRUWTdVMoFAqldRDabPvMmTMICwvju8YzOWvTpg2GDBkitEMTCoVCoVD+FzEwMEBWVhZSU1MxY8YMuLu7Iy8vjy+Pj48PsrKycPv2bcTFxQEAhg8f3mBh2xTXrl1DRkYGwsLCoK+vjx07djTIM2DAAGRlZfEd9R1nAQ0XgoJQUlKCh4cH7Ozs4ODggODgYJSUlDRZ5siRI7C2toaamhrYbDaWLl2K4uJivjza2tp8TgfV1dXx4sULAHVa6crKSj6NvJKSUrMLfaBO613/npOTk0W65/oafN541j/OnTsnUn085s+fj8mTJ8PW1haBgYEoLCxsNO+6deugqKjIHJqamkK1QaFQKJSvQ+jF86ZNm5gv2ACQnJyM5cuXY9myZTh69CiePHmCVatWfRMhKRQKhUL5LyAlJQVdXV307NkT69atg5mZWQN/Ie3atYOuri709PQwcOBAbNmyBcnJyYiPjxe6nc6dO8PAwADu7u6YPHkynJycGuSRl5dv4CG/Q4cOfHn09fWF2isdGhqKlJQU9OnTB0eOHIG+vn6jzrVSUlLg4uICe3t7xMTEIDMzE0uWLGng0OxLTS2LxUJtbW2zsjSHmJgY3z136dKFSdPT02O2pH0J77q+vj5zjTee9Q8tLS2+cvr6+nj48GGjIf14BAQEIDc3F8OHD8eVK1fQtWtXREdHC8zr5+eH8vJy5njy5IlQ906hUCiUr0PoxXNubi769OnDnB8/fhyDBw/GkiVLMGbMGAQFBeHMmTPfREgKhUKhUP6L1NbW8pnfCkJcXBxAXQilljBr1izk5OQ0uhBriokTJ+LevXs4depUgzRCCMrLy5nz7t27w8/PD8nJyejWrRsiIyMF1pmcnAwtLS0sWbIEFhYW0NPTa9K5mCB0dHQgKSmJ1NRU5tqbN29w7949ker5EmdnZ1y+fBnZ2dl812tra7F582ZYWFg0MLNvjokTJ4LL5WL79u0C0+uHBdPX18e8efNw6dIljBkzBqGhoQLLSEtLMyHPeAeFQqFQvj1CL57fvXsHZWVl5vz69evMPiMAMDY2xrNnz1pXOgqFQqFQ/iP4+fnh6tWrKCoqwp07d+Dn54eEhAQmTBKPd+/eobS0FCUlJbh58yZ8fHygoqLC9wFbFOTk5DBlyhT4+/uL7Cl6woQJcHJygrOzM9auXYv09HQ8fvwYMTExsLW1RXx8PB49egQ/Pz+kpKTg8ePHuHTpEu7fv9/ovmc9PT0UFxfj8OHDKCwsxNatW0Ve2LPZbHh6esLHxwdXrlxBTk4OPDw8ICYmchARPubNm4devXrBwcEBx44dQ3FxMdLS0jB27Fjcv38f4eHhItfZu3dv+Pr6YsGCBfD19WX6KS4uDuPHj0d4eDg+fvwILy8vJCQk4PHjx0hKSkJaWlqze8cpFAqF8n0R2mFYhw4dkJ+fj06dOoHL5SI7OxubN29m0svKyiAnJ/dNhKRQKBQK5d/Oixcv4ObmhpKSEigqKsLU1BQXL17E4MGD+fItX74cy5cvBwCoqKjA0tISly5d4vuALSpeXl7YtGkTjh07hgkTJghdjsViITIyErt27cK+ffuwZs0aSEhIQE9PD25ubrCzs0NFRQXu3r2L8PBwlJWVQV1dHbNmzcK0adME1jly5EjMmzcPXl5eTAzqZcuWISAgQKR72rBhA7hcLhwcHMDhcLBgwQI+TXhLkJGRQVxcHNatWwc/Pz88fvwY1dXV0NXVRU5OjlAOyQTxxx9/oGfPnvjrr7+wY8cO1NbWQkdHB+PGjYO7uzvExcVRVlYGNzc3PH/+HO3atcOYMWOwYsWKr7ofCoVCobQuLCLkZ2g/Pz+cPHkSv//+O86dO4fk5GQ8fPiQMSfbtWsX9u/fj+vXr39TgSkUCoVCoVC+F+fPn8fo0aOxceNGeHl5/WhxBFJRUQFFRUWUl5dTE24KhUIREVHeoULbNy1fvhyWlpbw9vZGVlYWDh48yCycAeDQoUNwcHBoudQUCoVCoVAo/zCGDRuG8+fP4/Xr13j16tWPFodCoVAoPxChNc8UCoVCoVB+LMOGDcO1a9cEpv3+++/4/fffv7NElH8CVPNMoVAoLUeUd6jQe54pFArla/Hw8MDbt29x8uTJHy3Kfx5tbW3MnTsXc+fOBVC3dzU6OhqjRo1qtMw/YXxKS0vh6uqK5ORkSEpK8nki/rfy5VgIukdhxgcA9uzZ06jXbSUlpSbLhoWFYe7cuf+JPqUIppv/RYhJi+5/pihw+DeQhkKhUP57fJ1bSgrlP0RISAhMTU2ZsB9WVlY4f/58g3yZmZkYP3482rdvDxkZGejp6WHKlClChUgpKioCi8ViDiUlJdjY2DTQJAUEBMDc3LzR8llZWXzXo6Ki0L9/fygqKoLNZsPU1BQrV67E69evReqDH01CQgJf//COpUuXMnlqamqwefNmmJiYQEZGBm3btsWwYcOQlJTEV1dYWBjatGkjsB0Wi9VggRgfHw97e3soKytDTk4OXbt2xYIFC/D333+3+H4ePHiA3377DR07doS0tDQ6d+4MZ2dnpKent7jOllJSUoJhw4YBaHweBQcHIyws7LvLVp/NmzejpKQEWVlZXx12SBCEEOzatQu9e/cGm81GmzZtYGFhgS1btuDDhw9fVXdjcy4tLQ1Tp05lzgXdY/3xaYoOHTo0iCvMO+ovnrW1tbFlyxa+sk5OTt+kT781/5X3G4VCoVD+/dDFM4Xy/+nYsSMCAwORkZGB9PR0DBw4EI6OjsjNzWXyxMTE4KeffsLnz58RERGB/Px8HDx4EIqKili2bJnQbV2+fBklJSW4evUqNDQ0MGLECDx//rxFci9ZsgROTk6wtLTE+fPnkZOTg6CgIGRnZ+PAgQMtqvNHU1BQgJKSEuZYvHgxgLqFzy+//IKVK1dizpw5yM/PR0JCAjQ1NdG/f/8Wa0x37twJW1tbqKmpISoqCnl5edixYwfKy8sRFBTUojrT09PRs2dP3Lt3Dzt37kReXh6io6NhaGiIBQsWtKjOr0FNTQ3S0tJN5lFUVGz0g8P3orCwED179oSenh5UVVVbVEdlZWWjaa6urpg7dy4cHR0RHx+PrKwsLFu2DKdOncKlS5daKjaqqqoaTVNRUeGLRiHoHoUZn69FVla2xX36LampqUFtba3AtH/q+40Qgurq6h/WPoVCoVB+EIRCoTRK27ZtyZ49ewghhLx//560a9eOjBo1SmDeN2/eNFvfo0ePCACSmZnJXLt9+zYBQE6dOsVc8/f3J2ZmZs2WT01NJQDIli1bmpQpKyuL9O/fn7DZbMLhcEiPHj1IWlpao3IGBQWRbt26ETk5OdKxY0cyY8YM8u7dOyY9NDSUKCoqkgsXLhBDQ0MiLy9P7OzsyLNnz5g81dXVZN68eURRUZEoKSkRHx8f4ubmRhwdHRttNz4+ngBotC8PHz5MAJDTp083SBszZgxRVlYmXC6XT0ZBACDR0dGEEEKePHlCpKSkyNy5cwXm5clSVFRERowYQdq0aUPk5ORI165dydmzZwWWqa2tJcbGxqRnz56kpqam0ToJqRv/AQMGEBkZGaKkpESmTJnC19fu7u7E0dGRbNiwgaipqRElJSUyc+ZMUllZyeR5/vw5GTFiBJGRkSHa2trk4MGDREtLi2zevFngPQPgO2xsbPja4vHp0ycye/ZsoqKiQqSlpYm1tTW5efMmk84br8uXL5OePXsSWVlZYmVlRe7evcvkEWXuaWlp8cnl7u5OCCHk8ePHZOTIkUReXp5wOBwyfvx4UlpaypTjPS+7d+8m2trahMViCaz/yJEjBAA5efJkg7Ta2lry9u1b5nz37t3E0NCQSEtLEwMDA/LXX38xabzn8PDhw6Rfv35EWlqahIaGNuhXf39/5r54Y9HYPdYfH0Lq5uUvv/xC2rZtS+Tk5EjPnj3JjRs3CCGEPHjwgIwcOZKoqqoSeXl5YmFhQWJjY5myNjY2DWQhRPAzsX37dtKlSxciKSlJ9PX1yf79+/nSAZDdu3eTUaNGEVlZWaKrq8v3rhLE69eviaurK2nTpg2RlZUlQ4cOJffu3WPSeXKcOnWKGBkZEXFxcfLo0aMG9Qj7fmvuPpydncmECRP4ylZWVhJlZWUSHh5OCCGkpqaGrF27lmhraxMZGRliampKjh07xuTnzfVz586RHj16EElJSRIfH9/sWBBCyLNnz4i9vT3zfEZERDR4Pt+8eUM8PT1Ju3btCIfDIQMGDCBZWVlN9nN9ysvLCQCiOfco0VoUI/JBoVAo/8vw3qHl5eXN5hVZ8/zw4UORF+gUyr+NmpoaHD58GO/fv4eVlRUA4OLFi3j16hV8fX0FlmmJxu7jx4/Yv38/AEBKSkrk8hEREWCz2Zg5c2aTMrm4uKBjx45IS0tDRkYGFi9eDElJyUbrFRMTw9atW5Gbm4vw8HBcuXKlwX1/+PABGzduxIEDB3D16lUUFxdj4cKFTHpQUBDCwsKwb98+XL9+Ha9fv0Z0dLTI91ifyMhI6OvrC/Tsv2DBApSVlSE2NlakOo8dO4bKyspmx3XWrFn4/Pkzrl69ijt37uCPP/4Am80WWCYrKwu5ublYsGABxMQavmZ5db5//x52dnZo27Yt0tLScOzYMVy+fLlBOJz4+HgUFhYiPj4e4eHhCAsL4zOv9vDwwJMnTxAfH4/jx49j+/btePHiRaP3fPPmTQD/ZwFx4sQJgfl8fX0RFRWF8PBw3Lp1C7q6urCzs2tgLrtkyRIEBQUhPT0dEhISmDRpEpMmytxLS0vD0KFDMWHCBJSUlCA4OBi1tbVwdHTE69evkZiYiNjYWDx8+BBOTk58ZR88eICoqCicOHGigTk6j4iICBgYGMDR0bFBGovFgqKiIpNv+fLlWLNmDfLz87F27VosW7YM4eHhfGUWL17MWEAMGDAAW7ZsgYKCAmMxUf95aOoev4TL5cLGxgZ///03Tp8+jezsbPj6+jLaWS6XC3t7e8TFxSEzMxNDhw6Fg4MDiouLAQAnTpxAx44dsXLlSkYWQURHR2POnDlYsGABcnJyMG3aNPz222+Ij4/ny7dixQpMmDABt2/fhr29PVxcXJo0mfbw8EB6ejpOnz6NlJQUEEJgb2/Pp53/8OED/vjjD+zZswe5ubkCNeLCvt+auw8XFxecOXMGXC6XKXvx4kV8+PABo0ePBgCsW7cO+/fvx44dO5Cbm4t58+bh119/RWJiIl+bixcvRmBgIPLz82FqatrsWACAm5sbnj17hoSEBERFRWHXrl0Nns/x48fjxYsXOH/+PDIyMtCjRw8MGjSImqZTKBTKPw1RV+YsFov079+fHDhwgHz8+LEli3sK5R/L7du3iby8PBEXFyeKiop8msU//viDACCvX79ucf08jZWsrCyRl5cnLBaLACA9e/bk0yT6+/sTMTExIi8vz3fIycnxaZ6HDRtGTE1Nm22Xw+GQsLCwFst97NgxoqyszJzztGwPHjxgrv3111+kffv2zLm6ujpZv349c15VVUU6duwolOb5y/t+9eoVIYQQQ0PDRsu/fv2aACB//PEHn4xf1iUvL8+n5ZsxYwZRUFBotg9MTExIQEBAs/kI+T8N561bt5rMt2vXLtK2bVtGW04IIWfPniViYmKMZtXd3Z1oaWmR6upqJs/48eOJk5MTIYSQgoICAoBPI5yfn08ANKp5FmQBwWuL179cLpdISkqSiIgIJr2yspJoaGgw41pf81xffgDM/wdR556joyOjjSWEkEuXLhFxcXFSXFzMXMvNzeW7Z39/fyIpKUlevHjRZN1GRkZk5MiRzcqgo6NDIiMj+a6tWrWKWFlZEUL+r/++1Ig2Zu3wpZbxy3skhH98du7cSTgcDikrK2tWVh7Gxsbkzz//bLRNQfL16dOHTJkyhS/P+PHjib29PZ9cS5cuZc65XC4BQM6fPy9Qjnv37hEAJCkpibn26tUrIisrS44ePcrIAaBZzaqw77fm7qOqqoq0a9eugTaa9wx9+vSJyMnJkeTkZL46PD09ibOzMyHk/+a6IKuFL6k/Frxnsb61xf379/mez2vXrhEFBQXy6dMnvnp0dHTIzp07Bbbx6dMnUl5ezhxPnjyhmmcKhUJpId9U83zr1i2Ymppi/vz5UFNTw7Rp0xgtBoXyb8fAwABZWVlITU3FjBkz4O7ujry8PAB1e9xaiyNHjiAzMxNRUVHQ1dVFWFhYA20cT5b6x7lz5/jyCCvT/PnzMXnyZNja2iIwMBCFhYVN5r98+TIGDRqEDh06gMPhwNXVFWVlZXwOleTk5KCjo8Ocq6urM9qU8vJylJSUoHfv3ky6hIQELCwshJL32rVrfPfdtm1boe+5vgafw+E06MMvtZKEELBYrGZl8vb2xurVq2FtbQ1/f3/cvn270bzCjkt+fj7MzMwgLy/PXLO2tkZtbS0KCgqYa8bGxhAXF2fO6/d1fn4+JCQk0LNnTybd0NDwq/cuFxYWoqqqCtbW1sw1SUlJ9OrVC/n5+Xx5TU1N+WQDwMgn6tz7kvz8fGhqakJTU5O51rVrV7Rp04ZPDi0tLaioqDRZlzDj8v79exQWFsLT0xNsNps5Vq9e3UB2YeezqGRlZaF79+6Nes/mcrlYuHAhjIyM0KZNG7DZbOTn5/NpO4UhPz+fb3yBuvnX1PjKy8tDQUGhUcsG3nys/+wrKyvDwMCAr14pKSm+egUhynPU1H1ISEhgwoQJiIiIAFA3xqdOnYKLiwuAOquFDx8+YPDgwXxjvn///mbHvLmxKCgogISEBHr06MGU0dXV5XunZWdng8vlQllZma/9R48eNfq8rFu3DoqKisxR//mgUCgUyrdD5MWzubk5goOD8ezZM+zbtw8lJSX4+eef0a1bN2zatAkvX778FnJSKN8FKSkp6OrqomfPnli3bh3MzMwYs0p9fX0AwN27d7+6HU1NTejp6WH06NFYu3YtRo8ejc+fPwuUpf6hpaXFl0dfXx8PHz5s0lkRUOe9Ozc3F8OHD8eVK1fQtWvXRk2oi4qKMGLECJiamiIqKgoZGRn466+/APA7Yvpysc9isVrtA0Pnzp357ptn+qynp9fghz0P3nXeOAF15ueCvBLXR19fn1nsN8XkyZPx8OFDuLq64s6dO7CwsMCff/4pMG9rzhVAcF835mDpR1BfPt6HCJ58osy9r6H+B4jG0NfXb3ZMeKa9u3fv5vvgkpOTgxs3bojcZkuQlZVtMn3hwoWIjo7G2rVrmQ9NJiYmTTpK+xq+xfyTlZVt9qOVsO83YXBxcUFcXBxevHiBkydPQlZWFkOHDgXwf2N+9uxZvjHPy8vD8ePH+er5csxbYyy4XC7U1dUbfOQrKCiAj4+PwDJ+fn4oLy9njidPnojSHRQKhUJpIS32ti0hIYExY8bg2LFj+OOPP/DgwQMsXLgQmpqacHNza/aHKIXyb6C2tpZZ1A4ZMgTt2rXD+vXrBeZtaezUcePGQUJCAtu3bxe57MSJE8HlchstW18mfX19zJs3D5cuXcKYMWMQGhoqsExGRgZqa2sRFBSEn376Cfr6+nj27JlIcikqKkJdXR2pqanMterqamRkZIhUz5c4Ozvj/v37OHPmTIO0oKAgaGhoYPDgwSLVOW7cOEhJSQk1rpqampg+fTpOnDiBBQsWYPfu3QLLmJubo2vXrggKChK4yODVaWRkhOzsbLx//55JS0pKgpiYGAwMDISS39DQsEHfFhQUNDkfedr5mpqaRvPo6OhASkqKLwRYVVUV0tLS0LVrV6Fk4yHs3BOEkZERnjx5wrc4yMvLw9u3b0WWY+LEibh37x5OnTrVII0QgvLycrRv3x4aGhp4+PBhg48unTt3brJ+KSmpJvtUWExNTZGVldXoftekpCR4eHhg9OjRMDExgZqaGoqKikSWxcjIqEGIt6SkJJH79cs6q6ur+Z79srIyFBQUtGi8hHm/CXMfffr0gaamJo4cOYKIiAiMHz+e+SjQtWtXSEtLo7i4uMGYN6fRbW4sDAwMUF1djczMTObagwcP8ObNG+a8R48eKC0thYSERIP227VrJ7BdaWlpJqwi76BQKBTKt6fFi+f09HTMnDkT6urq2LRpExYuXIjCwkLExsbi2bNnAh2yUCj/ZPz8/HD16lUUFRXhzp078PPzQ0JCAmPaJy8vjz179uDs2bMYOXIkLl++jKKiIqSnp8PX1xfTp09vUbssFgve3t4IDAwUOc5s79694evriwULFsDX1xcpKSl4/Pgx4uLiMH78eISHh+Pjx4/w8vJCQkICHj9+jKSkJKSlpcHIyEhgnbq6uqiqqsKff/6Jhw8f4sCBA9ixY4fI9zVnzhwEBgbi5MmTuHv3LmbOnNniDww8fvnlF4waNQru7u7Yu3cvioqKcPv2bUybNg0xMTE4ePBgk47QBKGpqYnNmzcjODgYnp6eSExMZPpp2rRpWLVqFQBg7ty5uHjxIh49eoRbt24hPj6+0T5ksVgIDQ3FvXv30LdvX5w7dw4PHz7E7du3sWbNGub96OLiAhkZGbi7uyMnJwfx8fGYPXs2XF1d0b59e6HkNzAwwNChQzFt2jSkpqYiIyMDkydPblJ7qaqqCllZWVy4cAHPnz9HeXl5gzzy8vKYMWMGfHx8cOHCBeTl5WHKlCn48OEDPD09hZJN1LknCFtbW5iYmMDFxQW3bt3CzZs34ebmBhsbG5HNpidMmAAnJyc4Oztj7dq1SE9Px+PHjxETEwNbW1vGwdSKFSuwbt06bN26Fffu3cOdO3cQGhqKTZs2NVm/trY2uFwu4uLi8OrVqxbHjXZ2doaamhpGjRqFpKQkPHz4EFFRUUhJSQFQZ4HBc4yWnZ2NiRMnNvhIo62tjatXr+Lvv//Gq1evBLbj4+ODsLAwhISE4P79+9i0aRNOnDgh0NGZsOjp6cHR0RFTpkzB9evXkZ2djV9//RUdOnQQ+XeBMO83Ue5j4sSJ2LFjB2JjY5n3OlC3vWPhwoWYN28ewsPDUVhYiFu3buHPP/9s4CRO0P02NRaGhoawtbXF1KlTcfPmTWRmZmLq1Kl8mndbW1tYWVlh1KhRuHTpEoqKipCcnIwlS5b8kJjwFAqFQmkCUTdU80LYSEpKEkdHR3LmzJkGoViePHlCxMXFRa2aQvmhTJo0iWhpaREpKSmioqJCBg0aRC5dutQgX1paGhkzZgwTvkdXV5dMnTqV3L9/v9k2GnPU9P79e9K2bVvG2ZWwoap4HDlyhPTr149wOBwiLy9PTE1NycqVK8mbN2/I58+fyS+//EI0NTWJlJQU0dDQIF5eXk06/Nu0aRNRV1cnsrKyxM7Ojuzfv58vhJQgx0jR0dGk/iulqqqKzJkzhygoKJA2bdqQ+fPnf3WoKl69GzZsIMbGxkRKSooAIEpKSiQ3N5cvn7ChqnjExsYSOzs70rZtWyIjI0MMDQ3JwoULmfBbXl5eREdHh0hLSxMVFRXi6urKODJrjIKCAuLm5kY0NDSIlJQU0dLSIs7OznyOxIQNVVWfOXPmMOGlCCGkpKSEDB8+nEhLS5NOnTqR/fv3p2ie5AABAABJREFUNxmqipC6UEyamppETEys0VBVHz9+JLNnzybt2rVrMlRV/fHKzMwkAMijR49aNPcEOdMSNlSVMNTU1JCQkBBiaWlJ5OTkiIKCAunZsycJDg4mHz58YPJFREQQc3NzIiUlRdq2bUv69etHTpw4QQhp/DkkhJDp06cTZWXlRkNVNXaPX45PUVERGTt2LFFQUCBycnLEwsKCpKamMu0PGDCAyMrKEk1NTbJt2zZiY2ND5syZw5RPSUkhpqamRFpa+qtDVX35rCgqKpLQ0FDBHUz+L1SVoqIi8w4RFKpKWJp6vwl7H4QQkpeXRwAQLS0tUltby5dWW1tLtmzZQgwMDIikpCRRUVEhdnZ2JDExkRDS+LtJmLF49uwZGTZsGJGWliZaWlokMjKSqKqqkh07djB5KioqyOzZs4mGhgaRlJQkmpqaxMXFhc9RXlPQUFUUCoXSckRxGMYiRLRNinp6epg0aRI8PDwYxzBfUllZiUOHDsHd3V301TyFQqGIwK1bt2BrawtPT09s2LDhR4tDoVAoTfL06VNoamoyjhlbg4qKCigqKqK8vJyacFMoFIqIiPIOFXnxTKFQKP80MjMzcerUKbi6uvJ5AKdQKJQfzZUrV8DlcmFiYoKSkhL4+vri77//xr1790TeZtIYdPFMoVAoLUeUd6hESxp48+YN9u7dy3i3NTIywqRJkxoNq0Gh/K8wffp0HDx4UGDar7/+2qK9w5Tm6d69O7p37/6jxaBQKJQGVFVV4ffff8fDhw/B4XDQp08fREREtNrCmUKhUCjfD5E1z1evXoWDgwMUFRUZZy0ZGRl4+/Ytzpw5g379+n0TQSmUfwMvXrxARUWFwDQFBQWoqqp+Z4koFIqwBAQE4OTJk0wscA8PD7x9+xYnT54Uug4Wi4Xo6GiMGjWqVWTS1tbG3LlzMXfu3Fap70sSEhIwYMAAvHnz5qtjg//Tae2x4dG/f3+Ym5tjy5YtQuUvKipC586dkZmZCXNz81aRgac10Zx7FGLSciKXLwoc3ipyUCgUyr8RUTTPInvbnjVrFpycnPDo0SOcOHECJ06cwMOHD/HLL79g1qxZLRaaQvkvoKqqKjCusK6uLl04UyhfEBISAlNTUybUjpWVFc6fP8+XR1tbGywWCywWC7KystDW1saECRNw5coVkduLiopC//79oaioCDabDVNTU6xcubLRkFDBwcEICwsTqY2SkhIMGzZMZNlaSkBAQKstwESh/rjwjo4dO37TNnfv3g0zMzOw2Wy0adMG3bt3x7p1675pmxQKhUKh1EfkxfODBw+wYMECiIuLM9fExcUxf/58PHjwoFWFo1AoFMp/l44dOyIwMBAZGRlIT0/HwIED4ejoiNzcXL58K1euRElJCQoKCrB//360adMGtra2WLNmjdBtLVmyBE5OTrC0tMT58+eRk5ODoKAgZGdn48CBAwLLKCoqiqyNVVNTg7S0tEhl/q3wxoV31I9l3Nrs27cPc+fOhbe3N7KyspCUlARfX19wudxv1iaFQqFQKF8i8uK5R48ezF7n+uTn58PMzKxVhKJQKBTKfx8HBwfY29tDT08P+vr6WLNmDdhsNm7cuMGXj8PhQE1NDZ06dUK/fv2wa9cuLFu2DMuXL0dBQUGz7dy8eRNr165FUFAQNmzYgD59+kBbWxuDBw9GVFRUo5EhPDw8+Ex8+/fvD29vb/j6+kJJSQlqamoICAjgK8NisfjMvJ8+fQpnZ2coKSlBXl4eFhYWSE1NBQAUFhbC0dER7du3B5vNhqWlJS5fvixc5wnJgQMHYGFhwfThxIkT8eLFiwb5kpKSYGpqChkZGfz000/Iyclptm5enbxDRUUFAFBbW4t169ahc+fOkJWVhZmZGY4fP85XNicnB8OGDQObzUb79u3h6uraaDxqADh9+jQmTJgAT09P6OrqwtjYGM7Ozg0+oOzbtw/GxsaQlpaGuro6vLy8+NJfvXqF0aNHQ05ODnp6ejh9+rRIcr1//x5ubm5gs9lQV1dHUFBQA1m/nAMA0KZNmyatGETtDwqFQqH8GIRaPN++fZs5vL29MWfOHGzcuBHXr1/H9evXsXHjRsybNw/z5s371vJSKBQK5T9ITU0NDh8+jPfv38PKyqrZ/HPmzAEhBKdOnWo2b0REBNhsNmbOnCkwXRTtcnh4OOTl5ZGamor169dj5cqViI2NFZiXy+XCxsYGf//9N06fPo3s7Gz4+vqitraWSbe3t0dcXBwyMzMxdOhQODg4oLi4WGh5mqOqqgqrVq1CdnY2Tp48iaKiInh4eDTI5+Pjg6CgIKSlpUFFRQUODg6oqqpqUZvr1q3D/v37sWPHDuTm5mLevHn49ddfkZiYCAB4+/YtBg4ciO7duyM9PR0XLlzA8+fPMWHChEbrVFNTw40bN/D48eNG84SEhGDWrFmYOnUq7ty5g9OnT0NXV5cvz4oVKzBhwgTcvn0b9vb2cHFxYcz2hZHLx8cHiYmJOHXqFC5duoSEhATcunWrRf3EoyX9QaFQKJQfg1Dets3NzcFisVDft5ivr2+DfBMnToSTk1PrSUehUCiU/zR37tyBlZUVPn36BDabjejoaHTt2rXZckpKSlBVVUVRUVGzee/fv48uXbq0indjU1NT+Pv7AwD09PSwbds2xMXFYfDgwQ3yRkZG4uXLl0hLS2OiUdRfzJmZmfFZbK1atQrR0dE4ffp0A41pS5k0aRLzd5cuXbB161ZYWlqCy+WCzWYzaf7+/sw9hIeHo2PHjoiOjm5yAbdo0SIsXbqUOV+7di2mTZuGtWvX4vLly8xHkC5duuD69evYuXMnbGxssG3bNnTv3h1r165lyu7btw+ampq4d+8e9PX1G7Tl7++PMWPGQFtbG/r6+rCysoK9vT3GjRsHMbE6PcDq1auxYMECzJkzhylnaWnJV4+HhwecnZ0Zebdu3YqbN29i6NChzcqloaGBvXv34uDBg0x8Zl5ffQ0t6Y/Pnz/j8+fPzHljjiopFAqF0roItXh+9OjRt5aDQqFQKP+DGBgYICsrC+Xl5Th+/Djc3d2RmJgo1AKaEAIWiyVUvtbC1NSU71xdXV2gGTQAZGVloXv37o2GceRyuQgICMDZs2dRUlKC6upqfPz4sVU1zxkZGQgICEB2djbevHnDaL2Li4v5+ri+tl9JSQkGBgYCt2jVx8fHh0+L3a5dOzx48AAfPnxo8DGhsrKSCSeXnZ2N+Ph4vsU7j8LCQoGLRXV1daSkpCAnJwdXr15FcnIy3N3dsWfPHly4cAGvXr3Cs2fPmEVtY9QfP3l5eSgoKDDj15xcHz9+RGVlJXr37s1c5/XV19CS/li3bh1WrFjxVe1SKBQKRXSEWjxraWl9azkoFAqF8j+IlJQUo43t2bMn0tLSEBwcjJ07dzZZrqysDC9fvkTnzp2bbUNfXx/Xr19HVVXVV2ufvyzPYrGYBemXyMrKNlnXwoULERsbi40bN0JXVxeysrIYN24cKisrv0pGHu/fv4ednR3s7OwQEREBFRUVFBcXw87OrlXaaNeuXQOzaN4e9LNnz6JDhw58aTxHalwuFw4ODvjjjz8a1Kmurt5km926dUO3bt0wc+ZMTJ8+HX379kViYiITOrM5mhq/5uQS1inql5Z6AJo0gW9Jf/j5+WH+/PnMeUVFBTQ1NYWSj0KhUCgtR6jFM4VCoVAo34Pa2lo+c9TGCA4OhpiYmFAxeydOnIitW7di+/btfCa9PN6+fftNYhybmppiz549eP36tUDtc1JSEjw8PDB69GgAdYsoYczQheXu3bsoKytDYGAgs7BKT08XmPfGjRvo1KkTAODNmze4d+8ejIyMRG6za9eukJaWRnFxMWxsbATm6dGjB6KioqCtrQ0JiZb/DOFpzt+/fw8OhwNtbW3ExcVhwIABLaqvObl0dHQgKSmJ1NTUBn1V/15VVFRQUlLCnN+/fx8fPnxocbuCkJaW/p/x6k6hUCj/JET2tk2hUCgUSmvg5+eHq1evoqioCHfu3IGfnx8SEhLg4uLCl+/du3coLS3FkydPcPXqVUydOhWrV6/GmjVrGmg+BdG7d2/4+vpiwYIF8PX1RUpKCh4/foy4uDiMHz8e4eHh3+T+nJ2doaamhlGjRiEpKQkPHz5EVFQUUlJSANTtmT5x4gSysrKQnZ2NiRMnNqrFboqPHz8iKyuL7ygsLESnTp0gJSWFP//8Ew8fPsTp06exatUqgXWsXLkScXFxyMnJgYeHB9q1ayfUh4kv4XA4WLhwIebNm4fw8HAUFhbi1q1b+PPPP5l+njVrFl6/fg1nZ2ekpaWhsLAQFy9exG+//YaamhqB9c6YMQOrVq1CUlISHj9+jBs3bsDNzQ0qKiqMyXlAQACCgoKwdetW3L9/n2lXWJqTi81mw9PTEz4+Prhy5QrTV7w91zwGDhyIbdu2ITMzE+np6Zg+fXqTFg8t6Q8KhfL/2LvzeK6yx3/grzeyvlGUpWxli4pIC81QUqS0R8ZEZdobWpRMi6WFNqVZZNqoIdq0ow2VNoSEJNGqZVqIiuL8/uj3vl/X+433W9TMfM7z8biPmfe9555z7rlLzj3nnkNR3wZteaYoiqK+iefPn8Pd3R1lZWVQVFSEiYkJkpKS+L6XXblyJVauXAlJSUmoqalhwIABIrcwrlu3Dn369MHvv/+Obdu2oa6uDrq6upgwYUKjU1V9KUlJSZw+fRqLFi2Co6MjPn36BGNjY/z+++8AgNDQUEybNg1WVlbo2LEjfH19WzTw0507d5jviXmGDBmCs2fPIjIyEr/88gu2bt0Kc3NzbNy4EaNGjeKLIyQkBN7e3igqKkLv3r1x/PhxSEpKtui4V61ahU6dOiE4OBj37t1D+/btYW5ujl9++QUA0LlzZ6SlpcHX1xfDhg1DdXU1tLW14eDgwFcR5bGzs8OuXbsQHh6Oly9fomPHjrC0tMS5c+egrKwMAPDw8MCHDx+wefNm+Pj4oGPHjpgwYYLQ+RYmXxs2bGC6WcvLy2PRokUoLy9nxbNp0yZMnToV33//PTp37oywsDBkZmZ+UboURVHUPwOHtOZIKhRFURRFUdRXVVFRAUVFRZSXl0NBQeFbZ4eiKOpfRZRnKH2lSVEURVEURVEURVHNEKrbdocOHYSaDgQAXr169UUZoiiKoihRzJo1C3/99ZfAbT/++CO2bdv2lXNEURRFUdR/kVAtz1u2bMHmzZuxefNmLF++HABgb2+PgIAABAQEwN7eHgCwYsWKtsvp/4jIyMg2GfX1WwgICEDv3r2Z31OmTGnRADT/RSkpKeBwOHjz5s23zkqranj9NrwG/qlaI5+lpaXgcDjIzs5ulTz923zLcx0UFMQaLGvp0qWQl5fHu3fv+KZL+q8Q5RnyX33eNGfQoEGYP39+k2H+S//mAkBP/yToLD3JWiiKoqjWI1Tl2cPDg1nS0tIQFBSEffv2wcvLC15eXti3bx+CgoKQmpra1vn9IuHh4TAxMYGCggIUFBRgaWmJhIQEVhgdHR1wOBy+JSQkpNn4eX888xZlZWUMGzYMWVlZbXVIzeratSvOnj0LACCE4M8//0T//v3B5XLRvn17WFhYYMuWLU1Oo9FawsLCEBkZ2erxRkVF4bvvvgMg3B9L9X2rCo+VlRUzSFJbO3ToEAYNGgRFRUVwuVyYmJggKCjoq/QS8fHxwblz59o0jfr3rKysLHr16oUdO3a0aZqtadCgQQKfObNmzfrWWRPJ1zjXjVFRUYGenh709PSgoqKCoKAgLFu2DI8fP8aiRYsE7pOamgpbW1soKSlBVlYW+vr68PDwaLU5ltuaKM+Qr/W84VXSeYuqqirGjx+Pe/fufZV0G74cOHz4MGt0cR0dHWzZsoUVxsXFBXfu3GnT/FEURVH/HSJ/85yUlAQHBwe+9Q4ODkwl7Z9KQ0MDISEhyMzMREZGBmxtbTF69Gjk5eWxwgUFBaGsrIy1/Pzzz0Knc/bsWZSVlSEpKQmVlZUYPnz4N3njf/PmTbx+/ZqZf3Ly5MmYP38+Ro8ejeTkZGRnZ2PFihU4evQoTp8+3eJ0Pn78KFQ4RUXFNnnDf/ToUYGjx/6T8UYNFvZziJZatmwZXFxc0LdvXyQkJODWrVvYtGkTcnJysHfv3hbHK2wFg8vlMiPhtiXePXvr1i38+OOPmD59Ot+LsX+y6dOn8z1z1q9f/62zJZKvda6b8+DBA3z8+BEjRoyAuro6ZGVl+cLk5+fDwcEBFhYWuHDhAnJzc/Hrr79CUlLym08NRAjBp0+fmg0nyjPkaz1veAoLC/HkyRMcOHAAeXl5cHJyEliuwh5rSykpKUFeXr7JMDIyMlBRUWmzPAjr3/LShqIo6n8eEZGWlhbZuHEj3/qNGzcSLS0tUaP75jp06EB27NjB/NbW1iabN29uUVwlJSUEAMnKymLWpaWlEQAkMTGRJCcnEwDk9evXzPasrCwCgJSUlBBCCNm9ezdRVFRktvv7+xNTU1Oyc+dOoqmpSeTk5Mjs2bPJp0+fyLp164iqqirp1KkTWb16NV9+goKCiIuLCyGEkLi4OAKAHDlyhC9cXV0defPmDSGEkOvXrxM7OzuirKxMFBQUiLW1NcnMzGSFB0D++OMP4uTkRGRlZYm/vz8hhJDg4GCioqJCuFwumTZtGvH19SWmpqbMfh4eHmT06NHM74SEBDJw4ECiqKhIlJSUyIgRI8jdu3dZaT18+JBMmjSJdOjQgcjKypI+ffqQq1evMtvfv39P5OTkSEFBASGEEBsbG+Lt7c1s19bWJmvWrCFTp04lXC6XaGpqkoiICNax1F9sbGyYbdu3byfdu3cnUlJSxNDQkPz+++/MNt65PnToEBk0aBCRkZEhJiYm5PLly0yY0tJSMnLkSNK+fXsiKytLjI2NycmTJwkhhHUtlJeXE2lpaXLq1CnWsR8+fJhwuVxSVVVFCCHkwYMHZOLEiURRUZF06NCBjBo1irluBLl27RoBQLZs2SJwO+86vHv3Lhk1ahRRUVEhcnJyxMLCgpw5c4YVVltbmwQFBZHJkycTeXl54uHhQQj5fL1qamoSGRkZMmbMGLJx40aB1y+PMNfX69evyYwZM4iKigqRkpIiPXr0IMePH2/0OAXds0pKSmTBggWsOD09PUnHjh2JvLw8GTx4MMnOzubL5549e4i2tjZRUFAgLi4upKKiggnT3PXKuyb27dtHLC0tmbynpKQ0mndC+K/ZhqKiooicnBy5c+cOs2727NnE0NCQuTZ452fSpElEVlaWdO7cmfz222+seDZt2kR69uxJZGVliYaGBpk9ezZ5+/Yts5337ElMTCTdu3cncnJyxN7enjx58oQJk5ycTPr27UtkZWWJoqIisbKyIqWlpawy5KmtrSWBgYGkS5cuRFJSkpiampKEhAS+8mrqHhLk/v37ZNSoUUROTo7Iy8uTiRMnkqdPnzLH0PCeFnSPbN68mejo6DSZTsPj4e2nra3N/OY90wICAphra+bMmaS6uppVDmvXriU6OjpEWlqamJiYkAMHDrDKFAA5deoUMTc3J+3atSMREREEAPNc4wkNDSXdunVj7ce7j4V93vDKqblz/fHjR/Lzzz8z1/uSJUuIu7s76xnekKB/46KjowkAcvv2bYHHmpycLNQz6MOHD2TJkiVEQ0ODSEpKEl1dXbJjxw7mOqq/8J5P9e8tGxsbvnD1y6K+P/74g3Tr1o20a9eOGBgYkD179rC2AyDbt28nY8aMITIyMkRPT48cPXqUFSY3N5c4ODgQOTk5oqKiQn788Ufy4sULZruNjQ2ZO3cu8fb2JsrKymTQoEGkrq6O+Pv7E01NTSIpKUnU1dXJzz//3Gh511deXk4AEM35+4m27wnWQlEURTWN9wwtLy9vNqzILc+BgYHw9fWFk5MTVq9ejdWrV8PJyQlLly5FYGCgqNF9M7W1tYiNjUVVVRUsLS3bLB0ZGRkAX/ZWubi4GAkJCUhMTMS+ffuwc+dOjBgxAo8ePUJqairWrVuH5cuX49q1a6z9jh07htGjRwMAoqOjYWhoyPyuj8PhMN353r59Cw8PD1y6dAlXr16Fvr4+HB0d8fbtW9Y+AQEBGDt2LHJzczFt2jTs378fAQEBWLt2LTIyMqCuro4//vijyeOqqqrCwoULkZGRgXPnzkFMTAxjx45FXV0dAKCyshI2NjZ4/Pgxjh07hpycHCxZsoTZDgDnzp1Dly5d0L1790bT2bRpEywsLJCVlYU5c+Zg9uzZKCwsBABcv34dwP/1Fjh8+DBTXitXrsSaNWtQUFCAtWvXYsWKFYiKimLFvWzZMvj4+CA7OxsGBgZwdXVlWlLmzp2L6upqpmVr3bp14HK5fPlTUFDAyJEjERMTw1ofHR2NMWPGQFZWFh8/foS9vT3k5eVx8eJFpKWlgcvlwsHBodFrKzo6GlwuF3PmzBG4ndcLoLKyEo6Ojjh37hyysrLg4OAAJycnPHjwgBV+48aNMDU1RVZWFlasWIFr167B09MT8+bNQ3Z2NgYPHozVq1c3eh6A5q+vuro6DB8+HGlpafjrr7+Qn5+PkJAQiIuLNxkvT11dHQ4dOoTXr1+z5qidOHEinj9/joSEBGRmZsLc3BxDhgxhdV0vLi7GkSNHcOLECZw4cQKpqamszzWau155Fi9ejEWLFiErKwuWlpZwcnLCy5cvhcq/IO7u7nB0dISbmxs+ffqEkydPYseOHYiOjma1qm7YsIE5P0uXLoW3tzfOnDnDbBcTE8PWrVuRl5eHqKgonD9/HkuWLGGl9e7dO2zcuBF79+7FhQsX8ODBA/j4+AAAPn36hDFjxsDGxgY3b97ElStXMGPGjEZbM8PCwrBp0yZs3LgRN2/ehL29PUaNGoWioiJWuKbuoYbq6uowevRovHr1CqmpqThz5gzu3bsHFxcXAJ+74PJ6QF2/fh1lZWXQ1NTki0dNTQ1lZWW4cOFCc8XfrHPnzqGgoAApKSnYt28fDh8+zPq3MDg4GHv27MG2bduQl5eHBQsW4Mcff+T7zGnp0qUICQlBQUEBJkyYAAsLC0RHR7PCREdH44cffhCYD2GfNzxNnWvg87zY0dHR2L17N9LS0lBRUYEjR46IXD6C/g2sf6wmJiZCPYPc3d2xb98+bN26FQUFBYiIiACXy4WmpiYOHToE4HOLd1lZGcLCwvjycfjwYWhoaLB6lgkSHx8Pb29vLFq0CLdu3cLMmTMxdepUJCcns8IFBgbC2dkZN2/eZO5P3vPkzZs3sLW1hZmZGTIyMpCYmIhnz57B2dmZFUdUVBQkJSWRlpaGbdu24dChQ9i8eTMiIiJQVFSEI0eOoFevXiKXOUVRFNWGWlI7v3r1Kvnhhx+ImZkZMTMzIz/88AOrNfCf7ObNm0ROTo6Ii4sTRUVF5s08j7a2NpGUlCRycnKs5cKFC83G3bDl+fXr12Ts2LGEy+WSp0+ftrjlWVZWltUCZm9vT3R0dEhtbS2zztDQkAQHBzO/Hz16RCQlJZm0jIyMyKhRo4Qspf9TW1tL5OXlWS1/AMj8+fNZ4SwtLcmcOXNY6/r3799ky3NDL168IABIbm4uIYSQiIgIIi8vT16+fNnoPtOnTyc+Pj7Mb0Etzz/++CPzu66ujqioqJDw8HBCiODeAoQQoqurS2JiYljrVq1aRSwtLVn71e+1kJeXx2ot6tWrFwkICBCY74bXQnx8PKuVmdcazWup27t3LzE0NCR1dXVMHNXV1URGRoYkJSUJTGP48OHExMRE4Lbm9OjRg/z666/Mb21tbTJmzBhWGFdXV+Lo6Mha5+Li0mTLc0MNr6+kpCQiJiZGCgsLhc5r/XtWQkKCACBKSkqkqKiIEELIxYsXiYKCAvnw4QNrP11dXaYXgqD7bPHixaR///6NptvweuVdEyEhIUyYjx8/Eg0NDbJu3bpG47GxsSHt2rXje+b89ddfTJhXr14xrcWqqqpkzZo1fGXg4ODAWufi4kKGDx/eaLoHDhwgysrKzG9eq2391vTff/+dqKqqEkIIefnyJQHQaEt6w3PduXNnvnz27duXeU4Icw81dPr0aSIuLk4ePHjAt8/169cJIfzPVEE+ffpEpkyZQgAQNTU1MmbMGPLrr7+y3jgL2/KspKTE3LeEEBIeHk64XC6pra0lHz58ILKysnyt6Z6ensTV1ZUQ8n/Pgoa9gjZv3kx0dXWZ34WFhayyafgMEeV509y5JoQQVVVVsmHDBlaZaWlpidTy/OTJE2JlZUW6dOlCqqurGz1WQeo/g3jH3rA1urF0eQT9e9Cwl0rDf3OtrKzI9OnTWWEmTpzIetYBIMuXL2d+V1ZWEgDM83rVqlVk2LBhrDgePnxIADDPNhsbG2JmZsYKs2nTJmJgYEBqamoEHmd9Hz58IOXl5czCi5+2PFMURYmuTVueAaB///6Ijo7GjRs3cOPGDURHR6N///4tieqrMzQ0RHZ2Nq5du4bZs2fDw8MD+fn5rDCLFy9mjdyanZ0NCwsLodOwsrICl8tFhw4dkJOTg7i4OKiqqrY4zzo6OqzvtlRVVWFsbAwxMTHWuufPnzO/jx07hu+++45pXSSECJXWs2fPMH36dOjr60NRUREKCgqorKzka4VsWB4FBQV810BzLfpFRUVwdXVFt27doKCgAB0dHQBg0srOzoaZmRmUlJQE7k8IwfHjx5v93tnExIT5fw6HAzU1NVZZNVRVVYXi4mJ4enqCy+Uyy+rVq1FcXNxo3Orq6gDAxO3l5YXVq1dj4MCB8Pf3x82bNxtN09HREe3atcOxY8cAfB7kS0FBAXZ2dgCAnJwc3L17F/Ly8kx+lJSU8OHDB7488Qh7zisrK+Hj4wMjIyO0b98eXC4XBQUFbXLOm7u+srOzoaGhAQMDA6HyzsO7Z8+fP4/+/ftj8+bN0NPTA/C57CorK6GsrMw6nyUlJayya3ifqaurs66T5q5XQWUgISEBCwsLFBQUNJl/Nzc3vmdO/eu6Q4cO2LlzJ8LDw6Grq4ulS5fyxdGw7C0tLVnpnj17FkOGDEGXLl0gLy+PyZMn4+XLl6zBAmVlZaGrqyuwDJSUlDBlyhTY29vDyckJYWFhjbbeVVRU4MmTJxg4cCBr/cCBA/nKoql7qKGCggJoamqyWpONjY3Rvn37Zsu4PnFxcezevRuPHj3C+vXr0aVLF6xduxY9evRo9JgaY2pqyuoBYGlpicrKSjx8+BB3797Fu3fvMHToUNa1t2fPHr77tuH9NWnSJJSWluLq1asAPrc6m5ubN9rLRpTnDdD0uS4vL8ezZ8/Qr18/Zru4uDj69OkjRIl8Hl9ETk4OnTt3RlVVFQ4dOsTqCdLwWJt7BmVnZ0NcXJwZv6MtFRQUiHzdysnJQUFBgSm/nJwcJCcns84577zVP+8Ny3PixIl4//49unXrhunTpyM+Pr7RXhjBwcFQVFRkFkE9LCiKoqjWJ9Q8zw0VFxdj9+7duHfvHrZs2QIVFRUkJCRAS0sLPXr0aO08tipJSUnmj+o+ffogPT0dYWFhiIiIYMJ07NiRCdMScXFxMDY2hrKyMmuALF5lt36lRpjBttq1a8f6zeFwBK6r33302LFjrD++DQwMcPv27WbT8vDwwMuXLxEWFgZtbW1ISUnB0tKSr2uwnJxcs3E1x8nJCdra2ti+fTs6d+6Muro69OzZk0mL192vMdevX8enT59gZWXVZLjmyqqhyspKAMD27dv5KocNuw/Xj5vXfZUX908//QR7e3ucPHkSp0+fRnBwMDZt2iRw8DlJSUlMmDABMTExmDRpEmJiYuDi4gIJCQkmT3369OHrxgkAnTp1EngcBgYGuHTpEj5+/MhXBvX5+PjgzJkz2LhxI/T09CAjI4MJEya0yTlv7vpq7pw3hnfP6unp4cCBA+jVqxcsLCxgbGyMyspKqKurIyUlhW+/+vdnc9dJc9frl1BUVGz2mXPhwgWIi4ujrKwMVVVVzQ6EVF9paSlGjhyJ2bNnY82aNVBSUsKlS5fg6emJmpoapvInqAzqP692794NLy8vJCYmIi4uDsuXL8eZM2cwYMAAEY6Wral7qK116dIFkydPxuTJk7Fq1SoYGBhg27ZtCAwMhJiYGN8LKGEHR+ThPUtOnjzJN2WWlJQU63fD+0tNTQ22traIiYnBgAEDEBMTg9mzZzealijPG6D5c/0lLl68CAUFBaioqAi8Thsea3PPoJY+F9pSU8+LyspKODk5Yd26dXz78V4QAfzloKmpicLCQpw9exZnzpzBnDlzsGHDBqSmpvKl5+fnh4ULFzK/KyoqaAWaoijqKxC55Tk1NRW9evXCtWvXcOjQIeaPg5ycHPj7+7d6BttaXV0dqqurWzVOTU1N6Orq8o0szavk1G/ZaIspkiorK5GcnMz6vvmHH37AnTt3cPToUb7whBCUl5cDANLS0uDl5QVHR0f06NEDUlJS+Pvvv5tN08jIiO+ba16LiSAvX75EYWEhli9fjiFDhsDIyAivX79mhTExMUF2dnajUyodPXoUI0aMEPp7WEF4rSH1R4JVVVVF586dce/ePaZCxlu6du0qUvyampqYNWsWDh8+jEWLFmH79u2NhnVzc0NiYiLy8vJw/vx5uLm5MdvMzc1RVFTEmpKHtzQ2/cwPP/yAysrKRr89540An5aWhilTpmDs2LHo1asX1NTUUFpa2uyxiXrOeWk1dX2ZmJjg0aNHXzR1jKamJlxcXODn5wfgc9k9ffoUEhISfGXXsWNHoeIU5nrlqV8Gnz59QmZmJoyMjFp8PABw+fJlrFu3DsePHweXy8W8efOaTJf3m5duZmYm6urqsGnTJgwYMAAGBgZ48uRJi/JiZmYGPz8/XL58GT179uT7Vh/4/B1/586dkZaWxlqflpYGY2PjFqULfL7mHj58iIcPHzLr8vPz8ebNmy+KF/jcuq+uro6qqioAn5/XT58+ZVUoBT2vc3Jy8P79e+b31atXmW9xjY2NISUlhQcPHvBde8JUdNzc3BAXF4crV67g3r17mDRpUpPhRXneNEVRURGqqqpIT09n1tXW1uLGjRtC7d+1a1fo6uoK/YKnuWdQr169UFdX1+h0mIKe442Fay6MkZHRF1+35ubmyMvLg46ODt95b+4lpIyMDJycnLB161akpKTgypUryM3N5QsnJSXFTLvJWyiKoqi2J3LleenSpVi9ejXOnDnD6oZla2vb7B/O35qfnx8uXLiA0tJS5Obmws/PDykpKaxKCvB5UKOnT5+yloqKii9On/cHU0BAAIqKinDy5Els2rTpi+NtKDExEQYGBky3UgBwdnaGi4sLXF1dmUG97t+/jxMnTsDOzo4ZDEVfXx979+5FQUEBrl27Bjc3N6He+nt7e2PXrl3YvXs37ty5A39/f74pwOrr0KEDlJWV8eeff+Lu3bs4f/486y06ALi6ukJNTQ1jxoxBWloa7t27h0OHDuHKlSsA+FvXW0JFRQUyMjLMgC68lwiBgYEIDg7G1q1bcefOHeTm5mL37t0IDQ0VOu758+cjKSkJJSUluHHjBpKTk5usRFlbW0NNTQ1ubm7o2rUrq9Xbzc0NHTt2xOjRo3Hx4kWUlJQgJSUFXl5eePTokcD4+vfvjyVLlmDRokVYsmQJrly5gvv37+PcuXOYOHEiM/iZvr4+Dh8+jOzsbOTk5OCHH34QquWP1wK5ceNGFBUV4bfffkNiYmKT+zR3fdnY2MDa2hrjx4/HmTNnUFJSwgyWJwpvb28cP34cGRkZsLOzg6WlJcaMGYPTp0+jtLQUly9fxrJly5CRkSFUfMJcrzy///474uPjcfv2bcydOxevX7/GtGnTmoz/3bt3fM8cXuX87du3mDx5Mry8vDB8+HBER0cjLi4OBw8eZMWRlpaG9evX486dO/j9999x4MABeHt7A/j87Pn48SN+/fVX3Lt3D3v37sW2bduEOnaekpIS+Pn5MdfR6dOnUVRU1Og1vXjxYqxbtw5xcXEoLCzE0qVLkZ2dzeSpJezs7NCrVy+4ubnhxo0buH79Otzd3WFjYyPSpzURERGYPXs2Tp8+jeLiYuTl5cHX15eZVgn4PP/2ixcvsH79ehQXF+P3338XOP1ZTU0NPD09kZ+fj1OnTsHf3x/z5s2DmJgY5OXl4ePjgwULFiAqKgrFxcW4ceMGfv31V77BBwUZN24c3r59i9mzZ2Pw4MHo3Llzo2FFfd405+eff0ZwcDCOHj2KwsJCeHt74/Xr120y3VVzzyAdHR14eHhg2rRpOHLkCPP8279/PwBAW1sbHA4HJ06cwIsXL5iX+g3p6OjgwoULePz4caMvhRcvXozIyEiEh4ejqKgIoaGhOHz4MGswtebMnTsXr169gqurK9LT01FcXIykpCRMnTq1ycp7ZGQkdu7ciVu3buHevXv466+/ICMjA21tbaHTpiiKotqWyJXn3NxcjB07lm+9ioqKUC2U39Lz58/h7u4OQ0NDDBkyBOnp6UhKSsLQoUNZ4VauXAl1dXXW0nBU2pZo164d9u3bh9u3b8PExATr1q1rdnTilhA07zGHw0FMTAxCQ0Nx5MgR2NjYwMTEBAEBARg9ejTs7e0BADt37sTr169hbm7O/MEuzByYLi4uWLFiBZYsWYI+ffrg/v37TXYxFBMTQ2xsLDIzM9GzZ08sWLAAGzZsYIWRlJTE6dOnoaKiAkdHR/Tq1YsZebm4uBh3795l8t1SEhIS2Lp1KyIiItC5c2emtf6nn37Cjh07sHv3bvTq1Qs2NjaIjIwUqeW5trYWc+fOhZGRERwcHGBgYNDkCOQcDgeurq7Iycnhe6EjKyuLCxcuQEtLC+PGjYORkRE8PT3x4cOHJlsc1q1bh5iYGFy7dg329vbo0aMHFi5cCBMTE3h4eAAAQkND0aFDB1hZWcHJyQn29vYwNzdv9vgGDBiA7du3IywsDKampjh9+jSWL1/e5D7CXF+HDh1C37594erqCmNjYyxZskTkuXeNjY0xbNgwrFy5EhwOB6dOnYK1tTWmTp0KAwMDTJo0Cffv3xd6LAJhrleekJAQhISEwNTUFJcuXcKxY8eabeHevn073zPH1dUVwOcXAXJycli7di2Az61wa9euxcyZM/H48WMmjkWLFiEjIwNmZmZYvXo1QkNDmfvD1NQUoaGhWLduHXr27Ino6GgEBwcLdew8srKyuH37NsaPHw8DAwPMmDEDc+fOxcyZMwWG9/LywsKFC7Fo0SL06tULiYmJOHbsGPT19UVKtz4Oh4OjR4+iQ4cOsLa2hp2dHbp164a4uDiR4unXrx8qKysxa9Ys9OjRAzY2Nrh69SrzbAQ+t0D+8ccf+P3332Fqaorr168LrEANGTIE+vr6sLa2houLC0aNGoWAgABm+6pVq7BixQoEBwczz4KTJ08K9SyRl5eHk5OTwGdCQ6I+b5rj6+sLV1dXuLu7w9LSElwuF/b29pCWlm5xnI0R5hkUHh6OCRMmYM6cOejevTumT5/O9BLo0qULAgMDsXTpUqiqqgrsmQF8ng++tLQUurq6jX7uMmbMGISFhWHjxo3o0aMHIiIisHv3bgwaNEjo4+H1uqitrcWwYcPQq1cvzJ8/H+3bt2eNVdJQ+/btsX37dgwcOBAmJiY4e/Ysjh8//o+YP52iKIr6jENE/MhJQ0MD+/fvh5WVFeTl5ZGTk4Nu3bohPj4ePj4+jQ5eRH0dnz59gqqqKhISEliDvfzXhIaG4uzZszh16tS3zgpFfXM6OjqYP38+5s+f/62z8j9lypQpePPmTYumcPq3qaurg5GREZydnbFq1apvnR2qgYqKCigqKqK8vJx24aYoihKRKM9QkVueJ02aBF9fXzx9+pQZICMtLQ0+Pj5wd3dvcaap1vHq1SssWLAAffv2/dZZaVMaGhrMN60URVFU67p//z62b9/OfLYye/ZslJSUNDrPNEVRFEX9LxC58rx27Vp0794dmpqaqKyshLGxMaytrWFlZdVsl81/u1mzZrGmnqi/zJo161tnD8Dn7vPLly9vk+/S/kmcnZ3x/ffff+tsUBRF/SeJiYkhMjISffv2xcCBA5Gbm4uzZ89+8eB3FEVRFPVvJnK3bZ6HDx8iNzcXlZWVMDMz+6Lv2P4tnj9/3ujAYbxpOSiKoiiKor4mXpdDzfn7ISYl22TY0pARXylXFEVR/w5t2m07KCgI7969g6amJhwdHeHs7Ax9fX28f/8eQUFBLc70v4GgaYJ4C604UxRF/feFh4fDxMSEmR7I0tKSbxRuHR0dcDgc1qKhoSF0GpcvX4ajoyM6dOgAaWlp9OrVC6GhoayB80pLS8HhcAROnzVo0CDW9+/18yMjIwMdHR04Ozvj/PnzQuUnLy8Pzs7O6NSpE6SkpGBgYICVK1fi3bt3AICUlBS+4224pKSkIDIykvktJiYGDQ0NTJ06Fc+fP28y/adPn+Lnn39Gt27dICUlBU1NTTg5OeHcuXNC5Z+iKIqiWovIlefAwECB00C8e/cOgYGBrZIpiqIoivon0tDQQEhICDIzM5GRkQFbW1uMHj2ab2q+oKAglJWVMUtWVpZQ8cfHx8PGxgYaGhpITk7G7du34e3tjdWrV2PSpEloYWcxJj+FhYXYs2cP2rdvDzs7O6xZs6bJ/a5evYr+/fujpqYGJ0+exJ07d7BmzRpERkZi6NChqKmpgZWVFetYnZ2d4eDgwFpnZWUF4HMvrbKyMjx69Ajbt29HQkICJk+e3Gj6paWl6NOnD86fP48NGzYgNzcXiYmJGDx4MObOnduismgtNTU13zR9iqIo6usTufJMCBH4PW1OTg6UlJRaJVMURVEU9U/k5OQER0dH6Ovrw8DAAGvWrAGXy8XVq1dZ4eTl5aGmpsYsjU2NVF9VVRWmT5+OUaNG4c8//0Tv3r2ho6ODn376CVFRUTh48CAzt7GoePnR0tKCtbU1/vzzT6xYsQIrV65EYWGhwH0IIfD09ISRkREOHz6Mfv36QVtbGxMnTsTx48dx5coVbN68GZKSkqxjlZGRgZSUFGudpKQkgM/TjampqaFz584YPnw4vLy8cPbsWbx//15gHubMmQMOh4Pr168z06TxptyrX+YPHjzA6NGjweVyoaCgAGdnZzx79gwAcOfOHXA4HNy+fZsV9+bNm6Grq8v8vnXrFoYPHw4ulwtVVVVMnjyZNQXnoEGDMG/ePMyfPx8dO3ZkpoILDQ1Fr169ICcnB01NTcyZM4evkWH79u3Q1NSErKwsxo4di9DQULRv354V5ujRozA3N4e0tDS6deuGwMBAfPr0qanTSlEURX1lQleeO3ToACUlJXA4HBgYGEBJSYlZFBUVMXToUDg7O7dlXimKoijqH6O2thaxsbGoqqqCpaXlF8d3+vRpvHz5UuB80k5OTjAwMMC+ffu+OB0eb29vEEJw9OhRgduzs7ORn5+PhQsX8s1PbGpqCjs7uy/Oj4yMDOrq6gRWEl+9eoXExETMnTsXcnJyfNt5lc+6ujqMHj0ar169QmpqKs6cOYN79+7BxcUFAGBgYAALCwtER0ez9o+OjmZGD3/z5g1sbW1hZmaGjIwMJCYm4tmzZ3x/10RFRUFSUhJpaWnYtm0bgM+Dq23duhV5eXmIiorC+fPnsWTJEmaftLQ0zJo1C97e3sjOzsbQoUP5WvwvXrwId3d3eHt7Iz8/HxEREYiMjGy2ZwBFURT1dUkIG3DLli0ghGDatGkIDAyEoqIis01SUhI6Ojqt8scDRVEURf2T5ebmwtLSEh8+fACXy0V8fDyMjY1ZYXx9fVkzUKxduxZeXl5Nxnvnzh0AaHRE6+7duzNhWoOSkhJUVFRQWlraovwYGRnh0qVLLU6/qKgI27Ztg4WFBeTl5fm23717F4QQdO/evcl4zp07h9zcXJSUlEBTUxMAsGfPHvTo0QPp6eno27cv3Nzc8NtvvzFzVN+5cweZmZn466+/AAC//fYbzMzMsHbtWibeXbt2QVNTE3fu3IGBgQEAQF9fH+vXr2el3/D78tWrV2PWrFn4448/AAC//vorhg8fzrwUMTAwwOXLl3HixAlmv8DAQCxduhQeHh4AgG7dumHVqlVYsmQJ/P39+Y65uroa1dXVzO/GBjOlKIqiWpfQlWcPDw98+vQJHA4Htra2zD9QFEVRFPW/xNDQENnZ2SgvL8fBgwfh4eGB1NRUVgV68eLFmDJlCvO7Y8eOQsff0u+aW6KxT7Eahmkt5eXl4HK5qKurw4cPH/Ddd99hx44dX5RuQUEBNDU1WX+XGBsbo3379igoKEDfvn0xadIk+Pj44OrVqxgwYACio6Nhbm7OVMxzcnKQnJwMLpfLF39xcTFTee7Tpw/f9rNnzyI4OBi3b99GRUUFPn36hA8fPuDdu3eQlZVFYWEhxo4dy9qnX79+rMpzTk4O0tLSWC3NtbW1rHjqCw4OpuPMUBRFfQNCV54BQEJCArNnz0ZBQUFb5YeiKIqi/tEkJSWhp6cH4HNlKj09HWFhYYiIiGDCdOzYkQkjLF4FraCggBlgq76CggKmgs6bSqO8vJwv3Js3b1i9wxrz8uVLvHjxAl27dm02P2ZmZgLzwwsjLHl5edy4cQNiYmJQV1eHjIxMo2H19fUFfqvcEmpqarC1tUVMTAwGDBiAmJgYzJ49m9leWVkJJycnrFu3jm9fdXV15v8bdh8vLS3FyJEjMXv2bKxZswZKSkq4dOkSPD09UVNTw1fpbUxlZSUCAwMxbtw4vm3S0tJ86/z8/LBw4ULmd0VFBW3UoCiK+gpEHjCsX79+Qo8aSlEURVH/dXV1dawutC01bNgwKCkpYdOmTXzbjh07hqKiIri6ugL43OW6Y8eOyMzMZIWrqKjA3bt3harUhoWFQUxMDGPGjBG4vXfv3ujevTs2b96Muro61racnBycPXuWyY+wxMTEoKenh27dujVZcQY+H6O9vT1+//13VFVV8W1/8+YNgM/dxx8+fIiHDx8y2/Lz8/HmzRtWbwA3NzfExcXhypUruHfvHiZNmsRsMzc3R15eHnR0dPimohT0vTVPZmYm6urqsGnTJgwYMAAGBgZ48uQJK4yhoSHS09NZ6xr+Njc3R2FhocCpMBt+bw4AUlJSzHRpvIWiKIpqeyJXnufMmYNFixbht99+w5UrV3Dz5k3WQlEURVH/VX5+frhw4QJKS0uRm5sLPz8/pKSkwM3N7YvjlpOTQ0REBI4ePYoZM2bg5s2bKC0txc6dOzFlyhRMmDCBNYDVwoULsXbtWkRHR6O4uBjXr1+Hm5sbOnXqxNeC+fbtWzx9+hQPHz7EhQsXMGPGDKxevRpr1qxptIWcw+Fg586dyM/Px/jx43H9+nU8ePAABw4cgJOTEywtLVnf+7aF33//HbW1tejXrx8OHTqEoqIiFBQUYOvWrcw4K3Z2dujVqxfc3Nxw48YNXL9+He7u7rCxsYGFhQUT17hx4/D27VvMnj0bgwcPRufOnZltc+fOxatXr+Dq6or09HQUFxcjKSkJU6dOZc2v3ZCenh4+fvyIX3/9Fffu3cPevXuZgcR4fv75Z5w6dQqhoaEoKipCREQEEhISWN3lV65ciT179iAwMBB5eXkoKChAbGws67t5iqIo6tsTufI8adIklJSUwMvLCwMHDkTv3r1hZmbG/JeiKIqi/queP38Od3d3GBoaYsiQIUhPT0dSUhKGDh3aKvFPmDABycnJePDgAb7//nsYGhpi8+bNWLZsGWJjY1kVLt5gUuvWrYOJiQnGjx8POTk5JCcn87Xqrly5Eurq6tDT08PkyZNRXl6Oc+fOwdfXt8n8WFlZ4erVqxAXF8fw4cOhp6cHPz8/eHh44MyZM5CSkmqV425Mt27dcOPGDQwePBiLFi1Cz549MXToUJw7dw7h4eEAPlfyjx49ig4dOsDa2hp2dnbo1q0b4uLiWHHJy8vDyckJOTk5fC87OnfujLS0NNTW1mLYsGHo1asX5s+fj/bt2wts+eUxNTVFaGgo1q1bh549eyI6OhrBwcGsMAMHDsS2bdsQGhoKU1NTJCYmYsGCBazu2Pb29jhx4gROnz6Nvn37YsCAAdi8eTO0tbW/tAgpiqKoVsQhIo4Ecv/+/Sa30wc9RVEURVFU46ZPn47bt2/j4sWLrRJfRUUFFBUVUV5eTrtwUxRFiUiUZ6hIA4YBtHJMURRFURQlio0bN2Lo0KGQk5NDQkICoqKimKmsKIqiqH8PkSvPwOdpG7Zs2cKMum1sbAxvb2/o6uq2auYoiqIo6r8iOjoaM2fOFLhNW1sbeXl5XzlH1Ndy/fp1rF+/Hm/fvkW3bt2wdetW/PTTT986WxRFUZSIRO62nZSUhFGjRqF3794YOHAgACAtLQ05OTk4fvx4q333RVEURVH/JW/fvsWzZ88EbmvXrh3t2UW1GK/Loeb8/RCTEm56LIqiqP+S0pARLd5XlG7bIg8YtnTpUixYsADXrl1DaGgoQkNDce3aNcyfP7/ZgUcoiqIo6n+VvLy8wKmI9PT0aMW5GeHh4TAxMWGmZbK0tERCQgIrTFZWFlxcXKCurg4pKSloa2tj5MiROH78OIRpJygtLQWHw4G4uDgeP37M2lZWVgYJCQlwOByUlpYy6+Pj4zFgwAAoKipCXl4ePXr0YI1AXltbi5CQEHTv3h0yMjJQUlJC//79sWPHDibMlClTwOFwwOFwmDnEg4KC8OnTp5YVFkVRFNVmRK48FxQUwNPTk2/9tGnTkJ+f3yqZoiiKoiiK4tHQ0EBISAgyMzORkZEBW1tbjB49munqfvToUQwYMACVlZWIiopCQUEBEhMTMXbsWCxfvhzl5eVCp9WlSxfs2bOHtS4qKgpdunRhrTt37hxcXFyYabwyMzOxZs0afPz4kQkTGBiIzZs3Y9WqVcjPz0dycjJmzJjBzFHN4+DggLKyMhQVFWHRokUICAjAhg0bRCwliqIoqq2J3G1bU1MToaGhmDhxImv9/v374ePjgwcPHrRqBimKoiiKohpSUlLChg0bMGnSJGhra8Pa2hqHDx8WGJYQwprmS5DS0lJ07doVy5cvR1xcHO7cucNsMzQ0hIuLC1atWoWSkhLo6Ohg/vz5yMnJQXJycqNx9u7dG2PHjoW/v3+jYaZMmYI3b97gyJEjzLphw4bh7du3uHLlSpN55qHdtimK+l/3j+22PX36dMyYMQPr1q3DxYsXcfHiRYSEhGDmzJmYPn16izNNURRFURTVnNraWsTGxqKqqgqWlpY4ffo0Xr58iSVLljS6T3MV5/pGjRqF169f49KlSwCAS5cu4fXr13BycmKFU1NTQ15eHm7dutVoXGpqajh//jxevHghdPoAICMjg5qaGpH2oSiKotqeyJXnFStWYOXKlfj1119hY2MDGxsb/PbbbwgICMDy5cvbIo8URVEURf2Py83NBZfLhZSUFGbNmoX4+HgYGxszLcSGhoZM2PT0dHC5XGY5ceKE0Om0a9cOP/74I3bt2gUA2LVrF3788Ue0a9eOFe7nn39G37590atXL+jo6GDSpEnYtWsXqqurmTChoaF48eIF1NTUYGJiglmzZvF9q10fIQRnz55FUlISbG1tGw1XXV2NiooK1kJRFEW1PZErzxwOBwsWLMCjR49QXl6O8vJyPHr0CN7e3iK92aUoiqIoihKWoaEhsrOzce3aNcyePRseHh6NjrViYmKC7OxsZGdno6qqSuTBt6ZNm4YDBw7g6dOnOHDgAKZNm8YXRk5ODidPnsTdu3exfPlycLlcLFq0CP369cO7d+8AfJ7K89atW7h69SqmTZuG58+fw8nJiW+aqhMnToDL5UJaWhrDhw+Hi4sLAgICGs1fcHAwFBUVmUVTU1Ok46MoiqJaRuRvnhtKTU3Fu3fvMGDAAHTo0KG18kVRFEVRFNUoOzs76Orqwt7eHuPHj8eVK1cwYMAAvnAcDgfx8fEYM2ZMk/HxvnnOyspC79690bdvX3C5XFRVVeH69evIzs6GmZkZ882zICUlJTAwMMCff/6JqVOnCgzz119/YfLkybh37x66du2KKVOm4PHjxwgPD4ekpCQ6d+4MCQmJJvNaXV3NauGuqKiApqYm/eaZoqj/Wf+4b57XrVuHFStWML8JIXBwcMDgwYMxYsQIGBkZMaNeUhRFURRFtaW6ujpUV1dj2LBhUFJSwrp161o1/mnTpiElJUVgq3NjdHR0ICsri6qqqkbDGBsbAwArjJycHPT09KClpdVsxRkApKSkmGm7eAtFURTV9pp/Qv9/cXFxrHmcDx48iAsXLuDixYswMjKCu7s7AgMDsX///jbJKEVRFEVR/5v8/PwwfPhwaGlp4e3bt4iJiUFKSgqSkpLA5XKxY8cOuLi4YMSIEfDy8oK+vj4qKyuRmJgIABAXFxc5zenTp2PixIlo3769wO0BAQF49+4dHB0doa2tjTdv3mDr1q34+PEjhg4dCgCYMGECBg4cCCsrK6ipqaGkpAR+fn4wMDBA9+7dW1weFEVR1LchdMtzSUkJTExMmN+nTp1i/lFQUlLC8uXLhZ5SgaIoiqIoSljPnz+Hu7s7DA0NMWTIEKSnpyMpKYmppI4dOxaXL1+GrKwsE87W1hbnz59HbGwsRo4cKXKaEhIS6NixY6MtwTY2Nrh37x7c3d3RvXt3DB8+HE+fPsXp06eZwcvs7e1x/PhxODk5wcDAAB4eHujevTtOnz4tVAszRVEU9c8i9DfP8vLyyMnJQbdu3QAA3bt3x/z58zFr1iwAwIMHD2BoaIj379+3XW4piqIoiqIoFlG+16MoiqLY2uSbZ11dXVy4cAHA54rynTt3YG1tzWx/9OgRlJWVW5hliqIoiqIoiqIoivrnErryPHfuXMybNw+enp4YPnw4LC0tmUEvAOD8+fMwMzNrk0xSFEVRFEV9iVmzZrHmfq6/8HrRURRFUVRThP7gZvr06RAXF8fx48dhbW0Nf39/1vYnT56INCIlRVEURVH/W1JSUjB48GC8fv260YG42kpQUBB8fHwEbmvtrs7CTo/V2nr6J7XaVFVfMu0LRVHUf5XQLc/A52kb4uPjER4eDjU1Nda2P/74A2PHjm3VzFEURf1XhYeHw8TEhJlmxtLSEgkJCawwOjo62LJlC9++AQEB6N27t1DpBAQEgMPhgMPhQEJCAjo6OliwYAEqKyu/KP/C5qF++hwOB4qKivj++++Rmpr6TfL9T5CSkgIOh4M3b94IFY63qKqqYvz48bh3797XyegXGjRoEObPn89aZ2VlhbKyMigqKrZJmpmZmeBwOLh69SrfNhUVFcycORNLliyBnp4ea1FRUWnVfJSVlWH48OGtGidFURT17QlVeW5qvsLWCE9RFPW/RkNDAyEhIcjMzERGRgZsbW0xevRo5OXltXpaPXr0QFlZGUpLS7Fu3Tr8+eefWLRoUYviIoTg06dPLUq/rKwMV65cgb6+PkaOHIny8vKvlu9/s8LCQjx58gQHDhxAXl4enJycUFtbyxeuJefma5OUlISamho4HE6bxN+nTx+Ymppi165dfNtKS0uRnJwMT0/PNkm7PjU1NUhJSbV5OhRFUdTXJVTlWU9PDyEhISgrK2s0DCEEZ86cwfDhw7F169ZWyyBFUdR/kZOTExwdHaGvrw8DAwOsWbMGXC5XYIvZl5KQkICamho0NDTg4uICNzc3HDt2DACwd+9eWFhYQF5eHmpqavjhhx/w/PlzZl9e62dCQgL69OkDKSkp/PXXXwgMDEROTg7TKhoZGdls+mpqajA2NkZQUBAqKytx586dNsk3IQR6enrYuHEjK77s7GxwOBzcvXsXwOeutRERERg5ciRkZWVhZGSEK1eu4O7duxg0aBDk5ORgZWWF4uJiVjxHjx6Fubk5pKWl0a1bNwQGBrIqrRwOBzt27MDYsWMhKysLfX19Jt+lpaUYPHgwAKBDhw7gcDiYMmVKk+WgoqICdXV1WFtbY+XKlcjPz8fdu3cFnptLly6hrq4OwcHB6Nq1K2RkZGBqaoqDBw8CAOrq6qChoYHw8HBWGllZWRATE8P9+/cBAG/evMFPP/2ETp06QUFBAba2tsjJyWHC83oe7N27Fzo6OlBUVMSkSZPw9u1bAMCUKVOQmpqKsLAw5hopLS1ltbpXVFRARkaGr8dFfHw85OXl8e7dOwDAw4cP4ezsjPbt20NJSQmjR49GaWlpo+Xl6emJuLg4Zn+eyMhIqKurw8HBodnrHgDy8vIwcuRIKCgoQF5eHt9//z3rWti1axd69OgBKSkpqKurY968ecw2DoeDI0eOAPh8zjkcDg4fPozBgwdDVlYWpqamfNN7Xrp0Cd9//z1kZGSgqakJLy8v2hhBURT1DyNU5TklJQXp6eno2rUr+vfvj7lz52LNmjXYtGkTli9fjnHjxqFz586YNm0anJycsGTJkrbON0VR1H9GbW0tYmNjUVVVBUtLyzZPT0ZGBjU1NQCAjx8/YtWqVcjJycGRI0dQWloqsDK3dOlShISEoKCgAEOHDsWiRYtYLcouLi5CpV1dXY3du3ejffv2zFy4rZ1vDoeDadOmYffu3az9d+/eDWtra+jp6THrVq1aBXd3d2RnZ6N79+744YcfMHPmTPj5+SEjIwOEEFal6OLFi3B3d4e3tzfy8/MRERGByMhIrFmzhpVWYGAgnJ2dcfPmTTg6OsLNzQ2vXr2CpqYmDh06BOBzi3JZWRnCwsJEKgMATDkA7HNjYmKC4OBg7NmzB9u2bUNeXh4WLFiAH3/8EampqRATE4OrqytiYmJY8UZHR2PgwIHQ1tYGAEycOBHPnz9HQkICMjMzYW5ujiFDhuDVq1fMPsXFxThy5AhOnDiBEydOIDU1FSEhIQCAsLAwWFpaYvr06cw1oqmpyUpTQUEBI0eOFJiXMWPGQFZWFh8/foS9vT3k5eVx8eJFpKWlgcvlwsHBgVUG9bm5uaG6upp5YQB8fqESFRWFKVOmQFxcvNnr/vHjx7C2toaUlBTOnz+PzMxMTJs2jXlJEh4ejrlz52LGjBnIzc3FsWPHWNeVIMuWLYOPjw+ys7NhYGAAV1dXJr7i4mI4ODhg/PjxuHnzJuLi4nDp0iXWtUdRFEX9AxAR3L9/n2zcuJGMHj2a9O7dmxgaGpKBAweSefPmkePHj5NPnz6JEh1FUdT/tJs3bxI5OTkiLi5OFBUVycmTJ1nbtbW1iaSkJJGTk2Mt7dq1I6ampkKl4e/vzwqbkZFBOnbsSCZMmCAwfHp6OgFA3r59SwghJDk5mQAgR44caTLeptIXExNj8s7hcIiCggJJSEho03w/fvyYiIuLk2vXrhFCCKmpqSEdO3YkkZGRzD4AyPLly5nfV65cIQDIzp07mXX79u0j0tLSzO8hQ4aQtWvXstLeu3cvUVdXbzTeyspKAoA5Zl6Zvn79uskyaBjuyZMnxMrKinTp0oVUV1cLPDcfPnwgsrKy5PLly6y4PD09iaurKyGEkKysLMLhcMj9+/cJIYTU1taSLl26kPDwcEIIIRcvXiQKCgrkw4cPrDh0dXVJREQEIeTz+ZGVlSUVFRXM9sWLF5P+/fszv21sbIi3t3eTxxQfH0+4XC6pqqoihBBSXl5OpKWlmbLau3cvMTQ0JHV1dUwc1dXVREZGhiQlJTVadpMmTSI2NjbM73PnzhEApKioSGD4htePn58f6dq1K6mpqREYvnPnzmTZsmWNpg+AxMfHE0IIKSkpIQDIjh07mO15eXkEACkoKCCEfD4/M2bMYMVx8eJFIiYmRt6/f88X/4cPH0h5eTmzPHz4kAAgmvP3E23fE62yUBRF/a8oLy8nAEh5eXmzYYUebRsAtLS0sGjRov/Jb84oiqJam6GhIbKzs1FeXo6DBw/Cw8MDqamprGkAFy9ezNcSvHXrVly4cEHodHJzc8HlclFbW4uamhqMGDECv/32G4DPAywFBAQgJycHr1+/Rl1dHQDgwYMHrHxYWFh80XHyui2/ffsWcXFxmDhxIpKTk5uM90vy3blzZ4wYMQK7du1Cv379cPz4cVRXV2PixImsNExMTJj/V1VVBQD06tWLte7Dhw+oqKiAgoICcnJykJaWxmpprq2txYcPH/Du3TvIysryxSsnJwcFBQW+bsHC0tDQACEE7969g6mpKQ4dOgRJSUlme/0yvHv3Lt69e4ehQ4ey4qipqWGmk+zduzeMjIwQExODpUuXIjU1Fc+fP2fKJicnB5WVlVBWVmbF8f79e1a3ZR0dHcjLyzO/1dXVRT5GR0dHtGvXDseOHcOkSZNw6NAhKCgowM7OjsnL3bt3WekAwIcPH/i609c3bdo02Nvbo7i4GLq6uti1axdsbGyY1uHmrp/s7Gx8//33aNeuHV/cz58/x5MnTzBkyBCRjrX+NaGurs7E1b17d+Tk5ODmzZuIjo5mwhBCUFdXh5KSEhgZGbHiCg4ORmBgoEjpUxRFUV9OpMozRVEU1XokJSWZP+b79OmD9PR0hIWFISIiggnTsWNHvu6gSkpKIqXDq7xKSEigc+fOTMWrqqoK9vb2sLe3R3R0NDp16oQHDx7A3t6er0usnJxcSw4RAPs4AcDMzAxHjhzBli1b8Ndff7VZvn/66SdMnjwZmzdvxu7du+Hi4sJUbnnqV454g1gJWserXFVWViIwMBDjxo3jy6+0tLTAeHnx8OIQ1cWLF6GgoAAVFRW+SiTAPje80chPnjyJLl26sMLVH8DKzc2NqTzHxMTAwcGBqSxXVlZCXV0dKSkpfGnVn16qNY5RUlISEyZMQExMDCZNmoSYmBi4uLhAQkKCyUufPn1YlUqeTp06NRrvkCFDoKWlhcjISCxevBiHDx9m7ithrh9e93hBmtrWlOauq5kzZ8LLy4tvPy0tLb51fn5+WLhwIfO7oqKCr1s8RVEU1fpo5ZmiKOofoq6uDtXV1a0eb8PKK8/t27fx8uVLhISEMH94Z2RkCB2noBGfhSUuLo737983m8aX5NvR0RFycnIIDw9HYmKiSK31jTE3N0dhYWGz37c2hfcSQNjy69q1q9BzIhsbG0NKSgoPHjyAjY1No+F++OEHLF++HJmZmTh48CC2bdvGbDM3N8fTp0+ZKcJaSthrxM3NDUOHDkVeXh7Onz+P1atXs/ISFxcHFRUVkeZiFhMTw9SpU7Fz50506dKFqaQDwl0/JiYmiIqKwsePH/leEsjLy0NHRwfnzp1jBn/7Uubm5sjPzxf6upKSkqKjeVMURX0DIs3zTFEURbUOPz8/XLhwAaWlpcjNzYWfnx9SUlLg5ub21fKgpaUFSUlJ/Prrr7h37x6OHTuGVatWCbWvjo4OSkpKkJ2djb///rvJSv+nT5/w9OlTPH36FEVFRVi9ejXy8/MxevToNs23uLg4pkyZAj8/P+jr67fKYGwrV67Enj17EBgYiLy8PBQUFCA2NhbLly8XOg5tbW1wOBycOHECL168aNW5q+Xl5eHj44MFCxYgKioKxcXFuHHjBn799VdERUUx4XR0dGBlZQVPT0/U1tZi1KhRzDY7OztYWlpizJgxOH36NEpLS3H58mUsW7ZM6JcrvDSuXbuG0tJS/P333422SltbW0NNTQ1ubm7MwKQ8bm5u6NixI0aPHo2LFy+ipKQEKSkp8PLywqNHj5pMf+rUqXj8+DF++eUXuLq6Mi3Gwlw/8+bNQ0VFBSZNmoSMjAwUFRVh7969KCwsBPB5tPFNmzZh69atKCoqYsq4pXx9fXH58mXMmzcP2dnZKCoqwtGjR+mAYRRFUf8wtPJMURT1DTx//hzu7u4wNDTEkCFDkJ6ejqSkJL5vVdtSp06dEBkZiQMHDsDY2BghISF80zs1Zvz48XBwcMDgwYPRqVMn7Nu3r9GweXl5UFdXh7q6Onr37o39+/cjPDwc7u7ubZ5vT09P1NTUYOrUqS1KqyF7e3ucOHECp0+fRt++fTFgwABs3ryZGaVaGF26dEFgYCCWLl0KVVXVVq8grVq1CitWrEBwcDCMjIzg4OCAkydPomvXrqxwbm5uyMnJwdixY1ldkTkcDk6dOgVra2tMnToVBgYGmDRpEu7fv898Fy4MHx8fiIuLw9jYmOkaLQiHw4GrqytycnL4Xh7JysriwoUL0NLSwrhx42BkZARPT098+PCh2ZZoLS0t2NnZ4fXr15g2bRqzXpjrR1lZGefPn0dlZSVsbGzQp08fbN++nWmF9vDwwJYtW/DHH3+gR48eGDlyJIqKioQum4ZMTEyQmpqKO3fu4Pvvv4eZmRlWrlyJzp07tzhOiqIoqvVxCCHkW2eCoiiKotrCxYsXMWTIEDx8+FCkih9F/ZtUVFRAUVER5eXlInVvpyiKokR7horc8rx7924cOHCAb/2BAwdYXcIoiqIo6luprq7Go0ePEBAQgIkTJ9KKM0VRFEVRX0zkynNwcDA6duzIt15FRQVr165tlUxRFEVRwuFyuY0uFy9e/NbZ+2b27dsHbW1tvHnzBuvXr//W2aEoiqIo6j9A5G7b0tLSuH37Nt8InKWlpTAyMmp29FSKoiiq9dy9e7fRbV26dGnxtDoURf178Locas7fDzEp2eZ3+ApKQ0Z86yxQFEUJpU27bauoqODmzZt863Nycpg5IimKoqivQ09Pr9GFVpyp/7Lw8HCYmJhAQUEBCgoKsLS0REJCArNdR0cHW7ZsESouHR0dcDgcxMbG8m3r0aMHOBwOIiMj+cJzOBzIyMhAR0cHzs7OOH/+PGvf0tJSJhyHw4GysjKGDRuGrKwsJsygQYOY7dLS0jA2NsYff/whWmFQFEVRX4XIlWdXV1d4eXkhOTkZtbW1qK2txfnz5+Ht7Y1Jkya1RR4piqIoiqJYNDQ0EBISgszMTGRkZMDW1hajR49GXl5ei+LT1NTE7t27WeuuXr2Kp0+fQk5Oji98UFAQysrKUFhYiD179qB9+/aws7PDmjVr+MKePXsWZWVlSEpKQmVlJYYPH443b94w26dPn46ysjLk5+fD2dkZc+fObXIEe4qiKOrbELnyvGrVKvTv3x9DhgyBjIwMZGRkMGzYMNja2tJvnimKoiiK+iqcnJzg6OgIfX19GBgYYM2aNeByubh69WqL4nNzc0NqaioePnzIrNu1axfc3NwgISHBF15eXh5qamrQ0tKCtbU1/vzzT6xYsQIrV65k5oPmUVZWhpqaGiwsLLBx40Y8e/YM165dY7bLyspCTU0N3bp1Q0BAAPT19XHs2LEWHQdFURTVdkSuPEtKSiIuLg63b99GdHQ0Dh8+jOLiYuzatQuSkpJtkUeKoiiKoqhG1dbWIjY2FlVVVbC0tGxRHKqqqrC3t2dmDnn37h3i4uJYc0Q3x9vbG4QQHD16tNEwvM8pampqmgzT1Pbq6mpUVFSwFoqiKKrtiVx55jEwMMDEiRMxcuRIaGtrt2aeKIqiKIqimpWbmwsulwspKSnMmjUL8fHxMDY2bnF806ZNQ2RkJAghOHjwIHR1ddG7d2+h91dSUoKKigpKS0sFbn/z5g1WrVoFLpeLfv368W2vra3FX3/9hZs3b8LW1rbRdIKDg6GoqMgsmpqaQueRoiiKajn+fkgCLFy4EKtWrYKcnBwWLlzYZNjQ0NBWyRhFURRFUVRTDA0NkZ2djfLychw8eBAeHh5ITU1tcQV6xIgRmDlzJi5cuIBdu3aJ1OrMQwgBh8NhrbOysoKYmBiqqqrQrVs3xMXFseYe/+OPP7Bjxw7U1NRAXFwcCxYswOzZsxtNw8/Pj/X3WEVFBa1AUxRFfQVCVZ6zsrLw8eNH5v8b0/AfC4qiKIqiqLYiKSkJPT09AECfPn2Qnp6OsLAwREREtCg+CQkJTJ48Gf7+/rh27Rri4+NF2v/ly5d48eIFunbtylofFxcHY2NjKCsro3379nz7ubm5YdmyZZCRkYG6ujrExJruGCglJQUpKSmR8kZRFEV9OaEqz8nJyQL/n6IoiqIo6p+irq4O1dXVXxTHtGnTsHHjRri4uKBDhw4i7RsWFgYxMTGMGTOGtV5TUxO6urqN7qeoqMi8BKAoiqL+uYSqPDeGNyIl7SpEURRFUdTX5Ofnh+HDh0NLSwtv375FTEwMUlJSkJSU9EXxGhkZ4e+//4asrGyT4d6+fYunT5/i48ePKCkpwV9//YUdO3YgODiYVoQpiqL+o0QeMOzTp09YsWIFFBUVoaOjAx0dHSgqKmL58uVM126KoiiKoqi29Pz5c7i7u8PQ0BBDhgxBeno6kpKSMHTo0C+OW1lZmRkVuzErV66Euro69PT0MHnyZJSXl+PcuXPw9fX94vQpiqKofyYOIYSIssPs2bNx+PBhBAUFMdNBXLlyBQEBARgzZgzCw8PbJKMURVEURVEUv4qKCigqKqK8vBwKCgrfOjsURVH/KqI8Q0WuPCsqKiI2NhbDhw9nrT916hRcXV1RXl4ueo4piqIoiqKoFqGVZ4qiqJYT5RkqcrdtKSkp6Ojo8K3v2rUrJCUlRY2OoiiKoiiqzURHR4PL5QpcevTo8a2zR1EURf2LiNzyHBQUhNu3b2P37t3MNAnV1dXw9PSEvr4+/P392ySjFEX9s5SWlqJr167IyspC7969v3V2/hWmTJmCN2/e4MiRI20SP4fDQXx8PN9Iv6K4ffs2pkyZguzsbHTv3h3Z2dmtlr+WSklJweDBg/H69WuB0/z8m7TmNdDW19PXFBkZifnz5+PNmzetHvfbt2/x7NkzgdvatWsHbW3tVk0vICAAR44c+ar3Dq/VRHP+fohJNT3QWWspDRnxVdKhKIpqa23a8pyVlYUTJ05AQ0MDdnZ2sLOzg4aGBo4fP46cnByMGzeOWSjq3yY8PBwmJiZQUFCAgoICLC0tkZCQwAqjo6ODLVu2iBRvcHAwxMXFsWHDhlbM7belqamJsrIy9OzZU+h9pkyZ8kUVO56UlBRwOByBf2i35PyIKjk5GY6OjlBWVoasrCyMjY2xaNEiPH78uMn9wsLCEBkZyfweNGgQ5s+f32r5Kisr4/ukRlT+/v6Qk5NDYWEhzp0710o5Y3v//j2UlJTQsWPHL55W6L+Gd21zOByIiYlBUVERZmZmWLJkCcrKylhhG15P/xaC7lEXFxfcuXOnxXFGRkY2+mJFXl4eenp6ApfWrjgDgI+PT5vdOxRFUdS3JXLluX379hg/fjxGjhwJTU1NaGpqYuTIkRg3bhwUFRVZC0X922hoaCAkJASZmZnIyMiAra0tRo8ejby8vC+Kd9euXViyZAl27drVSjltXk1NTZvGLS4uDjU1NUhIfNGMd/86ERERsLOzg5qaGg4dOoT8/Hxs27YN5eXl2LRpk8B9amtrUVdXB0VFxTZpOeWdazU1NaZHUEsVFxfju+++g7a2NpSVlb8oP405dOgQevToge7du/8nWk3bQmFhIZ48eYL09HT4+vri7Nmz6NmzJ3Jzc5kwbXU9fQsyMjJQUVH51tloFVwut8X3DkVRFPXPJnLleffu3UIvFPVv4+TkBEdHR+jr68PAwABr1qwBl8vF1atXWxxnamoq3r9/j6CgIFRUVODy5cus7QEBAejduzciIiKgqakJWVlZODs7swbf47XYBgYGolOnTlBQUMCsWbNYlZRBgwZh3rx5mD9/Pjp27Ah7e3sm/X79+kFKSgrq6upYunQpPn36xLffvHnzoKioiI4dO2LFihWo/0WHjo4OVq1aBXd3dygoKGDGjBkoLS0Fh8NhuibW1tbC09MTXbt2hYyMDAwNDREWFsY6zqioKBw9epRpWUtJSQHwec54Z2dntG/fHkpKShg9ejRKS0tbXOY8NTU1mDdvHtTV1SEtLQ1tbW0EBwcz29+8eYOffvqJKVNbW1vk5OQ0Gt+jR4/g5eUFLy8v7Nq1C4MGDYKOjg6sra2xY8cOrFy5EsD/tYIdO3YMxsbGkJKSwoMHD1gt71OmTEFqairCwsKY8uAd861btzB8+HBwuVyoqqpi8uTJ+Pvvv5l8NHauORwOqzLq6+sLAwMDyMrKolu3blixYkWTUwpyOBxkZmYiKCgIHA4HAQEBAIDc3FzY2tpCRkYGysrKmDFjBiorK5n9eMe1Zs0adO7cGYaGhk2el507d+LHH3/Ejz/+iJ07d/JtP3XqFAwMDCAjI4PBgwezroWKigrIyMjw9QiJj4+HvLw83r17J9Sx8+67vXv3MlMuTpo0CW/fvmXC1NXVYf369dDT04OUlBS0tLSwZs0aZntz121tbS0WLlyI9u3bQ1lZGUuWLIGwX0qpqKhATU0NBgYGmDRpEtLS0tCpUyfMnj2bCdOwJ0diYiK+++47Jr2RI0eiuLiYFe/ly5fRu3dvSEtLw8LCAkeOHGHdx7yW73PnzsHCwgKysrKwsrJCYWEhK57w8HDo6upCUlIShoaG2Lt3L7ONEIKAgABoaWlBSkoKnTt3hpeXF4DP1+79+/exYMEC5roHBLccHz9+HH379oW0tDQ6duyIsWPHClV2wP+d3127dkFLSwtcLhdz5sxBbW0t1q9fDzU1NaioqLDOJwCEhoaiV69ekJOTg6amJubMmcO61gFg+/btzLN67NixCA0NZeWdlzYP7zxt3LgR6urqUFZWxty5c1nXY1lZGUaMGAEZGRl07doVMTExX6UXDUVRFCUakSvPPC9evMClS5dw6dIlvHjxojXzRFH/CLW1tYiNjUVVVRUzLVtL7Ny5E66urmjXrh1cXV0FVhbu3r2L/fv34/jx40hMTERWVhbmzJnDCnPu3DkUFBQgJSUF+/btw+HDhxEYGMgKExUVBUlJSaSlpWHbtm14/PgxHB0d0bdvX+Tk5CA8PBw7d+7E6tWr+faTkJDA9evXERYWhtDQUOzYsYMVZuPGjTA1NUVWVhZWrFjBdwx1dXXQ0NDAgQMHkJ+fj5UrV+KXX37B/v37AXzuyujs7AwHBweUlZWhrKwMVlZW+PjxI+zt7SEvL4+LFy8iLS0NXC4XDg4OX9x6vnXrVhw7dgz79+9HYWEhoqOjWQMeTpw4Ec+fP0dCQgIyMzNhbm6OIUOG4NWrVwLjO3DgAGpqarBkyRKB2+v/Af3u3TusW7cOO3bsQF5eHl+rWlhYGCwtLTF9+nSmPDQ1NfHmzRvY2trCzMwMGRkZSExMxLNnz+Ds7Mzav+G5FkReXh6RkZHIz89HWFgYtm/fjs2bNzdaXmVlZejRowcWLVqEsrIy+Pj4oKqqCvb29ujQoQPS09Nx4MABnD17FvPmzWPte+7cORQWFuLMmTM4ceJEo2kUFxfjypUrcHZ2hrOzMy5evIj79+8z2x8+fIhx48bByckJ2dnZ+Omnn7B06VJmu4KCAkaOHImYmBhWvNHR0RgzZgxkZWWFPvbi4mIcOXIEJ06cwIkTJ5CamoqQkBBmu5+fH0JCQrBixQrk5+cjJiYGqqqqACDUdbtp0yZERkZi165duHTpEl69eoX4+PhGy6YpMjIymDVrFtLS0vD8+XOBYaqqqrBw4UJkZGTg3LlzEBMTw9ixY1FXVwfg84sHJycn9OrVCzdu3MCqVasanZN42bJl2LRpEzIyMiAhIYFp06Yx2+Lj4+Ht7Y1Fixbh1q1bmDlzJqZOnYrk5GQAn3sWbN68GRERESgqKsKRI0fQq1cvAMDhw4ehoaGBoKAg5roX5OTJkxg7diwcHR2RlZWFc+fOoV+/fiKVWXFxMRISEpCYmIh9+/Zh586dGDFiBB49eoTU1FSsW7cOy5cvx7Vr15h9xMTEsHXrVuTl5SEqKgrnz59n3e9paWmYNWsWvL29kZ2djaFDh/JVwAVJTk5GcXExkpOTERUVhcjISFaXe3d3dzx58gQpKSk4dOgQ/vzzz0bPM/B5rJmKigrWQlEURX0FRESVlZVk6tSpRFxcnHA4HMLhcIiEhASZNm0aqaqqEjU6ivrHuXnzJpGTkyPi4uJEUVGRnDx5krVdW1ubbN68Wai4ysvLiYyMDMnOziaEEJKVlUW4XC55+/YtE8bf35+Ii4uTR48eMesSEhKImJgYKSsrI4QQ4uHhQZSUlFj3WHh4OOFyuaS2tpYQQoiNjQ0xMzNjpf/LL78QQ0NDUldXx6z7/fff+fYzMjJihfH19SVGRkasYx4zZgwr7pKSEgKAZGVlNXr8c+fOJePHj2d+e3h4kNGjR7PC7N27ly+P1dXVREZGhiQlJQmMNzk5mQAgr1+/5ttW//z8/PPPxNbWlhU3z8WLF4mCggL58OEDa72uri6JiIgQmO7s2bOJgoKCwG317d69mwBgzjtPw+O3sbEh3t7erDCrVq0iw4YNY617+PAhAUAKCwuZ/Rqea0IIAUDi4+MbzdeGDRtInz59msy7qakp8ff3Z37/+eefpEOHDqSyspJZd/LkSSImJkaePn3KHJeqqiqprq5uMm5CPl+T9a+l0aNHs9Lz8/MjxsbGrH18fX1Z5zs+Pp5wuVzmfigvLyfS0tIkISGh0XQbHru/vz+RlZUlFRUVzLrFixeT/v37E0IIqaioIFJSUmT79u0C4xPmulVXVyfr169ntn/8+JFoaGjw3QP1NXVtJyQkEADk2rVrhBDB91N9L168IABIbm4uIeTzM0NZWZm8f/+eCbN9+3bWfcxL/+zZs0yYkydPEgDMflZWVmT69OmstCZOnEgcHR0JIYRs2rSJGBgYkJqaGoH5EvQM3b17N1FUVGR+W1paEjc3t0aPraGG+ws6v/b29kRHR4d59hFCiKGhIQkODm403gMHDhBlZWXmt4uLCxkxYgQrjJubG1/apqamzG8PDw+ira1NPn36xKybOHEicXFxIYQQUlBQQACQ9PR0ZntRUREB0Oi/Nf7+/gQA36I5fz/R9j3xVRaKoqj/ivLycgKAlJeXNxtW5JbnhQsXIjU1FcePH8ebN2/w5s0bHD16FKmpqVi0aNGX1uUp6pszNDREdnY2rl27htmzZ8PDwwP5+fktimvfvn3Q1dWFqakpAKB3797Q1tZGXFwcK5yWlha6dOnC/La0tERdXR2rq6SpqSnTqsYLU1lZiYcPHzLr+vTpw4q3oKAAlpaWTNdIABg4cCAqKyvx6NEjZt2AAQNYYSwtLVFUVITa2lpmnYWFRbPH+/vvv6NPnz7o1KkTuFwu/vzzTzx48KDJfXJycnD37l3Iy8sz08coKSnhw4cPfF1ORcUbNdrQ0BBeXl44ffo0K93KykooKyuzpq4pKSlpNF1CCKucmiIpKQkTExOR85yTk4Pk5GRWnrp37w4ArHw1PNeCxMXFYeDAgVBTUwOXy8Xy5cubPR8NFRQUwNTUFHJycsy6gQMH8l2fvXr1ana6wtraWkRFReHHH39k1v3444+IjIxkWkcLCgrQv39/1n4Ne344OjqiXbt2OHbsGIDPLZ0KCgqws7MT6dh1dHQgLy/P/FZXV2da+woKClBdXY0hQ4YIPJbmrtvy8nKUlZWxjkVCQkKo+6gx5P93+W7sGiwqKoKrqyu6desGBQUFppcF77gLCwthYmICaWlpZp/GWnPrX7vq6uoAwCqbgQMHssIPHDgQBQUFAD736Hj//j26deuG6dOnIz4+nvWpiDCys7MbLXthNTy/qqqqMDY2hpiYGGtd/Rbes2fPYsiQIejSpQvk5eUxefJkvHz5kvkcoLCwkK/MhGkR79GjB8TFxZnf9a+1wsJCSEhIwNzcnNmup6eHDh06NBqfn58fysvLmaX+vwMURVFU2xF5pJ9Dhw7h4MGDGDRoELPO0dERMjIycHZ2Rnh4eGvmj6K+OklJSejp6QH4XEFJT09HWFgYIiIiRI5r586dyMvLYw2qVVdXh127dsHT07PV8sxTv4LzteOOjY2Fj48PNm3aBEtLS8jLy2PDhg2sLpGCVFZWok+fPoiOjubb1qlTJ4H78KYRKC8v5/tO8s2bN8yAhebm5igpKUFCQgLOnj0LZ2dn2NnZ4eDBg6isrIS6ujrz3XV9jQ3CZGBgwFSKeBWKxsjIyAhd0a6vsrISTk5OWLduHd+2+mk2dz6uXLkCNzc3BAYGwt7eHoqKioiNjW10ULMvJcy1l5SUhMePH8PFxYW1vra2FufOncPQoUOFSktSUhITJkxATEwMJk2ahJiYGLi4uDD3mbDH3q5dO9ZvDofDVOJlZGSazENLrtsvxauc1v/0oD4nJydoa2tj+/bt6Ny5M+rq6tCzZ88Wff5Qv2x41zGvbJqjqamJwsJCnD17FmfOnMGcOXOwYcMGpKam8pV5Y5orf2EIOr9NnfPS0lKMHDkSs2fPxpo1a6CkpIRLly7B09MTNTU1rJeXrZEXYctTECkpqS8eHJCiKIoSncgtz+/evWO++apPRUWFeTNLUf8ldXV1LZpOJzc3FxkZGUhJSUF2djazpKSk4MqVK7h9+zYT9sGDB3jy5Anz++rVqxATE2MNvJSTk4P379+zwnC5XGhqajaaByMjI1y5coU1SFFaWhrk5eWhoaHBrGtYwb169Sr09fVZLSXNSUtLg5WVFebMmQMzMzPo6enxteBKSkqyWrOBzxXcoqIiqKio8E0j09io/fr6+hATE0NmZiZr/b1791BeXg4DAwNmnYKCAlxcXLB9+3bExcXh0KFDePXqFczNzfH06VNISEjwpduxY0eB6U6YMAGSkpJYv369wO2izlHbWHnk5eVBR0eHL1+ivBy5fPkytLW1sWzZMlhYWEBfX5/1bbGwjIyMkJOTg6qqKmZdWloa3/UpjJ07d2LSpEms+yE7OxuTJk1ixgIwMjLC9evXWfsJGrDPzc0NiYmJyMvLw/nz5+Hm5sZsa41j19fXh4yMTKNTDjV33SoqKkJdXZ11b3369InvmhXW+/fv8eeff8La2lpg5fzly5coLCzE8uXLMWTIEBgZGeH169esMIaGhsjNzWU9z9LT00XOi5GREdLS0ljr0tLSYGxszPyWkZGBk5MTtm7dyjzzeCOFC7ruGzIxMfnq0z1lZmairq4OmzZtwoABA2BgYMB6LgOfy7BhmbWkDBvG+enTJ2RlZTHr7t69y3f+KIqiqG9P5MqzpaUl/P398eHDB2bd+/fvERgY+EWDKlHUP4Gfnx8uXLiA0tJS5Obmws/PDykpKaw/zIW1c+dO9OvXD9bW1ujZsyezWFtbo2/fvqyBw6SlpeHh4YGcnBxcvHgRXl5ecHZ2hpqaGhOmpqYGnp6eyM/Px6lTp+Dv74958+axuiA2NGfOHDx8+BA///wzbt++jaNHj8Lf3x8LFy5k7ffgwQMsXLgQhYWF2LdvH3799Vd4e3uLdLz6+vrIyMhAUlIS7ty5gxUrVvD9Uamjo4ObN2+isLAQf//9Nz5+/Ag3Nzd07NgRo0ePxsWLF1FSUoKUlBR4eXmxupbXJy8vj59++gmLFi3CsWPHUFJSggsXLsDNzQ0DBgyAlZUVgM8j5+7btw+3b9/GnTt3cODAAaipqaF9+/aws7ODpaUlxowZg9OnT6O0tBSXL1/GsmXLkJGRITBdTU1NbN68GWFhYfD09ERqairu37+PtLQ0zJw5E6tWrRKpzHR0dHDt2jWUlpbi77//Rl1dHebOnYtXr17B1dUV6enpKC4uRlJSEqZOndpshaM+fX19PHjwALGxsSguLsbWrVtbNFiVm5sbc33eunULycnJ+PnnnzF58mSBL1Ib8+LFCxw/fhweHh6s+6Fnz55wd3fHkSNH8OrVK8yaNQtFRUVYvHgxCgsLERMTI3AuY2tra6ipqcHNzQ1du3ZldY9ujWOXlpaGr68vlixZgj179qC4uBhXr15l7lthrltvb2+EhITgyJEjuH37NubMmSP0C5bnz5/j6dOnKCoqQmxsLAYOHIi///670d5dHTp0gLKyMv7880/cvXsX58+fx8KFC1lhfvjhB9TV1WHGjBkoKChAUlISNm7cCKDxruCCLF68GJGRkQgPD0dRURFCQ0Nx+PBh+Pj4APg8cvbOnTtx69Yt3Lt3D3/99RdkZGSYOZV1dHRw4cIFPH78mDWKfH3+/v7Yt28f/P39UVBQgNzcXIG9MVqTnp4ePn78iF9//RX37t3D3r17+Qbj+/nnn3Hq1CmEhoaiqKgIERERSEhIaFEvE57u3bvDzs4OM2bMwPXr15GVlYUZM2a0uPcKRVEU1XaErjyLi4vj+fPn2LJlC9LS0qChoYEhQ4ZgyJAh0NTUxOXLl1nT0lDUv9Hz58/h7u4OQ0NDDBkyBOnp6UhKSmJ1J62rq2t2buOamhr89ddfGD9+vMDt48ePx549e5ipSvT09DBu3Dg4Ojpi2LBhMDExwR9//MHaZ8iQIdDX14e1tTVcXFwwatQoZiqhxnTp0gWnTp3C9evXYWpqilmzZsHT0xPLly9nhXN3d8f79+/Rr18/zJ07F97e3pgxY0aTcTc0c+ZMjBs3Di4uLujfvz9evnzJN2L49OnTYWhoCAsLC3Tq1AlpaWmQlZXFhQsXoKWlhXHjxsHIyAienp748OED0z1bkLCwMHh4eMDX1xc9evTAlClTYGJiguPHjzN/cMrLy2P9+vWwsLBA3759UVpailOnTkFMTAwcDgenTp2CtbU1pk6dykwJdP/+/SYrhXPmzMHp06fx+PFjjB07Ft27d8dPP/0EBQUFpvIgLB8fH4iLi8PY2BidOnXCgwcP0LlzZ6SlpaG2thbDhg1Dr169MH/+fLRv377JFyUNjRo1CgsWLMC8efPQu3dvXL58WeAo6c2RlZVFUlISXr16hb59+2LChAkYMmQIfvvtN5Hi2bNnD+Tk5AR+xzpkyBDIyMjgr7/+gpaWFg4dOoQjR47A1NQU27Ztw9q1a/n24XA4cHV1RU5ODt/LrdY69hUrVmDRokVYuXIljIyM4OLiwnynKsx1u2jRIkyePBkeHh7MpwzCTrdkaGiIzp07o0+fPggJCYGdnR1u3brFat2tT0xMDLGxscjMzETPnj2xYMECbNiwgRVGQUEBx48fR3Z2Nnr37o1ly5Yx06vV/w66OWPGjEFYWBg2btyIHj16ICIiArt372Y+52rfvj22b9+OgQMHwsTEBGfPnsXx48eZuY+DgoJQWloKXV3dRru4Dxo0CAcOHMCxY8fQu3dv2Nra8vVIaG2mpqYIDQ3FunXr0LNnT0RHR7OmtgM+f9u9bds2hIaGwtTUFImJiViwYIFI5SfInj17oKqqCmtra4wdOxbTp0+HvLz8F8dLURRFtS4OIcJNOikmJoanT58y3bOjo6OZbqdGRkZwc3NrlW+UKOqfrLa2FgoKCoiKisKECRNaJc6AgAAcOXKEmWdVkClTpuDNmzesOXxby6BBg9C7d286nyhF/Q+Kjo7G1KlTUV5eTv8Nb6Hp06fj9u3buHjxYqvF+ejRI2hqajIDmDWnoqICioqKKC8vb/KlI0VRFMVPlGeoyAOGAZ/fuE+fPr1FmaOof6tHjx5hz549qK2txXffffets0NRFCWyPXv2oFu3bujSpQtycnLg6+sLZ2dnWnEWwcaNGzF06FDIyckhISEBUVFRfD2FRHX+/HlUVlaiV69eKCsrw5IlS6CjowNra+tWyjVFURTVGkSqPO/YsQNcLrfJMF5eXl+UIYr6p+rduzeUlZWxd+9eqKmpITo6GjNnzhQYVltbG3l5eV85hxRFUU17+vQpVq5ciadPn0JdXR0TJ07EmjVrvnW2/lWuX7+O9evX4+3bt+jWrRu2bt2Kn3766Yvi/PjxI3755Rfcu3cP8vLysLKyQnR0tNCjk1MURVFfh0jdtjU0NJocfZfD4eDevXutljmK+id7+/Ytnj17JnBbu3btmMFxKIr6dhp+FtHan0B8688uvhSHw0F8fDzGjBkjcHtpaSm6du2KrKws9O7d+6vmrS01PK6UlBQMHjwYr1+/bnSqun8yXpdDzfn7ISbV8im1/m1KQ0Z86yxQFPUfIEq3bZFG287IyEBJSUmjC604U/9L5OXl+aao4S204kz924WHh8PExAQKCgpQUFCApaUlEhISWGF0dHRY38oTQuDj4wMFBQWB82c3pKOjAw6Hg9jYWL5tPXr0AIfDETjS9pcICwtr1Th9fHy+eEqllJQUcDgcZlFVVcX48eO/yr+pZWVlGD58eJunI0hAQADruHlL9+7dv0l+/immTJnS6MsMiqIo6tsSuvJMp0ugKIr636GhoYGQkBBkZmYiIyMDtra2GD16dKOfI9TW1sLT0xN79uxBcnIyM/JyczQ1NbF7927WuqtXr+Lp06cizWstLEVFxVZtWeRyucwo0l+qsLAQT548wYEDB5CXlwcnJyeB05MRQvDp06dWSVNNTQ1SUlKtEldjampqGt3Wo0cPlJWVsZZLly59UXq8WQwoiqIoqrUJXXkWsnc3RVEU9R/g5OQER0dH6Ovrw8DAAGvWrAGXy8XVq1f5wlZXV2PixIk4e/YsLl68iD59+gidjpubG1JTU/Hw4UNm3a5du+Dm5sY3JdybN2/w008/oVOnTlBQUICtrS1ycnJYYUJCQqCqqgp5eXlm6qj6Grbq1dXVYf369dDT04OUlBS0tLRY3wD7+vrCwMAAsrKy6NatG1asWMGqnAUEBLC6M9fW1mLhwoVo3749lJWVsWTJEqH//VRRUYG6ujqsra2xcuVK5Ofn4+7du0zLdEJCAvr06QMpKSlcunQJ1dXV8PLygoqKCqSlpfHdd98xc6vX1dVBQ0ODb17orKwsiImJ4f79+wA+vxiv3538+vXrMDMzg7S0NCwsLJCVlcWXz1u3bmH48OHgcrlQVVXF5MmTWfM1Dxo0CPPmzcP8+fPRsWNH2NvbN3rMEhISUFNTYy0dO3Zktuvo6GDt2rWYNm0a5OXloaWlhT///JPZXlpaCg6Hg7i4ONjY2EBaWhrR0dGoq6tDUFAQNDQ0ICUlhd69eyMxMVGo8wB8nqu6ffv2OHHiBAwNDSErK4sJEybg3bt3iIqKgo6ODjp06AAvLy/WC47q6mr4+PigS5cukJOTQ//+/Vm9MHjxJiUlwcjICFwuFw4ODigrKwPw+XqKiorC0aNHmZZ4YXpxUBRFUV+H0JVnf3//ZgcLq2/OnDmsf0wpiqKof6fa2lrExsaiqqoKlpaWrG2VlZUYMWIE8vPzkZaWBkNDQ5HiVlVVhb29PaKiogAA7969Q1xcHKZNm8YXduLEiXj+/DkSEhKQmZkJc3NzDBkyBK9evQIA7N+/HwEBAVi7di0yMjKgrq7e7CjIfn5+CAkJwYoVK5Cfn4+YmBjWPN/y8vKIjIxEfn4+wsLCsH37dmzevLnR+DZt2oTIyEjs2rULly5dwqtXrxAfHy9SmQBgRr+u32q7dOlShISEoKCgACYmJliyZAkOHTqEqKgo3LhxA3p6erC3t8erV68gJiYGV1dXxMTEsOKNjo7GwIEDBX5aUllZiZEjR8LY2BiZmZkICAjgm7v8zZs3sLW1hZmZGTIyMpCYmIhnz57B2dmZFS4qKgqSkpJIS0vDtm3bRD7++jZt2sRU5OfMmYPZs2ejsLCQFWbp0qXw9vZGQUEB7O3tERYWhk2bNmHjxo24efMm7O3tMWrUKBQVFQmd7rt377B161bExsYiMTERKSkpGDt2LE6dOoVTp05h7969iIiIwMGDB5l95s2bhytXriA2NhY3b97ExIkT4eDgwEr33bt32LhxI/bu3YsLFy7gwYMHTDn7+PjA2dmZqVCXlZXBysqKL2/V1dWoqKhgLRRFUVTbE6nyLCsr/CAUf/31F32YUxRF/Yvl5uaCy+VCSkoKs2bNQnx8PIyNjVlhVq1ahezsbFy8eBGampotSmfatGmIjIwEIQQHDx6Erq4u3+BUly5dwvXr13HgwAFYWFhAX18fGzduRPv27ZnKy5YtW+Dp6QlPT08YGhpi9erVfPmt7+3btwgLC8P69evh4eEBXV1dfPfdd6yRk5cvXw4rKyvo6OjAyckJPj4+2L9/f6NxbtmyBX5+fhg3bhyMjIywbds2KCoqilQeZWVl2LhxI7p06cJ6GREUFIShQ4dCV1cXUlJSCA8Px4YNGzB8+HAYGxtj+/btkJGRwc6dOwF8btVPS0vDgwcPAHxujY6NjYWbm5vAdGNiYlBXV4edO3eiR48eGDlyJBYvXswK89tvv8HMzAxr165F9+7dYWZmhl27diE5ORl37txhwunr62P9+vUwNDRs8oUK7xqrv8yaNYsVxtHREXPmzIGenh58fX3RsWNHJCcns8LMnz8f48aNQ9euXaGuro6NGzfC19cXkyZNgqGhIdatWyfyfPYfP35EeHg4zMzMYG1tjQkTJuDSpUvYuXMnjI2NMXLkSAwePJjJy4MHD7B7924cOHAA33//PXR1deHj44PvvvuO9WnCx48fsW3bNlhYWMDc3Bzz5s1jvpvncrmQkZGBlJQU0xIvKSnJl7fg4GAoKioyS0vvPYqiKEo0Ig0YJgrazZuiKOrfzdDQENnZ2bh27Rpmz54NDw8P5Ofns8IMGzYMVVVVWLt2bYvTGTFiBCorK3HhwgXs2rVLYKtzTk4OKisroayszKpolZSUoLi4GABQUFCA/v37s/Zr2FJeX0FBAaqrqzFkyJBGw8TFxWHgwIFQU1MDl8vF8uXLmcpoQ+Xl5SgrK2PlQUJCAhYWFk0eP4+Ghgbk5OTQuXNnVFVV4dChQ6yKU/14iouL8fHjRwwcOJBZ165dO/Tr1w8FBQUAPk+vZ2RkxLQ+p6am4vnz55g4caLA9Hkt2tLS0sy6huWXk5OD5ORk1jngDfDFOw8AhO66z7vG6i9BQUGsMCYmJsz/czgcqKmp4fnz56ww9cumoqICT548YZUNAAwcOJApG2HIyspCV1eX+a2qqgodHR1WLzxVVVUmL7m5uaitrYWBgQGrfFJTU1ll0zBedXV1vuNpjp+fH8rLy5ml/mcPFEVRVNsRaZ5niqIo6n+HpKQk9PT0AHyuDKWnpyMsLAwRERFMmCFDhuDnn3/G6NGjUVdXh7CwMJHTkZCQwOTJk+Hv749r164J7OZcWVkJdXV1gd9/tnQAMF7X6MZcuXIFbm5uCAwMhL29PRQVFREbG4tNmza1KL3mXLx4EQoKClBRUYG8vDzf9pYMoObm5oaYmBgsXboUMTExcHBw+KIBziorK+Hk5IR169bxbVNXVxc5r/WvscY0nOuYw+Ggrq6Ota4tBpcTlG5TeamsrIS4uDgyMzP5pvWsX+EWFIeoDQ5SUlJtPtAbRVEUxa/NWp4piqKo/5a6ujpUV1fzrR82bBiOHz+O7du3w8vLq0VxT5s2DampqRg9ejQ6dOjAt93c3BxPnz6FhIQE39RwvAGmjIyMcO3aNdZ+ggY449HX14eMjEyjU01dvnwZ2traWLZsGdNVnDfQliCKiopQV1dn5eHTp0/IzMxs8th5unbtCl1dXYEV54Z0dXWZb4p5Pn78iPT0dFZX9R9++AG3bt1CZmYmDh482GiXbeBz+d28eZM1yFrD8jM3N0deXh50dHT4zkNbVGBbQkFBAZ07d2aVDQCkpaU12Y3/S5mZmaG2thbPnz/nKxs1NTWh45GUlBQ4yjpFURT17dGWZ4qiKIqPn58fhg8fDi0tLbx9+xYxMTFISUlBUlKSwPB2dnY4ceIEnJycUFdXh99++02k9IyMjPD33383OraGnZ0dLC0tMWbMGKxfvx4GBgZ48uQJTp48ibFjx8LCwgLe3t6YMmUKLCwsMHDgQERHRyMvLw/dunUTGKe0tDR8fX2xZMkSSEpKYuDAgXjx4gXy8vLg6ekJfX19PHjwALGxsejbty9OnjzZ7OBf3t7eCAkJgb6+Prp3747Q0FC8efNGpLIQhpycHGbPno3FixdDSUkJWlpaWL9+Pd69ewdPT08mnI6ODqysrODp6Yna2lqMGjWq0Th/+OEHLFu2DNOnT4efnx9KS0uxceNGVpi5c+di+/btcHV1xZIlS6CkpIS7d+8iNjYWO3bs4Gtxbc6nT5/w9OlT1jreXNdfYvHixfD392e+n9+9ezeys7MRHR39RfE2xcDAAG5ubnB3d8emTZtgZmaGFy9e4Ny5czAxMcGIESOEikdHRwdJSUkoLCyEsrIyFBUV+VqrKYqiqG+DVp4piqIoPs+fP4e7uzvKysqgqKgIExMTJCUlYejQoY3uY2tri5MnT2LkyJEghOC3334Dh8MROs2muhNzOBycOnUKy5Ytw9SpU/HixQuoqanB2tqaqWi5uLiguLgYS5YswYcPHzB+/HjMnj270Qo/AKxYsQISEhJYuXIlnjx5AnV1dWbAqlGjRmHBggWYN28eqqurMWLECKxYsQIBAQGNxrdo0SKUlZXBw8MDYmJimDZtGsaOHYvy8nKhy0FYISEhqKurw+TJk/H27VtYWFggKSmJr+Xezc0Nc+bMgbu7e5Nd1blcLo4fP45Zs2bBzMwMxsbGWLduHcaPH8+E4bXo+vr6YtiwYaiuroa2tjYcHBwgJiZ6Z7a8vDxWd2/gc5fkhlOMicrLywvl5eVYtGgRnj9/DmNjYxw7dgz6+vpfFG9zdu/ejdWrV2PRokV4/PgxOnbsiAEDBmDkyJFCxzF9+nSkpKTAwsIClZWVIs2bTlEURbUtDmmjkb1mz56NVatWseZrpCiKoiiKolpXRUUFFBUVUV5eDgUFhW+dHYqiqH8VUZ6hQrc837x5U6hwvFExw8PDhY2aoiiKoiiKoiiKov7RhK489+7du9ERIXnrORwOHeSCoiiKQnR0NGbOnClwm7a2NvLy8r5yjiiKoiiKor6M0JXnkpKStswHRVGUUDgcDuLj4zFmzJivHldAQACOHDmC7OzsL077v27UqFF8cy7zCDP4UWue529h0KBB6N27N7Zs2fLV40pJScHgwYPx+vXrFk/j9W91+/ZtTJkyBdnZ2ejevTuOHDmCrl27IisrC7179xYqDmHu89LSUpHj/Rp6+idBTErwoHstURoi3CBnFEVR/yuEHt1DW1u72eXt27dtmVeK+p8QHh4OExMTKCgoQEFBAZaWlkhISGCF0dHRadEf5aWlpeBwOAKXpqb0+TeZMmUKc0zt2rWDqqoqhg4dil27dvHNDVtWVobhw4d/1fzxzkFbV8DfvXsHPz8/6OrqQlpaGp06dYKNjQ2OHj3apunyyMvL803Xw1u0tbWb3f9bnJuvKTIykrlOxcXF0aFDB/Tv3x9BQUF8g4sdPnwYq1at+up5bOlzRhQpKSlMOYiJiUFRURFmZmZYsmQJysrKRI7P398fcnJyKCwsxLlz56CpqYmysjL07NlT6Dh8fHxY05dNmTKF7yVOS+KlKIqi/v2+eLTtt2/fYt++fdixYwcyMzNpt22K+kIaGhrMVDeEEERFRWH06NHIyspCjx49WiWNs2fP8sXV1EjH/zYODg7YvXs3amtr8ezZMyQmJsLb2xsHDx7EsWPHICHx+dEnytyr/zazZs3CtWvX8Ouvv8LY2BgvX77E5cuX8fLlyxbFRwhBbW0tU3Zt7b98bngUFBRQWFgIQgjevHmDy5cvIzg4GLt370ZaWho6d+4MAFBSUvrGOW17hYWFUFBQQEVFBW7cuIH169dj586dSElJQa9evYSOp7i4GCNGjGC9oBH1WuJyueByuU2GERcX/5+4RimKoig20eeV+P8uXLgADw8PqKurY+PGjbC1tf3PtFxR1Lfk5OQER0dH6Ovrw8DAAGvWrAGXy23V+0tZWRlqamqspV27diCEwM7ODvb29sz4Bq9evYKGhgZWrlwJ4P9aik6ePAkTExNIS0tjwIABuHXrFhP/y5cv4erqii5dukBWVha9evXCvn37WHkYNGgQvLy8mLli1dTU+KYAKioqgrW1NaSlpWFsbIwzZ84IdXxSUlJQU1NDly5dYG5ujl9++QVHjx5FQkICIiMjmXAcDgdHjhxhfvv6+sLAwACysrLo1q0bVqxYgY8fP/LFHxERAU1NTcjKysLZ2ZmvpXDHjh0wMjKCtLQ0unfvjj/++IPZ1rVrVwCAmZkZOBwOawqapvarqanBvHnzoK6uDmlpaWhrayM4OLjRMjh27Bh++eUXODo6QkdHB3369MHPP/+MadOmMWGqq6vh6+sLTU1NSElJQU9PDzt37gTwf+c5ISEBffr0gZSUFC5duoS6ujoEBweja9eukJGRgampKQ4ePMhK+9atWxg+fDi4XC5UVVUxefJk/P3338x2Yc59/XPDa60/fPgwBg8eDFlZWZiamuLKlSusfbZv386cl7FjxyI0NLTZbsvNnfOAgAD07t0be/fuhY6ODhQVFTFp0iRWT6uqqiq4u7uDy+VCXV0dmzZtajLN+seopqYGdXV1GBkZwdPTE5cvX0ZlZSWWLFnCKq/58+czv/fu3QsLCwvIy8tDTU0NP/zwA54/f84Xf1paWqP3KABcunQJ33//PWRkZKCpqQkvLy9UVVUxad6/fx8LFixgWoaF2Q8A/vjjD+jr60NaWhqqqqqYMGFCs2WhoqICNTU1GBgYYNKkSUhLS0OnTp0we/ZsVrim7hEOh4PMzEwEBQWBw+EgICCAr6cH77o+d+4cLCwsICsrCysrKxQWFjLx8M457/+joqJw9OhRphxSUlIE9iBJTU1Fv379ICUlBXV1dSxduhSfPn1itjd33RNCEBAQAC0tLUhJSaFz587w8vJqtuwoiqKor0ekyvPTp0+ZFrGJEydCQUEB1dXVOHLkCEJCQtC3b9+2yidF/U+qra1FbGwsqqqqYGlp2ebpcTgcREVFIT09HVu3bgXwuQWzS5cuTOWZZ/Hixdi0aRPS09PRqVMnODk5MZWODx8+oE+fPjh58iRu3bqFGTNmYPLkybh+/TorjqioKMjJyeHatWtYv349goKCmApyXV0dxo0bB0lJSVy7dg3btm2Dr69vi4/N1tYWpqamOHz4cKNh5OXlERkZifz8fISFhWH79u3YvHkzK8zdu3exf/9+HD9+HImJicjKysKcOXOY7dHR0Vi5ciXWrFmDgoICrF27FitWrEBUVBQAMGVw9uxZlJWVMflpbr+tW7fi2LFj2L9/PwoLCxEdHQ0dHZ1Gj0VNTQ2nTp1q8nMad3d37Nu3D1u3bkVBQQEiIiL4WtyWLl2KkJAQFBQUwMTEBMHBwdizZw+2bduGvLw8LFiwAD/++CNSU1MBAG/evIGtrS3MzMyQkZGBxMREPHv2DM7Ozqx4mzr3jVm2bBl8fHyQnZ0NAwMDuLq6MpWTtLQ0zJo1C97e3sjOzsbQoUOxZs2aJuMDhDvnxcXFOHLkCE6cOIETJ04gNTUVISEhzPbFixcjNTUVR48exenTp5GSkoIbN240m7YgKioqcHNzw7FjxxrtyfXx40esWrUKOTk5OHLkCEpLSzFlyhS+cE3do8XFxXBwcMD48eNx8+ZNxMXF4dKlS5g3bx6Az13FNTQ0EBQUhLKyMqYLdXP7ZWRkwMvLC0FBQSgsLERiYiKsra1FLgcZGRnMmjULaWlpzIuB5u6RsrIy9OjRg5lr28fHp9H4ly1bhk2bNiEjIwMSEhKsl0r1+fj4wNnZGQ4ODkw5WFlZ8YV7/PgxHB0d0bdvX+Tk5CA8PBw7d+7E6tWrWeGauu4PHTqEzZs3IyIiAkVFRThy5Eijre7V1dWoqKhgLRRFUdRXQIQ0cuRIoqCgQFxdXcmJEyfIp0+fCCGESEhIkLy8PGGjoShKCDdv3iRycnJEXFycKCoqkpMnT7K2a2trk82bN4scb0lJCQFAZGRkiJycHGupb//+/URaWposXbqUyMnJkTt37jDbkpOTCQASGxvLrHv58iWRkZEhcXFxjaY9YsQIsmjRIua3jY0N+e6771hh+vbtS3x9fQkhhCQlJREJCQny+PFjZntCQgIBQOLj4xtNx8PDg4wePVrgNhcXF2JkZMT8bi6uDRs2kD59+jC//f39ibi4OHn06BErT2JiYqSsrIwQQoiuri6JiYlhxbNq1SpiaWlJCPm/c5CVlcUK09x+P//8M7G1tSV1dXWN5re+1NRUoqGhQdq1a0csLCzI/PnzyaVLl5jthYWFBAA5c+aMwP155/nIkSPMug8fPhBZWVly+fJlVlhPT0/i6urK5HnYsGGs7Q8fPiQASGFhISGk+XNPCPvc8Mpsx44dzPa8vDwCgBQUFBBCPp/bESNGsOJ0c3MjioqKjZaRIILOuaysLKmoqGDWLV68mPTv358QQsjbt2+JpKQk2b9/P7Oddz94e3s3ms7u3bsbzVt4eDgBQJ49e0YI+VxeTcWVnp5OAJC3b98SQoS7Rz09PcmMGTNY8Vy8eJGIiYmR9+/fE0IEP2ea2+/QoUNEQUGBVV5N4eX19evXfNt49/u1a9cIIc3fI4QQYmpqSvz9/ZnfDe83Xnpnz55lwpw8eZIAYI7b39+fmJqaMtsFPVMaxvvLL78QQ0ND1v35+++/Ey6XS2prawkhzV/3mzZtIgYGBqSmpqaR0vo//v7+BADfojl/P9H2PdFqC0VR1P+C8vJyAoCUl5c3G1boj9cSEhLg5eWF2bNnQ19f/8tr7RRFNcrQ0BDZ2dkoLy/HwYMH4eHhgdTUVBgbG7dK/HFxcTAyMmp0+8SJExEfH4+QkBCEh4cLvOfrt4QrKSnB0NAQBQUFAD63mK9duxb79+/H48ePUVNTg+rqasjKskeB5c0Lz6Ours60MhUUFEBTU5P57rNhmi1B/v+Ueo2Ji4vD1q1bUVxcjMrKSnz69AkKCgqsMFpaWujSpQsrT3V1dSgsLIS8vDyKi4vh6emJ6dOnM2E+ffoERUXFRtOtqqpqdr8pU6Zg6NChMDQ0hIODA0aOHIlhw4Y1Gqe1tTXu3buHq1ev4vLlyzh37hzCwsIQGBiIFStWIDs7G+Li4rCxsWm8wABYWFgw/3/37l28e/cOQ4cOZYWpqamBmZkZACAnJwfJyckCvxktLi6GgYEBgKbPfWPq76Ourg4AeP78Obp3747CwkKMHTuWFb5fv344ceJEk3EKc851dHQgLy8vMK/FxcWoqalhjSzOux9aivz/TyYau1YzMzMREBCAnJwcvH79mhkI78GDB6xnRFP3aE5ODm7evIno6GhWunV1dSgpKWn0+dDcfkOHDoW2tja6desGBwcHODg4YOzYsXz3vqjlIMw9IorGriUtLS2R4wI+P68sLS1Z52zgwIGorKzEo0ePmHibuu4nTpyILVu2MGXn6OgIJycngeMM+Pn5YeHChczviooKaGpqtijvFEVRlPCErjxfunQJO3fuRJ8+fWBkZITJkydj0qRJbZk3ivqfJSkpCT09PQBAnz59kJ6ejrCwMERERLRK/Jqamkz8grx79w6ZmZkQFxdHUVGRyPFv2LABYWFh2LJlC3r16gU5OTnMnz8fNTU1rHANpyzicDh8I2K3poKCAuab44auXLkCNzc3BAYGwt7eHoqKioiNjRX6+1UAqKysBPD529uG0zSJi4t/0X7m5uYoKSlBQkICzp49C2dnZ9jZ2fF9b1xfu3bt8P333+P777+Hr68vVq9ejaCgIPj6+kJGRkaoY5KTk+PL58mTJ1kvEIDP35nzwjg5OWHdunV8cfEqKby81SfMua+/D6+S8iXXi7Dn/FtcpwoKCgIH8auqqoK9vT3s7e0RHR2NTp064cGDB7C3t+e7v5pSWVmJmTNnCvymtqkKZHP7SUpK4saNG0hJScHp06excuVKBAQEID09XeRps3gVfR0dnRbfW41p7WupJeny0ualq6mpicLCQpw9exZnzpzBnDlzsGHDBqSmpvLtJyUlxdxzFEVR1NcjdOV5wIABGDBgALZs2YK4uDjs2rULCxcuRF1dHc6cOQNNTU3Wm3mKolpPXV0dqqurv1p6ixYtgpiYGBISEuDo6IgRI0bA1taWFebq1avMH9mvX7/GnTt3mNaqtLQ0jB49Gj/++COT/zt37ojUcm5kZISHDx+irKyMqXR9yaBp58+fR25uLhYsWCBw++XLl6GtrY1ly5Yx6+7fv88X7sGDB3jy5AnTIn716lWIiYnB0NAQqqqq6Ny5M+7duwc3NzeB6UhKSgIA63tWYfYDPo/O7OLiAhcXF0yYMAEODg549eqV0KMxGxsb49OnT/jw4QN69eqFuro6pKamws7OTuj9paSk8ODBg0ZbrM3NzXHo0CHo6Oh8tZG5gc+9NdLT01nrGv5uSNhz3hRdXV20a9cO165d47sfmmvVF+T58+eIiYnBmDFjICbGPyzJ7du38fLlS4SEhDAtjRkZGQLjauoeNTc3R35+fpMv0SQlJfm+uxZmPwkJCdjZ2cHOzg7+/v5o3749zp8/j3HjxjV98PW8f/8ef/75J6ytrdGpUycAEOoeaQuCyqEhIyMjHDp0iNW7JS0tDfLy8tDQ0BA6LRkZGTg5OcHJyQlz585F9+7dkZubC3Nz8y86BoqiKKp1iPyXjZycHKZNm4Zp06ahsLAQO3fuREhICJYuXYqhQ4fi2LFjbZFPivqf4efnh+HDh0NLSwtv375FTEwMUlJSkJSUxAr3+PFjvrmCtbW10aFDh2bTePnyJZ4+fcpa1759e0hLS+PkyZPYtWsXrly5AnNzcyxevBgeHh64efMmK+6goCAoKytDVVUVy5YtQ8eOHZm5UPX19XHw4EFcvnwZHTp0QGhoKJ49eyZS5dnOzg4GBgbw8PDAhg0bUFFRwarkNKW6uhpPnz5lTVUVHByMkSNHwt3dXeA++vr6ePDgAWJjY9G3b1+cPHkS8fHxfOGkpaXh4eGBjRs3oqKiAl5eXnB2dmamrQkMDISXlxcUFRXh4OCA6upqZGRk4PXr11i4cCFUVFQgIyODxMREaGhoQFpaGoqKis3uFxoaCnV1dZiZmUFMTAwHDhyAmppao615gwYNgqurKywsLKCsrIz8/Hz88v/YO/O4mrb//7+O5umkkgalUxpUSmSqLqGI3GQOoS4yXcI13a6hzJmn65oVPoZMmVN0VYRUVChJiri5XVMJhXr//vBrf9udU50Id1jPx2M/Hu01vNd7rb327rz3Wvv9/uUXdOnShYsh7uPjg5EjR2L9+vVo2bIlHjx4gIKCAjHnXhWoqalh+vTpmDp1KsrLy/Hdd9+hsLAQ8fHxnLwff/wR27Ztw5AhQzivwvfu3cOBAwewffv2T1ollIZJkyahU6dOWL16NTw8PPD7778jIiKixm360l7zmlBVVcWoUaMwY8YMaGlpoXHjxpg9e7ZEw7cqRIQnT55woaquXLmCJUuWQF1dneeQrDIVq7sbNmzAuHHjcOvWrWpjQNd0j86aNQsdOnTAxIkTMXr0aKioqCA9PR3nzp3Dr7/+CuDjim9cXBwGDx4MBQUFNGrUqNZ6p06dwv3799GpUydoaGjgzJkzKC8vr3Ube0FBAUpKSvDq1SskJydj+fLlePr0Kc/BX233yJdCJBIhMjISmZmZ0NLSkrhNfMKECVi7di0mTZqEiRMnIjMzE4GBgfjpp5+kmgvAx9jfZWVlaN++PZSVlfG///0PSkpKUsVFZzAYDMbX4ZNDVQEf3/QvX74cjx49EgtDw2AwPo2CggKMGDECFhYWcHFxQWJiIiIjI8W+M125ciVatWrFO06fPi1VG66urtDT0+Mdx44dw19//YVRo0YhKCiIW+mYP38+dHR0MG7cOJ6M4OBgTJ48Gfb29njy5AlOnjzJrarOmTMHrVu3hpubGzp37gxdXV3uR7u0NGjQAOHh4Xj79i3atWuH0aNHS+U9GQDOnj0LPT09iEQi9OjRAxcuXMD69etx/Pjxao233r17Y+rUqZg4cSLs7Oxw+fJlzJ07V6ycqakp+vXrB3d3d3Tv3h22tra8cDmjR4/G9u3bERISAhsbGzg7OyM0NJTbLi4rK4v169djy5Yt0NfXh6enp1T11NTUsHz5crRp0wZt27ZFbm4uzpw5U+0Pczc3N+zatQvdu3eHpaUlJk2aBDc3Nxw8eJArs2nTJgwYMAATJkxA8+bN4efnxws5JImFCxdi7ty5WLp0KSwtLdGjRw+cPn2a01NfXx/x8fEoKytD9+7dYWNjgylTpqBhw4ZSGxGfgpOTEzZv3ozVq1ejZcuWOHv2LKZOnQpFRcVq60h7zWtjxYoV6NixIzw8PODq6orvvvsO9vb2tdYrKiqCnp4emjRpAgcHB2zZsgU+Pj64ceMGb4t7ZbS1tREaGopDhw7BysoKwcHBWLlypcSyNd2jtra2iI2Nxd27d9GxY0e0atUK8+bN4/kYWLBgAXJzc9GsWTNu9be2eg0bNsTRo0fRtWtXWFpaYvPmzdi/f3+tMeotLCygr68Pe3t7BAcHw9XVFbdu3eK9cKvtHvlS+Pn5wcLCAm3atIG2tjbi4+PFyjRp0gRnzpzBtWvX0LJlS4wbNw6jRo3CnDlzpG6nYcOG2LZtG5ycnGBra4vz58/j5MmTErfvMxgMBuPbIKAKjxyfSFFREX7//XdYWFjU6ICIwWD8O4iJiUGXLl3w4sWLOn/DyGB8Tfz8/HDnzh1cvHjxW6vCYHxRioqKoK6ujsLCQjGHdwwGg8Gombo8Q+u8DDBo0CBuS9fbt2/Rpk0bDBo0CLa2tjhy5MinacxgMBgMxmeycuVKpKam4t69e9iwYQN27doFHx+fb60Wg8FgMBiMfwl1Np7j4uLQsWNHAEB4eDj3rdb69euxaNGieleQwWBIz7hx46CqqirxqLrtmsH4t3Ht2jV069YNNjY22Lx5M9avX4/Ro0d/a7UYDAaDwWD8S6jztm0lJSXcvXsXhoaGGDFiBPT19REcHMzFl6wIJ8FgML4+BQUFKCoqkpgnFArRuHHjr6wRg8FgML40FVsODaccRAOFusfUronc4F71Ko/BYDD+bnzRbduGhoa4cuUKXr9+jbNnz6J79+4APobBqMkxC4PB+PI0btwYpqamEg9mODMYjE2bNsHW1pbzuO7g4ICIiAheGZFIBIFAgAMHDojVt7a2hkAgQGhoqFTtVciqelR4E8/NzeWla2lpoXv37rhx4wZPzr179/DDDz/AwMAACgoKMDY2xpAhQ3hhumJjY9G1a1doampCWVkZZmZm8PHxqTH+dWX9VFRU0Lp1axw6dEiqvtXW77Vr10pVrqJ9JSUliEQiDBo0CL///vtn68BgMBiM+qfOxvOUKVPg7e0NAwMD6Ovro3PnzgA+bue2sbGpb/0YDAaDwWDUEwYGBggODkZycjKSkpLQtWtXeHp64vbt27xyhoaGCAkJ4aVdvXoVT548gYqKSp3aXLBgAfLz83nHpEmTeGXOnz+P/Px8REZGori4GD179sTLly8BfIxjbW9vj7t372LLli1IT09HeHg4mjdvjmnTpgEA0tPT0aNHD7Rp0wZxcXG4efMmNmzYIFWM5gr9bty4gbZt28LLywuXL1+uUx8rqMlQr639zMxM7N69Gw0bNoSrq6vU0QUYDAaD8fWoc5znCRMmoH379nj48CG6devGhR4xMTFhD3oGg8FgMP7GeHh48M4XL16MTZs24erVq7xwUt7e3lizZg3y8vJgaGgIANi5cye8vb2xe/fuOrWppqbGxUGvDi0tLejq6kJXVxcrV66Ek5MTEhIS0L17d/j6+sLMzAwXL17khTuzs7PD5MmTAQBRUVHQ1dXF8uXLufxmzZqhR48eUuunq6uLjRs34n//+x9OnjyJ9u3bY8yYMfj999/x5MkTNG3aFBMmTODaBABfX1+8fPkSbdu2xcaNG6GgoAAjIyM8ePAAU6dOxdSpUwF8jOktzfg0bdoUnTp1gp6eHubNm4cBAwbUGiObwWAwGF+POq88L1iwAJaWlujbty9UVVW59K5du+L8+fP1qhyDwWAwGIwvQ1lZGQ4cOIDXr1/DwcGBl6ejo8PFCgeAN2/eICwsDCNHjvzieikpKQH4uIqbkpKC27dvY9q0aRLjhFeEy9PV1UV+fj7i4uI+q21ZWVnIycnh3bt3KC8vh4GBAQ4dOoT09HTMmzcPv/zyCy9WOgBER0cjMzMT586dw6lTp3D06FEYGBjwVtzryuTJk0FEOH78uMT80tJSFBUV8Q4Gg8FgfHnqbDzPnz9folOwN2/eYP78+fWiFIPBYDAYjC/DzZs3oaqqCgUFBYwbNw7h4eGwsrISKzdy5EiEhoaCiHD48GE0a9YMdnZ2dW5v1qxZYt7/q4u9/fLlSyxcuBCqqqpo164dsrKyAADNmzevsY2BAwdiyJAhcHZ2hp6eHvr27Ytff/21Tkblu3fvsHTpUhQWFqJr166Qk5PD/Pnz0aZNGxgbG8Pb2xs//PCDmPGsoqKC7du3w9raGtbW1tDU1ISMjAxvRbuuaGpqonHjxsjNzZWYv3TpUqirq3NHxe4ABoPBYHxZ6mw8ExEEAoFYempqKjQ1NetFKQaDwWAwGF8GCwsLpKSkICEhAePHj4ePjw/S09PFyvXq1QvFxcWIi4vDzp07P3nVecaMGUhJSeEdbdq04ZVxdHSEqqoqNDQ0kJqairCwMOjo6NS43bkyMjIyCAkJwaNHj7B8+XI0adIES5YsgbW1da0rvxXGvbKyMpYtW4bg4GD06vXRw/TGjRthb28PbW1tqKqqYuvWrXj48CGvvo2NDeTl5eswItJR3e8tAAgICEBhYSF35OXl1Xv7DAaDwRBH6m+eNTQ0OI+Q5ubmvAd6WVkZiouLWRxZBoPBYDD+5sjLy8PU1BQAYG9vj8TERKxbtw5btmzhlZOVlcXw4cMRGBiIhIQEhIeHf1J7jRo14tqrjrCwMFhZWUFLS4vbig0A5ubmAIA7d+6gVatWtbbVpEkTDB8+HMOHD8fChQthbm6OzZs317gzbsaMGfD19YWqqip0dHS43zcHDhzA9OnTsWrVKjg4OEBNTQ0rVqxAQkICr35dHahJw7Nnz/DXX3/B2NhYYr6CggIUFBTqvV0Gg8Fg1IzUxvPatWtBRBg5ciTmz58PdXV1Lk9eXh4ikUjsmykGg8FgMBh/b8rLy1FaWioxb+TIkVi5ciW8vLygoaHxxXQwNDREs2bNxNLt7OxgZWWFVatWwcvLS+y755cvX/KM7cpoaGhAT08Pr1+/rrHt6oz7+Ph4ODo6YsKECVxadna2FL2BVF6+a2LdunVo0KAB+vTp88kyGAwGg1H/SG08+/j4AACMjY3h6OgIOTm5L6YUg8FgMBiM+icgIAA9e/ZE06ZN8erVK+zbtw8xMTGIjIyUWN7S0hJPnz6FsrLyJ7f56tUrPHnyhJemrKwMoVBYa12BQICQkBC4urqiY8eOmD17Npo3b47i4mKcPHkSUVFRiI2NxZYtW5CSkoK+ffuiWbNmKCkpwe7du3H79m1s2LDhk/Q2MzPD7t27ERkZCWNjY+zZsweJiYnVrgZXRiQSIS4uDoMHD4aCggIaNWpUbdmK8Xn//j1ycnLwv//9D9u3b8fSpUtrXbFnMBgMxtelzqGqnJ2dUV5ejrt376KgoADl5eW8/E6dOtWbcgwGg8FgMOqPgoICjBgxAvn5+VBXV4etrS0iIyPRrVu3autoaWl9Vpvz5s3DvHnzeGljx47F5s2bparfrl07JCUlYfHixfDz88PTp0+hp6cHR0dHrF27litz6dIljBs3Dn/88QdUVVVhbW2NY8eOwdnZ+ZP0Hjt2LG7cuAEvLy8IBAIMGTIEEyZMQERERK11FyxYgLFjx6JZs2YoLS2t8dvtivGRl5eHrq4uOnTogOjoaHTp0uWT9GYwGAzGl0NA0nrj+P9cvXoVQ4cOxYMHD8T+GQgEgs/apsRgMBgMBoPBqBtFRUVQV1dHYWGhVCv6DAaDwfg/6vIMrfPK87hx49CmTRucPn0aenp61XqCZDAYDAaDwWAwGAwG499CnY3nrKwsHD58mH2Hw2AwGAzGf5i9e/di7NixEvOMjIxw+/btr6wRg8FgMBhfljobz+3bt8e9e/eY8cxgMBiMfw2+vr54+fIljh079llyBAIBwsPD/xNeknv37o327dtLzPtaTkVjYmLQpUsXvHjxolqv2/8lWgRGooHCpzl3yw3uVc/aMBgMxr+PBrUXAdLS0rhj0qRJmDZtGkJDQ5GcnMzLS0tL+9L6MhgMBuNvxqZNm2BrawuhUAihUAgHBwcxp0oikQgCgQBXr17lpU+ZMgWdO3euU3uPHj2CvLw8WrRo8bmq/yfJzc2FQCAQO4YNG1YnOWpqajA1NZV4GBkZfSHtP40Kx196enpQUFCAkZERvv/+e5w8eVKiMy83NzfIyMggMTFRLM/X15cbMzk5Oejo6KBbt27YuXOnmBPVirYHDhwIHR0dKCoqwszMDH5+frh79y5XJjw8HB06dIC6ujrU1NRgbW2NKVOm1OsYMBgMBuPzkWrl2c7ODgKBgPcPZuTIkdzfFXnMYRiDwWD89zAwMEBwcDDMzMxARNi1axc8PT1x48YNWFtbc+UUFRUxa9YsxMbGflZ7oaGhGDRoEOLi4pCQkFDt6iejZs6fP8+7PkpKSt9Qmy/H8ePHMWjQILi6umLXrl0wNTVFaWkpLl++jDlz5qBjx468VeuHDx/i8uXLmDhxInbu3Im2bduKyezRowdCQkJQVlaGP//8E2fPnsXkyZNx+PBhnDhxArKyH39enTp1Cv3794ebmxv27t2LZs2aoaCgAIcOHcLcuXMRFhaG6OhoeHl5YfHixejduzcEAgHS09Nx7ty5rzVEDAaDwZASqVaec3JycP/+feTk5Eg8KvLu37//pfVlMBgMxt8MDw8PuLu7w8zMDObm5li8eDFUVVXFVpnHjBmDq1ev4syZM5/cFhEhJCQEw4cPx9ChQ7Fjxw5efsWq6sGDB9GxY0coKSmhbdu2uHv3LhITE9GmTRuoqqqiZ8+e+Ouvv8Tkz58/H9ra2hAKhRg3bhzevXvH5YlEIi40UgV2dnYICgqqVt9Zs2bB3NwcysrKMDExwdy5c/H+/XsuPygoCHZ2dtizZw9EIhHU1dUxePBgvHr1iitTXl6O5cuXw9TUFAoKCmjatCkWL17M5efl5WHQoEFo2LAhNDU14enpidzc3FrHUktLC7q6utyhrq4OAHj58iVGjx7NjUPXrl2RmprKq3v8+HG0bt0aioqKMDExwfz58/Hhw4dq20pMTES3bt3QqFEjqKurw9nZGdevX+eVEQgE2L59O/r27QtlZWWYmZnhxIkTvDJnzpyBubk5lJSU0KVLl1r7+fr1a4waNQq9evXC6dOn0b17d5iYmMDS0hKjRo1Camoq1+8KQkJC8P3332P8+PHYv38/3r59KyZXQUEBurq6aNKkCVq3bo1ffvkFx48fR0REBEJDQwEAb968wQ8//AB3d3ecOHECrq6uMDY2Rvv27bFy5Ups2bIFAHDy5Ek4OTlhxowZsLCwgLm5Ofr06YONGzfW2DcGg8FgfH2kMp6NjIykPhgMBoPx36WsrAwHDhzA69ev4eDgwMszNjbGuHHjEBAQIHF7qzRcuHABb968gaurK4YNG8a1VZXAwEDMmTMH169fh6ysLIYOHYqZM2di3bp1uHjxIu7duycWezg6OhoZGRmIiYnB/v37cfToUcyfP/+T9KxATU0NoaGhSE9Px7p167Bt2zasWbOGVyY7OxvHjh3DqVOncOrUKcTGxiI4OJjLDwgIQHBwMObOnYv09HTs27cPOjo6AID379/Dzc0NampquHjxIuLj46GqqooePXrwDP+6MHDgQBQUFCAiIgLJyclo3bo1XFxc8Pz5cwDAxYsXMWLECEyePBnp6enYsmULQkNDeQZ9VV69egUfHx9cunQJV69ehZmZGdzd3XkvCYCPLy8GDRqEtLQ0uLu7w9vbm2s3Ly8P/fr1g4eHB1JSUjB69Gj8/PPPNfYlKioKz549w8yZM6stUzlqSMXLmWHDhqF58+YwNTXF4cOHax0zAOjatStatmyJo0ePAgAiIyPx9OnTatuuWO3W1dXF7du3cevWLanaAYDS0lIUFRXxDgaDwWB8BaiOHD9+XOJx4sQJioqKovv379dVJIPBYDD+4aSlpZGKigrJyMiQuro6nT59mpdvZGREa9asoYKCAlJTU6Pdu3cTEdHkyZPJ2dlZ6naGDh1KU6ZM4c5btmxJISEh3HlOTg4BoO3bt3Np+/fvJwAUHR3NpS1dupQsLCy4cx8fH9LU1KTXr19zaZs2bSJVVVUqKyvj9aEyLVu2pMDAQO4cAIWHh1er/4oVK8je3p47DwwMJGVlZSoqKuLSZsyYQe3btycioqKiIlJQUKBt27ZJlLdnzx6ysLCg8vJyLq20tJSUlJQoMjJSYp2KMVJSUiIVFRXuuH79Ol28eJGEQiGVlJTw6jRr1oy2bNlCREQuLi60ZMkSMT309PSq7XdVysrKSE1NjU6ePMmlAaA5c+Zw58XFxQSAIiIiiIgoICCArKyseHJmzZpFAOjFixcS2wkODiYA9Pz5cy7t2rVrvH5X1iEqKoq0tbXp/fv3RES0Zs0asfnp4+NDnp6eEtvz8vIiS0tLIiJatmyZWNuSKC4uJnd3dwJARkZG5OXlRTt27BC7BpUJDAwkAGKH4ZSDZDTr1CcdDAaD8V+lsLCQAFBhYWGtZevsbbtPnz5i3z8D/O+ev/vuOxw7dgwaGhqfbNQzGAwG45+DhYUFUlJSUFhYiMOHD8PHxwexsbGwsrLildPW1sb06dMxb948eHl51amNly9f4ujRo7h06RKXNmzYMOzYsQO+vr68sra2ttzfFau0NjY2vLSCggJenZYtW0JZ+f88FTs4OKC4uBh5eXmfvLMqLCwM69evR3Z2NoqLi/HhwwcIhUJeGZFIBDU1Ne5cT0+P0y0jIwOlpaVwcXGRKD81NRX37t3j1QeAkpISZGdn16qbpaUld25oaIjt27ejuLgYWlpavLJv377l5KWmpiI+Pp630lxWVoaSkhK8efOGN4YV/Pnnn5gzZw5iYmJQUFCAsrIyvHnzBg8fPuSVq3zdVFRUIBQKeWNR9fv2qrsbpMHW1hYpKSkAADMzM9528507d8LLy4v7ZnnIkCGYMWMGsrOz0axZs1plV/wOqvhbGlRUVHD69GlkZ2fjwoULuHr1KqZNm4Z169bhypUrEsczICAAP/30E3deVFQEQ0NDqdpjMBgMxqdTZ+P53LlzmD17NhYvXox27doBAK5du4a5c+dizpw5UFdXx9ixYzF9+nSxb9EYDAaD8e9EXl6eC2Fob2+PxMRErFu3jvuuszI//fQTfvvtN/z22291amPfvn0oKSnhGVBEhPLycty9exfm5uZceuVQSRXGTNW0um4db9CggZhBVPn75apcuXIF3t7emD9/Ptzc3KCuro4DBw5g1apVvHJVwzpV1q02J17FxcWwt7fH3r17xfK0tbVrrGtoaCgWdrK4uBh6enqIiYkRK1+xzbi4uBjz589Hv379xMooKipKbMvHxwfPnj3DunXrYGRkBAUFBTg4OIhtLa9pLD4FMzMzAEBmZiY6dOgA4OP3ypLCbT5//hzh4eF4//49Nm3axKWXlZVh586dNW5LryAjIwPGxsYAwM3HO3fuSGXkN2vWDM2aNcPo0aMxe/ZsmJubIywsDD/88INYWQUFBSgoKNQqk8FgMBj1S52N58mTJ2Pr1q1wdHTk0lxcXKCoqIgxY8bg9u3bWLt2Lc8bN4PBYDD+W5SXl6O0tFRinqqqKubOnYugoCD07t1bapk7duzAtGnTxFaZJ0yYgJ07d/K+E/4UUlNT8fbtW85gvXr1KlRVVbkVPW1tbeTn53Pli4qKkJOTU628y5cvw8jICLNnz+bSHjx4UCedzMzMoKSkhOjoaIwePVosv3Xr1ggLC0Pjxo3FVrQ/hdatW+PJkyeQlZWFSCSqtkxmZqZEA7Q64uPj8dtvv8Hd3R3Ax++Xnz59WifdLC0txRyIVXVKV5Xu3btDU1MTy5YtQ3h4eI1l9+7dCwMDA7FY31FRUVi1ahUWLFgAGRmZauv//vvvuHnzJqZOncq13ahRIyxfvlxi2y9fvqw2NrVIJIKysrLE7/kZDAaD8e2QymFYZbKzsyX+gxYKhZy3bTMzszr/U2QwGAzGP5OAgADExcUhNzcXN2/eREBAAGJiYuDt7V1tnTFjxkBdXR379u2Tqo2UlBRcv34do0ePRosWLXjHkCFDsGvXrhq9PUvDu3fvMGrUKKSnp+PMmTMIDAzExIkT0aDBx3+VXbt2xZ49e3Dx4kXcvHkTPj4+NRpTZmZmePjwIQ4cOIDs7GysX7++VgOuKhXhvWbOnIndu3cjOzsbV69e5XZ2eXt7o1GjRvD09MTFixeRk5ODmJgY+Pv749GjR3UeA1dXVzg4OKBPnz6IiopCbm4uLl++jNmzZyMpKQkAMG/ePOzevRvz58/H7du3kZGRgQMHDmDOnDk1jsWePXuQkZGBhIQEeHt71zk01rhx45CVlYUZM2YgMzMT+/bt4zxbV4eqqiq2b9+O06dPo1evXoiMjMT9+/eRlpaG5cuXAwB3DXfs2IEBAwaIza9Ro0bh6dOnOHv2LCe3tLQUT548wePHj3H9+nUsWbIEnp6e+P777zFixAgAH7djV7Tdu3dvnD9/Hrm5uUhKSsLMmTMxbtw4AB89rs+cORMxMTHIycnBjRs3MHLkSLx//x7dunWr0xgxGAwG48tSZ+PZ3t4eM2bM4IX4+OuvvzBz5kwuFmJWVhb79obBYDD+IxQUFGDEiBGwsLCAi4sLEhMTERkZWeMPfzk5OSxcuBAlJSVStbFjxw5YWVmhefPmYnl9+/ZFQUHBZ4XAAj7uojIzM0OnTp3g5eWF3r1788JQBQQEwNnZGd9//z169eqFPn361PgdbO/evTF16lRMnDgRdnZ2uHz5MubOnVtnvebOnYtp06Zh3rx5sLS0hJeXF/cdsLKyMuLi4tC0aVP069ePC8FUUlLySSvRAoEAZ86cQadOnfDDDz/A3NwcgwcPxoMHD7hvx93c3HDq1ClERUWhbdu26NChA9asWVPjd+E7duzAixcv0Lp1awwfPhz+/v5o3LhxnXRr2rQpjhw5gmPHjqFly5bYvHkzlixZUmu9vn374vLly1BWVubmadeuXfH777/jwIED+P7775GcnIzU1FT0799frL66ujpcXFx4n6KdPXsWenp6EIlE6NGjBy5cuID169fj+PHjvBcqnp6euHz5MuTk5DB06FA0b94cQ4YMQWFhIRYtWgQAcHZ2xv379zFixAg0b94cPXv2xJMnTxAVFQULC4s6jRGDwWAwviwCktajxf8nMzMTnp6eyMnJ4QzkvLw8mJiY4Pjx4zA3N8exY8fw6tUrDB8+/IsozWAwGAwGg8H4SFFREdTV1VFYWFgv2/cZDAbjv0RdnqF1Np6Bj9+yRUVF4e7duwA+elnt1q0bt7WNwWAwGAwGg/F1YMYzg8FgfDpf3HhmMBgMBqO+UVVVrTYvIiICHTt2/IraMBj/HJjxzGAwGJ9OXZ6hUnnbXr9+PcaMGQNFRUWsX7++xrL+/v7Sa8pgMBh/I2JiYtClSxe8ePGiWi+434qgoCAcO3aMi0/7b6SmvjVp0uTrKfKJ5ObmwtjYGDdu3ICdnZ3U80kkEmHKlCmYMmXKV9O1rhARxo4di8OHD+PFixdcH78lnTt3hp2dHdauXVtr2a95b4eGhmLKlCl4+fLlF21HEi0CI9FAQTwudG5wr6+uC4PBYPwbkWqf9Zo1a7hwCWvWrKn2kOYfGIPB+GewadMm2NraQigUQigUwsHBAREREWLlLl++DHd3d2hoaEBRURE2NjZYvXo1ysrKpG5LIBCIhYcBAF9fX/Tp0+czelE3HB0dkZ+fD3V19a/WZgVHjhxB586doa6uDlVVVdja2mLBggV4/vz5V9flaxMUFAQ7OzuYmppWe9TFM/OFCxfg7u4OLS0tKCsrw8rKCtOmTcPjx4+/YC/EqTqfQkNDJRpuiYmJGDNmzFfVra6cPXsWoaGhOHXqFPLz89GiRQuxMjExMRAIBNyho6OD/v37c5E4PpUKuVWN0aNHj2LhwoVSyfhS97ZIJBL77ePl5cV91sZgMBiMfxdSGc85OTnQ0tLi/q7u+Nx/kAwG4++DgYEBgoODkZycjKSkJHTt2hWenp64ffs2VyY8PBzOzs4wMDDAhQsXcOfOHUyePBmLFi3C4MGD8U/7KkReXh66uroQCARftd3Zs2fDy8sLbdu2RUREBG7duoVVq1YhNTUVe/bs+aq6/NPZsmULXF1doauriyNHjiA9PR2bN29GYWEhVq1a9VV1kXY+aWtrQ1lZfLXw70R2djb09PTg6OgIXV1dyMpWv3EtMzMTf/zxBw4dOoTbt2/Dw8OjTi/TKvP+/ftq8zQ1NaGmpiaVnK95byspKdXZkziDwWAw/iHQZ/Lhwwe6ceMGPX/+/HNFMRiMvzkaGhq0fft2IiIqLi4mLS0t6tevn1i5EydOEAA6cOCAVHIBUHh4uFi6j48PeXp6cuclJSU0adIk0tbWJgUFBXJycqJr165x+c+fP6ehQ4dSo0aNSFFRkUxNTWnnzp1ERJSTk0MAaP/+/eTg4EAKCgpkbW1NMTExXP0LFy4QAHrx4gWXdunSJXJ2diYlJSVq2LAhde/enXvelZWV0ZIlS0gkEpGioiLZ2trSoUOHpOpzBQkJCQSA1q5dKzG/QpfAwEBq2bIl7d69m4yMjEgoFJKXlxcVFRVxZSMiIsjJyYnU1dVJU1OTevXqRffu3ePyK8bgyJEj1LlzZ1JSUiJbW1u6fPkyr82tW7eSgYEBKSkpUZ8+fWjVqlWkrq7OK3Ps2DFq1aoVKSgokLGxMQUFBdH79++JiKi8vJwCAwPJ0NCQ5OXlSU9PjyZNmiSxfyEhIQSAd4SEhBAR0YMHD6h3796koqJCampqNHDgQHry5Em1Y5mXl0fy8vI0ZcqUGseSiOjw4cNkZWVF8vLyZGRkRCtXruSVNTIyosWLF9MPP/xAqqqqZGhoSFu2bOGVSUhIIDs7O1JQUCB7e3s6evQoAaAbN24QEX8+Vfxd+QgMDOTaWrNmDSe3tn5LMxcOHTpELVq0IEVFRdLU1CQXFxcqLi6uduxiYmKobdu2JC8vT7q6ujRr1izuevr4+PD0NjIykihD0v2zd+9eAkB37tyha9eukaurK2lpaZFQKKROnTpRcnIyTwYA+u2338jDw4OUlZXF2gZAPj4+RETk7OxMkydP5uqWlJTQzJkzycDAgOTl5alZs2bc86qqbiEhIaSurk7h4eFkampKCgoK1L17d3r48CEn7969e9S7d29q3LgxqaioUJs2bejcuXNcvrOzs5hulWVX5rfffiMTExOSk5Mjc3Nz2r17t1i/t23bRn369CElJSUyNTWl48ePV3u9qlJYWEgAyHDKQTKadUrsYDAYDEb1VDxDCwsLay1bZ+N58uTJ3D+jDx8+kKOjIwkEAlJRUaELFy7UWVkGg/H358OHD7R//36Sl5en27dvExFxhkJVw6sCc3NznuFbE9Iaz/7+/qSvr09nzpyh27dvk4+PD2loaNCzZ8+IiOjHH38kOzs7SkxMpJycHDp37hydOHGCiP7PcDQwMKDDhw9Teno6jR49mtTU1Ojp06dEJP4D+8aNG6SgoEDjx4+nlJQUunXrFm3YsIH++usvIiJatGgRNW/enM6ePUvZ2dkUEhJCCgoKPIPcyMiIM5Ik4e/vT6qqqvTu3bsaxygwMJBUVVWpX79+dPPmTYqLiyNdXV365ZdfuDKHDx+mI0eOUFZWFt24cYM8PDzIxsaGysrKeGPQvHlzOnXqFGVmZtKAAQPIyMiIM5QuXbpEDRo0oBUrVlBmZiZt3LiRNDU1ecZAXFwcCYVCCg0NpezsbIqKiiKRSERBQUFE9NFwEwqFdObMGXrw4AElJCTQ1q1bJfbrzZs3NG3aNLK2tqb8/HzKz8+nN2/eUFlZGdnZ2dF3331HSUlJdPXqVbK3tydnZ+dqx2j16tUEgP74448axzIpKYkaNGhACxYsoMzMTAoJCSElJSXOaCf6eN00NTVp48aNlJWVRUuXLqUGDRrQnTt3iIjo1atXpK2tTUOHDqVbt27RyZMnycTEpFrjubS0lNauXUtCoZDr56tXr7i2Koxnafpd21z4448/SFZWllavXk05OTmUlpZGGzdu5NqryqNHj0hZWZkmTJhAGRkZFB4eTo0aNeLm7cuXL2nBggVkYGBA+fn5VFBQIFGOJOO54jmRlpZG0dHRtGfPHsrIyKD09HQaNWoU6ejo8Ix+ANS4cWPauXMnZWdnU25uLh05coQAUGZmJuXn59PLly+JSNx4HjRoEBkaGtLRo0cpOzubzp8/z73Ak2Q8y8nJUZs2bejy5cuUlJRE7dq1I0dHR05eSkoKbd68mW7evEl3796lOXPmkKKiIj148ICIiJ49e0YGBga0YMEC7ppWyK58vxw9epTk5ORo48aNlJmZSatWrSIZGRn6/fffef02MDCgffv2UVZWFvdcqHi2VaWkpIQKCwu5Iy8vjxnPDAaD8Yl8UeO5SZMmlJiYSERE4eHhpK+vT5mZmTRnzhzePx0Gg/HPJy0tjVRUVEhGRobU1dXp9OnTXF5wcLDYD+XK9O7dmywtLaVqBwApKiqSiooK75CVleWM5+LiYpKTk6O9e/dy9d69e0f6+vq0fPlyIiLy8PCgH374QWIbFYZjcHAwl/b+/XsyMDCgZcuWEZH4D+whQ4aQk5OTRHklJSWkrKws9vJg1KhRNGTIEO68a9eutGHDhmr73rNnT7K1ta02v4LAwEBSVlbmGRozZsyg9u3bV1vnr7/+IgB08+ZNIvq/Mah4AUpEdPv2bQJAGRkZRETk5eVFvXr14snx9vbmGQMuLi60ZMkSXpk9e/aQnp4eERGtWrWKzM3Na30hULlvLVu25KVFRUWRjIwMbyWwQtfKuw0qM378eBIKhbW2N3ToUOrWrRsvbcaMGWRlZcWdGxkZ0bBhw7jz8vJyaty4MW3atImIiLZs2UJaWlr09u1brsymTZuqNZ6JJK9IVrRVYTxL0+/a5kJycjIBoNzc3FrHgojol19+IQsLCyovL+fSNm7cSKqqqtyLlzVr1lS74lxB1f7+8ccf5OjoSE2aNKHS0lKx8mVlZaSmpkYnT57k0gCI7RyQZJQT8Y3nzMxMAsBbGa5JRsWOh6tXr3JlMjIyCAAlJCRU20dra2ve/Vx110CF7MrX2dHRkfz8/HhlBg4cSO7u7rx+z5kzhzsvLi4mABQRESFRj8DAQLFVb2Y8MxgMxqdRF+O5zoGZnz59Cl1dXQDAmTNnMHDgQJibm2PkyJG4efNmXcUxGIy/MRYWFkhJSUFCQgLGjx8PHx8fpKen88pQPX3XvGbNGqSkpPCO3r17c/nZ2dl4//49nJycuDQ5OTm0a9cOGRkZAIDx48fjwIEDsLOzw8yZM3H58mWxdhwcHLi/ZWVl0aZNG65+VVJSUuDi4iIx7969e3jz5g26desGVVVV7ti9ezeys7O5ctHR0Zg4cWK1/a7L+IlEIt43nnp6eigoKODOs7KyMGTIEJiYmEAoFEIkEgEAHj58yJNja2vLkwGAk5OZmYl27drxylc9T01NxYIFC3j99vPzQ35+Pt68eYOBAwfi7du3MDExgZ+fH8LDw/Hhwwep+wkAGRkZMDQ0hKGhIZdmZWWFhg0bVnu9iEiqb1ozMjJ48wgAnJyckJWVxfs2t/I4CQQC6OrqcuOUkZEBW1tbKCoqcmUqz61PRdp+1zQXWrZsCRcXF9jY2GDgwIHYtm0bXrx4UWObDg4OvLFzcnJCcXExHj16VOc+GBgYQEVFBfr6+nj9+jWOHDkCeXl5/Pnnn/Dz84OZmRnU1dUhFApRXFwsNj/btGlT5zZTUlIgIyMDZ2dnqevIysqibdu23Hnz5s1541xcXIzp06fD0tISDRs2hKqqKjIyMsT0rY3q5lvVeVx5vqmoqEAoFPLu78oEBASgsLCQO/Ly8uqkE4PBYDA+DalCVVVGR0cH6enp0NPTw9mzZ7Fp0yYAwJs3byAjI1PvCjIYjG+HvLw8TE1NAQD29vZITEzEunXrsGXLFpibmwP4+MPQ0dFRrG5GRgasrKykbktXV5drqwI1NbU6hXvp2bMnHjx4gDNnzuDcuXNwcXHBjz/+iJUrV0otozI1eXguLi4GAJw+fVosjJKCgoLUbZibm+PSpUt4//495OTkaixbNV8gEKC8vJw79/DwgJGREbZt2wZ9fX2Ul5ejRYsWePfuXbVyKgymynJqo7i4GPPnz0e/fv3E8hQVFWFoaIjMzEycP38e586dw4QJE7BixQrExsbW2sfPwdzcHIWFhcjPz+deCnwOtY33t6Qm3WRkZHDu3DlcvnwZUVFR2LBhA2bPno2EhAQYGxt/cd0uXrwIoVCIxo0b8wx8Hx8fPHv2DOvWrYORkREUFBTg4OAgNj9VVFTq3GZdvLFLy/Tp03Hu3DmsXLmS8/g+YMAAMX3ri7rMNwUFhTo9ZxgMBoNRP9R55fmHH37AoEGD0KJFCwgEAri6ugIAEhIS0Lx583pXkMFg/H0oLy9HaWkpAKB79+7Q1NSU6MH4xIkT3CpofdGsWTPIy8sjPj6eS3v//j0SExN5Rrq2tjZ8fHzwv//9D2vXrsXWrVt5cq5evcr9/eHDByQnJ8PS0lJim7a2toiOjpaYZ2VlBQUFBTx8+FAsrFLlVcPaGDp0KIqLi/Hbb79JzJf25cGzZ8+QmZmJOXPmwMXFBZaWljWuNlaHhYUFEhMTeWlVz1u3bo3MzEyJIaUaNPj4b0VJSQkeHh5Yv349YmJicOXKlWp3J8nLy4t5Y7a0tEReXh5vRS09PR0vX76s9qXMgAEDIC8vj+XLl0vMrxhLS0tL3jwCgPj4eJibm0v9EtjS0hJpaWkoKSnh0irPLUlI6qckuXXttyQEAgGcnJwwf/583LhxA/Ly8ggPD6+2zStXrvB2QcTHx0NNTQ0GBgZSt1mBsbExmjVrJuYJOz4+Hv7+/nB3d4e1tTUUFBTw9OnTWuXJy8sDQI1jZ2Njg/LycsTGxkqt54cPH5CUlMSdZ2Zm4uXLl9zzID4+Hr6+vujbty9sbGygq6uL3NxcMd2kuaaS5ltdrieDwWAw/h7UeeU5KCgILVq0QF5eHgYOHMi9+ZSRkcHPP/9c7woyGIxvQ0BAAHr27ImmTZvi1atX2LdvH2JiYhAZGQng4+rQli1bMHjwYIwZMwYTJ06EUChEdHQ0ZsyYgQEDBmDQoEH1po+KigrGjx+PGTNmQFNTE02bNsXy5cvx5s0bjBo1CgAwb9482Nvbw9raGqWlpTh16pSYYbxx40aYmZnB0tISa9aswYsXLzBy5Mhqx8DGxgYTJkzAuHHjIC8vjwsXLmDgwIFo1KgRpk+fjqlTp6K8vBzfffcdCgsLER8fD6FQCB8fHwCAi4sL+vbtW+3W7fbt22PmzJlcHOK+fftCX18f9+7dw+bNm/Hdd99h8uTJtY6PhoYGtLS0sHXrVujp6eHhw4ef9EyeNGkSOnXqhNWrV8PDwwO///47IiIieFt6582bh++//x5NmzbFgAED0KBBA6SmpuLWrVtYtGgRQkNDUVZWhvbt20NZWRn/+9//oKSkBCMjI4ltikQi5OTkICUlBQYGBlBTU4OrqytsbGzg7e2NtWvX4sOHD5gwYQKcnZ2r3dZraGiINWvWYOLEiSgqKsKIESMgEonw6NEj7N69G6qqqli1ahWmTZuGtm3bYuHChfDy8sKVK1fw66+/VvsCQxJDhw7F7Nmz4efnh4CAAOTm5ta6w0EkEqG4uBjR0dFo2bIllJWVxUJUfUq/q5KQkIDo6Gh0794djRs3RkJCAv76669qXxJNmDABa9euxaRJkzBx4kRkZmYiMDAQP/30E/cypD4wMzPDnj170KZNGxQVFWHGjBlSrRgbGRlBIBDg1KlTcHd3h5KSElRVVXllRCIRfHx8MHLkSKxfvx4tW7bEgwcPUFBQUO1zSE5ODpMmTcL69eshKyuLiRMnokOHDtxnCmZmZjh69Cg8PDwgEAgwd+5csZVgkUiEuLg4DB48GAoKCmjUqJFYOzNmzMCgQYPQqlUruLq64uTJkzh69CjOnz8v7dAxGAwG4+/CF/7+msFg/EMZOXIkGRkZkby8PGlra5OLiwtFRUWJlYuLiyM3NzcSCoUkLy9P1tbWtHLlSvrw4YPUbUFKb9tv376lSZMmUaNGjSSGqlq4cCFZWlqSkpISaWpqkqenJ92/f5+I/s9Z1r59+6hdu3YkLy9PVlZWPI+3khwTxcTEkKOjIykoKFDDhg3Jzc2Nyy8vL6e1a9eShYUFycnJkba2Nrm5uVFsbCxXvzZv2xWEhYVRp06dSE1NjVRUVMjW1pYWLFggFqqqMlWdOJ07d44sLS1JQUGBbG1tKSYmhje2FWNQ4dCK6GP4JgC8aAlbt26lJk2acKGqFi1aRLq6ury2z549S46OjqSkpERCoZDatWvHedQODw+n9u3bk1AoJBUVFerQoQOdP3++2r6XlJRQ//79qWHDhp8VqqryOLi5uZGGhgYpKipS8+bNafr06Twv3BWhquTk5Khp06a0YsUKngxJjqBatmzJu5ZXrlyhli1bkry8PNnZ2XFeoatzGEZENG7cONLS0qqXUFWVqTwX0tPTyc3NjQvpZm5uXqPTOqKaQ1VVlV8d1Tn2quD69evUpk0bUlRUJDMzMzp06JBY36t7FixYsIB0dXVJIBBUG6rq7du3NHXqVNLT0yN5eXleqLrqnLcdOXKETExMSEFBgVxdXTlP2kQf75cuXbqQkpISGRoa0q+//irW5pUrV8jW1pYUFBQ+O1RV1X6rq6vzPMDXBAtVxWAwGJ9OXRyGCYjq7u0nOjoa0dHRKCgoEHsLu3Pnzk+14xkMBuOLkZubC2NjY9y4cQN2dnbfWp1/FH5+frhz5w4uXrz4rVVhMOqF0NBQTJkypU4+Ff7OFBUVQV1dHYWFhRAKhd9aHQaDwfhHUZdnaJ23bc+fPx8LFixAmzZtoKenJ5VnUwaDwWD8c1i5ciW6desGFRUVREREYNeuXXXa0sxgMBgMBoPxb6TOxvPmzZsRGhqK4cOHfwl9GAzGv4wlS5ZgyZIlEvM6duyIiIiIr6wRozauXbuG5cuX49WrVzAxMcH69esxevTob60Wg8FgMBgMxjelztu2tbS0cO3aNTRr1uxL6fS3ourWrqCgIBw7dgwpKSlS1RcIBAgPD0efPn3qXbe66vIt+JL9/xrUh/6dO3eGnZ0d1q5dW296/ZN4/vw5nj9/Lpa+fv16REdH4/bt299Aq2+DSCTClClTMGXKlHqVU9d5Wt9bVmNiYtClSxe8ePECDRs2rBeZ/zXqa24w/hn/G+ubii2HhlMOooGCcu0V/j+5wb2+oFYMBoPxz6Au27br7EZz9OjR2Ldv3ycrV5lNmzbB1tYWQqEQQqEQDg4OYqtQIpEIAoEAAoEAKioqaN26NQ4dOiSV/Ddv3iAgIADNmjWDoqIitLW14ezsjOPHj3+yztOnT682dI0k8vPz0bNnTwAfv7kUCASf9A9dIBDg2LFjn6VLfRETEwOBQCDxh7dIJOIZiZX7XxuS+vi1CAoK+k9+B/vu3TssX76c8/zbqFEjODk5ISQkBO/fv5dKRm1jp6mpKTGkkaam5heN+ftPpaioCLNnz0bz5s2hqKgIXV1duLq64ujRo6juXWdd7jMA8PLywt27d+tLZam5ceMGBg4cCB0dHSgqKsLMzAx+fn510uVbPifqg9DQUIkvGBITEzFmzJgv0mbnzp25/6OKioowNzfH0qVLq51PjJqpbR7X9r++ujnw9u1baGpqolGjRlxIQAaDwWD8vajztu2SkhJs3boV58+fh62trdiP39WrV0sty8DAAMHBwTAzMwMRYdeuXfD09MSNGzdgbW3NlVuwYAH8/PxQVFSEVatWwcvLC02aNIGjo2ON8seNG4eEhARs2LABVlZWePbsGS5fvoxnz57VrdOVUFVVFQuRURO6urqf3FZ96/It+JL9Z3we7969g5ubG1JTU7Fw4UI4OTlBKBTi6tWrWLlyJVq1avWffKHwLXn58iUX8mrRokVo27YtZGVlERsbi5kzZ6Jr164Sf3TX9T5TUlKSKkRQfXLq1Cn0798fbm5u2Lt3L5o1a4aCggIcOnQIc+fORVhY2FfV5++Gtrb2F5Xv5+eHBQsWoLS0FL///jvGjBmDhg0bYvz48V+03X8q79+/l/hy70vO4yNHjsDa2hpEhGPHjsHLy+tzusBgMBiML0CdV57T0tJgZ2eHBg0a4NatW7hx4wZ31HVF1cPDA+7u7jAzM4O5uTkWL14MVVVVXL16lVdOTU0Nurq6MDc3x8aNG6GkpISTJ0/WKv/EiRP45Zdf4O7uDpFIBHt7e0yaNIkX0/XFixcYMWIENDQ0oKysjJ49eyIrK6tamZJW2Xbu3Alra2soKChAT0+PF8+18iqJsbExAKBVq1YQCATo3LkzgI8rDt26dUOjRo2grq4OZ2dnXL9+nZMhEokAAH379oVAIODOq+pSXl6OBQsWwMDAAAoKCrCzs8PZs2e5/Iq34UePHkWXLl2grKyMli1b4sqVK7WO5adSuf/v3r3DxIkToaenB0VFRRgZGWHp0qU19hH4uEOhWbNmkJeXh4WFBfbs2SPWxqZNm9CzZ08oKSnBxMQEhw8f5pWZNWsWzM3NoaysDBMTE8ydO5dbWQ0NDcX8+fORmprKrc6EhoZydZ8+fYq+fftCWVkZZmZmOHHiBE92bGws2rVrx13/n3/+GR8+fKh2TKSZc9u2bYOhoSGUlZXRt29frF69mjOacnNz0aBBAyQlJfHqrF27FkZGRmIe8Ktj7dq1iIuLQ3R0NH788UfY2dnBxMQEQ4cORUJCAszMzLB7925oaWmJrYL06dMHw4cPr3HsHj58CE9PT6iqqkIoFGLQoEH4888/q9WntvkLAJcvX4adnR0UFRXRpk0bHDt2jFvhISKYmpqKxdpNSUmBQCDAvXv3pBqXsrIyjBo1CsbGxlBSUoKFhQXWrVvHK+Pr64s+ffpg5cqV0NPTg5aWFn788Ufean1BQQE8PDygpKQEY2Nj7N27t9a2f/nlF+Tm5iIhIQE+Pj6wsrKCubk5/Pz8kJKSUu3Lssr3mTT3uaSVr5MnT6Jt27ZQVFREo0aN0LdvXy6vIjZvxbN46NChKCgoqLU/Fbx58wY//PAD3N3dceLECbi6usLY2Bjt27fHypUrsWXLFqmu3+c8J+7cuYPvvvsOioqKsLKywvnz58VWsfPy8jBo0CA0bNgQmpqa8PT0RG5uLpcvzXUvLS3F9OnT0aRJE6ioqKB9+/aIiYkB8HHXzg8//IDCwkLufgkKCgIgvmvn5cuXGDt2LLe62aJFC5w6dQoA8ODBA3h4eEBDQwMqKiqwtrbGmTNnarwGysrK0NXVhZGREX744QfY2tri3LlzUuldQU3PJQBITU1Fly5doKamBqFQCHt7e7HnVAWSVmdfvnwJgUDAGy+BQIDo6Gi0adMGysrKcHR0RGZmJk9WcHAwdHR0oKamhlGjRqGkpESsve3bt8PS0hKKiopo3rw5zwFehS5hYWFwdnaGoqKixPtVmnn8OezYsQPDhg3DsGHDsGPHjs+SxWAwGIwvxBcLmFVHPnz4QPv37yd5eXm6ffs2ly4p1qa6ujr99NNPtcq0sLCgQYMGUVFRUbVlevfuTZaWlhQXF0cpKSnk5uZGpqam9O7dOyISj9dYNb7mb7/9RoqKirR27VrKzMyka9euVRuz8tq1awSAzp8/T/n5+fTs2TMiIoqOjqY9e/ZQRkYGpaen06hRo0hHR4fTu6CggIt9mp+fTwUFBRJ1Wb16NQmFQtq/fz/duXOHZs6cSXJycnT37l0i+r8Yr82bN6dTp05RZmYmDRgwgIyMjHjxPFEpzqokaorlWVPMzhUrVpChoSHFxcVRbm4uXbx4kfbt21djH48ePUpycnK0ceNGyszMpFWrVpGMjAwvNi8A0tLSom3btlFmZibNmTOHZGRkKD09nSuzcOFCio+Pp5ycHDpx4gTp6OjQsmXLiIjozZs3NG3aNLK2tqb8/HzKz8+nN2/ecLINDAxo3759lJWVRf7+/qSqqspdu0ePHpGysjJNmDCBMjIyKDw8nBo1asSLBVs1Lmhtc+7SpUvUoEEDWrFiBWVmZtLGjRtJU1OTNw+7detGEyZM4I29ra0tzZs3r9rrVhVbW1vq3r17jWXevHlD6urqdPDgQS7tzz//JFlZWfr999+rHbuysjKys7Oj7777jpKSkujq1atkb29Pzs7OnJy6zt/CwkLS1NSkYcOG0e3bt+nMmTNkbm7Oi6u7ePFisrKy4vXB39+fOnXqJPW4vHv3jubNm0eJiYl0//59+t///kfKysoUFhbGlfHx8SGhUEjjxo2jjIwMOnnyJCkrK3NxjomIevbsSS1btqQrV65QUlISFxO56vOsgrKyMtLQ0KAxY8bUqmNN95k093nV59qpU6dIRkaG5s2bR+np6ZSSkkJLlizh8nfs2EFnzpyh7OxsunLlCjk4OFDPnj25/Nri+x49epQA0OXLl2vsV23X71OfEx8+fCALCwvq1q0bpaSk0MWLF6ldu3a8cXv37h1ZWlrSyJEjKS0tjdLT02no0KFkYWFBpaWlRCTddR89ejQ5OjpSXFwc3bt3j1asWEEKCgp09+5dKi0tpbVr15JQKOTul1evXold07KyMurQoQNZW1tTVFQUZWdn08mTJ+nMmTNERNSrVy/q1q0bpaWlcXmVY4tXpfIzqLy8nOLi4khZWZm8vLyk0ptIuueStbU1DRs2jDIyMuju3bt08OBBSklJkaiTNDHHK+ZV+/btKSYmhm7fvk0dO3YkR0dHrk5YWBgpKCjQ9u3b6c6dOzR79mxSU1PjPVv+97//kZ6eHh05coTu379PR44cIU1NTQoNDeXpIhKJuDKVY4JXIO08ltS3ykiKA33v3j1SUFCg58+f07Nnz0hRUZFyc3OrbaOkpIQKCwu5Iy8vr8Y4z9UdDAaDwahbnOdvbjynpaWRiooKycjIkLq6Op0+fZqXX/kHRWlpKS1ZsoQA0KlTtT/0Y2NjycDAgOTk5KhNmzY0ZcoUunTpEpd/9+5dAkDx8fFc2tOnT0lJSYkzFmoznvX19Wn27NnV6iDpR211/1ArKCsrIzU1NTp58qREOTXpsnjxYl6Ztm3bckZWRfvbt2/n8m/fvk0AKCMjg0uzsLCgo0ePVqtfxQ8aFRUVsUMgEFT7o37SpEnUtWtXKi8vlyhXUh8dHR3Jz8+PlzZw4EByd3fn1Rs3bhyvTPv27Wn8+PHV9mHFihVkb2/PnVcdy8qy58yZw50XFxcTAIqIiCAiol9++YUsLCx4fdq4cSOpqqpSWVkZEfF/uEoz57y8vKhXr148Pby9vXnzMCwsjDQ0NKikpISIiJKTk0kgEFBOTk61fa6KkpIS+fv711pu/PjxPENp1apVZGJiwvVZ0thFRUWRjIwMPXz4kEurmGvXrl2TWK+2+btp0ybS0tKit2/fcvnbtm3j3VOPHz8mGRkZSkhIIKKPBlGjRo24H8mfyo8//kj9+/fnzn18fMjIyIg+fPjApQ0cOJAzRjIzM3l9JSLKyMggANUaz3/++ScBoNWrV9eqjzTGc033edXnmoODA3l7e9fabgWJiYkEgDP8ajOely1bRgDo+fPnNcqV5vp9ynMiIiKCZGVlKT8/n8s/d+4cT9aePXvE7uXS0lJSUlKiyMhIIqr9uj948IBkZGTo8ePHPF1cXFwoICCAiCQbTkT8axoZGUkNGjSgzMxMieNkY2NDQUFBEvMk4ezsTHJycqSiokJycnIEgBQVFbnnkDR6S/NcUlNTk/peq4vxfP78ea7M6dOnCQD3HHBwcBB7kdi+fXves6VZs2bci9oKFi5cSA4ODjxd1q5dW6PO0s7jTzGef/nlF+rTpw937unpyXsJW5XAwEACIHYw45nBYDDqTl2MZ6m3bffr10+qo65YWFggJSUFCQkJGD9+PHx8fJCens4rM2vWLKiqqkJZWRnLli1DcHAwevWq3UNkp06dcP/+fURHR2PAgAG4ffs2OnbsiIULFwIAMjIyICsri/bt23N1tLS0YGFhgYyMjFrlFxQU4I8//oCLi0sde83nzz//hJ+fH8zMzKCurg6hUIji4mI8fPhQahlFRUX4448/4OTkxEt3cnIS64utrS33t56eHgDwtmDeuXOHt2WzOi5evIiUlBTeoa+vX215X19fpKSkwMLCAv7+/oiKiqq1jYyMDKn65ODgIHZeuUxYWBicnJygq6sLVVVVzJkzR+rxrTxeKioqEAqF3HhlZGTAwcGBF+/cyckJxcXFePTokcT+1DbnMjMz0a5dO169qud9+vSBjIwMwsPDAXzchtulSxfeNtbaICmdBfn5+SEqKgqPHz/m2vL19a0xxntGRgYMDQ1haGjIpVlZWaFhw4YS7y1p5m9mZiZsbW2hqKjI5VcdF319ffTq1Qs7d+4E8HErcmlpKQYOHChVXyvYuHEj7O3toa2tDVVVVWzdulVsvlhbW0NGRoY719PT480LWVlZ2Nvbc/nNmzev0RO1tNdDWmq7zyuTkpJS43MsOTkZHh4eaNq0KdTU1ODs7AwAUt9D0vbtU69fbc+JzMxMGBoa8r4Nrzp3UlNTce/ePaipqXH+JDQ1NVFSUoLs7GyuXE3X/ebNmygrK4O5uTknQ1VVFbGxsTwZtZGSkgIDAwOYm5tLzPf398eiRYvg5OSEwMBApKWl1SrT29sbKSkpiI+PR8+ePTF79mzOb4g0ekvzXPrpp58wevRouLq6Ijg4uE59roma5nJGRgbveQrw/x+8fv0a2dnZGDVqFK9vixYtEtOvTZs2NepR3/doBWVlZdi1axeGDRvGpQ0bNgyhoaHVfoYTEBCAwsJC7sjLy/siujEYDAaDj9QOw9TV1b+IAvLy8jA1NQUA2NvbIzExEevWreN9OzRjxgz4+vpCVVUVOjo6Nf5or4qcnBw6duyIjh07YtasWVi0aBEWLFiAWbNmfbbu9eVwx8fHB8+ePcO6detgZGQEBQUFODg44N27d/UivyqVnaBUjKW038lWxtjYWMwYkJWtfkq1bt0aOTk5iIiIwPnz5zFo0CC4urqKfZ9c31y5cgXe3t6YP38+3NzcoK6ujgMHDmDVqlVS1a/qNEYgEHzSeNUn8vLyGDFiBEJCQtCvXz/s27dP7Lvc2jA3N8edO3dqLdeqVSu0bNkSu3fvRvfu3XH79m2cPn36U1X/4owePRrDhw/HmjVrEBISAi8vLygrSx+65cCBA5g+fTpWrVoFBwcHqKmpYcWKFUhISOCVq+95oa2tjYYNG0p1TaShLvd5Tc+y169fw83NjXOQpK2tjYcPH8LNzU3qZ1SFEXjnzh2xF11V+dzr96kUFxfD3t5e4reulZ151XTdi4uLISMjg+TkZJ6BDaBOzh1r+98yevRouLm54fTp04iKisLSpUuxatUqTJo0qdo66urq3P/agwcPwtTUFB06dICrq2u96R0UFIShQ4fi9OnTiIiIQGBgIA4cOCDxZWyDBh/f3Vc2SKvz8P85/7OKi4sBfPxeu6qRXbWvKioqNcqqyzyuC5GRkXj8+LGYg7CysjJER0ejW7duYnUUFBSgoKBQbzowGAwGQzqkXnkOCQmR6vhcysvLxZwTNWrUCKamptDV1a2T4SwJKysrfPjwASUlJbC0tMSHDx94P4qfPXuGzMxMWFlZ1SpLTU0NIpFI6nBR8vLyAD7+Q6xMfHw8/P394e7uzjkee/r0Ka+MnJycWL3KCIVC6OvrIz4+Xky2NH35WgiFQnh5eWHbtm0ICwvDkSNHuBjAkvpoaWkpVZ+qOpm7evUqLC0tAXx0MmVkZITZs2ejTZs2MDMzw4MHD3jl5eXlaxzf6rC0tMSVK1d4PwDj4+OhpqYGAwMDieVrm3MWFhZITEzk1at6Dnz8AX3+/Hn89ttv+PDhQ513fgwdOhTnz5/HjRs3xPLev3+P169f89oKDQ1FSEgIXF1deSvKksbO0tISeXl5vNWQ9PR0vHz5UuJ8lGb+WlhY4ObNm7zng6RxcXd3h4qKCjZt2oSzZ8/yHARKQ3x8PBwdHTFhwgS0atUKpqamdV5Ba968OT58+IDk5GQuLTMzs8a4yg0aNMDgwYOxd+9e/PHHH2L5xcXFNTqi+xxsbW2rfY7duXMHz549Q3BwMDp27IjmzZvXyVkYAHTv3h2NGjXC8uXLJeZXHpfart+nPCcsLCyQl5fHc1hXde60bt0aWVlZaNy4sVhYNWlfHrdq1QplZWUoKCgQk1Gx6i3Ns8bW1haPHj2qMYSXoaEhxo0bh6NHj2LatGnYtm2bVDoCHw3iyZMnY/r06SAiqfSW9rlkbm6OqVOnIioqCv369av2d0HFC4n8/Hwu7VPCOFpaWoq92Kr8/0BHRwf6+vq4f/++WN8qnHhKS13mcV3YsWMHBg8eLLaTa/DgwcxxGIPBYPzNqLO37fokICAAcXFxyM3Nxc2bNxEQEICYmBh4e3vXi/zOnTtjy5YtSE5ORm5uLs6cOYNffvkFXbp0gVAohJmZGTw9PeHn54dLly4hNTUVw4YNQ5MmTeDp6SlVG0FBQVi1ahXWr1+PrKwsXL9+HRs2bJBYtnHjxlBSUsLZs2fx559/orCwEABgZmaGPXv2ICMjAwkJCfD29hZbeagw0p88eYIXL15IlD9jxgwsW7YMYWFhyMzMxM8//4yUlBRMnjy5DqP28Yd/xXbg+mT16tXYv38/7ty5g7t37+LQoUPQ1dXlVq8l9XHGjBkIDQ3Fpk2bkJWVhdWrV+Po0aOYPn06T/ahQ4ewc+dO3L17F4GBgbh27Rrn9dzMzAwPHz7EgQMHkJ2djfXr14v1TyQSIScnBykpKXj69KnUMTYnTJiAvLw8TJo0CXfu3MHx48cRGBiIn376iVtZqYw0c27SpEk4c+YMVq9ejaysLGzZsgURERFiL44sLS3RoUMHzJo1C0OGDKnzTogpU6bAyckJLi4u2LhxI1JTU3H//n0cPHgQHTp04HkAHzp0KB49eoRt27aJGTOSxs7V1RU2Njbw9vbG9evXce3aNYwYMQLOzs7Vbo2sbf4OHToU5eXlGDNmDDIyMhAZGcl5Zq48NjIyMvD19UVAQADMzMzqvEJkZmaGpKQkREZG4u7du5g7d65EI6EmLCws0KNHD4wdOxYJCQlITk7G6NGja71GixcvhqGhIdq3b4/du3cjPT0dWVlZ2LlzJ1q1asWtotU3gYGB2L9/PwIDA5GRkYGbN29i2bJlAICmTZtCXl4eGzZswP3793HixAnu0xdpUVFRwfbt23H69Gn07t0b58+fR25uLpKSkjBz5kyMGzeOK1vb9fuU50S3bt3QrFkz+Pj4IC0tDfHx8ZgzZw6A/5s73t7eaNSoETw9PXHx4kXk5OQgJiYG/v7+Ej/BkIS5uTm8vb0xYsQIHD16FDk5Obh27RqWLl3K7dYQiUQoLi5GdHQ0nj59ijdv3ojJcXZ2RqdOndC/f3+cO3eO27FT4X1+ypQpiIyMRE5ODq5fv44LFy5wLwulZezYsbh79y6OHDkild61PZfevn2LiRMnIiYmBg8ePEB8fDwSExOr1UtJSQkdOnRAcHAwMjIyEBsby12TujB58mTs3LkTISEh3PP/9u3bvDLz58/H0qVLsX79ety9exc3b95ESEhInUJrAnWbx8DHF2ZVDeKqq+t//fUXTp48CR8fH7Ro0YJ3jBgxAseOHeNeMDMYDAbjb8CX/Pi6NkaOHElGRkYkLy9P2tra5OLiQlFRUbwykrxtS8uSJUvIwcGBNDU1SVFRkUxMTMjf35+ePn3KlXn+/DkNHz6c1NXVSUlJidzc3DjvokS1OwwjItq8eTNZWFiQnJwc6enp0aRJk7g8VHFus23bNjI0NKQGDRpwnoevX79Obdq0IUVFRTIzM6NDhw6J9fvEiRNkampKsrKyZGRkJFGXsrIyCgoKoiZNmpCcnBy1bNmSc2xFJJ2Dlgqdv4S37a1bt5KdnR2pqKiQUCgkFxcXun79eo19JPro0dzExITk5OTI3Nycdu/ezWsTAG3cuJG6detGCgoKJBKJeJ6RiYhmzJhBWlpapKqqSl5eXrRmzRredS0pKaH+/ftTw4YNef2vev2IPnp7rzw+MTEx1LZtW5KXlyddXV2aNWsWz3t5VW/btc25irFq0qQJKSkpUZ8+fWjRokWkq6srNt47duwQc0xVgZGRUY0OZyr6vXTpUrKxsSFFRUXS1NQkJycnCg0N5fWBiGj48OGkqanJOSmrLEPS2D148IB69+5NKioqpKamRgMHDqQnT55w9eo6f4mI4uPjydbWluTl5cne3p727dtHAOjOnTu8ctnZ2QSAli9fLtZnHx8fntdvSWPi6+tL6urq1LBhQxo/fjz9/PPPPF19fHzI09OTV2/y5Mk8ufn5+dSrVy9SUFCgpk2b0u7du6V6nr18+ZJ+/vlnMjMzI3l5edLR0SFXV1cKDw/nnFlJ4zCspvtcksOiI0eOkJ2dHcnLy1OjRo2oX79+XN6+fftIJBKRgoICOTg40IkTJ3ht1OYwrILExETq168faWtrk4KCApmamtKYMWMoKyuLV66m6/epz4mMjAxycnIieXl5at68OZ08eZIA0NmzZ7ky+fn5NGLECGrUqBEpKCiQiYkJ+fn5cQ5EpLnuFd7aRSIR9z+hb9++lJaWxpUZN24caWlpEQDuHq16TZ89e0Y//PADaWlpkaKiIrVo0YJzlDlx4kRq1qwZKSgokLa2Ng0fPpz3f60qVZ9BFYwdO5asra2prKxMKr1rei6VlpbS4MGDydDQkOTl5UlfX58mTpzIc/BXlfT0dHJwcCAlJSWys7OjqKgoiQ7DKs+rGzduEACec8TFixdTo0aNSFVVlXx8fGjmzJli/6f37t3LzW8NDQ3q1KkT5xhTWmeeFdQ2jyvkSTry8vJ499/KlSupYcOGXLSFypSWllLDhg1p3bp1tepU4eyGOQxjMBiMulMXh2ECoi/kAYPB+EoIBAKEh4ejT58+31qVL4afnx/u3LmDixcv8tIXLlyIQ4cOiTkMevPmDbS0tBAREcHFE/9cXFxcYG1tjfXr19eLvPpg7969XNzcyqu6Fy9ehIuLC/Ly8qCjo8Or4+zsjC5dunDxdRl/P2q6fvVFfHw8vvvuO9y7dw/NmjX7Im3826nuucT4+hQVFUFdXR2FhYUQCoXfWh0Gg8H4R1GXZ6jUDsMYDMbXY+XKlejWrRtUVFQQERGBXbt24bfffuPyi4uLkZubi19//RWLFi0Sq3/hwgV07dq1XgznFy9eICYmBjExMTwdvgW7d++GiYkJmjRpgtTUVMyaNQuDBg3iDOfS0lL89ddfCAoKwsCBA8UMr8LCQmRnZ/+tHZ79l6nt+n0O4eHhUFVVhZmZGe7du4fJkyfDycmJGc51oLbnEoPBYDAY/3b+0cZzTV5AIyIi0LFjx6+oDYNRf1y7dg3Lly/Hq1evYGJigvXr12P06NFc/sSJE7F//3706dNHokOsXr16SRXOTRpatWqFFy9eYNmyZbCwsKgXmZ/KkydPMG/ePDx58gR6enoYOHAgFi9ezOXv378fo0aNgp2dHXbv3i1WX11dXervVxlfn9qu3+fw6tUrzJo1Cw8fPkSjRo3g6uoqtcd9xkdqey4xGAwGg/Fv5x+9bfvevXvV5jVp0qTeQkkxGIzPJzQ0FFOmTPlkj7T/ZYKCgnDs2LFP8kb8rfkn6Z6bmwtjY2PcuHEDdnZ21Zbr3Lkz7OzssHbt2q+mG6N+iImJQZcuXfDixYsa465/LTn1RcWWQ8MpB9FAoX5Du+UG18+LWAaDwfi7Updt29/U2/bnUjXsROWDGc6M/zqbNm2Cra0thEIhhEIhHBwcEBERIVbu8uXLcHd3h4aGBhQVFWFjY4PVq1fXOXTXhQsX4O7uDi0tLSgrK8PKygrTpk3D48eP66tLf1tCQ0Pr7Qe0QCDAsWPH6kVWbXTu3BkCgYA7dHR0MHDgQLFQbp/D9OnTpQ7nJ4mgoCCJhmxubi4EAsEXNcpjYmIgEAjq5YVPUFAQN86ysrIQiUSYOnXqF/Og/neiYhwrDm1tbbi7u+PmzZvfWjWp6Ny5M6ZMmcJLc3R0RH5+vtRhzBgMBoPx7+AfbTwzGIzqMTAwQHBwMJKTk5GUlISuXbvC09OTF8YlPDwczs7OMDAwwIULF3Dnzh1MnjwZixYtwuDBgyHtxpQtW7bA1dUVurq6OHLkCNLT07F582YUFhayrbF/c/z8/JCfn48//vgDx48fR15eHoYNG1Zv8lVVVaGlpVVv8v7JWFtbIz8/H7m5uVi2bBm2bt2KadOmSSz77t27L6bHl5RdE5mZmcjPz0dkZCRKS0vRq1evb6bL5yIvLw9dXV2xEIIMBoPB+HfDjGcG41+Kh4cH3N3dYWZmBnNzcyxevBiqqqq4evUqAOD169fw8/ND7969sXXrVtjZ2UEkEmH06NHYtWsXDh8+jIMHD9bazqNHj+Dv7w9/f3/s3LkTnTt3hkgkQqdOnbB9+3bMmzePVz4yMhKWlpZQVVVFjx49kJ+fz+UlJiaiW7duaNSoEdTV1eHs7Izr16/z6gsEAmzfvh19+/aFsrIyzMzMcOLECV6ZEydOwMzMDIqKiujSpQt27doltoJ46dIldOzYEUpKSjA0NIS/vz9ev37N5f/222+cDB0dHQwYMEBi/2NiYjiP3xUraxWevF+8eIERI0ZAQ0MDysrK6NmzJy9+dlVEIhEAoG/fvhAIBNx5BXv27IFIJIK6ujoGDx6MV69ecXnl5eVYunQpjI2NoaSkhJYtW+Lw4cPVtlWBsrIydHV1oaenhw4dOmDixIm8MS8rK8OoUaM4uRYWFli3bp3YGLRr1w4qKipo2LAhnJycuNVrSSvHO3fuhLW1NRQUFKCnp8fFZP9cbt26hZ49e0JVVRU6OjoYPnw4nj59yuWfPXsW3333HRo2bAgtLS18//33yM7OligrNzcXXbp0AQBoaGhAIBDA19eXyy8vL8fMmTOhqakJXV1dqby3y8rKQldXFwYGBvDy8oK3tzc3dyvGafv27TA2NoaioiIA4OHDh/D09ISqqiqEQiEGDRqEP//8kyd30aJFaNy4MdTU1DB69Gj8/PPPvDH39fVFnz59sHjxYujr63O+C/bs2YM2bdpATU0Nurq6GDp0KAoKCrh6FSvGkZGRaNWqFZSUlNC1a1cUFBQgIiIClpaWEAqFGDp0qMR41VVp3LgxdHV10bp1a0yZMgV5eXm4c+cOl1/bPZmfn49evXpBSUkJxsbG2LdvH0QiEbd9XtJuhJcvX0IgECAmJkaiTs+ePcOQIUPQpEkTKCsrw8bGBvv37+eNXWxsLNatW8fd37m5uRJ3JRw5coSb1yKRSOzFoUgkwpIlSzBy5EioqamhadOm2Lp1K5f/7t07TJw4EXp6elBUVISRkRGWLl1a67gyGAwG4+vBjGcG4z9AWVkZDhw4gNevX8PBwQEAEBUVhWfPnmH69Oli5T08PGBubs77EVkdhw4dwrt37zBz5kyJ+ZW3M7958wYrV67Enj17EBcXh4cPH/Laf/XqFXx8fHDp0iVcvXoVZmZmcHd35xmJADB//nwMGjQIaWlpcHd3h7e3N54/fw4AyMnJwYABA9CnTx+kpqZi7NixmD17Nq9+dnY2evTogf79+yMtLQ1hYWG4dOkSZ8QlJSXB398fCxYsQGZmJs6ePYtOnTpJ7J+joyPWrl0LoVCI/Px85Ofnc33y9fVFUlISTpw4gStXroCI4O7ujvfv30uUlZiYCAAICQlBfn4+d16h87Fjx3Dq1CmcOnUKsbGxCA4O5vKXLl2K3bt3Y/Pmzbh9+zamTp2KYcOGITY2VmJbknj+/DkOHjyI9u3bc2nl5eUwMDDAoUOHkJ6ejnnz5uGXX37hXqx8+PABffr0gbOzM9LS0nDlyhWMGTOm2hW5TZs24ccff8SYMWNw8+ZNnDhxAqamplLrWB0vX75E165d0apVKyQlJeHs2bP4888/MWjQIK7M69ev8dNPPyEpKQnR0dFo0KAB+vbti/LycjF5hoaGOHLkCID/WzGt/NJg165dUFFRQUJCApYvX44FCxbg3LlzddJZSUmJt/J67949HDlyBEePHkVKSgrKy8vh6emJ58+fIzY2FufOncP9+/fh5eXF1dm7dy8WL16MZcuWITk5GU2bNsWmTZvE2oqOjkZmZibOnTuHU6dOAQDev3+PhQsXIjU1FceOHUNubi7vBUEFQUFB+PXXX3H58mXk5eVh0KBBWLt2Lfbt24fTp08jKioKGzZskLrfhYWFOHDgAICPK7hA7fckAIwYMQJ//PEHYmJicOTIEWzdupVn7H8KJSUlsLe3x+nTp3Hr1i2MGTMGw4cPx7Vr1wAA69atg4ODA7dDIz8/H4aGhmJykpOTMWjQIAwePBg3b95EUFAQ5s6di9DQUF65VatWoU2bNrhx4wYmTJiA8ePHIzMzEwCwfv16nDhxAgcPHkRmZib27t0r9gKtgtLSUhQVFfEOBoPBYHwFvmjEaQaD8U1JS0sjFRUVkpGRIXV1dTp9+jSXFxwcTADoxYsXEuv27t2bLC0ta21j/PjxJBQKay0XEhJCAOjevXtc2saNG0lHR6faOmVlZaSmpkYnT57k0gDQnDlzuPPi4mICQBEREURENGvWLGrRogVPzuzZs3l9HTVqFI0ZM4ZX5uLFi9SgQQN6+/YtHTlyhIRCIRUVFdXar4q+qaur89Lu3r1LACg+Pp5Le/r0KSkpKdHBgwerlQWAwsPDeWmBgYGkrKzM02fGjBnUvn17IiIqKSkhZWVlunz5Mq/eqFGjaMiQIdW25ezsTHJycqSiokLKysoEgMzNzSknJ6fG/v7444/Uv39/IiJ69uwZAaCYmBiJZQMDA6lly5bcub6+Ps2ePbtG+VXrN2jQgFRUVHhHhb43btwgIqKFCxdS9+7deXXz8vIIAGVmZkqU/ddffxEAunnzJhER5eTk8GReuHBB4j3i7OxM3333HS+tbdu2NGvWrBr7UXkckpKSqFGjRjRgwAAuX05OjgoKCrgyUVFRJCMjQw8fPuTSbt++TQDo2rVrRETUvn17+vHHH3ltOTk58dry8fEhHR0dKi0trVY/IqLExEQCQK9eveL1//z581yZpUuXEgDKzs7m0saOHUtubm7Vyq2QU3HtABAA6t27N1emtnsyIyODAFBiYiKXn5WVRQBozZo1RCR+/YiIXrx4QQDowoULPF2qe+4REfXq1YumTZvGnTs7O9PkyZMl9qlCztChQ6lbt268MjNmzCArKyvu3MjIiIYNG8adl5eXU+PGjWnTpk1ERDRp0iTq2rUrlZeXV6tbBYGBgdw4Vj4Mpxwko1mn6vVgMBiMfzuFhYUEgAoLC2sty1aeGYx/MRYWFkhJSUFCQgLGjx8PHx8fpKen88pQDd81V6wK1QQRSf3dn7KyMi+urp6eHm/l6M8//4Sfnx/MzMygrq4OoVCI4uJiPHz4kCfH1taW+1tFRQVCoZCTk5mZibZt2/LKt2vXjneempqK0NBQqKqqcoebmxvKy8uRk5ODbt26wcjICCYmJhg+fDj27t0r1bbUymRkZEBWVpa3iqulpQULCwtkZGTUSRbwccunmpoad1557O7du4c3b96gW7duvD7t3r272m3JFXh7eyMlJQWpqam4dOkSTE1N0b17d95q/8aNG2Fvbw9tbW2oqqpi69at3DXR1NSEr68v3Nzc4OHhgXXr1vG24lemoKAAf/zxB1xcXOrU94p5XPk4c+YMr0xqaiouXLjA63/z5s0BgBuDrKwsDBkyBCYmJhAKhdyqXtX5JQ2V5yAgPpclcfPmTaiqqkJJSQnt2rWDg4MDfv31Vy7fyMgI2tra3HlGRgYMDQ15K51WVlZo2LAhN4cyMzPF5nfVcwCwsbERu5+Tk5Ph4eGBpk2bQk1NDc7OzgDEx6NyX3V0dKCsrAwTExNemjQrwBcvXkRycjJCQ0Nhbm6OzZs3c3m13ZOZmZmQlZVF69atuTqmpqbQ0NCotd2aKCsrw8KFC2FjYwNNTU2oqqoiMjKyznMiIyMDTk5OvDQnJydkZWXxnC9WHkuBQABdXV1u7Hx9fZGSkgILCwv4+/sjKiqq2vYCAgJQWFjIHXl5eXXSl8FgMBifxj86zjODwagZeXl5bkusvb09EhMTsW7dOmzZsgVmZmYAPv7oc3R0FKubkZFRY7ieCszNzVFYWIj8/Hzo6enVWFZOTo53LhAIeMa7j48Pnj17hnXr1sHIyAgKCgpwcHAQcyokSY6krbfVUVxcjLFjx8Lf318sr2nTppCXl8f169cRExODqKgozJs3D0FBQUhMTPxmYWlq6nOFx+bTp0+jSZMmvHIKCgo1ylVXV+fmiKmpKXbs2AE9PT2EhYVh9OjROHDgAKZPn45Vq1bBwcEBampqWLFiBRISEjgZISEh8Pf3x9mzZxEWFoY5c+bg3Llz6NChA6+tT42CUHkeVyAry//3VVxcDA8PDyxbtkysfsW89PDwgJGREbZt2wZ9fX2Ul5ejRYsWn+S06lPmoIWFBU6cOAFZWVno6+uLGbMqKip11kNaqsp+/fo13Nzc4Obmhr1790JbWxsPHz6Em5tbjfebQCD45PvP2NgYDRs2hIWFBQoKCuDl5YW4uDgAtd+Td+/erVV+gwYf1wMqP1Oq+0SighUrVmDdunVYu3YtbGxsoKKigilTpnwxR2Y1jV3r1q2Rk5ODiIgInD9/HoMGDYKrq6tE3wUKCgq13tsMBoPBqH/YyjOD8R+ivLwcpaWlAAA3NzdoampK9IZ94sQJZGVlSfz+sSoDBgyAvLw8li9fLjG/LmF+4uPj4e/vD3d3d87xTmWHT9JgYWGBpKQkXlrlb4eBjz9S09PTJYa5qzBoZGVl4erqiuXLlyMtLQ25ubn4/fffJbYpLy8vFtrL0tISHz584BmZz549Q2ZmJqysrKrVX05Ors5hwqysrKCgoICHDx+K9UfS95k1ISMjAwB4+/YtgI/XxNHRERMmTECrVq1gamoqcTW7VatWCAgIwOXLl9GiRQvs27dPrIyamhpEItFnha6qjtatW+P27dsQiURiY6CiosKN/Zw5c+Di4gJLS0u8ePGiRpkVc6Gu16MmeaamphCJRFLt6rC0tEReXh5vVTE9PR0vX77k5pCFhYXY/K56Lok7d+7g2bNnCA4ORseOHdG8efPP/n64Lvz444+4desWwsPDAdR+T1pYWODDhw+4ceMGJ+PevXu8a1ixal9550Ntoczi4+Ph6emJYcOGoWXLljAxMREz1CXd31WxtLREfHy8mGxzc3PunpIGoVAILy8vbNu2DWFhYThy5Ajnz4HBYDAY3x5mPDMY/1ICAgIQFxeH3Nxc3Lx5EwEBAYiJiYG3tzeAjytRW7ZswfHjxzFmzBjOQNyxYwd8fX3h5+cHd3f3WtsxNDTEmjVrsG7dOowaNQqxsbF48OAB4uPjMXbsWCxcuFBqnc3MzLBnzx5kZGQgISEB3t7edV6tHDt2LO7cuYNZs2bh7t27OHjwIOe0p2J7+axZs3D58mVMnDgRKSkpyMrKwvHjxznnRKdOncL69euRkpKCBw8eYPfu3SgvL+e8FFdFJBKhuLgY0dHRePr0Kd68eQMzMzN4enrCz88Ply5dQmpqKoYNG4YmTZrA09OzWv0rjMsnT57UatxVoKamhunTp2Pq1KnYtWsXsrOzcf36dWzYsAG7du2qse6bN2/w5MkTPHnyBKmpqRg/fjwUFRXRvXt3AB+vSVJSEiIjI3H37l3MnTuXZ5zl5OQgICAAV65cwYMHDxAVFYWsrCxYWlpKbC8oKAirVq3C+vXrkZWVxen5ufz44494/vw5hgwZgsTERGRnZyMyMhI//PADysrKoKGhAS0tLWzduhX37t3D77//jp9++qlGmUZGRhAIBDh16hT++uuvrx6T2dXVFTY2NvD29sb169dx7do1jBgxAs7OzmjTpg0AYNKkSdixYwd27dqFrKwsLFq0CGlpabV+SlGxw2LDhg24f/8+Tpw4Uad79XNRVlaGn58fAgMDQUS13pPNmzeHq6srxowZg2vXruHGjRsYM2YMlJSUuL4qKSmhQ4cOCA4ORkZGBmJjYzFnzpwa9TAzM8O5c+dw+fJlZGRkYOzYsWLezEUiERISEpCbm4unT59KXGWfNm0aoqOjsXDhQty9exe7du3Cr7/+KtEhY3WsXr0a+/fvx507d3D37l0cOnQIurq632y3C4PBYDDEYcYzg/EvpaCgACNGjICFhQVcXFyQmJiIyMhIdOvWjSszYMAAXLhwAQ8fPkTHjh1hbGzMhbqpHEKlNiZMmICoqCg8fvwYffv2RfPmzTF69GgIhcI6/XjcsWMHXrx4gdatW2P48OHw9/dH48aN69RvY2NjHD58GEePHoWtrS02bdrEeduu2OZoa2uL2NhY3L17Fx07dkSrVq0wb9486OvrA/joIfzo0aPo2rUrLC0tsXnzZuzfvx/W1tYS23R0dMS4cePg5eUFbW1tbhU+JCQE9vb2+P777+Hg4AAiwpkzZ8S2blZm1apVOHfuHAwNDdGqVSup+71w4ULMnTsXS5cuhaWlJXr06IHTp0/D2Ni4xnrbtm2Dnp4e9PT00KVLFzx9+hRnzpzhXhSMHTsW/fr1g5eXF9q3b49nz55hwoQJXH1lZWXcuXMH/fv3h7m5OcaMGYMff/wRY8eOldiej48P1q5di99++w3W1tb4/vvvawzfJS36+vqIj49HWVkZunfvDhsbG0yZMgUNGzZEgwYN0KBBAxw4cADJyclo0aIFpk6dihUrVtQos0mTJpg/fz5+/vln6Ojo1FtILWkRCAQ4fvw4NDQ00KlTJ7i6usLExARhYWFcGW9vbwQEBGD69Onctl9fX18u1FV1aGtrIzQ0FIcOHYKVlRWCg4OxcuXKL90lHhMnTkRGRgYOHTpU6z0JALt374aOjg46deqEvn37ws/PD2pqary+7ty5Ex8+fIC9vT2mTJmCRYsW1ajDnDlz0Lp1a7i5uaFz587Q1dVFnz59eGWmT58OGRkZWFlZcdvbq9K6dWscPHgQBw4cQIsWLTBv3jwsWLBAqt07FaipqWH58uVo06YN2rZti9zcXJw5c4bbjs5gMBiMb4+AavIWxGAw/lOUlJTA09MTeXl5iI2N5Tkv+iezePFibN68mTnVYfwn6NatG3R1dbFnz55vrcoX5dGjRzA0NMT58+fr7ITu30ZRURHU1dVRWFgIoVD4rdVhMBiMfxR1eYYyh2EMBoNDUVERx48fx9q1axEXF4f+/ft/a5U+id9++w1t27aFlpYW4uPjsWLFiq++ashgfA3evHmDzZs3w83NDTIyMti/fz/Onz9f55jT/wR+//13FBcXw8bGBvn5+Zg5cyZEIlG1MdgZDAaDwahvmPHMYDB4KCoq4ueff+bOlyxZglRyuDgAAGrySURBVCVLlkgs27FjR0RERHwt1aSm4tvP58+fo2nTppg2bRoCAgK+tVoMRr0jEAhw5swZLF68GCUlJbCwsMCRI0fg6ur6rVWrd96/f49ffvkF9+/fh5qaGhwdHbF3794aP4NgMBgMBqM+Ydu2GQxGjTx//rxab69KSkpioZEY/y5CQ0MxZcqUOnlN/zcQFBSEY8eO1eqt+VsTFBSETZs2oaCgAOHh4Th27BhevnyJY8eOSS1DIBAgPDxc7Fvfyvj6+tZZ7rdg69atWLhwIR4/fozVq1djypQp31qlr0LFlkPDKQfRQEG5xrK5wb2+klYMBoPxz6Au27aZFwoGg1EjmpqaEsPHmJqaMsO5FjZt2gRbW1sIhUIIhUI4ODiIrdSLRCIIBAIIBAIoKyvDxsYG27dvl7qN0NDQar3xCgSCb2LsiEQirF279ou2UVO/68rXHKfOnTtz11tBQQFNmjSBh4cHjh49WmdZGRkZmD9/PrZs2YL8/Hz07NkT69at47zLS0tFXQDIzc2FQCAQe2nwKXK/NkVFRZg4cSJmzZqFx48fY8yYMdWWvXDhAtzd3aGlpQVlZWVYWVlh2rRpePz4MQAgJiaGu05VjydPngD4+OLCzs5OTHbVMaw4rzg0NTXh7OyMixcvAuA/AyQddXE6xmAwGIwvCzOeGQwG4wthYGCA4OBgJCcnIykpCV27doWnpydu377NK7dgwQLk5+fj1q1bGDZsGPz8/P6W2+EZ9YOfnx/y8/ORnZ2NI0eOwMrKCoMHD67R2JNERbxtT09P6OrqQkFBAerq6nV+qVBRtyY+Re7X5uHDh3j//j169eoFPT09KCtLXoHdsmULXF1doauriyNHjiA9PR2bN29GYWGhWNz7zMxM5Ofn8466RgCo4Pz588jPz0dcXBz09fXx/fff488//0RiYiIn+8iRI2Ltrlu37pPaYzAYDEb9w4xnBoPB+EJ4eHjA3d0dZmZmMDc3x+LFi6GqqoqrV6/yyqmpqUFXVxcmJiaYNWsWNDU1693hU8VK2unTp2FrawtFRUV06NABt27d4pULDQ1F06ZNoaysjL59++LZs2e8/OzsbHh6ekJHRweqqqpo27Ytzp8/z+V37twZDx48wNSpU7mVswouXbqEjh07QklJCYaGhvD398fr16+5/N9++w1mZmZQVFSEjo4OBgwYUG1ffvjhBxQWFnJtBAUFAQBevHiBESNGQENDA8rKyujZs2eNobBEIhEAoG/fvhAIBNx5BXv27IFIJIK6ujoGDx6MV69ecXnl5eVYunQpjI2NoaSkhJYtW+Lw4cPVtlWBsrIydHV1YWBggA4dOmDZsmXYsmULtm3bxhvLvLw8DBo0CA0bNoSmpiY8PT2Rm5sL4OOqp4eHBwCgQYMG3Dj7+vrytl937twZ/v7+mDlzJjQ1NaGrq8uNVQWVV94rQpu1atUKAoEAnTt3lii3tLSUCyWnqKiI7777jhf/u2K+RUdHo02bNlBWVoajoyMyMzO5MqmpqejSpQvU1NQgFAphb2+PpKSkasft4cOH8PT0hKqqKoRCIQYNGsTFZA4NDYWNjQ0AwMTEBAKBgBuryjx69Aj+/v7w9/fHzp070blzZ87p2Pbt2zFv3jxe+caNG0NXV5d3fGroKC0tLejq6qJFixb45ZdfUFRUhISEBGhra3OyNTU1xdpVV1f/pPYYDAaDUf8w45nBYDC+AmVlZThw4ABev34NBwcHiWXKy8tx5MgRvHjxAvLy8l9EjxkzZmDVqlVITEyEtrY2PDw88P79ewBAQkICRo0ahYkTJyIlJQVdunQRi5NbXFwMd3d3REdH48aNG+jRowc8PDy42LdHjx6FgYEBt5qen58P4KPR3aNHD/Tv3x9paWkICwvDpUuXOC/oSUlJ8Pf3x4IFC5CZmYmzZ89W60XZ0dERa9euhVAo5NqoiCfu6+uLpKQknDhxAleuXAERwd3dnetjVSoMvpCQEOTn5/MMwOzsbBw7dgynTp3CqVOnEBsbi+DgYC5/6dKl2L17NzZv3ozbt29j6tSpGDZsGGJjY+t8XXx8fKChocFt337//j3c3NygpqaGixcvIj4+HqqqqujRowfevXuH6dOnIyQkBAB44yyJXbt2QUVFBQkJCVi+fDkWLFhQ7cuZa9euAfi/VdLqtpPPnDkTR44cwa5du3D9+nWYmprCzc1NzD/C7NmzsWrVKiQlJUFWVhYjR47k8ry9vWFgYIDExEQkJyfj559/rtb5V3l5OTw9PfH8+XPExsbi3LlzuH//Pry8vAAAXl5e3IuHa9euIT8/H4aGhmJyDh06hHfv3mHmzJkS2/kaq+tv377F7t27AeCT7/PS0lIUFRXxDgaDwWB8BYjBYDAYX4y0tDRSUVEhGRkZUldXp9OnT/PyjYyMSF5enlRUVEhWVpYAkKamJmVlZUklPyQkhNTV1SXmAaDw8HAiIrpw4QIBoAMHDnD5z549IyUlJQoLCyMioiFDhpC7uztPhpeXV7XyK7C2tqYNGzbw+rRmzRpemVGjRtGYMWN4aRcvXqQGDRrQ27dv6ciRIyQUCqmoqKjGtiqQ1O+7d+8SAIqPj+fSnj59SkpKSnTw4MFqZVUepwoCAwNJWVmZp8+MGTOoffv2RERUUlJCysrKdPnyZbF+DhkypNq2nJ2dafLkyRLz2rdvTz179iQioj179pCFhQWVl5dz+aWlpaSkpESRkZFERBQeHk5V/437+PiQp6cnr73vvvuOV6Zt27Y0a9Ysif3PyckhAHTjxo1q5RYXF5OcnBzt3buXy3/37h3p6+vT8uXLiej/5tv58+e5MqdPnyYA9PbtWyIiUlNTo9DQUIljUZWoqCiSkZGhhw8fcmm3b98mAHTt2jUiIrpx4wYBoJycnGrljB8/noRCYa3tVeivoqLCO6ysrLgygYGB1KBBA7EyysrKvDGsGFMlJSVSUVEhgUBAAMje3p7evXsnsd0XL17UqF9gYCABEDsMpxwko1mnajwYDAaDwaewsJAAUGFhYa1lWagqBoPB+IJYWFggJSUFhYWFOHz4MHx8fBAbGwsrKyuuzIwZM+Dr64v8/HzMmDEDEyZMgKmp6RfRp/Kqt6amJiwsLJCRkQHgowOqvn37ipU/e/Ysd15cXIygoCCcPn0a+fn5+PDhA96+fcutPFdHamoq0tLSsHfvXi6NiFBeXo6cnBx069YNRkZGMDExQY8ePdCjRw/07du32u9WJZGRkQFZWVm0b9+eS9PS0uL1sS6IRCKoqalx53p6eigoKAAA3Lt3D2/evEG3bt14dd69e4dWrVrVuS3g43hUbL9OTU3FvXv3eO0DQElJCfets7TY2tryziv341PIzs7G+/fv4eTkxKXJycmhXbt2YuNcuW09PT0AQEFBAZo2bYqffvoJo0ePxp49e+Dq6oqBAweiWbNmEtvMyMiAoaEhbzXZysoKDRs2REZGBtq2bSuV7pXHWBouXrzIuwZVV8YtLCxw4sQJXtrjx4+57e6VCQsLQ/PmzXHr1i3MnDkToaGhnxxmKyAgAD/99BN3XlRUJHGlncFgMBj1CzOeGQwG4wsiLy/PGcL29vZITEzEunXrsGXLFq5Mo0aNOA/mhw4dgo2NDdq0acMzsKtDKBTi9evXKC8v532LWRFaqr6/l5w+fTrOnTuHlStXwtTUFEpKShgwYADevXtXY73i4mKMHTsW/v7+YnlNmzaFvLw8rl+/jpiYGERFRWHevHkICgpCYmLiN3NUVdWwEQgEKC8vB/CxPwBw+vRpMa/ztTnfkkRZWRmysrI4I7C4uBj29va8lw0VaGtr10l2Tf340lRuu8JorWg7KCgIQ4cOxenTpxEREYHAwEAcOHBA7AVOfWJubo7CwkLk5+dzxnxNGBsb1zj/Kt/fFcjKSv5pZWhoCDMzM5iZmeHDhw/o27cvbt269UnzRUFB4ZPqMRgMBuPzYN88MxgMxlekvLwcpaWl1eYbGhrCy8sLAQEBUsmzsLDAhw8fxEILXb9+HcBHY6EylZ2VvXjxAnfv3oWlpSUAwNLSEgkJCdWWB4D4+Hj4+vqib9++sLGxga6urphjJnl5eZSVlfHSWrdujfT0dIkhzyq++5SVlYWrqyuWL1+OtLQ05Obm4vfff5fYb0ltWFpa4sOHD7w+PHv2DJmZmTW+iJCTkxOTVRtWVlZQUFDAw4cPxfrzKSuAu3btwosXL9C/f38AH8crKysLjRs3FpP/JR1IVVyLmsajWbNmkJeXR3x8PJf2/v17JCYmSvXCpzLm5uaYOnUqoqKi0K9fP+477qpYWloiLy8PeXl5XFp6ejpevnxZpzYHDBgAeXl5LF++XGL+14pnPmDAAMjKyuK33377Ku0xGAwGo35gxjODwWB8IQICAhAXF4fc3FzcvHkTAQEBiImJgbe3d431Jk+ejJMnT9boebgCa2trdO/eHSNHjkR0dDRycnJw9uxZTJgwAV5eXmKrogsWLEB0dDRu3boFX19fNGrUiPOi7O/vj7Nnz2LlypXIysrCr7/+ytuyDQBmZmY4evQoUlJSkJqaiqFDh4qtYopEIsTFxeHx48d4+vQpAGDWrFm4fPky54wsKysLx48f5xyGnTp1CuvXr0dKSgoePHiA3bt3o7y8HBYWFhL7LRKJUFxcjOjoaDx9+hRv3ryBmZkZPD094efnh0uXLiE1NRXDhg1DkyZN4OnpWe0YikQiREdH48mTJ3jx4kWtYw589JA+ffp0TJ06Fbt27UJ2djauX7+ODRs2YNeuXTXWffPmDZ48eYJHjx7h6tWrmDVrFsaNG4fx48ejS5cuAD4602rUqBE8PT1x8eJF5OTkICYmBv7+/nj06JFUOn4KjRs3hpKSEs6ePYs///wThYWFYmVUVFQwfvx4zJgxA2fPnkV6ejr8/Pzw5s0bjBo1Sqp23r59i4kTJyImJgYPHjxAfHw8EhMTuRc5VXF1dYWNjQ28vb1x/fp1XLt2DSNGjICzszPatGkjdf8MDQ2xZs0arFu3DqNGjUJsbCzX/tixY7Fw4UJe+YKCAjx58oR3VOd8ri4IBAL4+/sjODgYb968+Wx5DAaDwfg6MOOZwWAwvhAFBQUYMWIELCws4OLigsTERERGRop9J1sVKysrdO/eXSxsTnWEhYXB2dkZY8eOhbW1Nfz9/eHp6Ynt27eLlQ0ODsbkyZNhb2+PJ0+e4OTJk9xqY4cOHbBt2zasW7cOLVu2RFRUFObMmcOrv3r1amhoaMDR0REeHh5wc3ND69ateWUWLFiA3NxcNGvWjNtibGtri9jYWNy9excdO3ZEq1atMG/ePOjr6wP46OX46NGj6Nq1KywtLbF582bs378f1tbWEvvs6OiIcePGwcvLC9ra2txKYkhICOzt7fH999/DwcEBRIQzZ87U+G3pqlWrcO7cORgaGtbpe+WFCxdi7ty5WLp0KSwtLdGjRw+cPn2aC/dUHdu2bYOenh6aNWuGfv36IT09HWFhYbxVSGVlZcTFxaFp06bo168fLC0tMWrUKJSUlEAoFEqtY12RlZXF+vXrsWXLFujr61f70iE4OBj9+/fH8OHD0bp1a9y7dw+RkZHQ0NCQqh0ZGRk8e/YMI0aMgLm5OQYNGoSePXti/vz5EssLBAIcP34cGhoa6NSpE1xdXWFiYoKwsLA693HChAmIiorC48eP0bdvXzRv3hyjR4+GUCjkvLZXYGFhAT09Pd6RnJxc5zYl4ePjg/fv3+PXX3+tF3kMBoPB+PIIiIi+tRIMBoPB+LLExMSgS5cuePHixTf7hpjBYHwZioqKoK6ujsLCwi/6coXBYDD+jdTlGcpWnhkMBoPBYDAYDAaDwagFZjwzGAzG35iePXtCVVVV4rFkyZJvrR6DwWAwGAzGfwa2bZvBYDD+xjx+/Bhv376VmKepqQlNTc2vrNHfh6CgIBw7dkzM0/jnlmV8eUQiEaZMmYIpU6bUq9zQ0FBMmTLlq3nN/rtQseXQcMpBNFCQPjZ6TeQG96oXOQwGg/F3h23bZjAYjH8ImzZtgq2tLYRCIYRCIRwcHBAREcHlN2nSBK9fv8ZPP/0ER0dHtGjRAq6urpg9ezY+fPggVRvh4eHo0KED1NXVoaamBmtra57REhoaCoFAAIFAABkZGWhoaKB9+/ZYsGCBRG/LeXl5GDlyJPT19SEvLw8jIyNMnjwZz54945Xr3LmzROMoNDS01u+uK/QRCAQQCoVo27Ytjh8/ziszffp0REdHSzUGn8PSpUshIyODFStWfPG2/ulUd82rkpiYiDFjxnxWWyKRCGvXrv0sGXXlypUrkJGRQa9efMNy8ODB6NGjBy/t7NmzEAgECAoK4qUHBQWhadOmSE5OhkAgEAsHV4GLiwv69etXr/ozGAwG4/NgxjODwWB8QwwMDBAcHIzk5GQkJSWha9eu8PT0xO3btwEAf/31F1xcXKCpqYnIyEhkZGQgJCQE+vr6eP36da3yo6Oj4eXlhf79++PatWtITk7G4sWLxcLtCIVC5Ofn49GjR7h8+TLGjBmD3bt3w87ODn/88QdX7v79+2jTpg2ysrKwf/9+3Lt3D5s3b0Z0dDQcHBzw/PnzehubkJAQ5OfnIykpCU5OThgwYABu3rzJ5auqqkJLS6ve2quOnTt3YubMmdi5c+cXb+u/gra2NpSV62eF9GuyY8cOTJo0CXFxcbz7okuXLoiPj+e90Lpw4QIMDQ0RExPDk3HhwgV06dIF9vb2aNmypcR5lZubiwsXLkgd+ovBYDAYXwdmPDMYDMY3xMPDA+7u7jAzM4O5uTkWL14MVVVVbjUqPj4ehYWF2L59O1q1agVjY2N06dIFa9asqTUkEgCcPHkSTk5OmDFjBiwsLGBubo4+ffpg48aNvHICgQC6urrQ09PjwiJdvnwZxcXFmDlzJlfuxx9/hLy8PKKiouDs7IymTZuiZ8+eOH/+PB4/fozZs2fX29g0bNgQurq6MDc3x8KFC/HhwwdcuHCByw8KCoKdnR13HhMTg3bt2kFFRQUNGzaEk5MTHjx4IFF2dnY2TExMMHHiRNT09VJsbCzevn2LBQsWoKioCJcvX+blp6amokuXLlBTU4NQKIS9vT0Xn/vBgwfw8PCAhoYGVFRUYG1tjTNnznB1b926xX3TrqOjg+HDh3NxsQHg8OHDsLGxgZKSErS0tODq6sq9MKmprxXjsnPnTjRt2hSqqqqYMGECysrKsHz5cujq6qJx48ZYvHgxry8vX77E6NGjoa2tDaFQiK5duyI1NVVsvPfs2QORSAR1dXUMHjwYr169AgD4+voiNjYW69at43YN5ObmShzXqqvGAoEA27dvR9++faGsrAwzMzOcOHGi2uvSuXNnPHjwAFOnTuXaqkxkZCQsLS2hqqqKHj16ID8/n5e/fft2WFpaQlFREc2bN+eFCauO4uJihIWFYfz48ejVqxdCQ0O5vC5duqC4uJgXmz0mJgY///wzEhISUFJSAgAoKSlBQkICF8971KhRCAsLE4v1HBoaCj09PbHVbAaDwWB8W5jxzGAwGH8TysrKcODAAbx+/RoODg4AAF1dXXz48AHh4eE1GnnVoauri9u3b+PWrVt1rtu4cWN4e3vjxIkTKCsrw/PnzxEZGYkJEyZASUlJrB1vb2+EhYV9kp418eHDB+zYsQMAuJjUksr06dMHzs7OSEtLw5UrVzBmzBgxowoA0tLS8N1332Ho0KH49ddfJZapYMeOHRgyZAjk5OQwZMgQTo8KvL29YWBggMTERCQnJ+Pnn3/mYkr/+OOPKC0tRVxcHG7evIlly5ZBVVUVwEdDtWvXrmjVqhWSkpJw9uxZ/Pnnnxg0aBAAID8/H0OGDMHIkSORkZGBmJgY9OvXD0QkVV+zs7MRERGBs2fPYv/+/dixYwd69eqFR48eITY2FsuWLcOcOXOQkJDA1Rk4cCAKCgoQERGB5ORktG7dGi4uLrzdBNnZ2Th27BhOnTqFU6dOITY2FsHBwQCAdevWwcHBAX5+fsjPz0d+fj4MDQ2rv7BVmD9/PgYNGoS0tDS4u7vD29u72p0MR48ehYGBARYsWMC1VcGbN2+wcuVK7NmzB3FxcXj48CEvfvPevXsxb948LF68GBkZGViyZAnmzp2LXbt21ajfwYMH0bx5c1hYWGDYsGHYuXMnN9fNzc2hr6/Pvdx59eoVrl+/joEDB0IkEuHKlSsAgMuXL6O0tJQznr29vVFaWorDhw9z7RARdu3aBV9fX8jIyEjUpbS0FEVFRbyDwWAwGF8BYjAYDMY3JS0tjVRUVEhGRobU1dXp9OnTvPxffvmFZGVlSVNTk3r06EHLly+nJ0+eSCW7uLiY3N3dCQAZGRmRl5cX7dixg0pKSrgyISEhpK6uLrH+pk2bCAD9+eefdPXqVQJA4eHhEsuuXr2aK0tE5OzsTHJycqSiosI7FBQUqm2vAgCkqKhIKioq1KBBAwJAIpGInj17xpUJDAykli1bEhHRs2fPCADFxMRIlFdRNj4+njQ0NGjlypU1tk9EVFhYSEpKSpSSkkJERDdu3CBVVVV69eoVV0ZNTY1CQ0Ml1rexsaGgoCCJeQsXLqTu3bvz0vLy8ggAZWZmUnJyMgGg3NxcsbrS9FVZWZmKioq4NDc3NxKJRFRWVsalWVhY0NKlS4mI6OLFiyQUCnnzgoioWbNmtGXLlmrlzpgxg9q3b8+dOzs70+TJkyXqVRkjIyNas2YNdw6A5syZw50XFxcTAIqIiJBaBtHHuQyA7t27x6Vt3LiRdHR0eH3at28fr97ChQvJwcGhRp0dHR1p7dq1RET0/v17atSoEV24cIHL9/b25q7p6dOnycrKioiIxowZQ/PmzSMiorlz55KxsTFP7uDBg8nZ2Zk7j46OJgCUlZVVrS6BgYEEQOwwnHKQjGadqpeDwWAw/isUFhYSACosLKy1LFt5ZjAYjG+MhYUFUlJSkJCQgPHjx8PHxwfp6elc/uLFi/HkyRNs3rwZ1tbW2Lx5M5o3b877/rc6VFRUcPr0ady7dw9z5syBqqoqpk2bhnbt2oltFZUE/f+VtcqrmlSHlWVvb2+kpKTwjgULFkhVd82aNUhJSUFERASsrKywffv2ar2La2pqwtfXF25ubvDw8MC6devEtuo+fPgQ3bp1w7x58zBt2rRa29+/fz+aNWuGli1bAgDs7OxgZGSEsLAwrsxPP/2E0aNHw9XVFcHBwcjOzuby/P39sWjRIjg5OSEwMBBpaWlcXmpqKi5cuMALPda8eXMAH1d3W7ZsCRcXF9jY2GDgwIHYtm0bXrx4IXVfRSIR1NTUuHMdHR1YWVmhQYMGvLSCggJOn+LiYmhpafF0ysnJ4fWpqlw9PT1Oxudia2vL/a2iogKhUPhJspWVldGsWTOJOr5+/RrZ2dkYNWoUr5+LFi3i9bMqmZmZuHbtGoYMGQIAkJWVhZeXF28nQufOnREfH4/3798jJiYGnTt3BgA4Oztz3z3HxMRwq84VjBw5EnFxcVz7O3fuhLOzM0xNTavVJyAgAP+vvfuOiuJq/wD+XZBddoEFqQtKUboKKliCRLBgEI2iUUFCFNSgIhbeYImJUdBYomJJfDVWMLHntQYrKFiQKBpAQUREEGNQYwFERRDu7w8P82PchQUbEJ/POXOOe++dO8+dAZJnZ+beoqIibrt161bdTxAhhJDXRskzIYQ0MKFQCCsrKzg7O2PhwoVo3749Vq5cyWujp6eHYcOGYenSpcjMzISJiQmWLl1a52NYWlriyy+/xIYNG/Dnn3/iypUrvCSwJpmZmZBKpdDT04OVlRUEAgEyMzNrbNu8eXMYGBhwZdra2rCysuJthoaGdYpZJpPBysoKn3zyCaKiouDr61trMhUVFYWkpCR069YNO3fuhI2NDW8mYwMDA3Tp0gXbt2+v02OuGzduREZGBpo1a8ZtV65c4U3wFB4ejoyMDPTv3x8nTpxAmzZtsHfvXgDAl19+iRs3bmDEiBG4fPkyOnXqhJ9++gnAy/dnBwwYIPfFQnZ2Ntzc3KCqqorY2Fjui4OffvoJtra2yM3NrdNYqx4dryIQCBSWVVZWcvEYGxvLxZOVlYVp06bV2m9VH2/qbfWtqJ+qL3xKSkoAAOvXr+eNMz09vcZZr4GXPwsvXryAiYkJ97OwZs0a7N69m5uRvmfPnnjy5AmSk5MRHx8Pd3d3AC+T53PnzuHhw4c4d+4cevXqxeu7d+/eMDMzQ3R0NIqLi7Fnzx6lE4WJRCJuhv6qjRBCyLtHyTMhhDQylZWVeP78eY31QqEQlpaWdZptWxELCwtIJBKl+9+7dw/btm3DoEGDoKKiAj09PfTp0werV6+WW3v6zp072Lp1K3x9fWt9h/h1denSBc7OznKTXL2qY8eOmDlzJs6ePYt27dph27ZtXJ1YLEZMTAzU1dXh6enJTXSlyOXLl3HhwgUkJCTwkqyEhAQkJSXh6tWrXFsbGxv85z//wbFjx/DZZ58hKiqKqzM1NcX48eOxZ88ehIWFYf369QAAJycnZGRkwMLCQu7LBQ0NDQAvkz5XV1dEREQgJSUFQqGQS8yVjbW+nJyccOfOHTRr1kwuHn19/Tr3IxQKUVFR8dpx1MfrHMvIyAgmJia4ceOG3DhrmoDvxYsX+OWXXxAZGcn7WUhLS4OJiQm2b98O4OUXVKampjhw4ABSU1O55LlFixZo0aIFIiMjUVZWJnfnWUVFBaNGjcLmzZuxbds2CIVCDB069DXOCCGEkHeNkmdCCGlAM2fOxKlTp5CXl4fLly9j5syZSEhIgL+/PwAgJiYGX3zxBWJiYnDt2jVkZWVh6dKlOHToELy9vZX2Hx4ejunTpyMhIQG5ublISUnB6NGjUV5ejj59+nDtGGO4c+cOCgoKkJmZiU2bNqFbt27Q1tbmJoQCgFWrVuH58+fw9PTEqVOncOvWLRw5cgR9+vRBixYtlCa3byI0NBRr167F7du35epyc3Mxc+ZMJCUl4ebNmzh27Biys7Nhb2/Pa1f1GHuzZs3g5eXF3Yl81caNG9GlSxe4ubmhXbt23Obm5obOnTtj48aNePbsGSZOnIiEhATcvHkTiYmJSE5O5o4ZGhqKo0ePIjc3F3/++Sfi4+O5upCQEDx8+BB+fn5ITk5GTk4Ojh49ilGjRqGiogLnzp3DggULcOHCBeTn52PPnj34559/YG9vX+ex1oeHhwdcXFwwaNAgHDt2DHl5eTh79iy+/fZb3gzSylhYWODcuXPIy8vD/fv339pd6ZqOderUKdy+fZs3S7kyERERWLhwIX788Udcu3YNly9fRlRUFJYtW6awfUxMDB49eoQxY8bwfhbatWuHIUOG8B7d7tmzJ1avXg0rKysYGRlx5e7u7vjpp5+4icVeNWrUKNy+fRvffPMN/Pz85CbkI4QQ0jhQ8kwIIQ3o3r17GDlyJGxtbdG7d28kJyfj6NGjXGLbpk0bSCQShIWFoUOHDvjoo4+wa9cubNiwASNGjFDav7u7O27cuIGRI0fCzs4OXl5euHPnDo4dOwZbW1uuXXFxMYyNjdGiRQu4uLhg7dq1CAgIQEpKCoyNjbl21tbWuHDhAlq3bg0fHx9YWlpi7Nix6NmzJ5KSkmp8J/lt6Nu3L1q1aqUwQZdIJLh69SqGDBkCGxsbjB07FiEhIRg3bpxcW01NTRw+fBiMMfTv31/uDnxZWRm2bNmCIUOGKIxjyJAh+OWXX6CiooIHDx5g5MiRsLGxgY+PD7y8vBAREQHg5ezpISEhsLe3R9++fWFjY8MtiWRiYoLExERUVFTgk08+gYODA0JDQ6GjowMVFRVIpVKcOnUK/fr1g42NDWbNmoXIyEh4eXnVa6x1JRAIcOjQIbi5uWHUqFGwsbHB8OHDcfPmTV4SqMzUqVOhqqqKNm3awMDAAPn5+a8dkzJz585FXl4eLC0tea8KKFP1+kJUVBQcHBzg7u6O6OjoGu88b9y4ER4eHtDW1parGzJkCC5cuMC9z96zZ088fvyYe9+5iru7Ox4/fix317mKmZkZPDw88OjRI4wePbrOYyGEEPJ+CVh9Zn4hhBBCCCGNSnFxMbS1tVFUVETvPxNCSD3V528o3XkmhBBCCCGEEEKUoOSZEEKasPHjx/OW3Km+jR8/vqHDI4QQQgj516DHtgkhpAm7d+9ejcsuSaXSOi8LRQhpuqoeOTQN3QUVkaShw2lQeYv6N3QIhJAmhh7bJoSQD4ShoaHckjv1XU+ZEAIsWrQIAoEAoaGhdd7n7Nmz6NevH5o3bw51dXU4ODhg2bJlcktoCQQCbtPW1oarqytOnDjB1QcGBnL1Veu+z507Fy9evHhbwyOEEPIWUPJMCCGEkA9acnIy1q5dC0dHxzrvs3fvXri7u6Nly5aIj4/H1atXMWXKFHz//fcYPnw4Xn2wLyoqCgUFBUhMTIS+vj4+/fRT3Lhxg6vv27cvCgoKkJ2djbCwMISHh2PJkiVvbYyEEELeHCXPhBBCCPlglZSUwN/fH+vXr0fz5s3rtM+TJ08QFBSEgQMHYt26dejQoQMsLCzw5ZdfYvPmzfjf//6HXbt28fbR0dGBTCZDu3btsGbNGjx79gyxsbFcvUgkgkwmg7m5OYKDg+Hh4YEDBw681bESQgh5M5Q8E0IIIeSDFRISgv79+8PDw6PO+xw7dgwPHjzA1KlT5eoGDBgAGxsbbN++vcb9xWIxgJdritfWpqb658+fo7i4mLcRQgh59yh5JoQQQsgHaceOHfjzzz+xcOHCeu137do1AIC9vb3Cejs7O67Nq54+fYpZs2ZBVVUV7u7ucvWMMcTFxeHo0aPo1auXwj4WLlwIbW1tbjM1Na1X/IQQQl5Ps4YOgBBCCCHkfbt16xamTJmC2NhYqKurv1YftS1YIhQKeZ/9/PygqqqKZ8+ewcDAABs3buS9Yx0TEwNNTU2Ul5ejsrISn3/+OcLDwxX2PXPmTHz11Vfc5+LiYkqgCSHkPaDkmRBCCCEfnIsXL+LevXtwcnLiyioqKnDq1CmsWrUKz58/h6qqqsJ9ra2tAQCZmZno1q2bXH1mZiY6dOjAK1u+fDk8PDygra0NAwMDuX169uyJNWvWQCgUwsTEBM2a1fy/aCKRCCKRqC7DJIQQ8hZR8kwIIYSQD07v3r1x+fJlXtmoUaNgZ2eHGTNm1Jg4A4Cnpyd0dXURGRkplzwfOHAA2dnZWLFiBa9cJpPBysqqxj41NDRqrSeEENLwKHkmhBBCyAdHS0sL7dq145VpaGhAT09PrvxVGhoaWLt2LYYPH46xY8di4sSJkEqlOH78OKZNm4agoCD069fvXYZPCCGkAVDyTAghhBBST0OHDkV8fDzmz5+P7t27czNe//DDD5g+fXoDR0cIIeRdELDaZrsghBBCCCFKlZaWwtvbG7du3cLJkycVvtf8rhQXF0NbWxtFRUWQSqXv7biEEPJvUJ+/obRUFSGEEELIG1JXV8f+/fsxcuRInDp1qqHDIYQQ8g7QnWdCCCGEkGq2bt2KcePGKawzNzdHRkbGe46odnTnmRBCXh/deSaEkCYmPDxcbmkbwicQCLBv374GOXZTuD4JCQkQCAQoLCys8z4WFhZys0K/C3W5doGBgRg0aNA7j6UuBg4ciNTUVIXboUOHALze+X7X2s052tAhEELIvxolz4SQD5KFhQUEAoHcFhISorCNWCyGhYUFfHx8cOLEiXofb/fu3ejRowe0tbWhqakJR0dHzJ07Fw8fPnybw2qUoqOjufOooqICY2Nj+Pr6Ij8//50e930mvG8jkcrLy1P4M1l9i46OfmsxN5Sqcaampr5xXxUVFVi0aBHs7OwgFouhq6uLrl27YsOGDW/Ur5aWFqysrBRu5ubmAIBu3bqhoKAA2trabzwOQgghTQMlz4SQD1JycjIKCgq4LTY2FgAwbNgwXru5c+eioKAAWVlZ+OWXX6CjowMPDw/Mnz+/zsf69ttv4evri86dO+Pw4cNIT09HZGQk0tLS8Ouvv77VcTVWUqkUBQUFuH37Nnbv3o2srCy5c/2hMzU15f1MhoWFoW3btrwyX1/fhg6zUYmIiMDy5csxb948XLlyBfHx8Rg7duwbfYnBGMOLFy+UthMKhZDJZBAIBK99LEIIIU0LJc+EkA+SgYEBZDIZt8XExMDS0hLu7u68dlpaWpDJZDAzM4ObmxvWrVuH7777DrNnz0ZWVpbS45w/fx4LFixAZGQklixZgm7dusHCwgJ9+vTB7t27ERAQwGv/66+/wsLCAtra2hg+fDgeP37M1R05cgQff/wxdHR0oKenh08//RQ5OTlcfdUdvT179qBnz56QSCRo3749kpKSeMdYv349TE1NIZFIMHjwYCxbtgw6Ojq8Nvv374eTkxPU1dXRunVrREREcAkFYwzh4eEwMzODSCSCiYkJJk+eXOt5EAgEkMlkMDY2Rrdu3TBmzBicP3+eW95H2TEVmTFjBmxsbCCRSNC6dWt89913KC8vB/DybndERATS0tLk7toWFhbiyy+/hIGBAaRSKXr16oW0tDRe34sWLYKRkRG0tLQwZswYlJaW1hhHXl4eevbsCQBo3rw5BAIBAgMDAQDPnz/H5MmTYWhoCHV1dXz88cdITk5W2I+qqirvZ1JTUxPNmjXjPhsaGmLFihVo1aoVxGIx2rdvj//973+1nvczZ86ge/fuEIvFMDU1xeTJk/HkyRNem6dPn2L06NHQ0tKCmZkZ1q1bx6u/desWfHx8oKOjA11dXXh7eyMvL4+rT05ORp8+faCvrw9tbW24u7vjzz//rDGmVq1aAQA6duwIgUCAHj168OqXLl0KY2Nj6OnpISQkhLumihw4cAATJkzAsGHD0KpVK7Rv3x5jxozB1KlTuTaVlZVYuHBhjeet6qmBw4cPw9nZGSKRCJs2bYJAIMDVq1d5x1u+fDksLS15+1VP1BMTE9GjRw9IJBI0b94cnp6eePToUZ3iePToEfz9/WFgYACxWAxra2tERUXVOHZCCCENgBFCyAfu+fPnTE9Pj82fP59Xbm5uzpYvXy7X/sGDB0wgELAffvhBad+TJ09mmpqarKysrNZ2c+bMYZqamuyzzz5jly9fZqdOnWIymYx98803XJv//e9/bPfu3Sw7O5ulpKSwAQMGMAcHB1ZRUcEYYyw3N5cBYHZ2diwmJoZlZWWxoUOHMnNzc1ZeXs4YY+zMmTNMRUWFLVmyhGVlZbH//ve/TFdXl2lra3PHOXXqFJNKpSw6Oprl5OSwY8eOMQsLCxYeHs4YY+y3335jUqmUHTp0iN28eZOdO3eOrVu3rsaxRUVF8fq/e/cu69mzJ1NVVWUlJSV1OiZjjAFge/fu5T7PmzePJSYmstzcXHbgwAFmZGTEXZOnT5+ysLAw1rZtW1ZQUMAKCgrY06dPGWOMeXh4sAEDBrDk5GR27do1FhYWxvT09NiDBw8YY4zt3LmTiUQitmHDBnb16lX27bffMi0tLda+fXuF43vx4gXbvXs3A8CysrJYQUEBKywsZIy9vP4mJibs0KFDLCMjgwUEBLDmzZtzx6rNnDlzeMf8/vvvmZ2dHTty5AjLyclhUVFRTCQSsYSEBMYYY/Hx8QwAe/ToEWOMsevXrzMNDQ22fPlydu3aNZaYmMg6duzIAgMDuT7Nzc2Zrq4u++9//8uys7PZwoULmYqKCrt69SpjjLGysjJmb2/PRo8ezS5dusSuXLnCPv/8c2Zra8ueP3/OGGPs+PHj7Ndff2WZmZnsypUrbMyYMczIyIgVFxcrvHbnz59nAFhcXBwrKCjgzkVAQACTSqVs/PjxLDMzk/3+++9MIpHU+rPl6enJ3Nzc2L1792psU9fz5ujoyI4dO8auX7/OHjx4wDp16sRmzZrF68vZ2Zkre/V8p6SkMJFIxIKDg1lqaipLT09nP/30E/vnn3/qFEdISAjr0KEDS05OZrm5uSw2NpYdOHBA4ZhKS0tZUVERt926dYsBYKahu2o8D4QQQhQrKipiAFhRUZHStpQ8E0I+eDt37mSqqqrs9u3bvPKakmfGGDMyMmLBwcFK+/by8mKOjo5K282ZM4dJJBJewjFt2jTWtWvXGvf5559/GAB2+fJlxtj/J88bNmzg2mRkZDAALDMzkzHGmK+vL+vfvz+vH39/f15y27t3b7ZgwQJem19//ZUZGxszxhiLjIxkNjY2Sr8QqBIVFcUAMA0NDSaRSBgABoBNnjy5zsdkTD55ftWSJUuYs7Mz9/nV5JMxxk6fPs2kUikrLS3llVtaWrK1a9cyxhhzcXFhEyZM4NV37dq1xuSZMflEijHGSkpKmJqaGtu6dStXVlZWxkxMTNjixYtr7EtR/KWlpUwikbCzZ8/y2owZM4b5+fkpjGHMmDFs7NixcuNXUVFhz549Y4y9/Bn/4osvuPrKykpmaGjI1qxZwxh7eQ1sbW1ZZWUl1+b58+dMLBazo0ePKoy7oqKCaWlpsd9//50rq37tqn5OU1JSePsFBAQwc3Nz9uLFC65s2LBhzNfXt8ZzlJGRwezt7ZmKigpzcHBg48aNY4cOHeLq63Pe9u3bx2uzfPlyZmlpyX3Oysri/S69er79/PyYq6urwjjrEseAAQPYqFGjahxrdXPmzOF+j6pvlDwTQkj91Sd5pse2CSEfvI0bN8LLywsmJiZ13ocxVqd3HVk9VgO0sLCAlpYW99nY2Bj37t3jPmdnZ8PPzw+tW7eGVCqFhYUFAMhNvOXo6MjrAwDXT1ZWFrp06cJr/+rntLQ0zJ07F5qamtwWFBSEgoICPH36FMOGDcOzZ8/QunVrBAUFYe/evUrfEdXS0kJqaiouXLiAyMhIODk58d4bV3ZMRXbu3AlXV1fuEedZs2YpnYQsLS0NJSUl0NPT4x0rNzeXewQ+MzMTXbt25e3n4uJSa7+K5OTkoLy8HK6urlyZmpoaunTpgszMzHr1df36dTx9+hR9+vThxf3LL7/wHt2vLi0tDdHR0bz2np6eqKysRG5uLteu+s9L1eP1VT8vaWlpuH79OrS0tLg+dHV1UVpayh337t27CAoKgrW1NbS1tSGVSlFSUvJaE8K1bdsWqqqq3OdXfwde1aZNG6Snp+OPP/7A6NGjce/ePQwYMABffvllvc9bp06deJ+HDx+OvLw8/PHHHwBeLl/l5OQEOzs7hbGkpqaid+/eCuvqEkdwcDB27NiBDh06YPr06Th79myN4545cyaKioq47datWzW2JYQQ8vY0a+gACCGkId28eRNxcXHYs2dPnfd58OAB/vnnH+7dzdrY2NjgzJkzKC8vh5qaWq1tX60XCASorKzkPg8YMADm5uZYv349TExMUFlZiXbt2qGsrKzGfqoS/Or9KFNSUoKIiAh89tlncnXq6uowNTVFVlYW4uLiEBsbiwkTJmDJkiU4efJkjWNUUVGBlZUVAMDe3h45OTkIDg7mJkxTdsxXJSUlwd/fHxEREfD09IS2tjZ27NiByMhIpWMzNjZGQkKCXN2r7303JiUlJQCAgwcPokWLFrw6kUhU4z7jxo1T+D66mZkZ9+/afu5KSkrg7OyMrVu3yvVhYGAAAAgICMCDBw+wcuVKmJubQyQSwcXFRe7nsi6U/Q4ooqKigs6dO6Nz584IDQ3Fli1bMGLECHz77bf1Om8aGhq8zzKZDL169cK2bdvw0UcfYdu2bQgODq4xDrFYXGNdXeLw8vLCzZs3cejQIcTGxqJ3794ICQnB0qVL5foTiUQ1XndCCCHvDiXPhJAPWlRUFAwNDdG/f/8677Ny5UqoqKjUaU3azz//HD/++CNWr16NKVOmyNUXFhbWKWl78OABsrKysH79enTv3h3Ay8mg6svW1lZuwqpXPzs5OSErK4tLdhURi8UYMGAABgwYgJCQENjZ2eHy5ctwcnKqUxxff/01LC0t8Z///AdOTk51OmZ1Z8+ehbm5Ob799luu7ObNm7w2QqEQFRUVcmO7c+cOmjVrxt25f5W9vT3OnTuHkSNHcmVVdx9rIhQKAYB3PEtLSwiFQiQmJnLLG5WXlyM5ORmhoaFKx1hdmzZtIBKJkJ+fLzepXU2cnJxw5cqVOp/TmvrYuXMnDA0NIZVKFbZJTEzE6tWr0a9fPwAvJxi7f/9+jX0qOldvU5s2bQAAT548ea3zVp2/vz+mT58OPz8/3LhxA8OHD6+xraOjI44fP46IiAiFMdUlDgMDAwQEBCAgIADdu3fHtGnTFCbPhBBCGgYlz4SQD1ZlZSWioqIQEBCAZs0U/zl8/Pgx7ty5g/LycuTm5mLLli3YsGEDFi5cWKekpGvXrpg+fTrCwsJw+/ZtDB48GCYmJrh+/Tp+/vlnfPzxxwqT6lc1b94cenp6WLduHYyNjZGfn4+vv/663mOeNGkS3NzcsGzZMgwYMAAnTpzA4cOHeY+gz549G59++inMzMwwdOhQqKioIC0tDenp6fj+++8RHR2NiooKdO3aFRKJBFu2bIFYLOYSxLowNTXF4MGDMXv2bMTExCg95qusra2Rn5+PHTt2oHPnzjh48CD27t3La2NhYYHc3FykpqaiZcuW0NLSgoeHB1xcXDBo0CAsXrwYNjY2+Pvvv3Hw4EEMHjwYnTp1wpQpUxAYGIhOnTrB1dUVW7duRUZGBlq3bl3jeMzNzSEQCBATE4N+/fpBLBZDU1MTwcHBmDZtGnR1dWFmZobFixfj6dOnGDNmTJ3PFfDysfepU6fiP//5DyorK/Hxxx+jqKgIiYmJkEqlcrO2Ay9nI//oo48wceJEfPnll9DQ0MCVK1cQGxuLVatW1em4/v7+WLJkCby9vTF37ly0bNkSN2/exJ49ezB9+nS0bNkS1tbW+PXXX9GpUycUFxdj2rRptd6FNTQ0hFgsxpEjR9CyZUuoq6u/9lrJQ4cOhaurK7p16waZTIbc3FzMnDkTNjY2sLOzQ7Nmzep93qr77LPPEBwcjODgYPTs2bPWVztmzpwJBwcHTJgwAePHj4dQKER8fDyGDRsGfX19pXHMnj0bzs7OaNu2LZ4/f46YmBjY29u/1nkhhBDyjrzzN7AJIaSROnr0KDdDsiLm5ubcRDxCoZCZmZkxHx8fduLEiXofa+fOnczNzY1paWkxDQ0N5ujoyObOnctNNqRocqvly5czc3Nz7nNsbCyzt7dnIpGIOTo6soSEBKUTMT169IgBYPHx8VzZunXrWIsWLZhYLGaDBg1i33//PZPJZLxjHzlyhHXr1o2JxWImlUpZly5duFmP9+7dy7p27cqkUinT0NBgH330EYuLi6tx7K/Otl0lKSmJAWDnzp1TekzG5CcMmzZtGtPT02OamprM19eXLV++nHec0tJSNmTIEKajo8MAsKioKMYYY8XFxWzSpEnMxMSEqampMVNTU+bv78/y8/O5fefPn8/09fWZpqYmCwgIYNOnT691wjDGGJs7dy6TyWRMIBCwgIAAxhhjz549Y5MmTWL6+vpMJBIxV1dXdv78+Vr7qfLqz0RlZSVbsWIFs7W1ZWpqaszAwIB5enqykydPMsYUT1p2/vx51qdPH6apqcn93FWfVV7RpHjt27dnc+bM4T4XFBSwkSNHcmNo3bo1CwoK4iZW+fPPP1mnTp2Yuro6s7a2Zr/99ptcv69eu/Xr1zNTU1OmoqLC3N3dGWMvJwzz9vbmxTJlyhSuXpF169axnj17MgMDA+53NDAwkOXl5b3ReavOx8eHAWCbNm3ilSvaLyEhgXXr1o2JRCKmo6PDPD09uXplccybN4/Z29szsVjMdHV1mbe3N7tx40aNY6+uarIbmjCMEELqrz4ThgkYq8dsNoQQQv51goKCcPXqVZw+fbqhQyGEvIbi4mJoa2ujqKioxsfrCSGEKFafv6H02DYhhHxgli5dij59+kBDQwOHDx/G5s2bsXr16oYOixBCCCGkUaOlqggh5A2MHz+et/RM9W38+PENHZ5C58+fR58+feDg4ICff/4ZP/74I7e0DyGEEEIIUYwe2yaEkDdw7949FBcXK6yTSqUwNDR8zxG9PxYWFggNDa33zNFNSV5eHlq1aoWUlBR06NDhrbV9V8LDw7Fv3z6kpqa+9b4FAgH27t1bp1nmm6KEhAT07NkTjx49eqNly95WP/VR9cihaeguqIgk7+WY5N3IW1T3lR8IIW9HfR7bpjvPhBDyBgwNDWFlZaVwe5PE2cLCAgKBQG4LCQlR2mbRokV1Ps7mzZvRuXNnSCQSaGlpwd3dHTExMbw20dHRDb4GcnR0NDc+FRUVtGzZEqNGjcK9e/fe6XFNTU1RUFCAdu3avdW278rUqVNx/PjxN+ojPDz8vSX/CQkJvJ9dAwMD9OvXD5cvX34vx39TPXr0kPvyqFu3bigoKHjtGcQJIYQ0XpQ8E0JII5ScnIyCggJui42NBQAMGzaM127u3Lm8dgUFBZg0aVKdjjF16lSMGzcOvr6+uHTpEs6fP4+PP/4Y3t7edV7K6G0rKyursU4qlaKgoAB//fUX1q9fj8OHD2PEiBEK21ZUVKCysvKN41FVVYVMJqtxKbPXbfuuaGpqQk9Pr8GO/7qysrJQUFCAo0eP4vnz5+jfv3+tPwuNmVAohEwm4y3/Rggh5N+BkmdCCGmEDAwMIJPJuC0mJgaWlpZwd3fntdPS0uK1k8lk0NDQUNr/H3/8gcjISCxZsgRTp06FlZUV7O3tMX/+fISGhuKrr77CrVu3kJCQgFGjRqGoqIi7OxgeHs718/TpU4wePRpaWlowMzPDunXreMe5desWfHx8oKOjA11dXXh7eyMvL4+rDwwMxKBBgzB//nyYmJjA1ta2xpgFAgFkMhlMTEzg5eWFyZMnIy4uDs+ePePujh84cABt2rSBSCRCfn4+Hj16hJEjR6J58+aQSCTw8vJCdnY2gJePaYnFYhw+fJh3nL1790JLSwtPnz5FXl4eBAIB9xj0o0eP4O/vDwMDA4jFYlhbWyMqKgoA5NoCwMmTJ9GlSxeIRCIYGxvj66+/xosXL7j6Hj16YPLkyZg+fTp0dXUhk8l455cxhvDwcJiZmUEkEsHExASTJ0+u8Ry9ete46vwuXboUxsbG0NPTQ0hICMrLyxXuHx0djYiICKSlpXHXOzo6mqu/f/8+Bg8eDIlEAmtraxw4cIC3f3p6Ory8vKCpqQkjIyOMGDEC9+/frzHeKoaGhpDJZHByckJoaChu3bqFq1evcvVnzpxB9+7dIRaLYWpqismTJ+PJkydcfUFBAfr37w+xWIxWrVph27ZtsLCwwIoVKwAovjaFhYUQCARISEhQGNODBw/g5+eHFi1aQCKRwMHBAdu3b+ed25MnT2LlypXcucrLy+PuphcWFnJtd+/ejbZt20IkEsHCwgKRkZG8Y1lYWGDBggW1/i4RQghpeJQ8E0JII1dWVoYtW7Zg9OjRb+1u1vbt26GpqYlx48bJ1YWFhaG8vBy7d+9Gt27dsGLFCu6ub0FBAaZOncq1jYyMRKdOnZCSkoIJEyYgODgYWVlZAIDy8nJ4enpCS0sLp0+fRmJiIjQ1NdG3b1/eXcXjx48jKysLsbGxco+M10YsFqOyspJLRp8+fYoffvgBGzZsQEZGBgwNDREYGIgLFy7gwIEDSEpKAmMM/fr1Q3l5OaRSKT799FNs27aN1+/WrVsxaNAgSCTy745+9913uHLlCg4fPozMzEysWbMG+vr6CuO7ffs2+vXrh86dOyMtLQ1r1qzBxo0b8f333/Pabd68GRoaGjh37hwWL16MuXPnck8a7N69G8uXL8fatWuRnZ2Nffv2wcHBoc7nCADi4+ORk5OD+Ph4bN68GdHR0byEuDpfX1+EhYWhbdu23PX29fXl6iMiIuDj44NLly6hX79+8Pf3x8OHDwG8TEZ79eqFjh074sKFCzhy5Aju3r0LHx+fOsdaVFSEHTt2AHh5BxcAcnJy0LdvXwwZMgSXLl3Czp07cebMGUycOJHbb+TIkfj777+RkJCA3bt3Y926dW/8SH9paSmcnZ1x8OBBpKenY+zYsRgxYgTOnz8PAFi5ciVcXFwQFBTEnStTU1O5fi5evAgfHx8MHz4cly9fRnh4OL777ju5a1Db79Krnj9/juLiYt5GCCHk3aOlqgghpJHbt28fCgsLERgYKFc3Y8YMzJo1i1d2+PBhdO/evdY+r127BktLSy5Bqc7ExARSqRTXrl2DUCiEtrY2d9f3Vf369cOECRO4WJYvX474+HjY2tpi586dqKysxIYNG7ikPyoqCjo6OkhISMAnn3wCANDQ0MCGDRsUxlKT7Oxs/Pzzz+jUqRO0tLQAvEzWV69ejfbt23NtDhw4gMTERHTr1g3Ay8TY1NQU+/btw7Bhw+Dv748RI0bg6dOnkEgkKC4uxsGDB7F3716Fx83Pz0fHjh3RqVMnAC/vGNZk9erVMDU1xapVqyAQCGBnZ4e///4bM2bMwOzZs6Gi8vL7a0dHR8yZMwcAYG1tjVWrVuH48ePo06cP8vPzIZPJ4OHhATU1NZiZmaFLly51Pk8A0Lx5c6xatQqqqqqws7ND//79cfz4cQQFBcm1FYvF0NTURLNmzRRe78DAQPj5+QEAFixYgB9//BHnz59H3759sWrVKnTs2BELFizg2m/atAmmpqa4du0abGxsaoyxZcuWAMDdTR44cCDs7OwAAAsXLoS/vz/3brG1tTV+/PFHuLu7Y82aNcjLy0NcXBySk5O567JhwwZYW1vX6zy9qkWLFrwviiZNmoSjR49i165d6NKlC7S1tSEUCiGRSBSeqyrLli1D79698d133wEAbGxscOXKFSxZsoT3O13b79KrFi5ciIiIiDcaHyGEkPqjO8+EENLIbdy4EV5eXjAxMZGrmzZtGlJTU3lbVQKhzNtYbMHR0ZH7d1WCXXXHLy0tDdevX4eWlha3fJeuri5KS0uRk5PD7efg4FCnxLmoqAiampqQSCSwtbWFkZERtm7dytULhUJePJmZmWjWrBm6du3Klenp6cHW1haZmZkAXiYsampq3OPHu3fvhlQqhYeHh8IYgoODsWPHDnTo0AHTp0/H2bNna4w3MzMTLi4uvKcFXF1dUVJSgr/++osrqx4zABgbG3PncNiwYXj27Blat26NoKAg7N27l/fYd120bdsWqqqqCvuvr+qxamhoQCqV8q53fHw8b7m2qgS4+vVW5PTp07h48SKio6NhY2ODn3/+matLS0tDdHQ0r19PT09UVlYiNzcXWVlZaNasGZycnLh9rKys0Lx589caY5WKigrMmzcPDg4O0NXVhaamJo4ePYr8/Px69ZOZmQlXV1demaurK7Kzs1FRUcGV1fa79KqZM2eiqKiI227dulWvmAghhLweuvNMCCGN2M2bNxEXF4c9e/YorNfX14eVlVW9+7WxscGZM2dQVlYml7j+/fffKC4urvVOYRU1NTXeZ4FAwE3UVVJSAmdnZ16CW8XAwID7d13e0QZevt/9559/QkVFBcbGxhCLxbx6sVhc78fahUIhhg4dim3btmH48OHYtm0bfH19a5z0y8vLCzdv3sShQ4cQGxuL3r17IyQkBEuXLq3Xcaur7RyampoiKysLcXFxiI2NxYQJE7BkyRKcPHlSbr/X6f9txlpSUoIBAwbghx9+kNvP2Ni41n5btWoFHR0d2Nra4t69e/D19cWpU6e4fseNG6fwXW8zMzNcu3ZNadxVd/mrf2FU03vfVZYsWYKVK1dixYoVcHBwgIaGBkJDQ9/ZRGb1uU4ikQgikeidxEEIIaRmdOeZEEIasaioKBgaGqJ//7e79ufw4cNRUlKCtWvXytUtXboUampqGDJkCICXCWb1O2R15eTkhOzsbIXLeb3OMj4qKiqwsrJC69at5RJnRezt7fHixQucO3eOK3vw4AGysrLQpk0brszf3x9HjhxBRkYGTpw4AX9//1r7NTAwQEBAALZs2YIVK1bUOLGTvb099551lcTERGhpaXGPKdeFWCzGgAED8OOPPyIhIQFJSUnvdCmnN7neGRkZsLCwkLvedf2CBABCQkKQnp7OPTrv5OSEK1euKFwOTigUwtbWFi9evEBKSgrXx/Xr1/Ho0SPuc9WXNQUFBVyZsrWwExMT4e3tjS+++ALt27dH69at5RL1upwre3t7JCYmyvVtY2PDeyKAEEJI40fJMyGENFKVlZWIiopCQEBAjXdCHz9+jDt37vC2ukwe5OLigilTpmDatGmIjIxETk4Orl69ilmzZmHlypWIjIzkJj+ysLBASUkJjh8/jvv37+Pp06d1it/f3x/6+vrw9vbG6dOnkZubi4SEBEyePJn32PK7Ym1tDW9vbwQFBeHMmTNIS0vDF198gRYtWsDb25tr5+bmBplMBn9/f7Rq1Yr3mPerZs+ejf379+P69evIyMhATEwM7O3tFbadMGECbt26hUmTJuHq1avYv38/5syZg6+++oq7E6pMdHQ0Nm7ciPT0dNy4cQNbtmyBWCyGubl5/U5GPVhYWCA3Nxepqam4f/8+nj9/Xqf9QkJC8PDhQ/j5+SE5ORk5OTk4evQoRo0aVa9kXCKRICgoCHPmzAFjDDNmzMDZs2cxceJEpKamIjs7G/v37+cmDLOzs4OHhwfGjh2L8+fPIyUlBWPHjuU9iSAWi/HRRx9h0aJFyMzMxMmTJ+XmCniVtbU1YmNjcfbsWWRmZmLcuHG4e/eu3Lk6d+4c8vLycP/+fYV3isPCwnD8+HHMmzcP165dw+bNm7Fq1Sre+9SEEEKaBkqeCSGkkYqLi0N+fj5Gjx5dY5vZs2fD2NiYt02fPr1O/a9YsQKrV6/G9u3b0a5dO3Tq1AmnTp3Cvn37eGtFd+vWDePHj4evry8MDAywePHiOvUvkUhw6tQpmJmZ4bPPPoO9vT3GjBmD0tJSSKXSOvXxpqKiouDs7IxPP/0ULi4uYIzh0KFDvEdkBQIB/Pz8kJaWpvSus1AoxMyZM+Ho6Ag3Nzeoqqpys0O/qkWLFjh06BDOnz+P9u3bY/z48RgzZozSpK06HR0drF+/Hq6urnB0dERcXBx+//33d7qW85AhQ9C3b1/07NkTBgYGvOWZamNiYoLExERUVFTgk08+gYODA0JDQ6Gjo1PnLwuqTJw4EZmZmfjtt9/g6OiIkydP4tq1a+jevTs6duyI2bNn8+YA+OWXX2BkZAQ3NzcMHjwYQUFB0NLSgrq6Otdm06ZNePHiBZydnREaGio36/mrZs2aBScnJ3h6eqJHjx6QyWQYNGgQr83UqVOhqqqKNm3awMDAQOH70E5OTti1axd27NiBdu3aYfbs2Zg7d67CCQAJIYQ0bgL2NmaMIYQQQghpJP766y+YmpoiLi4OvXv3buhw3rni4mJoa2ujqKjovX0xRQgh/xb1+RtKE4YRQgghpEk7ceIESkpK4ODggIKCAkyfPh0WFhZwc3Nr6NAIIYT8i9Bj24QQ8i80fvx43tI+1bfx48c3dHiEvFXl5eX45ptv0LZtWwwePBgGBgZISEio84zkhBBCSF3QY9uEEPIvdO/evRonDpNKpTA0NHzPEf27hIeHY9++fUpnbG5sEhIS0LNnTzx69Ag6OjoNHU6DEggE2Lt3r9x7zFXy8vLQqlUrpKSkoEOHDu81NgDo0aMHOnTogBUrVihtW/XIoWnoLqiIJLy6vEVvd6Z+Qgj5t6nPY9t055kQQv6FFC0PVbU19cTZwsICAoFAbgsJCam1TX2WhwKAhQsXQlVVFUuWLFHaNjAwsMYkrKH06NEDoaGhvLJu3bqhoKDgtZYKe5vi4+PRr18/6OnpQSKRoE2bNggLC8Pt27ffWwwFBQXw8vJ6b8cjhBDS9FHyTAghpElJTk5GQUEBt8XGxgIAhg0bxms3d+5cXrvq6wDXxaZNmzB9+nRs2rTprcWuTFlZ2TvtXygUQiaTcUs4NYS1a9fCw8MDMpkMu3fvxpUrV/Dzzz+jqKgIkZGR7y0OmUwGkUj0To/xrq8nIYSQ94uSZ0IIIU2KgYEBZDIZt8XExMDS0hLu7u68dlpaWrx2BgYGdT7GyZMn8ezZM8ydOxfFxcU4e/ZsjW3Dw8OxefNm7N+/n7vLnZCQAAC4desWfHx8oKOjA11dXXh7eyMvL4/bt+qO9fz582FiYgJbW1vk5eVBIBBgz5496NmzJyQSCdq3b4+kpCRuvwcPHsDPzw8tWrSARCKBg4MDb0mpwMBAnDx5EitXruRiysvLQ0JCAgQCAQoLC1FcXAyxWIzDhw/zxrN3715oaWlx63krG0NCQgK6dOkCDQ0N6OjowNXVFTdv3lR4rv766y9MnjwZkydPxqZNm9CjRw9uYq8NGzZg9uzZXNvdu3ejbdu2EIlEsLCwkEusLSwssGDBAowePRpaWlowMzPDunXruPqysjJMnDgRxsbGUFdXh7m5ORYuXMjVCwQC7Nu3j/t8/vx5dOzYEerq6ujUqZPCL1vS09Ph5eUFTU1NGBkZYcSIEbh//z5X36NHD0ycOBGhoaHQ19eHp6dnnfZ78uQJRo4cCU1NTRgbG7/XLxEIIYTUHSXPhBBCmqyysjJs2bIFo0ePfqt3Uzdu3Ag/Pz+oqanBz88PGzdurLHt1KlT4ePjg759+3J3ubt164by8nJ4enpCS0sLp0+fRmJiIjQ1NdG3b1/eHcnjx48jKysLsbGxiImJ4cq//fZbTJ06FampqbCxsYGfnx9evHgBACgtLYWzszMOHjyI9PR0jB07FiNGjMD58+cBACtXroSLiwuCgoK4mExNTXlxS6VSfPrpp9i2bRuvfOvWrRg0aBAkEonSMbx48QKDBg2Cu7s7Ll26hKSkJIwdO7bGa/Hbb7+hrKysxrXIq97DvnjxInx8fDB8+HBcvnwZ4eHh+O677xAdHc1rHxkZySW6EyZMQHBwMLKysgAAP/74Iw4cOIBdu3YhKysLW7duhYWFhcLjlpSU4NNPP0WbNm1w8eJFhIeHY+rUqbw2hYWF6NWrFzp27IgLFy7gyJEjuHv3Lnx8fHjtNm/eDKFQiMTERPz888912m/atGk4efIk9u/fj2PHjiEhIQF//vmnwlgB4Pnz5yguLuZthBBC3gNGCCGENFE7d+5kqqqq7Pbt27xyc3NzJhQKmYaGBretXLmyTn0WFRUxsVjMUlNTGWOMpaSkME1NTfb48WOuzZw5c1j79u25zwEBAczb25vXz6+//spsbW1ZZWUlV/b8+XMmFovZ0aNHuf2MjIzY8+fPuTa5ubkMANuwYQNXlpGRwQCwzMzMGuPu378/CwsL4z67u7uzKVOm8NrEx8czAOzRo0eMMcb27t3LNDU12ZMnT7ixq6urs8OHD9dpDA8ePGAAWEJCQo1xVRccHMykUqnSdp9//jnr06cPr2zatGmsTZs23Gdzc3P2xRdfcJ8rKyuZoaEhW7NmDWOMsUmTJrFevXrxYq8OANu7dy9jjLG1a9cyPT099uzZM65+zZo1DABLSUlhjDE2b9489sknn/D6uHXrFgPAsrKyGGMvz3nHjh15bZTt9/jxYyYUCtmuXbu4+gcPHjCxWCx3/arMmTOHAZDbTEN3MfMZMbyNEEJI7YqKihgAVlRUpLQt3XkmhBDSZG3cuBFeXl4wMTGRq5s2bRpSU1O5beTIkXXqc/v27bC0tET79u0BAB06dIC5uTl27txZr9jS0tJw/fp1aGlpccuE6erqorS0FDk5OVw7BwcHCIVCuf0dHR25fxsbGwN4OYs6AFRUVGDevHlwcHCArq4uNDU1cfToUeTn59crxn79+kFNTQ0HDhwA8PJRaalUCg8PjzqNQVdXF4GBgfD09MSAAQOwcuVKFBQU1Hg8xlidnhDIzMyEq6srr8zV1RXZ2dmoqKjgyqqfI4FAAJlMxp2jwMBApKamwtbWFpMnT8axY8dqPZ6joyPU1dW5MhcXF16btLQ0xMfH85Z9s7OzAwDe9XR2dq7Xfjk5OSgrK0PXrl25fXR1dWFra1tjvDNnzkRRURG33bp1q8a2hBBC3p5mDR0AIYQQ8jpu3ryJuLg47NmzR2G9vr4+rKys6t3vxo0bkZGRgWbN/v8/kZWVldi0aRPGjBlT535KSkrg7OyMrVu3ytVVf/9aQ0ND4f7V1yiuSjgrKysBAEuWLMHKlSuxYsUKODg4QENDA6GhofWeoEooFGLo0KHYtm0bhg8fjm3btsHX15cbe13GEBUVhcmTJ+PIkSPYuXMnZs2ahdjYWHz00Udy+9jY2KCoqAgFBQXcFwJv4tV1nAUCAXeOnJyckJubi8OHDyMuLg4+Pj7w8PDA//73v9c6VklJCQYMGIAffvhBrq76WF69nsr2u379er1jEYlE73yyM0IIIfIoeSaEENIkRUVFwdDQEP37v711bC9fvowLFy4gISEBurq6XPnDhw/Ro0cPXL16lbtrWJ1QKOTdEQVeJm87d+6EoaGh0nUj6ysxMRHe3t744osvALxMqq9du4Y2bdrUGpMi/v7+6NOnDzIyMnDixAl8//339R5Dx44d0bFjR8ycORMuLi7Ytm2bwuR56NCh+Prrr7F48WIsX75crr6wsBA6Ojqwt7dHYmKi3JhtbGygqqqqdExVpFIpfH194evri6FDh6Jv3754+PAh79oCgL29PX799VeUlpZyd5//+OMPXhsnJyfs3r0bFhYWvC9WlFG2n6WlJdTU1HDu3DmYmZkBAB49eoRr167JTYJHCCGkYdFj24QQQpqcyspKREVFISAgoF6JjDIbN25Ely5d4Obmhnbt2nGbm5sbOnfuXOPEYRYWFrh06RKysrJw//59lJeXw9/fH/r6+vD29sbp06eRm5uLhIQETJ48GX/99dcbxWltbY3Y2FicPXsWmZmZGDduHO7evSsX07lz55CXl4f79+9zd2Rf5ebmBplMBn9/f7Rq1Yr3+LCyMeTm5mLmzJlISkrCzZs3cezYMWRnZ8Pe3l7hsUxNTbF8+XKsXLkSY8aMwcmTJ3Hz5k0kJiZi3LhxmDdvHgAgLCwMx48fx7x583Dt2jVs3rwZq1atkpvEqzbLli3D9u3bcfXqVVy7dg2//fYbZDIZNylZdZ9//jkEAgGCgoJw5coVHDp0CEuXLuW1CQkJwcOHD+Hn54fk5GTk5OTg6NGjGDVqVK1fUijbT1NTE2PGjMG0adNw4sQJpKenIzAwECoq9L9ohBDS2NBfZkIIIU1OXFwc8vPzMXr06LfWZ9XM3UOGDFFYP2TIEPzyyy8oLy+XqwsKCoKtrS06deoEAwMDJCYmQiKR4NSpUzAzM8Nnn30Ge3t7jBkzBqWlpW98J3rWrFlwcnKCp6cnevToAZlMhkGDBvHaTJ06FaqqqmjTpg0MDAxqfB9aIBDAz88PaWlp8Pf359UpG4NEIsHVq1cxZMgQ2NjYYOzYsQgJCcG4ceNqjH3ChAk4duwYbt++jcGDB8POzg5ffvklpFIplxw7OTlh165d2LFjB9q1a4fZs2dj7ty5CAwMrPM50tLSwuLFi9GpUyd07twZeXl5OHTokMKkVFNTE7///jsuX76Mjh074ttvv5V7zNrExASJiYmoqKjAJ598AgcHB4SGhkJHR6fWRLcu+y1ZsgTdu3fHgAED4OHhgY8//lju3WlCCCENT8AYYw0dBCGEEEIIeT3FxcXQ1tZGUVHRW39FgBBC/u3q8zeU7jwTQgghhBBCCCFKUPJMCCHkg7F161bekkHVt7Zt2zZ0eIQQQghpxGi2bUIIIR+MgQMH8ibEqu7VZY8IIYQQQqqj5JkQQsgHQ0tLC1paWg0dBiGEEEKaIHpsmxBCCCGEEEIIUYKSZ0IIIYQQQgghRAlKngkhhBBCCCGEECUoeSaEEEIIIYQQQpSg5JkQQgghhBBCCFGCkmdCCCGEEEIIIUQJSp4JIYQQQgghhBAlKHkmhBBCCCGEEEKUoOSZEEIIIYQQQghRgpJnQgghhBBCCCFECUqeCSGEEEIIIYQQJSh5JoQQQgghhBBClKDkmRBCCCGEEEIIUYKSZ0IIIYQQQgghRAlKngkhhBBCCCGEECUoeSaEEEIIIYQQQpSg5JkQQgghhBBCCFGiWUMHQAghhBBCXh9jDABQXFzcwJEQQkjTU/W3s+pvaW0oeSaEEEIIacIePHgAADA1NW3gSAghpOl6/PgxtLW1a21DyTMhhBBCSBOmq6sLAMjPz1f6P35NQXFxMUxNTXHr1i1IpdKGDueN0XgaNxpP4/W+xsIYw+PHj2FiYqK0LSXPhBBCCCFNmIrKyylstLW1m/z/LFcnlUppPI0Yjadx+zeN532Mpa5fPNKEYYQQQgghhBBCiBKUPBNCCCGEEEIIIUpQ8kwIIYQQ0oSJRCLMmTMHIpGooUN5K2g8jRuNp3H7N42nMY5FwOoyJzchhBBCCCGEEPIBozvPhBBCCCGEEEKIEpQ8E0IIIYQQQgghSlDyTAghhBBCCCGEKEHJMyGEEEJIE/bf//4XFhYWUFdXR9euXXH+/Pn3evyFCxeic+fO0NLSgqGhIQYNGoSsrCxemx49ekAgEPC28ePH89rk5+ejf//+kEgkMDQ0xLRp0/DixQtem4SEBDg5OUEkEsHKygrR0dFy8bzp+QgPD5eL1c7OjqsvLS1FSEgI9PT0oKmpiSFDhuDu3buNciwAYGFhITcegUCAkJAQAI3/2pw6dQoDBgyAiYkJBAIB9u3bx6tnjGH27NkwNjaGWCyGh4cHsrOzeW0ePnwIf39/SKVS6OjoYMyYMSgpKeG1uXTpErp37w51dXWYmppi8eLFcrH89ttvsLOzg7q6OhwcHHDo0KF6x1LbeMrLyzFjxgw4ODhAQ0MDJiYmGDlyJP7++29eH4qu6aJFixrdeAAgMDBQLta+ffvy2jSm66MUI4QQQgghTdKOHTuYUChkmzZtYhkZGSwoKIjp6Oiwu3fvvrcYPD09WVRUFEtPT2epqamsX79+zMzMjJWUlHBt3N3dWVBQECsoKOC2oqIirv7FixesXbt2zMPDg6WkpLBDhw4xfX19NnPmTK7NjRs3mEQiYV999RW7cuUK++mnn5iqqio7cuQI1+ZtnI85c+awtm3b8mL9559/uPrx48czU1NTdvz4cXbhwgX20UcfsW7dujXKsTDG2L1793hjiY2NZQBYfHw8Y6zxX5tDhw6xb7/9lu3Zs4cBYHv37uXVL1q0iGlra7N9+/axtLQ0NnDgQNaqVSv27Nkzrk3fvn1Z+/bt2R9//MFOnz7NrKysmJ+fH1dfVFTEjIyMmL+/P0tPT2fbt29nYrGYrV27lmuTmJjIVFVV2eLFi9mVK1fYrFmzmJqaGrt8+XK9YqltPIWFhczDw4Pt3LmTXb16lSUlJbEuXbowZ2dn3pjNzc3Z3Llzedes+u9bYxkPY4wFBASwvn378mJ9+PAhr01juj7KUPJMCCGEENJEdenShYWEhHCfKyoqmImJCVu4cGGDxXTv3j0GgJ08eZIrc3d3Z1OmTKlxn0OHDjEVFRV2584drmzNmjVMKpWy58+fM8YYmz59Omvbti1vP19fX+bp6cl9fhvnY86cOax9+/YK6woLC5mamhr77bffuLLMzEwGgCUlJTW6sSgyZcoUZmlpySorKxljTevavJqcVVZWMplMxpYsWcKVFRYWMpFIxLZv384YY+zKlSsMAEtOTubaHD58mAkEAnb79m3GGGOrV69mzZs358bDGGMzZsxgtra23GcfHx/Wv39/Xjxdu3Zl48aNq3MsysajyPnz5xkAdvPmTa7M3NycLV++vMZ9GtN4AgICmLe3d42xNubrowg9tk0IIYQQ0gSVlZXh4sWL8PDw4MpUVFTg4eGBpKSkBourqKgIAKCrq8sr37p1K/T19dGuXTvMnDkTT58+5eqSkpLg4OAAIyMjrszT0xPFxcXIyMjg2lQfa1WbqrG+zfORnZ0NExMTtG7dGv7+/sjPzwcAXLx4EeXl5bxj2NnZwczMjDtGYxtLdWVlZdiyZQtGjx4NgUDAlTela1Ndbm4u7ty5w+tXW1sbXbt25V0PHR0ddOrUiWvj4eEBFRUVnDt3jmvj5uYGoVDIiz8rKwuPHj2q0xjrEsvrKCoqgkAggI6ODq980aJF0NPTQ8eOHbFkyRLeY/SNbTwJCQkwNDSEra0tgoOD8eDBA16sTen6NKvHuAkhhBBCSCNx//59VFRU8JIaADAyMsLVq1cbJKbKykqEhobC1dUV7dq148o///xzmJubw8TEBJcuXcKMGTOQlZWFPXv2AADu3LmjcBxVdbW1KS4uxrNnz/Do0aO3cj66du2K6Oho2NraoqCgABEREejevTvS09Nx584dCIVCuUTGyMhIaZwNMZZX7du3D4WFhQgMDOTKmtK1eVXV8RX1Wz02Q0NDXn2zZs2gq6vLa9OqVasax9i8efMax1i9D2Wx1FdpaSlmzJgBPz8/SKVSrnzy5MlwcnKCrq4uzp49i5kzZ6KgoADLli1rdOPp27cvPvvsM7Rq1Qo5OTn45ptv4OXlhaSkJKiqqja560PJMyGEEEIIeStCQkKQnp6OM2fO8MrHjh3L/dvBwQHGxsbo3bs3cnJyYGlp+b7DrJWXlxf3b0dHR3Tt2hXm5ubYtWsXxGJxA0b25jZu3AgvLy+YmJhwZU3p2nxIysvL4ePjA8YY1qxZw6v76quvuH87OjpCKBRi3LhxWLhwIUQi0fsOtVbDhw/n/u3g4ABHR0dYWloiISEBvXv3bsDIXg89tk0IIYQQ0gTp6+tDVVVVbqbnu3fvQiaTvfd4Jk6ciJiYGMTHx6Nly5a1tu3atSsA4Pr16wAAmUymcBxVdbW1kUqlEIvF7+x86OjowMbGBtevX4dMJkNZWRkKCwtrPEZjHcvNmzcRFxeHL7/8stZ2TenaVO1bW78ymQz37t3j1b948QIPHz58K9eser2yWOqqKnG+efMmYmNjeXedFenatStevHiBvLy8Rjme6lq3bg19fX3ez1dTuj6UPBNCCCGENEFCoRDOzs44fvw4V1ZZWYnjx4/DxcXlvcXBGMPEiROxd+9enDhxQu7xSkVSU1MBAMbGxgAAFxcXXL58mfc/0VVJQ5s2bbg21cda1aZqrO/qfJSUlCAnJwfGxsZwdnaGmpoa7xhZWVnIz8/njtFYxxIVFQVDQ0P079+/1nZN6dq0atUKMpmM129xcTHOnTvHux6FhYW4ePEi1+bEiROorKzkvihwcXHBqVOnUF5ezovf1tYWzZs3r9MY6xJLXVQlztnZ2YiLi4Oenp7SfVJTU6GiosI9/tyYxvOqv/76Cw8ePOD9fDWl60OzbRNCCCGENFE7duxgIpGIRUdHsytXrrCxY8cyHR0d3szI71pwcDDT1tZmCQkJvOVonj59yhhj7Pr162zu3LnswoULLDc3l+3fv5+1bt2aubm5cX1ULYf0ySefsNTUVHbkyBFmYGCgcDmkadOmsczMTPbf//5X4XJIb3o+wsLCWEJCAsvNzWWJiYnMw8OD6evrs3v37jHGXi5VZWZmxk6cOMEuXLjAXFxcmIuLS6McS5WKigpmZmbGZsyYwStvCtfm8ePHLCUlhaWkpDAAbNmyZSwlJYWbfXrRokVMR0eH7d+/n126dIl5e3srXKqqY8eO7Ny5c+zMmTPM2tqatxRSYWEhMzIyYiNGjGDp6elsx44dTCKRyC2F1KxZM7Z06VKWmZnJ5syZo3ApJGWx1DaesrIyNnDgQNayZUuWmprK+32qmmn67NmzbPny5Sw1NZXl5OSwLVu2MAMDAzZy5MhGN57Hjx+zqVOnsqSkJJabm8vi4uKYk5MTs7a2ZqWlpY3y+ihDyTMhhBBCSBP2008/MTMzMyYUClmXLl3YH3/88V6PD0DhFhUVxRhjLD8/n7m5uTFdXV0mEomYlZUVmzZtGm8tYcYYy8vLY15eXkwsFjN9fX0WFhbGysvLeW3i4+NZhw4dmFAoZK1bt+aOUd2bng9fX19mbGzMhEIha9GiBfP19WXXr1/n6p89e8YmTJjAmjdvziQSCRs8eDArKCholGOpcvToUQaAZWVl8cqbwrWJj49X+PMVEBDAGHu5BNF3333HjIyMmEgkYr1795Yb54MHD5ifnx/T1NRkUqmUjRo1ij1+/JjXJi0tjX388cdMJBKxFi1asEWLFsnFsmvXLmZjY8OEQiFr27YtO3jwIK++LrHUNp7c3Nwaf5+q1uW+ePEi69q1K9PW1mbq6urM3t6eLViwgJeMNpbxPH36lH3yySfMwMCAqampMXNzcxYUFCT3hUljuj7KCBhjrO73qQkhhBBCCCGEkA8PvfNMCCGEEEIIIYQoQckzIYQQQgghhBCiBCXPhBBCCCGEEEKIEpQ8E0IIIYQQQgghSlDyTAghhBBCCCGEKEHJMyGEEEIIIYQQogQlz4QQQgghhBBCiBKUPBNCCCGEEEIIIUpQ8kwIIYQQQsgHJi8vDwKBAKmpqQ0dCiFNBiXPhBBCCCGENEECgaDWLTw8vKFDVOj69esYNWoUWrZsCZFIhFatWsHPzw8XLlx4r3HQFwikvpo1dACEEEIIIYSQ+isoKOD+vXPnTsyePRtZWVlcmaamZkOEVasLFy6gd+/eaNeuHdauXQs7Ozs8fvwY+/fvR1hYGE6ePNnQIRJSI7rzTAghhBBCSBMkk8m4TVtbGwKBgPtsaGiIZcuWcXd3O3TogCNHjtTYV0VFBUaPHg07Ozvk5+cDAPbv3w8nJyeoq6ujdevWiIiIwIsXL7h9BAIBNmzYgMGDB0MikcDa2hoHDhyo8RiMMQQGBsLa2hqnT59G//79YWlpiQ4dOmDOnDnYv38/1/by5cvo1asXxGIx9PT0MHbsWJSUlHD1PXr0QGhoKK//QYMGITAwkPtsYWGBBQsWYPTo0dDS0oKZmRnWrVvH1bdq1QoA0LFjRwgEAvTo0aPW800IJc+EEEIIIYT8y6xcuRKRkZFYunQpLl26BE9PTwwcOBDZ2dlybZ8/f45hw4YhNTUVp0+fhpmZGU6fPo2RI0diypQpuHLlCtauXYvo6GjMnz+ft29ERAR8fHxw6dIl9OvXD/7+/nj48KHCmFJTU5GRkYGwsDCoqMinITo6OgCAJ0+ewNPTE82bN0dycjJ+++03xMXFYeLEifU+D5GRkejUqRNSUlIwYcIEBAcHc3fnz58/DwCIi4tDQUEB9uzZU+/+yYeFkmdCCCGEEEL+ZZYuXYoZM2Zg+PDhsLW1xQ8//IAOHTpgxYoVvHYlJSXo378//vnnH8THx8PAwADAy6T466+/RkBAAFq3bo0+ffpg3rx5WLt2LW//wMBA+Pn5wcrKCgsWLEBJSQmXlL6qKnG3s7OrNfZt27ahtLQUv/zyC9q1a4devXph1apV+PXXX3H37t16nYd+/fphwoQJsLKywowZM6Cvr4/4+HgA4Maqp6cHmUwGXV3devVNPjz0zjMhhBBCCCH/IsXFxfj777/h6urKK3d1dUVaWhqvzM/PDy1btsSJEycgFou58rS0NCQmJvLuNFdUVKC0tBRPnz6FRCIBADg6OnL1GhoakEqluHfvnsK4GGN1ij8zMxPt27eHhoYGL/bKykpkZWXByMioTv28Gl/VY+01xUeIMnTnmRBCCCGEkA9Uv379cOnSJSQlJfHKS0pKEBERgdTUVG67fPkysrOzoa6uzrVTU1Pj7ScQCFBZWanwWDY2NgCAq1evvnHcKioqcsl4eXm5XLv6xEeIMpQ8E0IIIYQQ8i8ilUphYmKCxMREXnliYiLatGnDKwsODsaiRYswcOBA3kzXTk5OyMrKgpWVldym6H3luujQoQPatGmDyMhIhQlsYWEhAMDe3h5paWl48uQJL3YVFRXY2toCePnIdfXZxisqKpCenl6veIRCIbcvIXVByTMhhBBCCCH/MtOmTcMPP/yAnTt3IisrC19//TVSU1MxZcoUubaTJk3C999/j08//RRnzpwBAMyePRu//PILIiIikJGRgczMTOzYsQOzZs167ZgEAgGioqJw7do1dO/eHYcOHcKNGzdw6dIlzJ8/H97e3gAAf39/qKurIyAgAOnp6YiPj8ekSZMwYsQI7pHtXr164eDBgzh48CCuXr2K4OBgLvmuK0NDQ4jFYhw5cgR3795FUVHRa4+NfBgoeSaEEEIIIeRfZvLkyfjqq68QFhYGBwcHHDlyBAcOHIC1tbXC9qGhoYiIiEC/fv1w9uxZeHp6IiYmBseOHUPnzp3x0UcfYfny5TA3N3+juLp06YILFy7AysoKQUFBsLe3x8CBA5GRkcFNZiaRSHD06FE8fPgQnTt3xtChQ9G7d2+sWrWK62f06NEICAjAyJEj4e7ujtatW6Nnz571iqVZs2b48ccfsXbtWpiYmHDJOyE1EbC6vrlPCCGEEEIIIYR8oOjOMyGEEEIIIYQQogQlz4QQQgghhBBCiBKUPBNCCCGEEEIIIUpQ8kwIIYQQQgghhChByTMhhBBCCCGEEKIEJc+EEEIIIYQQQogSlDwTQgghhBBCCCFKUPJMCCGEEEIIIYQoQckzIYQQQgghhBCiBCXPhBBCCCGEEEKIEpQ8E0IIIYQQQgghSlDyTAghhBBCCCGEKPF/l9JfGfFNKekAAAAASUVORK5CYII=\n",
            "text/plain": [
              "<Figure size 1000x600 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "#OPTIONAL ADDITION TO PRIOR MODULE:\n",
        "#Count tokens for later summarization task (gpt4-turbo takes 128k tokens)\n",
        "from transformers import GPT2TokenizerFast\n",
        "tokenizer = GPT2TokenizerFast.from_pretrained('Xenova/gpt-4')\n",
        "import matplotlib.pyplot as plt  # Import for plotting\n",
        "\n",
        "def num_tokens_from_string(text: str) -> int:\n",
        "    # Tokenize the text using the GPT-4 tokenizer\n",
        "    tokens = tokenizer.tokenize(text)\n",
        "    return len(tokens)\n",
        "\n",
        "# Count tokens for later summarization task\n",
        "min_obs_show=6700    # limit for gpt4 is 8192, for gpt4-turbo and gpt4o is 128000\n",
        "'''\n",
        "for index, text in enumerate(merged_df_Topic_text_combined['text'], start=1):\n",
        "    token_count = num_tokens_from_string(text)\n",
        "    if token_count >= min_obs_show:  # Add a condition to check for token count\n",
        "        print(f\"Row {index}: {token_count} tokens\")\n",
        "'''\n",
        "# Create a new DataFrame to store token counts\n",
        "tokens_by_topic_df = merged_df_Topic_text_combined.copy()  # Copy existing data\n",
        "tokens_by_topic_df['token_count'] = None  # Add new column for token count\n",
        "\n",
        "for index, row in tokens_by_topic_df.iterrows():\n",
        "  text = row['text']  # Access text from current row\n",
        "  token_count = num_tokens_from_string(text)\n",
        "  # Update the new `token_count` column in the DataFrame\n",
        "  tokens_by_topic_df.at[index, 'token_count'] = token_count\n",
        "\n",
        "if token_count >= min_obs_show:\n",
        "    print(f\"Row {index}: {token_count} tokens\")\n",
        "\n",
        "# Prepare data for the plot\n",
        "sorted_topics = tokens_by_topic_df.sort_values(by='Sort_seq')\n",
        "topics = sorted_topics['InsightsAI_Topic'].tolist()\n",
        "token_counts = sorted_topics['token_count'].tolist()\n",
        "\n",
        "# Create the plot with horizontal bars\n",
        "plt.figure(figsize=(10, 6))  # Set plot size\n",
        "plt.barh(topics, token_counts)  # Use `barh` for horizontal bars\n",
        "plt.xlabel('Token Count')\n",
        "plt.ylabel('InsightsAI_Topic (Sorted by Sort_seq)')\n",
        "plt.title('Token Count by InsightsAI_Topic (Sorted)')\n",
        "plt.gca().invert_yaxis()  # Invert y-axis to display topics from top to bottom\n",
        "plt.tight_layout()  # Adjust spacing for readability\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "eBENOMduGHHn",
        "outputId": "6662b9f4-f0a1-4660-e963-227340c534dd"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"tokens_by_topic_df\",\n  \"rows\": 33,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Topic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 33,\n        \"samples\": [\n          \"7E_Other Provisions in the Regulation\",\n          \"3F_OUD OTP Coverage\",\n          \"3Q_Changes to the Basic Health Program Regulations\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sort_seq\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 39.02762230818453,\n        \"min\": 1.0,\n        \"max\": 133.0,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          129.0,\n          104.0,\n          120.0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 33,\n        \"samples\": [\n          \"Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [E.  Other Provisions of the Regulation \\n1.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Impact of Proposals for Medicare Parts A and B Payment for Dental Services Inextricably \\nLinked to Specific Covered Medical Services \\nIn section II.K.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [of this proposed rule, we are: (1) proposing to allow payment for dental \\nexaminations, diagnostic, and treatment services prior to and during certain treatments for cancer \\n(chemotherapy and CAR-T cell therapy); (2) proposing to allow payment for dental \\nexaminations, diagnostic, and treatment services prior to and during antiresorptive and/or \\nantiangiogenic drug therapy associated with the treatment for cancer; and (3) requesting \\ncomments on other types of cardiovascular interventions (analogous to cardiac valve \\nreplacements and valvuloplasty procedures) where dental services may be inextricably linked to, \\nand substantially related and integral to the clinical success of, other cardiovascular covered \\nmedical services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [If we were to finalize the proposal that Medicare Part A and Part B payment can be made \\nfor oral or dental examination, and necessary treatment, performed prior to and during certain \\ncancer treatments or drug therapies associated with managing cancer related care, we do not \\nanticipate any significant increase in utilization or payment impact for additional dental services \\ngiven the historically low utilization of these therapies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Although, we acknowledge that the \\nobserved utilization of these services might have been low because of the size of the population \\nof patients whose treatment would include such dental services and also because the dental \\nservices have been viewed as subject to the payment preclusion under section 1862(a)(12).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [Based on an analysis of 2018-2022 incurred claims experience, we estimate that there are \\npotentially 155,000 additional beneficiaries who might receive dental services for which \\nMedicare payment could be made, relative to the current number of beneficiaries that received \\ndental services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1220: [These are beneficiaries who would receive any of the treatments identified in our \\nproposals for CY 2024 (that is, chemotherapy/CAR T/bone-modifying agent therapies used in \\nthe treatment of cancer) who would likely require dental services, and could utilize dental]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [services for which services Medicare could pay in CY 2024, if these proposals are finalized.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [The \\nestimated average cost for these additional dental services is about $525 per person.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [This \\nassumption is based on an analysis of 2019 incurred claims, but we believe results using more \\nrecent data would not be likely to change, due to the limited claims involving these services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Based on this same analysis, the effective rate of coverage was less than 0.2 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We do \\nacknowledge that the actual take-up rate of services could be higher due to the proposed \\nadditional examples of medical services to which dental services are inextricably linked, which \\nmay raise awareness that payment is available.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Therefore, we prepared impact estimates under \\nthe utilization assumptions of 0.2 percent and between 1-3 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We then applied these \\nutilization ratios to estimate projected payments for dental exams and treatments in connection \\nwith cancer therapies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We found that the estimated yearly impact beginning in CY 2024 to be \\nroughly $162,000 per year with a 0.2 percent utilization assumption, and roughly $800,000 to 2 \\nmillion per year for the utilization assumptions of 1-3 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Therefore, we do not anticipate a \\nsignificant payment impact for these provisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We note, however, that if we were to finalize, as \\ndiscussed in section II.K.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [of this proposed rule, payment in other clinical scenarios for dental \\nservices inextricably linked to, and substantially related and integral to the clinical success of, \\ncertain covered medical services, we may adjust this estimate for the final rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [We continue to believe that because we are updating existing Medicare payment policies \\nby proposing additional examples of clinical scenarios where dental services are inextricably \\nlinked to covered medical services, as stated in the CY 2023 PFS final rule, it is not appropriate \\nto incorporate these budget neutrality adjustments into the conversion factor.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [Additionally, while \\nthe impact of access to these services to some individuals enrolled in Medicare could be very \\nsignificant, we do not anticipate a significant impact in the context of overall spending and \\nutilization under the PFS nor do we anticipate significant utilization and spending impact of \\nthese policies finalized in section II.K.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1221: [of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We acknowledge that the actual take-up rate of services could be higher than the \\nutilization assumptions included within our current estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We continue to be open to \\nupdating and conducting further impact analysis once we have additional data and input from \\ninterested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [Impact of Proposal to Implement Separate Payment for the Office/Outpatient (O/O) E/M Visit \\nInherent Complexity Add-on Code (HCPCS G2211)\\nIn recent years, the AMA\\u2019s CPT Editorial Committee has restructured the E/M visit code \\nsets largely to acknowledge changes in medical practice.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [The AMA RUC has reviewed and \\nprovided us recommendations for the revised E/M visit code sets in the context of the generally \\nrecognized need to better recognize resources involved in furnishing different types of services \\nwithin the broader PFS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [While we adopted the RUC-recommended values for the O/O E/M visit \\ncode family in the CY 2021 final rule, recognizing that those values generally reflect the \\nresources involved in furnishing those services, we did not believe those valuations appropriately \\nreflected the resource costs involved in furnishing primary and other similarly longitudinal \\nmedical care for a serious or complex condition in office settings.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [To address this concern, \\neffective beginning in CY 2021, we finalized an add-on code to separately pay for visit \\ncomplexity inherent to O/O E/M visits for primary care and other medical care services that are \\npart of ongoing care related to a patient's single, serious, or complex condition in the office \\nsetting (the O/O E/M visit inherent complexity add-on).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [After we finalized the CY 2021 \\npayment changes for O/O E/M visits, in the CAA of 2021, Congress imposed a statutory \\nmoratorium on Medicare payment for the O/O E/M visit inherent complexity add-on code until \\nJanuary 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [We propose to implement payment for the O/O E/M visit inherent complexity add-on, \\nHCPCS code G2211, with significant refinements to target improved payment for primary and \\nother similar longitudinal care for serious or complex conditions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1222: [Specifically, we are proposing \\nthat the O/O E/M visit complexity add-on code cannot be billed with visits reported using]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Modifier 25 which is used to indicate that the service is billed on the same day as a minor \\nprocedure or another E/M visit.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [(Previously, in the CY 2021 final rule, we stated we would not \\nexpect such billing; but as there was no explicit prohibition, these visits were included in the \\nbudget neutrality adjustment (85 FR 84572)).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [We also propose to set PFS rates with a refined, \\nmore specific utilization assumption that better recognizes likely uptake of the code, differential \\nuse among specialties, and new and established patient visits, among other changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [These \\nrefined assumptions were developed, taking into consideration perspectives and information \\nprovided by interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [The resulting estimate reflects that the O/O E/M visit inherent \\ncomplexity add-on code would likely be reported with approximately 38 percent of all O/O E/M \\nvisits for CY 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [As discussed previously and shown below, we estimate the specific portion \\nof the total budget neutrality adjustment attributable to the proposal to make payment for the \\nO/O E/M inherent complexity add-on code to be approximately 2.00 percent compared to an \\nattributable budget neutrality adjustment of 3.20 percent as calculated in CY 2021 rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Advancing Access to Behavioral Health \\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Impact of Proposed Payment for Marriage and Family Therapist (MFT) Services and Mental \\nHealth Counselor (MHC) Services \\nAs discussed in section II.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [of this proposed rule, section 4121 of CAA, 2023 added \\nsection 1861(s)(2)(II) to establish a new Medicare benefit category for MFT services and MHC \\nservices furnished and billed by MFTs and MHCs, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [MFT and MHC services are \\ndefined in section 1861(lll)(2) and 1861(lll)(4), respectively, as services for the diagnosis and \\ntreatment of mental illnesses (other than services furnished to an inpatient of a hospital).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [An \\nMFT or MHC is defined as an individual who possesses a master\\u2019s or doctor\\u2019s degree, is \\nlicensed or certified by the State in which they furnish services, who has performed at least 2 \\nyears of clinical supervised experience, and meets other requirements as the Secretary \\ndetermines appropriate.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1223: [Section 1833(a)(1)(FF) of the statute requires that MFT and MHC \\nservices be paid at 75 percent of the amount determined for payment of a clinical psychologist.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [MFT and MHC services are excluded from consolidated billing requirements under the skilled \\nnursing facility prospective payment system.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Services furnished by an MFT and MHC are \\ncovered when furnished in a rural health clinic and federally qualified health center.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In addition, \\nthe hospice interdisciplinary team is required to include at least one social worker, MFT or \\nMHC.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Expenditures associated with payment for services furnished by MFTs and MHCs in CY \\n2024 will be incorporated into budget neutrality for PFS ratesetting in future years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [Drugs and Biological Products Paid Under Medicare Part B \\nSection 90004 of the Infrastructure Investment and Jobs Act (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [L. 117-9, November \\n15, 2021) amended section 1847A of the Act to require manufacturers to provide a refund to \\nCMS for certain discarded amounts from a refundable single-dose container or single-use \\npackage drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [The refund amount is either as noted in section 1847A(b)(1)(B) of the Act in the \\ncase of a single source drug or biological or as noted in section 1847A(b)(1)(C) of the Act in the \\ncase of a biosimilar biological product, multiplied by the amount of discarded drug that exceeds \\nan applicable percentage, which is required to be at least 10 percent, of total charges (subject to \\ncertain exclusions) for the drug in a given calendar quarter.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In the CY 2023 final rule, we \\nfinalized several policies to implement the provision, including: reporting requirements for the \\nJW and JZ modifiers; the date upon which we will begin to edit claims for appropriate use of the \\nJW and JZ modifiers, October 1, 2023; the definition of \\u201crefundable single-dose container or \\nsingle-use package drug\\u201d; the manner in which refund amounts will be calculated; the annual \\nbasis we will send reports to manufacturers; the dispute resolution process; and enforcement \\nprovisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1224: [In section III.A of this proposed rule, we are proposing the date of the initial report to \\nmanufacturers, the date for subsequent reports, method of calculation when there are multiple \\nmanufacturers for a refundable drug, increased applicable percentages for drugs with unique \\ncircumstances, and a future application process by which manufacturers may apply for an \\nincreased applicable percentage for a drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [For this proposed rule, we reanalyzed JW modifier data from 2021 as if the data \\nrepresented dates of service on or after the effective date of section 90004 of the Infrastructure \\nAct (that is, January 1, 2023).368 That is, to assess if there was a change in the status of the billing \\nand payment codes that were identified in the proposed rule as met the definition of refundable \\nsingle-dose container or single-use package drug and have 10 percent or more discarded units, \\nexcept for five drugs with higher applicable percentages finalized in the CY 2023 final rule or as \\nproposed under this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Overall in the 2021 calendar year, Medicare paid nearly $1.56 billion for discarded \\namounts of drugs from a single-dose container or single-use package paid under Part B.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [In that \\nyear, there were 51 billing and payment codes with 10 percent or more discarded units based on \\nJW modifier data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Of these, 11 did not meet the definition of refundable single-dose container or \\nsingle-use package drug in section 1847A(h)(8) of the Act because they are multiple source drug \\ncodes; 5 were excluded from the definition of refundable single-dose container or single-use \\npackage drug (as specified in section 1847A(h)(8)(B) of the Act) because they are identified as \\nradiopharmaceuticals or imaging agents in FDA-approved labeling; and 3 are products referred \\nto as skin substitutes, which were removed because we anticipate making changes to coding and \\npayment policies regarding those products in future rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [After these exclusions, there \\nwere 31 billing and payment codes that met the definition of refundable single-dose container or \\nsingle-use package drug and have discarded units above the relevant finalized applicable \\npercentage.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [Of these, three have discarded units that would fall below increased applicable \\npercentages proposed in this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1225: [We estimated refund amounts as described in section 1847A(h)(3) of the Act were \\ncalculated based on this data by subtracting the percent units discarded by 10 percent (the \\napplicable percentage), except for drugs with higher applicable percentages finalized in the CY \\n368 https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-\\npart-b-discarded-drug-units.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [2023 final rule or as proposed under this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [Then, we multiplied the appropriate \\npercentage by the CY 2021 total allowed amount to estimate the annual refund for a given billing \\nand payment code.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [The quarterly refund was estimated by dividing the annual estimate by 4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [Based on this data, there would be approximately $83.1 million in refunds due from \\nmanufacturers for the calendar year of 2021 ($20.8 million each calendar quarter).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1226: [See Table \\n108.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1227: [TABLE 108:  Estimated Refund Amounts Based on CY 2021 JW Modifier Data369\\nHCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nQ9965 $2,276,001.01 67.41% Y; Radiopharm \\nor imaging agent10%\\nJ7342 $4,559.95 53.26% N 10% 43.26% $1,972.63 $493.16 \\nJ9281 $26,703,749.86 37.60% N 35% 2.60% $694,297.50 $173,574.37 \\nJ9262 $220,987.21 30.98% N 26% (proposed) 4.98% $11,005.16 $2,751.29\\nJ9043 $146,745,385.39 29.11% N 10% 19.11% $28,043,043.15 $7,010,760.79 \\nJ9041 $380,429,509.43 27.00% Y; multiple \\nsource10%\\nJ9351 $475,677.64 26.37% Y; multiple \\nsource10%\\nQ9961 $19,366.66 26.28% Y; Radiopharm \\nor imaging agent10%\\nJ0894 $17,872,985.28 24.16% Y; multiple \\nsource10%\\nJ9044 $4,616,507.83 21.91% N; see new single \\nsource codes \\nJ9046, J9048, \\nJ904910% 11.91% $549,826.08 $137,456.52 \\nJ9025 $37,997,710.06 21.83% Y; multiple \\nsource10%\\nJ9017 $1,733,222.58 21.25% Y; multiple \\nsource10%\\nJ1448 $1,739,523.98 20.85% N 10% 10.85% $188,738.35 $47,184.59 \\nJ0775 $68,490,974.85 20.83% N 45% proposed \\nJ9065 $451,404.96 20.26% Y; multiple \\nsource10%\\nJ9223 $90,785,710.74 20.25% N 10% 10.25% $9,305,535.35 $2,326,383.84 \\nJ0565 $3,928,811.98 19.53% N 10% 9.53% $374,415.78 $93,603.95 \\nJ9178 $9,922.54 18.95% Y; multiple \\nsource10%\\n369 https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-b-discarded-drug-units.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1228: [HCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nJ9229 $17,911,595.08 18.21% N 10% 8.21% $1,470,541.96 $367,635.49 \\nJ0223 $10,731,531.69 17.00% N 26% (proposed)\\nQ9966 $2,230,516.82 16.89% Y; Radiopharm \\nor imaging agent10%\\nJ1640 $8,405,837.59 15.52% Y; filtered 10%\\nJ9153 $5,526,153.53 15.00% N 10% 5.00% $276,307.68 $69,076.92 \\nJ2425 $124,548.01 14.07% N 10% 4.07% $5,069.10 $1,267.28 \\nJ9027 $62,602.70 13.98% Y; multiple \\nsource10%\\nJ9264 $347,464,875.59 13.86% N 10% 3.86% $13,412,144.20 $3,353,036.05 \\nJ2796 $257,348,654.37 13.60% N 10% 3.60% $9,264,551.56 $2,316,137.89 \\nQ9956 $737,908.86 13.03% Y; Radiopharm \\nor imaging agent10%\\nJ0515 $16,911.88 12.88% Y; multiple \\nsource10%\\nJ2562 $18,752,340.26 12.81% N 10% 2.81% $526,940.76 $131,735.19 \\nJ9179 $43,581,966.38 12.71% N 10% 2.71% $1,181,071.29 $295,267.82 \\nJ9307 $22,805,063.36 12.65% N 10% 2.65% $604,334.18 $151,083.54 \\nJ9037 $33,082,159.80 12.10% N 10% 2.10% $694,725.36 $173,681.34 \\nJ3396 $2,537,428.32 11.93% N 10% 1.93% $48,972.37 $12,243.09 \\nJ9042 $169,482,924.33 11.89% N 10% 1.89% $3,203,227.27 $800,806.82 \\nJ9319 $6,572,808.69 11.78% Y; multiple \\nsource10%\\nQ9950 $516,142.11 11.77% Y; Radiopharm \\nor imaging agent10%\\nJ0485 $76,861,131.89 11.61% N 10% 1.61% $1,237,464.22 $309,366.06 \\nJ9205 $59,413,621.44 11.55% N 10% 1.55% $920,911.13 $230,227.78 \\nJ9228 $417,946,062.94 11.40% N 10% 1.40% $5,851,244.88 $1,462,811.22 \\nJ3241 $306,975,463.35 11.32% N 10% 1.32% $4,052,076.12 $1,013,019.03 \\nJ2997 $66,254,826.34 11.31% N 10% 1.31% $867,938.23 $216,984.56]] Topic: 7E_Other Provisions in the Regulation: [from p. 1229: [HCPCS \\nCode2021 Total \\nMedicare \\nAllowed \\nAmountPercent \\nUnits \\nDiscardedExcluded (Y/N) Applicable percentage % Exceeding \\napplicable \\npercentageEstimated \\nannual refundEstimated quarterly \\nrefund\\nJ3300 $8,964,090.01 10.97% N 90% proposed\\nJ0122 $144,528.76 10.84% N 10% 0.84% $1,214.04 $303.51 \\nJ3101 $12,921,647.56 10.67% N 10% 0.67% $86,575.04 $21,643.76 \\nJ9315 $23,154,637.13 10.33% Y; multiple \\nsource10%\\nJ9269 $7,755,186.19 10.15% N 26% proposed \\nJ9352 $9,225,195.63 10.10% N 10% 0.10% $9,225.20 $2,306.30 \\nQ4121 $6,484,123.19 17.85% Y; skin substitute\\n(proposed)10% 7.85%\\nQ4106 $1,511,046.28 16.64% Y; skin substitute\\n(proposed)10% 6.64%\\nQ4101 $2,176,035.02 14.58% Y; skin substitute\\n(proposed)10% 4.58%\\nTOTAL $82,883,368.59 $20,720,842.15]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [There are several limitations to this analysis that could substantially affect the total \\nquarterly refund.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Since new drugs are continually being approved, this estimate does not \\nconsider newer drugs that will meet the definition of refundable single-dose container or single-\\nuse package drug on or after the effective date of January 1, 2023.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Since section \\n1847A(h)(8)(B)(iii) of the Act excludes drugs approved by FDA on or after November 15, 2021 \\nand for which payment has been made under Part B for fewer than 18 months from this \\ndefinition, we expect an impact on refund amounts after the 18-month exclusion has ended if the \\ndrug otherwise meets the definition.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [We also note that this estimate is based on CY 2021 data \\nfor discarded drug amounts, which, for reasons discussed in the CY 2023 final rule (87 FR \\n69716), we believe to be an underestimate due to the frequent omission of the JW modifier.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Once \\nwe begin to edit claims for both the JW and JZ modifiers, reported discarded drug amounts will \\nlikely increase.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Other substantial changes to this estimate may occur if a billing and payment \\ncode no longer meets this definition.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [For example, if a generic version of one of these drugs is \\nmarketed, the billing and payment code will become a multiple source drug code and will no \\nlonger meet the definition of refundable single-dose container or single-use package drug.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Subsequently, the manufacturers will not be responsible for refunds under this provision.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [There \\nmay be changes in the percent discarded units for a given refundable single-dose container or \\nsingle-use package drug if the manufacturer introduces additional vial sizes or modifies the vial \\nsize to reduce the amount discarded.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [Lastly, since data from the CMS website only includes \\nbilling and payment codes on the ASP drug pricing file370 and implementation of section 90004 \\nof the Infrastructure Act is not restricted to billing and payment codes included on the file, there \\nmay be other applicable data that was not assessed as part of this estimate.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [a. Impacts Related to the Issuance of the Initial Report\\nIn section III.A.3.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [of this proposed rule, we propose to issue the initial refund report to \\nmanufacturers, to include all calendar quarters for 2023, no later than December 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1230: [370 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Accordingly, as discussed in section III.A.3.c., we propose to require that the refund amounts \\nspecified in the initial refund report be paid no later than February 28, 2025, except in \\ncircumstances where a report is under dispute.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Delaying the receipt of the rebate, that is in 2025 instead of 2024, only represents a cost \\nto the extent the SMI trust fund receives less interest revenue.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Only a portion of SMI trust fund \\nrevenue ends up invested in the bond portfolio.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Based on current SMI trust fund operation \\npatterns a delay in rebate collection as described in the rule would represent a cost less than $2 \\nmillion dollars in any given year and therefore would be negligible to SMI trust fund operations.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [b. Impacts Related to the Application for Consideration \\nAs described in section VII.B.1.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [of this proposed rule, the information collection \\nrequirements, we estimate the annual burden per applicant to be 5 hours.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [If we anticipate no \\nmore than 25 applications per year, the total annual drafting and submitting burden would be 125 \\nhours (25 applications per year x 5 hours per applicant).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [We estimate an annual cost of this \\nburden to be $4,937.50 ($39.50/hour x 125 hours).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs)\\nIn section III.B.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [of this proposed rule, we are proposing to include Remote Patient \\nMonitoring (RPM) and Remote Therapeutic Monitoring (RTM) services, and the proposed  \\nCommunity Health Integration (CHI) and Principal Illness Navigation (PIN) services if finalized, \\nin the general care management HCPCS code G0511 when these services are provided by RHCs \\nand FQHCs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Due to the growing number of services in the code, we are also proposing to revise \\nthe calculation for G0511 to include the weighted average of these services based on utilization \\nunder the PFS as this may provide a more complete and accurate payment amount.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [In terms of estimated impacts to the Medicare program, expanding use of General Care \\nManagement HCPCS code G0511 to include RPM, RTM, CHI, and PIN may result in an \\nincrease in spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [Prior updates to G0511 have resulted in negligible increases.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [6.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1231: [RHC and FQHC CfC changes: Permitting MFTs and MHCs to furnish services]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Section 4121 of the CAA, 2023 amends section 1861(aa)(1)(B) of the Act by adding \\nMFTs and MHCs as eligible practitioners of RHCs and FQHCs beginning January 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We \\nare proposing regulation text changes to permit MFT and MHCs to provide services furnished at \\nRHCs and FQHCs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [These changes would include MFTs and MHCs as members of the staff who \\nmay be the owner or an employee of the clinic or center, or furnish services under contract to the \\nclinic or center.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Along with other permitted physicians and nonphysician practitioners, MFT and \\nMHCs may be available to furnish patient care services at all times the clinic or center operates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [At \\u00a7 491.9(b)(3) RHCs and FQHCs must have patient care policies that include: (1) a \\ndescription of the services the clinic or center furnishes directly or through agreement or \\narrangement; (2) guidelines for medical management of health problems; and (3) rules for \\nstorage, handling, and administration of drugs and biologicals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Additionally, \\u00a7 491.9(b)(4) states \\nthat the RHC and FQHC patient policies must regularly be reviewed at least once every 2 years \\nby a group of professional personnel that includes one or more physicians, one or more physician \\nassistants (PAs) or nurse practitioners (NPs), and at least one person who is not a member of the \\nclinic or center staff.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [If an RHC or FQHC provides services furnished by an MHC or MFT they \\nmust update their patient care policies with a description of the services they will provide.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [The most recently published collection of information for RHCs and FQHCs (OMB \\ncontrol number 0938-0334), estimates that an annual review of the patient care policies may take \\napproximately 2 hours.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Therefore, we assume, it would take each medical professional (at least \\none physician and at least one PA or NP) 1 hour to review all policies and procedures, annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [Based on the prior analysis, we estimate it will take 15 minutes to add the description of MFT \\nand MHC services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We also assume that only half of the RHCs and half of the FQHCs would \\nhave this burden applied to them, for a total burden estimate of $361,891.05.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We note that there \\nwould be variations in how many clinics or centers employ or contract with an MFT and MHC \\nbased on their ability to expand their services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1232: [We also recognize that some RHCs and FQHCs \\nmay already provide these services as some States provide reimbursement under the Medicaid]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [program; however, we do not know the exact number of clinics or centers that already have these \\npractitioners on staff and would not incur the burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [While this proposed rule does have a 1-time burden, there is evidence to suggest there are \\nlong-term financial savings in integrating mental health in medical care.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [Effectively integrating \\nmental and medical care can save upwards of $52 billion annually due to the existing Medicare \\nmental health coverage gap.371 Though this total encompasses all facility types, expanding access \\nto MFT and MHC services in RHCs and FQHCs will have individual and societal cost savings.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [Older adults with mental health conditions have poorer health outcomes, higher hospitalization \\nrates, and emergency room visits.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [372 While there is an increasing need for mental health \\nservices, one barrier to effective treatment is access to mental health services.373  Ensuring access \\nto mental health care in rural communities is challenging as there are fewer mental health \\nproviders per capita in nonmetropolitan counties.374 This coincides with HRSA\\u2019s second quarter \\nof the fiscal year 2023 designated health professional shortage area (HPSA) quarterly summary, \\nwhich breaks down the number of HPSAs by primary medical care, dental, and mental health \\nHPSAs based on four categories (rural, non-rural, partial rural, and unknown); and as population \\nHPSAs, geographic HPSAs, or Facility HPSAs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [The report does not provide accumulative \\nHPSAs by the four categories.375 Approximately 65 percent of federally designated health \\nprofessional shortage areas are located in rural areas, and about 30 percent are located in non-\\nrural areas.376 The shortage of professionals in rural areas is severe, and the shortage of qualified \\nprofessionals in combination with geographic limitations only exacerbates the mental health \\n371 https://onlinelibrary.wiley.com/doi/full/10.1002/jcad.12409?casa_token=z412GCn3OuYAAAAA%3AHO3p-\\ncHeiVrLww0dZjTkIcuCbwMxvYtRUo4aj8AwB-tq2w_ZJV11gGpWW-oxilDK3awU0xIc2XKMnKhtAQ#jcad12409-\\nbib-0003.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [372 https://onlinelibrary.wiley.com/doi/full/10.1002/jcad.12409?casa_token=z412GCn3OuYAAAAA%3AHO3p-\\ncHeiVrLww0dZjTkIcuCbwMxvYtRUo4aj8AwB-tq2w_ZJV11gGpWW-oxilDK3awU0xIc2XKMnKhtAQ#jcad12409-\\nbib-0005.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [373 https://psycnet.apa.org/fulltext/2020-75725-002.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [374 https://psycnet.apa.org/record/2018-25164-007.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [375 https://data.hrsa.gov/topics/health-workforce/shortage-areas.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1233: [376 https://data.hrsa.gov/Default/GenerateHPSAQuarterlyReport.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [crisis in older adults.377 While there are disparities in the availability of the behavioral workforce \\nbetween rural and nonrural areas, counselors are integral to providing care in rural areas.378  \\n7.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Clinical Laboratory Fee Schedule\\nIn section III.D of this proposed rule, we discuss statutory revisions to the data reporting \\nperiod and phase-in of payment reductions under the CLFS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In accordance with section 4114 of \\nthe CAA, 2023, we are proposing certain conforming changes to the data reporting and payment \\nrequirements in our regulations at 42 CFR part 414, subpart G.  Specifically, for CDLTs that are \\nnot ADLTs, we are proposing to update certain definitions and revise \\u00a7 414.504(a)(1) to indicate \\nthat initially, data reporting begins January 1, 2017, and is required every 3 years beginning \\nJanuary 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [The CAA, 2023 delays the next data reporting period under the CLFS for CDLTs \\nthat are not ADLTs by 1 year, that is, it requires the next data reporting period for these tests to \\ntake place during the period of January 1, 2024 through March 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Subsequently, the next \\nprivate payor rate-based CLFS update for these tests will be effective January 1, 2025, instead of \\nJanuary 1, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In addition, we are proposing to make conforming changes to our requirements \\nfor the phase-in of payment reductions to reflect the CAA, 2023 amendments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [Specifically, we \\nare proposing to revise \\u00a7 414.507(d) to indicate that for CY 2023, payment may not be reduced \\nby more than 0.0 percent as compared to the amount established for CY 2022, and for CYs 2024 \\nthrough 2026, payment may not be reduced by more than 15 percent as compared to the amount \\nestablished for the preceding year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [We recognize that private payor rates for CDLTs paid on the CLFS and the volumes paid \\nat each rate for each test, which are used to determine the weighted medians of private payor \\nrates for the CLFS payment rates, have changed since the first data collection period (January 1, \\n2016 through June 30, 2016) and data reporting period (January 1, 2017 through March 31, \\n2017).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [In addition, as discussed in section III.D.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [of this proposed rule, in the CY 2019 PFS final \\n377 https://psycnet.apa.org/fulltext/2020-75725-002.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1234: [378 chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://depts.washington.edu/fammed/rhrc/wp-\\ncontent/uploads/sites/4/2016/09/RHRC_DB160_Larson.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [rule (83 FR 59671 through 59676), we amended the definition of applicable laboratory to include \\nhospital outreach laboratories that bill Medicare Part B using the CMS-1450 14x Type of Bill.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [As such, the CAA, 2023 amendments to the data reporting period will delay using updated \\nprivate payor rate data to set revised CLFS payment rates for CDLTs that are not ADLTs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Due to unforeseen changes in private payor rates due to shifts in market-based pricing for \\nlaboratory tests and the unpredictable nature of test volumes and their impact on calculating \\nupdated CLFS payment rates based on the weighted median of private payor rates, it is uncertain \\nwhether the delay in data reporting will result in a measurable budgetary impact.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [In other words, \\nto assess the impact of delayed reporting and subsequent implementation of updated CLFS rates, \\nwe will need to calculate weighted medians of private payor rates based on new data and \\ncompare the revised rates to the current rates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [As such, we believe that we will only know the \\nimpact of the delay in data reporting after collecting actual updated applicable information from \\napplicable laboratories, and calculating the updated CLFS rates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Regarding the conforming changes to our requirements for the phase-in of payment \\nreductions that we are proposing in this rule, we note that for CYs 2024 through 2026, payment \\nmay not be reduced by more than 15 percent as compared to the amount established for the \\npreceding year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Based on data reported in the 2017 data collection period, we estimate 14.8 \\npercent (191) of tests on the CLFS may be subject to the full 15 percent phase-in reduction in CY \\n2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [8.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [Pulmonary Rehabilitation (PR), Cardiac Rehabilitation (CR) and Intensive Cardiac \\nRehabilitation (ICR) Expansion of Supervising Practitioners\\nAs discussed in section III.E.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [of this proposed rule, we are proposing revisions to \\n\\u00a7\\u00a7 410.47 (PR) and 410.49 (CR/ICR) to codify the statutory changes made in section 51008 of \\nthe Bipartisan Budget Act of 2018 (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [L. 115-123, enacted February 9, 2018) (BBA of 2018) \\nwhich permit other specific types of practitioners to supervise these services effective January 1, \\n2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1235: [The amendments add to the types of practitioners who may supervise PR, CR and ICR]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [programs to also include a physician assistant (PA), nurse practitioner (NP) or clinical nurse \\nspecialist (CNS).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Accordingly, we are proposing additions and revisions to the PR and CR/ICR \\nregulations to reflect these statutory amendments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [To assess the potential impact from expanding the types of practitioners that may \\nsupervise PR/CR/ICR we searched the literature for articles that evaluated the utilization rates of \\nPR, CR and ICR to determine the historical utilization trends of these services as well as known \\nbarriers to utilization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Based on historical utilization trends as well as barriers to utilization \\ndiscussed in the literature, we do not expect the proposed changes to make a significant impact \\non the Medicare program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Nishi et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [(2016) investigated the number of Medicare beneficiaries with COPD who \\nreceived PR from January 1, 2003, to December 31, 2012.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Their results included both individuals \\nwho had experienced hospitalizations for COPD and those who were outpatients only.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [The \\nnumber of unique patients with COPD who initially participated in PR during the study period \\nwas 2.6 percent in 2003 (before conditions of coverage at \\u00a7 410.47 were established) and 2.88 \\npercent in 2012 (after conditions of coverage at \\u00a7 410.47 were established).379  In 2019, Spitzer, \\net al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [published an article based on Medicare claims data from 2012, finding that 2.7 percent of \\neligible Medicare beneficiaries received PR within 12 months of hospitalization with COPD.380  \\nUsing claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, \\nLindenauer et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [(2020) reported that only 3 percent initiated PR within 1 year of their hospital \\ndischarge.381 Taken together, this data informs us that utilization of PR in the Medicare \\npopulation is very low.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [379 Nishi SP, Zhang W, Kuo YF, Sharma G. Pulmonary Rehabilitation Utilization in Older Adults With Chronic \\nObstructive Pulmonary Disease, 2003 to 2012.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2016;36(5):375-382. \\ndoi:10.1097/HCR.0000000000000194.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [380 Spitzer KA, Stefan MS, Priya A, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Participation in pulmonary rehabilitation after hospitalization for chronic \\nobstructive pulmonary disease among Medicare beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Ann Am Thorac Soc.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2019;16:99-106.DOI: \\n10.1513/AnnalsATS.201805-332OC.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [PMID: 30417670; PMCID: PMC6344454.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [381 Lindenauer PK, Stefan MS, Pekow PS, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [Association Between Initiation of Pulmonary Rehabilitation After \\nHospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [JAMA.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [2020;323(18):1813\\u20131823.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1236: [doi:10.1001/jama.2020.4437.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Million Hearts\\u00ae 2027, a national initiative co-led by the Centers for Disease Control and \\nPrevention (CDC) and CMS to prevent 1 million preventable cardiovascular disease (CVD) \\nevents in the next 5 years382, includes a goal of increasing use of CR and states that CR \\nparticipation rates remain low, ranging from 19 percent to 34 percent.383  Fleg and colleagues \\n(2020) report that less than 25 percent \\u201cof eligible patients participate in CR\\u201d with a smaller \\nproportion completing 36 sessions as recommended.384  In their 2022 article, Varghese and \\ncolleagues state that less than 30 percent of eligible patients participate in CR in the United \\nStates.385 Husaini and colleagues (2022) analyzed a sample of Medicare fee-for-service claims \\nbetween 2012 and 2016 and reported that within 1 year of a qualifying event, 16 percent of \\npatients completed one or more CR session and 0.1 percent of patients completed one or more \\nICR sessions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [They observed an increase of combined CR and ICR utilization from 14 percent \\n(patients with qualifying events in 2012) to 18 percent (patients with qualifying events in \\n2015).386 Taken together, this data informs us that utilization of CR and ICR is low, although not \\nas low as PR.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Underutilization of PR, CR and ICR has been attributed to numerous factors as described \\nby Fleg et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [\\u201cincluding a lack of referral or strong recommendation from a physician and \\ninadequate follow-up or facilitation of enrollment after referral.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Financial issues such as limited \\nor absent health insurance coverage and the inability to afford copayments, even when insured, \\nalso limit CR/PR participation as do conflicting work and home responsibilities and distance and\\n382 https://millionhearts.hhs.gov/about-million-hearts/index.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [383 https://millionhearts.hhs.gov/about-million-hearts/optimizing-care/cardiac-rehabilitation.html.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [384 Fleg JL, Keteyian SJ, Peterson PN, Benzo R, Finkelstein J, Forman DE, Gaalema DE, Cooper LS, Punturieri A, \\nJoseph L, Shero S, Zieman S. Increasing Use of Cardiac and Pulmonary Rehabilitation in Traditional and \\nCommunity Settings: OPPORTUNITIES TO REDUCE HEALTH CARE DISPARITIES.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [J Cardiopulm Rehabil.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2020 Nov;40 (6):350-355. doi: 10.1097/HCR.0000000000000527.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [PMID: 33074849; PMCID: PMC7644593.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [385 Varghese MS, Beatty AL, Song Y, et al., Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Circ Cardiovasc \\nQual Outcomes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2022;15:e009618.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [DOI: 10.1161/CIRCOUTCOMES.122.009618.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [386 Husaini M, Deych E, Racette SB, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Intensive Cardiac Rehabilitation Is Markedly Underutilized by Medicare \\nBeneficiaries: RESULTS FROM A 2012-2016 NATIONAL SAMPLE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [2022 May \\n1;42(3):156-162. doi: 10.1097/HCR.0000000000000632.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [Epub 2021 Sep 9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1237: [PMID: 34508035.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [transportation difficulties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Social and cultural factors, including the lack of gender and racial \\ndiversity among CR/PR staff, language and cultural barriers, and lack of program availability \\nand access are additional challenges\\u2026 Many eligible patients are also commonly perceived as \\ntoo frail...\\u201d387 Husaini et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [(2022) reinforce the impact of similar factors in CR underuse.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [They \\ncite \\u201clower reimbursements relative to cost and variability in access\\u201d, physician \\u201cskepticism over \\nbenefit and a primary emphasis on cardiac medications and procedures\\u201d, and patient \\u201creluctance \\nor inability to commit 3-6 hr/wk for 8-12 wk to CR, logistical (transportation, work, etc) or \\nfinancial impediments, a preference for exercise/rehabilitation at home, fear of failure, and \\nphysical limitations.\\u201d388  \\nWhile the expansion of supervision requirements to include nonphysician practitioners \\ncould offer greater flexibility for PR and CR programs to operate, the barriers to utilization as \\ndescribed by Fleg and colleagues (2020) and Husiani and colleagues (2022) are widespread and \\ncomplex and low participation in PR, CR and ICR has remained steady for many years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [We do \\nnot believe the expansion of supervising practitioners is likely to address these barriers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Therefore, we do not anticipate any significant increase in utilization of PR, CR and ICR \\nservices and subsequent impact to the Medicare program or interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Modifications Related to Medicare Coverage for Opioid Use Disorder (OUD) Treatment \\nServices Furnished by Opioid Treatment Programs (OTPs)\\nAs discussed in section III.F.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [of this proposed rule, we are proposing allowing periodic \\nassessments to be furnished via audio-only communication when two-way audio-video \\ncommunications technology is not available to the beneficiary through the end of CY 2024, to \\n387 Fleg JL, Keteyian SJ, Peterson PN, Benzo R, Finkelstein J, Forman DE, Gaalema DE, Cooper LS, Punturieri A, \\nJoseph L, Shero S, Zieman S. Increasing Use of Cardiac and Pulmonary Rehabilitation in Traditional and \\nCommunity Settings: OPPORTUNITIES TO REDUCE HEALTH CARE DISPARITIES.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [J Cardiopulm Rehabil.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [2020 Nov;40 (6):350-355. doi: 10.1097/HCR.0000000000000527.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [PMID: 33074849; PMCID: PMC7644593.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [388 Husaini M, Deych E, Racette SB, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Intensive Cardiac Rehabilitation Is Markedly Underutilized by Medicare \\nBeneficiaries: RESULTS FROM A 2012-2016 NATIONAL SAMPLE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [J Cardiopulm Rehabil Prev.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [2022 May \\n1;42(3):156-162. doi: 10.1097/HCR.0000000000000632.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [Epub 2021 Sep 9.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1238: [PMID: 34508035.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [the extent that it is authorized by SAMHSA and DEA at the time the service is furnished and all \\nother applicable requirements are met.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [We believe the Part B cost impact of this flexibility for the use of telecommunications \\nwill be minimal because we do not expect that these flexibilities will increase the frequency with \\nwhich medically necessary assessments are furnished.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [10.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [Medicare Shared Savings Program \\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [General Impacts\\nAs of January 1, 2023, 10.9 million Medicare beneficiaries receive care from a health \\ncare provider in one of the 456 ACOs participating in the Shared Savings Program, the largest \\nvalue-based care program in the country.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The Shared Savings Program proposed policies \\nadvance Medicare\\u2019s overall value-based care strategy of growth, alignment, and equity, with \\nmany proposals overlapping these categories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The proposed policies in this proposed rule are \\nincremental refinements to the broader changes finalized in the CY 2023 PFS final rule (87 FR \\n69777 through 69968).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [Those changes were designed to reverse recent trends where program \\nparticipation had plateaued, higher spending populations were increasingly underrepresented in \\nthe program since the change to regionally-adjusted benchmarks, and access to ACOs appeared \\ninequitable as evidenced by data indicating underserved populations are less likely to be assigned \\nto a Shared Savings Program ACO, and to encourage growth of ACOs in underserved \\ncommunities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1239: [The changes to the Shared Savings Program regulations finalized with the CY 2023 PFS \\nfinal rule were designed to increase program participation for new ACOs through the AIP option \\nintended to promote health equity, and provide ACOs greater choice in the pace of progression to \\nperformance-based risk; sustain program participation by reducing the effect of ACO \\nperformance on benchmark updates and benchmark rebasing; mitigate the bias in regional \\nexpenditure calculations that benefits ACOs electing prospective assignment; strengthen \\nincentives for ACOs serving high risk and high dual populations; improve the risk adjustment]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [methodology to better account for medically complex, high cost beneficiaries while continuing \\nto guard against coding initiatives; increase opportunities for low revenue ACOs in the BASIC \\ntrack to share in savings by allowing ACOs that do not meet the minimum savings rate (MSR) \\nrequirement to share in savings at a lower rate; encourage ACOs to transition more quickly to \\nall-payer quality measure reporting; update the ACO beneficiary assignment methodology; and \\nreduce administrative burden on ACOs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The proposed changes to Shared Savings Program \\npolicies in this proposed rule include modifications designed to further these goals in concert \\nwith implementation of certain changes finalized in the CY 2023 PFS final rule, which are \\napplicable for agreement periods beginning on January 1, 2024, and in subsequent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [On average, updated benchmarks would marginally increase as a result of the proposal to \\nmodify the calculation of the regional component of the blended update factor used to update the \\nhistorical benchmark between benchmark year (BY) 3 and the performance year (PY) by \\ncapping an ACO\\u2019s regional service area risk score growth through use of an adjustment factor to \\nprovide more equitable treatment for ACOs and for symmetry with the cap on ACO risk score \\ngrowth (section III.G.4.b of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [This change is expected to increase the regional \\nupdate factor amount in certain cases where an ACO may operate in a regional service area with \\nrapid change in the average prospective HCC risk score for the FFS assignable beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The current methodology for calculating the regional update factor risk adjusts \\ncounty-level FFS expenditures in an ACO\\u2019s regional service area by Medicare enrollment type \\nby dividing average county-level FFS expenditures for assignable beneficiaries in the county by \\nthe average prospective HCC risk score for both the performance year and BY3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1240: [The expenditure \\ngrowth between BY3 and the performance year calculated  using risk-adjusted regional \\nexpenditures could therefore be reduced by large increases in average prospective HCC risk \\nscores in the ACO\\u2019s regional service area that would only be partly offset by the increase in \\nprospective HCC risk score growth for the ACO\\u2019s assigned beneficiary population due to the cap \\non ACO assigned beneficiary prospective HCC risk score growth when updating the benchmark]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [between BY3 and the performance year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [The proposed adjustment, applicable for agreement \\nperiods beginning on January 1, 2024, and in subsequent years, would effectively strengthen the \\nregional portion of the three-way blended update factor and help to limit losses ACOs may face \\nwhen operating in regional service areas with high risk score growth and a beneficiary \\npopulation that becomes more medically complex between BY3 and the performance year, \\nincreasing incentives for ACOs to form or continue participation in such areas.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [By utilizing a \\nmarket share adjusted cap to account for ACO market share in the ACO\\u2019s regional service area, \\nthe proposed adjustment would still retain a disincentive against coding intensity for ACOs that \\nmay have a high market share in their region and consequently have greater influence on \\nregional service area risk score changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [For example, this feature of the proposal would help \\ndissuade such ACOs from attempting to artificially increase their benchmark by selectively \\nserving lower risk beneficiaries and increasing the intensity of diagnoses submitted for those \\nbeneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [Analyses described in the section III.G.4.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [(2) of this proposed rule, surrounding tables \\n33 and 34, provide the basis for estimating the impact for the proposal to cap regional service \\narea risk score growth.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [Analysis of average prospective HCC risk score changes at the Hospital \\nReferral Region (HRR) level over an extended 2007 to 2021 historical period consistently \\nindicated that risk score changes would be highly unlikely to exceed the proposed cap in the first \\ntwo years of an ACO\\u2019s agreement period but would increase somewhat as the 5-year agreement \\nperiod progresses.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1241: [The analysis also notably showed that average prospective HCC risk score \\nvariation increased markedly in 2020 and 2021 with the COVID-19 PHE.389 The 11 percent of \\nACOs simulated to be impacted by the proposed adjustment in PY 2021 (a mix of ACOs with 2-\\nyear and 3-year gaps between their respective BY3 and the simulated PY 2021) is therefore \\n389 Public use data on Medicare Geographic Variation \\u2013 by Hospital Referral Region, used for this analysis, is \\navailable at https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-geographic-\\ncomparisons/medicare-geographic-variation-by-hospital-referral-region.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [anticipated to overstate variation expected in agreement periods that start on January 1, 2024 or \\nlater.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [Based on the simulation in the context of the longer-run HRR data, we project that \\nstarting in 2024 the proposed adjustment would impact less than 1 percent of ACOs in PY1 of an \\nagreement period, between 5 to 7 percent of ACOs by PY3, and up to 10 to 15 percent of ACOs \\nby PY5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The adjustment for ACOs that are simulated to be impacted is relatively small, \\nincreasing updated benchmarks by about 0.2 percent up to 0.4 percent on average by PY5, but \\nwith the potential for up to a net adjustment of about 1.5 percent in extreme scenarios.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The \\nestimated cost from additional shared savings payments resulting from these adjustments totals \\n$370 million over 10 years as shown in Table 109.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [TABLE 109:  Projected Impact of Proposed Adjustment Factor to Apply Risk Score Cap to \\nRegional Portion of Blended Update Factor Calculation ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 10 10 20 40 70 50 20 40 40 70 370\\nEstimate Range:            \\nLow Estimate 0 0 10 20 40 40 20 20 30 40 220\\nHigh Estimate 10 20 30 60 90 80 40 50 60 100 540\\nA material, albeit uncertain impact, is also estimated for the proposals to (a) use a rolling \\n3-year historical period instead of contemporary performance to calculate the 40th percentile of \\nthe MIPS Quality performance category scores starting in PY 2024 and (b) the proposal to use \\nthe higher of the ACO\\u2019s health equity adjusted quality performance score or the 40th percentile \\nMIPS Quality performance category score across all MIPS Quality performance scores if \\nmeasure suppression is required.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [It is likely that MIPS Quality performance will improve at least \\nmarginally over time and therefore the historical performance could produce a target that \\neffectively is lower than the contemporary 40th percentile stipulated at baseline.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1242: [The effective \\nreduction in the threshold when using the historical MIPS scores, combined with the \\u2018higher of\\u2019 \\nproposal when suppression is necessary, are assumed to effectively reduce the quality target by 0]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [to 5 percentage points (mode 1.5 percentage points), which would produce an estimated $110 \\nmillion in additional shared savings payments over 10 years, as shown in the Table 110.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [TABLE 110:  Projected Combined Impact of Quality Proposals to (a) Use Rolling 3-Year \\nHistorical Period to Calculate the 40th Percentile of the MIPS Quality Performance \\nCategory Scores and (b) Use the \\u2018Higher Of Value\\u2019 When Measures are Suppressed ($ \\nMillions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 0 10 10 10 10 10 10 10 20 20 110\\nEstimate Range:            \\nLow Estimate 0 0 0 0 0 0 0 0 0 0 0\\nHigh Estimate 0 30 30 30 40 40 30 40 40 40 320\\nThe impact is also estimated to be material for the proposal to mitigate the impact of the \\nnegative regional adjustment on the benchmark.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [In the CY 2023 PFS final rule, CMS finalized \\nchanges applicable for agreement periods beginning on January 1, 2024, and in subsequent years, \\nthat would reduce the cap on negative regional adjustments from 5 percent to 1.5 percent and \\nprovide an offset factor to gradually decrease the negative regional adjustment amount as an \\nACO\\u2019s proportion of dually eligible Medicare and Medicaid beneficiaries increases or its \\nweighted average prospective HCC risk score increases, or both.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [Removing the regional \\nadjustment entirely, when the ACO\\u2019s regional adjustment amount (expressed as a single per \\ncapita value) is negative, would incrementally increase benchmarks for higher spending ACOs \\n(increasing shared savings payments) but would also improve the incentive for higher spending \\nACOs to join the Shared Savings Program and drive down unnecessary spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [For a high cost \\nestimate we conservatively assume no new participation is generated in response to this change \\nand estimate the higher benchmarks would generate about $1.8 billion in additional shared \\nsavings payments partly offset by about $1.6 billion in reduced spending in response to improved \\nincentives.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1243: [For a mean estimate we additionally assume 10 percent growth in participation from]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [new high spending ACOs leading to about $490 million net savings over 10 years.390 For a low \\ncost estimate we instead assume 20 percent growth in participation from high spending ACOs \\nleading to about $1.2 billion in net savings over 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Table 111 shows these estimates over \\nthe 2024-2033 window.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [TABLE 111:  Projected Impact of Proposal to Mitigate the Impact of Negative Regional \\nAdjustment on Benchmarks ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 0 30 10 -20 -70 -110 -100 -70 -90 -70 -490\\nEstimate Range:  \\nLow Estimate -10 -10 -40 -80 -130 -200 -200 -180 -200 -170 -1,220\\nHigh Estimate 10 60 50 30 0 -20 0 30 20 30 210\\nThe proposal to specify the use of the CMS-HCC risk adjustment model(s) applicable to \\nthe calendar year corresponding to the performance year to calculate a Medicare FFS \\nbeneficiary\\u2019s prospective HCC risk score for the performance year, and for each benchmark year \\nof the ACO\\u2019s agreement period for agreement periods beginning January 1, 2024, and in \\nsubsequent years, is anticipated to remove a potential bias that may otherwise reduce \\nbenchmarks particularly for ACOs with beneficiaries exhibiting higher average renormalized risk \\nscores at baseline.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [An increase in average shared savings payments to ACOs that would have \\nparticipated regardless of this proposed modification is expected to ultimately be more than \\noffset by additional savings from increased participation from ACOs serving high risk \\nbeneficiaries that would have otherwise dropped out or avoided entering the Shared Savings \\nProgram under the current approach to calculating prospective HCC risk scores.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Net savings are \\nexpected to be greater at the end of the 10 year scoring window because residual savings from \\n390 Elimination of overall negative regional adjustments, under the proposed approach, would likely generate \\nparticipation growth from ACOs that will face significant negative adjustments despite the changes from the CY \\n2023 PFS final rule to reduce the impact of the negative regional adjustment, but also from other prospective high \\nspending ACOs that may have difficulty estimating the relief they will ultimately receive from the offsets applicable \\nto agreement periods beginning on January 1, 2024, and in subsequent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1244: [Eliminating overall negative regional \\nadjustment entirely would materially improve the business case for participation from ACOs in the former category \\nand may at least optically improve the business case for ACOs in the latter category without actually incurring cost \\nto the program by increasing their benchmarks.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [added participation would grow, whereas benchmarks would not be as impacted in the later part \\nof the scoring window because there is lower likelihood that later agreement periods would have \\nbeen impacted by changes in the CMS HCC risk adjustment methodology.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [Table 112 shows \\nthese estimates over the 2024-2033 window.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [TABLE 112:  Projected Impact of Proposal to Use Uniform Approach to Calculate Risk \\nScores in the Shared Savings Program Benchmark Calculations ($ Millions)\\n 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact Estimate 10 20 60 100 140 -70 -130 -180 -160 -110 -320\\nEstimate Range:  \\nLow Estimate 10 -10 10 30 50 -120 -200 -270 -280 -260 -1,040\\nHigh Estimate 20 80 130 190 240 70 10 -50 -40 -20 630\\nAn overall net impact is difficult to quantify for the proposed changes in section III.G.3.a \\nof this proposed rule, to incorporate use of a new third step in the step-wise beneficiary \\nassignment methodology and the proposed changes to identification of the assignable beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [These proposed changes are not currently estimated to have a net impact on program \\nspending in either direction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [Impacts on benchmark calculations for individual ACOs would \\nlikely be mixed and of relatively limited magnitude.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The proposed changes could allow some \\nACOs to increase efficiency by utilizing more non-physician clinicians in delivering primary \\ncare without jeopardizing assignment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [On the other hand, they could marginally increase shared \\nsavings payments for efficiencies that currently would accrue entirely to the program as spillover \\neffects on beneficiaries unable to be assigned.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The overall impact is currently anticipated to be \\nroughly neutral.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [We will continue to analyze data on the potential impact of these proposed \\nchanges on existing ACOs, and will monitor effects if the proposals are finalized and \\nimplemented in future agreement periods.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [The remaining proposed changes to the Shared Savings Program regulations are not \\nestimated to have an impact on program spending at the aggregate level.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1245: [These proposed changes \\ninclude modifying the definition of primary care services for purposes of determining beneficiary \\nassignment, recalculating the prior savings adjustment for changes in the amount of savings]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [earned by an ACO in a benchmark year due to compliance action taken to address avoidance of \\nat-risk beneficiaries or changes in the amount of savings or losses for a benchmark year as a \\nresult of the issuance of a revised initial determination of financial performance, expanding \\nquality reporting options to include Medicare CQMs, requiring reporting of MIPS PI \\nperformance category for all eligible clinicians participating in ACOs, and using beneficiary \\ncounts instead of person years in health equity adjustment calculations, as well as proposals to \\nfurther refine AIP policies, revise program eligibility requirements, and make technical changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [Compliance with Requirements of Section 1899(i)(3) of the Act\\nCertain policies, including both existing policies and the proposed new policies described \\nin this proposed rule, rely upon the authority granted in section 1899(i)(3) of the Act to use other \\npayment models that the Secretary determines will improve the quality and efficiency of items \\nand services furnished under the Medicare program, and that do not result in program \\nexpenditures greater than those that would result under the statutory payment model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [The \\nfollowing proposals require the use of our authority under section 1899(i) of the Act: the \\nproposed modifications to the calculation of regional component of the three-way blended update \\nfactor to cap regional service area risk score growth for symmetry with the ACO risk score \\ngrowth cap, as described in section III.G.4.b of this proposed rule and the refinements to AIP \\npolicies as described in section III.G.5.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [Further, certain existing policies \\nadopted under the authority of section 1899(i)(3) of the Act that depend on use of the assigned \\npopulation and assignable beneficiary populations, would be affected by the proposed addition of \\na new third step of the beneficiary assignment methodology and the proposed revisions to the \\ndefinition of assignable beneficiary, described in section III.G.3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1246: [of this proposed rule, including \\nthe following: the amount of advance investment payments; factors used in determining shared \\nlosses for ACOs under two-sided models (including calculation of the variable MSR/MLR based \\non the ACO\\u2019s number of assigned beneficiaries, and the applicability of the extreme and \\nuncontrollable circumstances policy for mitigating shared losses for two-sided model ACOs);]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [and calculation of the ACPT, regional and national components of the three-way blended \\nbenchmark update factor.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [When considered together these changes to the Shared Savings \\nProgram\\u2019s payment methodology are expected to improve the quality and efficiency of items and \\nservices furnished under the Medicare program by improving the ability for ACOs to sustain \\neffective participation in regions with changing populations and increasing the overall proportion \\nof Medicare beneficiaries assigned to ACOs, and are not expected to result in a situation in \\nwhich the payment methodology under the Shared Savings Program, including all policies \\nadopted under the authority of section 1899(i) of the Act, results in more spending under the \\nprogram than would have resulted under the statutory payment methodology in section 1899(d) \\nof the Act.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [In the CY 2023 PFS final rule we estimated that the projected impact of the payment \\nmethodology that incorporates all finalized changes from that final rule would result in $4.9 \\nbillion in greater program savings compared to a hypothetical baseline payment methodology \\nthat excludes the policies that require section 1899(i)(3) of the Act authority (see 87 FR 70195 \\nand 70196).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [The marginal impact of the proposed changes discussed in this proposed rule is \\nestimated to be $330 million lower net spending over the ten year window for all new proposals \\ncombined, including the proposal to cap an ACO\\u2019s regional service area risk score growth and \\nthe proposals to add a new third step to the beneficiary assignment methodology and to revise the \\napproach to identify the assignable beneficiary population.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [Therefore, we believe the \\nrequirements of section 1899(i)(3)(B) of the Act would not be violated by these relatively minor \\nchanges to program spending.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [We will continue to reexamine this projection in the future to ensure that the requirement \\nunder section 1899(i)(3)(B) of the Act that an alternative payment model not result in additional \\nprogram expenditures continues to be satisfied.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1247: [In the event that we later determine that the \\npayment model that includes policies established under section 1899(i)(3) of the Act no longer \\nmeets this requirement, we would undertake additional notice and comment rulemaking to make]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [adjustments to the payment model to assure continued compliance with the statutory \\nrequirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Medicare Part B Payment for At-Home Preventive Vaccine Administration Services\\nIn section III.H.3.c of this proposed rule, we propose to maintain the additional payment \\nwhen a COVID\\u201319 vaccine is administered in a beneficiary\\u2019s home under certain circumstances, \\nand to extend this payment to the administration of a pneumococcal, hepatitis B or influenza \\nvaccines.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [We estimated the impact of the proposal to maintain the additional payment for in-home \\nCOVID-19 vaccine administrations and to expand the policy to the administration of all Part B \\npreventive vaccines.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [For this estimate, we analyzed CY 2021-2022 utilization of HCPCS code \\nM0201 for the providers and suppliers that billed it, along with their utilization of the relevant \\npreventive vaccine administration codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [During this period, the in-home additional payment was \\nbilled about 200,000 times by roughly 1,500 different providers and suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [For those \\nproviders or suppliers who administered COVID-19 vaccine in the home in 2021-2022, HCPCS \\ncode M0201 was billed about 2 percent of the time they administered any COVID-19 \\nvaccination.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Total Medicare payments for this service in 2021 and 2022 were $4 million and $3 \\nmillion, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [While we expect that in-home administrations of COVID vaccines will continue into CY \\n2024, we note that the overall utilization of the COVID-19 vaccine was significantly lower in \\n2022 than in 2021, and future utilization is unknown.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Further, if we apply the prevalence of the \\nutilization of HCPCS code M0201 for in-home administration of the COVID-19 vaccine to the \\nutilization of the other three Part B preventive vaccinations, it would result in higher spending of \\nroughly $1-2 million.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [Therefore, the overall estimated impact of this proposal is increased \\nspending of less than $5 million in 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1248: [We note that our analysis assumed that there would be \\nno additional providers or suppliers who would decide to begin providing these vaccines at home \\nfor CY2024, given that COVID-19 PHE ended on May 11, 2023]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [Effects of Proposals Relating to the Medicare Diabetes Prevention Program Expanded \\nModel\\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [Effects on Beneficiaries\\nWe propose to modify certain Medicare Diabetes Prevention Program (MDPP) expanded \\nmodel policies to: (1) Extend the flexibilities allowed during the PHE for the COVID-191135 \\nwaiver event by 4 years (or until December 31, 2027), (2) update the MDPP payment structure to \\npay for beneficiary attendance on a fee-for-service basis while retaining the diabetes risk \\nreduction performance payments, (3) remove the requirement for MDPP interim preliminary \\nrecognition and replace it with CDC preliminary recognition, and (4) remove most references to, \\nand requirements of, the Ongoing Maintenance Sessions given that eligibility for these services \\nwill end on December 31, 2023.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [We anticipate that these proposed changes will have a positive \\nimpact on beneficiaries\\u2019 access to MDPP services by increasing the number of MDPP eligible \\norganizations that enroll in Medicare as MDPP suppliers and, more importantly, increasing \\nbeneficiary access to the Set of MDPP services by allowing them continued access to MDPP \\nthrough a live in-person or virtual classroom (or a combination of both modalities).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [The \\nproposed changes would also remove barriers specific to attending these classes solely in-person, \\nwhich may include a lack of MDPP suppliers in certain communities and challenges related to \\nbeneficiary logistics concerning course attendance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [These proposed modifications address MDPP supplier and beneficiary needs based upon \\navailable monitoring and evaluation data received to date, feedback from Medicare Advantage \\nplans and existing MDPP suppliers, and feedback from beneficiary focus groups.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [The proposed \\nchanges are also in response to comments from interested parties made through public comments \\nin response to prior rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [During the initial rulemaking for the MDPP expanded model, we sought to ensure that \\nMDPP would be delivered in-person, in a classroom-based setting, and within an established \\nperiod of service to maintain consistency with the original DPP model test.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1249: [At the time, priority]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [was placed on establishing a structured expanded model that, when delivered within the confines \\nof the rule, would create the least risk of fraud, waste, and abuse, increase the likelihood of \\nsuccess, and maintain the integrity of the data collected for evaluation purposes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [However, circumstances such as the PHE for COVID-19 led us to make changes to the \\nMDPP expanded model through implementation of an Emergency Policy for MDPP that allows \\nfor temporary flexibilities while prioritizing availability and continuity of services for MDPP \\nsuppliers and MDPP beneficiaries impacted by such section 1135 waiver events.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [For example, in \\nthe CY 2021 PFS, we finalized the regulations in the March 31st COVID-19 IFC to amend the \\nMDPP expanded model to revise certain MDPP policies during the COVID-19 PHE as well as \\nany future 1135 waiver events where such 1135 waiver event may cause a disruption to in-\\nperson MDPP service delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [These flexibilities allowed beneficiaries to either continue to \\nhave access to MDPP through participation in virtual sessions, pause an in-person MDPP class \\nand resume with the most recent attendance session of record, or restart MDPP from the \\nbeginning in accordance with the March 31st COVID-19 IFC (85 FR 19230).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [When establishing these flexibilities, we could not predict that the COVID-19 PHE \\nwould continue for over 3 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [Although beneficiary participation decreased significantly \\nduring the initial year of the COVID-19 PHE, MDPP participation has slowly increased since \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [As this additional modality of delivery has helped improve supplier access to beneficiaries, \\nremoving the PHE flexibilities and suppliers\\u2019 ability to deliver MDPP virtually after 3 years \\nwould not only be disruptive to suppliers, it may in-fact be detrimental to the operations of the \\nMDPP expanded model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [During the COVID-19 PHE, we permitted virtual delivery of the Set of MDPP services \\nby MDPP suppliers who were recognized by the CDC with Diabetes Prevention Recognition \\nProgram (DPRP) in-person delivery mode, but did not permit suppliers who were only \\nrecognized by the CDC with either online or distance learning delivery modes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1250: [Although we \\nfinalized in the CY 2021 PFS that suppliers had to be prepared to return to in-person delivery]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [when the PHE ended, the PHE lasted for over 39 months.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Therefore, returning to a solely in-\\nperson, pre-PHE delivery model may not be as simple for some suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Post-PHE, many beneficiaries and suppliers have reported the desire to continue utilizing \\nvirtual delivery of MDPP for a wide range of reasons.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Maintaining suppliers\\u2019 ability to offer both \\nsynchronous virtual (distance learning) and in-person MDPP may increase beneficiary uptake of \\nthese services.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [It is important to note that permitting virtual delivery of MDPP throughout the \\nPHE has not resulted in a spike in MDPP utilization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [A reason for a lack of beneficiary \\nparticipation may be tied to the fact that suppliers still had to maintain the ability to deliver in-\\nperson services (rent or own physical space), while some suppliers were unfortunately unable to \\npivot to virtual delivery during the COVID-19 PHE for a variety of reasons.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Current data depict that the most impactful MDPP results correspond to attending MDPP \\nsessions virtually or through utilizing a hybrid approach (attending classes both virtually and in-\\nperson).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Interim MDPP evaluation data illustrated that average participant weight loss is 5.1 \\npercent since the expanded model launched on April 1, 2018, surpassing the expanded model\\u2019s \\nweight loss goal of 5 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [In addition, the interim evaluation data show that, 53 percent of \\nMDPP participants attained the 5 percent weight-loss goal, and 24.6 percent attained the 9 \\npercent weight-loss goal.391 Aligning with the Diabetes Prevention Program (DPP) model test392 \\nand studies on the National DPP,393,394 MDPP participants who attended more sessions lost more \\nweight.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [For example, among beneficiaries who attended at least 9 sessions, 64 percent met the 5 \\npercent weight loss goal and 30 percent met the 9 percent weight loss goal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [For MDPP \\nparticipants impacted by the COVID-19 PHE, evaluation data confirm significantly increased \\n391 MDPP 2nd Annual Evaluation Report.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [392 RTI International.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Evaluation of the Health Care Innovation Awards: Community Resource Planning, \\nPrevention, and Monitoring:   THIRD ANNUAL REPORT.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [March 2017.  https://downloads.cms.gov/files/cmmi/hcia-\\ncrppm-thirdannrptaddendum.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [393 Knowler WC, Barrett-Connor E, Fowler SE, et al.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Reduction in the incidence of type 2 diabetes with lifestyle \\nintervention or metformin.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [N Engl J Med.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [2002;346(6):393-403. doi:10.1056/NEJMoa012512.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [394 Diabetes Prevention Program Research Group.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Long-term effects of lifestyle intervention or metformin on \\ndiabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program \\nOutcomes Study.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [Lancet Diabetes Endocrinol.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1251: [2015;3(11):866-875. doi:10.1016/S2213-8587(15)00291-0.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [weight loss accompanied with a higher number of sessions attended by participants completing \\nthe expanded model in 2021, with these participants attending primarily virtual sessions or a \\nmixture of virtual and in-person sessions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [To date, there have been no preliminary indications that the synchronous virtual delivery \\nof MDPP has limited supplier instruction or beneficiary success, as defined by achievement of \\nthe 5 percent weight loss goal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [However, it is too early to determine the impact of synchronous \\nvirtual delivery of MDPP on other outcomes such as cost-savings or incidence of diabetes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [MDPP has been fundamentally limited by low beneficiary participation and corresponding small \\nsample sizes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [We believe that an increase in supplier uptake, which may be accomplished \\nthrough our proposal to maintain more options of MDPP delivery modalities, will result in an \\nincrease in beneficiary enrollment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [This will be critical to conducting robust programmatic \\nevaluations, including a potential future certification of the synchronous virtual delivery of \\nMDPP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [To assist with our ability to improve monitoring and evaluation of the synchronous \\nvirtual delivery of MDPP, we have proposed a new HCPCS G-code specific to distance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Additionally, extending the flexibilities allowed during the PHE for COVID-19 by 4 years would \\nimprove MDPP eligible organizations\\u2019 MDPP service delivery opportunities due to the use of \\nmultiple modalities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Effects on the Market\\nWhile we acknowledge that additional changes will likely be necessary to improve \\nbeneficiary access to MDPP, we anticipate that the enhancements proposed in this rule are likely \\nto result in an increase of MDPP suppliers and increased beneficiary access to the Set of MDPP \\nservices.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [We anticipate that this will assist in contributing to a reduction of the incidence of \\ndiabetes among eligible Medicare beneficiaries, and in particular, those residing in underserved \\ncommunities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1252: [Currently, there are approximately 786 in-person organizations nationally that are \\neligible to become MDPP suppliers based on their preliminary or full CDC Diabetes Prevention]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Recognition Program (DPRP) status.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [However, only 25 percent of eligible in-person \\norganizations are participating in MDPP, and only one-third of MDPP suppliers have submitted \\nMDPP-related claims.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Through updating the payment structure to one that is similar to those of \\nexisting CMS Medicare Preventive Services such as the Intensive Behavioral Counseling for \\nObesity, the MDPP claims submission process may be more intuitive for existing Medicare \\nsuppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [In addition, we anticipate that simplifying the MDPP payment structure will address \\nsome of the complexities related to the process for submitting claims, while encouraging more \\nsuppliers to submit claims for MDPP due to a reduced set of codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Since MDPP was established through the CY 2017 PFS, we have consistently heard from \\ninterested parties that we should include virtual delivery of MDPP as part of the expanded model \\ntest, which would increase beneficiary access to the Set of MDPP services while providing \\nflexibility of where both a beneficiary may take the course and from where a supplier may \\ndeliver the course.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [Although we did not allow for a fully virtual delivery of MDPP until the \\nCOVID-19 PHE, we did allow a limited number of virtual make-up sessions, which could be \\ndelivered either synchronously or asynchronously.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [The rationale for allowing a limited number \\nof virtual make-up sessions was due to the fact that the data used to certify MDPP were based \\nupon in-person delivery, thereby fully virtual delivery was arguably outside the scope of \\ncertification.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [The COVID-19 PHE led CMS to establish MDPP flexibilities that allowed fully virtual \\ndelivery of the Set of MDPP services by suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [We established several emergency \\nflexibilities within the IFC-1 that removed the limit on the number of virtual makeup sessions, \\nand in the CY 2021 PFS, we finalized the MDPP flexibilities from the IFC-1 while establishing \\nthe MDPP Emergency Policy that allowed for virtual delivery of MDPP, including virtual weight \\ncollection.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1253: [However, the CY 2021 PFS stated that MDPP suppliers must retain the capacity to \\ndeliver the Set of MDPP services in-person, precluding organizations with CDC DPRP \\nrecognition solely in the distance learning or online modalities from participating in MDPP]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [during the COVID-19 PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Interested parties commented that some beneficiaries may have \\nlimited access or ability to use the technology required for participation in virtual MDPP sessions \\nIn the CY 2022 PFS, although outside the scope of rule, interested parties recommended \\nthat we continue the virtual option following the end of the COVID-19 PHE to assist in \\nincreasing access to MDPP, especially for those with transportation needs as well as for \\nbeneficiaries in rural and low-income communities, who may suffer from a lack of in-person \\nsuppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [As a result of these recommendations, in this rule, we are proposing to extend the \\nPHE flexibilities, specific to allowing synchronous virtual delivery of MDPP, also known as \\ndistance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Currently, there are numerous large geographic gaps of MDPP supplier locations, and \\nsynchronous virtual delivery may be part of the solution to increasing the accessibility of MDPP \\nto more beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [It is unclear how the market will respond to the proposed extension of the \\nPHE flexibilities allowed during the COVID-19 PHE, especially since we are still requiring \\nsuppliers to have and maintain an in-person DPRP recognition, but we believe organizations will \\nbe ready to engage in the delivery of the Set of MDPP services either in-person, through distance \\nlearning, or through a combination of in-person and distance learning.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [We also believe that \\nhaving more flexibility in how the Set of MDPP services are delivered will make MDPP more \\naccessible to beneficiaries, particularly those who live in rural areas or in communities with gaps \\nin MDPP supplier locations.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [c.  Payment for MDPP Services\\nRegulations at \\u00a7 414.84 specify MDPP suppliers may be eligible to receive payments for \\nfurnishing MDPP services and meeting performance targets related to beneficiary weight loss \\nand/or attendance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [However, we have consistently heard from suppliers and interested parties \\nthat the MDPP performance-based payment structure has been confusing to some suppliers, \\nincluding those new to Medicare as well as existing suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1254: [Approximately 37 percent of]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [MDPP suppliers have submitted FFS claims for MDPP.395 Confusion with claims submission has \\nbeen due, in part, to the MDPP payment structure, which pays for performance-based milestones \\nversus paying for traditional fee-for-service.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [The performance-based payment structure requires \\n15 HCPCS G-codes if including ongoing maintenance sessions, and 11 G-codes for the 12-\\nmonth MDPP service period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [Therefore, we are proposing to shift this payment structure to pay \\nfor attendance on a fee-for-service basis while retaining the diabetes risk reduction performance \\nmilestones, for example 5 percent and 9 percent weight loss as well as the maintenance of the 5 \\npercent weight loss in months 7-12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [This proposed streamlined payment structure will allow \\nsuppliers to receive a more consistent set of payments for their delivery of the Set of MDPP \\nservices and reduce the number of G-codes for easier billing.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [We anticipate that this updated payment structure will reduce the upfront beneficiary \\nretention costs while motivating eligible suppliers to enroll in Medicare to become MDPP \\nsuppliers and provide the Set of MDPP services to eligible Medicare beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [In the current \\nMDPP payment structure, suppliers submit claims after the 1st, 4th, and 9th sessions attended \\nduring the core sessions interval, and following attendance of the two (2) sessions during each of \\nthe core maintenance intervals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [Although the proposed per session payment of $25 is less than \\nthe current per session payment of $38, suppliers will receive up to 22 payments for attendance \\nin the proposed payment structure compared to seven attendance-based payments, for \\nparticipants who began participation in 2022 or later, or eleven attendance-based payments for \\nparticipants whose first core session was in 2021 or earlier.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [The total attendance-based payments \\nwill increase by $54 to $550 in the proposed payment structure, compared to $496 in the current \\none.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [This proposed payment schedule would not only eliminate gaps in payment by providing \\nsmaller but more frequent per-session payments, it would also reduce or eliminate some of the \\ncoding challenges related to the number of existing HCPCS codes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1255: [We have proposed to \\n395 Unpublished data from Acumen LLC, Quarter 4 2022 Quarterly Monitoring Report to CMS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [decrease the one-time performance payments for beneficiary achievement of the 5 percent and 9 \\npercent weight loss goals as well as propose a new HCPCS G-code for the maintenance of the 5 \\npercent weight loss during months 7-12.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [The proposed total maximum payment of $768 consists \\nof the attendance-based payments and the weight loss performance payments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Although the \\nproposed maximum payment of $768 over a one-year service period is the same as the current \\nmaximum payment, we believe this simplified payment structure will lead to fewer claims \\nrejections while encouraging more suppliers to submit MDPP claims for the beneficiaries they \\nserve, as well as motivate more eligible organizations enroll in Medicare to participate in MDPP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [d.  Effects on the Medicare Program \\n(a)  Estimated 10-Year Impact of MDPP \\nThere are two proposed changes to the Medicare Diabetes Prevention Program (MDPP) \\nwhich are relevant to this impact analysis.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Both changes will be implemented in 2024 if \\nfinalized: Simplifying the MDPP payment schedule; and allowing specified Public Health \\nEmergency (PHE) flexibilities to continue for 4 years after the PHE ends\\u2014namely, allowing for \\nsynchronous virtual delivery of the Set of MDPP services .]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [Table 113 shows the estimated impact (in millions) of these two proposed changes on \\nMedicare spending:\\nTABLE 113: Estimated Impact (in millions) of the Two Proposed Changes on Medicare \\nSpending\\nYear 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Total\\nImpact on \\nMedicare \\nSpending$0.3 $0.3 $0.1 $0.0 \\u2212$0.2 \\u2212$0.8 \\u2212$0.7 \\u2212$0.6 \\u2212$0.5 \\u2212$0.3 \\u2212$2.4\\n(b) Assumptions/Notes\\n\\u25cf  Simplifying the payment schedule will lead to fewer claim denials and more \\nparticipation from MDPP suppliers .]] Topic: 7E_Other Provisions in the Regulation: [from p. 1256: [For example, only 55-62% of FFS participants listed in the \\nsupplier crosswalks have an associated MDPP claim over the past 2 years, meaning that \\norganizations have submitted data to the CDC as part of their Diabetes Prevention Recognition]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Program (DPRP) requirements, and also have FFS claims submitted for the same participants for \\nthe same sessions recorded in the DPRP data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [The proposed payment schedule will reduce the \\nnumber of HCPCS codes to from 15 to 6 and eliminate some of the coding issues.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [It will also \\neliminate the gaps in payment by providing smaller but more frequent per-session payments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  The average payment per MDPP participant will increase by $150.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [The new payment \\nschedule will likely lead to more successful claim payment submissions and will motivate MDPP \\nproviders to retain participating beneficiaries for longer periods of time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  In 2022, 551 FFS claims were paid for the initial MDPP session, compared with 514 in \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [According to counts of new FFS participants, there have been about 700 new entrants per \\nyear in recent years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [With the implementation of a simpler payment schedule and the extension \\nof PHE flexibilities, we assume that new participation will be more in line with claim payments \\nfor HCPCS code G9873 and will increase to 1,000 in 2024 and 1,250 during the following years \\nuntil the extended flexibilities end.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [We estimate that there will be 500 new (in-person only) \\nparticipants each year starting in 2029.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  Since the start of the PHE, synchronous virtual delivery of MDPP services has been \\nmore prevalent than in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [However, given the coding/reporting issues during the \\nPHE, it is difficult to determine how many beneficiaries are still receiving MDPP services in-\\nperson.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Without the proposed changes, we assume that new participation will be capped at 400 \\nbeneficiaries per year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [\\u25cf  For preventing diabetes progression, synchronous virtual delivery of the Set of MDPP \\nservices  has the same level of effectiveness as in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Following 3 years of \\ndelivering MDPP almost solely virtually, suppliers and beneficiaries have become adept at \\nutilizing virtual delivery, as many providers in numerous healthcare settings have shifted to \\nutilizing technology.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1257: [Furthermore, preliminary MDPP data collected during the PHE indicates \\nthat beneficiaries have achieved similar weight loss and attendance goals as participants in both]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [the in-person DPP test and MDPP participants who enrolled in MDPP prior to the pandemic.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [This assumption is revisited in the Sensitivity Analysis section.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [(c) Sensitivity Analysis \\nOn March 14, 2016, the Office of the Actuary (OACT) published a certification \\nmemorandum setting out the conditions for expansion of the Medicare Diabetes Prevention \\nProgram (MDPP), which can be found at https://www.cms.gov/Research-Statistics-Data-and-\\nSystems/Research/ActuarialStudies/Downloads/Diabetes-Prevention-Certification-2016-03-\\n14.pdf.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Assumptions about the 10-year cost impacts of virtual delivery of MDPP services takes \\ninto account the assumptions of the original certification, and adjusts for diabetes costs in 2023 \\ndollars, and trends those costs over the next 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Since both the effectiveness and the future participation level of synchronous virtual \\ndelivery of MDPP services are largely unknown, Table 114 shows 10-year cost impacts (in \\nmillions) of varying levels of effectiveness of the virtual delivery of the Set of MDPP services \\nrelative to the in-person delivery of the Set of MDPP services, paired with varying levels of \\nvirtual MDPP participation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [TABLE 114: 10-year Cost Impacts (in millions) of Virtual Delivery of MDPP \\nServices\\nVirtual Beneficiaries Per Year/Effectiveness 25% 50% 75%\\n1,000 $0.7 \\u2212$0.8 \\u2212$2.3\\n2,000 $1.3 \\u2212$1.6 \\u2212$4.6\\n3,000 $2.0 \\u2212$2.4 \\u2212$6.9\\nAs indicated in Table 114, virtual delivery of MDPP services is estimated to produce \\nsavings when it is at least 50 percent as effective as in-person delivery.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [13.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [Appropriate Use Criteria for Advanced Diagnostic Imaging\\nSection 1834(q)(2) of the Act, as added by section 218(b) of the Protecting Access to \\nMedicare Act (Pub.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1258: [L. 113-93, April 1, 2014) (PAMA), directs CMS to establish a program to \\npromote the use of appropriate use criteria (AUC) for applicable imaging services furnished in an \\napplicable setting.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As discussed in detail in section III.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [of this proposed rule, since 2015, we have taken a \\nthoughtful, stepwise approach that maximized engagement and involvement of interested parties \\nto implement the statutory provisions set forth in section 1834(q), as added by section 218(b) of \\nthe PAMA, using notice and comment rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As codified at \\u00a7 414.94, we established the \\nfirst two components of the AUC statutory requirements - establishment of AUC and \\nmechanisms for consultation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [We began to build the parameters for the fourth component, outlier \\nidentification and prior authorization, leading to prior authorization, by establishing the priority \\nclinical areas (PCAs).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [We began implementing the third component, the AUC consultation and \\nreporting requirement, using the ongoing educational and operations testing period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [However, as \\ndiscussed previously in this proposed rule, at this time, we have exhausted all reasonable options \\nfor fully operationalizing the AUC program consistent with the statutory provisions as prescribed \\nin section 1834(q)(B) of the Act directing CMS to require real-time claims-based reporting to \\ncollect information on AUC consultation and imaging patterns for advanced diagnostic imaging \\nservices to ultimately inform outlier identification and prior authorization.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [As a result, we have \\nproposed to pause implementation of the AUC program for reevaluation and to rescind the \\ncurrent AUC program regulations at \\u00a7 414.94.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [In the CY 2019 PFS final rule (83 FR 59452), we performed an RIA for this program and \\nupdated that RIA in the CY 2022 PFS final rule (86 FR 64996).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [The estimated impacts in the CY \\n2022 PFS final rule are as follows:\\n\\u25cf  Cost to ordering clinicians of required AUC consultation: $51,039,109 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to Medicare beneficiaries for additional office visit time: $54,789,518 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to ordering clinicians of transmitting consultation information: $94,495,192 \\nannually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Cost to furnishing clinicians to update processes to report AUC information: \\n$1,851,356,888 (one time).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1259: [\\u25cf  Potential savings to Medicare program from decrease in imaging utilization:]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [$700,000,000 annually.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Table 115 also includes the AUC program-related activities and their corresponding \\nimpact estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [By pausing efforts to implement the AUC program for reevaluation and \\nrescinding the AUC program regulation at \\u00a7 414.94, the Medicare program may not realize the \\nestimated savings, and clinicians and beneficiaries will not experience the estimated costs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [TABLE 115:  AUC Program Related Activities with Impact Estimates From CY2022 PFS\\nAUC Program Related Activity CY 2022 PFS Rule Impact Estimate\\nImpact of required AUC consultations by ordering \\nprofessional$51,039,109\\nImpact to Medicare beneficiaries $54,789,518\\nImpact on transmitting orders for advanced diagnostic \\nimaging services$94,495,192\\nAUC automated solution $1,851,356,888\\nMedicare program impacts associated with advanced \\ndiagnostic imaging services$700,000,000\\n14.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Medicare and Medicaid Provider and Supplier Enrollment Changes \\nIn this section, we discuss the impact of our proposed Medicare provider enrollment \\nrevocation provisions and our Medicaid termination database proposal.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [For all provider \\nenrollment proposals not referenced in this section, we have determined that they would not have \\nan economic impact.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [a.  Medicare Revocation Reasons\\nAs discussed in section III.J of this proposed rule, we are proposing several new or \\nexpanded revocation reasons in \\u00a7 424.535(a).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [First, we propose to expand \\u00a7 424.535(a)(1) to include instances where the provider or \\nsupplier is non-compliant with the enrollment requirements in Title 42.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [Paragraph (a)(1) would \\nno longer be restricted to non-compliance with the provisions of 42 CFR part 424, subpart P.\\nSecond, new \\u00a7 424.535(a)(15) would give CMS the authority to revoke enrollment if the \\nprovider or supplier, an owning or managing employee or organization thereof, or an officer or \\ndirector thereof has had a civil judgment under the False Claims Act (31 U.S.C.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1260: [\\u00a7\\u00a7 3729 \\u2013 3733) \\nimposed against them within the previous 10 years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Third, \\u00a7 424.535(a)(16) would permit CMS to revoke enrollment if a provider or \\nsupplier, or any owner, managing employee or organization, officer, or director thereof, has been \\nconvicted of a misdemeanor under Federal or State law within the previous 10 years that CMS \\ndeems detrimental to the best interests of the Medicare program and its beneficiaries.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Fourth, we propose in new \\u00a7 424.535(a)(243) that CMS may revoke an IDTF\\u2019s, \\nDMEPOS supplier\\u2019s, OTP\\u2019s, or HIT supplier\\u2019s, or MDPP\\u2019s enrollment based on a violation of \\nany standard or condition in, respectively, \\u00a7\\u00a7 410.33(g), 424.57(c), 424.67(b) or (e), or 424.68(c) \\nor (e), or 424.205(b) or (d)..     \\nBased on CMS statistics concerning the average annual amount of Medicare payments a \\nprovider or supplier receives, we project a figure of $50,000.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [We note that we have recently \\nused this figure when estimating the potential savings associated with several new revocation \\nreasons.396  For purposes of consistency and accuracy, we propose to use this $50,000 amount in \\nthis proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Table 116 outlines the estimated annual number of revocations that would ensue with the \\nfour aforementioned revocation proposals:\\nTABLE 116:  Estimated Annual Number of Revocations\\nProposed Revocation \\nReasonNumber of Revocations\\n\\u00a7 424.535(a)(1) 5\\n\\u00a7 424.535(a)(15) 5\\n\\u00a7 424.535(a)(16) 5\\n\\u00a7 424.535(a)(23) 5\\nTotal 20\\nThese revocations would represent a savings to the Federal Government because Trust \\nFund dollars would no longer be paid to the revoked providers and suppliers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [Accordingly, we \\nproject an annual savings to the Federal Government of $1,000,000 ($50,000 x 20 revocations).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1261: [396 For example, see the final rule published in the Federal Register on November 18, 2022 (87 FR 69404), titled \\nMedicare and Medicaid Programs; CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes \\nto Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Implementing \\nRequirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs To Provide Refunds \\nWith Respect to Discarded Amounts; and COVID-19 Interim Final Rules\\u201d.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [b.  Medicaid Termination Database\\nAs discussed in section III.J.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [of this proposed rule, we are proposing certain provisions in \\n42 CFR part 455 concerning the length of time a provider remains in the Medicaid termination \\ndatabase and how this interacts with the termination periods that States impose upon terminated \\nproviders.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We do not believe these proposals involve any additional impact or burden on \\nproviders or States.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [In fact, it could result in a reduction of burden because a provider\\u2019s potential \\nlength of time in the termination database would be capped at 10 years, although we have no data \\navailable with which to assist us in calculating the possible burden reduction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [As a result, since \\nwe are uncertain of how much of the burden will be reduced, we are seeking public comments \\nfrom the public to aid in understanding how to measure said burden reduction.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [15.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [Expand Diabetes Screening and Diabetes Definitions\\nAs discussed in section III.L.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [in this proposed rule, we propose to: (1) expand coverage of \\ndiabetes screening tests to include the Hemoglobin A1C test (HbA1c) test, ( 2) expand and \\nsimplify the frequency limitations for diabetes screening, and (3) simplify the regulatory \\ndefinition of \\u201cdiabetes\\u201d for diabetes screening, Medical Nutrition Therapy (MNT) and Diabetes \\nOutpatient Self-Management Training Services (DSMT).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We anticipate that expanding coverage of diabetes screening to include the HbA1c test \\nand expanding and simplifying the frequency limitations for diabetes screening to result in some \\nadditional service utilization, but we also anticipate the additional utilization may be balanced, in \\npart, by potential long term benefits and savings resulting from increased prevention and early \\ndetection (allowing for less invasive and more effective treatment).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [As described earlier in our \\nproposal, Medicare currently covers the Fasting Plasma Glucose (FPG) test and the Glucose \\nTolerance Test (GTT) for diabetes screening.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [The HbA1c test does not require fasting and is \\nmore convenient than the currently covered FPG and GTT.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1262: [We also propose to expand and \\nsimplify the frequency limitations for diabetes screening by aligning to the statutory limitation of]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [\\u201cnot more often than twice within the 12-month period following the date of the most recent \\ndiabetes screening test of that individual.\\u201d  \\nWe estimate our proposal to expand diabetes screening to result in approximately $68.5 \\nmillion in additional annual expenditures for the Medicare Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Our estimate is based on the \\nfollowing assumptions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Based on calendar year 2022 actual experience, approximately 27.3 \\npercent of beneficiaries had a blood panel test that did not include the HbA1c test.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Medicare \\ncurrently pays approximately $9.50 per HbA1c test for diabetes management.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [The Medicare \\nstatutory and regulatory eligibility factors for an individual at risk for diabetes (section \\n1861(yy)(2) of the Act, 42 CFR 410.18(e)) cover much of the current Medicare beneficiary \\npopulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We assume that approximately 7.6 million potential additional HbA1c tests for \\ndiabetes screening to be billed under our proposal in calendar year 2024 and that the HbA1c test \\nwould be billed with a blood panel 95 percent of the time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Our estimate does not reflect \\nsecondary effects of the proposed policies, such as increased utilization of preventive screening \\nservices, additional follow-up services, and potential offsetting savings (including prevention and \\nmore effective treatment through early detection) that may result from these coverage \\nexpansions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [Secondary effects are difficult to predict, may materialize many years after the \\nintervention and may, in part, offset one another.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We do not anticipate that our proposal to simplify and expand the regulatory definition of \\n\\u201cdiabetes\\u201d for diabetes screening, MNT and DSMT to result in a significant economic impact on \\nthe Medicare program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [As described earlier, we propose to remove the regulatorily codified \\nclinical test requirements from the definition of \\u201cdiabetes\\u201d for diabetes screening, MNT and \\nDSMT and propose a shortened version of the existing definition that would simply define \\ndiabetes as diabetes mellitus, a condition of abnormal glucose metabolism.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We believe that our \\nproposal will empower health care professionals to apply clinically accurate and appropriate \\ncriteria and that we can ensure certain safeguards through medical coding and claims processing \\ninstructions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1263: [We do not anticipate our proposal to simplify and expand the regulatory definition]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of \\u201cdiabetes\\u201d for diabetes screening, MNT and DSMT to result in a significant economic impact \\non the Medicare Program because the regulatory simplification would not otherwise change \\nrequirements or conditions of coverage and payment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [16.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Requirement for Electronic Prescribing for Controlled Substances for a Covered Part D \\nDrug under a Prescription Drug Plan or an MA-PD Plan (section 2003 of the SUPPORT Act) \\nIn section III.M.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of this proposed rule, we are proposing several updates to the CMS \\nEPCS Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We are proposing to remove the same entity exception at \\u00a7 423.160(a)(5)(i) \\nfrom the CMS EPCS Program and to add \\u201csubject to the exemption in paragraph (a)(3)(iii) of \\nthis section\\u201d to \\u00a7 423.160(a)(5).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Under this proposal, prescriptions that are prescribed and \\ndispensed within the same legal entity are included in CMS EPCS Program compliance \\ncalculations as part of the 70 percent compliance threshold at \\u00a7 423.160(a)(5).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [This proposal \\nprovides flexibility to prescribers and dispensing pharmacies that are the same entity to choose \\neither of the electronic standards available at \\u00a7 423.160(a)(3)(iii) to conduct e-prescribing \\nappropriate for their internal systems without us having to exclude these prescriptions completely \\nfrom the CMS EPCS Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [This proposal would affect prescriptions where the prescriber and \\nthe dispensing pharmacy are part of the same legal entity.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Due to the limitations in identifying \\nthese prescriptions in the Prescription Drug Event (PDE) data, the ability to quantify the impact \\nof this proposal is unknown.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [Please see section III.M.3.b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [of this proposed rule for our \\ndiscussion.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We are proposing to specify how we count prescriptions for the compliance calculation \\nby proposing to use the unique identifier given to a prescription by the pharmacy in the \\nmeasurement year and included in the Part D claims data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [We will count renewals as an \\nadditional prescription in the CMS EPCS Program compliance threshold calculation, and we will \\nnot count refills as an additional prescription in the CMS EPCS Program compliance threshold \\ncalculation unless the refill is the first occurrence of the unique prescription in the measurement \\nyear.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1264: [If each refill included on the original prescription were counted as a separate prescription,]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [we believe there would be an incremental impact on small prescribers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Preliminary analysis of \\n2021 Part D data shows that approximately 23,000 prescribers would no longer qualify for the \\nsmall prescriber exception and that approximately 6,900 additional prescribers would be \\nnoncompliant.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing updates to the CMS EPCS Program recognized emergency exception \\nand waiver exception presently found at \\u00a7 423.160(a)(5)(iii) and (iv) and proposed to be codified \\nat \\u00a7 423.160(a)(5)(ii) and \\u00a7 423.160(a)(5)(iii) respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing to have discretion \\nto determine which emergencies trigger the recognized emergency exception starting in the 2024 \\nmeasurement year and proposing that prescribers to whom the exception applies would be \\nexcepted from the CMS EPCS Program requirements for the entire measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are \\nproposing to modify how we have previously defined \\u201cextraordinary circumstance\\u201d for purposes \\nof the waiver exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We propose that an \\u201cextraordinary circumstance\\u201d means a situation \\noutside of the control of a prescriber that prevents the prescriber from electronically prescribing a \\nSchedule II-V controlled substance that is a Part D drug and does not exclude \\u201ccases of an \\nemergency or disaster.\\u201d In cases of extraordinary circumstances, we are proposing the timeframe \\nthat would be covered by a waiver authorized under the CMS EPCS Program to be the entire \\nmeasurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [We are proposing that a prescriber has a period of 60 days from the date of \\nthe notice of non-compliance to request a waiver.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Approved waivers would apply to \\nprescriptions written by a prescriber for the entire measurement year, and the waiver would \\nexpire on December 31 of the applicable measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [Although we are modifying the \\nsituations in which a prescriber can apply for an extraordinary circumstances waiver and limiting \\nthe recognized emergencies exception that applies to the CMS EPCS Program, we do not \\nanticipate these proposals to affect many clinicians compared to the current policies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1265: [First, we \\nbelieve that the proposal for CMS to identify which emergencies trigger the recognized \\nemergency exception would still capture the vast majority of emergencies or disasters that affect \\na prescriber's ability to achieve EPCS compliance and would remove any need for additional]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [prescribers to apply for a waiver.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Second, some prescribers who experience an emergency may \\nstill meet the 70 percent compliance threshold by the end of the emergency period and would not \\nneed to apply for a waiver exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Finally, we are unable to quantify the additional number of \\npotential disasters or emergencies prescribers might experience due to variability in the number \\nof disasters and emergencies in a given measurement year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Therefore, we are not increasing our \\nassumption that 100 waiver requests would be submitted to the CMS EPCS program, as we \\ndiscussed in the CY 2022 PFS final rule (86 FR 65562).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We are proposing to continue sending non-compliance notices to prescribers identified as \\nnon-compliant with the CMS EPCS Program for any individual measurement year, and we do \\nnot believe that causes additional costs or will require additional time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Please see section III.M.6.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [of this proposed rule for our discussion.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We do not anticipate the provisions to have any \\nincremental impact on the cost or time associated with prescriber compliance with the electronic \\nprescribing for controlled substances requirement or the cost to interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [17.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [Proposed Changes to the Regulations Associated with the Ambulance Fee Schedule and the \\nMedicare Ground Ambulance Data Collection System (GADCS) \\nAs discussed in section III.N.2.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [of this proposed rule, section 4103 of the CAA amended \\nsection 1834(l)(12)(A) and (l)(13) of the Act to extend the payment add-ons set forth in those \\nsubsections through December 31, 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [The ambulance extender provisions are enacted through \\nlegislation that is self-implementing.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [A plain reading of the statute requires only a ministerial \\napplication of the mandated rate increase and does not require any substantive exercise of \\ndiscretion on the part of the Secretary.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [As a result, there are no policy proposals associated with \\nthese legislative provisions legislative provisions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [The Congressional Budget Office (CBO)\\u2019s \\nestimated cost of these provisions was $55 million in 2023, $91 million in 2024, and $29 million \\nin 2025 (https://www.cbo.gov/system/files/2023-01/PL117-328_1-12-23.pdf, p. 17).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1266: [We are \\nproposing only to revise the dates in \\u00a7 414.610(c)(1)(ii) and (c)(5)(ii) to conform the regulations \\nto these self-implementing statutory requirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [In addition, as discussed in section III.N.3.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [of this proposed rule, we are proposing the \\nfollowing changes to the Medicare Ground Ambulance Data Collection Instrument: Adding the \\nability to address partial year responses from ground ambulance organizations, introducing a \\nminor edit to improve the reporting consistency of hospital-based ambulance organizations, and \\nfour technical corrections to typos.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [The changes and clarifications aim to reduce burden on \\nrespondents, improve data quality, or both.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [While we believe that these changes and clarifications will be well received by the \\nground ambulance interested parties, we do not believe that these changes would have any \\nsubstantive impact on the cost or time associated with completing the Medicare Ground \\nAmbulance Data Collection Instrument.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [We note that the overall length of the Medicare Ground \\nAmbulance Data Collection Instrument will be the same as previously finalized (84 FR 62888) \\nwith these changes.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Additionally, some of the instructions which we propose to add are intended \\nto improve clarity and may therefore reduce the time the ground ambulance organizations spend \\naddressing the questions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [18.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Hospice CoP Changes\\na.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Permitting MFT and MCH to serve as members of the interdisciplinary group (IDG)\\nUnder the Medicare Program in accordance with Subtitle C, Section 4121 of the CAA \\n2023, we are proposing conforming regulations text changes to permit MFT or MHC to serve as \\nmembers of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [These proposed changes will require hospices to include at least one SW, \\nMFT or MHC to serve as a member of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Hospices will have the flexibility to determine \\nwhich discipline(s) are appropriate to serve on the IDG based on the needs of the patients.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [Modification of the hospice personnel requirements with the addition of MFT and MHC\\nUnder the Medicare Program in accordance with Subtitle C, Section 4121 of the CAA \\n2023, we are proposing conforming regulations text changes to permit MFT or MHC to serve as \\nmembers of the IDG.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1267: [With the proposed addition of MFT and MHC into the hospice CoPs, it is \\nimportant to include these new disciplines into the personnel qualifications at \\u00a7 418.114.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [However, in section III.C.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [of this rule, we are proposing to add both MHC and MFT to the \\nprovider requirements under 42 CFR subpart B Medical and Other Health Services at \\u00a7\\u00a7 410.53 \\nand 410.54.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Therefore, to avoid duplication and confusion between the CoP and the provider \\nrequirements under the Medical and Other Health Services provision, we are proposing to add \\nboth MHC and MFT to the requirements at \\u00a7 418.114(c)(3) and (4) and referencing the new \\nrequirement at \\u00a7\\u00a7 410.53 and 410.54 respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We do not expect any increase in burden for \\nthis modification.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [In addition, we do not expect the changes for this provision to cause any \\nappreciable amount of expense or anticipated saving and we do not believe this standard would \\nimpose any additional regulatory burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [19.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [RFI:  Histopathology, Cytology, and Clinical Cytogenetics Regulations under the Clinical \\nLaboratory Improvement Amendments (CLIA) of 1988\\nWe are publishing this RFI in this proposed rule to seek comments from interested \\nparties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [There is no impact for this RFI.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [20.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Basic Health Program Provisions\\nIn this proposed rule, we are proposing to update the requirements for a BHP Blueprint \\nrevision.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We also propose to allow a State with a BHP to suspend its BHP, if necessary, and \\nprovide requirements related to a BHP suspension.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We also propose updates to the annual report \\ncontent and timing, if a BHP is suspended.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [This proposal includes requirements for accessible \\nnotices.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [Finally, we propose changes related to an individual\\u2019s appeals rights.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We do not \\nanticipate that these provisions would impose any additional regulatory burden.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [21.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [A Social Determinants of Health Risk Assessment in the Annual Wellness Visit\\nWe propose in section III.S.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [to exercise our authority in section 1861(hhh)(2)(I) of the \\nAct to add elements to the Annual Wellness Visit (AWV) by adding a new Social Determinants \\nof Health (SDOH) Risk Assessment as an optional, additional element with an additional \\npayment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1268: [We propose that the SDOH Risk Assessment be separately payable with no beneficiary \\ncost sharing when furnished as part of the same visit with the same date of service as the AWV.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Our proposal builds upon our separate proposal described earlier to establish a stand-alone G \\ncode (GXXX5) for SDOH Risk Assessment furnished in conjunction with an Evaluation and \\nManagement (E/M) visit.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [See section II.E.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [of this proposed rule for additional information on \\ncoding, pricing, and additional conditions of payment for the proposed new SDOH Risk \\nAssessment service.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We anticipate our proposal to add a SDOH Risk Assessment as an optional, \\nadditional element with additional payment within the AWV to result in some additional service \\nutilization, but we also anticipate the additional utilization may be balanced, in part or in whole, \\nby potential long term benefits and savings resulting from a more effective AWV and increased \\nprevention and early detection (allowing for less invasive and more effective treatment).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We do \\nnot anticipate that the addition of an optional SDOH Risk Assessment to the AWV would result \\nin a significant impact to the Medicare Program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [22.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Updates to the Quality Payment Program \\nIn this section, we estimate the overall and incremental impacts of the Quality Payment \\nProgram policies proposed in this rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We estimate participation, final scores, and payment \\nadjustment for clinicians participating through traditional MIPS, MVPs, and the Advanced \\nAPMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [We also present the incremental impacts to the number of expected Qualified \\nParticipants (QPs) and associated APM Incentive Payments that result from our policies relative \\nto a baseline model that reflects the status quo in the absence of any modifications to the \\npreviously finalized policies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Overall MIPS Modeling Approach and Data Assessment \\n(1) MIPS Modeling Approach\\nFor this proposed rule we create two MIPS RIA models: a baseline and proposed policy \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Our baseline model includes previously finalized policies that would be in effect for the \\nCY 2024 performance period/2026 MIPS payment year if none of our proposed policies are \\nfinalized.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1269: [Examples of previously finalized policies are an updated methodology for calculating \\nthe complex patient bonus, and an increase in the data completeness threshold for quality]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [measures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The proposed policies model builds off the baseline model and incorporates the MIPS \\npolicy proposals for the CY 2024 performance period/2026 MIPS payment year included in this \\nproposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The aim of the baseline and proposed policy models is to estimate the incremental \\nimpacts of the policies in this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [We used a similar approach in the CY 2023 PFS \\nfinal rule (87 FR 70199 through 70200).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [As discussed in the CY 2023 PFS final rule, our modeling approach utilizes the same \\nscoring engine that is used to determine MIPS payment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [This modeling approach \\nenables our model to align as much as possible with actual MIPS scoring and minimizes \\ndifferences between our projections and policy implementation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [There are still some limitations \\nto our model due to data limitations and assumptions.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [These limitations are discussed later in this \\nRIA.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [The aim of the baseline model is to reflect participation, final scores, and payment \\nadjustments for the upcoming performance period and associated MIPS payment year based on \\npreviously finalized policies for the performance period and MIPS and MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [(2)  Data Used to Estimate Future MIPS Performance\\nIn the 2023 PFS final rule (87 FR 70200), we discussed our decision to use the \\nsubmissions data for the CY 2021 performance period to estimate eligibility, final scoring, and \\npayment adjustments supplemented by CY 2019 performance period data to estimate \\nparticipation and payment adjustments for the sake of estimating the size of the budget neutral \\npool.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [To mitigate the potential effect of the PHE on our engagement estimates for the CY 2024 \\nperformance period/2026 MIPS payment year, for MIPS eligible clinicians who submitted data \\nfor the CY 2019 performance period and did not submit data for the CY 2021 performance \\nperiod, we assigned their participation status and final score data from the CY 2023 PFS \\nproposed rule baseline model (87 FR 46408).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [This is because the CY 2023 PFS proposed rule \\nbaseline model (87 FR 46408) is based on submissions data for the CY 2019 performance period \\n(hereafter called \\u201c2019 data supplement\\u201d).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1270: [We indicated that we believed this approach would reflect data that is generally more]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [current while mitigating the impacts of changes in reporting behavior during the PHE on our \\nparticipation estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Although we believe that this is the best data source to accurately model \\nthe impact of our proposed policies, the use of data from the CY 2021 performance period \\nsupplemented by data from the CY 2019 performance period, has the same limitations as \\ndiscussed in the 2023 PFS final rule (87 FR 70200).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [We took a similar approach this year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [The submissions for the CY 2022 performance period were not available in time to assess \\nwhether the data for that performance period can be used to predict future performance.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [For the \\nfinal rule, we will evaluate whether it is appropriate to use the CY 2022 performance period data \\nand whether adjustments to this RIA model based on factors such as clinician behavior or \\nperformance category data availability would need to be made if CY 2022 performance category \\nsubmissions data were used instead.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [b.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Estimated APM Incentive Payments to QPs in Advanced APMs and Other Payer Advanced \\nAPMs\\nFor payment years from 2019 through 2025, through the Medicare Option, eligible \\nclinicians who have a sufficient percentage of their Medicare Part B payments for covered \\nprofessional services or Medicare patients through Advanced APMs will be QPs for the \\napplicable QP Performance Period for a year and the corresponding payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [In payment \\nyears 2019 through 2024 these QPs will receive a lump-sum APM Incentive Payment equal to 5 \\npercent of their estimated aggregate paid amounts for covered professional services furnished \\nduring the calendar year immediately preceding the payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [In payment year 2025, QPs \\nwill receive a lump-sum APM Incentive Payment equal to 3.5 percent payment of their estimated \\naggregate paid amounts for covered professional services furnished during CY 2024.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [Beginning \\nin payment year 2021, in addition to the Medicare Option, eligible clinicians may become QPs \\nthrough the All-Payer Combination Option.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1271: [The All-Payer Combination Option allows eligible \\nclinicians to become QPs by meeting the QP payment amount or patient count threshold through \\na pair of calculations that assess a combination of both Medicare Part B covered professional]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [services furnished or patients through Advanced APMs and services furnished or patients \\nthrough Other Payer Advanced APMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Eligible clinicians who become QPs for a year are not \\nsubject to MIPS reporting requirements and payment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Eligible clinicians who do not \\nbecome QPs but meet a lower threshold to become Partial QPs for the year may elect to report to \\nMIPS and, if they elect to report, will then be scored under MIPS and receive a MIPS payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Partial QPs are not eligible to receive the APM Incentive Payment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [If an eligible clinician does not attain either QP or Partial QP status, and is not excluded \\nfrom MIPS on another basis, the eligible clinician will be subject to the MIPS reporting \\nrequirements and will receive the corresponding MIPS payment adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Beginning in payment year 2026, the update to the PFS CF for services that are furnished \\nby clinicians who achieve QP status for a year is 0.75 percent, while the update to the PFS CF \\nfor services that are furnished by clinicians who do not achieve QP status for a year is 0.25 \\npercent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Thus, eligible clinicians who are QPs for the year will receive differentially higher PFS \\npayment rates than those who are not QPs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [We incorporated this change into our baseline eligibility determination.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [In addition, the \\nthresholds to achieve QP status beginning in the 2024 QP Performance Period will increase to 75 \\npercent for the payment amount method, and 50 percent for the patient count method.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [Overall, \\nwe estimate that for the 2024 QP Performance Period between 187,000 and 241,000 eligible \\nclinicians will become QPs, and therefore be excluded from MIPS reporting requirements and \\npayment adjustments.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [In section VII.E.23.b of this proposed rule, we projected the number of eligible clinicians \\nthat will be QPs, and thus excluded from MIPS, using several sources of information.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [First, the \\nprojections are anchored in the most recently available public information on Advanced APMs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [The projections reflect Advanced APMs that will be operating during the 2024 QP Performance \\nPeriod, as well as some Advanced APMs anticipated to be operational during the 2024 QP \\nPerformance Period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1272: [The projections also reflect an estimated number of eligible clinicians that]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [will attain QP status through the All-Payer Combination Option.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [The following APMs are \\nexpected to be Advanced APMs for the 2024 QP Performance Period:  \\n\\u25cf  Bundled Payments for Care Improvement Advanced Model; \\n\\u25cf  Comprehensive Care for Joint Replacement Payment Model (CEHRT Track); \\n\\u25cf  ACO REACH Model (formerly Global and Professional Direct Contracting) Model;\\n\\u25cf  Kidney Care Choices Model (Comprehensive Kidney Care Contracting Options, \\nProfessional Option and Global Option);\\n\\u25cf  Maryland Total Cost of Care Model (Care Redesign Program; Maryland Primary Care \\nProgram);\\n\\u25cf  Medicare Shared Savings Program (Level E of the BASIC Track and the ENHANCED \\nTrack);\\n\\u25cf  Primary Care First (PCF) Model; and,\\n\\u25cf  Vermont All-Payer ACO Model (Vermont Medicare ACO Initiative).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [\\u25cf  Making Care Primary (MCP) tracks 2 and 3 \\nWe used the Participation Lists and Affiliated Practitioner Lists, as applicable, (see 42 \\nCFR 414.1425(a) for information on the APM Participant Lists and QP determinations) for the \\n2022 QP performance period third snapshot QP determination date to estimate the number of \\nQPs, total Part B paid amounts for covered professional services, and the aggregate total of APM \\nIncentive Payments for the 2024 QP Performance Period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [We examined the extent to which \\nAdvanced APM participants will meet the QP Thresholds of having at least 75 percent of their \\nPart B covered professional services or at least 50 percent of their Medicare beneficiaries \\nfurnished Part B covered professional services through the APM Entity.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1273: [c. Estimated Number of MIPS Eligible Clinicians for the CY 2024 Performance Period/2026 \\nMIPS Payment Year\\n(1) Clinicians Included in the RIA Baseline and Final Policies Models Prior to Applying the \\nLow-Volume Threshold Exclusion]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [For this proposed rule, we applied the same assumptions as in the CY 2023 PFS final rule \\n(87 FR 70201 through 70202), unless otherwise noted.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In the CY 2023 PFS final rule (87 FR \\n70202), we explained that we modified some of our assumptions to estimate engagement in \\nMIPS to mitigate the effects of potential non-engagement due to the extreme and uncontrollable \\ncircumstances policies related to the PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In the CY 2023 PFS final rule (87 FR 70201), we explained our use of the final \\nreconciled eligibility determination file.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [This file reconciles eligibility from two determination \\nperiods and aligns with the CY 2021 performance period submissions data on which we based \\nthis model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [In this proposed rule, we again used the final reconciled 2021 eligibility \\ndetermination file which aligns with CY 2021 performance period submissions data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [We did not \\npropose any modifications to MIPS eligibility requirements, therefore the same eligibility \\nassumptions apply to both the baseline and proposed policies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [Our analysis found that \\nthere were 1.7 million clinicians who had PFS claims from October 1, 2020 to September 30, \\n2021.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [This initial population of clinicians was used to determine eligibility using the processes \\ndescribed in the following sections.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [(2)  Estimated Number of MIPS Eligible Clinicians after Applying Assumptions for the Low-\\nVolume Threshold Exclusion and Considering the Extreme and Uncontrollable Circumstances \\nPolicies Related to COVID-19 PHE\\nThe low-volume threshold policy may be applied at the individual (TIN/NPI) or group \\n(TIN) levels based on how data are submitted to MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [Generally, if a clinician or group does \\nnot exceed the low-volume threshold criteria then that clinician or group is excluded from \\nparticipation in MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [The low volume threshold uses three criteria: allowed charges, number of \\nMedicare patients who receive covered professional services, and number of services provided.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1274: [A clinician or group that exceeds at least one, but not all three low-volume threshold criteria may \\nbecome MIPS eligible by electing to opt-in and subsequently submitting data to MIPS, thereby \\nbeing measured on performance and receiving a MIPS payment adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We describe below the estimated MIPS eligibility status and the associated PFS allowed \\ncharges of clinicians in the initial population of 1.7 million clinicians for the proposed policies \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We applied the same assumptions as in the CY 2023 PFS final rule (87 FR 70201 through \\n70202) to apply the low-volume threshold and to determine whether clinicians participate in \\nMIPS as a group, virtual group, APM entity, or as individuals.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [In the CY 2023 PFS final rule (87 \\nFR 70202), we explained our use of the CY 2019 performance period data to update eligibility \\nassumptions to account for the effects of the extreme and uncontrollable circumstances (EUC) \\npolicy that was applied due to the PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We noted that the use of CY 2021 performance period \\ndata alone might overstate the number of clinicians with \\u201crequired eligibility\\u201d who do not \\nparticipate in MIPS due to the PHE under the EUC policy and therefore may not have submitted \\ndata.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [If we assumed in this RIA model, which estimates of CY 2024 performance period/CY \\n2026 payment year, participation and non-participation to be similar to the CY 2019 performance \\nperiod, we would likely overstate the number of clinicians receiving a negative payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [Since these clinicians actually would have received a neutral score under the CY \\n2021 performance period EUC reweighting policy but would receive a negative payment \\nadjustment in our simulation.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [As we noted in section VII.E.22 of this RIA, in order to mitigate the potential effect of \\nthe PHE on our engagement estimates for the CY 2024 performance period, for MIPS eligible \\nclinicians who submitted data for the CY 2019 performance period and did not submit data for \\nthe CY 2021 performance period, we followed the same process described in the CY 2023 PFS \\nfinal rule (87 FR 70202) and assigned their participation status and final score data from the CY \\n2023 PFS proposed rule baseline model (87 FR 46408).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [This is because the CY 2023 PFS \\nproposed rule baseline model (87 FR 46408) is based on the 2019 data supplement.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1275: [We believed \\nthese clinicians may participate and perform more similarly to the CY 2019 performance period \\nthan the CY 2021 performance period during the CY 2024 performance period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [We do not have ability to assess the performance of clinicians reflected in our 2019 data \\nsupplement in our model, so we used the same score for this final rule\\u2019s baseline and proposed \\npolicies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [Because we used the same score for the baseline and proposed policies model, \\nwe were not able to assess the incremental impact of policies for this group.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [However, we \\nbelieve making this adjustment is valuable because it helps mitigate the potential effect of \\noverestimating the number of clinicians eligible for, and participating in MIPS, versus non-\\nparticipants, which in turn would affect our estimation of the MIPS redistribution payment and \\nthe size of the budget neutral pool.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [For our RIA model, we established the \\u201crequired eligibility\\u201d category, which means the \\nclinician exceeds the low-volume threshold in all 3 criteria and is subject to a payment \\nadjustment is separated into three buckets this year: (1) \\u201cClinicians who Report\\u201d; (2) \\u201cDid not \\nreport in 2021, but did report in 2019\\u201d; and (3) \\u201cDid not report in either 2021 or 2019.\\u201d  We have \\ndone this so that we can isolate both the effects of our proposed policies, which are modeled \\nusing 2021 data, the effect of the 2019 data supplement, and model the population of clinicians \\nwho did not engage in either year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [The year refers to which population of data we used (that is, \\nthe 2021 population of clinicians or the 2019 supplement).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [a) MIPS Eligibility Estimates\\nTable 117 summarizes our eligibility estimates for the proposed policies model after \\napplying our assumptions discussed previously.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1276: [We estimate approximately 122,183 MIPS eligible clinicians have the required eligibility \\ncriteria and submitted data for at least one performance category in MIPS for the CY 2019 and \\n2021 performance periods, 9,906 MIPS eligible clinicians who did not engage in MIPS based on \\n2021 performance period MIPS data but did engage based on 2019 performance period MIPS \\ndata, and 14,289 MIPS eligible clinicians counted in our model as \\u201cdid not submit in data to \\nMIPS for the CY 2019 or CY 2021 performance period.\\u201d These are clinicians who did not]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [submit data to MIPS for the CY 2019 or CY 2021 performance periods, or did not submit data to \\nMIPS for the CY 2021 performance period and do not have CY 2019 performance period data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We estimate approximately 664,562 MIPS eligible clinicians as having \\u201cgroup \\neligibility\\u201d in Table 117.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [\\u201cGroup eligibility\\u201d means that these clinicians belong to a group that \\nexceeds the low-volume threshold.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [If they were not associated with the group submission, these \\nclinicians will not be eligible for MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [Finally, we estimate about 9,107 clinicians will be eligible for MIPS and participate \\nthrough \\u201copt-in eligibility\\u201d through the \\u201copt-in\\u201d policy.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We updated our opt-in policy to reflect \\nthat a clinician can elect to opt-in into MIPS and will be scored, even if they do not submit data \\nto MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [We estimate a total MIPS eligible clinician population of approximately 1,741,607 with \\n$9 billion PFS allowed charges estimated to be included in the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1277: [TABLE 117:  Description of MIPS Eligibility Status for CY 2023 Performance Period/2025 \\nMIPS Payment Year Using the CY 2023 PFS Final Rule Assumptions**\\nCY 2024 PFS Proposed Rule \\nestimates \\nEligibility StatusPredicted Participation \\nStatus in MIPS Among \\nClinicians *Number of \\nCliniciansPFS allowed \\ncharges ($ in \\nmil)***\\nRequired eligibility\\n(always subject to a MIPS payment adjustment because \\nindividual clinicians exceed the low-volume threshold in all 3 \\ncriteria)Reported to MIPS *122,183 $34,134\\nDid not Report in 2021 \\nbut Reported in 20199,906 $2,963\\nDid not Report in 2021 \\nand did not Report 2019 \\n(or did not have data in \\n2019)*14,289$4,261\\nGroup eligibility\\n(only subject to payment adjustment because clinicians' groups \\nexceed low-volume threshold in all 3 criteria)Had a group submission664,562 $17,533\\nOpt-In eligibility assumptions \\n (only subject to a positive, neutral, or negative adjustment \\nbecause the individual or group exceeds the low-volume \\nthreshold in at least 1 criterion but not all 3, and they elect to \\nopt-in to MIPS)Opted-in To MIPS 9,107 $473\\nTotal Number of MIPS Eligible Clinicians and the associated PFS allowed charges 820,047 $59,363]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [CY 2024 PFS Proposed Rule \\nestimates \\nEligibility StatusPredicted Participation \\nStatus in MIPS Among \\nClinicians *Number of \\nCliniciansPFS allowed \\ncharges ($ in \\nmil)***\\nPotentially MIPS Eligible \\n(not subject to payment adjustment for non-participation; could \\nbe eligible for one of two reasons: (1) meet group eligibility; or \\n(2) opt-in eligibility criteria)Opt-in Eligible; Do not \\nopt-in185,342 $6,211\\nGroup Eligible; Did not \\nReport294,729 $6,701\\nBelow the low-volume threshold \\n(never subject to payment adjustment; both individual and group \\nis below all 3 low-volume threshold criteria) Not applicable 123,231 $834\\nExcluded for other reasons \\n(Non-eligible clinician type, newly enrolled) Not applicable 75,836 $4,442\\nQualified Participant (QP)***Not applicable 242,422 $13,502\\nTotal Number of Clinicians Not MIPS Eligible 921,560 $31,690\\nTotal Number of Clinicians (MIPS and Not MIPS Eligible) 1,741,607 $91,053\\n* Participation excludes facility-based clinicians who do not have scores in the 2021 MIPS submission data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [** Allowed charges estimated in 2021 dollars.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [Low-volume threshold is calculated using allowed charges.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [MIPS payment adjustments \\nare applied to the paid amount.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [*** Our QP estimate differs from that reported in section VII.E.23.b) of this proposed rule because we 2021 data and a different \\nsimulation methodology \\nFurthermore, we estimate there will be approximately 185,342 clinicians who are not \\nMIPS eligible, but could be if the clinician or their group elects to opt-in.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We describe this group \\nas \\u201cPotentially MIPS eligible\\u201d in Table 117.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [These potentially MIPS clinicians would all be \\nincluded as MIPS eligible in the unlikely scenario in which all group practices elect to submit \\ndata as a group, or clinicians in a group that does not submit are eligible to opt-into MIPS \\nindividually and choose to do so.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We do not expect that every potentially MIPS eligible clinician \\nwill elect to submit data to MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [We estimate another 294,729 clinicians would be eligible for \\nparticipation as a group but do not report data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [These assumptions are important because they \\nquantify the maximum number of MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [When this unlikely scenario is \\nmodeled, we estimate the MIPS eligible clinician population could be as high as 1,300,118 \\nclinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1278: [Finally, we estimate approximately 123,231 clinicians will not be MIPS eligible]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [because they and their group are below the low-volume threshold on all three criteria and another \\napproximately 318,258 will not be MIPS eligible for other reasons, including 242,422 clinicians \\nwith QP status.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [Eligibility among many clinicians is contingent on submission to MIPS as a group or \\nelection to opt-in, therefore we will not know the number of MIPS eligible clinicians who submit \\nuntil the submission period for the CY 2023 performance period is closed.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [For the remaining \\nanalysis, we use the estimated population of 820,047 MIPS eligible clinicians described above.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [c. Estimated Impacts on Payments to MIPS Eligible Clinicians for the CY 2023 Performance \\nPeriod/2025 MIPS Payment Year\\n(1) Summary of Approach for MIPS Value Pathways (MVPs) and Traditional MIPS \\nIn this proposed rule, we present several proposals which impact the measures and \\nactivities, the performance category scores, final score calculation, and the MIPS payment \\nadjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [We discuss these changes in more detail in section VII.E.23.d.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [(3) of this RIA as we \\ndescribe our methodology to estimate MIPS payments for the CY 2024 performance period/2026 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [We then present the impact of the overall proposed policies in the CY 2024 \\nperformance period/2026 MIPS payment year and then compare select metrics to the baseline \\nmodel, which only incorporates previously finalized policies for the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [By comparing the baseline model to the proposed policies \\nmodel, we are able to estimate the incremental impact of the proposed policies for the CY 2024 \\nperformance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [The payment impact for a MIPS eligible clinician is based on the clinician\\u2019s final score, \\nwhich is calculated based on the clinician\\u2019s performance on measures and activities under the \\nfour MIPS performance categories: quality, cost, improvement activities, and Promoting \\nInteroperability.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [MIPS eligible clinicians can participate as an individual, group, virtual group, \\nAPM Entity, clinicians participating in MIPS through the APM Performance Pathway (APP) or \\nthrough an MVP in the four MIPS performance categories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1279: [MIPS APM participants can]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [participate in the APP as an individual, group, virtual group, APM Entity and are only scored on \\nthree MIPS performance categories:  quality, improvement activities, and Promoting \\nInteroperability.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [The average percentage change in total revenues that clinicians earn is less than the \\nimpact displayed here because MIPS eligible clinicians generally furnish services to both \\nMedicare and non-Medicare patients; MIPS does not impact payment from non-Medicare \\npatients.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [In addition, MIPS eligible clinicians may receive Medicare revenues for services under \\nother Medicare payment systems, such as the Medicare Federally Qualified Health Center \\nProspective Payment System, that will not be affected by MIPS payment adjustment factors.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [(2) Methodology to Assess Impact for MIPS Value Pathways \\nIn the CY 2022 PFS final rule (86 FR 65394 through 65397), we finalized policies at \\u00a7 \\n414.1365 for implementing MVPs beginning in the CY 2023 performance period/2025 MIPS \\npayment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [In this RIA, we take a similar approach to modeling MVP participation and \\nscoring as described in the CY 2022 PFS final rule (87 FR 70204), incorporating changes to our \\nproposed policies model as described below.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [(a) MVP Participant Assumptions\\nAt \\u00a7 414.1365(b), we require MVP Participants (which can be a group, individual, \\nsubgroup, or APM entity) to register prior to submitting an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [As we do not yet have \\ninformation on who will register, we assume for purposes of this model, that MVP Participants \\nare MIPS eligible individual clinicians or groups that currently submit at least four quality \\nmeasures that are in an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [For these MVP Participants, we calculate both an MVP and a \\ntraditional MIPS score and take the highest score consistent with the existing scoring hierarchy \\nwhich was finalized in the CY 2023 PFS final rule (86 FR 65537).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1280: [For the baseline model, we \\nused the quality measures finalized for MVPs in the CY 2023 PFS final rule Appendix 3: MVP \\nInventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [In section IV.A.4.b and Appendix 3 of this proposed rule, we propose modifications to \\nthe 12 existing MVPs finalized in the CY 2022 PFS final rule (86 FR 65998 through 66031) and \\nCY 2023 PFS final rule (87 FR 70037) and the consolidation of the previously finalized \\nPromoting Wellness and Optimizing Chronic Disease Management MVPs into a single \\nconsolidated primary care MVP titled Value in Primary Care.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [In section IV.A.4.a of this proposed rule, we are proposing the inclusion of 5 new MVPs\\n\\u25cf Focusing on Women\\u2019s Health;\\n\\u25cf  Prevention and Treatment of Infectious Disease Including Hepatitis C and HIV; \\n\\u25cf  Quality Care in Mental Health and Substance Use Disorder; \\n\\u25cf  Quality Care for Ear, Nose, and Throat (ENT); and \\n\\u25cf  Rehabilitative Support for Musculoskeletal Care\\nFor the proposed policies model, we incorporate the quality measure revisions for the \\nexisting MVPs and use the quality measures to model scores for the new MVPs in Appendix 3 of \\nthis proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [Our MVP Participant assumptions have limitations: we are not incorporating subgroups \\ndue to a lack of data, not all of the assumed participants may elect to register for an MVP, and \\nwe may have additional clinicians or groups register for an MVP.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [However, we believe this is a \\nreasonable approach to simulate the impact of MVPs and we sought comment on this \\nassumption, but did not receive any feedback.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [(b) MVP Scoring Methods and Assumptions\\nWe simulate an MVP score using the same data sources as we did for traditional MIPS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We scored according to \\u00a7 414.1365(d) and \\u00a7 414.1365(e) using the MVP reporting requirements \\nlisted in \\u00a7 414.1365(c) with one exception.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We did not restrict the improvement activities to the \\nactivities listed in the MVP inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [We believed this would lower our estimated MVP score \\nas clinicians and groups were not required to select from a limited inventory in the CY 2021 \\nperformance period (upon which our model is based).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1281: [Therefore, we scored any improvement]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [activities the MVP Participants submitted in 2021 as if those improvement activities are in the \\nMVP inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(3) Methodology to Assess Impact for Traditional MIPS\\nTo estimate the impact of the proposed policies on MIPS eligible clinicians, we generally \\nused the CY 2021 performance period\\u2019s submissions data, including data submitted or calculated \\nfor the quality, cost, improvement activities, and Promoting Interoperability performance \\ncategories.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [As discussed in section VII.E.23.a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(2) of this proposed rule, we supplemented with \\n2019 data supplement.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [We supplemented this information with the most recent data available for CAHPS for \\nMIPS and CAHPS for ACOs, administrative claims data for the new quality performance \\ncategory measures, and other data sets.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [We calculated a hypothetical final score for the CY 2024 \\nperformance period/2026 MIPS payment year for the baseline and proposed policies scoring \\nmodels for each MIPS eligible clinician using score estimates for quality, cost, Promoting \\nInteroperability, and improvement activities performance categories, where each are described in \\ndetail in the following sections.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [(a) Methodology to Estimate the Quality Performance Category Score\\nWe estimated the quality performance category score using a methodology like the one \\ndescribed in the CY 2023 PFS final rule (87 FR 70205) for the baseline and proposed policies \\nRIA models for the CY 2024 performance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1282: [To create the baseline policies RIA model, which does not reflect the policies proposed in \\nthis rule, we made the following modifications to the CY 2023 PFS final rule final policies \\nmodel to reflect the previously finalized quality performance category policies for the CY 2024 \\nperformance period/2026 MIPS payment year:\\n\\u25cf  As discussed in the CY 2023 PFS final rule (87 FR 70049), we increased the data \\ncompleteness criteria threshold to at least 75 percent for CY 2024 and CY 2025 performance \\nperiods/2026 and 2027 MIPS payment years.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [For the proposed policies model, we did not implement any changes to the quality \\nperformance category relative to the baseline model because we use 2021 data and cannot \\nsimulate the addition of new measures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(b) Methodology to Estimate the Cost Performance Category Score\\nWe estimated the cost performance category score using a methodology similar to the \\nmethodology described in the CY 2023 PFS final rule (87 FR 70205) for the baseline and the \\nproposed policies RIA models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [For this proposed rule, the baseline policies RIA model included \\nthe same method used for the final policies RIA model in the CY 2023 PFS final rule (87 FR \\n70205).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [Due to technical limitations, we did not model cost improvement scoring in the baseline \\npolicies RIA model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [The proposed policies RIA model incorporated and implemented the following changes: \\nIn section IV.A.4.f.(2).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(a) of this proposed rule, we proposed 5 new episode-based cost \\nmeasures.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [\\u25cf  In section IV.A.4.g.(1).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(c) of this proposed rule, we proposed to: \\n++ Determine cost improvement scoring at the category level; \\n++  Modify how to calculate cost improvement scoring and remove statistical \\nsignificance requirement; and \\n++  Set the maximum improvement scoring to 1 percentage point, beginning in CY 2023 \\nperformance period/2025 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [(c) Methodology to Estimate the Facility-Based Measurement Scoring\\nA limitation of using data from the CY 2021 performance period is that we are not able to \\nestimate facility-based scores because there are no Hospital Value-Based Purchasing total \\nperformance scores calculated for the performance period due the COVID-19 PHE.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1283: [However, \\nfor clinicians who did not participate in MIPS during the CY 2021 performance period, we did \\nuse the 2019 data supplement to identify final scores based on the CY 2019 performance period \\nsubmission and these scores include facility-based scores.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(d) Methodology to Estimate the Promoting Interoperability Performance Category Score\\nWe estimated the baseline Promoting Interoperability performance category score by \\nusing the same methodology that we used in the CY 2023 PFS final rule (87 FR 70206) final \\npolicies.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [We incorporated the final policies model from that rule into our baseline model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [In \\nsection IV.A.4.F.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(4)(f) of this proposed rule, we proposed to continue reweighting clinical social \\nworkers.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [This is incorporated into our proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [We did not incorporate changes \\nto the performance period or measure level changes because we are not able to model this using \\ndata for the CY 2021 performance period.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(e) Methodology to Estimate the Improvement Activities Performance Category Score\\nFor the baseline and proposed policies model we used the same method to estimate the \\nimprovement activities performance category score as described in the CY 2023 PFS final rule \\n(87 FR 70206).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(f) Methodology to Estimate the Complex Patient Bonus Points\\nFor the baseline and proposed policies RIA model, we used the previously established \\nmethod to calculate the complex patient bonus as described in the CY 2022 PFS final rule (86 \\nFR 64996).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [(g) Methodology to Estimate the Final Score\\nWe did not propose any changes for how we calculated the MIPS final score.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [Our \\nbaseline and proposed policies RIA models assigned a final score for each TIN/NPI by \\nmultiplying each estimated performance category score by the corresponding performance \\ncategory weight, adding the products together, multiplying the sum by 100 points, adding the \\ncomplex patient bonus, and capping at 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For the baseline policies RIA model, we applied the performance category weights and \\nredistribution weights finalized in the CY 2022 PFS final rule (86 FR 65519 through 65524).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For both models, after adding any applicable bonus for complex patients, we reset any \\nfinal scores that exceeded 100 points to equal 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1284: [For MIPS eligible clinicians who were]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [assigned a weight of zero percent for any performance category, we redistributed the weights \\naccording to \\u00a7 414.1380(c).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(h) Methodology to Estimate the MIPS Payment Adjustment\\nFor the baseline and proposed policies RIA models, we applied the hierarchy as finalized \\nin the CY 2022 PFS final rule (86 FR 65536 through 65537) to determine which final score \\nshould be used for the payment adjustment for each MIPS eligible clinician when more than one \\nfinal score is available.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [We then calculated the parameters of an exchange function in accordance \\nwith the statutory requirements related to the linear sliding scale, budget neutrality, and \\nminimum and maximum adjustment percentages.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For the baseline model, we applied the performance threshold of 75 points finalized in \\nthe CY 2023 PFS final rule (87 FR 70097).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In section IV.A.4.h.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(2) of this proposed rule, we are \\nproposing a performance threshold of 82 points for the CY 2024 performance period/2026 MIPS \\npayment year, which we incorporated into our proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For both the baseline \\nand proposed policies models, we used these resulting parameters to estimate the positive or \\nnegative MIPS payment adjustment based on the estimated final score and the allowed charges \\nfor covered professional services furnished by the MIPS eligible clinician.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [(4) Impact of Payments \\nWe noticed minimal changes to the mean and median final score between our baseline \\nand proposed policies models.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In our baseline model, the mean and median final scores are 73.26 \\nand 79.99 points, respectively.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [In the proposed policies model, the mean final score is 73.52 and \\nthe median final score is 80.53.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [Many clinicians have scores clustered near the proposed \\nperformance threshold of 82 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [For instance, 51% of clinicians have a final score between \\n80 and 100 points and 63.28% of clinicians have final score between 75 and 100 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1285: [Because \\nso many clinicians have final scores near our proposed performance threshold, a small change in \\nactual final scores relative to our model would significantly impact the number of clinicians with \\na positive, neutral, or negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Our proposed policies are expected to increase the number of clinicians receiving a \\nnegative adjustment from 36.75 percent of eligible clinicians to 54.31 percent of eligible \\nclinicians, but decrease the average negative adjustment from -2.89 percent to -2.40 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [This \\nis because the increased performance threshold will cause many clinicians who previously scored \\nslightly above the performance threshold to now score slightly below the performance threshold, \\nshifting their expected payment from a small positive adjustment to a small negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Among MIPS eligible clinicians who reported data, 35.38 percent receive a negative \\nadjustment in our baseline model compared to 52.24 percent in the proposed policies model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Because many clinicians\\u2019 scores are close to the performance threshold, the payment adjustments \\nfor these clinicians are fairly small and many negative adjustments are much lower in magnitude \\nthan the statutory maximum negative adjustment of 9 percent.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our proposed policies model, \\nwe project the maximum negative payment adjustment of negative 9 percent for clinicians with a \\nscore of 20 points or below compared to a score of 18 in our baseline model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our baseline model, 2.13 percent of MIPS eligible clinicians and 1.41 percent of \\nclinicians who report clinicians receive the max negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our proposed rule \\nmodel, 1.99 percent of MIPS eligible clinicians and 1.19 percent of clinicians who report data \\nreceive the max negative adjustment.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [This is because, while the range of scores subject to the \\nmaximum negative adjustment increases slightly (from 18 to 20 points), slightly fewer clinicians \\nin our proposed policies model have a final score below 20 points compared to the baseline \\nmodel.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [The increase in the number of clinicians receiving a negative score will contribute to an \\nincrease in the size of the budgetary dollars available, as a result of the budget neutral nature of \\nthe program.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In the baseline model, we anticipate redistributing $7.4 million and, in the proposed \\npolicies model we anticipate, redistributing $8.9 million as a result of budget neutrality.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [Because of this increase in the size of the budget neutral pool, the size of our positive \\npayment adjustments increases.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1286: [In our baseline model, the average positive payment adjustment]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [is 1.99 percent among MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [In the CY 2024 performance period/2026 MIPS \\npayment year proposed policies model, the average positive payment adjustment is 3.35 percent \\namong MIPS eligible clinicians.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [The maximum positive payment adjustment increased from 4.60 \\npercent in the baseline model to 8.82 percent in the proposed rule model.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [We want to highlight that we are primarily using submissions data for the CY 2021 \\nperformance period to simulate a final score for the CY 2024 performance period/2026 MIPS \\npayment year, and it is likely that there will be changes that we cannot account for at this time.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [It \\nshould also be noted that the estimated number of clinicians who do not submit data to MIPS \\nmay be an overestimate of non-engagement in MIPS for the CY 2023 performance period/2025 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [This is because the PHE may have resulted in fewer clinicians submitting \\ndata to MIPS or more clinicians electing to apply for the extreme and uncontrollable \\ncircumstances policies due to the PHE for the CY 2019 and CY 2021 performance periods.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [Therefore, engagement levels in MIPS for the CY 2024 performance period/2026 MIPS payment \\nyear may differ from these reported estimates.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [We also note this participation data is generally \\nbased off participation for the CY 2021 performance period/2023 MIPS payment year, which is \\nassociated with a performance threshold of 60 points.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1287: [TABLE 118: Estimated Proportion of Eligible Clinicians with a Positive or Neutral and a \\nNegative Payment Adjustment CY 2024 Performance Period/2026 MIPS Payment year by \\nPractice Size\\nPractice Size*Percent Eligible Clinicians with \\nPositive or Neutral Payment \\nAdjustmentPercent Eligible Clinicians with Negative \\nPayment Adjustment\\nBaseline\\n1) Solo 46.94% 53.05%\\n2) 2-15 53.76% 46.23%\\n3) 16-99 54.55% 45.44%\\n4) 100+ 68.68% 31.31%\\nOverall 63.24% 36.75%\\nProposed Policies Model\\n1) Solo 35.39% 64.60%\\n2) 2-15 39.81% 60.18%\\n3) 16-99 37.44% 62.55%\\n4) 100+ 50.15% 49.84%\\nOverall 45.68% 54.31%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1288: [TABLE 119: Average and Maximum Positive Adjustments for Eligible Clinicians in the CY \\n2024 Performance Period /2026 MIPS Payment Year By Practice Size \\nPractice \\nSize Number of \\nMIPS \\nEligible \\nClinicians Average \\nPositive \\nAdjustmentMaximum Positive Payment \\nAdjustment\\nBaseline\\nSolo (1) 7,059 2.49% 4.60%\\nSmall \\n(2-15)50,559 2.40% 4.60%\\nMedium \\n(16-99)104,742 2.01% 4.60%\\nLarge \\n(>99)353,970 1.92% 4.60%\\nOverall 516,330 1.99% 4.60%\\nCY 2024 PFS Proposed Rule\\nSolo (1) 5,322 4.62% 8.82%\\nSmall \\n(2-15)37,503 4.10% 8.82%\\nMedium \\n(16-99)72,935 3.38% 8.82%\\nLarge \\n(>99)258,849 3.21% 8.82%\\nOverall 374,609 3.35% 8.82%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1289: [TABLE 120: Average and Maximum Negative Adjustments for Eligible Clinicians in the \\nCY 2024 Performance Period /2026 MIPS Payment Year By Practice Size\\nPractice Size  Number of MIPS \\nEligible Clinicians Average \\nNegative \\nAdjustmentMaximum Negative \\nPayment \\nAdjustment\\nBaseline\\nSolo (1) 7,977 -4.32% -9.00%\\nSmall (2-15) 43,476 -4.17% -9.00%\\nMedium (16-99) 87,250 -2.95% -9.00%\\nLarge (>99) 161,379 -2.44% -9.00%\\nOverall 300,082 -2.89%\\nCY 2024 PFS Proposed Rule\\nSolo (1) 9,714 -3.93% -9.00%\\nSmall (2-15) 56,683 -3.59% -9.00%\\nMedium (16-99) 121,819 -2.54% -9.00%\\nLarge (>99) 257,222 -2.01% -9.00%\\nOverall 445,438 -2.40% -9.00%]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [FIGURE 4: Distribution of Final Scores in the Baseline and Proposed Policies Model\\ne. Additional Impacts from Outside Payment Adjustments\\n(1) Burden Overall\\nIn addition to policies affecting the payment adjustments, we are proposing several \\npolicies that have an impact on burden in the CY 2024 performance period/2026 MIPS payment \\nyear.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [In section V.B.11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [of this proposed rule, we outline estimates of the costs of data collection \\nthat includes both the effect of proposed policy updates and adjustments due to the use of \\nupdated data sources.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [For each proposed provision included in this proposed rule which impacts \\nour estimate of collection burden, the incremental burden for each is summarized in Table 121.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1290: [We also provide proposed additional burden discussions that we are not able to quantify.020,00040,00060,00080,000100,000120,000140,000160,000\\n0-4.99 5-9.9910-14.99 15-19.99 20-24.99 25-29.99 30-34.99 35-39.99 40-44.99 45-49.99 50-54.99 55-59.99 60-64.99 65-69.99 70-74.99 75-79.99 80-84.99 85-89.99 90-94.9995-100\\nBaseline NPRMDistribution of Final Scores in Baseline and Number of MIPS Eligible Clinicians\\nFinal Score Range]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [TABLE 121:  Incremental Burden from Associated Proposed Policies\\nBurden Description and associated finalized provisions Burden Hours Burden Dollars\\nTotal burden associated with the provision to continue the \\npolicies and ICRs set forth in the CY 2023 PFS final rule into \\nthe CY 2024 performance period/2026 MIPS payment year (as \\ndiscussed in section V.B11.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [630,570 $71,317,983\\nBurden change for MVP registration ICR due to the provision of \\nadditional MVPs (as discussed in section V.B.11e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(7)(a) of this \\nproposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*+321 +$33,192\\nBurden change for Quality Data Submission by Clinicians: \\nMedicare Part B Claims-Based Collection Type ICR for \\ncapturing reduced number of quality submissions due to the \\nprovision of additional MVPs (as discussed in section \\nV.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(4) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-4,743 -$530,492\\nBurden change for Quality Data Submission by Clinicians: \\nCQM/QCDR Collection Type ICR for capturing reduced \\nnumber of quality submissions due to the provision of additional \\nMVPs (as discussed in section V.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(5) of this proposed \\nrule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-3,697 -$423,093\\nBurden change for Quality Data Submission by Clinicians: \\neCQM Collection Type ICR for capturing reduced number of \\nquality submissions due to the provision of additional MVPs (as \\ndiscussed in section V.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(6) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*-4,344 -$503,665\\nBurden change for MVP Quality Submission ICR submissions \\ndue to the provision of additional MVPs (as discussed in section \\nV.B.11.e.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(7)(a)(iii) of this proposed rule).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [*+8,461 +$964,505\\nTotal change in burden due to policy for CY 2024 -4,002 -$459,553\\nTotal burden set forth in the CY 2024 PFS proposed rule 626,568 $70,858,430\\n* The total change in burden due to this provision includes an increase in burden due to an anticipated increase in the number of \\nrespondents that will participate in MVP reporting based on the proposed addition of new MVPs.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [Therefore, there will be a \\ndecrease in burden in the \\u201cQuality Data Submission: MIPS CQM and QCDR collection type,\\u201d \\u201cQuality Data Submission: eCQM \\ncollection type,\\u201d and \\u201cQuality Data Submission: Claims collection type\\u201d ICRS due to respondents who previously submitted \\nMIPS through those collection types submitting data with reduced Quality submission requirements as a MVP participant.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [Total \\nchange in burden also includes the increase in submission burden due to the increase in the number of respondents for \\u201cMVP \\nregistration.\\u201d See section V.B.11 of this proposed rule.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1291: [(2) Additional Impacts to Clinicians\\n(a) Impact on Third Party Intermediaries\\nIn section IV.A.4.k of this rule, we are proposing to: (1) add requirements for third party \\nintermediaries to obtain documentation; (2) add requirements for third party intermediaries to \\nsubmit data in the form and manner specified by CMS; (3) specify the use of a simplified self-\\nnomination process for existing QCDRs and qualified registries; (4) add requirements for \\nQCDRs and qualified registries to provide measure numbers and identifiers for performance \\ncategories; (5) Add a requirement for QCDRs and qualified registries to attest that information \\non the qualified posting is correct; (6) Modify requirements for QCDRs and qualified registries \\nto support MVP reporting; (7) Specify requirements for a transition plan for QCDRs and]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [qualified registries; (8) Specify requirements for data validation execution reports; (9) Add \\nadditional criteria for rejecting QCDR measures; (10) Add a requirement for QCDR measure \\nspecifications to be displayed throughout the performance period and data submission period; \\n(10) eliminate the Health IT vendor category; (11) Add failure to maintain updated contact \\ninformation as criteria for remedial action; (12) Revise corrective action plan requirements; (13) \\nSpecify the process for publicly posting remedial action; and (14) Specify the criteria for audits.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [Due to the technical nature of these proposed changes, we are unable to quantify the burden for \\nthird party intermediaries during the CY 2024 performance period/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We \\nrefer readers to section V.B.11.c of this rule for additional information on proposed changes to \\nthe third party intermediary requirements.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [(b) Compare Tools: Public Reporting \\nIn section IV.A.4.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [of this rule, we are proposing to update our policy for identifying \\nclinicians furnishing telehealth services, such that we remain current with CMS coding changes, \\nwithout proposing and finalizing such coding changes via rulemaking.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [Specifically, instead of \\nonly using place of service (POS) codes 02, 10, or modifier 95 to identify telehealth services \\nfurnished for the telehealth indicator, we would use the most recent codes at the time the data are \\nrefreshed.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing that at the time of such a data refresh we would publish the details \\nof which codes are used for the telehealth indicator through education and outreach, such as via a \\nfact sheet, listserv, or information posted on the Care Compare: Doctors and Clinicians Initiative \\npage, available at https://www.cms.gov/medicare/quality-initiatives-patient-assessment-\\ninstruments/care-compare-dac-initiative.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing to revise the policy to publicly report \\na subset of the Medicare public use file (PUF) on the Provider Data Catalog (PDC) to instead \\nprovide a single downloadable dataset reflecting including the procedure utilization data that \\nwould appear on clinician profile pages.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1292: [We are proposing to modify the existing policy such \\nthat, in addition to the two previously finalized sources (Restructured BETOS categorization \\nsystem and code sources used in MIPS), we may use alternate sources to create clinically]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [meaningful and appropriate procedural categories, particularly when no relevant grouping exists.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [If we develop new procedure categories for publicly reporting utilization data on clinician profile \\npages, we are proposing to engage subject matter experts and interested parties through periodic \\nrequests for feedback using methods outside of rulemaking, such as but not limited to listserv \\nemails, listening sessions, and focus groups, to solicit feedback on bespoke procedure categories \\nplanned for future releases of utilization data, as appropriate and technically feasible.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We are also \\nproposing to publicly report aggregated counts of procedures performed by providers based on \\nMedicare Advantage (MA) encounter data (also known as MA risk adjustment data) in addition \\nto Medicare fee-for-service (FFS) utilization data counts; as part of this proposal, we are \\nproposing to amend 42 CFR \\u00a7 422.310(f) (the regulation that addresses permissible uses and \\nreleases of MA risk adjustment data) to permit use of MA encounter data in developing the data \\nposted on the Care Compare website and release of the MA encounter data as part of the data set \\nthat will be downloadable from the Care Compare website more quickly than the regulation \\nwould currently permit releases of MA encounter data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [While the Compare tool provisions do \\nnot increase the burden of collections, we note that the PRA package may require relevant \\nmodification to reflect the Compare tool\\u2019s new uses and public display.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We refer readers to \\nsection IV.A.I of this rule for additional information on the proposed changes to public reporting \\non Compare tools.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [(c) Data Completeness Criteria for the Quality Measures, Excluding the Medicare CQMs\\nIn section IV.A.5.a.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [(1) of this proposed rule, we are proposing to maintain the data \\ncompleteness criteria threshold at 75 percent for the CY 2025 and 2026 performance \\nperiods/2027 and 2028 MIPS payment years, and increase the data completeness criteria \\nthreshold by 5 percent from 75 percent to 80 percent for the CY 2027 performance period/2029 \\nMIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1293: [We believe that the proposed policy to maintain the threshold for data \\ncompleteness at 75 percent for the CY 2025 and 2026 performance periods/2027 and 2028 MIPS \\npayment years is consistent with the existing data completeness criteria and therefore, would not]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [result in additional burden to the applicable interested parties.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We assume that the proposed \\nincrease in data completeness criteria threshold from 75 to 80 percent for the CY 2027 \\nperformance period/2029 MIPS payment year would not result in substantive burden to the \\napplicable interested parties We believe that the increase in data completeness criteria threshold \\nwould reduce burden for clinicians using EHRs and eCQMs as the collection of eCQM data \\nwithin the EHR can allow eligible clinicians to report on 100 percent of the eligible population \\nwith data in the EHR for a measure.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [Additionally, we recognize that individual MIPS eligible \\nclinicians, groups, virtual groups, subgroups, and APM Entities that continue to utilize other \\nmeans of data collection for MIPS CQMs, including the collection of MIPS CQM data reported \\nby registries and/or QCDRs, would need have the logic code of their EHRs to be updated to \\naccount for the increased data completeness criteria threshold.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We believe that increasing the \\ndata completeness criteria threshold would not pose a substantial burden to MIPS eligible \\nclinicians, groups, virtual groups, subgroups, and APM Entities, unless they are manually \\nextracting and reporting quality data.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We refer readers to section IV.A.4.f.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(1)(d) of this rule for \\nadditional information on proposed changes to the data completeness threshold criteria.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(d) Modifications to the Improvement Activities Inventory\\nAs discussed in section IV.A.4.f.(3).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [(b)(ii) of this proposed rule, we are proposing \\nchanges to the improvement activities Inventory for the CY 2024 performance period/2026 \\nMIPS payment year and future years as follows:  adding five new improvement activities; \\nmodifying one existing improvement activity; and removing three previously adopted \\nimprovement activities.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We refer readers to Appendix 2: Improvement Activities of this \\nproposed rule for further details.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We do not believe these proposed changes to the improvement \\nactivities inventory would significantly impact time or financial burden on interested parties \\nbecause MIPS eligible clinicians are still required to submit the same number of activities and \\nthe per response time for each activity is uniform.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1294: [We do not expect these proposed changes to \\nthe improvement activities inventory to affect our currently approved information collection]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [burden estimates in terms of neither the number of estimated respondents nor the burden per \\nresponse.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We anticipate most clinicians performing improvement activities, to comply with \\nexisting MIPS policies, would continue to perform the same activities under the policies in this \\nproposed rule because previously finalized improvement activities continue to apply for the \\ncurrent and future years unless otherwise modified per rulemaking (82 FR 54175).]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Most of the \\nimprovement activities in the Inventory remain unchanged for the CY 2024 performance \\nperiod/2026 MIPS payment year.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We refer readers to section IV.A.4.f.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [(3)(b) of this rule for \\nadditional information on proposed changes to the improvement activities Inventory.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [(3)  Update to CEHRT Definition for the Medicare Promoting Interoperability Program and the \\nQuality Payment Program\\nIn section III.R of this proposed rule, we propose to update the definitions of CEHRT for \\nthe Medicare Promoting Interoperability Program for eligible hospitals and CAHs and for the \\nMIPS Promoting Interoperability performance category.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Under this proposal, we would revise \\nthe definitions of CEHRT for the Medicare Promoting Interoperability Program at \\u00a7\\u2009495.4, and \\nfor the Quality Payment Program at \\u00a7\\u2009414.1305.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Specifically, we propose to add a reference to \\nthe \\u201cBase EHR Definition\\u201d where the regulatory text refers to the \\u201c2015 Edition Base EHR \\ndefinition,\\u201d remove \\u201c2015 Edition\\u201d where we reference \\u201c2015 Edition health IT certification \\ncriteria,\\u201d and add a cross-reference to health IT certification criteria at \\u00a7 170.315.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [We also \\npropose to specify that technology meeting the CEHRT definitions must meet ONC\\u2019s \\ncertification criteria at \\u00a7 170.315, \\u201cas adopted and updated by ONC.\\u201d  We believe that these \\nrevisions to the CEHRT definitions, if finalized, would ensure that updates to the definition at \\u00a7 \\n170.102 and updates to applicable health IT certification criteria in \\u00a7 170.315 would be \\nincorporated into CEHRT definitions, without requiring additional regulatory action by CMS.]] Topic: 7E_Other Provisions in the Regulation: [from p. 1295: [Finally, we note that while this proposal is consistent with the approach in ONC\\u2019s HTI-1 \\nproposed rule (88 FR 23746 through 23917), we do not believe that ONC must finalize their \\nproposed revisions for us to be able to finalize the changes proposed in this section for our]]\",\n          \"Topic: 3F_OUD OTP Coverage: [from p. 441: [We are proposing to amend language at \\u00a7\\u00a7 410.47(d) and 410.49(e) by specifying that \\nthese sections include supervising practitioner standards, rather than just supervising physician \\nstandards.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [We are also removing the third standard in each section (\\u00a7\\u00a7 410.47(d)(3) and \\n410.49(e)(3)) because specifying that a physician or NPP is licensed to practice medicine in the \\nstate where a PR/CR/ICR program is offered, or any corresponding reference to a NPP being \\nlicensed or authorized to practice, is redundant to the definition for each practitioner type in the \\nAct.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Since the physicians and NPPs that may supervise PR/CR/ICR are defined at \\u00a7\\u00a7 410.47(a) \\nand 410.49(a) by cross-reference to the Act, we believe repeating part of that definition in these \\nsections is unnecessary.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [4.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Summary\\nWe are proposing additions and revisions that are necessary to implement the \\namendments to section 1861(eee) and (fff) of the Act set forth in section 51008 of the BBA of \\n2018, which expand the types of practitioners that may supervise PR, CR and ICR.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [This \\nincludes changes to the regulatory language in the definitions, settings and supervising \\npractitioner standards sections under \\u00a7\\u00a7 410.47 and 410.49.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [We believe these proposed \\namendments to \\u00a7\\u00a7 410.47 and 410.49 would serve to implement the provisions in the BBA of \\n2018 regarding the types of practitioners that may supervise PR, CR and ICR beginning January \\n1, 2024.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [All other provisions of these regulations would remain unchanged.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [F.  Modifications Related to Medicare Coverage for Opioid Use Disorder (OUD) Treatment \\nServices Furnished by Opioid Treatment Programs (OTPs) \\n1.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [Background\\nSection 2005 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery \\nand Treatment (SUPPORT) for Patients and Communities Act (SUPPORT Act) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [L. 115-\\n271, October 24, 2018) established a new Medicare Part B benefit for OUD treatment services \\nfurnished by OTPs during an episode of care beginning on or after January 1, 2020.]] Topic: 3F_OUD OTP Coverage: [from p. 441: [In the CY \\n2020 PFS final rule (84 FR 62630 through 62677 and 84 FR 62919 through 62926), we]] Topic: 3F_OUD OTP Coverage: [from p. 442: [implemented Medicare coverage and provider enrollment requirements and established a \\nmethodology for determining the bundled payments for episodes of care for the treatment of \\nOUD furnished by OTPs.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [We also established in the CY 2020 PFS final rule new codes and \\nfinalized bundled payments for weekly episodes of care that include methadone, oral \\nbuprenorphine, implantable buprenorphine, injectable buprenorphine or naltrexone, and non-\\ndrug episodes of care, as well as add-on codes for intake and periodic assessments, take-home \\ndosages for methadone and oral buprenorphine, and additional counseling.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [In the CY 2021 PFS \\nfinal rule (85 FR 84683 through 84692), we adopted new add-on codes for take home supplies of \\nnasal naloxone and injectable naloxone.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [In the CY 2022 PFS final rule (86 FR 65340 and \\n65341), we established a new add-on code and payment for a higher dose of nasal naloxone.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [We \\nalso revised paragraphs (iii) and (iv) in the definition of \\u201cOpioid disorder treatment service\\u201d at \\n\\u00a7 410.67(b) to allow OTPs to furnish individual and group therapy and substance use counseling \\nusing audio-only telephone calls rather than two-way interactive audio/video communication \\ntechnology after the conclusion of the public health emergency (PHE) for COVID-19 in cases \\nwhere audio/video communication technology is not available to the beneficiary, provided all \\nother applicable requirements are met (86 FR 65342).]] Topic: 3F_OUD OTP Coverage: [from p. 442: [More recently, CMS made further modifications and expansions to covered services for \\nthe treatment of OUD by OTPs in the CY 2023 PFS final rule (87 FR 69768 through 69777).]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Specifically, we revised our methodology for pricing the drug component of the methadone \\nweekly bundle and the add-on code for take-home supplies of methadone by using the payment \\namount for methadone for CY 2021 updated by the PPI for Pharmaceuticals for Human Use \\n(Prescription) to better reflect the changes in methadone costs for OTPs over time.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Additionally, \\nwe finalized a modification to the payment rate for individual therapy in the non-drug component \\nof the bundled payment for an episode of care to base the payment rate on the rate for longer \\ntherapy sessions that better account for the greater severity of needs for patients with an OUD \\nand receiving treatment in the OTP setting.]] Topic: 3F_OUD OTP Coverage: [from p. 442: [Moreover, for the purposes of the geographic]] Topic: 3F_OUD OTP Coverage: [from p. 443: [adjustment, we clarified that services furnished via OTP mobile units will be treated as if the \\nservices were furnished in the physical location of the OTP for purposes of determining \\npayments to OTPs under the Medicare OTP bundled payment codes and/or add-on codes to the \\nextent that the services are medically reasonable and necessary and are furnished in accordance \\nwith Substance Abuse and Mental Health Services Administration (SAMHSA) and Drug \\nEnforcement Administration (DEA) guidance.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [We believe that this policy enables OTPs to \\nbetter serve Medicare beneficiaries living in underserved areas by providing access to many of \\nthe same OUD treatment services offered at the brick and mortar location of the OTP.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [We are \\ncontinuing to monitor utilization of OUD treatment services furnished by OTPs to ensure that \\nMedicare beneficiaries have appropriate access to care.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [For CY 2024, we are proposing several \\nmodifications to the policies governing Medicare coverage and payment for OUD treatment \\nservices furnished by OTPs.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [2.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [Additional Flexibilities for Periodic Assessments furnished via Audio-only \\nTelecommunications\\nWe have finalized several flexibilities for OTPs regarding the use of telecommunications, \\nboth during the PHE for COVID-19 and outside of the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [In the CY 2020 PFS final rule, we \\nfinalized a policy allowing OTPs to furnish substance use counseling and individual and group \\ntherapy via two-way interactive audio-video communication technology.]] Topic: 3F_OUD OTP Coverage: [from p. 443: [In the IFC entitled \\n\\u201cMedicare and Medicaid Programs:  Policy and Regulatory Revisions in Response to the \\nCOVID-19 Public Health Emergency,\\u201d which appeared in the April 6, 2020 Federal Register \\n(85 FR 19258), we revised paragraphs (iii) and (iv) in the definition of opioid use disorder \\ntreatment service at \\u00a7 410.67(b) on an interim final basis to allow the therapy and counseling \\nportions of the weekly bundles, as well as the add-on code for additional counseling or therapy, \\nto be furnished using audio-only telephone calls rather than via two-way interactive audio-video \\ncommunication technology during the PHE for the COVID-19 if beneficiaries do not have access \\nto two-way audio-video communications technology, provided all other applicable requirements]] Topic: 3F_OUD OTP Coverage: [from p. 444: [are met.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [In the CY 2022 PFS final rule (86 FR 65341 through 65343), we finalized that after the \\nconclusion of the PHE for COVID-19, OTPs are permitted to furnish substance use counseling \\nand individual and group therapy via audio-only telephone calls when audio and video \\ncommunication technology is not available to the beneficiary.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [As we explained in the CY 2022 \\nPFS final rule (86 FR 65342), we interpret the requirement that audio/video technology is \\u201cnot \\navailable to the beneficiary\\u201d to include circumstances in which the beneficiary is not capable of \\nor has not consented to the use of devices that permit a two-way, audio/video interaction because \\nin each of these instances audio/video communication technology is not able to be used in \\nfurnishing services to the beneficiary.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [More recently in the CY 2023 PFS final rule (87 FR \\n69775 through 69777), we further extended telecommunication flexibilities for the initiation of \\ntreatment with buprenorphine outside of the COVID-19 PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [Specifically, we allowed the OTP \\nintake add-on code to be furnished via two-way, audio-video communications technology when \\nbilled for the initiation of treatment with buprenorphine, to the extent that the use of audio-video \\ntelecommunications technology to initiate treatment with buprenorphine is authorized by DEA \\nand SAMHSA at the time the service is furnished.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [We also permitted the use of audio-only \\ncommunication technology to initiate treatment with buprenorphine in cases where audio-video \\ntechnology is not available to the beneficiary, provided all other applicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 444: [In the IFC entitled \\u201cMedicare and Medicaid Programs, Basic Health Program, and \\nExchanges; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public \\nHealth Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility \\nQuality Reporting Program,\\u201d which appeared in the May 8, 2020 Federal Register (85 FR \\n27558), we revised paragraph (vii) in the definition of \\u201cOpioid use disorder treatment service\\u201d at \\n\\u00a7 410.67(b) on an interim final basis to allow periodic assessments to be furnished during the \\nPHE for COVID-19 via two-way interactive audio-video telecommunication technology and, in \\ncases where beneficiaries do not have access to two-way audio-video communication \\ntechnology, to permit the periodic assessments to be furnished using audio-only telephone calls]] Topic: 3F_OUD OTP Coverage: [from p. 445: [rather than via two-way interactive audio-video communication technology, provided all other \\napplicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [In the CY 2021 PFS final rule (85 FR 84690), we finalized our \\nproposal to revise paragraph (vii) in the definition of \\u201cOpioid use disorder treatment service\\u201d at \\n\\u00a7 410.67(b) to provide that periodic assessments (HCPCS code G2077) must be furnished during \\na face-to-face encounter, which includes services furnished via two-way interactive audio-video \\ncommunication technology, as clinically appropriate, provided all other applicable requirements \\nare met, on a permanent basis.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Furthermore, in the CY 2023 PFS proposed rule (87 FR 46093), we sought comment on \\nwhether we should allow periodic assessments to continue to be furnished using audio-only \\ncommunication technology following the end of the PHE for COVID-19 for patients who are \\nreceiving treatment via buprenorphine, and if this flexibility should also continue to apply to \\npatients receiving methadone or naltrexone.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [In response, several commenters advocated for CMS \\nto continue to allow periodic assessments to be furnished audio-only when video is not available \\nafter the end of the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Commenters highlighted that making audio-only flexibilities permanent \\nwould further promote equity for individuals who are economically disadvantaged, live in rural \\nareas, are racial and ethnic minorities, lack access to reliable broadband or internet access, or do \\nnot possess devices with video capability.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Additionally, a commenter cited a 2020 HHS Issue \\nBrief indicating higher utilization of audio-only visits for older adults.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Specifically, evidence \\nsuggests that the proportion of telephonic audio-only visits increases with the age of the patient, \\nwith \\u201c17 percent of visits delivered via audio-only interaction for patients 41-60 years of age, 30 \\npercent for patients 61-80 years of age, and 47 percent of visits for patients over 81.\\u201d 142 One \\ncommenter stated that periodic assessments are no less complex than intake/initial assessments, \\nand thus are equally appropriate for audio-video and audio-only care.]] Topic: 3F_OUD OTP Coverage: [from p. 445: [Lastly, several commenters \\nexpressed support for the use of telecommunications in circumstances when the provider and \\n142 HHS ASPE Issue Brief: Medicare beneficiary use of telehealth visits: Early Data from the Start of the COVID-19 \\nPandemic (July 27, 2020).]] Topic: 3F_OUD OTP Coverage: [from p. 445: [https://aspe.hhs.gov/reports/medicare-beneficiary-use-telehealth-visits-early-data-start-\\ncovid-19-pandemic.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [patient have together determined that the patient would individually benefit from telehealth \\nservices and a high quality of care is maintained.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [They encouraged CMS to expand flexibilities \\nto furnish substance use disorder (SUD) services via telecommunications to allow providers and \\npatients to decide collaboratively the best modality for individualized care.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [After considering \\nthese comments, CMS determined that it would be appropriate to allow periodic assessments to \\nbe furnished audio-only when video is not available through the end of CY 2023, to the extent \\nthat it is authorized by SAMHSA and DEA at the time the service is furnished and, in a manner \\nconsistent with all applicable requirements.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [We stated our belief that this modification would \\nallow continued beneficiary access to these services for the duration of CY 2023 in the event the \\nPHE terminated before the end of 2023 and that it would also grant additional time for CMS to \\nfurther consider telecommunication flexibilities associated with periodic assessments.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Accordingly, we revised the requirements related to the periodic assessment services in \\nparagraph (vii) in the definition of \\u201cOpioid use disorder treatment services\\u201d at \\u00a7 410.67(b) of the \\nregulations to reflect these changes.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Section 4113 of Division FF, Title IV, Subtitle A of the Consolidated Appropriations Act \\nof 2023 (CAA, 2023) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [L. 117-328, December 29, 2022) extended the telehealth flexibilities \\nenacted in the Consolidated Appropriations Act of 2022 (CAA, 2022) (Pub.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [L. 117-103, March \\n15, 2022).]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Specifically, it amended sections 1834(m), 1834(o), and 1834(y) of the Act to delay \\nthe requirement for an in-person visit prior to furnishing certain mental health services via \\ntelecommunications technology by physicians and other practitioners, Rural Health Clinics \\n(RHCs), and Federally Qualified Health Centers (FQHCs) until dates of service on or after \\nJanuary 1, 2025 if the COVID-19 PHE ends prior to that date.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [Additionally, it extended the \\nflexibilities available during the PHE that allow for certain Medicare telehealth services defined \\nin section 1834(m)(4)(F)(i) of the Act to be furnished via an audio-only telecommunications \\nsystem through December 31, 2024 if the PHE for COVID-19 ends prior to that date.]] Topic: 3F_OUD OTP Coverage: [from p. 446: [The PHE \\nfor COVID-19, which was declared under section 319 of the Public Health Service Act, expired]] Topic: 3F_OUD OTP Coverage: [from p. 447: [at the end of the day on May 11, 2023, so the aforementioned flexibilities will be extended \\nthrough the end of CY 2024 or CY 2025, as applicable.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [To better align coverage for periodic assessments furnished by OTPs with the telehealth \\nflexibilities described in section 4113 of the CAA, 2023, we are proposing to extend the audio-\\nonly flexibilities for periodic assessments furnished by OTPs through the end of CY 2024.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [Under \\nthis proposal, we would allow periodic assessments to be furnished audio-only when video is not \\navailable to the extent that use of audio-only communications technology is permitted under the \\napplicable SAMHSA and DEA requirements at the time the service is furnished and all other \\napplicable requirements are met.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [We believe extending this flexibility would promote continued \\nbeneficiary access to these services following the end of the PHE and for the duration of CY \\n2024.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [During the COVID-19 pandemic, substance use disorder treatment facilities increased \\ntelemedicine offerings by 143 percent, and as of 2021, almost 60 percent of SUD treatment \\nfacilities offer telehealth.143 Notably, telephone-based (that is, audio-only) therapy and recovery \\nsupport services provided by SUD programs have been found to be one of the most common \\nmodes of telehealth for treatment of opioid use disorder.144 Therefore, extending these audio-\\nonly flexibilities for an additional year may minimize disruptions associated with the conclusion \\nof the PHE.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [Additionally, evidence has shown that Medicare beneficiaries who are older than 65 \\nyears-old, racial/ethnic minorities, dual-enrollees, or living in rural areas, or who experience low \\nbroadband access, low-income, and/or not speaking English as their primary language, are more \\nlikely to be offered and use audio-only telemedicine services than audio-video services.145 Other \\nevidence also suggests that while Tribal populations, including American Indian and Alaska \\nNatives, have the highest rates of OUD prevalence among Medicare beneficiaries, one-third of \\nthese populations do not have adequate access to high-speed broadband and continue to rely on \\n143 https://pubmed.ncbi.nlm.nih.gov/34407631/.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [144 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250742/.]] Topic: 3F_OUD OTP Coverage: [from p. 447: [145 https://pubmed.ncbi.nlm.nih.gov/33471458/; https://www.kff.org/medicare/issue-brief/medicare-and-telehealth-\\ncoverage-and-use-during-the-covid-19-pandemic-and-options-for-the-future/; https://journals.lww.com/lww-\\nmedicalcare/Fulltext/2021/11000/Disparities_in_Audio_only_Telemedicine_Use_Among.10.aspx.]]\",\n          \"Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [b.  Histopathology and Cytology Testing at Remote Locations\\nWe are seeking public comments on the following:\\n\\u25cf  How should \\u201cremote testing location\\u201d be defined?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should the CLIA regulations be revised to allow pathologists to examine \\nhistopathology and cytology slides/images at a remote testing location?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What conditions (including, location(s)) should apply for a pathologist to examine \\nhistopathology or cytology slides/images remotely without obtaining a separate CLIA \\ncertification?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  Under what conditions should a primary location cease permitting testing at the remote \\nlocation?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should the remote location be included on the final patient report?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  How should CMS, SAs, or Accreditation Organizations perform onsite surveys at \\nremote locations?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [c.  Clinical cytogenetics\\nWe are seeking public comments on the following: \\n\\u25cf  Under what circumstances should CLIA allow remote locations or testing facilities to \\nexamine clinical cytogenetics images without obtaining a separate CLIA certification?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  Under what circumstances would the examination of clinical cytogenetics images be \\nunacceptable for the remote location scenario?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What clinical cytogenetics testing processes should the primary laboratory have in \\nplace to ensure the remote site complies with the CLIA requirements?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [\\u25cf  What \\u201cconditions\\u201d or \\u201ccriteria\\u201d  would be necessary for the remote location to ensure \\nquality testing for the examination of clinical cytogenetics images?]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [Q.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [Changes to the Basic Health Program Regulations \\nSection 1331 of the Patient Protection and Affordable Care Act (Pub.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 835: [L. 111-148, enacted \\nMarch 23, 2010), as amended by the Health Care and Education Reconciliation Act of 2010]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [(Pub.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [L. 111-152, enacted March 30, 2010) (collectively referred to as the Affordable Care Act \\nor ACA), provides States with the option to operate a Basic Health Program (BHP).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [In the States \\nthat elect to operate a BHP, the State\\u2019s BHP makes affordable health benefits coverage available \\nfor lawfully present individuals under age 65 with household incomes between 133 and 200 \\npercent of the Federal poverty level (or in the case of a lawfully present non-citizen, ineligible \\nfor Medicaid or the Children\\u2019s Health Insurance Program (CHIP) due to immigration status, \\nwhose household income is between zero and 200 percent of the FPL) who are not eligible for \\nMedicaid, CHIP, or other minimum essential coverage.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [As of the date of this proposed rule, only \\nNew York and Minnesota have implemented a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Federal funding for BHP is based on 95 percent of the value of the premium tax credits \\n(PTC) and cost sharing reduction (CSR) subsidies that BHP enrollees would have received had \\nthey instead enrolled in Qualified Health Plans (QHPs) through the Exchange in accordance with \\nsection 1331(d)(3)(A)(i) of the ACA.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [These funds are paid to trusts established by the States and \\ndedicated to the BHP, and the States then administer the payments to BHP standard health plans \\nwithin the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Under section 1331(d)(2) of the ACA, Federal funding for the BHP can only be \\nused to reduce the premiums and cost-sharing of, or to provide additional benefits for, eligible \\nindividuals enrolled in standard health plans within the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [1.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Allowing States to Suspend a BHP \\nCurrent regulations require States to operate a BHP under a certified Blueprint approved \\nby CMS, and to operate the BHP as long as their approved certified Blueprint is in place.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [Under \\n42 CFR 600.140, a State may terminate its BHP, which requires that the BHP trust fund balance \\nmust be refunded to the Federal government.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 836: [A State has inquired about whether it could \\n\\u201csuspend\\u201d its program for a portion of time, so that it could shift BHP enrollees to other coverage \\nwith comparable benefits and cost sharing, while maintaining its BHP trust fund, which it could \\nuse if the State were to resume the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We see the value in allowing a State currently operating a BHP to experiment with other \\nways of providing coverage that may increase the number of people covered while not increasing \\nFederal costs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose to give a State the option of temporarily \\u201csuspending\\u201d its BHP \\nprogram, while retaining accrued funds in the BHP trust fund for a limited period of time.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Should \\nthe State decide to resume operating its BHP, the suspension would allow the State to leverage \\naccrued funds and avoid the processes of terminating the program and refunding trust funds, and \\nthen later having to submit a new BHP application for approval.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [For that reason, under the \\nauthority of section 1331(c)(4) of the ACA, which requires coordination with other State health \\nprograms, we are proposing to amend \\u00a7 600.140 to add an option at paragraph (b) for a State to \\nsuspend its BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose at \\u00a7 600.140(b)(1) that States wishing to suspend their BHP must submit an \\napplication to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Under proposed \\u00a7 600.140(b)(1), States could also seek approval to extend a \\nBHP suspension previously approved by HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [In \\u00a7 600.140(b)(1)(vi), we propose that the \\napplication must be submitted at least 9 months in advance of the proposed effective date of the \\nsuspension or extension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [In \\u00a7 600.140(c), we propose that the State cannot implement the \\nsuspension or extension without prior approval by the Secretary.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [However, for States seeking to \\nsuspend a BHP in the first plan year that begins following publication of a final rule adopting \\nthis proposal, States must submit an application within 30 days of the publication of such a final \\nrule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [HHS will approve or deny such application as expeditiously as possible.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [We propose in \\u00a7 \\n600.140(b)(2) that a suspension application would need to be approved prior to the effective date \\nof suspension, except in the case of a State seeking to suspend a BHP in the first plan year that \\nbegins following publication of a final rule adopting this proposal.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [The proposed substantive requirements for the suspension application are described in \\n\\u00a7 600.140(b)(1)(i) through (v).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [During the period of suspension, BHP enrollees should receive \\ncomparable coverage that is as comprehensive and affordable as, or more comprehensive and \\naffordable than, BHP coverage during the period of suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 837: [Therefore, in \\u00a7 600.140(b)(1)(i)]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [through (iii), we propose to require that the suspension and extension application demonstrates \\nthat the benefits that will be provided to individuals that meet the BHP eligibility criteria are at \\nleast equivalent to the benefits offered in the State\\u2019s BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We propose that the cost sharing and \\npremiums that will be charged to such individuals under the new coverage option do not exceed \\nthe amounts charged under the BHP to reduce the risk that these individuals are harmed by the \\ntransition to other coverage.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We propose at \\u00a7 600.140(b)(1)(i) to require that benefits provided under the new \\ncoverage option must be at least equal to the BHP benefits in the certified Blueprint in effect on \\nthe effective day of suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [This is the same standard that is used in the Medicaid regulations \\nat \\u00a7 440.330 to determine if a State\\u2019s alternative benefit package is equivalent to the benchmark \\nbenefit package.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [Additionally, it is similar to the standard that is used by CHIP at \\u00a7 457.420 to \\ndetermine if a State\\u2019s CHIP benefit package is equivalent to the benchmark benefit package, \\nalthough the CHIP standard allows for some variation if the State is adding additional benefits as \\nrequired by Title XXI.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We note that it would be acceptable to provide additional benefits under \\nthe new coverage option, such that individuals receive more or greater benefits under the new \\ncoverage option.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [We considered whether there should be a look back period, such that benefits \\nunder the new coverage option would be compared to the BHP benefits provided under the \\ncertified Blueprint in effect for a period of time prior to the effective date of the suspension and \\nseek comments on this alternative approach.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [In order to determine that the cost sharing required of individuals under the new coverage \\noption does not exceed the BHP cost sharing levels, we propose at \\u00a7 600.140(b)(1)(ii) to require \\nthat the actuarial value of the new coverage option must meet or exceed the actuarial value of the \\nBHP standard health plans in effect immediately prior to the suspension period.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [This may result \\nin cost sharing for individual benefits differing between the BHP and the new coverage program, \\nprovided the actuarial value of the new coverage options meets or exceeds the actuarial value of \\nthe BHP standard health plans.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 838: [If there are multiple health plans being offered under the new]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [coverage option and/or multiple standard health plans in effect in the State, we propose that the \\nmedian actuarial value of the health plans offered under the new coverage option must meet or \\nexceed the median actuarial value of the BHP standard health plans.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We considered whether to \\nrequire that cost sharing under the new coverage option instead meet the cost sharing \\nrequirements under current regulations at \\u00a7 600.520(c) and seek comment on whether this \\nalternative approach should be adopted in the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Similarly, we propose at \\u00a7 600.140(b)(1)(iii) to require that the premiums charged to \\nindividuals under the new coverage option must be comparable to BHP standard health plan \\npremiums in effect immediately prior to the suspension period, beyond reasonable increases due \\nto inflation as measured by the Consumer Price Index (CPI).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We considered alternative methods \\nfor measuring equivalency in premiums.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [First, we considered whether to require that premiums \\nunder the new coverage option instead meet the premium requirements under \\u00a7 600.505(a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Second, we considered whether premiums charged to individuals under the new coverage option \\nshould instead not exceed the premiums in effect on December 31, 2020, as these premiums \\nlevels do not account for any additional premium tax credit subsidies offered under the American \\nRescue Plan Act or the Inflation Reduction Act.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Third, we considered whether premium and cost \\nsharing levels, considered together, under the new coverage option would be considered \\nsufficient, if those levels meet the requirements under a section 1115 demonstration or section \\n1332 waiver.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also seek comment on whether these alternative approaches should be adopted \\nin the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also considered alternatives to the timing of the comparison of benefits and cost \\nsharing in BHP to the new coverage option.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [Specifically, we considered whether benefits and \\ncost sharing under the new coverage option should be compared to the benefits and cost sharing \\nunder the BHP on the date the suspension application is submitted to HHS, or some other date.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 839: [We also seek comment on the potential adoption of these alternatives in the final rule.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Finally, we believe that the suspension period should not result in individuals losing \\ncoverage, solely due to a change in eligibility criteria for the program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Therefore, we are \\nproposing in \\u00a7 600.140(b)(1)(iv) that a state must demonstrate in its application that the \\neligibility criteria for coverage during the suspension is not more restrictive than the criteria \\ndescribed in \\u00a7 600.305.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We believe that the suspension period should be long enough to allow the State to \\nevaluate the alternative coverage provided to BHP eligible individuals, but should not be \\nindefinite.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Therefore, we are proposing in \\u00a7 600.140(b)(1)(v) that a State could request a \\nsuspension of up to 5 years in an initial suspension application, after which a State could request \\nan extension of up to 5 additional years.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Additional extension periods would not be allowed.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [When the suspension period, including any extension period, ends, we propose that the State \\nwould need to transition the BHP eligible population back to the BHP, or terminate the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We \\npropose at \\u00a7 600.140(b)(7) that at least 9 months before the end of the suspension period, a State \\nmust submit a transition plan to HHS that explains how the State will reinstate its BHP, or \\nterminate the program under \\u00a7 600.140(a) of the current regulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [The state must also notify \\nthe public of this change.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Under proposed \\u00a7 600.140(b)(7), a State also could elect to end a BHP \\nsuspension before the end of the initial or extended suspension period by following the same \\nprocess.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We chose 5 years for the initial approval period because this aligns with the duration of \\ninitial waivers and demonstration projects approved under section 1332 of the ACA and section \\n1115 of the Act.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We believe these are the most likely authorities under which States could seek \\nto provide alternative coverage to BHP enrollees.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [Similarly, we chose 5 years for the extension \\nperiod because it aligns with the duration of typical extensions or amendment periods under \\nsection 1332 waiver and section 1115 demonstration projects.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 840: [We considered a shorter extension]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [period of 2 or 3 years, and allowing multiple extension periods given both section 1332 waiver \\nand 1115 demonstrations can be extended.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We seek comment on these alternatives.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Under proposed \\u00a7 600.140(b)(1)(vii), States requesting an extension of a previously-\\napproved BHP suspension also would need to provide an evaluation of the alternative coverage \\nin its application.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [In the case of alternative coverage provided through a section 1115 \\ndemonstration project or section 1332 waiver, the evaluation and application required for such \\ndemonstration projects and waivers would satisfy this requirement.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [If individuals and/or standard health plans will experience a change in the terms of the \\ncoverage, including receiving additional benefits or being charged different cost sharing \\namounts, in \\u00a7 600.140(b)(3), we propose to require that the state provide notice to them at least \\n90 days prior to the effective date of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [The notices would need to include \\ninformation regarding the State\\u2019s assessment of their eligibility for all other insurance \\naffordability programs in the State, and meet the accessibility and readability standards at 45 \\nCFR 155.230(b).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [In order to calculate a State\\u2019s BHP payments, the State provides CMS an estimate of the \\nnumber of BHP enrollees it projects will enroll in the upcoming BHP program quarter each \\nquarter of program operations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We use those estimates to calculate the prospective payment, \\nwhich is deposited in the State\\u2019s BHP trust fund.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Once the State provides us with actual \\nenrollment data for those periods, the actual enrollment data is used to calculate the final BHP \\npayment amount and make any necessary reconciliation adjustments to the prior quarters\\u2019 \\nprospective payment amounts due to differences between projected and actual enrollment.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We believe that having an accurate accounting of the balance of the State\\u2019s trust fund is \\ncritical for any State suspending its BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [Therefore, we propose to require in \\u00a7 600.140(b)(4) \\nthat States that suspend their BHP must submit the data necessary to complete the BHP payment \\nreconciliation process within 12 months of the effective date of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 841: [We believe that]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [12 months is a reasonable amount of time for a State to submit the actual enrollment data for the \\nperiods it was operating a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [One reason it is important for a State to complete the BHP payment reconciliation \\nprocess is to establish a baseline balance for calculating interest.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Currently, States\\u2019 BHP trust \\nfunds can accrue interest, and this interest is retained in the BHP trust fund.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [However, we believe \\nthat interest accrued on the BHP trust fund during any suspension must be remitted to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Since the State is not operating a BHP during the suspension period, suspension should not \\ngenerate additional funds for the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We propose in \\u00a7600.140(b)(6) that while the State is not \\nproviding BHP coverage, any accrued interest on the trust fund must be remitted to HHS on an \\nannual basis in the form and manner set out by HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [States currently submit the balance of their trust fund and any interest accrued through \\nthe BHP annual report described in \\u00a7600.170.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We proposed revisions to \\u00a7\\u00a7 600.140(b) and \\n600.170(a) to require States that suspend their BHP continue to submit an annual report in order \\nto document the interest earned and to provide assurance that the coverage provided to BHP-\\neligible individuals meets the standards discussed above.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We propose in \\u00a7 600.140(b)(5) to \\nrequire States that suspend their BHP continue to submit an annual report during the suspension \\nperiod.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [We proposed amendments to \\u00a7 600.170(a), which describes the requirements for the \\nannual reports, to describe the standards that will apply to States that have suspended their BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 842: [Specifically, we propose to redesignate the introductory language in paragraph (a) as paragraph \\n(a)(1), to redesignate paragraphs (a)(1) through (a)(4) as paragraphs (a)(1)(i) through (a)(1)(iv), \\nand to add a new paragraph \\u00a7 600.170(a)(2) to require that States that have suspended their BHP \\nunder \\u00a7 600.140(b) must submit an annual report that includes (1) the balance of the BHP trust \\nfund and any interest accrued on that balance; (2) an assurance that the coverage provided to \\nindividuals who would be eligible for a BHP under \\u00a7 600.305 continues to meet the standards \\ndescribed in \\u00a7 600.140(b)(1)(i) through (iii); and (3) any additional information specified by the \\nSecretary at least 120 days prior to the date that the annual report is due.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [ If a State does not meet the proposed requirements (that is, completing the financial \\nreconciliation process, remitting interest on the trust fund, and submitting the required \\ninformation in its annual report), we propose in \\u00a7 600.140(d) that the Secretary can withdraw \\napproval of the suspension.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Specifically, we propose that the Secretary can withdraw approval of \\nthe suspension if the State ends implementation of the alternative coverage program for any \\nreason, or if the State fails to continue to meet the coverage and cost sharing requirements of the \\nalternative coverage program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [If the State seeks an amendment to the alternative coverage \\nprogram, the State must inform CMS of this proposed change so that CMS may evaluate if the \\ncoverage is sufficient.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [In addition, we propose at paragraph (d) that we could also withdraw \\napproval if we have significant evidence of harm, financial malfeasance, fraud, waste, or abuse \\nconsistent with \\u00a7 600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [In \\u00a7 600.140(d)(1) through (4), we propose a process for withdrawing \\napproval, which mirrors the process for withdrawing certification of a BHP Blueprint in \\u00a7 \\n600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Specifically, we propose that the Secretary will withdraw approval only after providing \\nthe State with notice of the findings upon which the Secretary is basing the withdrawal, a \\nreasonable period for the State to address the finding, and an opportunity for a hearing before \\nissuing a final finding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [We propose that the Secretary shall make every reasonable effort to \\nresolve proposed findings without withdrawing approval of the suspension plan and in the event \\nof a decision to withdraw approval, will accept a request from the State for reconsideration.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [The \\neffective date of an HHS determination withdrawing approval of the suspension plan would not \\nbe earlier than 120 days following issuance of a final finding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Within 30 days following a final \\nfinding under paragraph (d)(1) of this paragraph, the State shall submit a transition plan to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [During the transition period from the BHP to other coverage the state may not use funds \\nfrom the BHP trust fund toward the unwinding of the BHP program and transition to the new \\ncoverage program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 843: [Under section 1331(d)(2) of the ACA and current regulations at \\u00a7 600.705(c), \\nFederal funding for BHP can only be used to reduce the premiums and cost-sharing, or to \\nprovide additional benefits, for BHP-eligible individuals enrolled in standard health plans within]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Therefore, Federal funding is not available for administrative expenses associated with \\ntransitioning BHP enrollees to a new coverage program or for costs associated with providing \\nnew coverage after the transition has occurred.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [States cannot use Federal BHP funding to cover \\npremiums and cost sharing (or additional benefits) for individuals that would otherwise be \\neligible for BHP funding.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We solicit comment on these proposals.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We seek comment on the proposed process for suspending a BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Specifically, we seek \\ncomment on how far in advance of suspension a state must submit a suspension application to \\nCMS and how far in advance of suspension CMS must approve or deny the suspension request.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We also seek comment on duration of time a state may suspend their BHP, without terminating \\nthe program.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [2.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Submission and Review of BHP Blueprints\\nAs noted above, under current \\u00a7 600.110, States must submit to the Secretary and receive \\ncertification of a BHP Blueprint describing their operational design choices prior to \\nimplementation.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Under the current \\u00a7 600.125(a) a State that seeks to make significant changes to \\nits BHP must submit a revised Blueprint to the Secretary for review and certification; however, \\nthe current regulation does not specify any timeframes for the submission and review of revised \\nBlueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [The current \\u00a7 600.125(a) also describes a limited number of changes under which \\nsubmission of a revised Blueprint is required.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Most notably, the current regulation does not \\nrequire the submission of a revised Blueprint in response to changes in Federal law or \\nregulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Additionally, under current \\u00a7 600.125(a) and (b), any changes made in a revised \\nBlueprint can be implemented prospective from the date of certification; no changes can be \\nimplemented until HHS certifies the revised Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [We believe that additional parameters are necessary in order to ensure effective and \\nefficient operation of the BHPs and HHS review of a revised Blueprint, consistent with section \\n1331(a)(1) of the ACA.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 844: [Therefore, we propose changes to \\u00a7 600.125 to establish timeframes and \\nprocedures for the submission and review of BHP Blueprints, similar to the Medicaid and CHIP]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [State plan amendment (SPA) submission and review processes.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We note that these proposed \\ntimeframes only apply to the submission and review of revised Blueprints; we are not proposing \\nchanges to the timeframes for the submission and review of an initial Blueprint, set forth in \\ncurrent regulations at \\u00a7 600.120, in the event additional States seek to establish BHPs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Additionally, we believe States need flexibility to receive approval of a retroactive \\neffective date for changes to their BHP Blueprint, similar to flexibilities allowed under \\nregulations at \\u00a7\\u00a7 430.20(b) and 457.60 for the submission of Medicaid and CHIP SPAs.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We \\nnote, however, that in the event that a State implements a change to its BHP Blueprint that is \\nultimately disapproved by HHS, the State could be required to implement a corrective action \\nplan under \\u00a7\\u2009600.715.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Specifically, under existing regulations at \\u00a7 600.125(a), States must submit a revised \\nBlueprint whenever they seek to make significant change(s) that alter program operations the \\nBHP benefit package, enrollment, disenrollment and verification policies described in its \\ncertified BHP Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [Under the proposed revisions to \\u00a7 600.125(a), we would broaden the \\ncircumstances requiring submission of a revised Blueprint to include States\\u2019 significant changes \\nthat alter any core program operations under \\u00a7 600.145(f).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [States also would be required to \\nsubmit a revised Blueprint to HHS whenever necessary to reflect changes in Federal law, \\nregulations, policy interpretations, or court decisions that affect provisions in their certified \\nBlueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [States would continue to be required to submit a revised Blueprint to make changes to \\nthe BHP benefit package or to enrollment, disenrollment, and verification policies described in \\nthe certified Blueprint, as currently required under \\u00a7 600.125(a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [At \\u00a7 600.125, we also propose to redesignate paragraph (b) as paragraph (d) and to add \\nnew paragraph (b) to provide that the effective date of a revised Blueprint may be as early as, but \\nnot earlier than, the first day of the quarter in which an approvable revision is submitted to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [This policy mirrors the standards for submission of a Medicaid SPA at \\u00a7 430.20(b).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [The current \\nregulations do not specify as to when revision is considered received.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 845: [We believe that it is]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [reasonable to consider a revised Blueprint to be received when HHS receives an electronic copy \\nof a cover letter signed by the Governor or Governor\\u2019s designee and a copy of the currently \\napproved Blueprint with proposed changes indicated in track changes.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [In the event a State is \\nunable to submit a revised Blueprint electronically, due to a disaster or other event outside of the \\nState\\u2019s control, CMS may consider other modes of submission on a case-by-case basis.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\ncurrent regulations at \\u00a7 600.125(b), redesignated at \\u00a7 600.125(d) in this proposed rule, the State \\nis responsible for continuing to operate under the terms of the existing certified Blueprint until \\nthe State adopts a revised Blueprint, the State terminates or suspends the BHP, or the Secretary \\nwithdraws certification for the BHP.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [We are also proposing to redesignate paragraph (c) as paragraph (g) and to add a new \\nparagraph (c) to create clear timelines for HHS\\u2019s review, approval, and disapproval of revised \\nBlueprints similar to the timelines currently applicable to CHIP SPAs under \\u00a7 457.150.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\nproposed \\u00a7 600.125(c)(1), a revised Blueprint will be deemed approved unless HHS, within 90 \\ndays after receipt of the revised Blueprint, sends the State written notice of disapproval or written \\nnotice of additional information HHS needs in order to make a final determination.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [If HHS \\nrequests additional information, the 90-day review period will be stopped and will resume the \\nday after HHS receives all of the requested additional information from the State.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under \\nproposed paragraph (c)(2), if 90 days from the date a Blueprint revision is received does not fall \\non a business day, the 90-day review period will end on the next business day.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [Under proposed \\nparagraph (c)(3), HHS may send written requests for additional information as many times as \\nneeded to obtain all information necessary to certify the revised Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [This mirrors the \\nprocess used by CHIP, of having one 90-day review period that can start and stop multiple times \\nwith a request for additional information and response.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [It differs from Medicaid, which has a 90-\\nday review period that can be stopped once by a request for additional information, followed by \\na second 90-day review period when the state responds.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 846: [At paragraph (c), we propose that HHS \\nmay disapprove a Blueprint amendment if the Secretary determines that the Blueprint revision is]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [not consistent with section 1331 of the ACA or the regulations set forth in this part at any time \\nduring the review process, including when the 90-day review clock is stopped due to a request \\nfor additional information.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Once a Blueprint is approved, current paragraph (b) specifies that the State is responsible \\nfor continuing to operate under the terms of the existing certified Blueprint until and unless a \\nrevised Blueprint that seeks to make significant change(s) is certified, except during a public \\nhealth emergency, as described in paragraph (c).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [We propose to revise paragraph (b), \\nredesignated as paragraph (d) in this proposed rulemaking, to provide that the State must \\ncontinue to operate under the terms of an existing certified Blueprint until the State adopts a \\nrevised Blueprint, terminates the BHP following the procedures described in \\u00a7 600.140(a), \\nsuspends the BHP following the procedures described in \\u00a7 600.140(b), or the Secretary \\nwithdraws certification of the BHP under \\u00a7 600.142.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Finally, we propose to apply some of the existing parameters for initial Blueprint \\nsubmissions to Blueprint revisions.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [In paragraph (e), we propose that a State may withdraw the \\nproposed revised Blueprint during HHS review if the State has not yet implemented the proposed \\nchanges and provides written notice to HHS.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [This proposal mirrors current \\u00a7 600.130 for initial \\nBHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [In paragraph (f), we propose that HHS will accept a State\\u2019s request for \\nreconsideration of a decision not to certify a revised Blueprint and provide an impartial review \\nagainst standards for certification if requested.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [This proposal mirrors current \\u00a7 600.135(c) for \\ninitial BHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Under current \\u00a7 600.135, HHS must act on all initial BHP Blueprint certification and \\nrevision requests in a timely matter.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Because we are proposing to specify timeframes for the \\nsubmission and review of revised BHP Blueprints under \\u00a7600.125, we propose to revise \\n\\u00a7 600.135 to apply only to the submission of initial BHP Blueprints.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 847: [Specifically, we propose to \\nrevise the title to clearly state that this section is applicable to only initial Blueprints and to \\nremove the reference to BHP Blueprint revisions in paragraph (a).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [3.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [BHP Notices\\nUnder current \\u00a7 600.330, States must provide written notice to beneficiaries conveying \\nfinal determination of eligibility or ineligibility.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [The regulation does not require States to provide \\nthose notices in a manner that is accessible to individuals with disabilities or limited English \\nproficiency (LEP).]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Although HHS Office for Civil Rights regulations at 45 CFR 92.101, which \\napply to programs such as Medicaid, CHIP and BHP, require States to take reasonable steps to \\nprovide meaningful access for individuals with LEP and to ensure effective communication with \\nindividuals with disabilities, we believe it is important for these obligations to also be described \\nclearly in the BHP regulations.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Therefore, we are proposing to add paragraph (f) to \\u00a7 600.330 to \\nrequire that BHP eligibility notices be written in plain language and be provided in a manner \\nwhich ensures that eligible individuals with LEP are provided with meaningful language access \\nand individuals with disabilities are provided with effective communication.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [4.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [BHP Appeals\\nUnder current \\u00a7 600.335(b), individuals must be given the opportunity to appeal BHP \\neligibility determinations through the appeals rules of the State\\u2019s Medicaid program or the \\nExchange, as indicated in the State\\u2019s Blueprint.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Current BHP and Exchange regulations do not \\nprovide for appeals of health services matters.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [We believe all BHP enrollees should be afforded \\nthe opportunity to appeal not only eligibility determinations but also decisions about health \\nservices matters.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [The Exchange rules do not include an opportunity to appeal a health services \\nmatter, as such appeals are typically handled by State Departments of Insurance, as opposed to \\nby the Exchange itself.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [Therefore, we propose in paragraph (b) to remove the option for States to \\nconduct their BHP appeals process according to Exchange rules.]] Topic: 3Q_Changes to the Basic Health Program Regulations: [from p. 848: [In paragraph (b)(2), we propose \\nto require States to provide individuals an opportunity to appeal a delay, denial, reduction, \\nsuspension, or termination of health services, in whole or in part, including a determination about \\nthe type or level of service, after individuals exhaust appeals or grievances through the BHP \\nstandard health plans.]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"token_count\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": 655,\n        \"max\": 154679,\n        \"num_unique_values\": 33,\n        \"samples\": [\n          54937,\n          4861,\n          10438\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "tokens_by_topic_df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-53b8c9d6-614e-4233-a909-94245e56798b\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Topic</th>\n",
              "      <th>Sort_seq</th>\n",
              "      <th>text</th>\n",
              "      <th>token_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B_Determination of Practice Expense RVUs</td>\n",
              "      <td>1.0</td>\n",
              "      <td>Topic: 2B_Determination of Practice Expense RV...</td>\n",
              "      <td>28149</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2C_Potentially Misvalued Services</td>\n",
              "      <td>5.0</td>\n",
              "      <td>Topic: 2C_Potentially Misvalued Services: [fro...</td>\n",
              "      <td>14546</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2D_Telehealth Services</td>\n",
              "      <td>6.0</td>\n",
              "      <td>Topic: 2D_Telehealth Services: [from p. 68: [D...</td>\n",
              "      <td>41814</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2E_Valuation of Specific Codes</td>\n",
              "      <td>20.0</td>\n",
              "      <td>Topic: 2E_Valuation of Specific Codes: [from p...</td>\n",
              "      <td>74752</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2F_E&amp;M Visits</td>\n",
              "      <td>49.0</td>\n",
              "      <td>Topic: 2F_E&amp;M Visits: [from p. 240: [F.  Evalu...</td>\n",
              "      <td>11539</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>2G_Geographic Practice Cost Indices</td>\n",
              "      <td>52.0</td>\n",
              "      <td>Topic: 2G_Geographic Practice Cost Indices: [f...</td>\n",
              "      <td>3096</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>2H_Payment for Skin Substitutes</td>\n",
              "      <td>55.0</td>\n",
              "      <td>Topic: 2H_Payment for Skin Substitutes: [from ...</td>\n",
              "      <td>2687</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>2I_Supervision of OP Therapy Svcs, KX Modifier...</td>\n",
              "      <td>58.0</td>\n",
              "      <td>Topic: 2I_Supervision of OP Therapy Svcs, KX M...</td>\n",
              "      <td>10856</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>2J_Advancing Access to Behavioral Health Services</td>\n",
              "      <td>64.0</td>\n",
              "      <td>Topic: 2J_Advancing Access to Behavioral Healt...</td>\n",
              "      <td>21798</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>2K_Medicare Parts A and B Payment for Dental S...</td>\n",
              "      <td>73.0</td>\n",
              "      <td>Topic: 2K_Medicare Parts A and B Payment for D...</td>\n",
              "      <td>36485</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>3A_Drugs and Biological Products Paid Under Pa...</td>\n",
              "      <td>80.0</td>\n",
              "      <td>Topic: 3A_Drugs and Biological Products Paid U...</td>\n",
              "      <td>25960</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>3B_RHCs and FQHCs</td>\n",
              "      <td>87.0</td>\n",
              "      <td>Topic: 3B_RHCs and FQHCs: [from p. 386: [admin...</td>\n",
              "      <td>25401</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>3C_RHCs and FQHCs Conditions for Certification...</td>\n",
              "      <td>99.0</td>\n",
              "      <td>Topic: 3C_RHCs and FQHCs Conditions for Certif...</td>\n",
              "      <td>7019</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>3D_Clinical Lab Fee Schedule</td>\n",
              "      <td>100.0</td>\n",
              "      <td>Topic: 3D_Clinical Lab Fee Schedule: [from p. ...</td>\n",
              "      <td>7121</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...</td>\n",
              "      <td>103.0</td>\n",
              "      <td>Topic: 3E_Pulm/Cardiac/Intensive Cardiac Rehab...</td>\n",
              "      <td>2612</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>3F_OUD OTP Coverage</td>\n",
              "      <td>104.0</td>\n",
              "      <td>Topic: 3F_OUD OTP Coverage: [from p. 441: [We ...</td>\n",
              "      <td>4861</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>3G_MSSP</td>\n",
              "      <td>107.0</td>\n",
              "      <td>Topic: 3G_MSSP: [from p. 448: [audio-only visi...</td>\n",
              "      <td>154679</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>3H_Part B Payment Preventive Vaccine</td>\n",
              "      <td>108.0</td>\n",
              "      <td>Topic: 3H_Part B Payment Preventive Vaccine: [...</td>\n",
              "      <td>9435</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>3I_MDPP</td>\n",
              "      <td>112.0</td>\n",
              "      <td>Topic: 3I_MDPP: [from p. 701: [information on ...</td>\n",
              "      <td>17346</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>3J_Appropriate Use Criteria for Advanced Diagn...</td>\n",
              "      <td>113.0</td>\n",
              "      <td>Topic: 3J_Appropriate Use Criteria for Advance...</td>\n",
              "      <td>13368</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>3K_Medicaid Provider Enrollment</td>\n",
              "      <td>114.0</td>\n",
              "      <td>Topic: 3K_Medicaid Provider Enrollment: [from ...</td>\n",
              "      <td>29237</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>3L_Expand Diabetes Screening and Diabetes Defi...</td>\n",
              "      <td>115.0</td>\n",
              "      <td>Topic: 3L_Expand Diabetes Screening and Diabet...</td>\n",
              "      <td>10095</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>3M_EPCS Part D</td>\n",
              "      <td>116.0</td>\n",
              "      <td>Topic: 3M_EPCS Part D: [from p. 799: [Medicare...</td>\n",
              "      <td>10473</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>3N_Ambulance Fee and GADCS</td>\n",
              "      <td>117.0</td>\n",
              "      <td>Topic: 3N_Ambulance Fee and GADCS: [from p. 81...</td>\n",
              "      <td>7492</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>3O_Hospice: Changes to Conditions of Participa...</td>\n",
              "      <td>118.0</td>\n",
              "      <td>Topic: 3O_Hospice: Changes to Conditions of Pa...</td>\n",
              "      <td>3186</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>3P_Solicitation: Histopathology, Cytology, and...</td>\n",
              "      <td>119.0</td>\n",
              "      <td>Topic: 3P_Solicitation: Histopathology, Cytolo...</td>\n",
              "      <td>6310</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>3Q_Changes to the Basic Health Program Regulat...</td>\n",
              "      <td>120.0</td>\n",
              "      <td>Topic: 3Q_Changes to the Basic Health Program ...</td>\n",
              "      <td>10438</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>3R_Updates to the Definitions of CEHRT</td>\n",
              "      <td>121.0</td>\n",
              "      <td>Topic: 3R_Updates to the Definitions of CEHRT:...</td>\n",
              "      <td>4734</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>3S_SDOH Risk Assessment in the AWV</td>\n",
              "      <td>122.0</td>\n",
              "      <td>Topic: 3S_SDOH Risk Assessment in the AWV: [fr...</td>\n",
              "      <td>9494</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>4_QPP</td>\n",
              "      <td>123.0</td>\n",
              "      <td>Topic: 4_QPP: [from p. 1175: [ICR Title Change...</td>\n",
              "      <td>31890</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>7D_Changes Related to Telehealth Services</td>\n",
              "      <td>128.0</td>\n",
              "      <td>Topic: 7D_Changes Related to Telehealth Servic...</td>\n",
              "      <td>655</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>7E_Other Provisions in the Regulation</td>\n",
              "      <td>129.0</td>\n",
              "      <td>Topic: 7E_Other Provisions in the Regulation: ...</td>\n",
              "      <td>54937</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>7F_Alternatives Considered</td>\n",
              "      <td>133.0</td>\n",
              "      <td>Topic: 7F_Alternatives Considered: [from p. 12...</td>\n",
              "      <td>2701</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-53b8c9d6-614e-4233-a909-94245e56798b')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-53b8c9d6-614e-4233-a909-94245e56798b button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-53b8c9d6-614e-4233-a909-94245e56798b');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-9d1faeee-ed76-4def-92bd-fcdb6e8a4872\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-9d1faeee-ed76-4def-92bd-fcdb6e8a4872')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-9d1faeee-ed76-4def-92bd-fcdb6e8a4872 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_7f5dbbf3-ca2d-42d9-98c6-e2facf1080bb\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('tokens_by_topic_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_7f5dbbf3-ca2d-42d9-98c6-e2facf1080bb button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('tokens_by_topic_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                     InsightsAI_Topic  Sort_seq  \\\n",
              "0           2B_Determination of Practice Expense RVUs       1.0   \n",
              "1                   2C_Potentially Misvalued Services       5.0   \n",
              "2                              2D_Telehealth Services       6.0   \n",
              "3                      2E_Valuation of Specific Codes      20.0   \n",
              "4                                       2F_E&M Visits      49.0   \n",
              "5                 2G_Geographic Practice Cost Indices      52.0   \n",
              "6                     2H_Payment for Skin Substitutes      55.0   \n",
              "7   2I_Supervision of OP Therapy Svcs, KX Modifier...      58.0   \n",
              "8   2J_Advancing Access to Behavioral Health Services      64.0   \n",
              "9   2K_Medicare Parts A and B Payment for Dental S...      73.0   \n",
              "10  3A_Drugs and Biological Products Paid Under Pa...      80.0   \n",
              "11                                  3B_RHCs and FQHCs      87.0   \n",
              "12  3C_RHCs and FQHCs Conditions for Certification...      99.0   \n",
              "13                       3D_Clinical Lab Fee Schedule     100.0   \n",
              "14  3E_Pulm/Cardiac/Intensive Cardiac Rehab Expans...     103.0   \n",
              "15                                3F_OUD OTP Coverage     104.0   \n",
              "16                                            3G_MSSP     107.0   \n",
              "17               3H_Part B Payment Preventive Vaccine     108.0   \n",
              "18                                            3I_MDPP     112.0   \n",
              "19  3J_Appropriate Use Criteria for Advanced Diagn...     113.0   \n",
              "20                    3K_Medicaid Provider Enrollment     114.0   \n",
              "21  3L_Expand Diabetes Screening and Diabetes Defi...     115.0   \n",
              "22                                     3M_EPCS Part D     116.0   \n",
              "23                         3N_Ambulance Fee and GADCS     117.0   \n",
              "24  3O_Hospice: Changes to Conditions of Participa...     118.0   \n",
              "25  3P_Solicitation: Histopathology, Cytology, and...     119.0   \n",
              "26  3Q_Changes to the Basic Health Program Regulat...     120.0   \n",
              "27             3R_Updates to the Definitions of CEHRT     121.0   \n",
              "28                 3S_SDOH Risk Assessment in the AWV     122.0   \n",
              "29                                              4_QPP     123.0   \n",
              "30          7D_Changes Related to Telehealth Services     128.0   \n",
              "31              7E_Other Provisions in the Regulation     129.0   \n",
              "32                         7F_Alternatives Considered     133.0   \n",
              "\n",
              "                                                 text token_count  \n",
              "0   Topic: 2B_Determination of Practice Expense RV...       28149  \n",
              "1   Topic: 2C_Potentially Misvalued Services: [fro...       14546  \n",
              "2   Topic: 2D_Telehealth Services: [from p. 68: [D...       41814  \n",
              "3   Topic: 2E_Valuation of Specific Codes: [from p...       74752  \n",
              "4   Topic: 2F_E&M Visits: [from p. 240: [F.  Evalu...       11539  \n",
              "5   Topic: 2G_Geographic Practice Cost Indices: [f...        3096  \n",
              "6   Topic: 2H_Payment for Skin Substitutes: [from ...        2687  \n",
              "7   Topic: 2I_Supervision of OP Therapy Svcs, KX M...       10856  \n",
              "8   Topic: 2J_Advancing Access to Behavioral Healt...       21798  \n",
              "9   Topic: 2K_Medicare Parts A and B Payment for D...       36485  \n",
              "10  Topic: 3A_Drugs and Biological Products Paid U...       25960  \n",
              "11  Topic: 3B_RHCs and FQHCs: [from p. 386: [admin...       25401  \n",
              "12  Topic: 3C_RHCs and FQHCs Conditions for Certif...        7019  \n",
              "13  Topic: 3D_Clinical Lab Fee Schedule: [from p. ...        7121  \n",
              "14  Topic: 3E_Pulm/Cardiac/Intensive Cardiac Rehab...        2612  \n",
              "15  Topic: 3F_OUD OTP Coverage: [from p. 441: [We ...        4861  \n",
              "16  Topic: 3G_MSSP: [from p. 448: [audio-only visi...      154679  \n",
              "17  Topic: 3H_Part B Payment Preventive Vaccine: [...        9435  \n",
              "18  Topic: 3I_MDPP: [from p. 701: [information on ...       17346  \n",
              "19  Topic: 3J_Appropriate Use Criteria for Advance...       13368  \n",
              "20  Topic: 3K_Medicaid Provider Enrollment: [from ...       29237  \n",
              "21  Topic: 3L_Expand Diabetes Screening and Diabet...       10095  \n",
              "22  Topic: 3M_EPCS Part D: [from p. 799: [Medicare...       10473  \n",
              "23  Topic: 3N_Ambulance Fee and GADCS: [from p. 81...        7492  \n",
              "24  Topic: 3O_Hospice: Changes to Conditions of Pa...        3186  \n",
              "25  Topic: 3P_Solicitation: Histopathology, Cytolo...        6310  \n",
              "26  Topic: 3Q_Changes to the Basic Health Program ...       10438  \n",
              "27  Topic: 3R_Updates to the Definitions of CEHRT:...        4734  \n",
              "28  Topic: 3S_SDOH Risk Assessment in the AWV: [fr...        9494  \n",
              "29  Topic: 4_QPP: [from p. 1175: [ICR Title Change...       31890  \n",
              "30  Topic: 7D_Changes Related to Telehealth Servic...         655  \n",
              "31  Topic: 7E_Other Provisions in the Regulation: ...       54937  \n",
              "32  Topic: 7F_Alternatives Considered: [from p. 12...        2701  "
            ]
          },
          "execution_count": 10,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "tokens_by_topic_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "ifUcdez-rc8t",
        "outputId": "db2c601a-5283-4b95-d319-6cfff394aad6"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"merged_df_Subtopic_text_combined\",\n  \"rows\": 101,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Subtopic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 101,\n        \"samples\": [\n          \"3B4d_Revision to General Care Management G0511\",\n          \"2J1_Coverage of MFT Services and MHC Services\",\n          \"2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sort_seq\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 35,\n        \"min\": 2,\n        \"max\": 134,\n        \"num_unique_values\": 101,\n        \"samples\": [\n          97,\n          65,\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 101,\n        \"samples\": [\n          \"Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Facilitating behavioral change as necessary for meeting diagnosis and treatment \\ngoals, including promoting patient motivation to participate in care and reach person-centered \\ndiagnosis or treatment goals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Facilitating and providing social and emotional support to help the patient cope with \\nthe condition, SDOH need(s), and adjust daily routines to better meet diagnosis and treatment \\ngoals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Leverage knowledge of the serious, high-risk condition and/or lived experience when \\napplicable to provide support, mentorship, or inspiration to meet treatment goals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [GXXX4 \\u2013 Principal Illness Navigation services, additional 30 minutes per calendar \\nmonth (List separately in addition to GXXX3).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [Allowing a separate payment for CHI and PIN services in RHCs and FQHCs is intended \\nto reflect the additional time and resources necessary for the unique components of care \\ncoordination services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [In an effort to be consistent with the new services that are being proposed \\nfor practitioners billing under the PFS, we are proposing to include PIN services in the general \\ncare management HCPCS code G0511 when these services are provided by RHCs and FQHCs.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [We note that under the proposals to expand the billable services under HCPCS code \\nG0511 to include CHI and PIN, each of these services must be medically reasonable and \\nnecessary, meet all requirements, and not be duplicative of services paid to RHCs and FQHCs \\nunder the general care management code for an episode of care in a given calendar month.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [We \\nexpect that our proposal to add the new codes for CHI and PIN to the general care management \\ncode would also support the CMS pillars120 for equity, inclusion, and access to care for the \\nMedicare population, and improve patient outcomes, including for underserved and low-income \\npopulations where there is a disparity in access to quality care.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [120 CMS Strategic Plan.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [https://www.cms.gov/cms-strategic-plan.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [d.  Proposed Revision to the Calculation of the Payment Amount for the General Care \\nManagement HCPCS Code G0511\\nCurrently, HCPCS code G0511 is based on the PFS national average non-facility \\npayment rate for each of the services identified as billable general care management services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Then we add each payment rate and divide by the total number of codes to arrive at the payment \\namount for HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [This payment amount is a flat rate that is not subsequently \\nadjusted for locality.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [As we noted in the CY 2023 PFS final rule (87 FR 69735), when \\ndetermining which services are billable under HCPCS code G0511, we do not include the add-on \\nHCPCS codes payable under the PFS because RHCs and FQHCs do not pay their practitioners \\nbased on additional minutes spent by practitioners.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Instead we generally include the base codes.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [In the CY 2023 PFS final rule (87 FR 69736), we mentioned that we may consider other \\napproaches for calculating the payment rate for HCPCS code G0511 as the number of services \\nincluded in the general care management code is growing each year and provided examples.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [We \\nthought to consider in the future valuing HCPCS code G0511 using a weighted average of the \\nservices that comprise HCPCS code G0511 or using the national average of the top three \\nservices comprising HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [We welcomed comments on potential methodologies, \\nbut noted we did not receive any comments.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [As we discuss above, we have been engaged in a multi-year examination of coordinated \\nand collaborative care services in professional settings, and as a result established codes and \\nseparate payment in the PFS to separately recognize and pay for these important services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [The \\ncare coordination included in services, such as office visits, do not always adequately describe \\nthe non-face-to-face care management work involved in primary care.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Payment for in-person \\nencounters may not reflect all the services and resources required to furnish comprehensive, \\ncoordinated care management.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Through the last few payment rules, we have expanded the \\ngeneral care management services billable using the HCPCS code G0511to be consistent with \\nthe policies implemented under the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [In section III.B.4.b and c. of this proposed rule, we are proposing to expand the billable \\nservices under HCPCS code G0511 to include RPM, RTM, CHI, and PIN.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [If we continue to \\ncalculate HCPCS code G0511 using our current approach, we believe that the value may no \\nlonger be appropriate payment for those services since we are simply dividing by the number of \\ncodes that comprise HCPCS code G0511 and as that number of services with lower payment \\nrates increases, the value diminishes.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Therefore, we are proposing to revise our method for \\ncalculating HCPCS code G0511 so that payment for general care management is more \\nappropriate.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Below, we compare our current method to the proposed revised approach.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Based on the current methodology for HCPCS code G0511 as shown in Table 22, general \\ncare management services are paid at the average of the national non-facility PFS payment rates \\nfor CPT codes 99490, 99487, 99484, 99491, 99424 and 99426.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [TABLE 22:  CY 2023 National Non-Facility PFS Payment Rate for G0511\\nCPT Code National Non-Facility PFS Payment Rate\\n99424 $81.33\\n99426 $61.34\\n99484 $43.04\\n99487 $133.18\\n99490 $62.69\\n99491 $85.06\\nG0511 $77.941\\n1 Noting when averaging the six codes, the total RVU for HCPCS \\ncode G0511 is 2.295.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Multiplying that by the conversion factor of \\n33.8872 results in $77.77.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [However, RVUs on the PFS file are \\nexpressed in two decimal places.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Thus, we round the 2.295 \\naverage to 2.30 which yields 2.30 * 33.8872, resulting in $77.94, \\nthe current payment rate for HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [As shown in Table 23, when we include RPM and RTM services in the national non-\\nfacility average as discussed above, the payment rate for HCPCS code G0511 is reduced to \\n$64.13 based on the national non-facility PFS payment rates for CY 2023.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [TABLE 23:  CY 2023 National Non-Facility PFS Payment Rate for G0511 with RPM and \\nRTM Base Codes\\nCPT Code National Non-Facility PFS Payment Rate\\n99454 $50.15\\n99457 $48.80\\n99091 $54.22\\n98976 $50.15\\n98977 $50.15\\n98980 $49.48\\n99424 $81.33\\n99426 $61.34\\n99484 $43.04\\n99487 $133.18\\n99490 $62.69\\n99491 $85.06\\nG0511 $64.13*\\n*Noting when averaging the 12 codes, the total RVU for HCPCS code G0511 is 2.30.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Multiplying that by the conversion factor of 33.8872 results in $64.13.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [As demonstrated by comparing Table 22 to Table 23, using the current method of \\ncalculating the average of the non-facility rates but adding in RPM and RTM services base codes \\nwould result in a lower payment amount for HCPCS code G0511 compared to the current \\npayment amount.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We believe that while the policy may address providing a payment for \\nfurnishing non-face-to-face services, the magnitude of the value may not appropriately account \\nfor the costs.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Therefore, we considered and are proposing a revised methodology for the \\ncalculation by looking at the actual utilization of the services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [That is, we are proposing to use a \\nweighted average of the services that comprise HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [In order to use a weighted \\naverage, there needs to be data on the utilization of the services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We do not have data on \\nutilization of the services that comprise HCPCS code G0511 for RHCs and FQHCs since \\nHCPCS code G0511 accounts for a variety of services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Therefore, we would use the most \\nrecently available utilization data from the services paid under the PFS, that is, in the physician \\noffice setting.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We believe that the physician office setting provides an appropriate proxy for \\nutilization of these services in the absence of actual data because this setting most closely aligns \\nwith the types of services furnished in RHCs and FQHCs since they typically furnish primary \\ncare.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [ In order to analyze utilization for services paid under the PFS and to ensure we \\naccounted for payments accurately, we would use CY 2021 claims data to look at utilization of \\nthe base code for the service and any applicable add-on codes used in the same month as well as \\nany base codes reported alone in a month for all of the services encompassing general care \\nmanagement, that is the array of services that make up HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [We believe we \\nneed to account for the payment associated with the base code along with an applicable add-on \\ncode in our calculation as this demonstrates a complete encounter.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Until actual utilization \\nbecomes available, RHCs and FQHCs that furnish CPM, GBHI, CHI and PIN services would \\nreport HCPCS code G0511 when those services are furnished; however, they would not be \\nincluded in the weighted average at this time.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Once more data is available, we will revisit the \\nvaluation of HCPCS code G0511 to include CPM, GBHI, CHI, and PIN as necessary.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Table 24 shows the payment amount using this calculation.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [The national non-facility \\npayment rate associated with each code that comprises HCPCS code G0511 can be found in \\nAddendum B of this proposed rule.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [We note that the revised methodology does reduce the \\npayment rate for HCPCS code G0511 from its current rate for CY 2023, although not \\nsignificantly.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [TABLE 24: Weighted Average Payment Rate for G0511 with RPM, RTM, CHI, and PIN \\nServices Using CY 2023 Rates and Conversion Factor\\nCPT Code 2021 NF Utilization Weighted Average\\n99454 931,411 46,710,262\\n99457 492,286 24,023,557\\n99457+99458 398,209 35,221,586\\n99474 1,581 24,110\\n99091 55,435 3,005,686\\n98976 93,141 4,671,028\\n98977 93,141 4,671,028\\n98980 14,112 698,243\\n98980+98981 119,463 10,647,711\\n99424 13,719 1,115,766\\n99424+99425 4,573 638,482\\n99426 28,858 1,770,134\\n99426+99427 9,619 1,046,382\\n99484 151,808 6,533,816\\n99487 26,441 3,521,412\\n99487+99489 229,004 46,641,245\\n99490 3,436,429 215,429,734\\n99490+99439 802,656 88,396,505\\n99491 29,665 2,523,322\\n99491+99437 118,661 17,210,562\\nG0511 $72.98\\nTherefore, we propose to take the weighted average of the base code and add-on code \\npairs, in addition to the individual base codes for all of the services that comprise HCPCS code \\nG0511 by using the CY 2021 PFS utilization to calculate the payment rate for the general care \\nmanagement services furnished in RHCs and FQHCs on or after January 1, 2024.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [The number \\non the right side of Table 24 is a weighted average which grants more relative weight to the \\ncodes in proportion to their utilization in 2021 claims data.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [To calculate the weighted average, \\nwe multiple the non-facility payment rate times the non-facility utilization for each code, sum \\nthis total, then divide by the summed non-facility utilization for the codes included in the \\naverage.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [In an effort to be consistent with practitioners billing under the PFS and to account for \\nthe additional time spent in care coordination, we determined that this approach was more \\naccurate representation of the payment.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [We would also update HCPCS code G0511 annually \\nbased on current data available in the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [We propose revisions at \\u00a7 405.2464(c) to reflect the revised methodology for calculating \\nthe payment amount for general care management services beginning January 1, 2024 which]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [would be based on a weighted average of the services that comprise HCPCS code G0511 using \\nthe most recently available PFS utilization data.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We welcome comments on this proposed \\nmethodology.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [e. Chronic Care Management Services and Virtual Communication Services Requirement for \\nObtaining Beneficiary Consent\\n(1) Chronic Care Management Services\\nRHCs and FQHCs have been authorized to bill for Chronic Care Management (CCM) \\nservices since January 1, 2016.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [The RHC and FQHC requirements for billing CCM services have \\ngenerally followed the requirements for practitioners billing under the PFS, with some \\nadaptations based on the RHC and FQHC payment methodologies.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [In fact, in the CY 2017 PFS \\nfinal rule (81 FR 80256-80257) to assure that CCM requirements for RHCs and FQHCs were not \\nmore burdensome than those for practitioners billing under the PFS, we finalized revisions to the \\nrequirements for CCM services furnished by RHCs and FQHCs similar to revisions to the \\nrequirements for CCM services finalized under the PFS (81 FR 80243 through 80251).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [Information regarding CCM services is available on the CMS Care Management Site.121\\nIn the CY 2022 PFS proposed rule (86 FR 39175), we solicited public comment on the \\nstandard practice used by practitioners to obtain beneficiary consent for CCM services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We \\nstated that we have received questions from interested parties regarding the consent requirements \\nfor CCM services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We explained that these questions may have arisen because of the many \\nflexibilities allowed in response to the PHE for COVID\\u201319.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [In particular, during the PHE for \\nCOVID\\u201319, we allowed interested parties to obtain beneficiary consent for certain services \\nunder general supervision (85 FR 19230, April 6, 2020).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We noted that before the PHE for \\nCOVID\\u201319, we required that beneficiary consent be obtained either by or under the direct \\nsupervision of the primary care practitioner.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We noted that this requirement was consistent with \\nthe conditions of payment for this service under the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We stated that as we consider what \\n121 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Care-Management.]]\",\n          \"Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [injection training for insulin-dependent patients.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [We do not want our policies to prevent \\ninjection training via telehealth when clinically appropriate.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Consequently, we are proposing to \\nrevise our policy at 410.78(e) to allow the 1 hour of in-person training (for initial and/or follow-\\nup training), when required for insulin-dependent beneficiaries, to be provided via telehealth.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [If \\nfinalized, we anticipate revising the Medicare Claims Processing Manual, Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [100-04, chapter \\n12, section 190.3.6 to reflect that flexibility.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [J.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Advancing Access to Behavioral Health Services\\n1.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Implementation of Section 4121(a) of the Consolidated Appropriations Act, 2023 \\na. Statutory Amendments\\nSection 4121(a) of Division FF, Title IV, Subtitle C of the Consolidated Appropriations \\nAct of 2023 (CAA, 2023) (Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [L. 117-328, December 29, 2022), Coverage of Marriage and \\nFamily Therapist Services and Mental Health Counselor Services under Part B of the Medicare \\nProgram, provides for Medicare coverage of and payment for the services of health care \\nprofessionals who meet the qualifications for marriage and family therapists (MFTs) and mental \\nhealth counselors (MHCs) when billed by these professionals.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Specifically, section 4121(a)(1) of the CAA, 2023 amended section 1861(s)(2) of the Act \\nby adding a new benefit category under Medicare Part B in new subparagraph (II) to include \\nmarriage and family therapist services (as defined in an added section 1861(lll)(1) of the Act) \\nand mental health counselor services (as defined in an added section 1861(lll)(3) of the Act).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Section 4121(a)(2) of the CAA, 2023 added a new subsection (lll) to section 1861 of the \\nAct, which defines marriage and family therapist services, marriage and family therapist (MFT), \\nmental health counselor services, and mental health counselor (MHC).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Section 1861(lll)(1) of the \\nAct defines \\u201cmarriage and family therapist services\\u201d as services furnished by an MFT for the \\ndiagnosis and treatment of mental illnesses (other than services furnished to an inpatient of a \\nhospital), which the MFT is legally authorized to perform under State law (or the State \\nregulatory mechanism provided by State law) of the State in which such services are furnished,]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [as would otherwise be covered if furnished by a physician or as an incident to a physician\\u2019s \\nprofessional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(2) of the Act defines the term MFT to mean an individual \\nwho:\\n\\u25cf  Possesses a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or certification as \\na MFT pursuant to State law of the State in which such individual furnishes marriage and family \\ntherapist services; \\n\\u25cf  Is licensed or certified as a MFT by the State in which such individual furnishes such \\nservices;\\n\\u25cf  After obtaining such degree has performed at least 2 years of clinical supervised \\nexperience in marriage and family therapy; and \\n\\u25cf  Meets such other requirements as specified by the Secretary.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(3) of the Act defines \\u201cmental health counselor services\\u201d as services \\nfurnished by a mental health counselor (MHC) for the diagnosis and treatment of mental \\nillnesses (other than services furnished to an inpatient of a hospital), which the MHC is legally \\nauthorized to perform under State law (or the State regulatory mechanism provided by the State \\nlaw) of the State in which such services are furnished, as would otherwise be covered if \\nfurnished by a physician or as incident to a physician\\u2019s professional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(4) \\nof the Act defining MHC as an individual who:\\n\\u25cf  Possesses a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or certification as \\na mental health counselor, clinical professional counselor, or professional counselor under State \\nlaw of the State in which such individual furnishes MHC services; \\n\\u25cf  Is licensed or certified as a mental health counselor, clinical professional counselor, or \\nprofessional counselor by the State in which the services are furnished; \\n\\u25cf  After obtaining such degree has performed at least 2 years of clinical supervised \\nexperience in mental health counseling; and  \\n\\u25cf  Meets such other requirements as specified by the Secretary.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 4121(a)(3) of the CAA, 2023 amended section 1833(a)(1) of the Act to add a new \\nsubparagraph (FF), which provides that, with respect to MFT services and MHC services under \\nsection 1861(s)(2)(II) of the Act, the amounts paid shall be 80 percent of the lesser of the actual \\ncharge for the services or 75 percent of the amount determined for payment of a psychologist \\nunder subparagraph (L).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 1888(e)(2)(A)(ii) of the Act, as amended by section 4121(a)(4) of the CAA, \\n2023, excludes MFT and MHC services from consolidated billing requirements under the skilled \\nnursing facility (SNF) prospective payment system.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [For further discussion about this exclusion \\nof MFT and MHC services from SNF consolidated billing, see discussion in the FY 2024 SNF \\nProspective Payment System (PPS) proposed rule (88 FR 21316)32.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 4121(a)(5) of the \\nCAA, 2023 amended section 1842(b)(18)(C) of the Act to add MFTs and MHCs to the list of \\npractitioners whose services can only be paid by Medicare on an assignment-related basis.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [MFTs, MHCs, and other practitioners described in section 1842(b)(18)(C) of the Act may not \\nbill (or collect any amount from) the beneficiary or another person for any services for which \\nMedicare makes payment, except for deductible and coinsurance amounts applicable under Part \\nB.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [More information on assignment of claims can be found at in the Medicare Claims \\nProcessing Manual, Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [100-04, Chapter 1, Section 30.3.1.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [We also note that section 1861(aa)(1)(B) of the Act was amended by section 4121(b)(1) \\nof the CAA, 2023 to add services furnished by MFTs and MHCs to the definition of rural health \\nclinic services.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [See section III.B of this proposed rule for discussion related to MFT and MHC \\nservices furnished in RHCs and FQHCs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Additionally, section 1861(dd)(2)(B)(i)(III) of the Act was amended by 4121(b)(2) of the \\nCAA, 2023 to require a hospice program to have an interdisciplinary team that includes at least \\none social worker, MFT or MHC.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [For further discussion about this amended requirement for \\nhospice program interdisciplinary teams, see section III.O of this proposed rule.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [32 https://www.govinfo.gov/content/pkg/FR-2023-04-10/pdf/2023-07137.pdf.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [b.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Proposed Changes to Regulations\\nConsistent with the changes to the statute described above, we are proposing to create two \\nnew regulation sections at \\u00a7 410.53 and \\u00a7 410.54 to codify the coverage provisions for MFTs and \\nMHCs, respectively.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Specifically, we are proposing to define a marriage and family therapist at \\u00a7 410.53 as an \\nindividual who: \\n\\u25cf  Possesses a master's or doctor's degree which qualifies for licensure or certification as \\na marriage and family therapist pursuant to State law of the State in which such individual \\nfurnishes the services defined as marriage and family therapist services; \\n\\u25cf  After obtaining such degree, has performed at least 2 years or 3,000 hours of post \\nmaster\\u2019s degree clinical supervised experience in marriage and family therapy in an appropriate \\nsetting such as a hospital, SNF, private practice, or clinic; and \\n\\u25cf  Is licensed or certified as a marriage and family therapist by the State in which the \\nservices are performed.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We note that we are aware that there may be some States that require a number of hours \\nof clinical supervised experience for MFT licensure that may be inconsistent with the statutory \\nrequirement in section 1861(s)(2) of the Act that requires at least 2 years of clinical supervised \\nexperience.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We believe it could be possible for an MFT to have completed the required number \\nof clinical supervised hours required for licensure in their State, but to have accomplished this in \\nless than two years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Therefore, we are proposing a requirement for MFTs to have performed at \\nleast 2 years or 3,000 hours of post master\\u2019s degree clinical supervised experience, if consistent \\nwith State licensure requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We believe that 3,000 hours is roughly equivalent to the \\nstatutory requirement to have performed 2 years of clinical supervised experience and note that \\nthe regulatory requirements for clinical social workers (CSWs) at \\u00a7 410.73(a)(3)(ii) allow 2 years \\nor 3,000 hours of supervised experience.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Additionally, the statutory benefit category for both \\nMFTs and CSWs is defined as services for the diagnosis and treatment of mental illnesses.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [As]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [such, we believe it would be appropriate to provide similar flexibility in the required amount of \\nclinical supervised experience for MFTs and CSWs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are also interested in public comments \\nregarding States that have a supervised clinical hour requirement for MFT licensure that is less \\nthan 2 years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are proposing to define \\u201cMarriage and family therapist services\\u201d at \\u00a7 410.53(b)(1) as \\nservices furnished by a marriage and family therapist for the diagnosis and treatment of mental \\nillnesses (other than services furnished to an inpatient of a hospital), which the marriage and \\nfamily therapist is legally authorized to perform under State law (or the State regulatory \\nmechanism provided by State law) of the State in which such services are furnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are also \\nproposing at \\u00a7 410.53(b)(1) that the services must be of a type that would be covered if they \\nwere furnished by a physician or as an incident to a physician's professional service and must \\nmeet the requirements of this section.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [Lastly, we are proposing at \\u00a7 410.53(b)(2) that the following services do not fall under \\nthe Medicare Part B benefit category for MFT services: \\n\\u25cf  Services furnished by a marriage and family therapist to an inpatient of a Medicare-\\nparticipating hospital.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [Similarly, we are proposing to define a mental health counselor at \\u00a7 410.54 as an \\nindividual who:\\n\\u25cf  Possesses a master's or doctor's degree which qualifies for licensure or certification as \\na mental health counselor, clinical professional counselor, or professional counselor under the \\nState law of the State in which such individual furnishes the services defined as mental health \\ncounselor services; \\n\\u25cf  After obtaining such a degree, has performed at least 2 years or 3,000 hours of post \\nmaster\\u2019s degree clinical supervised experience in mental health counseling in an appropriate \\nsetting such as a hospital, SNF, private practice, or clinic; and]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [\\u25cf  Is licensed or certified as a mental health counselor, clinical professional counselor, or \\nprofessional counselor by the State in which the services are performed.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [As previously \\nexplained for MFTs, and for the same reasons, we are proposing a requirement for MHCs to \\nhave performed at least 2 years or 3,000 hours of post master\\u2019s degree clinical supervised \\nexperience, if consistent with State licensure requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We believe that 3,000 hours is \\nroughly equivalent to the statutory requirement to have performed 2 years of clinical supervised \\nexperience and note that the regulatory requirements for clinical social workers at \\u00a7 \\n410.73(a)(3)(ii) allows 2 years or 3,000 hours.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [The MHC statutory benefit category authorizes \\nMHCs to furnish services for the diagnosis and treatment of mental illnesses as it does for \\nCSWs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are also interested in public comments regarding States that have a supervised \\nclinical hour requirement for MHC licensure that is less than 2 years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing to define \\u201cmental health counselor services\\u201d at \\u00a7 410.54(b)(1) as \\nservices furnished by a mental health counselor (as defined in paragraph (a) of this section) for \\nthe diagnosis and treatment of mental illnesses (other than services furnished to an inpatient of a \\nhospital), which the mental health counselor is legally authorized to perform under State law (or \\nthe State regulatory mechanism provided by State law) of the State in which such services are \\nfurnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are also proposing at \\u00a7 410.54(b)(1) that the services must be of a type that would \\nbe covered if they were furnished by a physician or as an incident to a physician's professional \\nservice.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing at \\u00a7 410.54(b)(2) that the following services do not fall under the \\nMedicare Part B benefit category for MHC services: \\n\\u25cf  Services furnished by a mental health counselor to an inpatient of a Medicare-\\nparticipating hospital.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing to amend \\u00a7 410.10 to add marriage and family therapist services and \\nmental health counselor services to the list of included medical and other health services.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [also proposing to amend \\u00a7 410.150 to add marriage and family therapists and mental health \\ncounselors, to the list of individuals or entities to whom payment is made.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Currently, \\u00a7 410.32(a)(2) lists the health care practitioners that may order diagnostic \\ntests.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Since this list currently includes CSWs and clinical psychologists (CPs), who are also \\nauthorized by statute to furnish services for the diagnosis and treatment of mental illnesses, we \\nare proposing to amend \\u00a7 410.32(a)(2) to add MFTs and MHCs to the list of practitioners who \\nmay order diagnostic tests, as for the other non-physician practitioners, to the extent that the \\nMFT or MHC is legally authorized to perform the service under State law (or the State \\nregulatory mechanism provided by State law) of the State in which such services are furnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [We are also proposing to codify in a new \\u00a7 414.53 the payment amounts authorized under \\nsection 1833(a)(1)(FF) for MFT and MHC services .]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Additionally, we are proposing to codify at \\n\\u00a7 414.53 the payment amount for clinical social worker (CSW) services as authorized under \\nsection 1833(a)(1)(F) of the Act.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [As we reviewed our regulations to implement section 4121 of \\nthe CAA, 2023, we found that the payment amounts for CSWs are not yet codified under \\nregulations.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Specifically, we are proposing to add that the payment amount for CSW, MFT, and \\nMHC services is 80 percent of the lesser of the actual charge for the services or 75 percent of the \\namount determined for clinical psychologist services under the PFS.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [We are also proposing to add MFTs and MHCs to the list of practitioners who are eligible \\nto furnish Medicare telehealth services at the distant site.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [See section II.D.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [of this proposed rule \\nfor a discussion of this proposal.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Additionally, we are proposing to allow Addiction Counselors who meet all of the \\napplicable requirements (possess a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or \\ncertification as a mental health counselor; after obtaining such degree have performed at least 2 \\nyears (or, as proposed, 3,000 hours) of clinical supervised experience in mental health \\ncounseling; and licensed or certified as a MHC, clinical professional counselor, or professional \\ncounselor by the State in which the services are furnished) to enroll in Medicare as MHCs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [That]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [is, under this proposal, Addiction Counselors would be considered Mental Health Counselors \\nand would be eligible to enroll and bill Medicare for MHC services if they meet these \\nrequirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We understand there is variation in the terminology used for licensure across \\nStates for MHCs and MFTs and are seeking information pertaining to other types of \\nprofessionals who may meet the applicable requirements for enrollment as mental health \\ncounselors.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We note that in past rulemaking, we have discussed the term \\u2018mental health\\u2019 to be \\ninclusive of diagnosis and treatment of substance use disorders.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [For example, in the CY 2022 \\nPFS final rule (86 FR 65061), we stated that SUD services are considered mental health services \\nfor the purposes of the expanded definition of \\u201cinteractive telecommunications system.\\u201d We \\npropose to apply that same interpretation for purposes of the mental health services included in \\nthe definition of MFT, MHC, and to clarify that the same interpretation applies for CSW, and CP \\nservices.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [c.  Coding Updates to Allow MFT and MHC Billing\\nIn light of the new statutory benefits for MFTs and MHCs authorized by section 4121(a) \\nof the CAA, 2023, we have considered whether updates to certain HCPCS codes are required in \\norder to allow MFTs and MHCs to bill for the services described by those HCPCS codes.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [In the \\nCY 2023 PFS final rule, we finalized new coding and payment for General Behavioral Health \\nIntegration services performed by CPs or CSWs to account for monthly care integration where \\nthe mental health services furnished by a CP or CSW serve as the focal point of care integration.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [In light of the new coverage under Medicare for MFT and MHC services for the diagnosis and \\ntreatment of mental illness, we are proposing to revise the code descriptor for HCPCS code \\nG0323 in order to allow MFTs and MHCs, as well as CPs and CSWs, to be able to bill for this \\nmonthly care integration service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We note that MFTs and MHCs, like CSWs, are authorized by \\nstatute for the diagnosis and treatment of mental illnesses (other than services furnished to an \\ninpatient of a hospital), which the MFT or MHC is legally authorized to perform under State law \\n(or the State regulatory mechanism provided by State law) of the State in which such services are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [furnished, as would otherwise be covered if furnished by a physician or as an incident to a \\nphysician\\u2019s professional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [The proposed code descriptor for HCPCS code G0323 is: Care \\nmanagement services for behavioral health conditions, at least 20 minutes of clinical \\npsychologist, clinical social worker, mental health counselor, or marriage and family therapist \\ntime, per calendar month.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [(These services include the following required elements: Initial \\nassessment or follow-up monitoring, including the use of applicable validated rating scales; \\nbehavioral health care planning in relation to behavioral/psychiatric health problems, including \\nrevision for patients who are not progressing or whose status changes; facilitating and \\ncoordinating treatment such as psychotherapy, coordination with and/or referral to physicians \\nand practitioners who are authorized by Medicare to prescribe medications and furnish E/M \\nservices, counseling and/or psychiatric consultation; and continuity of care with a designated \\nmember of the care team.)]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [Lastly, we note that consistent with the proposed changes to valuation of CPT code \\n99484 in the Valuation of Specific Codes section (section II.E.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [of this proposed rule), which \\ndescribes General BHI and is the crosswalk code used for valuation of HCPCS code G0323, we \\nare also proposing conforming updates to the valuation for work and PE inputs for HCPCS code \\nG0323.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [See section II.E.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [of this proposed rule for further discussion of changes to the valuation \\nfor HCPCS code G0323.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [We welcome comments regarding any other HCPCS codes that may require updating to \\nallow MFTs and MHCs to bill for the services described in the HCPCS code descriptor.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [d. Medicare Enrollment of MFTs and MHCs\\nMFTs and MHCs who meet the applicable requirements (possess a master\\u2019s or doctor\\u2019s \\ndegree which qualifies for licensure or certification as a mental health counselor; after obtaining \\nsuch degree have performed at least 2 years (or, as proposed, 3,000 hours) of clinical supervised \\nexperience in mental health counseling; and is licensed or certified as a MHC, clinical \\nprofessional counselor, or professional counselor by the State in which the services are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [furnished) described in detail above in this section, as finalized, will need to enroll in Medicare \\nas MFTs and MHCs in order to submit claims for marriage and family therapist services and \\nmental health counselor services, respectively, furnished to Medicare beneficiaries.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [Under \\u00a7 \\n424.510, a provider or supplier must complete, sign, and submit to its assigned MAC the \\nappropriate Form CMS\\u2013855 (OMB Control No.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [0938\\u20130685) application in order to enroll in the \\nMedicare program and obtain Medicare billing privileges.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [The Form CMS\\u2013855, which can be \\nsubmitted via paper or electronically through the internet-based Provider Enrollment, Chain, and \\nOwnership System (PECOS) process (SORN: 09\\u201370\\u20130532; 104 Provider Enrollment, Chain, and \\nOwnership System), captures information about the provider or supplier that is needed for CMS \\nor its MACs to determine whether the provider or supplier meets all Medicare requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [We \\npropose that the MFT and MHC supplier types, like most non-physician practitioner types, be \\nsubject to limited-risk screening under \\u00a7 424.518, for we have no basis on which to assign these \\nsuppliers as a class to a higher screening category.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [MFTs and MHCs that meet the proposed requirements in \\u00a7\\u00a7 410.53 and 410.54 as \\nfinalized, would enroll in Medicare via the Form CMS-855I application (Medicare Enrollment \\nApplication \\u2013 Physicians and Non-Physician Practitioners; OMB No.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [0938-1355) and could \\nbegin submitting their enrollment applications after the publication of the CY 2024 PFS final \\nrule.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [However, as the new benefit categories authorized by section 4121(a) of the CAA, 2023, \\ndo not take effect until January 1, 2024, MFT or MHC claims for MFT or MHC services \\nfurnished to Medicare beneficiaries with dates of service prior to January 1, 2024 will not be \\npayable under Medicare Part B.  MFTs and MHCs can visit \\nhttps://www.cms.gov/medicare/provider-enrollment-and-certification for basic information on \\nthe provider enrollment process.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [2.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [Implementation of Section 4123 of the CAA, 2023\\nSection 4123(a)(1) of the CAA, 2023, Improving Mobile Crisis Care in Medicare, \\namended section 1848 of the Act by adding a new paragraph (b)(12) regarding payment for]]\",\n          \"Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [evidence that certain dental services are so integral to the clinical success that they are \\ninextricably linked to other covered service(s).]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We encourage interested parties to use the public \\nsubmission process to submit recommendations and relevant clinical evidence for establishing \\nthis connection.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [Above, in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [of this proposed rule, we have described the various \\ntypes of documentation to support recommendations through this process.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We are considering, \\nand seek comment on, whether the following cardiac interventions are examples of specific \\nmedical services for which dental services are inextricably linked to clinical success: \\nimplantation of electronic devices in the heart, such as pacemakers, cardioverter defibrillators, \\nand monitors.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We are also considering, and seek comment on, whether the following procedures \\nwould be considered examples of specific medical services for which dental services are \\ninextricably linked to their clinical success: the placement of intracardiac or intravascular foreign \\nmaterial, such as a stent or for hemodialysis, or for a vascular access graft, whereas you would \\nnot proceed with the medical service without having first completed a dental evaluation and/or \\ntreatment as determined necessary.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We seek comment on whether preoperative and \\nperioperative dental services are inextricably linked to any other covered cardiac interventions as \\nsupported by clinical evidence.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [4.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [Request for Comment on Dental Services Integral to Specific Covered Services to Treat Sickle \\nCell Disease (SCD) and Hemophilia \\nInterested parties using the public submission process we finalized in the CY 2023 PFS \\nfinal rule urged us to propose to provide that payment can be made for dental services for \\nindividuals living with SCD and hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [These submissions provided information and references supporting prevention of dental \\ninfection among individuals with SCD to reduce need for more extensive procedures that may \\nresult in bleeding complications and require hospitalization.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [They also provided information]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [detailing increased dental caries and periodontal disease in people with SCD,90 many of whom \\nlose a number of teeth, which greatly limits nutrition, general well-being, and overall quality of \\nlife.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We seek comment on whether certain dental services are inextricably linked to other \\ncovered services used in the treatment of SCD, such as, but not limited to, hydroxyurea therapy.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We seek comment identifying such covered services for SCD and whether an inextricable link is \\nsupported by clinical evidence as described in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [of this proposed rule.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Interested parties also urged us to propose a policy to permit payment for dental services \\nfor individuals living with hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [They noted that periodic dental care reduces the risks of \\ndental complications requiring haemostatic therapy (such as tooth extractions that may require \\nclotting factor treatment) or oral surgeries requiring clotting factor replacement therapy.91 92 93  \\nWe note that many submitters stated that good dental and oral health benefits a patient\\u2019s \\noverall health generally.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Several commenters on the CY 2023 PFS proposed rule also expressed \\nthat good oral hygiene, along with routine dental services, contributes to better outcomes for \\npatients.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We recognized in the CY 2023 PFS final rule in response to those comments that there \\nis a great deal of evidence suggesting that dental health is generally an important component of \\noverall health; however, we are interested in comments on whether certain dental services are \\nconsidered so integral to the primary covered services that the necessary dental interventions are \\ninextricably linked to, and substantially related and integral to clinical success of, the primary \\n90 Kakkar M, Holderle K, ShethM, Arany S, Schiff L, Planerova A. Orofacial Manifestation and Dental \\nManagement of Sickle Cell Disease: A Scoping Review.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Anemia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2021 Oct22; 2021:5556708.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Doi: \\n10.1155/2021/5556708.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 34721900; PMCID: PMC8556080.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [91 Raso S, Napolitano M, Sirocchi D, Siragusa S, Hermans C. The important impact of dental care on haemostatic \\ntreatment burden in patients with mild haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2022 Nov;28(6):996-999. doi: \\n10.1111/hae.14626.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Epub 2022 Jul 25.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 35879819.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [92 Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, \\nWindyga J, Llin\\u00e1s A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce \\nGF; WFH Guidelines for the Management of Hemophilia panelists and co-authors.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [WFH Guidelines for the \\nManagement of Hemophilia, 3rd edition.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Epub \\n2020 Aug 3.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Erratum in: Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2021 Jul;27(4):699.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 32744769.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [93 Peisker A, Raschke GF, Schultze-Mosgau S. Management of dental extraction in patients with Haemophilia A and \\nB: a report of 58 extractions.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Med Oral Patol Oral Cir Bucal.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2014 Jan 1;19(1):e55-60.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [doi: 10.4317/medoral.19191.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 24121912; PMCID: PMC3909433.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [covered services such that they are not subject to the statutory preclusion on Medicare payment \\nfor dental services under section 1862(a)(12) of the Act.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We seek comment on whether certain dental services are inextricably linked to certain \\nother covered services for hemophilia, supported by clinical evidence as described in section \\nII.K.1.c., above.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We seek comment identifying such covered services for the treatment of \\nhemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We also seek comment specifically on whether dental services such as prophylaxis \\nare a standard of care in the management of hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [5.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Request for Comment Regarding Dental Services Possibly Inextricably Linked to Other \\nMedicare-Covered Services, \\nCommenters, submitters, and other interested parties have urged us to consider the \\nimportance of access to oral health care for people with chronic auto-immune conditions, and \\nother chronic disease conditions, such as, but not limited to, diabetes.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We understand and \\nappreciate the interest in such requests.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Because the Medicare statute generally prohibits \\npayment for dental services payment may only be made when the dental services are inextricably \\nlinked to, and substantially related and integral to the clinical success of, certain other covered \\nservices.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We urge interested parties to consider the circumstances under which dental services \\nare inextricably linked to specific covered services (not diagnoses) used to treat patients with \\nauto-immune conditions or other chronic conditions, supported by clinical evidence as described \\nin section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [of this proposed rule.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We have encouraged interested parties who believe certain dental services are \\ninextricably linked to certain covered services to use our public submission process to provide \\ninformation on these clinical scenarios, supported by clinical evidence or other documentation, \\nas discussed in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [of this proposed rule, such as that it would be the standard of \\ncare to not proceed with the medical service without having completed the dental service.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Commenters are welcome to submit additional information regarding clinical scenarios presented \\nin the CY 2023 PFS rulemaking discussions, which we are not proposing for the CY 2024, such]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "merged_df_Subtopic_text_combined"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-949b93e5-2e35-4b12-8bd4-b07c0183e799\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Subtopic</th>\n",
              "      <th>Sort_seq</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B4b_Supply and Equipment Pricing</td>\n",
              "      <td>2</td>\n",
              "      <td>Subtopic: 2B4b_Supply and Equipment Pricing: [...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2B4c_Clinical Labor Pricing</td>\n",
              "      <td>3</td>\n",
              "      <td>Subtopic: 2B4c_Clinical Labor Pricing: [from p...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2B5_Solicitation: Updates to PE Data Collectio...</td>\n",
              "      <td>4</td>\n",
              "      <td>Subtopic: 2B5_Solicitation: Updates to PE Data...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2D1b_Requests to Add to Telehealth List</td>\n",
              "      <td>7</td>\n",
              "      <td>Subtopic: 2D1b_Requests to Add to Telehealth L...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2D1c_Solicitation: Telehealth List Process for...</td>\n",
              "      <td>8</td>\n",
              "      <td>Subtopic: 2D1c_Solicitation: Telehealth List P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>7C3_Health Equity</td>\n",
              "      <td>127</td>\n",
              "      <td>Subtopic: 7C3_Health Equity: [from p. 1203: [2...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>7E1_Impact of Medicare Parts A and B Payment f...</td>\n",
              "      <td>130</td>\n",
              "      <td>Subtopic: 7E1_Impact of Medicare Parts A and B...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>7E2_Impact of Separate Pmnt for O/O E/M Visit ...</td>\n",
              "      <td>131</td>\n",
              "      <td>Subtopic: 7E2_Impact of Separate Pmnt for O/O ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>7E3a_Impact of Proposed Payment for MFT Servic...</td>\n",
              "      <td>132</td>\n",
              "      <td>Subtopic: 7E3a_Impact of Proposed Payment for ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>100</th>\n",
              "      <td>7F1_Alts Considered Related to the O/O E/M Vis...</td>\n",
              "      <td>134</td>\n",
              "      <td>Subtopic: 7F1_Alts Considered Related to the O...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>101 rows  3 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-949b93e5-2e35-4b12-8bd4-b07c0183e799')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-949b93e5-2e35-4b12-8bd4-b07c0183e799 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-949b93e5-2e35-4b12-8bd4-b07c0183e799');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-016bce54-95f0-4a63-9657-ae44d59ffba5\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-016bce54-95f0-4a63-9657-ae44d59ffba5')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-016bce54-95f0-4a63-9657-ae44d59ffba5 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_a434e686-0b54-4a88-ba1b-a1c71545baa1\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('merged_df_Subtopic_text_combined')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_a434e686-0b54-4a88-ba1b-a1c71545baa1 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('merged_df_Subtopic_text_combined');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                   InsightsAI_Subtopic  Sort_seq  \\\n",
              "0                    2B4b_Supply and Equipment Pricing         2   \n",
              "1                          2B4c_Clinical Labor Pricing         3   \n",
              "2    2B5_Solicitation: Updates to PE Data Collectio...         4   \n",
              "3              2D1b_Requests to Add to Telehealth List         7   \n",
              "4    2D1c_Solicitation: Telehealth List Process for...         8   \n",
              "..                                                 ...       ...   \n",
              "96                                   7C3_Health Equity       127   \n",
              "97   7E1_Impact of Medicare Parts A and B Payment f...       130   \n",
              "98   7E2_Impact of Separate Pmnt for O/O E/M Visit ...       131   \n",
              "99   7E3a_Impact of Proposed Payment for MFT Servic...       132   \n",
              "100  7F1_Alts Considered Related to the O/O E/M Vis...       134   \n",
              "\n",
              "                                                  text  \n",
              "0    Subtopic: 2B4b_Supply and Equipment Pricing: [...  \n",
              "1    Subtopic: 2B4c_Clinical Labor Pricing: [from p...  \n",
              "2    Subtopic: 2B5_Solicitation: Updates to PE Data...  \n",
              "3    Subtopic: 2D1b_Requests to Add to Telehealth L...  \n",
              "4    Subtopic: 2D1c_Solicitation: Telehealth List P...  \n",
              "..                                                 ...  \n",
              "96   Subtopic: 7C3_Health Equity: [from p. 1203: [2...  \n",
              "97   Subtopic: 7E1_Impact of Medicare Parts A and B...  \n",
              "98   Subtopic: 7E2_Impact of Separate Pmnt for O/O ...  \n",
              "99   Subtopic: 7E3a_Impact of Proposed Payment for ...  \n",
              "100  Subtopic: 7F1_Alts Considered Related to the O...  \n",
              "\n",
              "[101 rows x 3 columns]"
            ]
          },
          "execution_count": 11,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Module 5c - MERGE SUBTOPICS and SENTENCES\n",
        "# Import necessary libraries\n",
        "import pandas as pd\n",
        "from nltk.tokenize import sent_tokenize\n",
        "\n",
        "def merge_with_Subtopic(segments, Subtopic_only_df):\n",
        "    \"\"\"\n",
        "    Merges segments with topics based on page numbers and adds a 'Topic' column.\n",
        "\n",
        "    Args:\n",
        "        segments (list): List of page content strings.\n",
        "        Subtopic_only_df (pd.DataFrame): Dataframe with subtopics, start pages, and end pages.\n",
        "\n",
        "    Returns:\n",
        "        pd.DataFrame: Dataframe with segments, page numbers, and a 'Subtopic' column.\n",
        "    \"\"\"\n",
        "    # Initialize variables\n",
        "    page_number = 1\n",
        "    all_sentences = []\n",
        "\n",
        "    for page_content in segments:\n",
        "        # Tokenize sentences\n",
        "        page_sentences = sent_tokenize(page_content)\n",
        "        for sentence in page_sentences:\n",
        "            # Create a dictionary for each sentence with page and topic (initially None),\n",
        "            # and save it in the list called 'all_sentences'\n",
        "            all_sentences.append({\n",
        "                'text': f\"from p. {page_number}: [{sentence}]\",\n",
        "                'page': page_number\n",
        "            })\n",
        "        page_number += 1\n",
        "\n",
        "    # Convert list of dictionaries to a dataframe\n",
        "    df_sentences = pd.DataFrame(all_sentences)\n",
        "\n",
        "    # Initialize lists to store results\n",
        "    text_list = []\n",
        "    subtopic_list = []\n",
        "    seq_list = []\n",
        "    page_list = []\n",
        "\n",
        "    # Iterate through each sentence and assign subtopics\n",
        "    for _, row in df_sentences.iterrows():\n",
        "        matched_subtopics = Subtopic_only_df[(Subtopic_only_df['Start_Page'] <= row['page']) &\n",
        "                                             (Subtopic_only_df['End Page']+1 >= row['page'])]\n",
        "\n",
        "        for _, subtopic_row in matched_subtopics.iterrows():\n",
        "            text_list.append(row['text'])\n",
        "            subtopic_list.append(subtopic_row['InsightsAI_Subtopic'])\n",
        "            seq_list.append(subtopic_row['Sort_seq'])\n",
        "            page_list.append(row['page'])  # Keep page number for filtering\n",
        "\n",
        "    # Create final DataFrame\n",
        "    merged_df = pd.DataFrame({\n",
        "        'text': text_list,\n",
        "        'InsightsAI_Subtopic': subtopic_list,\n",
        "        'Sort_seq': seq_list,\n",
        "        'page': page_list  # Include page numbers for later filtering if necessary\n",
        "    })\n",
        "\n",
        "    return merged_df\n",
        "\n",
        "# Processing the segments and subtopics\n",
        "merged_df = merge_with_Subtopic(segments, Subtopic_only_df)\n",
        "merged_df = merged_df[merged_df['InsightsAI_Subtopic'].notnull()]  # Ensure subtopic column is not null\n",
        "\n",
        "# Remove stubborn last row if it has 'NA'\n",
        "merged_df = merged_df[merged_df['InsightsAI_Subtopic'] != \"NA\"]\n",
        "\n",
        "# Optionally modify the text by prepending the subtopic information\n",
        "merged_df['text'] = 'Subtopic: ' + merged_df['InsightsAI_Subtopic'].astype(str) + ': [' + merged_df['text'] + ']'\n",
        "\n",
        "# Removing specific page ranges, if necessary\n",
        "#merged_df = merged_df[~merged_df['page'].isin([i for i in range(869, 1175)])]\n",
        "#merged_df = merged_df[~merged_df['page'].isin([i for i in range(1300, 1922)])]\n",
        "\n",
        "# Aggregate text for each Topic into a single entry\n",
        "merged_df_Subtopic_text_combined = merged_df.groupby(['InsightsAI_Subtopic', 'Sort_seq'])['text'].agg(lambda x: ' '.join(x)).reset_index()\n",
        "\n",
        "merged_df_Subtopic_text_combined"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 717
        },
        "id": "M4Byq27-jBEi",
        "outputId": "a29333d2-fbb9-4f3a-ece3-60bf8cbdd32a"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Special tokens have been added in the vocabulary, make sure the associated word embeddings are fine-tuned or trained.\n",
            "Token indices sequence length is longer than the specified maximum sequence length for this model (21648 > 8192). Running this sequence through the model will result in indexing errors\n"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Row 2: 6916 tokens\n",
            "Row 4: 21648 tokens\n",
            "Row 42: 8483 tokens\n",
            "Row 43: 28182 tokens\n",
            "Row 44: 9792 tokens\n",
            "Row 56: 7431 tokens\n",
            "Row 64: 9003 tokens\n",
            "Row 65: 21081 tokens\n",
            "Row 75: 18497 tokens\n",
            "Row 92: 7363 tokens\n",
            "Row 95: 7115 tokens\n",
            "Row 97: 15125 tokens\n",
            "Row 100: 61164 tokens\n"
          ]
        },
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"tokens_by_Subtopic_df\",\n  \"rows\": 101,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Subtopic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 101,\n        \"samples\": [\n          \"3B4d_Revision to General Care Management G0511\",\n          \"2J1_Coverage of MFT Services and MHC Services\",\n          \"2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Sort_seq\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 35,\n        \"min\": 2,\n        \"max\": 134,\n        \"num_unique_values\": 101,\n        \"samples\": [\n          97,\n          65,\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 101,\n        \"samples\": [\n          \"Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Facilitating behavioral change as necessary for meeting diagnosis and treatment \\ngoals, including promoting patient motivation to participate in care and reach person-centered \\ndiagnosis or treatment goals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Facilitating and providing social and emotional support to help the patient cope with \\nthe condition, SDOH need(s), and adjust daily routines to better meet diagnosis and treatment \\ngoals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [\\u25cf  Leverage knowledge of the serious, high-risk condition and/or lived experience when \\napplicable to provide support, mentorship, or inspiration to meet treatment goals.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [GXXX4 \\u2013 Principal Illness Navigation services, additional 30 minutes per calendar \\nmonth (List separately in addition to GXXX3).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [Allowing a separate payment for CHI and PIN services in RHCs and FQHCs is intended \\nto reflect the additional time and resources necessary for the unique components of care \\ncoordination services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [In an effort to be consistent with the new services that are being proposed \\nfor practitioners billing under the PFS, we are proposing to include PIN services in the general \\ncare management HCPCS code G0511 when these services are provided by RHCs and FQHCs.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [We note that under the proposals to expand the billable services under HCPCS code \\nG0511 to include CHI and PIN, each of these services must be medically reasonable and \\nnecessary, meet all requirements, and not be duplicative of services paid to RHCs and FQHCs \\nunder the general care management code for an episode of care in a given calendar month.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [We \\nexpect that our proposal to add the new codes for CHI and PIN to the general care management \\ncode would also support the CMS pillars120 for equity, inclusion, and access to care for the \\nMedicare population, and improve patient outcomes, including for underserved and low-income \\npopulations where there is a disparity in access to quality care.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [120 CMS Strategic Plan.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 410: [https://www.cms.gov/cms-strategic-plan.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [d.  Proposed Revision to the Calculation of the Payment Amount for the General Care \\nManagement HCPCS Code G0511\\nCurrently, HCPCS code G0511 is based on the PFS national average non-facility \\npayment rate for each of the services identified as billable general care management services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Then we add each payment rate and divide by the total number of codes to arrive at the payment \\namount for HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [This payment amount is a flat rate that is not subsequently \\nadjusted for locality.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [As we noted in the CY 2023 PFS final rule (87 FR 69735), when \\ndetermining which services are billable under HCPCS code G0511, we do not include the add-on \\nHCPCS codes payable under the PFS because RHCs and FQHCs do not pay their practitioners \\nbased on additional minutes spent by practitioners.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Instead we generally include the base codes.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [In the CY 2023 PFS final rule (87 FR 69736), we mentioned that we may consider other \\napproaches for calculating the payment rate for HCPCS code G0511 as the number of services \\nincluded in the general care management code is growing each year and provided examples.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [We \\nthought to consider in the future valuing HCPCS code G0511 using a weighted average of the \\nservices that comprise HCPCS code G0511 or using the national average of the top three \\nservices comprising HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [We welcomed comments on potential methodologies, \\nbut noted we did not receive any comments.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [As we discuss above, we have been engaged in a multi-year examination of coordinated \\nand collaborative care services in professional settings, and as a result established codes and \\nseparate payment in the PFS to separately recognize and pay for these important services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [The \\ncare coordination included in services, such as office visits, do not always adequately describe \\nthe non-face-to-face care management work involved in primary care.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Payment for in-person \\nencounters may not reflect all the services and resources required to furnish comprehensive, \\ncoordinated care management.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 411: [Through the last few payment rules, we have expanded the \\ngeneral care management services billable using the HCPCS code G0511to be consistent with \\nthe policies implemented under the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [In section III.B.4.b and c. of this proposed rule, we are proposing to expand the billable \\nservices under HCPCS code G0511 to include RPM, RTM, CHI, and PIN.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [If we continue to \\ncalculate HCPCS code G0511 using our current approach, we believe that the value may no \\nlonger be appropriate payment for those services since we are simply dividing by the number of \\ncodes that comprise HCPCS code G0511 and as that number of services with lower payment \\nrates increases, the value diminishes.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Therefore, we are proposing to revise our method for \\ncalculating HCPCS code G0511 so that payment for general care management is more \\nappropriate.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Below, we compare our current method to the proposed revised approach.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Based on the current methodology for HCPCS code G0511 as shown in Table 22, general \\ncare management services are paid at the average of the national non-facility PFS payment rates \\nfor CPT codes 99490, 99487, 99484, 99491, 99424 and 99426.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [TABLE 22:  CY 2023 National Non-Facility PFS Payment Rate for G0511\\nCPT Code National Non-Facility PFS Payment Rate\\n99424 $81.33\\n99426 $61.34\\n99484 $43.04\\n99487 $133.18\\n99490 $62.69\\n99491 $85.06\\nG0511 $77.941\\n1 Noting when averaging the six codes, the total RVU for HCPCS \\ncode G0511 is 2.295.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Multiplying that by the conversion factor of \\n33.8872 results in $77.77.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [However, RVUs on the PFS file are \\nexpressed in two decimal places.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [Thus, we round the 2.295 \\naverage to 2.30 which yields 2.30 * 33.8872, resulting in $77.94, \\nthe current payment rate for HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 412: [As shown in Table 23, when we include RPM and RTM services in the national non-\\nfacility average as discussed above, the payment rate for HCPCS code G0511 is reduced to \\n$64.13 based on the national non-facility PFS payment rates for CY 2023.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [TABLE 23:  CY 2023 National Non-Facility PFS Payment Rate for G0511 with RPM and \\nRTM Base Codes\\nCPT Code National Non-Facility PFS Payment Rate\\n99454 $50.15\\n99457 $48.80\\n99091 $54.22\\n98976 $50.15\\n98977 $50.15\\n98980 $49.48\\n99424 $81.33\\n99426 $61.34\\n99484 $43.04\\n99487 $133.18\\n99490 $62.69\\n99491 $85.06\\nG0511 $64.13*\\n*Noting when averaging the 12 codes, the total RVU for HCPCS code G0511 is 2.30.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Multiplying that by the conversion factor of 33.8872 results in $64.13.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [As demonstrated by comparing Table 22 to Table 23, using the current method of \\ncalculating the average of the non-facility rates but adding in RPM and RTM services base codes \\nwould result in a lower payment amount for HCPCS code G0511 compared to the current \\npayment amount.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We believe that while the policy may address providing a payment for \\nfurnishing non-face-to-face services, the magnitude of the value may not appropriately account \\nfor the costs.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Therefore, we considered and are proposing a revised methodology for the \\ncalculation by looking at the actual utilization of the services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [That is, we are proposing to use a \\nweighted average of the services that comprise HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [In order to use a weighted \\naverage, there needs to be data on the utilization of the services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We do not have data on \\nutilization of the services that comprise HCPCS code G0511 for RHCs and FQHCs since \\nHCPCS code G0511 accounts for a variety of services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [Therefore, we would use the most \\nrecently available utilization data from the services paid under the PFS, that is, in the physician \\noffice setting.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 413: [We believe that the physician office setting provides an appropriate proxy for \\nutilization of these services in the absence of actual data because this setting most closely aligns \\nwith the types of services furnished in RHCs and FQHCs since they typically furnish primary \\ncare.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [ In order to analyze utilization for services paid under the PFS and to ensure we \\naccounted for payments accurately, we would use CY 2021 claims data to look at utilization of \\nthe base code for the service and any applicable add-on codes used in the same month as well as \\nany base codes reported alone in a month for all of the services encompassing general care \\nmanagement, that is the array of services that make up HCPCS code G0511.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [We believe we \\nneed to account for the payment associated with the base code along with an applicable add-on \\ncode in our calculation as this demonstrates a complete encounter.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Until actual utilization \\nbecomes available, RHCs and FQHCs that furnish CPM, GBHI, CHI and PIN services would \\nreport HCPCS code G0511 when those services are furnished; however, they would not be \\nincluded in the weighted average at this time.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Once more data is available, we will revisit the \\nvaluation of HCPCS code G0511 to include CPM, GBHI, CHI, and PIN as necessary.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [Table 24 shows the payment amount using this calculation.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [The national non-facility \\npayment rate associated with each code that comprises HCPCS code G0511 can be found in \\nAddendum B of this proposed rule.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 414: [We note that the revised methodology does reduce the \\npayment rate for HCPCS code G0511 from its current rate for CY 2023, although not \\nsignificantly.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [TABLE 24: Weighted Average Payment Rate for G0511 with RPM, RTM, CHI, and PIN \\nServices Using CY 2023 Rates and Conversion Factor\\nCPT Code 2021 NF Utilization Weighted Average\\n99454 931,411 46,710,262\\n99457 492,286 24,023,557\\n99457+99458 398,209 35,221,586\\n99474 1,581 24,110\\n99091 55,435 3,005,686\\n98976 93,141 4,671,028\\n98977 93,141 4,671,028\\n98980 14,112 698,243\\n98980+98981 119,463 10,647,711\\n99424 13,719 1,115,766\\n99424+99425 4,573 638,482\\n99426 28,858 1,770,134\\n99426+99427 9,619 1,046,382\\n99484 151,808 6,533,816\\n99487 26,441 3,521,412\\n99487+99489 229,004 46,641,245\\n99490 3,436,429 215,429,734\\n99490+99439 802,656 88,396,505\\n99491 29,665 2,523,322\\n99491+99437 118,661 17,210,562\\nG0511 $72.98\\nTherefore, we propose to take the weighted average of the base code and add-on code \\npairs, in addition to the individual base codes for all of the services that comprise HCPCS code \\nG0511 by using the CY 2021 PFS utilization to calculate the payment rate for the general care \\nmanagement services furnished in RHCs and FQHCs on or after January 1, 2024.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [The number \\non the right side of Table 24 is a weighted average which grants more relative weight to the \\ncodes in proportion to their utilization in 2021 claims data.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [To calculate the weighted average, \\nwe multiple the non-facility payment rate times the non-facility utilization for each code, sum \\nthis total, then divide by the summed non-facility utilization for the codes included in the \\naverage.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [In an effort to be consistent with practitioners billing under the PFS and to account for \\nthe additional time spent in care coordination, we determined that this approach was more \\naccurate representation of the payment.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [We would also update HCPCS code G0511 annually \\nbased on current data available in the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 415: [We propose revisions at \\u00a7 405.2464(c) to reflect the revised methodology for calculating \\nthe payment amount for general care management services beginning January 1, 2024 which]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [would be based on a weighted average of the services that comprise HCPCS code G0511 using \\nthe most recently available PFS utilization data.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We welcome comments on this proposed \\nmethodology.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [e. Chronic Care Management Services and Virtual Communication Services Requirement for \\nObtaining Beneficiary Consent\\n(1) Chronic Care Management Services\\nRHCs and FQHCs have been authorized to bill for Chronic Care Management (CCM) \\nservices since January 1, 2016.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [The RHC and FQHC requirements for billing CCM services have \\ngenerally followed the requirements for practitioners billing under the PFS, with some \\nadaptations based on the RHC and FQHC payment methodologies.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [In fact, in the CY 2017 PFS \\nfinal rule (81 FR 80256-80257) to assure that CCM requirements for RHCs and FQHCs were not \\nmore burdensome than those for practitioners billing under the PFS, we finalized revisions to the \\nrequirements for CCM services furnished by RHCs and FQHCs similar to revisions to the \\nrequirements for CCM services finalized under the PFS (81 FR 80243 through 80251).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [Information regarding CCM services is available on the CMS Care Management Site.121\\nIn the CY 2022 PFS proposed rule (86 FR 39175), we solicited public comment on the \\nstandard practice used by practitioners to obtain beneficiary consent for CCM services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We \\nstated that we have received questions from interested parties regarding the consent requirements \\nfor CCM services.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We explained that these questions may have arisen because of the many \\nflexibilities allowed in response to the PHE for COVID\\u201319.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [In particular, during the PHE for \\nCOVID\\u201319, we allowed interested parties to obtain beneficiary consent for certain services \\nunder general supervision (85 FR 19230, April 6, 2020).]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We noted that before the PHE for \\nCOVID\\u201319, we required that beneficiary consent be obtained either by or under the direct \\nsupervision of the primary care practitioner.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We noted that this requirement was consistent with \\nthe conditions of payment for this service under the PFS.]] Subtopic: 3B4d_Revision to General Care Management G0511: [from p. 416: [We stated that as we consider what \\n121 https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Care-Management.]]\",\n          \"Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [injection training for insulin-dependent patients.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [We do not want our policies to prevent \\ninjection training via telehealth when clinically appropriate.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Consequently, we are proposing to \\nrevise our policy at 410.78(e) to allow the 1 hour of in-person training (for initial and/or follow-\\nup training), when required for insulin-dependent beneficiaries, to be provided via telehealth.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [If \\nfinalized, we anticipate revising the Medicare Claims Processing Manual, Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [100-04, chapter \\n12, section 190.3.6 to reflect that flexibility.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [J.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Advancing Access to Behavioral Health Services\\n1.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Implementation of Section 4121(a) of the Consolidated Appropriations Act, 2023 \\na. Statutory Amendments\\nSection 4121(a) of Division FF, Title IV, Subtitle C of the Consolidated Appropriations \\nAct of 2023 (CAA, 2023) (Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [L. 117-328, December 29, 2022), Coverage of Marriage and \\nFamily Therapist Services and Mental Health Counselor Services under Part B of the Medicare \\nProgram, provides for Medicare coverage of and payment for the services of health care \\nprofessionals who meet the qualifications for marriage and family therapists (MFTs) and mental \\nhealth counselors (MHCs) when billed by these professionals.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Specifically, section 4121(a)(1) of the CAA, 2023 amended section 1861(s)(2) of the Act \\nby adding a new benefit category under Medicare Part B in new subparagraph (II) to include \\nmarriage and family therapist services (as defined in an added section 1861(lll)(1) of the Act) \\nand mental health counselor services (as defined in an added section 1861(lll)(3) of the Act).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Section 4121(a)(2) of the CAA, 2023 added a new subsection (lll) to section 1861 of the \\nAct, which defines marriage and family therapist services, marriage and family therapist (MFT), \\nmental health counselor services, and mental health counselor (MHC).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 277: [Section 1861(lll)(1) of the \\nAct defines \\u201cmarriage and family therapist services\\u201d as services furnished by an MFT for the \\ndiagnosis and treatment of mental illnesses (other than services furnished to an inpatient of a \\nhospital), which the MFT is legally authorized to perform under State law (or the State \\nregulatory mechanism provided by State law) of the State in which such services are furnished,]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [as would otherwise be covered if furnished by a physician or as an incident to a physician\\u2019s \\nprofessional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(2) of the Act defines the term MFT to mean an individual \\nwho:\\n\\u25cf  Possesses a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or certification as \\na MFT pursuant to State law of the State in which such individual furnishes marriage and family \\ntherapist services; \\n\\u25cf  Is licensed or certified as a MFT by the State in which such individual furnishes such \\nservices;\\n\\u25cf  After obtaining such degree has performed at least 2 years of clinical supervised \\nexperience in marriage and family therapy; and \\n\\u25cf  Meets such other requirements as specified by the Secretary.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(3) of the Act defines \\u201cmental health counselor services\\u201d as services \\nfurnished by a mental health counselor (MHC) for the diagnosis and treatment of mental \\nillnesses (other than services furnished to an inpatient of a hospital), which the MHC is legally \\nauthorized to perform under State law (or the State regulatory mechanism provided by the State \\nlaw) of the State in which such services are furnished, as would otherwise be covered if \\nfurnished by a physician or as incident to a physician\\u2019s professional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 278: [Section 1861(lll)(4) \\nof the Act defining MHC as an individual who:\\n\\u25cf  Possesses a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or certification as \\na mental health counselor, clinical professional counselor, or professional counselor under State \\nlaw of the State in which such individual furnishes MHC services; \\n\\u25cf  Is licensed or certified as a mental health counselor, clinical professional counselor, or \\nprofessional counselor by the State in which the services are furnished; \\n\\u25cf  After obtaining such degree has performed at least 2 years of clinical supervised \\nexperience in mental health counseling; and  \\n\\u25cf  Meets such other requirements as specified by the Secretary.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 4121(a)(3) of the CAA, 2023 amended section 1833(a)(1) of the Act to add a new \\nsubparagraph (FF), which provides that, with respect to MFT services and MHC services under \\nsection 1861(s)(2)(II) of the Act, the amounts paid shall be 80 percent of the lesser of the actual \\ncharge for the services or 75 percent of the amount determined for payment of a psychologist \\nunder subparagraph (L).]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 1888(e)(2)(A)(ii) of the Act, as amended by section 4121(a)(4) of the CAA, \\n2023, excludes MFT and MHC services from consolidated billing requirements under the skilled \\nnursing facility (SNF) prospective payment system.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [For further discussion about this exclusion \\nof MFT and MHC services from SNF consolidated billing, see discussion in the FY 2024 SNF \\nProspective Payment System (PPS) proposed rule (88 FR 21316)32.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Section 4121(a)(5) of the \\nCAA, 2023 amended section 1842(b)(18)(C) of the Act to add MFTs and MHCs to the list of \\npractitioners whose services can only be paid by Medicare on an assignment-related basis.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [MFTs, MHCs, and other practitioners described in section 1842(b)(18)(C) of the Act may not \\nbill (or collect any amount from) the beneficiary or another person for any services for which \\nMedicare makes payment, except for deductible and coinsurance amounts applicable under Part \\nB.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [More information on assignment of claims can be found at in the Medicare Claims \\nProcessing Manual, Pub.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [100-04, Chapter 1, Section 30.3.1.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [We also note that section 1861(aa)(1)(B) of the Act was amended by section 4121(b)(1) \\nof the CAA, 2023 to add services furnished by MFTs and MHCs to the definition of rural health \\nclinic services.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [See section III.B of this proposed rule for discussion related to MFT and MHC \\nservices furnished in RHCs and FQHCs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [Additionally, section 1861(dd)(2)(B)(i)(III) of the Act was amended by 4121(b)(2) of the \\nCAA, 2023 to require a hospice program to have an interdisciplinary team that includes at least \\none social worker, MFT or MHC.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [For further discussion about this amended requirement for \\nhospice program interdisciplinary teams, see section III.O of this proposed rule.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 279: [32 https://www.govinfo.gov/content/pkg/FR-2023-04-10/pdf/2023-07137.pdf.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [b.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Proposed Changes to Regulations\\nConsistent with the changes to the statute described above, we are proposing to create two \\nnew regulation sections at \\u00a7 410.53 and \\u00a7 410.54 to codify the coverage provisions for MFTs and \\nMHCs, respectively.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Specifically, we are proposing to define a marriage and family therapist at \\u00a7 410.53 as an \\nindividual who: \\n\\u25cf  Possesses a master's or doctor's degree which qualifies for licensure or certification as \\na marriage and family therapist pursuant to State law of the State in which such individual \\nfurnishes the services defined as marriage and family therapist services; \\n\\u25cf  After obtaining such degree, has performed at least 2 years or 3,000 hours of post \\nmaster\\u2019s degree clinical supervised experience in marriage and family therapy in an appropriate \\nsetting such as a hospital, SNF, private practice, or clinic; and \\n\\u25cf  Is licensed or certified as a marriage and family therapist by the State in which the \\nservices are performed.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We note that we are aware that there may be some States that require a number of hours \\nof clinical supervised experience for MFT licensure that may be inconsistent with the statutory \\nrequirement in section 1861(s)(2) of the Act that requires at least 2 years of clinical supervised \\nexperience.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We believe it could be possible for an MFT to have completed the required number \\nof clinical supervised hours required for licensure in their State, but to have accomplished this in \\nless than two years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Therefore, we are proposing a requirement for MFTs to have performed at \\nleast 2 years or 3,000 hours of post master\\u2019s degree clinical supervised experience, if consistent \\nwith State licensure requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [We believe that 3,000 hours is roughly equivalent to the \\nstatutory requirement to have performed 2 years of clinical supervised experience and note that \\nthe regulatory requirements for clinical social workers (CSWs) at \\u00a7 410.73(a)(3)(ii) allow 2 years \\nor 3,000 hours of supervised experience.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [Additionally, the statutory benefit category for both \\nMFTs and CSWs is defined as services for the diagnosis and treatment of mental illnesses.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 280: [As]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [such, we believe it would be appropriate to provide similar flexibility in the required amount of \\nclinical supervised experience for MFTs and CSWs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are also interested in public comments \\nregarding States that have a supervised clinical hour requirement for MFT licensure that is less \\nthan 2 years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are proposing to define \\u201cMarriage and family therapist services\\u201d at \\u00a7 410.53(b)(1) as \\nservices furnished by a marriage and family therapist for the diagnosis and treatment of mental \\nillnesses (other than services furnished to an inpatient of a hospital), which the marriage and \\nfamily therapist is legally authorized to perform under State law (or the State regulatory \\nmechanism provided by State law) of the State in which such services are furnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [We are also \\nproposing at \\u00a7 410.53(b)(1) that the services must be of a type that would be covered if they \\nwere furnished by a physician or as an incident to a physician's professional service and must \\nmeet the requirements of this section.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [Lastly, we are proposing at \\u00a7 410.53(b)(2) that the following services do not fall under \\nthe Medicare Part B benefit category for MFT services: \\n\\u25cf  Services furnished by a marriage and family therapist to an inpatient of a Medicare-\\nparticipating hospital.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 281: [Similarly, we are proposing to define a mental health counselor at \\u00a7 410.54 as an \\nindividual who:\\n\\u25cf  Possesses a master's or doctor's degree which qualifies for licensure or certification as \\na mental health counselor, clinical professional counselor, or professional counselor under the \\nState law of the State in which such individual furnishes the services defined as mental health \\ncounselor services; \\n\\u25cf  After obtaining such a degree, has performed at least 2 years or 3,000 hours of post \\nmaster\\u2019s degree clinical supervised experience in mental health counseling in an appropriate \\nsetting such as a hospital, SNF, private practice, or clinic; and]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [\\u25cf  Is licensed or certified as a mental health counselor, clinical professional counselor, or \\nprofessional counselor by the State in which the services are performed.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [As previously \\nexplained for MFTs, and for the same reasons, we are proposing a requirement for MHCs to \\nhave performed at least 2 years or 3,000 hours of post master\\u2019s degree clinical supervised \\nexperience, if consistent with State licensure requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We believe that 3,000 hours is \\nroughly equivalent to the statutory requirement to have performed 2 years of clinical supervised \\nexperience and note that the regulatory requirements for clinical social workers at \\u00a7 \\n410.73(a)(3)(ii) allows 2 years or 3,000 hours.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [The MHC statutory benefit category authorizes \\nMHCs to furnish services for the diagnosis and treatment of mental illnesses as it does for \\nCSWs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are also interested in public comments regarding States that have a supervised \\nclinical hour requirement for MHC licensure that is less than 2 years.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing to define \\u201cmental health counselor services\\u201d at \\u00a7 410.54(b)(1) as \\nservices furnished by a mental health counselor (as defined in paragraph (a) of this section) for \\nthe diagnosis and treatment of mental illnesses (other than services furnished to an inpatient of a \\nhospital), which the mental health counselor is legally authorized to perform under State law (or \\nthe State regulatory mechanism provided by State law) of the State in which such services are \\nfurnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are also proposing at \\u00a7 410.54(b)(1) that the services must be of a type that would \\nbe covered if they were furnished by a physician or as an incident to a physician's professional \\nservice.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing at \\u00a7 410.54(b)(2) that the following services do not fall under the \\nMedicare Part B benefit category for MHC services: \\n\\u25cf  Services furnished by a mental health counselor to an inpatient of a Medicare-\\nparticipating hospital.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are proposing to amend \\u00a7 410.10 to add marriage and family therapist services and \\nmental health counselor services to the list of included medical and other health services.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 282: [We are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [also proposing to amend \\u00a7 410.150 to add marriage and family therapists and mental health \\ncounselors, to the list of individuals or entities to whom payment is made.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Currently, \\u00a7 410.32(a)(2) lists the health care practitioners that may order diagnostic \\ntests.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Since this list currently includes CSWs and clinical psychologists (CPs), who are also \\nauthorized by statute to furnish services for the diagnosis and treatment of mental illnesses, we \\nare proposing to amend \\u00a7 410.32(a)(2) to add MFTs and MHCs to the list of practitioners who \\nmay order diagnostic tests, as for the other non-physician practitioners, to the extent that the \\nMFT or MHC is legally authorized to perform the service under State law (or the State \\nregulatory mechanism provided by State law) of the State in which such services are furnished.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [We are also proposing to codify in a new \\u00a7 414.53 the payment amounts authorized under \\nsection 1833(a)(1)(FF) for MFT and MHC services .]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Additionally, we are proposing to codify at \\n\\u00a7 414.53 the payment amount for clinical social worker (CSW) services as authorized under \\nsection 1833(a)(1)(F) of the Act.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [As we reviewed our regulations to implement section 4121 of \\nthe CAA, 2023, we found that the payment amounts for CSWs are not yet codified under \\nregulations.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Specifically, we are proposing to add that the payment amount for CSW, MFT, and \\nMHC services is 80 percent of the lesser of the actual charge for the services or 75 percent of the \\namount determined for clinical psychologist services under the PFS.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [We are also proposing to add MFTs and MHCs to the list of practitioners who are eligible \\nto furnish Medicare telehealth services at the distant site.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [See section II.D.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [of this proposed rule \\nfor a discussion of this proposal.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [Additionally, we are proposing to allow Addiction Counselors who meet all of the \\napplicable requirements (possess a master\\u2019s or doctor\\u2019s degree which qualifies for licensure or \\ncertification as a mental health counselor; after obtaining such degree have performed at least 2 \\nyears (or, as proposed, 3,000 hours) of clinical supervised experience in mental health \\ncounseling; and licensed or certified as a MHC, clinical professional counselor, or professional \\ncounselor by the State in which the services are furnished) to enroll in Medicare as MHCs.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 283: [That]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [is, under this proposal, Addiction Counselors would be considered Mental Health Counselors \\nand would be eligible to enroll and bill Medicare for MHC services if they meet these \\nrequirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We understand there is variation in the terminology used for licensure across \\nStates for MHCs and MFTs and are seeking information pertaining to other types of \\nprofessionals who may meet the applicable requirements for enrollment as mental health \\ncounselors.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We note that in past rulemaking, we have discussed the term \\u2018mental health\\u2019 to be \\ninclusive of diagnosis and treatment of substance use disorders.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [For example, in the CY 2022 \\nPFS final rule (86 FR 65061), we stated that SUD services are considered mental health services \\nfor the purposes of the expanded definition of \\u201cinteractive telecommunications system.\\u201d We \\npropose to apply that same interpretation for purposes of the mental health services included in \\nthe definition of MFT, MHC, and to clarify that the same interpretation applies for CSW, and CP \\nservices.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [c.  Coding Updates to Allow MFT and MHC Billing\\nIn light of the new statutory benefits for MFTs and MHCs authorized by section 4121(a) \\nof the CAA, 2023, we have considered whether updates to certain HCPCS codes are required in \\norder to allow MFTs and MHCs to bill for the services described by those HCPCS codes.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [In the \\nCY 2023 PFS final rule, we finalized new coding and payment for General Behavioral Health \\nIntegration services performed by CPs or CSWs to account for monthly care integration where \\nthe mental health services furnished by a CP or CSW serve as the focal point of care integration.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [In light of the new coverage under Medicare for MFT and MHC services for the diagnosis and \\ntreatment of mental illness, we are proposing to revise the code descriptor for HCPCS code \\nG0323 in order to allow MFTs and MHCs, as well as CPs and CSWs, to be able to bill for this \\nmonthly care integration service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 284: [We note that MFTs and MHCs, like CSWs, are authorized by \\nstatute for the diagnosis and treatment of mental illnesses (other than services furnished to an \\ninpatient of a hospital), which the MFT or MHC is legally authorized to perform under State law \\n(or the State regulatory mechanism provided by State law) of the State in which such services are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [furnished, as would otherwise be covered if furnished by a physician or as an incident to a \\nphysician\\u2019s professional service.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [The proposed code descriptor for HCPCS code G0323 is: Care \\nmanagement services for behavioral health conditions, at least 20 minutes of clinical \\npsychologist, clinical social worker, mental health counselor, or marriage and family therapist \\ntime, per calendar month.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [(These services include the following required elements: Initial \\nassessment or follow-up monitoring, including the use of applicable validated rating scales; \\nbehavioral health care planning in relation to behavioral/psychiatric health problems, including \\nrevision for patients who are not progressing or whose status changes; facilitating and \\ncoordinating treatment such as psychotherapy, coordination with and/or referral to physicians \\nand practitioners who are authorized by Medicare to prescribe medications and furnish E/M \\nservices, counseling and/or psychiatric consultation; and continuity of care with a designated \\nmember of the care team.)]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [Lastly, we note that consistent with the proposed changes to valuation of CPT code \\n99484 in the Valuation of Specific Codes section (section II.E.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [of this proposed rule), which \\ndescribes General BHI and is the crosswalk code used for valuation of HCPCS code G0323, we \\nare also proposing conforming updates to the valuation for work and PE inputs for HCPCS code \\nG0323.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [See section II.E.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [of this proposed rule for further discussion of changes to the valuation \\nfor HCPCS code G0323.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [We welcome comments regarding any other HCPCS codes that may require updating to \\nallow MFTs and MHCs to bill for the services described in the HCPCS code descriptor.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 285: [d. Medicare Enrollment of MFTs and MHCs\\nMFTs and MHCs who meet the applicable requirements (possess a master\\u2019s or doctor\\u2019s \\ndegree which qualifies for licensure or certification as a mental health counselor; after obtaining \\nsuch degree have performed at least 2 years (or, as proposed, 3,000 hours) of clinical supervised \\nexperience in mental health counseling; and is licensed or certified as a MHC, clinical \\nprofessional counselor, or professional counselor by the State in which the services are]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [furnished) described in detail above in this section, as finalized, will need to enroll in Medicare \\nas MFTs and MHCs in order to submit claims for marriage and family therapist services and \\nmental health counselor services, respectively, furnished to Medicare beneficiaries.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [Under \\u00a7 \\n424.510, a provider or supplier must complete, sign, and submit to its assigned MAC the \\nappropriate Form CMS\\u2013855 (OMB Control No.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [0938\\u20130685) application in order to enroll in the \\nMedicare program and obtain Medicare billing privileges.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [The Form CMS\\u2013855, which can be \\nsubmitted via paper or electronically through the internet-based Provider Enrollment, Chain, and \\nOwnership System (PECOS) process (SORN: 09\\u201370\\u20130532; 104 Provider Enrollment, Chain, and \\nOwnership System), captures information about the provider or supplier that is needed for CMS \\nor its MACs to determine whether the provider or supplier meets all Medicare requirements.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [We \\npropose that the MFT and MHC supplier types, like most non-physician practitioner types, be \\nsubject to limited-risk screening under \\u00a7 424.518, for we have no basis on which to assign these \\nsuppliers as a class to a higher screening category.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [MFTs and MHCs that meet the proposed requirements in \\u00a7\\u00a7 410.53 and 410.54 as \\nfinalized, would enroll in Medicare via the Form CMS-855I application (Medicare Enrollment \\nApplication \\u2013 Physicians and Non-Physician Practitioners; OMB No.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [0938-1355) and could \\nbegin submitting their enrollment applications after the publication of the CY 2024 PFS final \\nrule.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [However, as the new benefit categories authorized by section 4121(a) of the CAA, 2023, \\ndo not take effect until January 1, 2024, MFT or MHC claims for MFT or MHC services \\nfurnished to Medicare beneficiaries with dates of service prior to January 1, 2024 will not be \\npayable under Medicare Part B.  MFTs and MHCs can visit \\nhttps://www.cms.gov/medicare/provider-enrollment-and-certification for basic information on \\nthe provider enrollment process.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [2.]] Subtopic: 2J1_Coverage of MFT Services and MHC Services: [from p. 286: [Implementation of Section 4123 of the CAA, 2023\\nSection 4123(a)(1) of the CAA, 2023, Improving Mobile Crisis Care in Medicare, \\namended section 1848 of the Act by adding a new paragraph (b)(12) regarding payment for]]\",\n          \"Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [evidence that certain dental services are so integral to the clinical success that they are \\ninextricably linked to other covered service(s).]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We encourage interested parties to use the public \\nsubmission process to submit recommendations and relevant clinical evidence for establishing \\nthis connection.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [Above, in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [of this proposed rule, we have described the various \\ntypes of documentation to support recommendations through this process.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We are considering, \\nand seek comment on, whether the following cardiac interventions are examples of specific \\nmedical services for which dental services are inextricably linked to clinical success: \\nimplantation of electronic devices in the heart, such as pacemakers, cardioverter defibrillators, \\nand monitors.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We are also considering, and seek comment on, whether the following procedures \\nwould be considered examples of specific medical services for which dental services are \\ninextricably linked to their clinical success: the placement of intracardiac or intravascular foreign \\nmaterial, such as a stent or for hemodialysis, or for a vascular access graft, whereas you would \\nnot proceed with the medical service without having first completed a dental evaluation and/or \\ntreatment as determined necessary.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [We seek comment on whether preoperative and \\nperioperative dental services are inextricably linked to any other covered cardiac interventions as \\nsupported by clinical evidence.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [4.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [Request for Comment on Dental Services Integral to Specific Covered Services to Treat Sickle \\nCell Disease (SCD) and Hemophilia \\nInterested parties using the public submission process we finalized in the CY 2023 PFS \\nfinal rule urged us to propose to provide that payment can be made for dental services for \\nindividuals living with SCD and hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [These submissions provided information and references supporting prevention of dental \\ninfection among individuals with SCD to reduce need for more extensive procedures that may \\nresult in bleeding complications and require hospitalization.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 342: [They also provided information]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [detailing increased dental caries and periodontal disease in people with SCD,90 many of whom \\nlose a number of teeth, which greatly limits nutrition, general well-being, and overall quality of \\nlife.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We seek comment on whether certain dental services are inextricably linked to other \\ncovered services used in the treatment of SCD, such as, but not limited to, hydroxyurea therapy.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We seek comment identifying such covered services for SCD and whether an inextricable link is \\nsupported by clinical evidence as described in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [of this proposed rule.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Interested parties also urged us to propose a policy to permit payment for dental services \\nfor individuals living with hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [They noted that periodic dental care reduces the risks of \\ndental complications requiring haemostatic therapy (such as tooth extractions that may require \\nclotting factor treatment) or oral surgeries requiring clotting factor replacement therapy.91 92 93  \\nWe note that many submitters stated that good dental and oral health benefits a patient\\u2019s \\noverall health generally.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Several commenters on the CY 2023 PFS proposed rule also expressed \\nthat good oral hygiene, along with routine dental services, contributes to better outcomes for \\npatients.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [We recognized in the CY 2023 PFS final rule in response to those comments that there \\nis a great deal of evidence suggesting that dental health is generally an important component of \\noverall health; however, we are interested in comments on whether certain dental services are \\nconsidered so integral to the primary covered services that the necessary dental interventions are \\ninextricably linked to, and substantially related and integral to clinical success of, the primary \\n90 Kakkar M, Holderle K, ShethM, Arany S, Schiff L, Planerova A. Orofacial Manifestation and Dental \\nManagement of Sickle Cell Disease: A Scoping Review.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Anemia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2021 Oct22; 2021:5556708.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Doi: \\n10.1155/2021/5556708.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 34721900; PMCID: PMC8556080.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [91 Raso S, Napolitano M, Sirocchi D, Siragusa S, Hermans C. The important impact of dental care on haemostatic \\ntreatment burden in patients with mild haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2022 Nov;28(6):996-999. doi: \\n10.1111/hae.14626.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Epub 2022 Jul 25.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 35879819.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [92 Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, \\nWindyga J, Llin\\u00e1s A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce \\nGF; WFH Guidelines for the Management of Hemophilia panelists and co-authors.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [WFH Guidelines for the \\nManagement of Hemophilia, 3rd edition.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Epub \\n2020 Aug 3.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Erratum in: Haemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2021 Jul;27(4):699.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 32744769.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [93 Peisker A, Raschke GF, Schultze-Mosgau S. Management of dental extraction in patients with Haemophilia A and \\nB: a report of 58 extractions.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [Med Oral Patol Oral Cir Bucal.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [2014 Jan 1;19(1):e55-60.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [doi: 10.4317/medoral.19191.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 343: [PMID: 24121912; PMCID: PMC3909433.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [covered services such that they are not subject to the statutory preclusion on Medicare payment \\nfor dental services under section 1862(a)(12) of the Act.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We seek comment on whether certain dental services are inextricably linked to certain \\nother covered services for hemophilia, supported by clinical evidence as described in section \\nII.K.1.c., above.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We seek comment identifying such covered services for the treatment of \\nhemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We also seek comment specifically on whether dental services such as prophylaxis \\nare a standard of care in the management of hemophilia.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [5.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Request for Comment Regarding Dental Services Possibly Inextricably Linked to Other \\nMedicare-Covered Services, \\nCommenters, submitters, and other interested parties have urged us to consider the \\nimportance of access to oral health care for people with chronic auto-immune conditions, and \\nother chronic disease conditions, such as, but not limited to, diabetes.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We understand and \\nappreciate the interest in such requests.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Because the Medicare statute generally prohibits \\npayment for dental services payment may only be made when the dental services are inextricably \\nlinked to, and substantially related and integral to the clinical success of, certain other covered \\nservices.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We urge interested parties to consider the circumstances under which dental services \\nare inextricably linked to specific covered services (not diagnoses) used to treat patients with \\nauto-immune conditions or other chronic conditions, supported by clinical evidence as described \\nin section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [of this proposed rule.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [We have encouraged interested parties who believe certain dental services are \\ninextricably linked to certain covered services to use our public submission process to provide \\ninformation on these clinical scenarios, supported by clinical evidence or other documentation, \\nas discussed in section II.K.1.c.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [of this proposed rule, such as that it would be the standard of \\ncare to not proceed with the medical service without having completed the dental service.]] Subtopic: 2K4_Solicitation: Dental Svcs Integral to Covered Svcs to Treat Sickle Cell Disease and Hemophilia: [from p. 344: [Commenters are welcome to submit additional information regarding clinical scenarios presented \\nin the CY 2023 PFS rulemaking discussions, which we are not proposing for the CY 2024, such]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"token_count\",\n      \"properties\": {\n        \"dtype\": \"date\",\n        \"min\": 1116,\n        \"max\": 61164,\n        \"num_unique_values\": 100,\n        \"samples\": [\n          5045,\n          2227,\n          2674\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "tokens_by_Subtopic_df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-514f90ab-84ae-4a06-a3da-093598c41217\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Subtopic</th>\n",
              "      <th>Sort_seq</th>\n",
              "      <th>text</th>\n",
              "      <th>token_count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B4b_Supply and Equipment Pricing</td>\n",
              "      <td>2</td>\n",
              "      <td>Subtopic: 2B4b_Supply and Equipment Pricing: [...</td>\n",
              "      <td>2162</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>2B4c_Clinical Labor Pricing</td>\n",
              "      <td>3</td>\n",
              "      <td>Subtopic: 2B4c_Clinical Labor Pricing: [from p...</td>\n",
              "      <td>6916</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>2B5_Solicitation: Updates to PE Data Collectio...</td>\n",
              "      <td>4</td>\n",
              "      <td>Subtopic: 2B5_Solicitation: Updates to PE Data...</td>\n",
              "      <td>4963</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>2D1b_Requests to Add to Telehealth List</td>\n",
              "      <td>7</td>\n",
              "      <td>Subtopic: 2D1b_Requests to Add to Telehealth L...</td>\n",
              "      <td>21648</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>2D1c_Solicitation: Telehealth List Process for...</td>\n",
              "      <td>8</td>\n",
              "      <td>Subtopic: 2D1c_Solicitation: Telehealth List P...</td>\n",
              "      <td>1739</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>96</th>\n",
              "      <td>7C3_Health Equity</td>\n",
              "      <td>127</td>\n",
              "      <td>Subtopic: 7C3_Health Equity: [from p. 1203: [2...</td>\n",
              "      <td>15125</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>97</th>\n",
              "      <td>7E1_Impact of Medicare Parts A and B Payment f...</td>\n",
              "      <td>130</td>\n",
              "      <td>Subtopic: 7E1_Impact of Medicare Parts A and B...</td>\n",
              "      <td>2329</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>98</th>\n",
              "      <td>7E2_Impact of Separate Pmnt for O/O E/M Visit ...</td>\n",
              "      <td>131</td>\n",
              "      <td>Subtopic: 7E2_Impact of Separate Pmnt for O/O ...</td>\n",
              "      <td>1813</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>99</th>\n",
              "      <td>7E3a_Impact of Proposed Payment for MFT Servic...</td>\n",
              "      <td>132</td>\n",
              "      <td>Subtopic: 7E3a_Impact of Proposed Payment for ...</td>\n",
              "      <td>61164</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>100</th>\n",
              "      <td>7F1_Alts Considered Related to the O/O E/M Vis...</td>\n",
              "      <td>134</td>\n",
              "      <td>Subtopic: 7F1_Alts Considered Related to the O...</td>\n",
              "      <td>3675</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>101 rows  4 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-514f90ab-84ae-4a06-a3da-093598c41217')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-514f90ab-84ae-4a06-a3da-093598c41217 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-514f90ab-84ae-4a06-a3da-093598c41217');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-6c2c1ad9-1e8d-4fdf-9615-b6a9a881535e\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-6c2c1ad9-1e8d-4fdf-9615-b6a9a881535e')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-6c2c1ad9-1e8d-4fdf-9615-b6a9a881535e button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_77553dd5-00f7-402a-a14b-d450a1d94dd3\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('tokens_by_Subtopic_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_77553dd5-00f7-402a-a14b-d450a1d94dd3 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('tokens_by_Subtopic_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                   InsightsAI_Subtopic  Sort_seq  \\\n",
              "0                    2B4b_Supply and Equipment Pricing         2   \n",
              "1                          2B4c_Clinical Labor Pricing         3   \n",
              "2    2B5_Solicitation: Updates to PE Data Collectio...         4   \n",
              "3              2D1b_Requests to Add to Telehealth List         7   \n",
              "4    2D1c_Solicitation: Telehealth List Process for...         8   \n",
              "..                                                 ...       ...   \n",
              "96                                   7C3_Health Equity       127   \n",
              "97   7E1_Impact of Medicare Parts A and B Payment f...       130   \n",
              "98   7E2_Impact of Separate Pmnt for O/O E/M Visit ...       131   \n",
              "99   7E3a_Impact of Proposed Payment for MFT Servic...       132   \n",
              "100  7F1_Alts Considered Related to the O/O E/M Vis...       134   \n",
              "\n",
              "                                                  text token_count  \n",
              "0    Subtopic: 2B4b_Supply and Equipment Pricing: [...        2162  \n",
              "1    Subtopic: 2B4c_Clinical Labor Pricing: [from p...        6916  \n",
              "2    Subtopic: 2B5_Solicitation: Updates to PE Data...        4963  \n",
              "3    Subtopic: 2D1b_Requests to Add to Telehealth L...       21648  \n",
              "4    Subtopic: 2D1c_Solicitation: Telehealth List P...        1739  \n",
              "..                                                 ...         ...  \n",
              "96   Subtopic: 7C3_Health Equity: [from p. 1203: [2...       15125  \n",
              "97   Subtopic: 7E1_Impact of Medicare Parts A and B...        2329  \n",
              "98   Subtopic: 7E2_Impact of Separate Pmnt for O/O ...        1813  \n",
              "99   Subtopic: 7E3a_Impact of Proposed Payment for ...       61164  \n",
              "100  Subtopic: 7F1_Alts Considered Related to the O...        3675  \n",
              "\n",
              "[101 rows x 4 columns]"
            ]
          },
          "execution_count": 12,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "##OPTIONAL ADDITION TO PRIOR MODULE:\n",
        "#Count tokens for later summarization task (gpt4-turbo takes 128k tokens)\n",
        "from transformers import GPT2TokenizerFast\n",
        "tokenizer = GPT2TokenizerFast.from_pretrained('Xenova/gpt-4')\n",
        "\n",
        "def num_tokens_from_string(text: str) -> int:\n",
        "    # Tokenize the text using the GPT-4 tokenizer\n",
        "    tokens = tokenizer.tokenize(text)\n",
        "    return len(tokens)\n",
        "\n",
        "# Count tokens for later summarization task\n",
        "min_obs_show=6700           #120000\n",
        "for index, text in enumerate(merged_df_Subtopic_text_combined['text'], start=1):\n",
        "    token_count = num_tokens_from_string(text)\n",
        "    if token_count >= min_obs_show:  # Add a condition to check for token count\n",
        "        print(f\"Row {index}: {token_count} tokens\")\n",
        "\n",
        "# Create a new DataFrame to store SUBTOPIC token counts\n",
        "tokens_by_Subtopic_df = merged_df_Subtopic_text_combined.copy()  # Copy existing data\n",
        "tokens_by_Subtopic_df['token_count'] = None  # Add new column for token count\n",
        "\n",
        "for index, row in tokens_by_Subtopic_df.iterrows():\n",
        "  text = row['text']  # Access text from current row\n",
        "  token_count = num_tokens_from_string(text)\n",
        "  # Update the new `token_count` column in the DataFrame\n",
        "  tokens_by_Subtopic_df.at[index, 'token_count'] = token_count\n",
        "\n",
        "if token_count >= min_obs_show:\n",
        "    print(f\"Row {index}: {token_count} tokens\")\n",
        "\n",
        "# Prepare data for the plot\n",
        "tokens_by_Subtopic_df = tokens_by_Subtopic_df.sort_values(by='Sort_seq')\n",
        "\n",
        "tokens_by_Subtopic_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 28,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 970
        },
        "id": "wiS33TCQhsUq",
        "outputId": "0ee5ce49-43ff-4537-e18b-de2ed028f827"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "           InsightsAI_Topic_Subtopic  \\\n",
              "0  2B4b_Supply and Equipment Pricing   \n",
              "\n",
              "                                                text  \n",
              "0  Subtopic: 2B4b_Supply and Equipment Pricing: [...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-c3f0212e-d639-4c24-900d-c3f3803f03db\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Topic_Subtopic</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B4b_Supply and Equipment Pricing</td>\n",
              "      <td>Subtopic: 2B4b_Supply and Equipment Pricing: [...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-c3f0212e-d639-4c24-900d-c3f3803f03db')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-c3f0212e-d639-4c24-900d-c3f3803f03db button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-c3f0212e-d639-4c24-900d-c3f3803f03db');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "  <div id=\"id_593021c2-9a9b-478f-bb13-d7ae266c43e2\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('merged_df_Topic_Subtopic_text_combined')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_593021c2-9a9b-478f-bb13-d7ae266c43e2 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('merged_df_Topic_Subtopic_text_combined');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "merged_df_Topic_Subtopic_text_combined",
              "summary": "{\n  \"name\": \"merged_df_Topic_Subtopic_text_combined\",\n  \"rows\": 1,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Topic_Subtopic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"2B4b_Supply and Equipment Pricing\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [2023, we are continuing to display two versions of the Labor Task Detail public use file: one \\nversion with the old listing of clinical labor tasks, and one with the same tasks cross-walked to \\nthe new listing of clinical labor activity codes.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [These lists are available on the CMS website \\nunder downloads for the CY 2024 PFS proposed rule at http://www.cms.gov/Medicare/Medicare-\\nFee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices.html.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [b.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [Updates to Prices for Existing Direct PE Inputs\\nIn the CY 2011 PFS final rule with comment period (75 FR 73205), we finalized a \\nprocess to act on public requests to update equipment and supply price and equipment useful life \\ninputs through annual rulemaking, beginning with the CY 2012 PFS proposed rule.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [Beginning in \\nCY 2019 and continuing through CY 2022, we conducted a market-based supply and equipment \\npricing update, using information developed by our contractor, StrategyGen, which updated \\npricing recommendations for approximately 1300 supplies and 750 equipment items currently \\nused as direct PE inputs.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [Given the potentially significant changes in payment that would occur, \\nin the CY 2019 PFS final rule we finalized a policy to phase in our use of the new direct PE \\ninput pricing over a 4-year period using a 25/75 percent (CY 2019), 50/50 percent (CY 2020), \\n75/25 percent (CY 2021), and 100/0 percent (CY 2022) split between new and old pricing.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [We \\nbelieved that implementing the proposed updated prices with a 4-year phase-in would improve \\npayment accuracy, while maintaining stability and allowing interested parties the opportunity to \\naddress potential concerns about changes in payment for particular items.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [This 4-year transition \\nperiod to update supply and equipment pricing concluded in CY 2022; for a more detailed \\ndiscussion, we refer readers to the CY 2019 PFS final rule with comment period (83 FR 59473 \\nthrough 59480).]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [For CY 2024, we are proposing to update the price of 16 supplies and two equipment \\nitems in response to the public submission of invoices following the publication of the CY 2023 \\nPFS final rule.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 35: [The 16 supply and equipment items with proposed updated prices are listed in the]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [valuation of specific codes section of the preamble under Table 14, CY 2024 Invoices Received \\nfor Existing Direct PE Inputs.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [We are not proposing to update the price of another eleven supplies which were the \\nsubject of public submission of invoices.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [Our rationale for not updating these prices is detailed \\nbelow:\\n\\u25cf  Extended external ECG patch, medical magnetic tape recorder (SD339): We received \\nadditional invoices for the SD339 supply from an interested party.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [Upon review of the invoices, \\nwe determined that they contained the identical price point that we previously incorporated into \\nlast year\\u2019s rule when we finalized a price of $260.35 for the supply item (87 FR 69514 through \\n69516).]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [Since these invoices did not contain any new information, we are maintaining the \\npreviously finalized price of $260.35 for the SD339 supply.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [\\u25cf  Permanent marking pen (SL477), Liquid coverslip (Ventana 650-010) (SL479), EZ \\nPrep (10X) (Ventana 950-102) (SL481), Cell Conditioning 1 (Ventana 950-124) (SL482), and \\nHematoxylin II (Ventana 790-2208) (SL483): We received invoices from interested parties for \\nuse in updating the price of these laboratory supplies.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [In each case, however, we were able to \\nfind the same supply item available for sale online at the current price or cheaper.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [Therefore, we \\ndo not believe that the submitted invoices represent typical market pricing for these supplies and \\nwe are not proposing to update their prices.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [\\u25cf  Mask, surgical (SB033), scalpel with blade, surgical (#10-20) (SF033), eye shield, \\nnon-fog (SG049), gauze, non-sterile 4in x 4in (SG051), and towel, paper (Bounty) (per sheet) \\n(SK082): We received invoices from interested parties for use in updating the price of these \\ncommon supply items.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [In each case, we received a single invoice and once again we were able to \\nfind the same supply items available for sale online at the current price or cheaper.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 36: [Generally \\nspeaking, we avoid updating the price for common supply items like the SB033 surgical mask \\n(included in approximately 380 HCPCS codes) based on the submission of a single invoice, as an \\ninvoice unrepresentative of current market pricing will have far-reaching effects across the PFS.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [We did not find that the typical price for a surgical mask had increased by more than 60% since \\nthe supply and equipment pricing update concluded in CY 2022, and as such we are maintaining \\nthe current price for these supply items.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [(1) Invoice Submission\\nWe remind readers that we routinely accept public submission of invoices as part of our \\nprocess for developing payment rates for new, revised, and potentially misvalued codes.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [Often \\nthese invoices are submitted in conjunction with the RUC-recommended values for the codes.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [To be included in a given year\\u2019s proposed rule, we generally need to receive invoices by the \\nsame February 10th deadline we noted for consideration of RUC recommendations.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [However, \\nwe will consider invoices submitted as public comments during the comment period following \\nthe publication of the PFS proposed rule, and would consider any invoices received after \\nFebruary 10th or outside of the public comment process as part of our established annual process \\nfor requests to update supply and equipment prices.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [Interested parties are encouraged to submit \\ninvoices with their public comments or, if outside the notice and comment rulemaking process, \\nvia email at PE_Price_Input_Update@cms.hhs.gov.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [c.  Clinical Labor Pricing Update\\nSection 220(a) of the PAMA provides that the Secretary may collect or obtain \\ninformation from any eligible professional or any other source on the resources directly or \\nindirectly related to furnishing services for which payment is made under the PFS, and that such \\ninformation may be used in the determination of relative values for services under the PFS.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [Such \\ninformation may include the time involved in furnishing services; the amounts, types and prices \\nof PE inputs; overhead and accounting information for practices of physicians and other \\nsuppliers, and any other elements that would improve the valuation of services under the PFS.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [Beginning in CY 2019, we updated the supply and equipment prices used for PE as part \\nof a market-based pricing transition; CY 2022 was the final year of this 4-year transition.]] Subtopic: 2B4b_Supply and Equipment Pricing: [from p. 37: [We \\ninitiated a market research contract with StrategyGen to conduct an in-depth and robust market]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 28
        }
      ],
      "source": [
        "merged_df_Topic_text_combined2 = merged_df_Topic_text_combined.rename(columns={'InsightsAI_Topic': 'InsightsAI_Topic_Subtopic'})\n",
        "merged_df_Subtopic_text_combined2 = merged_df_Subtopic_text_combined.rename(columns={'InsightsAI_Subtopic': 'InsightsAI_Topic_Subtopic'})\n",
        "\n",
        "merged_df_Topic_Subtopic_text_combined = pd.concat([merged_df_Topic_text_combined2, merged_df_Subtopic_text_combined2])\n",
        "merged_df_Topic_Subtopic_text_combined = merged_df_Topic_Subtopic_text_combined.sort_values(by=['Sort_seq'], ascending=[True])\n",
        "\n",
        "merged_df_Topic_Subtopic_text_combined=merged_df_Topic_Subtopic_text_combined.drop('Sort_seq', axis=1)\n",
        "\n",
        "#OPTIONALLY Set to HEAD (first 5 obs) for TEST RUNS in next Modules, until testing is complete (gpt4 is EXPENSIVE!)\n",
        "merged_df_Topic_Subtopic_text_combined=merged_df_Topic_Subtopic_text_combined\n",
        "\n",
        "# OPTIONALLY Extract select rows for testing output. TO get the 1st row, use 0 instead of 1. And to extract the ith row, use (i-1) in the list.\n",
        "#rows_to_extract = [46,48,57,73,109,115]\n",
        "rows_to_extract = [1]\n",
        "merged_df_Topic_Subtopic_text_combined = merged_df_Topic_Subtopic_text_combined.iloc[rows_to_extract]\n",
        "\n",
        "merged_df_Topic_Subtopic_text_combined"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "background_save": true,
          "base_uri": "https://localhost:8080/"
        },
        "id": "wW_DQf-t6x5m",
        "outputId": "1e2cf4f2-67e8-4301-e29f-8735b6323ddf"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Special tokens have been added in the vocabulary, make sure the associated word embeddings are fine-tuned or trained.\n",
            "Token indices sequence length is longer than the specified maximum sequence length for this model (28149 > 8192). Running this sequence through the model will result in indexing errors\n"
          ]
        }
      ],
      "source": [
        "#ALT-ALT  7C\n",
        "import openai\n",
        "from transformers import GPT2TokenizerFast\n",
        "import pandas as pd\n",
        "import re\n",
        "\n",
        "# Setup OpenAI API key\n",
        "openai.api_key = \"YOUR_OPENAI_API_KEY_HERE\"   #Tantus\n",
        "\n",
        "tokenizer = GPT2TokenizerFast.from_pretrained('Xenova/gpt-4')\n",
        "def num_tokens_from_string(text: str) -> int:\n",
        "    tokens = tokenizer.tokenize(text)\n",
        "    return len(tokens)\n",
        "\n",
        "def split_text_if_needed(text):\n",
        "    total_tokens = num_tokens_from_string(text)\n",
        "    if total_tokens <= 6700:\n",
        "        return [text]\n",
        "    else:\n",
        "        tokens = tokenizer.tokenize(text)\n",
        "        max_chunk_size = 6700  # set slightly lower than the max to account for prompt size\n",
        "        chunks = []\n",
        "        for i in range(0, len(tokens), max_chunk_size):\n",
        "            chunks.append(tokenizer.convert_tokens_to_string(tokens[i:i + max_chunk_size]))\n",
        "        return chunks\n",
        "\n",
        "def get_gpt4_summary(text_parts, prompt, model_choice=\"gpt-4\"):\n",
        "    summaries = []\n",
        "    for part in text_parts:\n",
        "        input_text = f\"{part}\\n\\nPrompt: {prompt}\"\n",
        "        response = openai.chat.completions.create(\n",
        "            model= \"gpt-4-turbo\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "            #model= \"gpt-4o\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "            messages=[{\"role\": \"user\", \"content\": input_text}],\n",
        "            max_tokens=675,\n",
        "            temperature=0.5,\n",
        "            n=1,\n",
        "        )\n",
        "        summarized_part = response.choices[0].message.content.strip()\n",
        "        summaries.append(summarized_part)\n",
        "\n",
        "    # Here we combine the chunk summaries and summarize them again\n",
        "    chunks_summary_text = \" \".join(summaries)\n",
        "    combined_summary_parts = split_text_if_needed(chunks_summary_text)\n",
        "\n",
        "    # Since we don't want to fall into recursion, we manually call OpenAI API here again\n",
        "    final_summaries = []\n",
        "    for part in combined_summary_parts:\n",
        "        input_text = f\"{part}\\n\\nPrompt: {prompt}\"\n",
        "        response = openai.chat.completions.create(\n",
        "            model= \"gpt-4-turbo\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "            #model= \"gpt4-o\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "\n",
        "            messages=[{\"role\": \"user\", \"content\": input_text}],\n",
        "            max_tokens=675,\n",
        "            temperature=0.5,\n",
        "            n=2,\n",
        "        )\n",
        "        summarized_part = response.choices[0].message.content.strip()\n",
        "        final_summaries.append(summarized_part)\n",
        "\n",
        "    # Combine final summaries into a single output\n",
        "    final_summary = \" \".join(final_summaries)\n",
        "    # Function to consolidate multiple BACKGROUND and PROVISION sections into one each\n",
        "    return final_summary\n",
        "\n",
        "def prepare_summary(row):\n",
        "    prompt = (\"\"\"\n",
        "    **This is a professional-level text summarization task. You will summarize text extracted from a large reference document. Follow these rules and guidelines:**\n",
        "\n",
        "    1. **Summary Length**:\n",
        "       - For 'Topics,' the summary should be 600 words or less but should ALWAYS include COMPLETE LISTS of codes as defined in item #9 below.\n",
        "       - For 'Subtopics,' the summary should be 250 words or less, UNLESS a code set is listed (see 9. below for instructions on handling codes and other itemized lists.)**.\n",
        "       - Summarize 5%-50% of the input text length within the given word limits.\n",
        "       - Ensure your summary is concise, coherent, and contextually relevant. Avoid filler words.\n",
        "\n",
        "\n",
        "    2. **Input Format**:\n",
        "       - Each sentence starts with a semi-coded Topic/Subtopic label, followed by the page number.\n",
        "       - Example: `{Subtopic: 2B4c_Clinical Labor Pricing: [from p. 37: [We did not find that the typical price for a surgical mask had increased by more than 60% since the supply and equipment pricing update concluded in CY 2022, and as such we are maintaining the current price for these supply items.]] }`\n",
        "       - You may receive input text with multiple BACKGROUND and PROVISION sections. These should be combined into just ONE of each category in your output\n",
        "          (see #6 below for more details.)\n",
        "      - ALWAYS LOOK FOR the appropriate Topic-specific BEGINNING AND END of the input text. The text has been split up strictly and only by page even though the\n",
        "         Topics and Subtopics usually start and end in the middle of a given page. For this reason, sentences from these pages may have a mislabeled Topic or\n",
        "         Subtopic. So please analyze and be VERY MINDFUL of the Topic/Subtopic theme, which you can infer from the name of the Topic or subtopic label\n",
        "         (e.g., 2B5_Solicitation: Updates to PE Data Collection and Methodology), and do NOT include these out of topic setences in your summarization.\n",
        "         In other words, you will have to apply some judgement on the start and end of a given topic on the first and last page of the input text. There will\n",
        "         probably be text on these pages that is irrelevant to the Topic/Subtopic, and I need you to ignore this, so that your summary only relates to the text\n",
        "         from the correct primary Topic/Subtopic of the input text. One way to solve this Topic/Subtopic parsing problem is to treat the Topic/Subtopic label\n",
        "         as an input for a Topic Modeling analysis. Using that approach, it might be easier to identify the text at the beginning and end of the inpt text that is\n",
        "         not relevant to the summarization task. (see #3 below for more about the Topic/Subtopic labels.)\n",
        "      - *ALWAYS NOTE WHEN ALL CONTENT COMES FROM THE SAME PAGE!** THis means that you are almost CERTAIN to have superfluous text. Do NOT incorporate irrelevant\n",
        "        input text to the text that you summarize. Make sure that Topic (or more likely for 1-page input text) the SUBTopic has been evalauted as a TOPIC so that\n",
        "        you can do you very best to idenitfy and summarize text directly related to this SINGLE topic. For example, if your input text was from Subtopic\n",
        "        '2B5_Solicitation: Updates to PE Data Collection and Methodology', your summary should come from the sentences on that page that relate to the topic\n",
        "        of 'Soliciation: Updates to PE Data Collection and Methodology', and not to any other topic that may have verbiage on that page. You can EXPECT and  PLAN\n",
        "        FOR about one-third to one-half of single-page input text to be IRRELEVANT to the topic even though it may be labeled as being related to the topic. THis\n",
        "        is a flaw in the data processing method that will be addressed later. For now, please look for this problem and address it, please. The same also goes for\n",
        "        2- and 3- page inputs, etc, but the ratio of superfluous text will be less of course, and limited to the first and last pages. Remember, for code lists\n",
        "        (See #9 below) and other input text, it will be a problem to bring in superfluous text, so if you aren't sure LEAVE OUT what does not seem to fit. Better\n",
        "        to leave out than to put in the wrong information.\n",
        "    3. **Label Usage**:\n",
        "       - Topic/Subtopic labels will include an alphanumeric code and a description.\n",
        "       - Example label:** `2B5_Solicitation: Updates to PE Data Collection and Methodology`\n",
        "       - Use the Topic/Subtopic label to identify the input text's context and to narrow the focus of the summary, but **do not** explictly restate this label in\n",
        "         the summary.\n",
        "\n",
        "    4. **Relevance**:\n",
        "       - Use the label to determine the relevance of each sentence.\n",
        "       - Focus only on text relevant to the Topic/Subtopic, especially at the beginning or end of the text block, which might contain unrelated information.\n",
        "       -**Incorporate Statutory References**: Include specific legal references, such as the section names and numbers from the relevant acts or regulations.\n",
        "       -**Emphasize Key Distinctions**: For example, clearly highlight distinctions between different types of RVUs (e.g., facility vs. non-facility) and their\n",
        "          implications.\n",
        "       - **Include Any Historical and Methodological Context given in the text**: Reference important historical rules and methodologies that influence current\n",
        "          practices, such as the CY 2010 PFS final rule.\n",
        "       -**Highlight Future Surveys and Data Collection Efforts**: Mention any upcoming data collection efforts or methodological changes that may impact future\n",
        "          valuations.\n",
        "    5. **Input Example**:\n",
        "       - Multi-page block:** `\"2B_Determination of Practice Expense RVUs: [from p. 12:[This is an example sentence]]  2B_Determination of Practice Expense RVUs: [from p. 13:[This is another example sentence]]\"`\n",
        "    6. **Output Structure**:\n",
        "       - Your 'Topic' summaries (and on occsion where appropriate, 'Subtopic' summaries from long input text) should ALWAYS include EXACTLY two sections:\n",
        "         **'BACKGROUND'** and **'PROVISION'**.\n",
        "       - Use ALL CAPS for these two section headers.\n",
        "       - Due text chunking strategy used, you may find that several text summaries have been combined into your intput text, causing your input to have several\n",
        "         iterations of the section structure of 2 sections shown below. But for your final summary you should  only have these two sectionsappear ONCE EACH, not\n",
        "         more: one 'BACKGROUND' and one'PROVISION', no matter how many different versions of these sections are in the input text. When writing a summary from\n",
        "         input with multiple examples of these two sections, you should first COMBINE all the text from all the BACKGROUND text and summarize that into one single\n",
        "         BACKGROUND section as shown below, and then do the same for the PROVISION sections.\n",
        "       - Example format:\n",
        "         ```\n",
        "          BACKGROUND: The CAA 2022 included several provisions certain Medicare telehealth flexibilities during COVID-19 PHE for 151 days after the end of the PHE. This act temporarily removed restrictions on telehealth originating sites allowing patients to be located in any site in the US at the time of the telehealth service, including the persons home, expanded the definition of telehealth practitioners to include qualified occupational therapists, qualified physical therapists, qualified speech language pathologists, and qualified audiologists, continued payments for telehealth services during the PHE, delayed requirements for in person visits, and continued to provide payment of telehealth services included on the MTSL as of March 15, 2020.\n",
        "\n",
        "          PROVISION:  The goal of this is to clarify in this proposed rule that certain telehealth flexibilities that were previously extended until 151 days after the end of the PHE, by the CA 2022, have been extended until December 31, 2024 in accordance with the amendments made in CAA 2023.\n",
        "                      In-person requirements for telehealth services:\n",
        "                      - Keep diagnosis, evaluation, or treatment of mental health disorders will again be effective on January 1, 2025.\n",
        "                      - Add the delay of in-person visit requirements for mental health visits by rural health clinics and federally qualifies centers via telecommunications tech until January 1, 2025 rather than 152nd day after the end of the PHE.\n",
        "                      - Originating Site Requirements: Will not issue any program instructions or proposals to limit or modify telehealth originating sites for CY 2023 or 2024.\n",
        "                      - Telehealth Practitioners: The list of telehealth practitioners remains as described in our CY 2023 final rule. Will also recognize marriage and family therapists (MFT) and Mental Health Counselors (MHC) as telehealth practitioners effective January 1, 2024. Propose to amend  410.78(b)(2) to add new paragraphs (xi) and (xii) to specify that a marriage and family therapist as described in proposed  410.53 and a mental health counselor as described in proposed  410.54 are included as distant site practitioners for purposes of furnishing telehealth services.\n",
        "                      - Audio-Only Services: Continue to provide coverage and payment of telehealth services via an audio-only communication system ending on December 31, 2024.\n",
        "\n",
        "         ```\n",
        "        -It is very important that the output only relates to the input Topic/Subtopic (Check carefully as you read in the text, in case there is a misslabeled\n",
        "        text block at the beginning or end of the text, this is very possble.)\n",
        "        -It is also very important that the output have only ONE 'BACKGROUND' section and one 'PROVISION' section, and that these relate only to the given Topic/Subtopic.\n",
        "    7. **Writing Style**:\n",
        "       - Avoid \"meta\" language and unnecessary introductions.\n",
        "       - No references to the reader or the writer.\n",
        "       - Prefer direct, factual statements.\n",
        "       - Avoid burdensome introductory phrases.\n",
        "       -Write to at least College-level (the summary readers are professional Policy Analysts who will easily understand concise, subtle phrases and relevant abbreviations.)\n",
        "\n",
        "    8. **Acronyms**:\n",
        "       - Do not spell out common acronyms more than once.\n",
        "       - Use the following known acronyms without explanation. DO NOT spell out the words, just use the acronyms when you see them in context of the below definitions:\n",
        "         - AMA (American Medical Association)\n",
        "         - CMS (Centers for Medicare and Medicaid Services)\n",
        "         - CY (Calendar Year)\n",
        "\n",
        "    9. **Codes**:\n",
        "       - If the text includes lists of medical procedure codes (i.e., CPT or similar codes),  diagnostic codes (i.e., DIAG or DX codes), or Prescription Medications,\n",
        "         Medical Equipment, or any other list of Medically-related codes or terms with names and/definitions; then identify and label them\n",
        "        clearly, explicitly, and COMPLETELY in your summary. Make sure EVERY CODE is spelled out. Do NOT leave out any, or charactrize a set of them with a collective\n",
        "        term. This is the one area in which you should not be brief in your summmary output.\n",
        "       - Example Output for Code lists as described above:\n",
        "         ```\n",
        "         {\n",
        "           The following CPT codes have been identified as potentially misvalued:\n",
        "           * CPT code 59200: Insertion cervical dilator\n",
        "           * CPT code 27279: Arthrodesis, sacroiliac joint\n",
        "           * CPT codes 99221, 99222, 99223: Hospital Inpatient and Observation Care visit codes\n",
        "           * CPT codes 36514, 36515, 36522: Therapeutic aphaeresis codes and photopheresis, extracorporeal code\n",
        "           * CPT codes 44205 and 44204: Laparoscopy, surgical, colectomy, partial codes\n",
        "         }\n",
        "         ```\n",
        "\n",
        "    10. **Final Details**:\n",
        "       - For longer Subtopic blocks (at least 5,000 tokens), apply the Background/Provision format for Subtopics as well.\n",
        "       - ALWAYS LOOK FOR the appropriate Topic-specific BEGINNING AND END of the input text (see and keep in mind #2 above for more details.)\n",
        "       - Be succinct\n",
        "        -OMIT NEEDLESS WORDS\n",
        "        -Use acronyms liberally and with minimal (and sometimes no) references to what are the words that they stand for.\n",
        "           \"\"\")\n",
        "\n",
        "    text_parts = split_text_if_needed(row['text'])\n",
        "    initial_summary = get_gpt4_summary(text_parts, prompt)\n",
        "\n",
        "    if num_tokens_from_string(initial_summary) > 750:\n",
        "        # If the concatenated summary is more than 750 tokens, further summarize it\n",
        "        secondary_summary_parts = split_text_if_needed(initial_summary)\n",
        "        final_summary = get_gpt4_summary(secondary_summary_parts, prompt)\n",
        "        if num_tokens_from_string(final_summary) > 750:\n",
        "            # Apply another round of summarization if still over 750 tokens\n",
        "            tertiary_summary_parts = split_text_if_needed(final_summary)\n",
        "            final_summary = get_gpt4_summary(tertiary_summary_parts, prompt)\n",
        "        return final_summary\n",
        "    else:\n",
        "        return initial_summary\n",
        "\n",
        "def consolidate_sections(row):\n",
        "    # Extract sections\n",
        "    background_matches = re.findall(r'BACKGROUND:.*?(?=\\n[A-Z]+:|\\Z)', row['Topic_Subtopic_Summary'], re.DOTALL)\n",
        "    provision_matches = re.findall(r'PROVISION:.*?(?=\\n[A-Z]+:|\\Z)', row['Topic_Subtopic_Summary'], re.DOTALL)\n",
        "\n",
        "    background_text = \" \".join([match.replace(\"BACKGROUND:\", \"\").strip() for match in background_matches])\n",
        "    provision_text = \" \".join([match.replace(\"PROVISION:\", \"\").strip() for match in provision_matches])\n",
        "    return f\"BACKGROUND: {background_text}\\n\\nPROVISION: {provision_text}\"\n",
        "\n",
        "# Application of the summarization function and fix the multiple category problem\n",
        "merged_df_Topic_Subtopic_text_combined['Topic_Subtopic_Summary'] = merged_df_Topic_Subtopic_text_combined.apply(prepare_summary, axis=1)\n",
        "merged_df_Topic_Subtopic_text_combined['Topic_Subtopic_Summary'] = merged_df_Topic_Subtopic_text_combined.apply(consolidate_sections,axis=1)\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 24,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 89
        },
        "collapsed": true,
        "id": "znEX82klK47o",
        "outputId": "09f3a287-fcb6-4a31-a28b-a638d0f55716"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                   InsightsAI_Topic_Subtopic  \\\n",
              "0  2B_Determination of Practice Expense RVUs   \n",
              "\n",
              "                                                text  \\\n",
              "0  Topic: 2B_Determination of Practice Expense RV...   \n",
              "\n",
              "                              Topic_Subtopic_Summary  \n",
              "0  BACKGROUND: The Medicare Physician Fee Schedul...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-6b1ad3a3-75ba-47ef-8be7-350517231650\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>InsightsAI_Topic_Subtopic</th>\n",
              "      <th>text</th>\n",
              "      <th>Topic_Subtopic_Summary</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>2B_Determination of Practice Expense RVUs</td>\n",
              "      <td>Topic: 2B_Determination of Practice Expense RV...</td>\n",
              "      <td>BACKGROUND: The Medicare Physician Fee Schedul...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-6b1ad3a3-75ba-47ef-8be7-350517231650')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-6b1ad3a3-75ba-47ef-8be7-350517231650 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-6b1ad3a3-75ba-47ef-8be7-350517231650');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "  <div id=\"id_64773629-f549-4357-a5a1-1248324e69c5\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('merged_df_Topic_Subtopic_text_combined')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_64773629-f549-4357-a5a1-1248324e69c5 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('merged_df_Topic_Subtopic_text_combined');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "merged_df_Topic_Subtopic_text_combined",
              "summary": "{\n  \"name\": \"merged_df_Topic_Subtopic_text_combined\",\n  \"rows\": 1,\n  \"fields\": [\n    {\n      \"column\": \"InsightsAI_Topic_Subtopic\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"2B_Determination of Practice Expense RVUs\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [In accordance with section 1848 of the Act, CMS has paid for physicians\\u2019 services under \\nthe Medicare physician fee schedule (PFS) since January 1, 1992.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [The PFS relies on national \\nrelative values that are established for work, practice expense (PE), and malpractice (MP), which \\nare adjusted for geographic cost variations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [These values are multiplied by a conversion factor \\n(CF) to convert the relative value units (RVUs) into payment rates.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [The concepts and \\nmethodology underlying the PFS were enacted as part of the Omnibus Budget Reconciliation \\nAct of 1989 (OBRA \\u201989) (Pub.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [L. 101-239, December 19, 1989), and the Omnibus Budget \\nReconciliation Act of 1990 (OBRA \\u201990) (Pub.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [L. 101-508, November 5, 1990).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [The final rule \\npublished in the November 25, 1991 Federal Register (56 FR 59502) set forth the first fee \\nschedule used for Medicare payment for physicians\\u2019 services.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [We note that throughout this proposed rule, unless otherwise noted, the term \\n\\u201cpractitioner\\u201d is used to describe both physicians and nonphysician practitioners (NPPs) who are \\npermitted to bill Medicare under the PFS for the services they furnish to Medicare beneficiaries.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [B.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [Determination of PE RVUs\\n1.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [Overview\\nPractice expense (PE) is the portion of the resources used in furnishing a service that \\nreflects the general categories of physician and practitioner expenses, such as office rent and \\npersonnel wages, but excluding malpractice (MP) expenses, as specified in section 1848(c)(1)(B) \\nof the Act.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [As required by section 1848(c)(2)(C)(ii) of the Act, we use a resource-based system \\nfor determining PE RVUs for each physicians\\u2019 service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [We develop PE RVUs by considering \\nthe direct and indirect practice resources involved in furnishing each service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [Direct expense \\ncategories include clinical labor, medical supplies, and medical equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [Indirect expenses \\ninclude administrative labor, office expense, and all other expenses.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [The sections that follow \\nprovide more detailed information about the methodology for translating the resources involved \\nin furnishing each service into service specific PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 12: [We refer readers to the CY 2010]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [Physician Fee Schedule (PFS) final rule with comment period (74 FR 61743 through 61748) for \\na more detailed explanation of the PE methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [2.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [Practice Expense Methodology\\na.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [Direct Practice Expense\\nWe determine the direct PE for a specific service by adding the costs of the direct \\nresources (that is, the clinical staff, medical supplies, and medical equipment) typically involved \\nwith furnishing that service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [The costs of the resources are calculated using the refined direct PE \\ninputs assigned to each CPT code in our PE database, which are generally based on our review of \\nrecommendations received from the Relative Value Scale Update Committee (RUC) and those \\nprovided in response to public comment periods.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [For a detailed explanation of the direct PE \\nmethodology, including examples, we refer readers to the 5-year review of work RVUs under the \\nPFS and proposed changes to the PE methodology in the CY 2007 PFS proposed rule (71 FR \\n37242) and the CY 2007 PFS final rule with comment period (71 FR 69629).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [b.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [Indirect Practice Expense per Hour Data\\nWe use survey data on indirect PEs incurred per hour worked, in developing the indirect \\nportion of the PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [Prior to CY 2010, we primarily used the PE/HR by specialty that was \\nobtained from the AMA\\u2019s Socioeconomic Monitoring System (SMS).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [The AMA administered a \\nnew survey in CY 2007 and CY 2008, the Physician Practice Information Survey (PPIS).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [The \\nPPIS is a multispecialty, nationally representative, PE survey of both physicians and NPPs paid \\nunder the PFS using a survey instrument and methods highly consistent with those used for the \\nSMS and the supplemental surveys.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [The PPIS gathered information from 3,656 respondents \\nacross 51 physician specialty and health care professional groups.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [We believe the PPIS is the \\nmost comprehensive source of PE survey information available.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 13: [We used the PPIS data to \\nupdate the PE/HR data for the CY 2010 PFS for almost all of the Medicare recognized \\nspecialties that participated in the survey.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [When we began using the PPIS data in CY 2010, we did not change the PE RVU \\nmethodology itself or the manner in which the PE/HR data are used in that methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [We \\nonly updated the PE/HR data based on the new survey.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Furthermore, as we explained in the CY \\n2010 PFS final rule with comment period (74 FR 61751), because of the magnitude of payment \\nreductions for some specialties resulting from the use of the PPIS data, we transitioned its use \\nover a 4-year period from the previous PE RVUs to the PE RVUs developed using the new PPIS \\ndata.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [As provided in the CY 2010 PFS final rule with comment period (74 FR 61751), the \\ntransition to the PPIS data was complete for CY 2013.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Therefore, PE RVUs from CY 2013 \\nforward are developed based entirely on the PPIS data, except as noted in this section.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Section 1848(c)(2)(H)(i) of the Act requires us to use the medical oncology supplemental \\nsurvey data submitted in 2003 for oncology drug administration services.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Therefore, the PE/HR \\nfor medical oncology, hematology, and hematology/oncology reflects the continued use of these \\nsupplemental survey data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Supplemental survey data on independent labs from the College of American \\nPathologists were implemented for payments beginning in CY 2005.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Supplemental survey data \\nfrom the National Coalition of Quality Diagnostic Imaging Services (NCQDIS), representing \\nindependent diagnostic testing facilities (IDTFs), were blended with supplementary survey data \\nfrom the American College of Radiology (ACR) and implemented for payments beginning in \\nCY 2007.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Neither IDTFs, nor independent labs, participated in the PPIS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Therefore, we \\ncontinue to use the PE/HR that was developed from their supplemental survey data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [Consistent with our past practice, the previous indirect PE/HR values from the \\nsupplemental surveys for these specialties were updated to CY 2006 using the Medicare \\nEconomic Index (MEI) to put them on a comparable basis with the PPIS data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 14: [We also do not use the PPIS data for reproductive endocrinology and spine surgery since \\nthese specialties currently are not separately recognized by Medicare, nor do we have a method \\nto blend the PPIS data with Medicare recognized specialty data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [Previously, we established PE/HR values for various specialties without SMS or \\nsupplemental survey data by cross-walking them to other similar specialties to estimate a proxy \\nPE/HR.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [For specialties that were part of the PPIS for which we previously used a cross-walked \\nPE/HR, we instead used the PPIS based PE/HR.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [We use cross-walks for specialties that did not \\nparticipate in the PPIS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [These cross-walks have been generally established through notice and \\ncomment rulemaking and are available in the file titled \\u201cCY 2024 PFS proposed rule PE/HR\\u201d on \\nthe CMS website under downloads for the CY 2024 PFS proposed rule at \\nhttp://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-\\nFederal-Regulation-Notices.html.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [c. Allocation of PE to Services\\nTo establish PE RVUs for specific services, it is necessary to establish the direct and \\nindirect PE associated with each service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [(1)  Direct Costs\\nThe relative relationship between the direct cost portions of the PE RVUs for any two \\nservices is determined by the relative relationship between the sum of the direct cost resources \\n(that is, the clinical staff, medical supplies, and medical equipment) typically involved with \\nfurnishing each of the services.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [The costs of these resources are calculated from the refined \\ndirect PE inputs in our PE database.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [For example, if one service has a direct cost sum of $400 \\nfrom our PE database and another service has a direct cost sum of $200, the direct portion of the \\nPE RVUs of the first service would be twice as much as the direct portion of the PE RVUs for \\nthe second service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [(2)  Indirect Costs  \\nWe allocate the indirect costs at the code level based on the direct costs specifically \\nassociated with a code and the greater of either the clinical labor costs or the work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [We \\nalso incorporate the survey data described earlier in the PE/HR discussion.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 15: [The general \\napproach to developing the indirect portion of the PE RVUs is as follows:]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [\\u25cf  For a given service, we use the direct portion of the PE RVUs calculated as previously \\ndescribed and the average percentage that direct costs represent of total costs (based on survey \\ndata) across the specialties that furnish the service to determine an initial indirect allocator.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [That \\nis, the initial indirect allocator is calculated so that the direct costs equal the average percentage \\nof direct costs of those specialties furnishing the service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [For example, if the direct portion of the \\nPE RVUs for a given service is 2.00 and direct costs, on average, represent 25 percent of total \\ncosts for the specialties that furnish the service, the initial indirect allocator would be calculated \\nso that it equals 75 percent of the total PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [Thus, in this example, the initial indirect \\nallocator would equal 6.00, resulting in a total PE RVU of 8.00 (2.00 is 25 percent of 8.00 and \\n6.00 is 75 percent of 8.00).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [\\u25cf  Next, we add the greater of the work RVUs or clinical labor portion of the direct \\nportion of the PE RVUs to this initial indirect allocator.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [In our example, if this service had a \\nwork RVU of 4.00 and the clinical labor portion of the direct PE RVU was 1.50, we would add \\n4.00 (since the 4.00 work RVUs are greater than the 1.50 clinical labor portion) to the initial \\nindirect allocator of 6.00 to get an indirect allocator of 10.00.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [In the absence of any further use \\nof the survey data, the relative relationship between the indirect cost portions of the PE RVUs for \\nany two services would be determined by the relative relationship between these indirect cost \\nallocators.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [For example, if one service had an indirect cost allocator of 10.00 and another service \\nhad an indirect cost allocator of 5.00, the indirect portion of the PE RVUs of the first service \\nwould be twice as great as the indirect portion of the PE RVUs for the second service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [\\u25cf  Then, we incorporate the specialty specific indirect PE/HR data into the calculation.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [In our example, if, based on the survey data, the average indirect cost of the specialties \\nfurnishing the first service with an allocator of 10.00 was half of the average indirect cost of the \\nspecialties furnishing the second service with an indirect allocator of 5.00, the indirect portion of \\nthe PE RVUs of the first service would be equal to that of the second service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 16: [(3)  Facility and Nonfacility Costs]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [For procedures that can be furnished in a physician\\u2019s office, as well as in a facility \\nsetting, where Medicare makes a separate payment to the facility for its costs in furnishing a \\nservice, we establish two PE RVUs:  facility and nonfacility.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [The methodology for calculating \\nPE RVUs is the same for both the facility and nonfacility RVUs, but is applied independently to \\nyield two separate PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [In calculating the PE RVUs for services furnished in a facility, we \\ndo not include resources that would generally not be provided by physicians when furnishing the \\nservice.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [For this reason, the facility PE RVUs are generally lower than the nonfacility PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [(4)  Services with Technical Components and Professional Components \\nDiagnostic services are generally comprised of two components:  a professional \\ncomponent (PC); and a technical component (TC).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [The PC and TC may be furnished \\nindependently or by different providers, or they may be furnished together as a global service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [When services have separately billable PC and TC components, the payment for the global \\nservice equals the sum of the payment for the TC and PC.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [To achieve this, we use a weighted \\naverage of the ratio of indirect to direct costs across all the specialties that furnish the global \\nservice, TCs, and PCs; that is, we apply the same weighted average indirect percentage factor to \\nallocate indirect expenses to the global service, PCs, and TCs for a service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [(The direct PE \\nRVUs for the TC and PC sum to the global.)]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [(5)  PE RVU Methodology\\nFor a more detailed description of the PE RVU methodology, we direct readers to the CY \\n2010 PFS final rule with comment period (74 FR 61745 through 61746).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [We also direct readers \\nto the file titled \\u201cCalculation of PE RVUs under Methodology for Selected Codes\\u201d which is \\navailable on our website under downloads for the CY 2024 PFS proposed rule at \\nhttp://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-\\nFederal-Regulation-Notices.html.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [This file contains a table that illustrates the calculation of PE \\nRVUs as described in this proposed rule for individual codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 17: [(a)  Setup File]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [First, we create a setup file for the PE methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [The setup file contains the direct \\ncost inputs, the utilization for each procedure code at the specialty and facility/nonfacility place \\nof service level, and the specialty specific PE/HR data calculated from the surveys.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [(b)  Calculate the Direct Cost PE RVUs\\nSum the costs of each direct input.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 1:  Sum the direct costs of the inputs for each service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 2:  Calculate the aggregate pool of direct PE costs for the current year.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [We set the \\naggregate pool of PE costs equal to the product of the ratio of the current aggregate PE RVUs to \\ncurrent aggregate work RVUs and the projected aggregate work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 3:  Calculate the aggregate pool of direct PE costs for use in ratesetting.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [This is the \\nproduct of the aggregate direct costs for all services from Step 1 and the utilization data for that \\nservice.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 4:  Using the results of Step 2 and Step 3, use the CF to calculate a direct PE scaling \\nadjustment to ensure that the aggregate pool of direct PE costs calculated in Step 3 does not vary \\nfrom the aggregate pool of direct PE costs for the current year.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Apply the scaling adjustment to \\nthe direct costs for each service (as calculated in Step 1).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 5:  Convert the results of Step 4 to an RVU scale for each service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [To do this, divide \\nthe results of Step 4 by the CF.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Note that the actual value of the CF used in this calculation does \\nnot influence the final direct cost PE RVUs as long as the same CF is used in Step 4 and Step 5.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Different CFs would result in different direct PE scaling adjustments, but this has no effect on \\nthe final direct cost PE RVUs since changes in the CFs and changes in the associated direct \\nscaling adjustments offset one another.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [(c)  Create the Indirect Cost PE RVUs\\nCreate indirect allocators.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 18: [Step 6:  Based on the survey data, calculate direct and indirect PE percentages for each \\nphysician specialty.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [Step 7:  Calculate direct and indirect PE percentages at the service level by taking a \\nweighted average of the results of Step 6 for the specialties that furnish the service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [Note that for \\nservices with TCs and PCs, the direct and indirect percentages for a given service do not vary by \\nthe PC, TC, and global service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [We generally use an average of the 3 most recent years of available Medicare claims data \\nto determine the specialty mix assigned to each code.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [Codes with low Medicare service volume \\nrequire special attention since billing or enrollment irregularities for a given year can result in \\nsignificant changes in specialty mix assignment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [We finalized a policy in the CY 2018 PFS final \\nrule (82 FR 52982 through 59283) to use the most recent year of claims data to determine which \\ncodes are low volume for the coming year (those that have fewer than 100 allowed services in \\nthe Medicare claims data).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [For codes that fall into this category, instead of assigning specialty \\nmix based on the specialties of the practitioners reporting the services in the claims data, we use \\nthe expected specialty that we identify on a list developed based on medical review and input \\nfrom expert interested parties.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [We display this list of expected specialty assignments as part of \\nthe annual set of data files we make available as part of notice and comment rulemaking and \\nconsider recommendations from the RUC and other interested parties on changes to this list on \\nan annual basis.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [Services for which the specialty is automatically assigned based on previously \\nfinalized policies under our established methodology (for example, \\u201calways therapy\\u201d services) \\nare unaffected by the list of expected specialty assignments.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [We also finalized in the CY 2018 \\nPFS final rule (82 FR 52982 through 52983) a policy to apply these service-level overrides for \\nboth PE and MP, rather than one or the other category.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [Step 8:  Calculate the service level allocators for the indirect PEs based on the \\npercentages calculated in Step 7.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [The indirect PEs are allocated based on the three components:  \\nthe direct PE RVUs; the clinical labor PE RVUs; and the work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 19: [For most services the indirect allocator is: indirect PE percentage * (direct PE \\nRVUs/direct percentage) + work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [There are two situations where this formula is modified:\\n\\u25cf  If the service is a global service (that is, a service with global, professional, and \\ntechnical components), then the indirect PE allocator is: indirect percentage (direct PE \\nRVUs/direct percentage) + clinical labor PE RVUs + work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [\\u25cf  If the clinical labor PE RVUs exceed the work RVUs (and the service is not a global \\nservice), then the indirect allocator is: indirect PE percentage (direct PE RVUs/direct percentage) \\n+ clinical labor PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [(Note:  For global services, the indirect PE allocator is based on both the work RVUs and \\nthe clinical labor PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [We do this to recognize that, for the PC service, indirect PEs would \\nbe allocated using the work RVUs, and for the TC service, indirect PEs would be allocated using \\nthe direct PE RVUs and the clinical labor PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [This also allows the global component \\nRVUs to equal the sum of the PC and TC RVUs.)]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [For presentation purposes, in the examples in the download file titled \\u201cCalculation of PE \\nRVUs under Methodology for Selected Codes\\u201d, the formulas were divided into two parts for \\neach service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [\\u25cf  The first part does not vary by service and is the indirect percentage (direct PE \\nRVUs/direct percentage).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [\\u25cf  The second part is either the work RVU, clinical labor PE RVU, or both depending on \\nwhether the service is a global service and whether the clinical PE RVUs exceed the work RVUs \\n(as described earlier in this step).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [Apply a scaling adjustment to the indirect allocators.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [Step 9:  Calculate the current aggregate pool of indirect PE RVUs by multiplying the \\nresult of step 8 by the average indirect PE percentage from the survey data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 20: [Step 10:  Calculate an aggregate pool of indirect PE RVUs for all PFS services by adding \\nthe product of the indirect PE allocators for a service from Step 8 and the utilization data for that \\nservice.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 11:  Using the results of Step 9 and Step 10, calculate an indirect PE adjustment so \\nthat the aggregate indirect allocation does not exceed the available aggregate indirect PE RVUs \\nand apply it to indirect allocators calculated in Step 8.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Calculate the indirect practice cost index.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 12:  Using the results of Step 11, calculate aggregate pools of specialty specific \\nadjusted indirect PE allocators for all PFS services for a specialty by adding the product of the \\nadjusted indirect PE allocator for each service and the utilization data for that service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 13:  Using the specialty specific indirect PE/HR data, calculate specialty specific \\naggregate pools of indirect PE for all PFS services for that specialty by adding the product of the \\nindirect PE/HR for the specialty, the work time for the service, and the specialty\\u2019s utilization for \\nthe service across all services furnished by the specialty.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 14:  Using the results of Step 12 and Step 13, calculate the specialty specific indirect \\nPE scaling factors.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 15:  Using the results of Step 14, calculate an indirect practice cost index at the \\nspecialty level by dividing each specialty specific indirect scaling factor by the average indirect \\nscaling factor for the entire PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 16:  Calculate the indirect practice cost index at the service level to ensure the \\ncapture of all indirect costs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Calculate a weighted average of the practice cost index values for \\nthe specialties that furnish the service.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [(Note:  For services with TCs and PCs, we calculate the \\nindirect practice cost index across the global service, PCs, and TCs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Under this method, the \\nindirect practice cost index for a given service (for example, echocardiogram) does not vary by \\nthe PC, TC, and global service.)]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [Step 17:  Apply the service level indirect practice cost index calculated in Step 16 to the \\nservice level adjusted indirect allocators calculated in Step 11 to get the indirect PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 21: [(d)  Calculate the Final PE RVUs]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [Step 18:  Add the direct PE RVUs from Step 5 to the indirect PE RVUs from Step 17 and \\napply the final PE budget neutrality (BN) adjustment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [The final PE BN adjustment is calculated \\nby comparing the sum of steps 5 and 17 to the aggregate work RVUs scaled by the ratio of \\ncurrent aggregate PE and work RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [This adjustment ensures that all PE RVUs in the PFS \\naccount for the fact that certain specialties are excluded from the calculation of PE RVUs but \\nincluded in maintaining overall PFS BN.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [(See \\u201cSpecialties excluded from ratesetting \\ncalculation\\u201d later in this proposed rule.)]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [Step 19:  Apply the phase-in of significant RVU reductions and its associated adjustment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [Section 1848(c)(7) of the Act specifies that for services that are not new or revised codes, if the \\ntotal RVUs for a service for a year would otherwise be decreased by an estimated 20 percent or \\nmore as compared to the total RVUs for the previous year, the applicable adjustments in work, \\nPE, and MP RVUs shall be phased in over a 2-year period.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [In implementing the phase-in, we \\nconsider a 19 percent reduction as the maximum 1-year reduction for any service not described \\nby a new or revised code.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [This approach limits the year one reduction for the service to the \\nmaximum allowed amount (that is, 19 percent), and then phases in the remainder of the \\nreduction.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [To comply with section 1848(c)(7) of the Act, we adjust the PE RVUs to ensure that \\nthe total RVUs for all services that are not new or revised codes decrease by no more than 19 \\npercent, and then apply a relativity adjustment to ensure that the total pool of aggregate PE \\nRVUs remains relative to the pool of work and MP RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [For a more detailed description of \\nthe methodology for the phase-in of significant RVU changes, we refer readers to the CY 2016 \\nPFS final rule with comment period (80 FR 70927 through 70931).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [(e)  Setup File Information\\n\\u25cf  Specialties excluded from ratesetting calculation:  For the purposes of calculating the \\nPE and MP RVUs, we exclude certain specialties, such as certain NPPs paid at a percentage of \\nthe PFS and low volume specialties, from the calculation.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [These specialties are included for the \\npurposes of calculating the BN adjustment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 22: [They are displayed in Table 1.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [TABLE 1:  Specialties Excluded from Ratesetting Calculation\\nSpecialty \\nCodeSpecialty Description\\n49 Ambulatory surgical center \\n50 Nurse practitioner\\n51 Medical supply company with certified orthotist \\n52 Medical supply company with certified prosthetist \\n53 Medical supply company with certified prosthetist-orthotist \\n54 Medical supply company not included in 51, 52, or 53.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [55 Individual certified orthotist\\n56 Individual certified prosthetist\\n57 Individual certified prosthetist-orthotist\\n58 Medical supply company with registered pharmacist\\n59 Ambulance service supplier, e.g., private ambulance companies, funeral homes, etc.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [60 Public health or welfare agencies\\n61 Voluntary health or charitable agencies \\n73 Mass immunization roster biller \\n74 Radiation therapy centers\\n87 All other suppliers (e.g., drug and department stores) \\n88 Unknown supplier/provider specialty \\n89 Certified clinical nurse specialist\\n96 Optician \\n97 Physician assistant\\nA0 Hospital \\nA1 SNF \\nA2 Intermediate care nursing facility \\nA3 Nursing facility, other \\nA4 HHA \\nA5 Pharmacy \\nA6 Medical supply company with respiratory therapist \\nA7 Department store \\nA8 Grocery store\\nB1 Supplier of oxygen and/or oxygen related equipment (eff.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [10/2/2007)\\nB2 Pedorthic personnel \\nB3 Medical supply company with pedorthic personnel \\nB4 Rehabilitation Agency\\nB5 Ocularist\\nC1 Centralized Flu\\nC2 Indirect Payment Procedure\\nC5 Dentistry\\n\\u25cf Cross-walk certain low volume physician specialties: Cross-walk the utilization of \\ncertain specialties with relatively low PFS utilization to the associated specialties.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [\\u25cf  Physical therapy utilization: Cross-walk the utilization associated with all physical \\ntherapy services to the specialty of physical therapy.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [\\u25cf  Identify professional and technical services not identified under the usual TC and 26 \\nmodifiers:  Flag the services that are PC and TC services but do not use TC and 26 modifiers (for \\nexample, electrocardiograms).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 23: [This flag associates the PC and TC with the associated global]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [code for use in creating the indirect PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [For example, the professional service, CPT code \\n93010 (Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only), is \\nassociated with the global service, CPT code 93000 (Electrocardiogram, routine ECG with at \\nleast 12 leads; with interpretation and report).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [\\u25cf  Payment modifiers:  Payment modifiers are accounted for in the creation of the file \\nconsistent with current payment policy as implemented in claims processing.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [For example, \\nservices billed with the assistant at surgery modifier are paid 16 percent of the PFS amount for \\nthat service; therefore, the utilization file is modified to only account for 16 percent of any \\nservice that contains the assistant at surgery modifier.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [Similarly, for those services to which \\nvolume adjustments are made to account for the payment modifiers, time adjustments are applied \\nas well.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [For time adjustments to surgical services, the intraoperative portion in the work time file \\nis used; where it is not present, the intraoperative percentage from the payment files used by \\ncontractors to process Medicare claims is used instead.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [Where neither is available, we use the \\npayment adjustment ratio to adjust the time accordingly.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [Table 2 details the manner in which the \\nmodifiers are applied.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 24: [TABLE 2:  Application of Payment Modifiers to Utilization Files\\nModifier Description Volume Adjustment Time Adjustment\\n80,81,82 Assistant at Surgery 16% Intraoperative portion\\nAS Assistant at Surgery \\u2013 \\nPhysician Assistant14% (85% * 16%) Intraoperative portion\\n50 or\\nLT and RTBilateral Surgery 150% 150% of work time\\n51 Multiple Procedure 50% Intraoperative portion\\n52 Reduced Services 50% 50%\\n53 Discontinued Procedure 50% 50%\\n54 Intraoperative Care only Preoperative + Intraoperative \\nPercentages on the payment files used \\nby Medicare contractors to process \\nMedicare claimsPreoperative + Intraoperative \\nportion\\n55 Postoperative Care only Postoperative Percentage on the \\npayment files used by Medicare \\ncontractors to process Medicare claimsPostoperative portion\\n62 Co-surgeons 62.5% 50%\\n66 Team Surgeons 33% 33%\\nCO, CQ Physical and Occupational \\nTherapy Assistant Services88% 88%]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [We also adjust volume and time that correspond to other payment rules, including special \\nmultiple procedure endoscopy rules and multiple procedure payment reductions (MPPRs).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [We \\nnote that section 1848(c)(2)(B)(v) of the Act exempts certain reduced payments for multiple \\nimaging procedures and multiple therapy services from the BN calculation under section \\n1848(c)(2)(B)(ii)(II) of the Act.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [These MPPRs are not included in the development of the \\nRVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [Beginning in CY 2022, section 1834(v)(1) of the Act required that we apply a 15 percent \\npayment reduction for outpatient occupational therapy services and outpatient physical therapy \\nservices that are provided, in whole or in part, by a physical therapist assistant (PTA) or \\noccupational therapy assistant (OTA).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [Section 1834(v)(2)(A) of the Act required CMS to \\nestablish modifiers to identify these services, which we did in the CY 2019 PFS final rule (83 FR \\n59654 through 59661), creating the CQ and CO payment modifiers for services provided in \\nwhole or in part by PTAs and OTAs, respectively.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [These payment modifiers are required to be \\nused on claims for services with dates of service beginning January 1, 2020, as specified in the \\nCY 2020 PFS final rule (84 FR 62702 through 62708).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [We applied the 15 percent payment \\nreduction to therapy services provided by PTAs (using the CQ modifier) or OTAs (using the CO \\nmodifier), as required by statute.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [Under sections 1834(k) and 1848 of the Act, payment is made \\nfor outpatient therapy services at 80 percent of the lesser of the actual charge or applicable fee \\nschedule amount (the allowed charge).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [The remaining 20 percent is the beneficiary copayment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [For therapy services to which the new discount applies, payment will be made at 85 percent of \\nthe 80 percent of allowed charges.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [Therefore, the volume discount factor for therapy services to \\nwhich the CQ and CO modifiers apply is: (0.20 + (0.80* 0.85), which equals 88 percent.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [For anesthesia services, we do not apply adjustments to volume since we use the average \\nallowed charge when simulating RVUs; therefore, the RVUs as calculated already reflect the \\npayments as adjusted by modifiers, and no volume adjustments are necessary.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 25: [However, a time \\nadjustment of 33 percent is made only for medical direction of two to four cases since that is the]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [only situation where a single practitioner is involved with multiple beneficiaries concurrently, so \\nthat counting each service without regard to the overlap with other services would overstate the \\namount of time spent by the practitioner furnishing these services.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [\\u25cf  Work RVUs:  The setup file contains the work RVUs from this proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [(6)  Equipment Cost per Minute\\nThe equipment cost per minute is calculated as:\\n(1/ (minutes per year * usage)) * price * ((interest rate/(1 (1/((1 + interest rate)^ life of \\nequipment)))) + maintenance)\\nWhere:\\nminutes per year = maximum minutes per year if usage were continuous (that is, \\nusage=1); generally, 150,000 minutes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [usage = variable, see discussion below in this proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [price = price of the particular piece of equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [life of equipment = useful life of the particular piece of equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [maintenance = factor for maintenance; 0.05.\\ninterest rate = variable, see discussion below in this proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [Usage:  We currently use an equipment utilization rate assumption of 50 percent for most \\nequipment, with the exception of expensive diagnostic imaging equipment, for which we use a \\n90 percent assumption as required by section 1848(b)(4)(C) of the Act.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [Useful Life:  In the CY 2005 PFS final rule we stated that we updated the useful life for \\nequipment items primarily based on the AHA\\u2019s \\u201cEstimated Useful Lives of Depreciable Hospital \\nAssets\\u201d guidelines (69 FR 66246).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [The most recent edition of these guidelines was published in \\n2018.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [This reference material provides an estimated useful life for hundreds of different types of \\nequipment, the vast majority of which fall in the range of 5 to 10 years, and none of which are \\nlower than 2 years in duration.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 26: [We believe that the updated editions of this reference material \\nremain the most accurate source for estimating the useful life of depreciable medical equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [In the CY 2021 PFS final rule, we finalized a proposal to treat equipment life durations of \\nless than 1 year as having a duration of 1 year for the purpose of our equipment price per minute \\nformula.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [In the rare cases where items are replaced every few months, we noted that we believe \\nit is more accurate to treat these items as disposable supplies with a fractional supply quantity as \\nopposed to equipment items with very short equipment life durations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [For a more detailed \\ndiscussion of the methodology associated with very short equipment life durations, we refer \\nreaders to the CY 2021 PFS final rule (85 FR 84482 through 84483).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [\\u25cf  Maintenance:  We finalized the 5 percent factor for annual maintenance in the CY \\n1998 PFS final rule with comment period (62 FR 33164).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [As we previously stated in the CY \\n2016 PFS final rule with comment period (80 FR 70897), we do not believe the annual \\nmaintenance factor for all equipment is precisely 5 percent, and we concur that the current rate \\nlikely understates the true cost of maintaining some equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [We also noted that we believe it \\nlikely overstates the maintenance costs for other equipment.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [When we solicited comments \\nregarding sources of data containing equipment maintenance rates, commenters were unable to \\nidentify an auditable, robust data source that could be used by CMS on a wide scale.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [We noted \\nthat we did not believe voluntary submissions regarding the maintenance costs of individual \\nequipment items would be an appropriate methodology for determining costs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [As a result, in the \\nabsence of publicly available datasets regarding equipment maintenance costs or another \\nsystematic data collection methodology for determining a different maintenance factor, we did \\nnot propose a variable maintenance factor for equipment cost per minute pricing as we did not \\nbelieve that we have sufficient information at present.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [We noted that we would continue to \\ninvestigate potential avenues for determining equipment maintenance costs across a broad range \\nof equipment items.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [\\u25cf  Interest Rate:  In the CY 2013 PFS final rule with comment period (77 FR 68902), we \\nupdated the interest rates used in developing an equipment cost per minute calculation (see 77 \\nFR 68902 for a thorough discussion of this issue).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 27: [The interest rate was based on the Small]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [Business Administration (SBA) maximum interest rates for different categories of loan size \\n(equipment cost) and maturity (useful life).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [The Interest rates are listed in Table 3.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [TABLE 3:  SBA Maximum Interest Rates\\nPrice Useful Life Interest Rate\\n<$25K <7 Years 7.50%\\n$25K to $50K <7 Years 6.50%\\n>$50K <7 Years 5.50%\\n<$25K 7+ Years 8.00%\\n$25K to $50K 7+ Years 7.00%\\n>$50K 7+ Years 6.00%\\nWe are not proposing any changes to the equipment interest rates for CY 2024.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [3.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [Adjusting RVUs To Match the PE Share of the Medicare Economic Index (MEI)\\nIn the past, we have stated that we believe that the MEI is the best measure available of \\nthe relative weights of the three components in payments under the PFS\\u2014work, practice expense \\n(PE), and malpractice (MP).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [Accordingly, we believe that to assure that the PFS payments \\nreflect the relative resources in each of these PFS components as required by section 1848(c)(3) \\nof the Act, the RVUs used in developing rates should reflect the same weights in each \\ncomponent as the Medicare Economic Index (MEI).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [In the past, we have proposed (and \\nsubsequently, finalized) to accomplish this by holding the work RVUs constant and adjusting the \\nPE RVUs, MP RVUs, and CF to produce the appropriate balance in RVUs among the three PFS \\ncomponents and payment rates for individual services, that is, that the total RVUs on the PFS are \\nproportioned to approximately 51 percent work RVUs, 45 percent PE RVUs, and 4 percent MP \\nRVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [As the MEI cost shares are updated, we would typically propose to modify steps 3 and 10 \\nto adjust the aggregate pools of PE costs (direct PE in step 3 and indirect PE in step 10) in \\nproportion to the change in the PE share in the rebased and revised MEI cost share weights, and \\nto recalibrate the relativity adjustment that we apply in step 18 as described \\u201c3.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [Adjusting RVUs \\nTo Match PE Share of the Medicare Economic Index (MEI)\\u201d of the CY 2023 PFS final rule (87 \\nFR 69414 and 69415) and CY 2014 PFS final rule (78 FR 74236 and 74237).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 28: [The most recent \\nrecalibration was done for the CY 2014 RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [In the CY 2014 PFS proposed rule (78 FR 43287 through 43288) and final rule (78 FR \\n74236 through 74237), we detailed the steps necessary to accomplish this result (see steps 3, 10, \\nand 18).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [The CY 2014 proposed and final adjustments were consistent with our longstanding \\npractice to make adjustments to match the RVUs for the PFS components with the MEI cost \\nshare weights for the components, including the adjustments described in the CY 1999 PFS final \\nrule (63 FR 58829), CY 2004 PFS final rule (68 FR 63246 and 63247), and CY 2011 PFS final \\nrule (75 FR 73275).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [In the CY 2023 PFS final rule (87 FR 69688 through 69711), we finalized to rebase and \\nrevise the Medicare Economic Index (MEI) to reflect more current market conditions faced by \\nphysicians in furnishing physicians' services.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [We also finalized a delay of the adjustments to the \\nPE pools in steps 3 and 10 and the recalibration of the relativity adjustment in step 18 until the \\npublic had an opportunity to comment on the  rebased and revised MEI (87 FR 69414 through \\n69416).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [Because we finalized significant methodological and data source changes to the MEI in \\nthe CY 2023 PFS final rule and significant time has elapsed since the last rebasing and revision \\nof the MEI in CY 2014, we believed that delaying the implementation of the finalized CY 2023 \\nrebased and revised MEI was consistent with our efforts to balance payment stability and \\npredictability with incorporating new data through more routine updates.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [We refer readers to the \\ndiscussion of our comment solicitation in the CY 2023 PFS final rule (87 FR 69429 through \\n69432), where we reviewed our ongoing efforts to update data inputs for PE to aid stability, \\ntransparency, efficiency, and data adequacy.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [We also solicited comment in the CY 2023 PFS \\nproposed rule on when and how to best incorporate the CY 2023 rebased and revised MEI into \\nPFS ratesetting, and whether it would be appropriate to consider a transition to full \\nimplementation for potential future rulemaking.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [We presented the impacts of implementing the \\nrebased and revised MEI in PFS ratesetting through a 4-year transition and through full \\nimmediate implementation, that is, with no transition period in the CY 2023 PFS proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 29: [We also solicited comment on other implementation strategies for potential future rulemaking in]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [the CY 2023 PFS proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [In the CY 2023 PFS final rule, we discussed that many \\ncommenters supported our proposed delayed implementation and many commenters expressed \\nconcerns with the redistributive impacts of the implementation of the rebased and revised MEI in \\nPFS ratesetting.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [Many commenters also noted that the AMA has said it intends to collect practice \\ncost data from physician practices in the near future which could be used to derive cost share \\nweights for the MEI and RVU shares.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [In light of the AMA\\u2019s intended data collection efforts in the near future and because the \\nmethodological and data source changes to the MEI finalized in the CY 2023 PFS final rule \\nwould have significant impacts on PFS payments, we continue to believe that delaying the \\nimplementation of the finalized 2017-based MEI cost weights for the RVUs is consistent with \\nour efforts to balance payment stability and predictability with incorporating new data through \\nmore routine updates.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [Therefore, we are not proposing to incorporate the 2017-based MEI in \\nPFS ratesetting for CY 2024.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [As discussed above, in the CY 2023 PFS rulemaking, we finalized to rebase and revise \\nthe MEI to reflect more current market conditions faced by physicians in furnishing physicians\\u2019 \\nservices.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [The final 2017-based MEI relies on a methodology that uses publicly available data \\nsources for input costs that represent all types of physician practice ownership, not limited to \\nonly self-employed physicians.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [The 2006-based MEI relied on the 2006 AMA PPIS survey data; \\nas of this CY 2024 rulemaking, this survey had not been updated.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [Given the changes in the \\nphysician and supplier industry and the time since the last update to the base year, we finalized a \\nmethodology that would allow us to update the MEI on a consistent basis in the future.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [The \\n2017-based MEI cost weights are derived predominantly from the annual expense data from the \\nU.S. Census Bureau\\u2019s Services Annual Survey (SAS, https://www.census.gov/programs-\\nsurveys/sas.html).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 30: [We supplement the 2017 SAS expense data by using several data sources to \\nfurther disaggregate compensation costs and all other residual costs (87 FR 69688 through \\n69708).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [We continue to review more recently available data from the Census Bureau Services \\nAnnual Survey, the main data source for the major components of the 2017-based MEI weights.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [Data is currently available through 2021.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [Given that the impact of the PHE may influence the \\n2020 and 2021 data, we continue to evaluate whether the recent trends are reflective of sustained \\nshifts in cost structures or were temporary as a result of the COVID-19 PHE.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [The 2022 data from \\nthe Services Annual Survey will be available later this year.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [We will monitor that data and any \\nother data that may become available related to physician services' input expenses and will \\npropose any changes to the MEI, if appropriate, in future rulemaking.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [4.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [Changes to Direct PE Inputs for Specific Services \\nThis section focuses on specific PE inputs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [The direct PE inputs are included in the CY \\n2024 direct PE input public use files, which are available on the CMS website under downloads \\nfor the CY 2024 PFS proposed rule at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-\\nPayment/PhysicianFeeSched/PFS-Federal-Regulation-Notices.html.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [a.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [Standardization of Clinical Labor Tasks\\nAs we noted in the CY 2015 PFS final rule with comment period (79 FR 67640 through \\n67641), we continue to make improvements to the direct PE input database to provide the \\nnumber of clinical labor minutes assigned for each task for every code in the database instead of \\nonly including the number of clinical labor minutes for the preservice, service, and post service \\nperiods for each code.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [In addition to increasing the transparency of the information used to set \\nPE RVUs, this level of detail would allow us to compare clinical labor times for activities \\nassociated with services across the PFS, which we believe is important to maintaining the \\nrelativity of the direct PE inputs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [This information would facilitate the identification of the usual \\nnumbers of minutes for clinical labor tasks and the identification of exceptions to the usual \\nvalues.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [It would also allow for greater transparency and consistency in the assignment of \\nequipment minutes based on clinical labor times.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 31: [Finally, we believe that the detailed \\ninformation can be useful in maintaining standard times for particular clinical labor tasks that can]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [be applied consistently to many codes as they are valued over several years, similar in principle \\nto the use of physician preservice time packages.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [We believe that setting and maintaining such \\nstandards would provide greater consistency among codes that share the same clinical labor tasks \\nand could improve relativity of values among codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [For example, as medical practice and \\ntechnologies change over time, changes in the standards could be updated simultaneously for all \\ncodes with the applicable clinical labor tasks, instead of waiting for individual codes to be \\nreviewed.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [In the CY 2016 PFS final rule with comment period (80 FR 70901), we solicited \\ncomments on the appropriate standard minutes for the clinical labor tasks associated with \\nservices that use digital technology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [After consideration of comments received, we finalized \\nstandard times for clinical labor tasks associated with digital imaging at 2 minutes for \\n\\u201cAvailability of prior images confirmed\\u201d, 2 minutes for \\u201cPatient clinical information and \\nquestionnaire reviewed by technologist, order from physician confirmed and exam protocoled by \\nradiologist\\u201d, 2 minutes for \\u201cReview examination with interpreting MD\\u201d, and 1 minute for \\u201cExam \\ndocuments scanned into PACS\\u201d and \\u201cExam completed in RIS system to generate billing process \\nand to populate images into Radiologist work queue.\\u201d  In the CY 2017 PFS final rule (81 FR \\n80184 through 80186), we finalized a policy to establish a range of appropriate standard minutes \\nfor the clinical labor activity, \\u201cTechnologist QCs images in PACS, checking for all images, \\nreformats, and dose page.\\u201d  These standard minutes will be applied to new and revised codes that \\nmake use of this clinical labor activity when they are reviewed by us for valuation.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [We finalized \\na policy to establish 2 minutes as the standard for the simple case, 3 minutes as the standard for \\nthe intermediate case, 4 minutes as the standard for the complex case, and 5 minutes as the \\nstandard for the highly complex case.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [These values were based upon a review of the existing \\nminutes assigned for this clinical labor activity; we determined that 2 minutes is the duration for \\nmost services and a small number of codes with more complex forms of digital imaging have \\nhigher values.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 32: [We also finalized standard times for a series of clinical labor tasks associated]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [with pathology services in the CY 2016 PFS final rule with comment period (80 FR 70902).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [We \\ndo not believe these activities would be dependent on number of blocks or batch size, and we \\nbelieve that the finalized standard values accurately reflect the typical time it takes to perform \\nthese clinical labor tasks.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [In reviewing the RUC-recommended direct PE inputs for CY 2019, we noticed that the 3 \\nminutes of clinical labor time traditionally assigned to the \\u201cPrepare room, equipment and \\nsupplies\\u201d (CA013) clinical labor activity were split into 2 minutes for the \\u201cPrepare room, \\nequipment and supplies\\u201d activity and 1 minute for the \\u201cConfirm order, protocol exam\\u201d (CA014) \\nactivity.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [We proposed to maintain the 3 minutes of clinical labor time for the \\u201cPrepare room, \\nequipment and supplies\\u201d activity and remove the clinical labor time for the \\u201cConfirm order, \\nprotocol exam\\u201d activity wherever we observed this pattern in the RUC-recommended direct PE \\ninputs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [Commenters explained in response that when the new version of the PE worksheet \\nintroduced the activity codes for clinical labor, there was a need to translate old clinical labor \\ntasks into the new activity codes, and that a prior clinical labor task was split into two of the new \\nclinical labor activity codes: CA007 (Review patient clinical extant information and \\nquestionnaire) in the preservice period, and CA014 (Confirm order, protocol exam) in the \\nservice period.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [Commenters stated that the same clinical labor from the old PE worksheet was \\nnow divided into the CA007 and CA014 activity codes, with a standard of 1 minute for each \\nactivity.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [We agreed with commenters that we would finalize the RUC-recommended 2 minutes \\nof clinical labor time for the CA007 activity code and 1 minute for the CA014 activity code in \\nsituations where this was the case.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [However, when reviewing the clinical labor for the reviewed \\ncodes affected by this issue, we found that several of the codes did not include this old clinical \\nlabor task, and we also noted that several of the reviewed codes that contained the CA014 \\nclinical labor activity code did not contain any clinical labor for the CA007 activity.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 33: [In these \\nsituations, we continue to believe that in these cases, the 3 total minutes of clinical staff time \\nwould be more accurately described by the CA013 \\u201cPrepare room, equipment and supplies\\u201d]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [activity code, and we finalized these clinical labor refinements.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [For additional details, we direct \\nreaders to the discussion in the CY 2019 PFS final rule (83 FR 59463 and 59464).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [Following the publication of the CY 2020 PFS proposed rule, one commenter expressed \\nconcern with the published list of common refinements to equipment time.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [The commenter stated \\nthat these refinements were the formulaic result of the applying refinements to the clinical labor \\ntime and did not constitute separate refinements; the commenter requested that CMS no longer \\ninclude these refinements in the table published each year.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [In the CY 2020 PFS final rule, we \\nagreed with the commenter that these equipment time refinements did not reflect errors in the \\nequipment recommendations or policy discrepancies with the RUC\\u2019s equipment time \\nrecommendations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [However, we believed that it was important to publish the specific equipment \\ntimes that we were proposing (or finalizing in the case of the final rule) when they differed from \\nthe recommended values due to the effect that these changes can have on the direct costs \\nassociated with equipment time.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [Therefore, we finalized the separation of the equipment time \\nrefinements associated with changes in clinical labor into a separate table of refinements.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [For \\nadditional details, we direct readers to the discussion in the CY 2020 PFS final rule (84 FR \\n62584).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [Historically, the RUC has submitted a \\u201cPE worksheet\\u201d that details the recommended \\ndirect PE inputs for our use in developing PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [The format of the PE worksheet has varied \\nover time and among the medical specialties developing the recommendations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [These variations \\nhave made it difficult for both the RUC\\u2019s development and our review of code values for \\nindividual codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [Beginning with its recommendations for CY 2019, the RUC has mandated the \\nuse of a new PE worksheet for purposes of their recommendation development process that \\nstandardizes the clinical labor tasks and assigns them a clinical labor activity code.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [We believe \\nthe RUC\\u2019s use of the new PE worksheet in developing and submitting recommendations will \\nhelp us to simplify and standardize the hundreds of different clinical labor tasks currently listed \\nin our direct PE database.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 34: [As we did in previous calendar years, to facilitate rulemaking for CY]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [2023, we are continuing to display two versions of the Labor Task Detail public use file: one \\nversion with the old listing of clinical labor tasks, and one with the same tasks cross-walked to \\nthe new listing of clinical labor activity codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [These lists are available on the CMS website \\nunder downloads for the CY 2024 PFS proposed rule at http://www.cms.gov/Medicare/Medicare-\\nFee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices.html.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [b.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [Updates to Prices for Existing Direct PE Inputs\\nIn the CY 2011 PFS final rule with comment period (75 FR 73205), we finalized a \\nprocess to act on public requests to update equipment and supply price and equipment useful life \\ninputs through annual rulemaking, beginning with the CY 2012 PFS proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [Beginning in \\nCY 2019 and continuing through CY 2022, we conducted a market-based supply and equipment \\npricing update, using information developed by our contractor, StrategyGen, which updated \\npricing recommendations for approximately 1300 supplies and 750 equipment items currently \\nused as direct PE inputs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [Given the potentially significant changes in payment that would occur, \\nin the CY 2019 PFS final rule we finalized a policy to phase in our use of the new direct PE \\ninput pricing over a 4-year period using a 25/75 percent (CY 2019), 50/50 percent (CY 2020), \\n75/25 percent (CY 2021), and 100/0 percent (CY 2022) split between new and old pricing.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [We \\nbelieved that implementing the proposed updated prices with a 4-year phase-in would improve \\npayment accuracy, while maintaining stability and allowing interested parties the opportunity to \\naddress potential concerns about changes in payment for particular items.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [This 4-year transition \\nperiod to update supply and equipment pricing concluded in CY 2022; for a more detailed \\ndiscussion, we refer readers to the CY 2019 PFS final rule with comment period (83 FR 59473 \\nthrough 59480).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [For CY 2024, we are proposing to update the price of 16 supplies and two equipment \\nitems in response to the public submission of invoices following the publication of the CY 2023 \\nPFS final rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 35: [The 16 supply and equipment items with proposed updated prices are listed in the]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [valuation of specific codes section of the preamble under Table 14, CY 2024 Invoices Received \\nfor Existing Direct PE Inputs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [We are not proposing to update the price of another eleven supplies which were the \\nsubject of public submission of invoices.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [Our rationale for not updating these prices is detailed \\nbelow:\\n\\u25cf  Extended external ECG patch, medical magnetic tape recorder (SD339): We received \\nadditional invoices for the SD339 supply from an interested party.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [Upon review of the invoices, \\nwe determined that they contained the identical price point that we previously incorporated into \\nlast year\\u2019s rule when we finalized a price of $260.35 for the supply item (87 FR 69514 through \\n69516).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [Since these invoices did not contain any new information, we are maintaining the \\npreviously finalized price of $260.35 for the SD339 supply.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [\\u25cf  Permanent marking pen (SL477), Liquid coverslip (Ventana 650-010) (SL479), EZ \\nPrep (10X) (Ventana 950-102) (SL481), Cell Conditioning 1 (Ventana 950-124) (SL482), and \\nHematoxylin II (Ventana 790-2208) (SL483): We received invoices from interested parties for \\nuse in updating the price of these laboratory supplies.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [In each case, however, we were able to \\nfind the same supply item available for sale online at the current price or cheaper.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [Therefore, we \\ndo not believe that the submitted invoices represent typical market pricing for these supplies and \\nwe are not proposing to update their prices.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [\\u25cf  Mask, surgical (SB033), scalpel with blade, surgical (#10-20) (SF033), eye shield, \\nnon-fog (SG049), gauze, non-sterile 4in x 4in (SG051), and towel, paper (Bounty) (per sheet) \\n(SK082): We received invoices from interested parties for use in updating the price of these \\ncommon supply items.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [In each case, we received a single invoice and once again we were able to \\nfind the same supply items available for sale online at the current price or cheaper.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 36: [Generally \\nspeaking, we avoid updating the price for common supply items like the SB033 surgical mask \\n(included in approximately 380 HCPCS codes) based on the submission of a single invoice, as an \\ninvoice unrepresentative of current market pricing will have far-reaching effects across the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [We did not find that the typical price for a surgical mask had increased by more than 60% since \\nthe supply and equipment pricing update concluded in CY 2022, and as such we are maintaining \\nthe current price for these supply items.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [(1) Invoice Submission\\nWe remind readers that we routinely accept public submission of invoices as part of our \\nprocess for developing payment rates for new, revised, and potentially misvalued codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [Often \\nthese invoices are submitted in conjunction with the RUC-recommended values for the codes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [To be included in a given year\\u2019s proposed rule, we generally need to receive invoices by the \\nsame February 10th deadline we noted for consideration of RUC recommendations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [However, \\nwe will consider invoices submitted as public comments during the comment period following \\nthe publication of the PFS proposed rule, and would consider any invoices received after \\nFebruary 10th or outside of the public comment process as part of our established annual process \\nfor requests to update supply and equipment prices.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [Interested parties are encouraged to submit \\ninvoices with their public comments or, if outside the notice and comment rulemaking process, \\nvia email at PE_Price_Input_Update@cms.hhs.gov.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [c.  Clinical Labor Pricing Update\\nSection 220(a) of the PAMA provides that the Secretary may collect or obtain \\ninformation from any eligible professional or any other source on the resources directly or \\nindirectly related to furnishing services for which payment is made under the PFS, and that such \\ninformation may be used in the determination of relative values for services under the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [Such \\ninformation may include the time involved in furnishing services; the amounts, types and prices \\nof PE inputs; overhead and accounting information for practices of physicians and other \\nsuppliers, and any other elements that would improve the valuation of services under the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [Beginning in CY 2019, we updated the supply and equipment prices used for PE as part \\nof a market-based pricing transition; CY 2022 was the final year of this 4-year transition.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 37: [We \\ninitiated a market research contract with StrategyGen to conduct an in-depth and robust market]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [research study to update the supply and equipment pricing for CY 2019, and we finalized a \\npolicy in CY 2019 to phase in the new pricing over a period of 4 years.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [However, we did not \\npropose to update the clinical labor pricing, and the pricing for clinical labor has remained \\nunchanged during this pricing transition.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [Clinical labor rates were last updated for CY 2002 \\nusing Bureau of Labor Statistics (BLS) data and other supplementary sources where BLS data \\nwere not available; we refer readers to the full discussion in the CY 2002 PFS final rule for \\nadditional details (66 FR 55257 through 55262).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [Interested parties raised concerns that the long delay since clinical labor pricing was last \\nupdated created a significant disparity between CMS\\u2019 clinical wage data and the market average \\nfor clinical labor.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [In recent years, a number of interested parties suggested that certain wage \\nrates were inadequate because they did not reflect current labor rate information.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [Some \\ninterested parties also stated that updating the supply and equipment pricing without updating the \\nclinical labor pricing could create distortions in the allocation of direct PE.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [They argued that \\nsince the pool of aggregated direct PE inputs is budget neutral, if these rates are not routinely \\nupdated, clinical labor may become undervalued over time relative to equipment and supplies, \\nespecially since the supply and equipment prices are in the process of being updated.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [There was \\nconsiderable interest among interested parties in updating the clinical labor rates, and when we \\nsolicited comment on this topic in past rules, such as in the CY 2019 PFS final rule (83 FR \\n59480), interested parties supported the idea.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [Therefore, we proposed to update the clinical labor pricing for CY 2022, in conjunction \\nwith the final year of the supply and equipment pricing update (86 FR 39118 through 39123).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [We believed it was important to update the clinical labor pricing to maintain relativity with the \\nrecent supply and equipment pricing updates.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [We proposed to use the methodology outlined in \\nthe CY 2002 PFS final rule (66 FR 55257), which draws primarily from BLS wage data, to \\ncalculate updated clinical labor pricing.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 38: [As we stated in the CY 2002 PFS final rule, the BLS\\u2019 \\nreputation for publishing valid estimates that are nationally representative led to the choice to use]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [the BLS data as the main source.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [We believe that the BLS wage data continues to be the most \\naccurate source to use as a basis for clinical labor pricing and this data will appropriately reflect \\nchanges in clinical labor resource inputs for purposes of setting PE RVUs under the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [We \\nused the most current BLS survey data (2019) as the main source of wage data for our CY 2022 \\nclinical labor proposal.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [We recognized that the BLS survey of wage data does not cover all the staff types \\ncontained in our direct PE database.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [Therefore, we cross-walked or extrapolated the wages for \\nseveral staff types using supplementary data sources for verification whenever possible.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [In \\nsituations where the price wages of clinical labor types were not referenced in the BLS data, we \\nused the national salary data from the Salary Expert, an online project of the Economic Research \\nInstitute that surveys national and local salary ranges and averages for thousands of job titles \\nusing mainly government sources.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [(A detailed explanation of the methodology used by Salary \\nExpert to estimate specific job salaries can be found at www.salaryexpert.com).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [We previously \\nused Salary Expert information as the primary backup source of wage data during the last update \\nof clinical labor pricing in CY 2002.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [If we did not have direct BLS wage data available for a \\nclinical labor type, we used the wage data from Salary Expert as a reference for pricing, then \\ncross-walked these clinical labor types to a proxy BLS labor category rate that most closely \\nmatched the reference wage data, similar to the crosswalks used in our PE/HR allocation.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [For \\nexample, there is no direct BLS wage data for the Mammography Technologist (L043) clinical \\nlabor type; we used the wage data from Salary Expert as a reference and identified the BLS wage \\ndata for Respiratory Therapists as the best proxy category.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [We calculated rates for the \\u201cblend\\u201d \\nclinical labor categories by combining the rates for each labor type in the blend and then dividing \\nby the total number of labor types in the blend.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [As in the CY 2002 clinical labor pricing update, the proposed cost per minute for each \\nclinical staff type was derived by dividing the average hourly wage rate by 60 to arrive at the per \\nminute cost.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 39: [In cases where an hourly wage rate was not available for a clinical staff type, the]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [proposed cost per minute for the clinical staff type was derived by dividing the annual salary \\n(converted to 2021 dollars using the Medicare Economic Index) by 2080 (the number of hours in \\na typical work year) to arrive at the hourly wage rate and then again by 60 to arrive at the per \\nminute cost.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [We ultimately finalized the use of median BLS wage data, as opposed to mean BLS \\nwage data, in response to comments in the CY 2022 PFS final rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [To account for the \\nemployers\\u2019 cost of providing fringe benefits, such as sick leave, we finalized the use of a benefits \\nmultiplier of 1.296 based on a BLS release from June 17, 2021 (USDL-21-1094).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [As an example \\nof this process, for the Physical Therapy Aide (L023A) clinical labor type, the BLS data \\nreflected a median hourly wage rate of $12.98, which we multiplied by the 1.296 benefits \\nmodifier and then divided by 60 minutes to arrive at the finalized per-minute rate of $0.28.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [After considering the comments on our CY 2022 proposals, we agreed with commenters \\nthat the use of a multi-year transition would help smooth out the changes in payment resulting \\nfrom the clinical labor pricing update, avoiding potentially disruptive changes in payment for \\naffected interested parties, and promoting payment stability from year-to-year.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [We believed it \\nwould be appropriate to use a 4-year transition, as we have for several other broad-based updates \\nor methodological changes.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [While we recognized that using a 4-year transition to implement the \\nupdate means that we will continue to rely in part on outdated data for clinical labor pricing until \\nthe change is fully completed in CY 2025, we agreed with the commenters that these significant \\nupdates to PE valuation should be implemented in the same way, and for the same reasons, as for \\nother major updates to pricing such as the recent supply and equipment update.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [Therefore, we \\nfinalized the implementation of the clinical labor pricing update over 4 years to transition from \\ncurrent prices to the final updated prices in CY 2025.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 40: [We finalized the implementation of this \\npricing transition over 4 years, such that one quarter of the difference between the current price \\nand the fully phased-in price is implemented for CY 2022, one third of the difference between \\nthe CY 2022 price and the final price is implemented for CY 2023, and one half of the difference \\nbetween the CY 2023 price and the final price is implemented for CY 2024, with the new direct]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [PE prices fully implemented for CY 2025.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [(86 FR 65025) An example of the transition from the \\ncurrent to the fully-implemented new pricing that we finalized in the CY 2022 PFS final rule is \\nprovided in Table 4.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [TABLE 4:  Example of Clinical Labor Pricing Transition\\nCurrent Price $1.00\\nFinal Price $2.00  \\nYear 1 (CY 2022) Price $1.25 1/4 difference between $1.00 and $2.00\\nYear 2 (CY 2023) Price $1.50 1/3 difference between $1.25 and $2.00\\nYear 3 (CY 2024) Price $1.75 1/2 difference between $1.50 and $2.00\\nFinal (CY 2025) Price $2.00  \\n(1) CY 2023 Clinical Labor Pricing Updates\\nFor CY 2023, we received information from one interested party regarding the pricing of \\nthe Histotechnologist (L037B) clinical labor type.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [The interested party provided data from the \\n2019 Wage Survey of Medical Laboratories which supported an increase in the per-minute rate \\nfrom the $0.55 finalized in the CY 2022 PFS final rule to $0.64.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [This rate of $0.64 for the L037B \\nclinical labor type is a close match to the online salary data that we had for the Histotechnologist \\nand matches the $0.64 rate that we initially proposed for L037B in the CY 2022 PFS proposed \\nrule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [Based on the wage data provided by the commenter, we proposed this $0.64 rate for the \\nL037B clinical labor type for CY 2023; we also proposed a slight increase in the pricing for the \\nLab Tech/Histotechnologist (L035A) clinical labor type from $0.55 to $0.60 as it is a blend of \\nthe wage rate for the Lab Technician (L033A) and Histotechnologist clinical labor types.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [We \\nalso proposed the same increase to $0.60 for the Angio Technician (L041A) clinical labor type, \\nas we previously established a policy in the CY 2022 PFS final rule that the pricing for the \\nL041A clinical labor type would match the rate for the L035A clinical labor type (86 FR 65032).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [Based on comments received on the CY 2023 proposed rule, we finalized a change in the \\ndescriptive text of the L041A clinical labor type from \\u201cAngio Technician\\u201d to \\u201cVascular \\nInterventional Technologist\\u201d.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 41: [We also finalized an update in the pricing of three clinical labor \\ntypes: from $0.60 to $0.84 for the Vascular Interventional Technologist (L041A), from $0.63 to]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 42: [$0.79 for the Mammography Technologist (L043A), and from $0.76 to $0.78 for the CT \\nTechnologist (L046A) based on submitted wage data from the 2022 Radiologic Technologist \\nWage and Salary Survey (87 FR 69422 through 69425).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 42: [(2) CY 2024 Clinical Labor Pricing Update Proposals\\nWe did not receive new wage data or other additional information for use in clinical labor \\npricing from interested parties prior to the publication of the CY 2024 PFS proposed rule.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 42: [Therefore, our proposed clinical labor pricing for CY 2024 is based on the clinical labor pricing \\nthat we finalized in the CY 2023 PFS final rule, incremented an additional step for Year 3 of the \\nupdate:\\nTABLE 5:  Proposed CY 2024 Clinical Labor Pricing\\nLabor \\nCode Labor Description SourceCY 2021 \\nRate Per \\nMinuteFinal \\nRate Per \\nMinuteY3 Phase-\\nIn Rate \\nPer MinuteTotal \\n% \\nChange\\nL023A Physical Therapy Aide BLS 31-2022 0.23 0.28 0.268 22%\\nL026A Medical/Technical Assistant BLS 31-9092 0.26 0.36 0.335 38%\\nL030A Lab Tech/MTA L033A, L026A 0.30 0.46 0.420 53%\\nL032B EEG Technician BLS 29-2098 0.32 0.44 0.410 38%\\nL033A Lab Technician BLS 29-2010 0.33 0.55 0.495 67%\\nL033B Optician/COMT BLS 29-2081, BLS 29-2057 0.33 0.39 0.375 18%\\nL035A* Lab Tech/Histotechnologist L033A, L037B 0.35 0.60 0.534 70%\\nL037A Electrodiagnostic Technologist BLS 29-2098 0.37 0.44 0.423 19%\\nL037B* Histotechnologist BLS 29-2010 0.37 0.64 0.573 73%\\nL037C Orthoptist BLS 29-1141 0.37 0.76 0.663 105%\\nL037D RN/LPN/MTA L051A, BLS 29-2061, L026A 0.37 0.54 0.498 46%\\nL037E Child Life Specialist BLS 21-1021 0.37 0.49 0.460 32%\\nL038ACOMT/COT/RN/CST BLS 29-2057, BLS 29-2055, \\nL051A, BLS 19-40100.38 0.52 0.485 37%\\nL038B Cardiovascular Technician BLS 29-2031 0.38 0.60 0.545 58%\\nL038C Medical Photographer BLS 29-2050 0.38 0.38 0.383 0%\\nL039A Certified Retinal Angiographer BLS 29-9000 0.39 0.52 0.488 33%\\nL039B Physical Therapy Assistant BLS 31-2021 0.39 0.61 0.555 56%\\nL039C Psychometrist BLS 21-1029 0.39 0.64 0.579 62%\\nL041A*Vascular Interventional \\nTechnologistASRT Wage Data 0.41 0.840.731104%\\nL041B Radiologic Technologist BLS 29-2034 0.41 0.63 0.575 54%\\nL041CSecond Radiologic Technologist \\nfor VertebroplastyBLS 29-2034 0.41 0.63 0.575 54%\\nL042A RN/LPN L051A, BLS 29-2061 0.42 0.63 0.578 50%\\nL042B Respiratory Therapist BLS 29-1126 0.42 0.64 0.585 52%\\nL043A* Mammography Technologist ASRT Wage Data 0.43 0.79 0.702 84%\\nL045A Cytotechnologist BLS 29-2035 0.45 0.76 0.683 69%\\nL045B Electron Microscopy Technologist BLS 29-1124 0.45 0.89 0.780 98%\\nL045C CORF social worker/psychologist BLS 21-1022, BLS 19-3031 0.45 0.70 0.638 56%\\nL046A CT Technologist* ASRT Wage Data 0.46 0.78 0.703 70%\\nL047A MRI Technologist BLS 29-2035 0.47 0.76 0.688 62%\\nL047BREEGT (Electroencephalographic \\nTech)BLS 29-2035 0.47 0.76 0.688 62%]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 43: [Labor \\nCode Labor Description SourceCY 2021 \\nRate Per \\nMinuteFinal \\nRate Per \\nMinuteY3 Phase-\\nIn Rate \\nPer MinuteTotal \\n% \\nChange\\nL047C RN/Respiratory Therapist L051A, L042B 0.47 0.70 0.643 49%\\nL047D RN/Registered Dietician L051A, BLS 29-1031 0.47 0.70 0.643 49%\\nL049A Nuclear Medicine Technologist BLS 29-2033 0.62 0.81 0.761 32%\\nL050A Cardiac Sonographer BLS 29-2032 0.50 0.77 0.703 54%\\nL050B Diagnostic Medical Sonographer BLS 29-2032 0.50 0.77 0.703 54%\\nL050C Radiation Therapist BLS 29-1124 0.50 0.89 0.793 78%\\nL050DSecond Radiation Therapist for \\nIMRTBLS 29-1124 0.50 0.89 0.793 78%\\nL051A RN BLS 29-1141 0.51 0.76 0.698 49%\\nL051BRN/Diagnostic Medical \\nSonographerL051A, BLS 29-2032 0.51 0.77 0.705 51%\\nL051C RN/CORF L051A  0.51 0.76 0.698 49%\\nL052A Audiologist BLS 29-1181 0.52 0.81 0.738 56%\\nL053A RN/Speech Pathologist L051A, L055A 0.53 0.79 0.725 49%\\nL054A Vascular Technologist BLS 19-1040 0.54 0.91 0.818 69%\\nL055A Speech Pathologist BLS 29-1127 0.55 0.82 0.753 49%\\nL056A RN/OCN BLS 29-2033 0.79 0.81 0.805 3%\\nL057A Genetics Counselor BLS 29-9092 0.57 0.85 0.779 50%\\nL057B Behavioral Health Care Manager BLS 21-1018 0.57 0.57 0.570 0%\\nL063A Medical Dosimetrist BLS 19-1040 0.63 0.91 0.840 44%\\nL107AMedical Dosimetrist/Medical \\nPhysicistL063A, L152A 1.08 1.52 1.409 41%\\nL152A Medical Physicist AAPM Wage Data 1.52 2.14 1.986 41%\\nAs was the case for the market-based supply and equipment pricing update, the clinical \\nlabor rates will remain open for public comment over the course of the 4-year transition period.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 43: [We updated the pricing of a number of clinical labor types in the CY 2022 and CY 2023 PFS \\nfinal rules in response to information provided by commenters.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 43: [For the full discussion of the \\nclinical labor pricing update, we direct readers to the CY 2022 PFS final rule (86 FR 65020 \\nthrough 65037).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 43: [d. Technical Corrections to Direct PE Input Database and Supporting Files\\nFollowing the publication of the CY 2023 PFS proposed rule, an interested party notified \\nCMS that CPT code 86153 (Cell enumeration using immunologic selection and identification in \\nfluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when \\nrequired) appeared to be missing its work time in the Physician Work Time public use file.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 43: [We \\nreviewed the request from the interested party and determined that this was indeed an unintended \\ntechnical error; we stated in the CY 2013 PFS final rule that we were finalizing 0 minutes pre-\\nservice time, 20 minutes intraservice time, and 0 minutes post-service time to CPT code 86153]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [(77 FR 69059), however work time was inadvertently completely missing for this code.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [Therefore, we are proposing to add the correct 20 minutes of intraservice work time to CPT code \\n86153 for CY 2024.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [5.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [Soliciting Public Comment on Strategies for Updates to Practice Expense Data Collection and \\nMethodology\\na.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [Background\\nThe AMA PPIS was first introduced in 2007 as a means to collect comprehensive and \\nreliable data on the direct and indirect PEs incurred by physicians (72 FR 66222).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In considering \\nthe use of PPIS data, the goal was to improve the accuracy and consistency of PE RVUs used in \\nthe PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [The data collection process included a stratified random sample of physicians across \\nvarious specialties, and the survey was administered between August 2007 and March 2008.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [Data points from that period of time that are integrated into PFS calculations today.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In the CY \\n2009 PFS proposed rule (73 FR 38507 through 3850), we discussed the indirect PE methodology \\nthat used data from the AMA's survey that predated the PPIS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In CY 2010 PFS rulemaking, we \\nannounced our intent to incorporate the AMA PPIS data into the PFS ratesetting process, which \\nwould first affect the PE RVU.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In the CY 2010 PFS proposed rule, we outlined a 4-year \\ntransition period, during which we would phase in the AMA PPIS data, replacing the existing PE \\ndata sources (74 FR 33554).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [We also explained that our proposals intended to update survey data \\nonly (74 FR 33530 through 33531).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In our CY 2010 final rule, we finalized our proposal, with \\nminor adjustments based on public comments (74 FR 61749 through 61750).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [We responded to \\nthe comments we received about the transition to using the PPIS to inform indirect PE \\nallocations (74 FR 61750).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [In the responses, we acknowledged concerns about potential gaps in \\nthe data, which could impact the allocation of indirect PE for certain physician specialties and \\nsuppliers, which are issues that remain important today.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [The CY 2010 PFS final rule explains \\nthat section 212 of the Balanced Budget Refinement Act of 1999 (BBRA) (Pub.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 44: [L. 106-113, \\nNovember 29, 1999) directed the Secretary to establish a process under which we accept and use,]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [to the maximum extent practicable and consistent with sound data practices, data collected or \\ndeveloped by entities and organizations to supplement the data we normally collect in \\ndetermining the PE component.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [BBRA required us to establish criteria for accepting \\nsupplemental survey data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [Since the supplemental surveys were specific to individual specialties \\nand not part of a comprehensive multispecialty survey, we had required that certain precision \\nlevels be met in order to ensure that the supplemental data was sufficiently valid, and acceptable \\nfor use in the development of the PE RVUs.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [At the time, our rationale included the assumption \\nthat because the PPIS is a contemporaneous, consistently collected, and comprehensive \\nmultispecialty survey, we do not believe similar precision requirements are necessary, and we \\ndid not propose to establish them for the use of the PPIS data (74 FR 61742).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [We noted potential \\ngaps in the data, which could impact the allocation of indirect PE for certain physician and \\nsuppliers.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [The CY 2010 final rule adopted the proposal, with minor adjustments based on public \\ncomments, and explained that these minor adjustments were in part due to non-response bias that \\nresults when the characteristics of survey respondents differ in meaningful ways, such as in the \\nmix of practices sizes, from the general population (74 FR 61749 through 61750).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [Throughout the 4-year transition period, from CY 2010 to CY 2013, we gradually \\nincorporated the AMA PPIS data into the PFS rates, replacing the previous data sources.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [The \\nprocess involved addressing concerns and making adjustments as necessary, such as refining the \\nPFS ratesetting methodology in consideration of interested party feedback.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [For background on \\nthe refinements that we considered after the transition began, we refer readers to discussions in \\nthe CY 2011-2014 final rules (75 FR 73178 through 73179; 76 FR 73033 through 73034; 77 FR \\n98892; 78 FR 74272 through 74276).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [In the CY 2011 PFS proposed rule, we requested comments on the methodology for \\ncalculating indirect PE RVUs, explicitly seeking input on using survey data, allocation methods, \\nand potential improvements (75 FR 40050).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 45: [In our CY 2011 PFS final rule, we addressed \\ncomments regarding the methodology for indirect PE calculations, focusing on using survey]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [data, allocation methods, and potential improvements (75 FR 73178 through 73179).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [We \\nrecognized some limitations of the current PFS ratesetting methodology but maintained that the \\napproach was the most appropriate at the time.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [In the CY 2012 PFS final rule, we responded to \\ncomments related to indirect PE methodology, including concerns about allocating indirect PE to \\nspecific services and using the AMA PPIS data for certain specialties (76 FR 73033 through \\n73034).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [We indicated that CMS would continue to review and refine the methodology and work \\nwith interested parties to address their concerns.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [In the CY PFS 2014 final rule, we responded to \\ncomments about fully implementing the AMA PPIS data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [By 2014, the AMA PPIS data had been \\nfully integrated into the PFS, serving as the primary source for determining indirect PE inputs \\n(78 FR 74235).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [We continued to review data and the PE methodology annually, considering \\ninterested party feedback and evaluating the need for updates or refinements to ensure the \\naccuracy and relevance of PE RVUs (79 FR 67548).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [In the years following the full \\nimplementation of the AMA PPIS data, we further engaged with interested parties, thought \\nleaders and subject matter experts to improve our PE inputs' accuracy and reliability.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [For further \\nbackground, we refer readers to our discussions in final rules for CY 2016-2022 (80 FR 70892; \\n81 FR 80175; 82 FR 52980 through 52981; 83 FR 59455 through 59456; 84 FR 62572; 85 FR \\n84476 through 84478; 86 FR 62572).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [In our CY 2023 PFS final rule, we issued an RFI to solicit public comment on strategies \\nto update PE data collection and methodology (87 FR 69429 to 69432).]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [We solicited comments \\non current and evolving trends in health care business arrangements, the use of technology, or \\nsimilar topics that might affect or factor into PE calculations.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [We remind readers that we have \\nworked with interested parties and CMS contractors for years to study the landscape and identify \\npossible strategies to reshape the PE portion of physician payments.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 46: [The fundamental issues are \\nclear, but thought leaders and subject matter experts have advocated for more than one tenable \\napproach to updating our PE methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [As described in last year's rule, we have continued interest in developing a roadmap for \\nupdates to our PE methodology that account for changes in the health care landscape.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [Of various \\nconsiderations necessary to form a roadmap for updates, we reiterate that allocations of indirect \\nPE continue to present a wide range of challenges and opportunities.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [As discussed in multiple \\ncycles of previous rulemaking, our PE methodology relies on AMA PPIS data, which may \\nrepresent the best aggregated available source of information at this time.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [However, we \\nacknowledge the limitations and challenges interested parties have raised about using the current \\ndata for indirect PE allocations, which we have also examined in related ongoing research.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [We \\nnoted in last year's rule that there are several competing concerns that CMS must take into \\naccount when considering updated data sources, which also should support and enable ongoing \\nrefinements to our PE methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [Many commenters last year asked that CMS wait for the AMA to complete a refresh of \\nAMA survey data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [We responded to these comments by explaining the tension that waiting \\ncreates in light of concerns raised by other interested parties.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [Waiting for refreshed survey data \\nwould result in CMS using data nearly 20 years old to form indirect PE inputs to set rates for \\nservices on the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [We remind readers that many of the critical issues discussed in the \\nbackground and history above are mainly unchanged and possibly would not be addressed by an \\nupdated survey alone but may also require revisions to the PFS ratesetting methodology.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [b.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [Request for Information\\nWe continue to encourage interested parties to provide feedback and suggestions to CMS \\nthat give an evidentiary basis to shape optimal PE data collection and methodological \\nadjustments over time.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [Submissions should discuss the feasibility and burden of implementing \\nany suggested adjustments and highlight opportunities to optimize the cadence, frequency, and \\nphase-in of resulting adjustments.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [We continue to consider ways that we may engage in dialogue \\nwith interested parties to better understand how to address possible long-term policies and \\nmethods for PFS ratesetting.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 47: [We believe some of those concerns may be alleviated by having]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [ways to refresh data and make transparent how the information affects valuations for services \\npayable under the PFS more accurately and precisely.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [Considering our ratesetting methodology and prior experiences implementing new data, \\nwe are issuing a follow-up solicitation for general information.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [We seek comments from \\ninterested parties on strategies to incorporate information that could address known challenges \\nwe experienced in implementing the initial AMA PPIS data.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [Our current methodology relies on \\nthe AMA PPIS data, legislatively mandated supplemental data sources (for, example, we use \\nsupplemental survey data collected in 2003, as required by section 1848(c)(2)(H)(i) of the Act to \\nset rates for oncology and hematology specialties), and in some cases crosswalks to allocate \\nindirect PE as necessary for certain specialties and provider types.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [We also seek to understand whether, upon completion of the updated PPIS data collection \\neffort by the AMA, contingencies or alternatives may be necessary and available to address lack \\nof data availability or response rates for a given specialty, set of specialties, or specific service \\nsuppliers who are paid under the PFS.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [In light of the considerations discussed above, we request feedback on the following:\\n(1) If CMS should consider aggregating data for certain physician specialties to generate \\nindirect allocators so that PE/HR calculations based on PPIS data would be less likely to over-\\nallocate (or under-allocate) indirect PE to a given set of services, specialties, or practice types.]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [Further, what thresholds or methodological approaches could be employed to establish such \\naggregations?]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [(2) Whether  aggregations of services, for purposes of assigning PE inputs, represent a \\nfair, stable and accurate means to account for indirect PEs across various specialties or practice \\ntypes?]] Topic: 2B_Determination of Practice Expense RVUs: [from p. 48: [(3) If and how CMS should balance factors that influence indirect PE inputs when these \\nfactors are likely driven by a difference in geographic location or setting of care, specific to]]\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Topic_Subtopic_Summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"BACKGROUND: The Medicare Physician Fee Schedule (PFS) was established by the Omnibus Budget Reconciliation Acts of 1989 and 1990. It uses a resource-based approach to calculate Practice Expense Relative Value Units (PE RVUs), which cover operational costs but exclude malpractice expenses. The PE RVUs are determined using data from various surveys like the AMA\\u2019s Socioeconomic Monitoring System and the Physician Practice Information Survey (PPIS). The calculation of indirect PE RVUs involves adjusting these RVUs based on service utilization and applying specialty-specific scaling factors. In the CY 2023 PFS final rule, CMS finalized the rebase and revision of the Medicare Economic Index (MEI) to reflect current market conditions. The new 2017-based MEI incorporates data from a variety of publicly available sources, moving away from the sole reliance on the 2006 AMA PPIS data. When Bureau of Labor Statistics (BLS) data was unavailable for specific clinical labor types, alternative sources such as Salary Expert were utilized.\\n\\nPROVISION: From CY 2010, CMS updated the PE/HR data using PPIS, with the transition completed by CY 2013. CMS also uses cross-walks for specialties not covered by PPIS, ensuring appropriate allocation of indirect costs. The final PE RVUs are determined by adding direct and indirect PE RVUs and applying a final budget neutrality adjustment. This adjustment ensures balance in payment distribution among various specialties. Some specialties are excluded from direct rate setting but are included in the budget neutrality adjustment. These include Ambulatory surgical center (Code 49), Nurse practitioner (Code 50), Medical supply companies with certified orthotist (Code 51), certified prosthetist (Code 52), certified prosthetist-orthotist (Code 53), and others not included in these categories (Code 54). The implementation of the 2017-based MEI cost weights in PFS ratesetting will be delayed to CY 2024. For the CY 2022 PFS final rule, CMS implemented a multi-year transition to update clinical labor pricing, with the transition set over four years to reach fully updated rates by CY 2025. CMS encourages feedback and suggestions for optimal PE data collection and methodological adjustments over time. They are also interested in understanding potential contingencies or alternatives upon completion of the updated PPIS data collection effort by the AMA.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 24
        }
      ],
      "source": [
        "#View the DF w/o having to re-run the summarization api call, and write out an excel.file\n",
        "merged_df_Topic_Subtopic_text_combined.to_excel('merged_df_Topic_Subtopic_text_combined.xlsx')\n",
        "merged_df_Topic_Subtopic_text_combined"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from nltk import tokenize\n",
        "\n",
        "def split_text_by_sentence(text, max_tokens):\n",
        "    sentences = tokenize.sent_tokenize(text)\n",
        "    chunks = []\n",
        "    current_chunk = []\n",
        "    current_length = 0\n",
        "\n",
        "    for sentence in sentences:\n",
        "        sentence_tokens = num_tokens_from_string(sentence)\n",
        "        if current_length + sentence_tokens <= max_tokens:\n",
        "            current_chunk.append(sentence)\n",
        "            current_length += sentence_tokens\n",
        "        else:\n",
        "            chunks.append(\" \".join(current_chunk))\n",
        "            current_chunk = [sentence]\n",
        "            current_length = sentence_tokens\n",
        "\n",
        "    if current_chunk:\n",
        "        chunks.append(\" \".join(current_chunk))\n",
        "\n",
        "    return chunks\n",
        "\n",
        "\n",
        "#summary post-processing\n",
        "def ensure_complete_sentences(summary):\n",
        "    sentences = tokenize.sent_tokenize(summary)\n",
        "    # Join without the potentially incomplete last sentence\n",
        "    return \" \".join(sentences[:-1]) if summary[-1].isalnum() and not summary.endswith('.') else summary\n",
        "\n",
        "#implementing\n",
        "def get_gpt4_summary(text_parts, prompt, model_choice=\"gpt-4\"):\n",
        "    summaries = []\n",
        "    for part in text_parts:\n",
        "        input_text = f\"{part}\\n\\nPrompt: {prompt}\"\n",
        "        response = openai.chat.completions.create(\n",
        "            model=\"gpt-4-turbo\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "            messages=[{\"role\": \"user\", \"content\": input_text}],\n",
        "            max_tokens=1500,  # Adjusting this value based on your plan limits would help\n",
        "            temperature=0.5,\n",
        "            n=1,\n",
        "        )\n",
        "        summarized_part = response.choices[0].message.content.strip()\n",
        "        summaries.append(ensure_complete_sentences(summarized_part))\n",
        "\n",
        "    combined_summary_text = \" \".join(summaries)\n",
        "    combined_summary_parts = split_text_by_sentence(combined_summary_text, 6700)\n",
        "\n",
        "    final_summaries = []\n",
        "    for part in combined_summary_parts:\n",
        "        input_text = f\"{part}\\n\\nPrompt: {prompt}\"\n",
        "        response = openai.chat.completions.create(\n",
        "            model=\"gpt-4-turbo\" if num_tokens_from_string(input_text) > 6700 else \"gpt-4\",\n",
        "            messages=[{\"role\": \"user\", \"content\": input_text}],\n",
        "            max_tokens=1500,  # Adjust if necessary\n",
        "            temperature=0.5,\n",
        "            n=1,\n",
        "        )\n",
        "        summarized_part = response.choices[0].message.content.strip()\n",
        "        final_summaries.append(ensure_complete_sentences(summarized_part))\n",
        "\n",
        "    final_summary = \" \".join(final_summaries)\n",
        "    return final_summary\n",
        "\n",
        "\n",
        "def consolidate_sections(row):\n",
        "    # Extract sections\n",
        "    background_matches = re.findall(r'BACKGROUND:.*?(?=\\n[A-Z]+:|\\Z)', row['Topic_Subtopic_Summary'], re.DOTALL)\n",
        "    provision_matches = re.findall(r'PROVISION:.*?(?=\\n[A-Z]+:|\\Z)', row['Topic_Subtopic_Summary'], re.DOTALL)\n",
        "\n",
        "    background_text = \" \".join([match.replace(\"BACKGROUND:\", \"\").strip() for match in background_matches])\n",
        "    provision_text = \" \".join([match.replace(\"PROVISION:\", \"\").strip() for match in provision_matches])\n",
        "    return f\"BACKGROUND: {background_text}\\n\\nPROVISION: {provision_text}\"\n",
        "\n",
        "# Application of the summarization function and fix the multiple category problem\n",
        "merged_df_Topic_Subtopic_text_combined['Topic_Subtopic_Summary'] = merged_df_Topic_Subtopic_text_combined.apply(prepare_summary, axis=1)\n",
        "merged_df_Topic_Subtopic_text_combined['Topic_Subtopic_Summary'] = merged_df_Topic_Subtopic_text_combined.apply(consolidate_sections,axis=1)\n"
      ],
      "metadata": {
        "id": "b5NU5TPIpGHC"
      },
      "execution_count": 25,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 528,
          "referenced_widgets": [
            "92bf2224d7284d9db02e978076061c05",
            "12b7e869949d4eebadabea635b740576",
            "e80f9b17a8954153b261ece7d69ee20a"
          ]
        },
        "id": "Hs_CAf5AhjLD",
        "outputId": "e162bd87-bc3f-451a-a86e-d13ec324de45"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "HTML(value='\\n    <style>\\n        body {\\n            font-family: \"Arial\", sans-serif;\\n        }\\n        ."
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "92bf2224d7284d9db02e978076061c05"
            }
          },
          "metadata": {}
        }
      ],
      "source": [
        "# Optionally, display the DataFrame ans save as an html file:\n",
        "#!pip install ipywidgets\n",
        "from ipywidgets import HTML\n",
        "\n",
        "def generate_html_output(df):\n",
        "    html_content = '''\n",
        "    <style>\n",
        "        body {\n",
        "            font-family: \"Arial\", sans-serif;\n",
        "        }\n",
        "        .summary-container {\n",
        "            margin: 20px;\n",
        "            padding: 15px;\n",
        "            border-radius: 8px;\n",
        "            background-color: #f9f9f9;\n",
        "            box-shadow: 0 2px 4px rgba(0,0,0,0.1);\n",
        "        }\n",
        "        .topic-title {\n",
        "            color: #333;\n",
        "            font-size: 18px;\n",
        "        }\n",
        "        .summary-text {\n",
        "            color: #555;\n",
        "            font-size: 14px;\n",
        "            margin-top: 5px;\n",
        "        }\n",
        "    </style>\n",
        "    <div class=\"summary-container\">\n",
        "        <h2 style=\"color: #4B0082;\">Summary Overview</h2>'''\n",
        "\n",
        "    for _, row in df.iterrows():\n",
        "        html_content += f'''\n",
        "            <div>\n",
        "                <h3 class=\"topic-title\">Topic: {row[\"InsightsAI_Topic_Subtopic\"]}</h3>\n",
        "                <p class=\"summary-text\"><strong>Summary:</strong> {row[\"Topic_Subtopic_Summary\"]}</p>\n",
        "            </div>'''\n",
        "\n",
        "    html_content += '</div>'\n",
        "    return HTML(html_content)\n",
        "\n",
        "\n",
        "# Call the function to display HTML output\n",
        "html_output = generate_html_output(merged_df_Topic_Subtopic_text_combined)\n",
        "\n",
        "###########################################################################################################################\n",
        "# write out html file\n",
        "with open('final_topic_summary.html', 'w', encoding='utf-8') as f:\n",
        "    f.write(str(html_output))  # Convert HTML object to string before writing\n",
        "\n",
        "html_output\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CSbE6h7RbOvY"
      },
      "source": [
        "# **END**"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyOOUpAgRbVuAz5MnU5DTWuJ",
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "00835d565ba04fda95d1dea9643fe26f": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "06433f4c888243a9ad597e6c2348ee7c": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0b1fc0c655734f889de3e4e894194a72": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "FloatProgressModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0d2b9bf8b5704515b3477717956cc753",
            "max": 4233780,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_3464245b802b4ed9a545f93076b90d24",
            "value": 4233780
          }
        },
        "0bfbc9ec33764a5282505b682e663ccb": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_393e229e1e3d47a6ae8885b7f035d697",
            "placeholder": "",
            "style": "IPY_MODEL_7eeff785256f4ba1a3eeaee104b681ba",
            "value": "917k/917k[00:00&lt;00:00,30.0MB/s]"
          }
        },
        "0d2b9bf8b5704515b3477717956cc753": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "11b1f4d1a27d439995c23b3267ff18cc": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "1321ede0616f4288b369b2aa42928f15": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "ProgressStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "1451ae94d89f4b0fbcccc03605b684a9": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_e95b2ac8238b4a1787c4ab0c1f343eed",
            "placeholder": "",
            "style": "IPY_MODEL_912f30acc17e42439365560bb042b341",
            "value": "vocab.json:100%"
          }
        },
        "1506b629451440dc96342b20f2a1f791": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "174f5a3e07294927a7c57e49979bffbc": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "2280f7628adb4a9b9cd2ae550c1d556d": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "FloatProgressModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_981ba01bf9ba4a16a7d3941d35dc355d",
            "max": 98,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_3a36911cccd444f3aff7beb51f825819",
            "value": 98
          }
        },
        "304c94c436014f64870dbe2c1699a6b1": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HBoxModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_d81442e3ba804b22a240ea7a6d470cea",
              "IPY_MODEL_0b1fc0c655734f889de3e4e894194a72",
              "IPY_MODEL_995ac051cef14ba99e69e5e398ca3d1d"
            ],
            "layout": "IPY_MODEL_44a44fdca8d4468e9d59c7717d522be6"
          }
        },
        "3195fbb2b11d495da35c07c063ca37c2": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3464245b802b4ed9a545f93076b90d24": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "ProgressStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "36cab25a61eb4ed9a03e3e134ba827d0": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "ProgressStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "393e229e1e3d47a6ae8885b7f035d697": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3a36911cccd444f3aff7beb51f825819": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "ProgressStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "425db4e707f3444884986688383e2de5": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HBoxModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_1451ae94d89f4b0fbcccc03605b684a9",
              "IPY_MODEL_999cb180dd7e4e96924f5ee8511c56ba",
              "IPY_MODEL_f598b9e1d39048e6867047c41026fee2"
            ],
            "layout": "IPY_MODEL_bf78d4323a4d4b9cb1a44b59996ab542"
          }
        },
        "44a44fdca8d4468e9d59c7717d522be6": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "44be0214b2214a368fa29738f4ee29c1": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5cd92255d25049758053ac0243f147e3": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "608be4b8f7fc425faa20c56f43a807e8": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HBoxModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_b612e793a28e41b09c1147ff52abd98d",
              "IPY_MODEL_e5c0b0427732417cacbcfd314b86b726",
              "IPY_MODEL_e15182da196b4a3ba9700be629b5324c"
            ],
            "layout": "IPY_MODEL_00835d565ba04fda95d1dea9643fe26f"
          }
        },
        "634165b43f3e4eeaab8172e47c56df06": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "6d298a3b32fb427db3bfe45aa905e4da": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_bfab5b22b27143ee915e2928258dedd9",
            "placeholder": "",
            "style": "IPY_MODEL_06433f4c888243a9ad597e6c2348ee7c",
            "value": "special_tokens_map.json:100%"
          }
        },
        "717e4b7fa01844c8b7a754ebbfe7295d": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "ProgressStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "72fd7769030b43f09094f5fd85a7725e": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "74f32e11b4ad47d59cc5f7a457a96e3c": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9af4123ce8524e34aa9bad508e308942",
            "placeholder": "",
            "style": "IPY_MODEL_11b1f4d1a27d439995c23b3267ff18cc",
            "value": "98.0/98.0[00:00&lt;00:00,5.80kB/s]"
          }
        },
        "7d91c1caf307493da3684eb1ea025cf1": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7eeff785256f4ba1a3eeaee104b681ba": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "847d0c4c150e46b09185a28a1a544fb9": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8694343126d441cda72cc50b868edf59": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "FloatProgressModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f14ea7e54d5a47ee833d651019395d3d",
            "max": 916645,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_717e4b7fa01844c8b7a754ebbfe7295d",
            "value": 916645
          }
        },
        "895d58c14786498db587df3a16078556": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HBoxModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_6d298a3b32fb427db3bfe45aa905e4da",
              "IPY_MODEL_2280f7628adb4a9b9cd2ae550c1d556d",
              "IPY_MODEL_74f32e11b4ad47d59cc5f7a457a96e3c"
            ],
            "layout": "IPY_MODEL_174f5a3e07294927a7c57e49979bffbc"
          }
        },
        "8d9066a597c64276a2060644f5f50880": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "912f30acc17e42439365560bb042b341": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "981ba01bf9ba4a16a7d3941d35dc355d": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "995ac051cef14ba99e69e5e398ca3d1d": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_e56fada64e654c07b8311e773f8fe9cb",
            "placeholder": "",
            "style": "IPY_MODEL_f9303b7b134a4995b174c60fafadb9a4",
            "value": "4.23M/4.23M[00:00&lt;00:00,48.7MB/s]"
          }
        },
        "999cb180dd7e4e96924f5ee8511c56ba": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "FloatProgressModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_ab4093c42ef749d0a42e6c14a5ef69c7",
            "max": 2011744,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_36cab25a61eb4ed9a03e3e134ba827d0",
            "value": 2011744
          }
        },
        "9ac9cf0c11484128a05220e830852879": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "9af4123ce8524e34aa9bad508e308942": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "ab4093c42ef749d0a42e6c14a5ef69c7": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b612e793a28e41b09c1147ff52abd98d": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_44be0214b2214a368fa29738f4ee29c1",
            "placeholder": "",
            "style": "IPY_MODEL_1506b629451440dc96342b20f2a1f791",
            "value": "tokenizer_config.json:100%"
          }
        },
        "bf78d4323a4d4b9cb1a44b59996ab542": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "bfab5b22b27143ee915e2928258dedd9": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d6125b1938ce4ec587a78a8949d2ca6d": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d81442e3ba804b22a240ea7a6d470cea": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7d91c1caf307493da3684eb1ea025cf1",
            "placeholder": "",
            "style": "IPY_MODEL_9ac9cf0c11484128a05220e830852879",
            "value": "tokenizer.json:100%"
          }
        },
        "e15182da196b4a3ba9700be629b5324c": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d6125b1938ce4ec587a78a8949d2ca6d",
            "placeholder": "",
            "style": "IPY_MODEL_634165b43f3e4eeaab8172e47c56df06",
            "value": "460/460[00:00&lt;00:00,23.0kB/s]"
          }
        },
        "e56fada64e654c07b8311e773f8fe9cb": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e5c0b0427732417cacbcfd314b86b726": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "FloatProgressModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_847d0c4c150e46b09185a28a1a544fb9",
            "max": 460,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_1321ede0616f4288b369b2aa42928f15",
            "value": 460
          }
        },
        "e95b2ac8238b4a1787c4ab0c1f343eed": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "efffabced29441cea3cf9cc1eaa8f6f9": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f14ea7e54d5a47ee833d651019395d3d": {
          "model_module": "@jupyter-widgets/base",
          "model_module_version": "1.2.0",
          "model_name": "LayoutModel",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f598b9e1d39048e6867047c41026fee2": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5cd92255d25049758053ac0243f147e3",
            "placeholder": "",
            "style": "IPY_MODEL_efffabced29441cea3cf9cc1eaa8f6f9",
            "value": "2.01M/2.01M[00:00&lt;00:00,6.36MB/s]"
          }
        },
        "f9303b7b134a4995b174c60fafadb9a4": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "fcd6cf741bf446da872abe50d78e8976": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HTMLModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3195fbb2b11d495da35c07c063ca37c2",
            "placeholder": "",
            "style": "IPY_MODEL_72fd7769030b43f09094f5fd85a7725e",
            "value": "merges.txt:100%"
          }
        },
        "fee2f61428284a18a1c93f9e7137e898": {
          "model_module": "@jupyter-widgets/controls",
          "model_module_version": "1.5.0",
          "model_name": "HBoxModel",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_fcd6cf741bf446da872abe50d78e8976",
              "IPY_MODEL_8694343126d441cda72cc50b868edf59",
              "IPY_MODEL_0bfbc9ec33764a5282505b682e663ccb"
            ],
            "layout": "IPY_MODEL_8d9066a597c64276a2060644f5f50880"
          }
        },
        "92bf2224d7284d9db02e978076061c05": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_12b7e869949d4eebadabea635b740576",
            "placeholder": "",
            "style": "IPY_MODEL_e80f9b17a8954153b261ece7d69ee20a",
            "value": "\n    <style>\n        body {\n            font-family: \"Arial\", sans-serif;\n        }\n        .summary-container {\n            margin: 20px;\n            padding: 15px;\n            border-radius: 8px;\n            background-color: #f9f9f9;\n            box-shadow: 0 2px 4px rgba(0,0,0,0.1);\n        }\n        .topic-title {\n            color: #333;\n            font-size: 18px;\n        }\n        .summary-text {\n            color: #555;\n            font-size: 14px;\n            margin-top: 5px;\n        }\n    </style>\n    <div class=\"summary-container\">\n        <h2 style=\"color: #4B0082;\">Summary Overview</h2>\n            <div>\n                <h3 class=\"topic-title\">Topic: 2B_Determination of Practice Expense RVUs</h3>\n                <p class=\"summary-text\"><strong>Summary:</strong> BACKGROUND: The Medicare Physician Fee Schedule (PFS) uses national relative values for work, practice expense (PE), and malpractice (MP), which are adjusted geographically. The calculation of PE RVUs involves determining direct and indirect PE, with direct PE being calculated by summing the costs of resources typically used in a service and indirect PE being calculated using per-hour data from surveys such as the PPIS. The methodology for determining PE RVUs includes several detailed steps such as calculating aggregate pools of indirect PE RVUs for all PFS services, applying adjustments to indirect allocators, and determining the final PE RVUs by adding direct PE RVUs to the adjusted indirect PE RVUs. In the CY 2023 PFS final rule, CMS finalized the rebasing and revision of the Medicare Economic Index (MEI) to better reflect current market conditions affecting physician practices, but the implementation of the 2017-based MEI cost weights in PFS ratesetting has been postponed to future rulemaking.\n\nPROVISION: The PE RVUs for a service are established by combining direct and indirect costs, considering factors like clinical labor costs or work RVUs. For services with technical and professional components, the payment sums the components, adjusted by indirect cost percentages. Starting CY 2013, PE RVUs fully incorporate PPIS data, except where specified. For services that can be provided in both facility and non-facility settings, separate RVUs are calculated, typically resulting in lower facility RVUs due to fewer resources used by physicians in these settings. For services experiencing significant RVU reductions, a phase-in approach is applied to limit the reduction impact per year. The methodology also accounts for various modifiers and adjustments in the utilization files to reflect accurate service volumes and times. For CY 2024, CMS has decided not to incorporate the 2017-based MEI in PFS ratesetting, continuing to prioritize payment stability while new practice cost data is anticipated from the AMA. CMS is seeking feedback on strategies to incorporate information that could address challenges experienced in implementing the initial AMA PPIS data.</p>\n            </div></div>"
          }
        },
        "12b7e869949d4eebadabea635b740576": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e80f9b17a8954153b261ece7d69ee20a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}